

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2009241589 B2**

(54) Title
Dual variable domain immunoglobulins and uses thereof

(51) International Patent Classification(s)
A61K 39/00 (2006.01) **G01N 33/53** (2006.01)

(21) Application No: **2009241589** (22) Date of Filing: **2009.04.28**

(87) WIPO No: **WO09/134776**

(30) Priority Data

(31) Number	(32) Date	(33) Country
61/125,834	2008.04.29	US
61/197,191	2008.10.23	US
61/134,283	2008.07.08	US
61/199,009	2008.11.12	US

(43) Publication Date: **2009.11.05**

(44) Accepted Journal Date: **2013.10.10**

(71) Applicant(s)
AbbVie Inc.

(72) Inventor(s)
Liu, Junjian;Ying, Hua;Norvell, Suzanne M.;Kingsbury, Gillian A.;Morgan-Lappe, Susan E.;Wang, Jieyi;Li, Yingchun;Bell, Randy L.;Ghayur, Tariq;Reilly, Edward B.;Phillips, Andrew

(74) Agent / Attorney
Spruson & Ferguson, L 35 St Martins Tower 31 Market St, Sydney, NSW, 2000

(56) Related Art
US 2007/0071675



(51) International Patent Classification:
A61K 39/00 (2006.01)

(71) Applicant (for all designated States except US): **ABBOTT LABORATORIES** [US/US]; 100 Abbott Park Road, Abbott Park, IL 60064 (US).

(21) International Application Number:

PCT/US2009/041945

(72) Inventors; and

(22) International Filing Date:

28 April 2009 (28.04.2009)

(75) Inventors/Applicants (for US only): **GHAYUR, Tariq** [PK/US]; 1014 Washington Street, Holliston, MA 01746 (US). **MORGAN-LAPPE, Susan, E.** [US/US]; 5419 North Canfield Avenue, Chicago, IL 60656 (US). **REILLY, Edward, B.** [US/US]; 1136 Winners Circle, Libertyville, IL 60048 (US). **KINGSBURY, Gillian, A.** [US/US]; 46 Aqueduct Road, Wayland, MA 01778 (US). **PHILLIPS, Andrew** [GB/US]; 519 Garfield Avenue, Libertyville, IL 60048 (US). **WANG, Jieyi** [US/US]; 29726 Butterfly Court, Lake Bluff, IL 60044 (US). **BELL, Randy, L.** [US/US]; 703 Federal Parkway, Lin-

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:


61/125,834	29 April 2008 (29.04.2008)	US
61/134,283	8 July 2008 (08.07.2008)	US
61/197,191	23 October 2008 (23.10.2008)	US
61/199,009	12 November 2008 (12.11.2008)	US

[Continued on next page]

(54) Title: DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF

Figure 1

(57) Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.



WO 2009/134776 A3



denhurst, IL 60046 (US). **NORVELL, Suzanne, M.** [US/US]; 4531 N Krueger Road, Long Grove, IL 60047 (US). **LI, Yingchun** [CN/US]; 103 Newfield Drive, Buffalo Grove, IL 60089 (US). **LIU, Junjian** [CN/US]; 527 W Thames Street, Unit 7, Norwich, CT 06360 (US). **YING, Hua** [US/US]; 15 Tyler Drive, Holden, MA 01520 (US).

(74) **Agents:** **STEEL, Diana M.** et al.; Abbott Bioresearch Center, 100 Research Drive, Worcester, MA 01605 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) **Date of publication of the international search report:**

23 December 2009

***DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES
THEREOF***

Reference to Related Applications

This application is a non-provisional application claiming priority to U.S. Provisional
5 Application Ser. No. 61/125,834, filed April 29, 2008, U.S. Provisional Application Ser. No.
61/134,283, filed July 8, 2008, U.S. Provisional Application Ser. No. 61/197,191, filed October
23, 2008, and U.S. Provisional Application Ser. No. 61/199,009, filed November 12, 2008, the
contents of which are hereby incorporated by reference.

Field of the Invention

10 The present invention relates to multivalent and multispecific binding proteins, methods
of making, and specifically to their uses in the, diagnosis, prevention and/or treatment of acute
and chronic inflammatory diseases, cancer, and other diseases.

Background of the Invention

15 Engineered proteins, such as multispecific antibodies capable of binding two or more
antigens are known in the art. Such multispecific binding proteins can be generated using cell
fusion, chemical conjugation, or recombinant DNA techniques.

Bispecific antibodies have been produced using quadroma technology (see Milstein, C.
and A.C. Cuello (1983) Nature 305(5934):537-40) based on the somatic fusion of two different
hybridoma cell lines expressing murine monoclonal antibodies (mAbs) with the desired
20 specificities of the bispecific antibody. Because of the random pairing of two different
immunoglobulin (Ig) heavy and light chains within the resulting hybrid-hybridoma (or quadroma)
cell line, up to ten different Ig species are generated, of which only one is the functional bispecific
antibody. The presence of mis-paired by-products, and significantly reduced production yields,
means sophisticated purification procedures are required.

25 Bispecific antibodies can also be produced by chemical conjugation of two different
mAbs (see Staerz, U.D., et al. (1985) Nature 314(6012): 628-31). This approach does not yield
homogeneous preparation. Other approaches have used chemical conjugation of two different
mAbs or smaller antibody fragments (see Brennan, M., et al. (1985) Science 229(4708): 81-3).

30 Another method used to produce bispecific antibodies is the coupling of two parental
antibodies with a hetero-bifunctional crosslinker, but the resulting bispecific antibodies suffer
from significant molecular heterogeneity because reaction of the crosslinker with the parental
antibodies is not site-directed. To obtain more homogeneous preparations of bispecific antibodies
two different Fab fragments have been chemically crosslinked at their hinge cysteine residues in a

site-directed manner (see Glennie, M.J., et al. (1987) *J. Immunol.* 139(7): 2367-75). But this method results in Fab'2 fragments, not full IgG molecule.

A wide variety of other recombinant bispecific antibody formats have been developed (see Kriangkum, J., et al. (2001) *Biomol. Eng.* 18(2): 31-40). Amongst them tandem single-chain Fv molecules and diabodies, and various derivatives thereof, are the most widely used. Routinely, construction of these molecules starts from two single-chain Fv (scFv) fragments that recognize different antigens (see Economides, A.N., et al. (2003) *Nat. Med.* 9(1): 47-52). Tandem scFv molecules (taFv) represent a straightforward format simply connecting the two scFv molecules with an additional peptide linker. The two scFv fragments present in these tandem scFv molecules form separate folding entities. Various linkers can be used to connect the two scFv fragments and linkers with a length of up to 63 residues (see Nakanishi, K., et al. (2001) *Ann. Rev. Immunol.* 19: 423-74). Although the parental scFv fragments can normally be expressed in soluble form in bacteria, it is, however, often observed that tandem scFv molecules form insoluble aggregates in bacteria. Hence, refolding protocols or the use of mammalian expression systems are routinely applied to produce soluble tandem scFv molecules. In a recent study, *in vivo* expression by transgenic rabbits and cattle of a tandem scFv directed against CD28 and a melanoma-associated proteoglycan was reported (see Gracie, J.A., et al. (1999) *J. Clin. Invest.* 104(10): 1393-401). In this construct, the two scFv molecules were connected by a CH1 linker and serum concentrations of up to 100 mg/L of the bispecific antibody were found. Various strategies including variations of the domain order or using middle linkers with varying length or flexibility were employed to allow soluble expression in bacteria. A few studies have now reported expression of soluble tandem scFv molecules in bacteria (see Leung, B.P., et al. (2000) *J. Immunol.* 164(12): 6495-502; Ito, A., et al. (2003) *J. Immunol.* 170(9): 4802-9; Kami, A., et al. (2002) *J. Neuroimmunol.* 125(1-2): 134-40) using either a very short Ala3 linker or long glycine/serine-rich linkers. In another recent study, phage display of a tandem scFv repertoire containing randomized middle linkers with a length of 3 or 6 residues was employed to enrich for those molecules that are produced in soluble and active form in bacteria. This approach resulted in the isolation of a tandem scFv molecule with a 6 amino acid residue linker (see Arndt, M. and J. Krauss (2003) *Methods Mol. Biol.* 207: 305-21). It is unclear whether this linker sequence represents a general solution to the soluble expression of tandem scFv molecules. Nevertheless, this study demonstrated that phage display of tandem scFv molecules in combination with directed mutagenesis is a powerful tool to enrich for these molecules, which can be expressed in bacteria in an active form.

Bispecific diabodies (Db) utilize the diabody format for expression. Diabodies are produced from scFv fragments by reducing the length of the linker connecting the VH and VL domain to approximately 5 residues (see Peipp, M. and T. Valerius (2002) *Biochem. Soc. Trans.*

30(4): 507-11). This reduction of linker size facilitates dimerization of two polypeptide chains by crossover pairing of the VH and VL domains. Bispecific diabodies are produced by expressing, two polypeptide chains with, either the structure VHA-VLB and VHB-VLA (VH-VL configuration), or VLA-VHB and VLB-VHA (VL-VH configuration) within the same cell. A large variety of different bispecific diabodies have been produced in the past and most of them are expressed in soluble form in bacteria. However, a recent comparative study demonstrates that the orientation of the variable domains can influence expression and formation of active binding sites (see Mack, M. et al.(1995) Proc. Natl. Acad. Sci. U S A 92(15): 7021-5). Nevertheless, soluble expression in bacteria represents an important advantage over tandem scFv molecules. However, since two different polypeptide chains are expressed within a single cell inactive homodimers can be produced together with active heterodimers. This necessitates the implementation of additional purification steps in order to obtain homogenous preparations of bispecific diabodies. One approach to force the generation of bispecific diabodies is the production of knob-into-hole diabodies (see Holliger, P., T. Prospero, and G. Winter (1993) Proc. Natl. Acad. Sci. U S A 90(14): 6444-8.18). This approach was demonstrated for a bispecific diabody directed against HER2 and CD3. A large knob was introduced in the VH domain by exchanging Val37 with Phe and Leu45 with Trp and a complementary hole was produced in the VL domain by mutating Phe98 to Met and Tyr87 to Ala, either in the anti- HER2 or the anti-CD3 variable domains. By using this approach the production of bispecific diabodies could be increased from 72% by the parental diabody to over 90% by the knob-into-hole diabody. Importantly, production yields only slightly decrease as a result of these mutations. However, a reduction in antigen-binding activity was observed for several constructs. Thus, this rather elaborate approach requires the analysis of various constructs in order to identify those mutations that produce heterodimeric molecule with unaltered binding activity. In addition, such approach requires mutational modification of the immunoglobulin sequence at the constant region, thus creating non-native and non-natural form of the antibody sequence, which may result in increased immunogenicity, poor *in vivo* stability, as well as undesirable pharmacokinetics.

Single-chain diabodies (scDb) represent an alternative strategy for improving the formation of bispecific diabody-like molecules (see Holliger, P. and G. Winter (1997) Cancer Immunol. Immunother. 45(3-4): 128-30; Wu, A.M., et al. (1996) Immunotechnology 2(1): p. 21-36). Bispecific single-chain diabodies are produced by connecting the two diabody-forming polypeptide chains with an additional middle linker with a length of approximately 15 amino acid residues. Consequently, all molecules with a molecular weight corresponding to monomeric single-chain diabodies (50-60 kDa) are bispecific. Several studies have demonstrated that bispecific single chain diabodies are expressed in bacteria in soluble and active form with the majority of purified molecules present as monomers (see Holliger, P. and G. Winter (1997)

Cancer Immunol. Immunother. 45(3-4): 128-30; Wu, A.M., et al. (1996) Immunotechnol. 2(1): 21-36; Pluckthun, A. and P. Pack (1997) Immunotechnol. 3(2): 83-105; Ridgway, J.B., et al. (1996) Protein Engin. 9(7): 617-21). Thus, single-chain diabodies combine the advantages of tandem scFvs (all monomers are bispecific) and diabodies (soluble expression in bacteria).

More recently diabodies have been fused to Fc to generate more Ig-like molecules, named di-diabodies (see Lu, D., et al. (2004) J. Biol. Chem. 279(4): 2856-65). In addition, multivalent antibody construct comprising two Fab repeats in the heavy chain of an IgG and capable of binding four antigen molecules has been described (see WO 0177342A1, and Miller, K., et al. (2003) J. Immunol. 170(9): 4854-61).

There is a need in the art for improved multivalent binding proteins capable of binding two or more antigens. U.S. Patent Application Serial No. 11/507,050 provides a novel family of binding proteins capable of binding two or more antigens with high affinity, which are called dual variable domain immunoglobulins (DVD-Ig™). The present invention provides further novel binding proteins capable of binding two or more antigens.

Summary of the Invention

This invention pertains to multivalent binding proteins capable of binding two or more antigens. The present invention provides a novel family of binding proteins capable of binding two or more antigens with high affinity.

In a first aspect, the present invention provides a binding protein comprising first and second polypeptide chains independently comprising VD1-(X1)_n-VD2-C-(X2)_n, wherein

VD1 is a first variable domain;

VD2 is a second variable domain;

C is a constant domain;

X1 is a linker with the proviso that it is not CH1;

X2 is an Fc region;

n is 0 or 1;

wherein the VD1 domains on the first and second polypeptide chains form a first functional target binding site and the VD2 domains on the first and second polypeptide chains form a second functional target binding site, wherein the binding protein is capable of binding VEGF and DLL4, and:

(a) the variable domains that form a functional target binding site for VEGF comprise

CDRs 1-3 from SEQ ID NO: 53 and CDRs 1-3 from SEQ ID NO: 54,

CDRs 1-3 from SEQ ID NO: 77 and CDRs 1-3 from SEQ ID NO: 78, or

CDRs 1-3 from SEQ ID NO: 79 and CDRs 1-3 from SEQ ID NO: 80;

and

(b) the variable domains that form a functional target binding site for DLL4 comprise CDRs 1-3 from SEQ ID NO: 55 and CDRs 1-3 from SEQ ID NO: 56, CDRs 1-3 from SEQ ID NO: 75 and CDRs 1-3 from SEQ ID NO: 76, CDRs 1-3 from SEQ ID NO: 81 and CDRs 1-3 from SEQ ID NO: 82, or CDRs 1-3 from SEQ ID NO: 83 and CDRs 1-3 from SEQ ID NO: 84;

wherein the binding protein is capable of binding to VEGF with a dissociation constant (K_D) of at most about 3.08×10^{-10} M as measured by surface plasmon resonance, and wherein the binding protein is capable of binding to DLL4 with a dissociation constant (K_D) of at most about 2.32×10^{-9} M as measured by surface plasmon resonance.

In a second aspect, the present invention provides a binding protein capable of binding VEGF and DLL4, wherein the binding protein comprises any one of:

DVD043 (comprising SEQ ID NOs: 239 and 240),
DVD044 (comprising SEQ ID NOs: 241 and 242),
DVD441 (comprising SEQ ID NOs: 407 and 408),
DVD442 (comprising SEQ ID NOs: 409 and 410),
DVD447 (comprising SEQ ID NOs: 411 and 412),
DVD448 (comprising SEQ ID NOs: 413 and 414),
DVD453 (comprising SEQ ID NOs: 415 and 416),
DVD454 (comprising SEQ ID NOs: 417 and 418),
DVD459 (comprising SEQ ID NOs: 419 and 420),
DVD460 (comprising SEQ ID NOs: 421 and 422),
DVD443 (comprising SEQ ID NOs: 423 and 424),
DVD444 (comprising SEQ ID NOs: 425 and 426),
DVD449 (comprising SEQ ID NOs: 427 and 428),
DVD450 (comprising SEQ ID NOs: 429 and 430),
DVD455 (comprising SEQ ID NOs: 431 and 432),
DVD456 (comprising SEQ ID NOs: 433 and 434),
DVD461 (comprising SEQ ID NOs: 435 and 436),
DVD462 (comprising SEQ ID NOs: 437 and 438),
DVD445 (comprising SEQ ID NOs: 439 and 440),
DVD446 (comprising SEQ ID NOs: 441 and 442),
DVD451 (comprising SEQ ID NOs: 443 and 444),
DVD452 (comprising SEQ ID NOs: 445 and 446),

DVD457 (comprising SEQ ID NOs: 447 and 448),
DVD458 (comprising SEQ ID NOs: 449 and 450),
DVD463 (comprising SEQ ID NOs: 451 and 452),
DVD464 (comprising SEQ ID NOs: 453 and 454),
DVD465 (comprising SEQ ID NOs: 455 and 456),
DVD466 (comprising SEQ ID NOs: 457 and 458),
DVD471 (comprising SEQ ID NOs: 459 and 460),
DVD472 (comprising SEQ ID NOs: 461 and 462),
DVD477 (comprising SEQ ID NOs: 463 and 464),
DVD478 (comprising SEQ ID NOs: 465 and 466),
DVD483 (comprising SEQ ID NOs: 467 and 468),
DVD484 (comprising SEQ ID NOs: 469 and 470),
DVD467 (comprising SEQ ID NOs: 471 and 472),
DVD468 (comprising SEQ ID NOs: 473 and 474),
DVD473 (comprising SEQ ID NOs: 475 and 476),
DVD474 (comprising SEQ ID NOs: 477 and 478),
DVD479 (comprising SEQ ID NOs: 479 and 480),
DVD480 (comprising SEQ ID NOs: 481 and 482),
DVD485 (comprising SEQ ID NOs: 483 and 484),
DVD486 (comprising SEQ ID NOs: 485 and 486),
DVD469 (comprising SEQ ID NOs: 487 and 488),
DVD470 (comprising SEQ ID NOs: 489 and 490),
DVD475 (comprising SEQ ID NOs: 491 and 492),
DVD476 (comprising SEQ ID NOs: 493 and 494),
DVD481 (comprising SEQ ID NOs: 495 and 496),
DVD482 (comprising SEQ ID NOs: 497 and 498),
DVD487 (comprising SEQ ID NOs: 499 and 500),
DVD488 (comprising SEQ ID NOs: 501 and 502),
DVD493 (comprising SEQ ID NOs: 503 and 504),
DVD494 (comprising SEQ ID NOs: 505 and 506),
DVD499 (comprising SEQ ID NOs: 507 and 508),
DVD500 (comprising SEQ ID NOs: 509 and 510),
DVD505 (comprising SEQ ID NOs: 511 and 512),
DVD506 (comprising SEQ ID NOs: 513 and 514),
DVD489 (comprising SEQ ID NOs: 515 and 516),

2009241589 01 Aug 2013

5
0

5

0

25

30

35

2009241589 01 Aug 2013

5
0

5

0

25

30

35

DVD490 (comprising SEQ ID NOs: 517 and 518),
DVD495 (comprising SEQ ID NOs: 519 and 520),
DVD496 (comprising SEQ ID NOs: 521 and 522),
DVD501 (comprising SEQ ID NOs: 523 and 524),
DVD502 (comprising SEQ ID NOs: 525 and 526),
DVD507 (comprising SEQ ID NOs: 527 and 528),
DVD508 (comprising SEQ ID NOs: 529 and 530),
DVD491 (comprising SEQ ID NOs: 531 and 532),
DVD492 (comprising SEQ ID NOs: 533 and 534),
DVD497 (comprising SEQ ID NOs: 535 and 536),
DVD498 (comprising SEQ ID NOs: 537 and 538),
DVD503 (comprising SEQ ID NOs: 539 and 540),
DVD504 (comprising SEQ ID NOs: 541 and 542),
DVD509 (comprising SEQ ID NOs: 543 and 544),
DVD510 (comprising SEQ ID NOs: 545 and 546),
DVD511 (comprising SEQ ID NOs: 547 and 548),
DVD512 (comprising SEQ ID NOs: 549 and 550),
DVD517 (comprising SEQ ID NOs: 551 and 552),
DVD518 (comprising SEQ ID NOs: 553 and 554),
DVD523 (comprising SEQ ID NOs: 555 and 556),
DVD524 (comprising SEQ ID NOs: 557 and 558),
DVD529 (comprising SEQ ID NOs: 559 and 560),
DVD530 (comprising SEQ ID NOs: 561 and 562),
DVD513 (comprising SEQ ID NOs: 563 and 564),
DVD514 (comprising SEQ ID NOs: 565 and 566),
DVD519 (comprising SEQ ID NOs: 567 and 568),
DVD520 (comprising SEQ ID NOs: 569 and 570),
DVD525 (comprising SEQ ID NOs: 571 and 572),
DVD526 (comprising SEQ ID NOs: 573 and 574),
DVD531 (comprising SEQ ID NOs: 575 and 576),
DVD532 (comprising SEQ ID NOs: 577 and 578),
DVD515 (comprising SEQ ID NOs: 579 and 580),
DVD516 (comprising SEQ ID NOs: 581 and 582),
DVD521 (comprising SEQ ID NOs: 583 and 584),
DVD522 (comprising SEQ ID NOs: 585 and 586),

DVD527 (comprising SEQ ID NOs: 587 and 588),
DVD528 (comprising SEQ ID NOs: 589 and 590),
DVD533 (comprising SEQ ID NOs: 591 and 592), and
DVD534 (comprising SEQ ID NOs: 593 and 594).

In a third aspect, the present invention provides a binding protein conjugate comprising the binding protein according to the first or second aspect, the binding protein conjugate further comprising an immunoadhesion molecule, an imaging agent, a therapeutic agent, or a cytotoxic agent,

wherein the imaging agent is optionally a radiolabel, an enzyme, a fluorescent label, a luminescent label, a bioluminescent label, a magnetic label, or biotin, wherein the radiolabel is optionally ^3H , ^{14}C , ^{35}S , ^{90}Y , ^{99}Tc , ^{111}In , ^{125}I , ^{131}I , ^{177}Lu , ^{166}Ho , or ^{153}Sm , or

wherein the therapeutic agent or cytotoxic agent is optionally an anti-metabolite, an alkylating agent, an antibiotic, a growth factor, a cytokine, an anti-angiogenic agent, an anti-mitotic agent, an anthracycline, a toxin, or an apoptotic agent.

In a fourth aspect, the present invention provides an isolated nucleic acid encoding the binding protein amino acid sequence according to the first or second aspect.

In a fifth aspect, the present invention provides a vector comprising the isolated nucleic acid according to the fourth aspect, wherein the vector is optionally pcDNA, pTT, pTT3, pEFBOS, pBV, pJV, pcDNA3.1 TOPO, pEF6 TOPO, pBJ, or pHybE.

In a sixth aspect, the present invention provides an isolated host cell comprising the vector according to the fifth aspect, wherein the host cell is optionally a prokaryotic cell, *Escherichia coli*, a eukaryotic cell, a protist cell, an animal cell, a plant cell, a fungal cell, a yeast cell, an Sf9 cell, a mammalian cell, an avian cell, an insect cell, a CHO cell, or a COS cell.

In a seventh aspect, the present invention provides a method of producing a binding protein, comprising culturing the host cell according to the sixth aspect in culture medium under conditions sufficient to produce the binding protein.

In an eighth aspect, the present invention provides a pharmaceutical composition comprising the binding protein according to the first or second aspect, and a pharmaceutically acceptable carrier.

In a ninth aspect, the present invention provides use of the binding protein according to the first or second aspect in the manufacture of a medicament for treating a subject for a disease or a disorder.

In a tenth aspect, the present invention provides an in vitro method of determining the presence, amount, or concentration of at least one target or fragment thereof in a test sample by an immunoassay,

wherein the immunoassay comprises contacting the test sample with at least one binding protein and at least one detectable label,

wherein the at least one binding protein comprises the binding protein according to the first or second aspect.

In an eleventh aspect, the present invention provides a kit for assaying an in vitro test sample for the presence, amount, or concentration of a target or fragment thereof, said kit comprising

(a) instructions for assaying the test sample for the target or fragment thereof; and

(b) at least one binding protein comprising the binding protein according to the first or second aspect.

In one embodiment the invention provides a binding protein comprising a polypeptide chain, wherein the polypeptide chain comprises $VD1-(X1)_n-VD2-C-(X2)_n$, wherein VD1 is a first variable domain, VD2 is a second variable domain, C is a constant domain, X1 represents an amino acid or polypeptide, X2 represents an Fc region and n is 0 or 1. In an embodiment the VD1 and VD2 in the binding protein are heavy chain variable domains. In another embodiment, the heavy chain variable domain is selected from the group consisting of a murine heavy chain variable domain, a human heavy chain variable domain, a CDR grafted heavy chain variable domain, and a humanized heavy chain variable domain. In yet another, embodiment VD1 and VD2 are capable of binding the same antigen. In another embodiment VD1 and VD2 are capable of binding different antigens. In still another embodiment, C is a heavy chain constant domain.

For example, X1 is a linker with the proviso that X1 is not CH1. For example, X1 is a linker selected from the group consisting of AKTTPKLEEGEFSEAR (SEQ ID NO: 1);

AKTTPKLEEGEFSEARV (SEQ ID NO: 2); AKTTPKLG (SEQ ID NO: 3); SAKTTPKLG (SEQ ID NO: 4); SAKTTP (SEQ ID NO: 5); RADAAP (SEQ ID NO: 6); RADAAPT (SEQ ID NO: 7); RAAAAAGGPGS (SEQ ID NO: 8); RAAAAA(G₄S)₄ (SEQ ID NO: 9);

SAKTTPKLEEGEFSEARV (SEQ ID NO: 10); ADAAP (SEQ ID NO: 11); ADAAPT (SEQ ID NO: 12); TVAAP (SEQ ID NO: 13); TVAAPSVFIFPP (SEQ ID NO: 14); QPKAAP

(SEQ ID NO: 15); QPKAAPSVTLFPP (SEQ ID NO: 16); AKTTPP (SEQ ID NO: 17);
 AKTTPPSVTPLAP (SEQ ID NO: 18); AKTTAP (SEQ ID NO: 19); AKTTAPSVYPLAP (SEQ
 ID NO: 20); ASTKGP (SEQ ID NO: 21); ASTKGPSVFPLAP (SEQ ID NO: 22),
 GGGGSGGGGSGGGGS (SEQ ID NO: 23); GENKVEYAPALMALS (SEQ ID NO: 24);
 5 GPAKELTPLKEAKVS (SEQ ID NO: 25); GHEAAVMQVQYPAS (SEQ ID NO: 26). In an
 embodiment, X2 is an Fc region. In another embodiment, X2 is a variant Fc region.

In an embodiment the binding protein disclosed herein comprises a polypeptide chain,
 wherein the polypeptide chain comprises VD1-(X1)_n-VD2-C-(X2)_n, wherein VD1 is a first heavy
 chain variable domain, VD2 is a second heavy chain variable domain, C is a heavy chain constant
 10 domain, X1 is a linker with the proviso that it is not CH1, and X2 is an Fc region.

In an embodiment, VD1 and VD2 in the binding protein are light chain variable domains. In an
 embodiment, the light chain variable domain is selected from the group consisting of a murine
 light chain variable domain, a human light chain variable domain, a CDR grafted light chain
 variable domain, and a humanized light chain variable domain. In one embodiment VD1 and
 15 VD2 are capable of binding the same antigen. In another embodiment VD1 and VD2 are capable
 of binding different antigens. In an embodiment, C is a light chain constant domain. In another
 embodiment, X1 is a linker with the proviso that X1 is not CL1. In an embodiment, X1 is a linker
 selected from the group consisting of AKTTPKLEEGEFSEAR (SEQ ID NO: 1);
 AKTTPKLEEGEFSEARV (SEQ ID NO: 2); AKTTPKLG (SEQ ID NO: 3); SAKTTPKLG
 20 (SEQ ID NO: 4); SAKTTP (SEQ ID NO: 5); RADAAP (SEQ ID NO: 6); RADAAPTVS (SEQ
 ID NO: 7); RADAAAAGGPGS (SEQ ID NO: 8); RADAAAA(G₄S)₄ (SEQ ID NO: 9);
 SAKTTPKLEEGEFSEARV (SEQ ID NO: 10); ADAAP (SEQ ID NO: 11); ADAAPTVSIFPP
 (SEQ ID NO: 12); TVAAP (SEQ ID NO: 13); TVAAPSVFIFPP (SEQ ID NO: 14); QPKAAP
 (SEQ ID NO: 15); QPKAAPSVTLFPP (SEQ ID NO: 16); AKTTPP (SEQ ID NO: 17);
 25 AKTTPPSVTPLAP (SEQ ID NO: 18); AKTTAP (SEQ ID NO: 19); AKTTAPSVYPLAP (SEQ
 ID NO: 20); ASTKGP (SEQ ID NO: 21); ASTKGPSVFPLAP (SEQ ID NO: 22)
 GGGGSGGGGSGGGGS (SEQ ID NO: 23); GENKVEYAPALMALS (SEQ ID NO: 24);
 GPAKELTPLKEAKVS (SEQ ID NO: 25); GHEAAVMQVQYPAS (SEQ ID NO: 26). In an
 embodiment, the binding protein does not comprise X2.

30 In an embodiment, both the variable heavy and variable light chain comprise the same
 linker. In another embodiment, the variable heavy and variable light chain comprise different
 linkers. In another embodiment, both the variable heavy and variable light chain comprise a short
 (about 6 amino acids) linker. In another embodiment, both the variable heavy and variable light
 chain comprise a long (greater than 6 amino acids) linker. In another embodiment, the variable
 35 heavy chain comprises a short linker and the variable light chain comprises a long linker. In

another embodiment, the variable heavy chain comprises a long linker and the variable light chain comprises a short linker.

In an embodiment the binding protein disclosed herein comprises a polypeptide chain, wherein said polypeptide chain comprises $VD1-(X1)_n-VD2-C-(X2)_n$, wherein VD1 is a first light chain variable domain, VD2 is a second light chain variable domain, C is a light chain constant domain, X1 is a linker with the proviso that it is not CH1, and X2 does not comprise an Fc region.

In another embodiment the invention provides a binding protein comprising two polypeptide chains, wherein said first polypeptide chain comprises $VD1-(X1)_n-VD2-C-(X2)_n$, wherein VD1 is a first heavy chain variable domain, VD2 is a second heavy chain variable domain, C is a heavy chain constant domain, X1 is a linker with the proviso that it is not CH1, and X2 is an Fc region; and said second polypeptide chain comprises $VD1-(X1)_n-VD2-C-(X2)_n$, wherein VD1 is a first light chain variable domain, VD2 is a second light chain variable domain, C is a light chain constant domain, X1 is a linker with the proviso that it is not CH1, and X2 does not comprise an Fc region. In a particular embodiment, the Dual Variable Domain (DVD) binding protein comprises four polypeptide chains wherein the first two polypeptide chains comprises $VD1-(X1)_n-VD2-C-(X2)_n$, respectively wherein VD1 is a first heavy chain variable domain, VD2 is a second heavy chain variable domain, C is a heavy chain constant domain, X1 is a linker with the proviso that it is not CH1, and X2 is an Fc region; and the second two polypeptide chain comprises $VD1-(X1)_n-VD2-C-(X2)_n$ respectively, wherein VD1 is a first light chain variable domain, VD2 is a second light chain variable domain, C is a light chain constant domain, X1 is a linker with the proviso that it is not CH1, and X2 does not comprise an Fc region. Such a Dual Variable Domain (DVD) protein has four antigen binding sites.

In another embodiment the binding proteins disclosed herein are capable of binding one or more targets. In an embodiment, the target is selected from the group consisting of cytokines, cell surface proteins, enzymes and receptors. In another embodiment, the binding protein is capable of modulating a biological function of one or more targets. In another embodiment, the binding protein is capable of neutralizing one or more targets. The binding protein of the invention is capable of binding cytokines selected from the group consisting of lymphokines, monokines, polypeptide hormones, receptors, or tumor markers. For example, the DVD-Ig of the invention is capable of binding two or more of the following: CD-20, CD-19, CD-80, CD-22, CD-40, CD-3, human epidermal growth factor receptor 2 (HER-2), epidermal growth factor receptor (EGFR), insulin-like growth factor 1,2 (IGF1,2), insulin-like growth factor receptor (IGF1R), macrophage stimulating protein receptor tyrosine kinase (RON), hepatocyte growth factor (HGF), mesenchymal-epithelial transition factor (c-MET), vascular endothelial growth factor (VEGF), Drosophila Delta homologue 4 (DLL4), neuropilin 1 (NRP1), placental growth factor (PLGF), v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 (ErbB3) (see also Table 2). In a

specific embodiment the binding protein is capable of binding pairs of targets selected from the group consisting of CD-20 and CD-19; CD-20 and CD-80; CD-20 and CD-22; CD-20 and CD-40; CD-3 and HER-2; CD-3 and CD-19; EGFR and HER-2; EGFR and CD-3; EGFR and IGF1,2; EGFR and IGF1R; EGFR and RON; EGFR and HGF; EGFR and c-MET; HER-2 and IGF1,2; 5 HER-2 and IGF1R; RON and HGF; VEGF and EGFR; VEGF and HER-2; VEGF and CD-20; VEGF and IGF1,2; VEGF and DLL4; VEGF and HGF; VEGF and RON; VEGF and NRP1; CD-20 and CD3; DLL-4 and PLGF; VEGF and PLGF; ErbB3 and EGFR; ErbB3 and HGF; HER-2 and ErbB3; c-Met and ErbB3; PLGF and HER-2; HER-2 and HER-2.

In an embodiment, the binding protein capable of binding CD-20 and CD-19 comprises a 10 DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 99 and SEQ ID NO. 101; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 100 and SEQ ID NO. 102. In an embodiment, the binding protein capable of binding CD-20 and CD-19 comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 99 and a DVD light chain amino acid sequence of SEQ ID NO: 100. In another embodiment, the 15 binding protein capable of binding CD-20 and CD-19 has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 101 and a DVD light chain amino acid sequence of SEQ ID NO: 102.

In an embodiment, the binding protein capable of binding CD-20 and CD-3 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID 20 NO. 103 and SEQ ID NO. 105; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 104 and SEQ ID NO. 106. In an embodiment, the binding protein capable of binding CD-20 and CD-3 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 103 and a DVD light chain amino acid sequence of SEQ ID NO: 104. In another embodiment, the binding protein capable of binding CD-20 and CD-3 (seq. 1) has a 25 reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 105 and a DVD light chain amino acid sequence of SEQ ID NO: 106.

In an embodiment, the binding protein capable of binding CD-20 and CD-80 comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 107 30 and SEQ ID NO. 109; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 108 and SEQ ID NO. 110. In an embodiment, the binding protein capable of binding CD-20 and CD-80 comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 107 and a DVD light chain amino acid sequence of SEQ ID NO: 108. In another embodiment, the binding protein capable of binding CD-20 and CD-80 has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 109 and a DVD light 35 chain amino acid sequence of SEQ ID NO: 110.

In an embodiment, the binding protein capable of binding CD-20 and CD-22 comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 111 and SEQ ID NO. 113; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 112 and SEQ ID NO. 114. In an embodiment, the binding protein capable of binding CD-20 and CD-22 comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 111 and a DVD light chain amino acid sequence of SEQ ID NO: 112. In another embodiment, the binding protein capable of binding CD-20 and CD-22 has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 113 and a DVD light chain amino acid sequence of SEQ ID NO: 114.

10 In an embodiment, the binding protein capable of binding CD-20 and CD-40 comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 115 and SEQ ID NO. 117; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 116 and SEQ ID NO. 118. In an embodiment, the binding protein capable of binding CD-20 and CD-40 comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 115 and a DVD light chain amino acid sequence of SEQ ID NO: 116. In another embodiment, the binding protein capable of binding CD-20 and CD-40 has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 117 and a DVD light chain amino acid sequence of SEQ ID NO: 118.

In an embodiment, the binding protein capable of binding CD-3 (seq. 1) and HER-2 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 119 and SEQ ID NO. 121; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 120 and SEQ ID NO. 122. In an embodiment, the binding protein capable of binding CD-3 (seq. 1) and HER-2 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 119 and a DVD light chain amino acid sequence of SEQ ID NO: 120. In another embodiment, the binding protein capable of binding CD-3 (seq. 1) and HER-2 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 121 and a DVD light chain amino acid sequence of SEQ ID NO: 122.

In an embodiment, the binding protein capable of binding CD-3 (seq. 1) and CD-19 comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 123 and SEQ ID NO. 125; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 124 and SEQ ID NO. 126. In an embodiment, the binding protein capable of binding CD-3 (seq. 1) and CD-19 comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 123 and a DVD light chain amino acid sequence of SEQ ID NO: 124. In another embodiment, the binding protein capable of binding CD-3 (seq. 1) and CD-19 has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 125 and a DVD light chain amino acid sequence of SEQ ID NO: 126.

In an embodiment, the binding protein capable of binding EGFR (seq. 2) and HER-2 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 127 and SEQ ID NO. 129; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 128 and SEQ ID NO. 130. In an embodiment, the binding protein capable of binding EGFR (seq. 2) and HER-2 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 127 and a DVD light chain amino acid sequence of SEQ ID NO: 128. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and HER-2 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 129 and a DVD light chain amino acid sequence of SEQ ID NO: 130.

10 In an embodiment, the binding protein capable of binding EGFR (seq. 2) and CD-3 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 131 and SEQ ID NO. 133; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 132 and SEQ ID NO. 136. In an embodiment, the binding protein capable of binding EGFR (seq. 2) and CD-3 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 131 and a DVD light chain amino acid sequence of SEQ ID NO: 132. In another embodiment, the binding protein capable of binding EGFR (seq. 1) and CD-3 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 133 and a DVD light chain amino acid sequence of SEQ ID NO: 134.

In an embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1,2 comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 135 and SEQ ID NO. 137; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 136 and SEQ ID NO. 138. In an embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1,2 comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 135 and a DVD light chain amino acid sequence of SEQ ID NO: 136. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1,2 has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 137 and a DVD light chain amino acid sequence of SEQ ID NO: 138.

In an embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 139 and SEQ ID NO. 140; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 141 and SEQ ID NO. 142. In an embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 139 and a DVD light chain amino acid sequence of SEQ ID NO: 140. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 141 and a DVD light chain amino acid sequence of SEQ ID NO: 142.

In a second embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 143 and SEQ ID NO. 145; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 144 and SEQ ID NO. 146. In an embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 143 and a DVD light chain amino acid sequence of SEQ ID NO: 144. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 145 and a DVD light chain amino acid sequence of SEQ ID NO: 146.

10 In a third embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 147 and SEQ ID NO. 149; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 148 and SEQ ID NO. 150. In an embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 147 and a DVD light chain amino acid sequence of SEQ ID NO: 148. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 149 and a DVD light chain amino acid sequence of SEQ ID NO: 150.

In a fourth embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 151 and SEQ ID NO. 153; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 152 and SEQ ID NO. 154. In an embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 151 and a DVD light chain amino acid sequence of SEQ ID NO: 152. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 153 and a DVD light chain amino acid sequence of SEQ ID NO: 154.

In an embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 155 and SEQ ID NO. 157; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 156 and SEQ ID NO. 158. In an embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 155 and a DVD light chain amino acid sequence of SEQ ID NO: 156. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 157 and a DVD light chain amino acid sequence of SEQ ID NO: 158.

In a second embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 159 and SEQ ID NO. 161; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 160 and SEQ ID NO. 162. In an embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 159 and a DVD light chain amino acid sequence of SEQ ID NO: 160. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 161 and a DVD light chain amino acid sequence of SEQ ID NO: 162.

10 In a third embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 163 and SEQ ID NO. 165; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 164 and SEQ ID NO. 166. In an embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 163 and a DVD light chain amino acid sequence of SEQ ID NO: 164. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 165 and a DVD light chain amino acid sequence of SEQ ID NO: 166.

In a fourth embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 167 and SEQ ID NO. 169; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 168 and SEQ ID NO. 170. In an embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 167 and a DVD light chain amino acid sequence of SEQ ID NO: 168. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 169 and a DVD light chain amino acid sequence of SEQ ID NO: 170.

In an embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 171 and SEQ ID NO. 173; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 172 and SEQ ID NO. 174. In an embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 171 and a DVD light chain amino acid sequence of SEQ ID NO: 172. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 173 and a DVD light chain amino acid sequence of SEQ ID NO: 174.

In a second embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 175 and SEQ ID NO. 177; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 176 and SEQ ID NO. 178. In an embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 175 and a DVD light chain amino acid sequence of SEQ ID NO: 176. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 177 and a DVD light chain amino acid sequence of SEQ ID NO: 178.

10 In a third embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 179 and SEQ ID NO. 181; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 180 and SEQ ID NO. 182. In an embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 179 and a DVD light chain amino acid sequence of SEQ ID NO: 180. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 181 and a DVD light chain amino acid sequence of SEQ ID NO: 182.

In a fourth embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 183 and SEQ ID NO. 185; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 184 and SEQ ID NO. 186. In an embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 183 and a DVD light chain amino acid sequence of SEQ ID NO: 184. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and IGF1R (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 185 and a DVD light chain amino acid sequence of SEQ ID NO: 186.

In an embodiment, the binding protein capable of binding EGFR (seq. 2) and RON (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 187 and SEQ ID NO. 189; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 188 and SEQ ID NO. 190. In an embodiment, the binding protein capable of binding EGFR (seq. 2) and RON (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 187 and a DVD light chain amino acid sequence of SEQ ID NO: 188. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and RON (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 189 and a DVD light chain amino acid sequence of SEQ ID NO: 190.

In a second embodiment, the binding protein capable of binding EGFR (seq. 2) and RON (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 191 and SEQ ID NO. 193; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 192 and SEQ ID NO. 194. In an embodiment, the binding protein capable of binding EGFR (seq. 2) and RON (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 191 and a DVD light chain amino acid sequence of SEQ ID NO: 192. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and RON (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO.193 and a DVD light chain amino acid sequence of SEQ ID NO: 194.

10 In a third embodiment, the binding protein capable of binding EGFR (seq. 2) and RON (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 195 and SEQ ID NO. 197; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 196 and SEQ ID NO. 198. In an embodiment, the binding protein capable of binding EGFR (seq. 2) and RON (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 195 and a DVD light chain amino acid sequence of SEQ ID NO: 196. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and RON (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 197 and a DVD light chain amino acid sequence of SEQ ID NO: 198.

In a fourth embodiment, the binding protein capable of binding EGFR (seq. 2) and RON (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 199 and SEQ ID NO. 201; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 200 and SEQ ID NO. 202. In an embodiment, the binding protein capable of binding EGFR (seq. 2) and RON (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 199 and a DVD light chain amino acid sequence of SEQ ID NO: 200. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and RON (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 201 and a DVD light chain amino acid sequence of SEQ ID NO: 202.

In an embodiment, the binding protein capable of binding EGFR (seq. 2) and HGF (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 203 and SEQ ID NO. 205; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 204 and SEQ ID NO. 206. In an embodiment, the binding protein capable of binding EGFR (seq. 2) and HGF (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 203 and a DVD light chain amino acid sequence of SEQ ID NO: 204. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and HGF (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 205 and a DVD light chain amino acid sequence of SEQ ID NO: 206.

In an embodiment, the binding protein capable of binding EGFR (seq. 1) and c-MET comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 207 and SEQ ID NO. 209; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 208 and SEQ ID NO. 210. In an embodiment, the binding
5 protein capable of binding EGFR (seq. 1) and c-MET comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 207 and a DVD light chain amino acid sequence of SEQ ID NO. 208. In another embodiment, the binding protein capable of binding EGFR (seq. 1) and c-MET has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 209 and a DVD light chain amino acid sequence of SEQ ID NO. 210.

10 In an embodiment, the binding protein capable of binding HER-2 (seq. 1) and IGF1,2 comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 211 and SEQ ID NO. 213; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 212 and SEQ ID NO. 214. In an embodiment, the binding
15 protein capable of binding HER-2 (seq. 1) and IGF1,2 comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 211 and a DVD light chain amino acid sequence of SEQ ID NO. 212. In another embodiment, the binding protein capable of binding HER-2 (seq. 1) and IGF1,2 has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 213 and a DVD light chain amino acid sequence of SEQ ID NO. 214.

In an embodiment, the binding protein capable of binding HER-2 (seq. 1) and IGF1R
20 comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 215 and SEQ ID NO. 217; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 216 and SEQ ID NO. 218. In an embodiment, the binding
protein capable of binding HER-2 (seq. 1) and IGF1R comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 215 and a DVD light chain amino acid sequence of SEQ ID NO. 216.
25 In another embodiment, the binding protein capable of binding HER-2 (seq. 1) and IGF1R has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 217 and a DVD light chain amino acid sequence of SEQ ID NO. 218.

In an embodiment, the binding protein capable of binding RON (seq. 1) and HGF (seq. 1)
30 comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 219 and SEQ ID NO. 221; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 220 and SEQ ID NO. 222. In an embodiment, the binding
protein capable of binding RON (seq. 1) and HGF (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 219 and a DVD light chain amino acid sequence of SEQ ID NO. 220. In another embodiment, the binding protein capable of binding RON (seq. 1) and HGF (seq.
35 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 221 and a DVD light chain amino acid sequence of SEQ ID NO. 222.

In an embodiment, the binding protein capable of binding VEGF (seq. 1) and EGFR (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 223 and SEQ ID NO. 225; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 224 and SEQ ID NO. 226. In an embodiment, the binding
5 protein capable of binding VEGF (seq. 1) and EGFR (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 223 and a DVD light chain amino acid sequence of SEQ ID NO: 224. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and EGFR (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 225 and a DVD light chain amino acid sequence of SEQ ID NO: 226.

10 In an embodiment, the binding protein capable of binding VEGF (seq. 1) and HER-2 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 227 and SEQ ID NO. 229; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 228 and SEQ ID NO. 230. In an embodiment, the binding
15 protein capable of binding VEGF (seq. 1) and HER-2 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 227 and a DVD light chain amino acid sequence of SEQ ID NO: 228. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and HER-2 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 229 and a DVD light chain amino acid sequence of SEQ ID NO: 230.

In an embodiment, the binding protein capable of binding VEGF (seq. 1) and CD-20
20 comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 231 and SEQ ID NO. 233; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 232 and SEQ ID NO. 234. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and CD-20 comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 231 and a DVD light chain amino acid sequence of SEQ ID NO: 232.
25 In another embodiment, the binding protein capable of binding VEGF (seq. 1) and CD-20 has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 233 and a DVD light chain amino acid sequence of SEQ ID NO: 234.

In an embodiment, the binding protein capable of binding VEGF (seq. 1) and IGF1,2
30 comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 235 and SEQ ID NO. 237; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 236 and SEQ ID NO. 238. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and IGF1,2 comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 235 and a DVD light chain amino acid sequence of SEQ ID NO: 236.
35 In another embodiment, the binding protein capable of binding VEGF (seq. 1) and IGF1,2 has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 237 and a DVD light chain amino acid sequence of SEQ ID NO: 238.

In an embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 239 and SEQ ID NO. 241; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 240 and SEQ ID NO. 242. In an embodiment, the binding
5 protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 239 and a DVD light chain amino acid sequence of SEQ ID NO: 240. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 241 and a DVD light chain amino acid sequence of SEQ ID NO: 242.

10 In an embodiment, the binding protein capable of binding VEGF (seq. 1) and HGF (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 243 and SEQ ID NO. 245; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 244 and SEQ ID NO. 246. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and HGF (seq. 1) comprises a DVD heavy chain amino
15 acid sequence of SEQ ID NO. 243 and a DVD light chain amino acid sequence of SEQ ID NO: 244. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and HGF (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 245 and a DVD light chain amino acid sequence of SEQ ID NO: 246.

In a second embodiment, the binding protein capable of binding VEGF (seq. 1) and HGF
20 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 247 and SEQ ID NO. 249; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 248 and SEQ ID NO. 250. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and HGF (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 247 and a DVD light chain amino acid sequence of
25 SEQ ID NO: 248. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and HGF (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 249 and a DVD light chain amino acid sequence of SEQ ID NO: 250.

In a third embodiment, the binding protein capable of binding VEGF (seq. 1) and HGF
30 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 251 and SEQ ID NO. 253; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 252 and SEQ ID NO. 254. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and HGF (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 251 and a DVD light chain amino acid sequence of
35 SEQ ID NO: 252. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and HGF (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 253 and a DVD light chain amino acid sequence of SEQ ID NO: 254.

In a fourth embodiment, the binding protein capable of binding VEGF (seq. 1) and HGF (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 255 and SEQ ID NO. 257; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 256 and SEQ ID NO. 258. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and HGF (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 255 and a DVD light chain amino acid sequence of SEQ ID NO: 256. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and HGF (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 257 and a DVD light chain amino acid sequence of SEQ ID NO: 258.

In an embodiment, the binding protein capable of binding VEGF (seq. 1) and RON (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 259 and SEQ ID NO. 261; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 260 and SEQ ID NO. 262. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and RON (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 259 and a DVD light chain amino acid sequence of SEQ ID NO: 260. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and RON (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 261 and a DVD light chain amino acid sequence of SEQ ID NO: 262.

In an embodiment, the binding protein capable of binding VEGF (seq. 1) and NRP1 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 263 and SEQ ID NO. 265; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 264 and SEQ ID NO. 266. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and NRP1 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 263 and a DVD light chain amino acid sequence of SEQ ID NO: 264. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and NRP1 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 265 and a DVD light chain amino acid sequence of SEQ ID NO: 266.

In an embodiment, the binding protein capable of binding RON (seq. 2) and HGF (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 267 and SEQ ID NO. 269; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 268 and SEQ ID NO. 270. In an embodiment, the binding protein capable of binding RON (seq. 2) and HGF (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 267 and a DVD light chain amino acid sequence of SEQ ID NO: 268. In another embodiment, the binding protein capable of binding RON (seq. 2) and HGF (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 269 and a DVD light chain amino acid sequence of SEQ ID NO: 270.

In an embodiment, the binding protein capable of binding RON (seq. 2) and EGFR (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 271 and SEQ ID NO. 273; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 272 and SEQ ID NO. 274. In an embodiment, the binding
5 protein capable of binding RON (seq. 2) and EGFR (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 271 and a DVD light chain amino acid sequence of SEQ ID NO: 272. In another embodiment, the binding protein capable of binding RON (seq. 2) and EGFR (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 273 and a DVD light chain amino acid sequence of SEQ ID NO: 274.

10 In an embodiment, the binding protein capable of binding RON (seq. 2) and VEGF (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 275 and SEQ ID NO. 277; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 276 and SEQ ID NO. 278. In an embodiment, the binding
15 protein capable of binding RON (seq. 2) and VEGF (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 275 and a DVD light chain amino acid sequence of SEQ ID NO: 276. In another embodiment, the binding protein capable of binding RON (seq. 2) and VEGF (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 277 and a DVD light chain amino acid sequence of SEQ ID NO: 278.

In an embodiment, the binding protein capable of binding EGFR (seq. 1) and HER-2 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ
20 ID NO. 279 and SEQ ID NO. 281; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 280 and SEQ ID NO. 282. In an embodiment, the binding protein capable of binding EGFR (seq. 1) and HER-2 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 279 and a DVD light chain amino acid sequence of SEQ ID
25 NO: 280. In another embodiment, the binding protein capable of binding EGFR (seq. 1) and HER-2 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 281 and a DVD light chain amino acid sequence of SEQ ID NO: 282.

In an embodiment, the binding protein capable of binding EGFR (seq. 1) and CD-3 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ
30 ID NO. 283 and SEQ ID NO. 285; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 284 and SEQ ID NO. 286. In an embodiment, the binding protein capable of binding EGFR (seq. 1) and CD-3 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 283 and a DVD light chain amino acid sequence of SEQ ID NO:
35 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 285 and a DVD light chain amino acid sequence of SEQ ID NO: 286.

In an embodiment, the binding protein capable of binding EGFR (seq. 1) and IGF1R comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 287 and SEQ ID NO. 289; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 288 and SEQ ID NO. 290. In an embodiment, the binding
5 protein capable of binding EGFR (seq. 1) and IGF1R comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 287 and a DVD light chain amino acid sequence of SEQ ID NO. 288. In another embodiment, the binding protein capable of binding EGFR (seq. 1) and IGF1R has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 289 and a DVD light chain amino acid sequence of SEQ ID NO. 290.

10 In an embodiment, the binding protein capable of binding EGFR (seq. 1) and RON (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 291 and SEQ ID NO. 293; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 292 and SEQ ID NO. 294. In an embodiment, the binding
15 protein capable of binding EGFR (seq. 1) and RON (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 291 and a DVD light chain amino acid sequence of SEQ ID NO. 292. In another embodiment, the binding protein capable of binding EGFR (seq. 1) and RON (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 293 and a DVD light chain amino acid sequence of SEQ ID NO. 294.

In an embodiment, the binding protein capable of binding EGFR (seq. 1) and RON (seq.
20 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 295 and SEQ ID NO. 297; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 296 and SEQ ID NO. 298. In an embodiment, the binding
protein capable of binding EGFR (seq. 1) and RON (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 295 and a DVD light chain amino acid sequence of SEQ ID NO.
25 296. In another embodiment, the binding protein capable of binding EGFR (seq. 1) and RON (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 297 and a DVD light chain amino acid sequence of SEQ ID NO. 298.

In an embodiment, the binding protein capable of binding EGFR (seq. 1) and HGF (seq.
30 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 299 and SEQ ID NO. 301; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 300 and SEQ ID NO. 302. In an embodiment, the binding
protein capable of binding EGFR (seq. 1) and HGF (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 299 and a DVD light chain amino acid sequence of SEQ ID NO.
35 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 301 and a DVD light chain amino acid sequence of SEQ ID NO. 302.

In an embodiment, the binding protein capable of binding EGFR (seq. 1) and c-MET comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 303 and SEQ ID NO. 305; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 304 and SEQ ID NO. 306. In an embodiment, the binding
5 protein capable of binding EGFR (seq. 1) and c-MET comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 303 and a DVD light chain amino acid sequence of SEQ ID NO. 304. In another embodiment, the binding protein capable of binding EGFR (seq. 1) and c-MET has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 305 and a DVD light chain amino acid sequence of SEQ ID NO. 306.

10 In an embodiment, the binding protein capable of binding EGFR (seq. 1) and VEGF (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 307 and SEQ ID NO. 309; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 308 and SEQ ID NO. 310. In an embodiment, the binding
15 protein capable of binding EGFR (seq. 1) and VEGF (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 307 and a DVD light chain amino acid sequence of SEQ ID NO. 308. In another embodiment, the binding protein capable of binding EGFR (seq. 1) and VEGF (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 309 and a DVD light chain amino acid sequence of SEQ ID NO. 310.

In an embodiment, the binding protein capable of binding NRP1 (seq. 2) and VEGF (seq.
20 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 311 and SEQ ID NO. 313; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 312 and SEQ ID NO. 314. In an embodiment, the binding
25 protein capable of binding NRP1 (seq. 2) and VEGF (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 311 and a DVD light chain amino acid sequence of SEQ ID NO. 312. In another embodiment, the binding protein capable of binding NRP1 (seq. 2) and VEGF (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 313 and a DVD light chain amino acid sequence of SEQ ID NO. 314.

In an embodiment, the binding protein capable of binding CD-3 (seq. 2) and CD-20
30 comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 315 and SEQ ID NO. 317; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 316 and SEQ ID NO. 318. In an embodiment, the binding
35 protein capable of binding CD-3 (seq. 2) and CD-20 comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 315 and a DVD light chain amino acid sequence of SEQ ID NO. 316. In another embodiment, the binding protein capable of binding CD-3 (seq. 2) and CD-20 has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 317 and a DVD light chain amino acid sequence of SEQ ID NO. 318.

In an embodiment, the binding protein capable of binding CD-3 (seq. 2) and HER-2 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 319 and SEQ ID NO. 321; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 320 and SEQ ID NO. 322. In an embodiment, the binding
5 protein capable of binding CD-3 (seq. 2) and HER-2 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 319 and a DVD light chain amino acid sequence of SEQ ID NO: 320. In another embodiment, the binding protein capable of binding CD-3 (seq. 2) and HER-2 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 321 and a DVD light chain amino acid sequence of SEQ ID NO: 322.

10 In an embodiment, the binding protein capable of binding CD-3 (seq. 2) and CD-19 comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 323 and SEQ ID NO. 325; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 324 and SEQ ID NO. 326. In an embodiment, the binding
15 protein capable of binding CD-3 (seq. 2) and CD-19 comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 323 and a DVD light chain amino acid sequence of SEQ ID NO: 324. In another embodiment, the binding protein capable of binding CD-3 (seq. 2) and CD-19 has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 325 and a DVD light chain amino acid sequence of SEQ ID NO: 326.

In an embodiment, the binding protein capable of binding CD-3 (seq. 2) and EGFR (seq.
20 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 327 and SEQ ID NO. 329; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 328 and SEQ ID NO. 330. In an embodiment, the binding
protein capable of binding CD-3 (seq. 2) and EGFR (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 327 and a DVD light chain amino acid sequence of SEQ ID NO:
25 328. In another embodiment, the binding protein capable of binding CD-3 (seq. 2) and EGFR (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 329 and a DVD light chain amino acid sequence of SEQ ID NO: 330.

In an embodiment, the binding protein capable of binding CD-3 (seq. 2) and EGFR (seq.
30 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 331 and SEQ ID NO. 333; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 332 and SEQ ID NO. 334. In an embodiment, the binding
protein capable of binding CD-3 (seq. 2) and EGFR (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 331 and a DVD light chain amino acid sequence of SEQ ID NO:
35 332. In another embodiment, the binding protein capable of binding CD-3 (seq. 2) and EGFR (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 333 and a DVD light chain amino acid sequence of SEQ ID NO: 334.

In an embodiment, the binding protein capable of binding EGFR (seq. 1) and IGF1,2 comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 335 and SEQ ID NO. 337; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 336 and SEQ ID NO. 338. In an embodiment, the binding
5 protein capable of binding EGFR (seq. 1) and IGF1,2 comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 335 and a DVD light chain amino acid sequence of SEQ ID NO: 336. In another embodiment, the binding protein capable of binding EGFR (seq. 1) and IGF1,2 has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 337 and a DVD light chain amino acid sequence of SEQ ID NO: 338.

10 In an embodiment, the binding protein capable of binding DLL-4 (seq. 1) and PLGF (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 339 and SEQ ID NO. 341; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 340 and SEQ ID NO. 342. In an embodiment, the binding
15 protein capable of binding DLL-4 (seq. 1) and PLGF (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 339 and a DVD light chain amino acid sequence of SEQ ID NO: 340. In another embodiment, the binding protein capable of binding DLL-4 (seq. 1) and PLGF (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 341 and a DVD light chain amino acid sequence of SEQ ID NO: 342.

In an embodiment, the binding protein capable of binding VEGF (seq. 1) and PLGF (seq.
20 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 343 and SEQ ID NO. 345; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 344 and SEQ ID NO. 346. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and PLGF (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 343 and a DVD light chain amino acid sequence of SEQ ID
25 NO: 344. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and PLGF (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 345 and a DVD light chain amino acid sequence of SEQ ID NO: 346.

In a second embodiment, the binding protein capable of binding VEGF (seq. 1) and PLGF
30 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 347 and SEQ ID NO. 349; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 348 and SEQ ID NO. 350. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and PLGF (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 347 and a DVD light chain amino acid sequence of
35 SEQ ID NO: 348. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and PLGF (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 349 and a DVD light chain amino acid sequence of SEQ ID NO: 350.

In a third embodiment, the binding protein capable of binding VEGF (seq. 1) and PLGF (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 351 and SEQ ID NO. 353; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 352 and SEQ ID NO. 354. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and PLGF (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 351 and a DVD light chain amino acid sequence of SEQ ID NO: 352. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and PLGF (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 353 and a DVD light chain amino acid sequence of SEQ ID NO: 354.

In a fourth embodiment, the binding protein capable of binding VEGF (seq. 1) and PLGF (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 355 and SEQ ID NO. 357; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 356 and SEQ ID NO. 358. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and PLGF (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 355 and a DVD light chain amino acid sequence of SEQ ID NO: 356. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and PLGF (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 357 and a DVD light chain amino acid sequence of SEQ ID NO: 358.

In an embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 359 and SEQ ID NO. 361; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 360 and SEQ ID NO. 362. In an embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 359 and a DVD light chain amino acid sequence of SEQ ID NO: 360. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 361 and a DVD light chain amino acid sequence of SEQ ID NO: 362.

In a second embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 363 and SEQ ID NO. 365; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 364 and SEQ ID NO. 366. In an embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 363 and a DVD light chain amino acid sequence of SEQ ID NO: 364. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 365 and a DVD light chain amino acid sequence of SEQ ID NO: 366.

In a third embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 367 and SEQ ID NO. 369; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 368 and SEQ ID NO. 370. In an embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 367 and a DVD light chain amino acid sequence of SEQ ID NO: 368. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 369 and a DVD light chain amino acid sequence of SEQ ID NO: 370.

10 In a fourth embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 371 and SEQ ID NO. 373; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 372 and SEQ ID NO. 374. In an embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 371 and a DVD light chain amino acid sequence of SEQ ID NO: 372. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 373 and a DVD light chain amino acid sequence of SEQ ID NO: 374.

In an embodiment, the binding protein capable of binding EGFR (seq. 1) and ErbB3 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 375 and SEQ ID NO. 377; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 376 and SEQ ID NO. 378. In an embodiment, the binding protein capable of binding EGFR (seq. 1) and ErbB3 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 375 and a DVD light chain amino acid sequence of SEQ ID NO: 376. In another embodiment, the binding protein capable of binding EGFR (seq. 1) and ErbB3 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 377 and a DVD light chain amino acid sequence of SEQ ID NO: 378.

In an embodiment, the binding protein capable of binding HGF (seq. 1) and ErbB3 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 379 and SEQ ID NO. 381; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 380 and SEQ ID NO. 382. In an embodiment, the binding protein capable of binding HGF (seq. 1) and ErbB3 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO.379 and a DVD light chain amino acid sequence of SEQ ID NO: 380. In another embodiment, the binding protein capable of binding HGF (seq. 1) and ErbB3 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 381 and a DVD light chain amino acid sequence of SEQ ID NO: 382.

In an embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 383 and SEQ ID NO. 385; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 384 and SEQ ID NO. 386. In an embodiment, the binding
5 protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 383 and a DVD light chain amino acid sequence of SEQ ID NO: 384. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 385 and a DVD light chain amino acid sequence of SEQ ID NO: 386.

10 In a second embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 387 and SEQ ID NO. 389; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 388 and SEQ ID NO. 390. In an embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 2) comprises a DVD heavy
15 chain amino acid sequence of SEQ ID NO. 387 and a DVD light chain amino acid sequence of SEQ ID NO: 388. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 389 and a DVD light chain amino acid sequence of SEQ ID NO: 390.

In a third embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3
20 (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 391 and SEQ ID NO. 393; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 392 and SEQ ID NO. 394. In an embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 391 and a DVD light chain amino acid sequence of
25 SEQ ID NO: 392. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 393 and a DVD light chain amino acid sequence of SEQ ID NO: 394.

In a fourth embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3
30 (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 395 and SEQ ID NO. 397; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 396 and SEQ ID NO. 398. In an embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 395 and a DVD light chain amino acid sequence of
35 SEQ ID NO: 396. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 397 and a DVD light chain amino acid sequence of SEQ ID NO: 398.

In an embodiment, the binding protein capable of binding EGFR (seq. 1) and ErbB3 (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 399 and SEQ ID NO. 401; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 400 and SEQ ID NO. 402. In an embodiment, the binding
5 protein capable of binding EGFR (seq. 1) and ErbB3 (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 399 and a DVD light chain amino acid sequence of SEQ ID NO: 400. In another embodiment, the binding protein capable of binding EGFR (seq. 1) and ErbB3 (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 401 and a DVD light chain amino acid sequence of SEQ ID NO: 402.

10 In an embodiment, the binding protein capable of binding HGF (seq. 1) and ErbB3 (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 403 and SEQ ID NO. 405; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 404 and SEQ ID NO. 406. In an embodiment, the binding
15 protein capable of binding HGF (seq. 1) and ErbB3 (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 403 and a DVD light chain amino acid sequence of SEQ ID NO: 404. In another embodiment, the binding protein capable of binding HGF (seq. 1) and ErbB3 (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 405 and a DVD light chain amino acid sequence of SEQ ID NO: 406.

In an embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ
20 ID NO. 407 and SEQ ID NO. 409; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 408 and SEQ ID NO. 410. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO.407 and a DVD light chain amino acid sequence of SEQ ID
25 NO: 408. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 409 and a DVD light chain amino acid sequence of SEQ ID NO: 410.

In a second embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting
30 of SEQ ID NO.411 and SEQ ID NO. 413; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 412 and SEQ ID NO. 414. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 411 and a DVD light chain amino acid sequence of
35 SEQ ID NO: 412. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 413 and a DVD light chain amino acid sequence of SEQ ID NO: 414.

In a third embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 415 and SEQ ID NO. 417; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 416 and SEQ ID NO. 418. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 415 and a DVD light chain amino acid sequence of SEQ ID NO: 416. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 417 and a DVD light chain amino acid sequence of SEQ ID NO: 418.

In a fourth embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 419 and SEQ ID NO. 421; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 420 and SEQ ID NO. 422. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 419 and a DVD light chain amino acid sequence of SEQ ID NO: 420. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 421 and a DVD light chain amino acid sequence of SEQ ID NO: 422.

In an embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 423 and SEQ ID NO. 425; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 424 and SEQ ID NO. 426. In an embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 423 and a DVD light chain amino acid sequence of SEQ ID NO: 424. In another embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 425 and a DVD light chain amino acid sequence of SEQ ID NO: 426.

In a second embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 427 and SEQ ID NO. 429; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 428 and SEQ ID NO. 430. In an embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 427 and a DVD light chain amino acid sequence of SEQ ID NO: 428. In another embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 429 and a DVD light chain amino acid sequence of SEQ ID NO: 430.

In a third embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 431 and SEQ ID NO. 433; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 432 and SEQ ID NO. 434. In an embodiment, the
5 binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 431 and a DVD light chain amino acid sequence of SEQ ID NO: 432. In another embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 433 and a DVD light chain amino acid sequence of SEQ ID NO: 434.

10 In a fourth embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 435 and SEQ ID NO. 437; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 436 and SEQ ID NO. 438. In an embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 2) comprises a DVD heavy
15 chain amino acid sequence of SEQ ID NO. 435 and a DVD light chain amino acid sequence of SEQ ID NO: 436. In another embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 437 and a DVD light chain amino acid sequence of SEQ ID NO: 438.

In an embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq.
20 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 439 and SEQ ID NO. 441; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 440 and SEQ ID NO. 442. In an embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 439 and a DVD light chain amino acid sequence of SEQ ID
25 NO: 440. In another embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 441 and a DVD light chain amino acid sequence of SEQ ID NO: 442.

In a second embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-
4 (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting
30 of SEQ ID NO. 443 and SEQ ID NO. 445; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 444 and SEQ ID NO. 446. In an embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 443 and a DVD light chain amino acid sequence of SEQ ID NO: 444. In another embodiment, the binding protein capable of binding VEGF (seq. 3)
35 and DLL-4 (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 445 and a DVD light chain amino acid sequence of SEQ ID NO: 446.

In a third embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 447 and SEQ ID NO. 449; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 448 and SEQ ID NO. 450. In an embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 447 and a DVD light chain amino acid sequence of SEQ ID NO: 448. In another embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 449 and a DVD light chain amino acid sequence of SEQ ID NO: 450.

In a fourth embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 451 and SEQ ID NO. 453; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 452 and SEQ ID NO. 454. In an embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 451 and a DVD light chain amino acid sequence of SEQ ID NO: 452. In another embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 453 and a DVD light chain amino acid sequence of SEQ ID NO: 454.

In an embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 455 and SEQ ID NO. 457; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 456 and SEQ ID NO. 458. In an embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 455 and a DVD light chain amino acid sequence of SEQ ID NO: 456. In another embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 457 and a DVD light chain amino acid sequence of SEQ ID NO: 458.

In a second embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 459 and SEQ ID NO. 461; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 460 and SEQ ID NO. 462. In an embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 459 and a DVD light chain amino acid sequence of SEQ ID NO: 460. In another embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 461 and a DVD light chain amino acid sequence of SEQ ID NO: 462.

In a third embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 463 and SEQ ID NO. 465; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 464 and SEQ ID NO. 466. In an embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 463 and a DVD light chain amino acid sequence of SEQ ID NO: 464. In another embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 465 and a DVD light chain amino acid sequence of SEQ ID NO: 466.

In a fourth embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 467 and SEQ ID NO. 469; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 468 and SEQ ID NO. 470. In an embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 467 and a DVD light chain amino acid sequence of SEQ ID NO: 468. In another embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 469 and a DVD light chain amino acid sequence of SEQ ID NO: 470.

In an embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 471 and SEQ ID NO. 473; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 472 and SEQ ID NO. 474. In an embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 471 and a DVD light chain amino acid sequence of SEQ ID NO: 472. In another embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 473 and a DVD light chain amino acid sequence of SEQ ID NO: 474.

In a second embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 475 and SEQ ID NO. 477; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 476 and SEQ ID NO. 478. In an embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 475 and a DVD light chain amino acid sequence of SEQ ID NO: 476. In another embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 477 and a DVD light chain amino acid sequence of SEQ ID NO: 478.

In a third embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 479 and SEQ ID NO. 481; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 480 and SEQ ID NO. 482. In an embodiment, the
5 binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 479 and a DVD light chain amino acid sequence of SEQ ID NO: 480. In another embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 481 and a DVD light chain amino acid sequence of SEQ ID NO: 482.

10 In a fourth embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 483 and SEQ ID NO. 485; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 484 and SEQ ID NO. 486. In an embodiment, the
15 binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 483 and a DVD light chain amino acid sequence of SEQ ID NO: 484. In another embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 485 and a DVD light chain amino acid sequence of SEQ ID NO: 486.

In an embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ
20 ID NO. 487 and SEQ ID NO. 489; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 488 and SEQ ID NO. 490. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 487 and a DVD light chain amino acid sequence of SEQ ID
25 NO: 488. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 489 and a DVD light chain amino acid sequence of SEQ ID NO: 490.

In a second embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting
30 of SEQ ID NO. 491 and SEQ ID NO. 493; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 492 and SEQ ID NO. 494. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 491 and a DVD light chain amino acid sequence of
35 SEQ ID NO: 492. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 493 and a DVD light chain amino acid sequence of SEQ ID NO: 494.

In a third embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 495 and SEQ ID NO. 497; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 496 and SEQ ID NO. 498. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 495 and a DVD light chain amino acid sequence of SEQ ID NO: 496. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 497 and a DVD light chain amino acid sequence of SEQ ID NO: 498.

In an embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 499 and SEQ ID NO. 501; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 500 and SEQ ID NO. 502. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 499 and a DVD light chain amino acid sequence of SEQ ID NO: 500. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 501 and a DVD light chain amino acid sequence of SEQ ID NO: 502.

In a second embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 503 and SEQ ID NO. 505; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 504 and SEQ ID NO. 506. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 503 and a DVD light chain amino acid sequence of SEQ ID NO: 504. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 505 and a DVD light chain amino acid sequence of SEQ ID NO: 506.

In a third embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 507 and SEQ ID NO. 509; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 508 and SEQ ID NO. 510. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 507 and a DVD light chain amino acid sequence of SEQ ID NO: 508. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 509 and a DVD light chain amino acid sequence of SEQ ID NO: 510.

In a fourth embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 511 and SEQ ID NO. 513; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 512 and SEQ ID NO. 514. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 511 and a DVD light chain amino acid sequence of SEQ ID NO: 512. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 513 and a DVD light chain amino acid sequence of SEQ ID NO: 514.

In an embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 515 and SEQ ID NO. 517; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 516 and SEQ ID NO. 518. In an embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 515 and a DVD light chain amino acid sequence of SEQ ID NO: 516. In another embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 517 and a DVD light chain amino acid sequence of SEQ ID NO: 518.

In a second embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 519 and SEQ ID NO. 521; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 520 and SEQ ID NO. 522. In an embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 519 and a DVD light chain amino acid sequence of SEQ ID NO: 520. In another embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 521 and a DVD light chain amino acid sequence of SEQ ID NO: 522.

In a third embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 523 and SEQ ID NO. 525; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 524 and SEQ ID NO. 526. In an embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 523 and a DVD light chain amino acid sequence of SEQ ID NO: 524. In another embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 525 and a DVD light chain amino acid sequence of SEQ ID NO: 526.

In a fourth embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 527 and SEQ ID NO. 529; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 528 and SEQ ID NO. 530. In an embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 527 and a DVD light chain amino acid sequence of SEQ ID NO: 528. In another embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 529 and a DVD light chain amino acid sequence of SEQ ID NO: 530.

In an embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 531 and SEQ ID NO. 533; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 532 and SEQ ID NO. 534. In an embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 531 and a DVD light chain amino acid sequence of SEQ ID NO: 532. In another embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 533 and a DVD light chain amino acid sequence of SEQ ID NO: 534.

In a second embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 535 and SEQ ID NO. 537; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 536 and SEQ ID NO. 538. In an embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 535 and a DVD light chain amino acid sequence of SEQ ID NO: 536. In another embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 537 and a DVD light chain amino acid sequence of SEQ ID NO: 538.

In a third embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 539 and SEQ ID NO. 541; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 540 and SEQ ID NO. 542. In an embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 539 and a DVD light chain amino acid sequence of SEQ ID NO: 540. In another embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 541 and a DVD light chain amino acid sequence of SEQ ID NO: 542.

In a fourth embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 543 and SEQ ID NO. 545; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 544 and SEQ ID NO. 546. In an embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 543 and a DVD light chain amino acid sequence of SEQ ID NO: 544. In another embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 545 and a DVD light chain amino acid sequence of SEQ ID NO: 546.

In an embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 4) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 547 and SEQ ID NO. 549; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 548 and SEQ ID NO. 550. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 4) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 547 and a DVD light chain amino acid sequence of SEQ ID NO: 548. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 4) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 549 and a DVD light chain amino acid sequence of SEQ ID NO: 550.

In a second embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 4) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 551 and SEQ ID NO. 553; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO.552 and SEQ ID NO. 554. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 4) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 551 and a DVD light chain amino acid sequence of SEQ ID NO: 552. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 4) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 553 and a DVD light chain amino acid sequence of SEQ ID NO: 554.

In a third embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 4) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 555 and SEQ ID NO. 557; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 556 and SEQ ID NO. 558. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 4) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 555 and a DVD light chain amino acid sequence of SEQ ID NO: 556. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 4) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 557 and a DVD light chain amino acid sequence of SEQ ID NO: 558.

In a fourth embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 4) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 559 and SEQ ID NO. 561; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 560 and SEQ ID NO. 562. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 4) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 559 and a DVD light chain amino acid sequence of SEQ ID NO: 560. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and DLL-4 (seq. 4) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 561 and a DVD light chain amino acid sequence of SEQ ID NO: 562.

In an embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 4) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 563 and SEQ ID NO. 565; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 564 and SEQ ID NO. 566. In an embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 4) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 563 and a DVD light chain amino acid sequence of SEQ ID NO: 564. In another embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 4) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 565 and a DVD light chain amino acid sequence of SEQ ID NO: 566.

In a second embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 4) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 567 and SEQ ID NO. 569; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 568 and SEQ ID NO. 570. In an embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 4) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 567 and a DVD light chain amino acid sequence of SEQ ID NO: 568. In another embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 4) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 569 and a DVD light chain amino acid sequence of SEQ ID NO: 570.

In a third embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 4) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 571 and SEQ ID NO. 573; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 572 and SEQ ID NO. 574. In an embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 4) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 571 and a DVD light chain amino acid sequence of SEQ ID NO: 572. In another embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 4.) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 573 and a DVD light chain amino acid sequence of SEQ ID NO: 574.

In a fourth embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 4) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 575 and SEQ ID NO. 577; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 576 and SEQ ID NO. 578. In an embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 4) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 575 and a DVD light chain amino acid sequence of SEQ ID NO: 576. In another embodiment, the binding protein capable of binding VEGF (seq. 2) and DLL-4 (seq. 4) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 577 and a DVD light chain amino acid sequence of SEQ ID NO: 578.

In an embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 4) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 579 and SEQ ID NO. 581; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 580 and SEQ ID NO. 582. In an embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 4) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 579 and a DVD light chain amino acid sequence of SEQ ID NO: 580. In another embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 4) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 581 and a DVD light chain amino acid sequence of SEQ ID NO: 582.

In a second embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 4) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 583 and SEQ ID NO. 585; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 584 and SEQ ID NO. 586. In an embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 4) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 583 and a DVD light chain amino acid sequence of SEQ ID NO: 584. In another embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 4) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 585 and a DVD light chain amino acid sequence of SEQ ID NO: 586.

In a third embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 4) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 587 and SEQ ID NO. 589; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 588 and SEQ ID NO. 590. In an embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 4) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 587 and a DVD light chain amino acid sequence of SEQ ID NO: 588. In another embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 4) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 589 and a DVD light chain amino acid sequence of SEQ ID NO: 590.

In a fourth embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 4) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 591 and SEQ ID NO. 593; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 592 and SEQ ID NO. 594. In an embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 4) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 591 and a DVD light chain amino acid sequence of SEQ ID NO: 592. In another embodiment, the binding protein capable of binding VEGF (seq. 3) and DLL-4 (seq. 4) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 593 and a DVD light chain amino acid sequence of SEQ ID NO: 594.

In an embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 595 and SEQ ID NO. 597; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 596 and SEQ ID NO. 598. In an embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 595 and a DVD light chain amino acid sequence of SEQ ID NO: 596. In another embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 597 and a DVD light chain amino acid sequence of SEQ ID NO: 598.

In a second embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 599 and SEQ ID NO. 601; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 600 and SEQ ID NO. 602. In an embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 599 and a DVD light chain amino acid sequence of SEQ ID NO: 600. In another embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 601 and a DVD light chain amino acid sequence of SEQ ID NO: 602.

In a third embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 603 and SEQ ID NO. 605; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 604 and SEQ ID NO. 606. In an embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 603 and a DVD light chain amino acid sequence of SEQ ID NO: 604. In another embodiment, the binding protein capable of binding HER-2 (seq. 1)

and ErbB3 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 605 and a DVD light chain amino acid sequence of SEQ ID NO: 606.

In a fourth embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 607 and SEQ ID NO. 609; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 608 and SEQ ID NO. 610. In an embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 607 and a DVD light chain amino acid sequence of SEQ ID NO: 608. In another embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 609 and a DVD light chain amino acid sequence of SEQ ID NO: 610.

In an embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 611 and SEQ ID NO. 613; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 612 and SEQ ID NO. 614. In an embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 611 and a DVD light chain amino acid sequence of SEQ ID NO: 612. In another embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 613 and a DVD light chain amino acid sequence of SEQ ID NO: 614.

In a second embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 615 and SEQ ID NO. 617; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 616 and SEQ ID NO. 618. In an embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 615 and a DVD light chain amino acid sequence of SEQ ID NO: 616. In another embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 617 and a DVD light chain amino acid sequence of SEQ ID NO: 618.

In a third embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 619 and SEQ ID NO. 621; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 622 and SEQ ID NO. 624. In an embodiment, the

binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 619 and a DVD light chain amino acid sequence of SEQ ID NO: 620. In another embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid
5 sequence of SEQ ID NO. 621 and a DVD light chain amino acid sequence of SEQ ID NO: 622.

In a fourth embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 623 and SEQ ID NO. 625; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 624 and SEQ ID NO. 626. In an embodiment,
10 the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 623 and a DVD light chain amino acid sequence of SEQ ID NO: 624. In another embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 625 and a DVD light chain amino acid sequence of SEQ ID
15 NO: 626.

In an embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 627 and SEQ ID NO. 629; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 628 and SEQ ID NO. 630. In an embodiment, the binding
20 protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 627 and a DVD light chain amino acid sequence of SEQ ID NO: 628. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 629 and a DVD light chain amino acid sequence of SEQ ID NO: 630.

In a second embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 631 and SEQ ID NO. 633; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 632 and SEQ ID NO. 634. In an embodiment,
25 the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 631 and a DVD light chain amino acid sequence of SEQ ID NO: 632. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 633 and a DVD light chain amino acid sequence of SEQ ID NO: 634.

In a third embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3
35 (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of

SEQ ID NO. 635 and SEQ ID NO. 637; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 636 and SEQ ID NO. 638. In an embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 635 and a DVD light chain amino acid sequence of SEQ ID NO: 636. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 637 and a DVD light chain amino acid sequence of SEQ ID NO: 638.

In a fourth embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 639 and SEQ ID NO. 641; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 640 and SEQ ID NO. 642. In an embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 639 and a DVD light chain amino acid sequence of SEQ ID NO: 640. In another embodiment, the binding protein capable of binding EGFR (seq. 2) and ErbB3 (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 641 and a DVD light chain amino acid sequence of SEQ ID NO: 642.

In an embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 643 and SEQ ID NO. 645; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 644 and SEQ ID NO. 646. In an embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 643 and a DVD light chain amino acid sequence of SEQ ID NO: 644. In another embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 645 and a DVD light chain amino acid sequence of SEQ ID NO: 646.

In a second embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 647 and SEQ ID NO. 649; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 648 and SEQ ID NO. 650. In an embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 647 and a DVD light chain amino acid sequence of SEQ ID NO: 648. In another embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 649 and a DVD light chain amino acid sequence of SEQ ID NO: 650.

In a third embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 651 and SEQ ID NO. 653; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 652 and SEQ ID NO. 654. In an embodiment, the
5 binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 651 and a DVD light chain amino acid sequence of SEQ ID NO: 652. In another embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 653 and a DVD light chain amino acid sequence of SEQ ID NO: 654.

10 In a fourth embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 655 and SEQ ID NO. 657; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 656 and SEQ ID NO. 658. In an embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 3) comprises a DVD
15 heavy chain amino acid sequence of SEQ ID NO. 655 and a DVD light chain amino acid sequence of SEQ ID NO: 656. In another embodiment, the binding protein capable of binding HER-2 (seq. 1) and ErbB3 (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 657 and a DVD light chain amino acid sequence of SEQ ID NO: 658.

20 In an embodiment, the binding protein capable of binding VEGF (seq. 1) and PLGF (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 659 and SEQ ID NO. 661; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 660 and SEQ ID NO. 662. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and PLGF (seq. 2) comprises a DVD heavy chain
25 amino acid sequence of SEQ ID NO. 659 and a DVD light chain amino acid sequence of SEQ ID NO: 660. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and PLGF (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 661 and a DVD light chain amino acid sequence of SEQ ID NO: 662.

In a second embodiment, the binding protein capable of binding VEGF (seq. 1) and PLGF
30 (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 663 and SEQ ID NO. 665; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 664 and SEQ ID NO. 666. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and PLGF (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 663 and a DVD light chain amino acid sequence of
35 SEQ ID NO: 664. In another embodiment, the binding protein capable of binding VEGF (seq. 1)

and PLGF (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 665 and a DVD light chain amino acid sequence of SEQ ID NO: 666.

In a third embodiment, the binding protein capable of binding VEGF (seq. 1) and PLGF (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 667 and SEQ ID NO. 669; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 668 and SEQ ID NO. 670. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and PLGF (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 667 and a DVD light chain amino acid sequence of SEQ ID NO: 668. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and PLGF (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 669 and a DVD light chain amino acid sequence of SEQ ID NO: 670.

In a fourth embodiment, the binding protein capable of binding VEGF (seq. 1) and PLGF (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 671 and SEQ ID NO. 673; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 672 and SEQ ID NO. 674. In an embodiment, the binding protein capable of binding VEGF (seq. 1) and PLGF (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 671 and a DVD light chain amino acid sequence of SEQ ID NO: 672. In another embodiment, the binding protein capable of binding VEGF (seq. 1) and PLGF (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 673 and a DVD light chain amino acid sequence of SEQ ID NO: 674.

In an embodiment, the binding protein capable of binding VEGF (seq. 2) and PLGF (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 675 and SEQ ID NO. 677; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 676 and SEQ ID NO. 678. In an embodiment, the binding protein capable of binding VEGF (seq. 2) and PLGF (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 675 and a DVD light chain amino acid sequence of SEQ ID NO: 676. In another embodiment, the binding protein capable of binding VEGF (seq. 2) and PLGF (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 677 and a DVD light chain amino acid sequence of SEQ ID NO: 678.

In a second embodiment, the binding protein capable of binding VEGF (seq. 2) and PLGF (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 679 and SEQ ID NO. 681; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 680 and SEQ ID NO. 682. In an embodiment, the binding protein capable of binding VEGF (seq. 2) and PLGF (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 679 and a DVD light chain amino acid sequence of

SEQ ID NO: 680. In another embodiment, the binding protein capable of binding VEGF (seq. 2) and PLGF (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 681 and a DVD light chain amino acid sequence of SEQ ID NO: 682.

In a third embodiment, the binding protein capable of binding VEGF (seq. 2) and PLGF
5 (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 683 and SEQ ID NO. 685; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 684 and SEQ ID NO. 686. In an embodiment, the binding protein capable of binding VEGF (seq. 2) and PLGF (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 683 and a DVD light chain amino acid sequence of
10 SEQ ID NO: 684. In another embodiment, the binding protein capable of binding VEGF (seq. 2) and PLGF (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 685 and a DVD light chain amino acid sequence of SEQ ID NO: 686.

In a fourth embodiment, the binding protein capable of binding VEGF (seq. 2) and PLGF
15 (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 687 and SEQ ID NO. 689; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 688 and SEQ ID NO. 690. In an embodiment, the binding protein capable of binding VEGF (seq. 2) and PLGF (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 687 and a DVD light chain amino acid sequence of SEQ ID NO: 688. In another embodiment, the binding protein capable of binding VEGF (seq. 2)
20 and PLGF (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 689 and a DVD light chain amino acid sequence of SEQ ID NO: 690.

In an embodiment, the binding protein capable of binding VEGF (seq. 3) and PLGF (seq.
2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 691 and SEQ ID NO. 693; and a DVD light chain amino acid sequence selected from the
25 group consisting of SEQ ID NO. 692 and SEQ ID NO. 694. In an embodiment, the binding protein capable of binding VEGF (seq. 3) and PLGF (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 691 and a DVD light chain amino acid sequence of SEQ ID NO: 692. In another embodiment, the binding protein capable of binding VEGF (seq. 3) and PLGF (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence
30 of SEQ ID NO. 693 and a DVD light chain amino acid sequence of SEQ ID NO: 694

In a second embodiment, the binding protein capable of binding VEGF (seq. 3) and PLGF
(seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of
SEQ ID NO. 695 and SEQ ID NO. 697; and a DVD light chain amino acid sequence selected
from the group consisting of SEQ ID NO. 696 and SEQ ID NO. 698. In an embodiment, the
35 binding protein capable of binding VEGF (seq. 3) and PLGF (seq. 2) comprises a DVD heavy

chain amino acid sequence of SEQ ID NO. 695 and a DVD light chain amino acid sequence of SEQ ID NO: 696. In another embodiment, the binding protein capable of binding VEGF (seq. 3) and PLGF (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 697 and a DVD light chain amino acid sequence of SEQ ID NO: 698.

5 In a third embodiment, the binding protein capable of binding VEGF (seq. 3) and PLGF (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 699 and SEQ ID NO. 701; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 700 and SEQ ID NO. 702. In an embodiment, the binding protein capable of binding VEGF (seq. 3) and PLGF (seq. 2) comprises a DVD heavy
10 chain amino acid sequence of SEQ ID NO. 699 and a DVD light chain amino acid sequence of SEQ ID NO: 700. In another embodiment, the binding protein capable of binding VEGF (seq. 3) and PLGF (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 701 and a DVD light chain amino acid sequence of SEQ ID NO: 702.

 In a fourth embodiment, the binding protein capable of binding VEGF (seq. 3) and PLGF
15 (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 703 and SEQ ID NO. 705; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 704 and SEQ ID NO. 706. In an embodiment, the binding protein capable of binding VEGF (seq. 3) and PLGF (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 703 and a DVD light chain amino acid sequence of
20 SEQ ID NO: 704. In another embodiment, the binding protein capable of binding VEGF (seq. 3) and PLGF (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 705 and a DVD light chain amino acid sequence of SEQ ID NO: 706.

 In an embodiment, the binding protein capable of binding HER-2 (seq. 1) and PLGF (seq.
2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ
25 ID NO. 707 and SEQ ID NO. 709; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 708 and SEQ ID NO. 710. In an embodiment, the binding protein capable of binding HER-2 (seq. 1) and PLGF (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 707 and a DVD light chain amino acid sequence of SEQ ID NO: 708. In another embodiment, the binding protein capable of binding HER-2 (seq. 1) and
30 PLGF (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 709 and a DVD light chain amino acid sequence of SEQ ID NO: 710.

 In a second embodiment, the binding protein capable of binding HER-2 (seq. 1) and PLGF (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 711 and SEQ ID NO. 713; and a DVD light chain amino acid sequence
35 selected from the group consisting of SEQ ID NO. 712 and SEQ ID NO. 714. In an embodiment,

the binding protein capable of binding HER-2 (seq. 1) and PLGF (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 711 and a DVD light chain amino acid sequence of SEQ ID NO: 712. In another embodiment, the binding protein capable of binding HER-2 (seq. 1) and PLGF (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid
5 sequence of SEQ ID NO. 713 and a DVD light chain amino acid sequence of SEQ ID NO: 714.

In a third embodiment, the binding protein capable of binding HER-2 (seq. 1) and PLGF (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 715 and SEQ ID NO. 717; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 716 and SEQ ID NO. 718. In an embodiment, the
10 binding protein capable of binding HER-2 (seq. 1) and PLGF (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 715 and a DVD light chain amino acid sequence of SEQ ID NO: 716. In another embodiment, the binding protein capable of binding HER-2 (seq. 1) and PLGF (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 717 and a DVD light chain amino acid sequence of SEQ ID NO: 718.

In a fourth embodiment, the binding protein capable of binding HER-2 (seq. 1) and PLGF (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 719 and SEQ ID NO. 721; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 720 and SEQ ID NO. 722. In an embodiment, the
15 binding protein capable of binding HER-2 (seq. 1) and PLGF (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 719 and a DVD light chain amino acid sequence of SEQ ID NO: 720. In another embodiment, the binding protein capable of binding HER-2 (seq. 1) and PLGF (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 721 and a DVD light chain amino acid sequence of SEQ ID NO: 722.

In an embodiment, the binding protein capable of binding PLGF (seq. 1) and VEGF (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 723 and SEQ ID NO. 725; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 724 and SEQ ID NO. 726. In an embodiment, the binding
25 protein capable of binding PLGF (seq. 1) and VEGF (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 723 and a DVD light chain amino acid sequence of SEQ ID NO: 724. In another embodiment, the binding protein capable of binding PLGF (seq. 1) and VEGF (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 725 and a DVD light chain amino acid sequence of SEQ ID NO: 726.

In a second embodiment, the binding protein capable of binding PLGF (seq. 1) and VEGF (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of
35 SEQ ID NO. 727 and SEQ ID NO. 729; and a DVD light chain amino acid sequence selected

from the group consisting of SEQ ID NO. 728 and SEQ ID NO. 730. In an embodiment, the binding protein capable of binding PLGF (seq. 1) and VEGF (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 727 and a DVD light chain amino acid sequence of SEQ ID NO: 728. In another embodiment, the binding protein capable of binding PLGF (seq. 1) and VEGF (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 729 and a DVD light chain amino acid sequence of SEQ ID NO: 730.

In a third embodiment, the binding protein capable of binding PLGF (seq. 1) and VEGF (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 731 and SEQ ID NO. 733; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 732 and SEQ ID NO. 734. In an embodiment, the binding protein capable of binding PLGF (seq. 1) and VEGF (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 731 and a DVD light chain amino acid sequence of SEQ ID NO: 732. In another embodiment, the binding protein capable of binding PLGF (seq. 1) and VEGF (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 733 and a DVD light chain amino acid sequence of SEQ ID NO: 734.

In a fourth embodiment, the binding protein capable of binding PLGF (seq. 1) and VEGF (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 735 and SEQ ID NO. 737; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 736 and SEQ ID NO. 738. In an embodiment, the binding protein capable of binding PLGF (seq. 1) and VEGF (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 735 and a DVD light chain amino acid sequence of SEQ ID NO: 736. In another embodiment, the binding protein capable of binding PLGF (seq. 1) and VEGF (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 737 and a DVD light chain amino acid sequence of SEQ ID NO: 738.

In an embodiment, the binding protein capable of binding PLGF (seq. 1) and VEGF (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 739 and SEQ ID NO. 741; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 740 and SEQ ID NO. 742. In an embodiment, the binding protein capable of binding PLGF (seq. 1) and VEGF (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 739 and a DVD light chain amino acid sequence of SEQ ID NO: 740. In another embodiment, the binding protein capable of binding PLGF (seq. 1) and VEGF (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 741 and a DVD light chain amino acid sequence of SEQ ID NO: 742.

In a second embodiment, the binding protein capable of binding PLGF (seq. 1) and VEGF (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of

SEQ ID NO. 743 and SEQ ID NO. 745; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 744 and SEQ ID NO. 746. In an embodiment, the binding protein capable of binding PLGF (seq. 1) and VEGF (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 743 and a DVD light chain amino acid sequence of SEQ ID NO: 744. In another embodiment, the binding protein capable of binding PLGF (seq. 1) and VEGF (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 745 and a DVD light chain amino acid sequence of SEQ ID NO: 746.

In a third embodiment, the binding protein capable of binding PLGF (seq. 1) and VEGF (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 747 and SEQ ID NO. 749; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 748 and SEQ ID NO. 750. In an embodiment, the binding protein capable of binding PLGF (seq. 1) and VEGF (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 747 and a DVD light chain amino acid sequence of SEQ ID NO: 748. In another embodiment, the binding protein capable of binding PLGF (seq. 1) and VEGF (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 749 and a DVD light chain amino acid sequence of SEQ ID NO: 750.

In a fourth embodiment, the binding protein capable of binding PLGF (seq. 1) and VEGF (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 751 and SEQ ID NO. 753; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 752 and SEQ ID NO. 754. In an embodiment, the binding protein capable of binding PLGF (seq. 1) and VEGF (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 751 and a DVD light chain amino acid sequence of SEQ ID NO: 752. In another embodiment, the binding protein capable of binding PLGF (seq. 1) and VEGF (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 753 and a DVD light chain amino acid sequence of SEQ ID NO: 754.

In an embodiment, the binding protein capable of binding HER-2 (seq. 1) and PLGF (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 755 and SEQ ID NO. 757; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 756 and SEQ ID NO. 758. In an embodiment, the binding protein capable of binding HER-2 (seq. 1) and PLGF (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 755 and a DVD light chain amino acid sequence of SEQ ID NO: 756. In another embodiment, the binding protein capable of binding HER-2 (seq. 1) and PLGF (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 757 and a DVD light chain amino acid sequence of SEQ ID NO: 758.

In a second embodiment, the binding protein capable of binding HER-2 (seq. 1) and PLGF (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 759 and SEQ ID NO. 761; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 760 and SEQ ID NO. 762. In an embodiment, the binding protein capable of binding HER-2 (seq. 1) and PLGF (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 759 and a DVD light chain amino acid sequence of SEQ ID NO: 760. In another embodiment, the binding protein capable of binding HER-2 (seq. 1) and PLGF (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 761 and a DVD light chain amino acid sequence of SEQ ID NO: 762.

10 In a third embodiment, the binding protein capable of binding HER-2 (seq. 1) and PLGF (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 763 and SEQ ID NO. 765; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 764 and SEQ ID NO. 766. In an embodiment, the binding protein capable of binding HER-2 (seq. 1) and PLGF (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 763 and a DVD light chain amino acid sequence of SEQ ID NO: 764. In another embodiment, the binding protein capable of binding HER-2 (seq. 1) and PLGF (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 765 and a DVD light chain amino acid sequence of SEQ ID NO: 766.

In a fourth embodiment, the binding protein capable of binding HER-2 (seq. 1) and PLGF (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 767 and SEQ ID NO. 769; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 768 and SEQ ID NO. 770. In an embodiment, the binding protein capable of binding HER-2 (seq. 1) and PLGF (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 767 and a DVD light chain amino acid sequence of SEQ ID NO: 768. In another embodiment, the binding protein capable of binding HER-2 (seq. 1) and PLGF (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 769 and a DVD light chain amino acid sequence of SEQ ID NO: 770.

In an embodiment, the binding protein capable of binding HGF (seq. 1) and VEGF (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 771 and SEQ ID NO. 773; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 772 and SEQ ID NO. 774. In an embodiment, the binding protein capable of binding HGF (seq. 1) and VEGF (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 771 and a DVD light chain amino acid sequence of SEQ ID NO: 772. In another embodiment, the binding protein capable of binding HGF (seq. 1) and VEGF (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 773 and a DVD light chain amino acid sequence of SEQ ID NO: 774.

In a second embodiment, the binding protein capable of binding HGF (seq. 1) and VEGF (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 775 and SEQ ID NO. 777; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 776 and SEQ ID NO. 778. In an embodiment, the binding protein capable of binding HGF (seq. 1) and VEGF (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 775 and a DVD light chain amino acid sequence of SEQ ID NO: 776. In another embodiment, the binding protein capable of binding HGF (seq. 1) and VEGF (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 777 and a DVD light chain amino acid sequence of SEQ ID NO: 778.

10 In a third embodiment, the binding protein capable of binding HGF (seq. 1) and VEGF (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 779 and SEQ ID NO. 781; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 780 and SEQ ID NO. 782. In an embodiment, the binding protein capable of binding HGF (seq. 1) and VEGF (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 779 and a DVD light chain amino acid sequence of SEQ ID NO: 780. In another embodiment, the binding protein capable of binding HGF (seq. 1) and VEGF (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 781 and a DVD light chain amino acid sequence of SEQ ID NO: 782.

In a fourth embodiment, the binding protein capable of binding HGF (seq. 1) and VEGF (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 783 and SEQ ID NO. 785; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 784 and SEQ ID NO. 786. In an embodiment, the binding protein capable of binding HGF (seq. 1) and VEGF (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 783 and a DVD light chain amino acid sequence of SEQ ID NO: 784. In another embodiment, the binding protein capable of binding HGF (seq. 1) and VEGF (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 785 and a DVD light chain amino acid sequence of SEQ ID NO: 786.

In an embodiment, the binding protein capable of binding HGF (seq. 1) and VEGF (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 787 and SEQ ID NO. 789; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 788 and SEQ ID NO. 790. In an embodiment, the binding protein capable of binding HGF (seq. 1) and VEGF (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 787 and a DVD light chain amino acid sequence of SEQ ID NO: 788. In another embodiment, the binding protein capable of binding HGF (seq. 1) and VEGF (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 789 and a DVD light chain amino acid sequence of SEQ ID NO: 790.

In a second embodiment, the binding protein capable of binding HGF (seq. 1) and VEGF (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 791 and SEQ ID NO. 793; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 792 and SEQ ID NO. 794. In an embodiment, the binding protein capable of binding HGF (seq. 1) and VEGF (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 791 and a DVD light chain amino acid sequence of SEQ ID NO: 792. In another embodiment, the binding protein capable of binding HGF (seq. 1) and VEGF (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 793 and a DVD light chain amino acid sequence of SEQ ID NO: 794.

10 In a third embodiment, the binding protein capable of binding HGF (seq. 1) and VEGF (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 795 and SEQ ID NO. 797; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 796 and SEQ ID NO. 798. In an embodiment, the binding protein capable of binding HGF (seq. 1) and VEGF (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 795 and a DVD light chain amino acid sequence of SEQ ID NO: 796. In another embodiment, the binding protein capable of binding HGF (seq. 1) and VEGF (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 797 and a DVD light chain amino acid sequence of SEQ ID NO: 798.

In a fourth embodiment, the binding protein capable of binding HGF (seq. 1) and VEGF (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 799 and SEQ ID NO. 801; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 800 and SEQ ID NO. 802. In an embodiment, the binding protein capable of binding HGF (seq. 1) and VEGF (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 799 and a DVD light chain amino acid sequence of SEQ ID NO: 800. In another embodiment, the binding protein capable of binding HGF (seq. 1) and VEGF (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 801 and a DVD light chain amino acid sequence of SEQ ID NO: 802.

In an embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 803 and SEQ ID NO. 805; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 804 and SEQ ID NO. 806. In an embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 803 and a DVD light chain amino acid sequence of SEQ ID NO: 804. In another embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 805 and a DVD light chain amino acid sequence of SEQ ID NO: 806.

In a second embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 807 and SEQ ID NO. 809; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 808 and SEQ ID NO. 810. In an embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 807 and a DVD light chain amino acid sequence of SEQ ID NO: 808. In another embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 809 and a DVD light chain amino acid sequence of SEQ ID NO: 810.

10 In a third embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 811 and SEQ ID NO. 813; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 812 and SEQ ID NO. 814. In an embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 811 and a DVD light chain amino acid sequence of SEQ ID NO: 812. In another embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 813 and a DVD light chain amino acid sequence of SEQ ID NO: 814.

In a fourth embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 1) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 815 and SEQ ID NO. 817; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 816 and SEQ ID NO. 818. In an embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 1) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 815 and a DVD light chain amino acid sequence of SEQ ID NO: 816. In another embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 1) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 817 and a DVD light chain amino acid sequence of SEQ ID NO: 818.

In an embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 819 and SEQ ID NO. 821; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 820 and SEQ ID NO. 822. In an embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 819 and a DVD light chain amino acid sequence of SEQ ID NO: 820. In another embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 821 and a DVD light chain amino acid sequence of SEQ ID NO: 822.

In a second embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 823 and SEQ ID NO. 825; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 824 and SEQ ID NO. 826. In an embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 823 and a DVD light chain amino acid sequence of SEQ ID NO: 824. In another embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 825 and a DVD light chain amino acid sequence of SEQ ID NO: 826.

10 In a third embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 827 and SEQ ID NO. 829; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 828 and SEQ ID NO. 830. In an embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 827 and a DVD light chain amino acid sequence of SEQ ID NO: 828. In another embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 829 and a DVD light chain amino acid sequence of SEQ ID NO: 830.

In a fourth embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 831 and SEQ ID NO. 833; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 832 and SEQ ID NO. 834. In an embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 831 and a DVD light chain amino acid sequence of SEQ ID NO: 832. In another embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 833 and a DVD light chain amino acid sequence of SEQ ID NO: 834.

In an embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 835 and SEQ ID NO. 837; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 836 and SEQ ID NO. 838. In an embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 835 and a DVD light chain amino acid sequence of SEQ ID NO: 836. In another embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 837 and a DVD light chain amino acid sequence of SEQ ID NO: 838.

In a second embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 839 and SEQ ID NO. 841; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 840 and SEQ ID NO. 842. In an embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 839 and a DVD light chain amino acid sequence of SEQ ID NO: 840. In another embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 841 and a DVD light chain amino acid sequence of SEQ ID NO: 842.

10 In a third embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 843 and SEQ ID NO. 845; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 844 and SEQ ID NO. 846. In an embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 843 and a DVD light chain amino acid sequence of SEQ ID NO: 844. In another embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 845 and a DVD light chain amino acid sequence of SEQ ID NO: 846.

In a fourth embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 3) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 847 and SEQ ID NO. 849; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 848 and SEQ ID NO. 850. In an embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 3) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 847 and a DVD light chain amino acid sequence of SEQ ID NO: 848. In another embodiment, the binding protein capable of binding HGF (seq. 2) and VEGF (seq. 3) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 849 and a DVD light chain amino acid sequence of SEQ ID NO: 850.

In an embodiment, the binding protein capable of binding HER-2 (seq. 1) and HER-2 (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 851 and SEQ ID NO. 853; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 852 and SEQ ID NO. 854. In an embodiment, the binding protein capable of binding HER-2 (seq. 1) and HER-2 (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 851 and a DVD light chain amino acid sequence of SEQ ID NO: 852. In another embodiment, the binding protein capable of binding HER-2 (seq. 1) and HER-2 (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 853 and a DVD light chain amino acid sequence of SEQ ID NO: 854.

In a second embodiment, the binding protein capable of binding HER-2 (seq. 1) and HER-2 (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 855 and SEQ ID NO. 857; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 856 and SEQ ID NO. 858. In an embodiment, the binding protein capable of binding HER-2 (seq. 1) and HER-2 (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 855 and a DVD light chain amino acid sequence of SEQ ID NO: 856. In another embodiment, the binding protein capable of binding HER-2 (seq. 1) and HER-2 (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 857 and a DVD light chain amino acid sequence of SEQ ID NO: 858.

In a third embodiment, the binding protein capable of binding HER-2 (seq. 1) and HER-2 (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 859 and SEQ ID NO. 861; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 860 and SEQ ID NO. 862. In an embodiment, the binding protein capable of binding HER-2 (seq. 1) and HER-2 (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 859 and a DVD light chain amino acid sequence of SEQ ID NO: 860. In another embodiment, the binding protein capable of binding HER-2 (seq. 1) and HER-2 (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 861 and a DVD light chain amino acid sequence of SEQ ID NO: 862.

In a fourth embodiment, the binding protein capable of binding HER-2 (seq. 1) and HER-2 (seq. 2) comprises a DVD heavy chain amino acid sequence selected from the group consisting of SEQ ID NO. 863 and SEQ ID NO. 865; and a DVD light chain amino acid sequence selected from the group consisting of SEQ ID NO. 864 and SEQ ID NO. 866. In an embodiment, the binding protein capable of binding HER-2 (seq. 1) and HER-2 (seq. 2) comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 863 and a DVD light chain amino acid sequence of SEQ ID NO: 864. In another embodiment, the binding protein capable of binding HER-2 (seq. 1) and HER-2 (seq. 2) has a reverse orientation and comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 865 and a DVD light chain amino acid sequence of SEQ ID NO: 866.

In another embodiment the invention provides a binding protein comprising a polypeptide chain, wherein said polypeptide chain comprises $VD1-(X1)_n-VD2-C-(X2)_n$, wherein; VD1 is a first heavy chain variable domain obtained from a first parent antibody or antigen binding portion thereof; VD2 is a second heavy chain variable domain obtained from a second parent antibody or antigen binding portion thereof; C is a heavy chain constant domain; $(X1)_n$ is a linker with the proviso that it is not CH1, wherein said $(X1)_n$ is either present or absent; and $(X2)_n$ is an Fc region, wherein said $(X2)_n$ is either present or absent. In an embodiment, the Fc region is absent from the binding protein.

In another embodiment, the invention provides a binding protein comprising a polypeptide chain, wherein said polypeptide chain comprises VD1-(X1)_n-VD2-C-(X2)_n, wherein, VD1 is a first light chain variable domain obtained from a first parent antibody or antigen binding portion thereof; VD2 is a second light chain variable domain obtained from a second parent antibody or antigen binding portion thereof; C is a light chain constant domain; (X1)_n is a linker with the proviso that it is not CH1, wherein said (X1)_n is either present or absent; and (X2)_n does not comprise an Fc region, wherein said (X2)_n is either present or absent. In an embodiment, (X2)_n is absent from the binding protein.

In another embodiment the binding protein of the invention comprises first and second polypeptide chains, wherein said first polypeptide chain comprises a first VD1-(X1)_n-VD2-C-(X2)_n, wherein VD1 is a first heavy chain variable domain obtained from a first parent antibody or antigen binding portion thereof; VD2 is a second heavy chain variable domain obtained from a second parent antibody or antigen binding portion thereof; C is a heavy chain constant domain; (X1)_n is a linker with the proviso that it is not CH1, wherein said (X1)_n is either present or absent; and (X2)_n is an Fc region, wherein said (X2)_n is either present or absent; and wherein said second polypeptide chain comprises a second VD1-(X1)_n-VD2-C-(X2)_n, wherein VD1 is a first light chain variable domain obtained from a first parent antibody or antigen binding portion thereof; VD2 is a second light chain variable domain obtained from a second parent antibody or antigen binding portion thereof; C is a light chain constant domain; (X1)_n is a linker with the proviso that it is not CH1, wherein said (X1)_n is either present or absent; and (X2)_n does not comprise an Fc region, wherein said (X2)_n is either present or absent. In another embodiment, the binding protein comprises two first polypeptide chains and two second polypeptide chains. In yet another embodiment, (X2)_n is absent from the second polypeptide. In still another embodiment, the Fc region, if present in the first polypeptide is selected from the group consisting of native sequence Fc region and a variant sequence Fc region. In still another embodiment, the Fc region is selected from the group consisting of an Fc region from an IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, and IgD.

In another embodiment the binding protein of the invention is a DVD-Ig capable of binding two antigens comprising four polypeptide chains, wherein, first and third polypeptide chains comprise VD1-(X1)_n-VD2-C-(X2)_n, wherein, VD1 is a first heavy chain variable domain obtained from a first parent antibody or antigen binding portion thereof; VD2 is a second heavy chain variable domain obtained from a second parent antibody or antigen binding portion thereof; C is a heavy chain constant domain; (X1)_n is a linker with the proviso that it is not CH1, wherein said (X1)_n is either present or absent; and (X2)_n is an Fc region, wherein said (X2)_n is either present or absent; and wherein second and fourth polypeptide chains comprise VD1-(X1)_n-VD2-C-(X2)_n, wherein VD1 is a first light chain variable domain obtained from a first parent antibody

or antigen binding portion thereof; VD2 is a second light chain variable domain obtained from a second parent antibody or antigen binding portion thereof; C is a light chain constant domain; (X1)_n is a linker with the proviso that it is not CH1, wherein said (X1)_n is either present or absent; and (X2)_n does not comprise an Fc region, wherein said (X2)_n is either present or absent.

5 The invention provides a method of making a DVD-Ig binding protein by preselecting the parent antibodies. In an embodiment, the method of making a Dual Variable Domain Immunoglobulin capable of binding two antigens comprising the steps of a) obtaining a first parent antibody or antigen binding portion thereof, capable of binding a first antigen; b) obtaining a second parent antibody or antigen binding portion thereof, capable of binding a second antigen; 10 c) constructing first and third polypeptide chains comprising VD1-(X1)_n-VD2-C-(X2)_n, wherein, VD1 is a first heavy chain variable domain obtained from said first parent antibody or antigen binding portion thereof; VD2 is a second heavy chain variable domain obtained from said second parent antibody or antigen binding portion thereof; C is a heavy chain constant domain; (X1)_n is a linker with the proviso that it is not CH1, wherein said (X1)_n is either present or absent; and 15 (X2)_n is an Fc region, wherein said (X2)_n is either present or absent; d) constructing second and fourth polypeptide chains comprising VD1-(X1)_n-VD2-C-(X2)_n, wherein, VD1 is a first light chain variable domain obtained from said first parent antibody or antigen binding portion thereof; VD2 is a second light chain variable domain obtained from said second parent antibody or antigen binding thereof; C is a light chain constant domain; (X1)_n is a linker with the proviso that it is not 20 CH1, wherein said (X1)_n is either present or absent; and (X2)_n does not comprise an Fc region, wherein said (X2)_n is either present or absent; e) expressing said first, second, third and fourth polypeptide chains; such that a Dual Variable Domain Immunoglobulin capable of binding said first and said second antigen is generated.

In still another embodiment, the invention provides a method of generating a Dual 25 Variable Domain Immunoglobulin capable of binding two antigens with desired properties comprising the steps of a) obtaining a first parent antibody or antigen binding portion thereof, capable of binding a first antigen and possessing at least one desired property exhibited by the Dual Variable Domain Immunoglobulin; b) obtaining a second parent antibody or antigen binding portion thereof, capable of binding a second antigen and possessing at least one desired property 30 exhibited by the Dual Variable Domain Immunoglobulin; c) constructing first and third polypeptide chains comprising VD1-(X1)_n-VD2-C-(X2)_n, wherein; VD1 is a first heavy chain variable domain obtained from said first parent antibody or antigen binding portion thereof; VD2 is a second heavy chain variable domain obtained from said second parent antibody or antigen binding portion thereof; C is a heavy chain constant domain; (X1)_n is a linker with the proviso 35 that it is not CH1, wherein said (X1)_n is either present or absent; and (X2)_n is an Fc region, wherein said (X2)_n is either present or absent; d) constructing second and fourth polypeptide

chains comprising VD1-(X1)_n-VD2-C-(X2)_n, wherein; VD1 is a first light chain variable domain obtained from said first parent antibody or antigen binding portion thereof; VD2 is a second light chain variable domain obtained from said second parent antibody or antigen binding portion thereof; C is a light chain constant domain; (X1)_n is a linker with the proviso that it is not CH1, wherein said (X1)_n is either present or absent; and (X2)_n does not comprise an Fc region, wherein said (X2)_n is either present or absent; e) expressing said first, second, third and fourth polypeptide chains; such that a Dual Variable Domain Immunoglobulin capable of binding said first and said second antigen with desired properties is generated.

In one embodiment, the VDI of the first and second polypeptide chains disclosed herein are obtained from the same parent antibody or antigen binding portion thereof. In another embodiment, the VDI of the first and second polypeptide chains disclosed herein are obtained from different parent antibodies or antigen binding portions thereof. In another embodiment, the VD2 of the first and second polypeptide chains disclosed herein are obtained from the same parent antibody or antigen binding portion thereof. In another embodiment, the VD2 of the first and second polypeptide chains disclosed herein are obtained from different parent antibodies or antigen binding portions thereof.

In one embodiment the first parent antibody or antigen binding portion thereof, and the second parent antibody or antigen binding portion thereof, are the same antibody. In another embodiment the first parent antibody or antigen binding portion thereof, and the second parent antibody or antigen binding portion thereof, are different antibodies.

In one embodiment the first parent antibody or antigen binding portion thereof, binds a first antigen and the second parent antibody or antigen binding portion thereof, binds a second antigen. In a particular embodiment, the first and second antigens are the same antigen. In another embodiment, the parent antibodies bind different epitopes on the same antigen. In another embodiment the first and second antigens are different antigens. In another embodiment, the first parent antibody or antigen binding portion thereof, binds the first antigen with a potency different from the potency with which the second parent antibody or antigen binding portion thereof, binds the second antigen. In yet another embodiment, the first parent antibody or antigen binding portion thereof, binds the first antigen with an affinity different from the affinity with which the second parent antibody or antigen binding portion thereof, binds the second antigen.

In another embodiment the first parent antibody or antigen binding portion thereof, and the second parent antibody or antigen binding portion thereof, are selected from the group consisting of, human antibody, CDR grafted antibody, and humanized antibody. In an embodiment, the antigen binding portions are selected from the group consisting of a Fab fragment, a F(ab')₂ fragment, a bivalent fragment comprising two Fab fragments linked by a

disulfide bridge at the hinge region; a Fd fragment consisting of the VH and CH1 domains; a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, a dAb fragment, an isolated complementarity determining region (CDR), a single chain antibody, and diabodies.

In another embodiment the binding protein of the invention possesses at least one desired
5 property exhibited by the first parent antibody or antigen binding portion thereof, or the second
parent antibody or antigen binding portion thereof. Alternatively, the first parent antibody or
antigen binding portion thereof and the second parent antibody or antigen binding portion thereof
possess at least one desired property exhibited by the Dual Variable Domain Immunoglobulin. In
an embodiment, the desired property is selected from one or more antibody parameters. In
10 another embodiment, the antibody parameters are selected from the group consisting of antigen
specificity, affinity to antigen, potency, biological function, epitope recognition, stability,
solubility, production efficiency, immunogenicity, pharmacokinetics, bioavailability, tissue cross
reactivity, and orthologous antigen binding. In an embodiment the binding protein is multivalent.
In another embodiment, the binding protein is multispecific. The multivalent and or multispecific
15 binding proteins described herein have desirable properties particularly from a therapeutic
standpoint. For instance, the multivalent and or multispecific binding protein may (1) be
internalized (and/or catabolized) faster than a bivalent antibody by a cell expressing an antigen to
which the antibodies bind; (2) be an agonist antibody; and/or (3) induce cell death and/or
apoptosis of a cell expressing an antigen which the multivalent antibody is capable of binding to.
20 The "parent antibody" which provides at least one antigen binding specificity of the multivalent
and or multispecific binding proteins may be one which is internalized (and/or catabolized) by a
cell expressing an antigen to which the antibody binds; and/or may be an agonist, cell death-
inducing, and/or apoptosis-inducing antibody, and the multivalent and or multispecific binding
protein as described herein may display improvement(s) in one or more of these properties.
25 Moreover, the parent antibody may lack any one or more of these properties, but may be endowed
with them when constructed as a multivalent binding protein as described herein.

In another embodiment the binding protein of the invention has an on rate constant (K_{on})
to one or more targets selected from the group consisting of: at least about $10^2 M^{-1} s^{-1}$; at least about
 $10^3 M^{-1} s^{-1}$; at least about $10^4 M^{-1} s^{-1}$; at least about $10^5 M^{-1} s^{-1}$; and at least about $10^6 M^{-1} s^{-1}$, as
30 measured by surface plasmon resonance. In an embodiment, the binding protein of the invention
has an on rate constant (K_{on}) to one or more targets between $10^2 M^{-1} s^{-1}$ and $10^3 M^{-1} s^{-1}$; between
 $10^3 M^{-1} s^{-1}$ and $10^4 M^{-1} s^{-1}$; between $10^4 M^{-1} s^{-1}$ and $10^5 M^{-1} s^{-1}$; or between $10^5 M^{-1} s^{-1}$ and $10^6 M^{-1} s^{-1}$, as
measured by surface plasmon resonance.

In another embodiment the binding protein has an off rate constant (K_{off}) for one or
35 more targets selected from the group consisting of: at most about $10^{-3} s^{-1}$; at most about $10^{-4} s^{-1}$; at
most about $10^{-5} s^{-1}$; and at most about $10^{-6} s^{-1}$, as measured by surface plasmon resonance. In an

embodiment, the binding protein of the invention has an off rate constant (K_{off}) to one or more targets of $10^{-3}s^{-1}$ to $10^{-4}s^{-1}$; of $10^{-4}s^{-1}$ to $10^{-5}s^{-1}$; or of $10^{-5}s^{-1}$ to $10^{-6}s^{-1}$, as measured by surface plasmon resonance.

5 In another embodiment the binding protein has a dissociation constant (K_D) to one or more targets selected from the group consisting of: at most about 10^{-7} M; at most about 10^{-8} M; at most about 10^{-9} M; at most about 10^{-10} M; at most about 10^{-11} M; at most about 10^{-12} M; and at most 10^{-13} M. In an embodiment, the binding protein of the invention has a dissociation constant (K_D) to its targets of 10^{-7} M to 10^{-8} M; of 10^{-8} M to 10^{-9} M; of 10^{-9} M to 10^{-10} M; of 10^{-10} to 10^{-11} M; of 10^{-11} M to 10^{-12} M; or of 10^{-12} to M 10^{-13} M.

10 In another embodiment, the binding protein described herein is a conjugate further comprising an agent selected from the group consisting of an immunoadhesion molecule, an imaging agent, a therapeutic agent, and a cytotoxic agent. In an embodiment, the imaging agent is selected from the group consisting of a radiolabel, an enzyme, a fluorescent label, a luminescent label, a bioluminescent label, a magnetic label, and biotin. In another embodiment, the imaging
15 agent is a radiolabel selected from the group consisting of: 3H , ^{14}C , ^{35}S , ^{90}Y , ^{99}Tc , ^{111}In , ^{125}I , ^{131}I , ^{177}Lu , ^{166}Ho , and ^{153}Sm . In yet another embodiment, the therapeutic or cytotoxic agent is selected from the group consisting of an anti-metabolite, an alkylating agent, an antibiotic, a growth factor, a cytokine, an anti-angiogenic agent, an anti-mitotic agent, an anthracycline, toxin, and an apoptotic agent.

20 In another embodiment, the binding protein described herein is a crystallized binding protein and exists as a crystal. In an embodiment, the crystal is a carrier-free pharmaceutical controlled release crystal. In yet another embodiment, the crystallized binding protein has a greater half life in vivo than the soluble counterpart of said binding protein. In still another embodiment, the crystallized binding protein retains biological activity.

25 In another embodiment, the binding protein described herein is glycosylated. For example, the glycosylation is a human glycosylation pattern.

One aspect of the invention pertains to an isolated nucleic acid encoding any one of the binding proteins disclosed herein. A further embodiment provides a vector comprising the isolated nucleic acid disclosed herein wherein said vector is selected from the group consisting of
30 pcDNA; pTT (Durocher et al., *Nucleic Acids Research* 2002, Vol 30, No.2); pTT3 (pTT with additional multiple cloning site); pEFBOS (Mizushima, S. and Nagata, S., (1990) *Nucleic acids Research* Vol 18, No. 17); pBV; pJV; pcDNA3.1 TOPO, pEF6 TOPO and pBJ. In an embodiment, the vector is a vector disclosed in US Patent Application Serial No. 61/021,282.

35 In another aspect a host cell is transformed with the vector disclosed herein. In an embodiment, the host cell is a prokaryotic cell. In another embodiment, the host cell is E.Coli. In

a related embodiment the host cell is a eukaryotic cell. In another embodiment, the eukaryotic cell is selected from the group consisting of protist cell, animal cell, plant cell and fungal cell. In yet another embodiment, the host cell is a mammalian cell including, but not limited to, CHO, COS; NS0, SP2, PER.C6 or a fungal cell such as *Saccharomyces cerevisiae*; or an insect cell such as Sf9.

In an embodiment, two or more DVD-Igs, e.g., with different specificities, are produced in a single recombinant host cell. For example, the expression of a mixture of antibodies has been called Oligoclonics™, (Merus B.V., The Netherlands) U.S. Patent Nos. 7,262,028; 7,429,486.

Another aspect of the invention provides a method of producing a binding protein disclosed herein comprising culturing any one of the host cells also disclosed herein in a culture medium under conditions sufficient to produce the binding protein. In an embodiment, 50%-75% of the binding protein produced by this method is a dual specific tetravalent binding protein. In a particular embodiment, 75%-90% of the binding protein produced by this method is a dual specific tetravalent binding protein. In a particular embodiment, 90%-95% of the binding protein produced is a dual specific tetravalent binding protein.

One embodiment provides a composition for the release of a binding protein wherein the composition comprises a formulation that in turn comprises a crystallized binding protein, as disclosed herein, and an ingredient, and at least one polymeric carrier. For example, the polymeric carrier is a polymer selected from one or more of the group consisting of: poly (acrylic acid), poly (cyanoacrylates), poly (amino acids), poly (anhydrides), poly (depsipeptide), poly (esters), poly (lactic acid), poly (lactic-co-glycolic acid) or PLGA, poly (b-hydroxybutyrate), poly (caprolactone), poly (dioxanone); poly (ethylene glycol), poly ((hydroxypropyl) methacrylamide, poly [(organo)phosphazene], poly (ortho esters), poly (vinyl alcohol), poly (vinylpyrrolidone), maleic anhydride-alkyl vinyl ether copolymers, pluronic polyols, albumin, alginate, cellulose and cellulose derivatives, collagen, fibrin, gelatin, hyaluronic acid, oligosaccharides, glycaninoglycans, sulfated polyeaccharides, blends and copolymers thereof. For example, the ingredient is selected from the group consisting of albumin, sucrose, trehalose, lactitol, gelatin, hydroxypropyl- β -cyclodextrin, methoxypolyethylene glycol and polyethylene glycol. Another embodiment provides a method for treating a mammal comprising the step of administering to the mammal an effective amount of the composition disclosed herein.

The invention also provides a pharmaceutical composition comprising a binding protein, as disclosed herein and a pharmaceutically acceptable carrier. In a further embodiment the pharmaceutical composition comprises at least one additional therapeutic agent for treating a disorder. For example, the additional agent is selected from the group consisting of: a therapeutic agent, an imaging agent, a cytotoxic agent, an angiogenesis inhibitor (including but not limited to

an anti-VEGF antibody or a VEGF-trap), a kinase inhibitor (including but not limited to a KDR and a TIE-2 inhibitor), a co-stimulation molecule blocker (including but not limited to anti-B7.1, anti-B7.2, CTLA4-Ig, anti-CD20), an adhesion molecule blocker (including but not limited to an anti-LFA-1 antibody, an anti-E/L selectin antibody, a small molecule inhibitor), an anti-cytokine
5 antibody or functional fragment thereof (including but not limited to an anti-IL-18, an anti-TNF, and an anti-IL-6/cytokine receptor antibody), methotrexate, cyclosporin, rapamycin, FK506, a detectable label or reporter, a TNF antagonist, an antirheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, a neuromuscular blocker, an antimicrobial, an antipsoriatic, a corticosteroid, an
10 anabolic steroid, an erythropoietin, an immunization, an immunoglobulin, an immunosuppressive, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an antidepressant, an antipsychotic, a stimulant, an asthma medication, a beta agonist, an inhaled steroid, an epinephrine or analog, a cytokine, and a cytokine antagonist.

In another aspect, the invention provides a method for treating a human subject suffering
15 from a disorder in which the target, or targets, capable of being bound by the binding protein disclosed herein is detrimental, comprising administering to the human subject a binding protein disclosed herein such that the activity of the target, or targets in the human subject is inhibited and one of more symptoms is alleviated or treatment is achieved. For example, the disorder is selected from the group comprising arthritis, osteoarthritis, juvenile chronic arthritis, septic
20 arthritis, Lyme arthritis, psoriatic arthritis, reactive arthritis, spondyloarthropathy, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, inflammatory bowel disease, insulin dependent diabetes mellitus, thyroiditis, asthma, allergic diseases, psoriasis, dermatitis scleroderma, graft versus host disease, organ transplant rejection, acute or chronic immune disease associated with organ transplantation, sarcoidosis, atherosclerosis, disseminated intravascular coagulation,
25 Kawasaki's disease, Grave's disease, nephrotic syndrome, chronic fatigue syndrome, Wegener's granulomatosis, Henoch-Schoenlein purpura, microscopic vasculitis of the kidneys, chronic active hepatitis, uveitis, septic shock, toxic shock syndrome, sepsis syndrome, cachexia, infectious diseases, parasitic diseases, acquired immunodeficiency syndrome, acute transverse myelitis, Huntington's chorea, Parkinson's disease, Alzheimer's disease, stroke, primary biliary
30 cirrhosis, hemolytic anemia, malignancies, heart failure, myocardial infarction, Addison's disease, sporadic polyglandular deficiency type I and polyglandular deficiency type II, Schmidt's syndrome, adult (acute) respiratory distress syndrome, alopecia, alopecia areata, seronegative arthropathy, arthropathy, Reiter's disease, psoriatic arthropathy, ulcerative colitic arthropathy, enteropathic synovitis, chlamydia, yersinia and salmonella associated arthropathy,
35 spondyloarthropathy, atheromatous disease/arteriosclerosis, atopic allergy, autoimmune bullous disease, pemphigus vulgaris, pemphigus foliaceus, pemphigoid, linear IgA disease, autoimmune

haemolytic anaemia, Coombs positive haemolytic anaemia, acquired pernicious anaemia, juvenile pernicious anaemia, myalgic encephalitis/Royal Free Disease, chronic mucocutaneous candidiasis, giant cell arteritis, primary sclerosing hepatitis, cryptogenic autoimmune hepatitis, Acquired Immunodeficiency Disease Syndrome, Acquired Immunodeficiency Related Diseases, Hepatitis B, Hepatitis C, common varied immunodeficiency (common variable hypogammaglobulinaemia), dilated cardiomyopathy, female infertility, ovarian failure, premature ovarian failure, fibrotic lung disease, cryptogenic fibrosing alveolitis, post-inflammatory interstitial lung disease, interstitial pneumonitis, connective tissue disease associated interstitial lung disease, mixed connective tissue disease associated lung disease, systemic sclerosis associated interstitial lung disease, rheumatoid arthritis associated interstitial lung disease, systemic lupus erythematosus associated lung disease, dermatomyositis/polymyositis associated lung disease, Sjögren's disease associated lung disease, ankylosing spondylitis associated lung disease, vasculitic diffuse lung disease, haemosiderosis associated lung disease, drug-induced interstitial lung disease, fibrosis, radiation fibrosis, bronchiolitis obliterans, chronic eosinophilic pneumonia, lymphocytic infiltrative lung disease, postinfectious interstitial lung disease, gouty arthritis, autoimmune hepatitis, type-1 autoimmune hepatitis (classical autoimmune or lupoid hepatitis), type-2 autoimmune hepatitis (anti-LKM antibody hepatitis), autoimmune mediated hypoglycaemia, type B insulin resistance with acanthosis nigricans, hypoparathyroidism, acute immune disease associated with organ transplantation, chronic immune disease associated with organ transplantation, osteoarthritis, primary sclerosing cholangitis, psoriasis type 1, psoriasis type 2, idiopathic leucopaenia, autoimmune neutropaenia, renal disease NOS, glomerulonephritides, microscopic vasculitis of the kidneys, lyme disease, discoid lupus erythematosus, male infertility idiopathic or NOS, sperm autoimmunity, multiple sclerosis (all subtypes), sympathetic ophthalmia, pulmonary hypertension secondary to connective tissue disease, Goodpasture's syndrome, pulmonary manifestation of polyarteritis nodosa, acute rheumatic fever, rheumatoid spondylitis, Still's disease, systemic sclerosis, Sjögren's syndrome, Takayasu's disease/arteritis, autoimmune thrombocytopaenia, idiopathic thrombocytopaenia, autoimmune thyroid disease, hyperthyroidism, goitrous autoimmune hypothyroidism (Hashimoto's disease), atrophic autoimmune hypothyroidism, primary myxoedema, phacogenic uveitis, primary vasculitis, vitiligo acute liver disease, chronic liver diseases, alcoholic cirrhosis, alcohol-induced liver injury, choleosatis, idiosyncratic liver disease, Drug-Induced hepatitis, Non-alcoholic Steatohepatitis, allergy and asthma, group B streptococci (GBS) infection, mental disorders (*e.g.*, depression and schizophrenia), Th2 Type and Th1 Type mediated diseases, acute and chronic pain (different forms of pain), and cancers such as lung, breast, stomach, bladder, colon, pancreas, ovarian, prostate and rectal cancer and hematopoietic malignancies (leukemia and lymphoma), Abetalipoproteinemia, Acrocyanosis, acute and chronic parasitic or infectious processes, acute leukemia, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML),

acute or chronic bacterial infection, acute pancreatitis, acute renal failure, adenocarcinomas, aerial ectopic beats, AIDS dementia complex, alcohol-induced hepatitis, allergic conjunctivitis, allergic contact dermatitis, allergic rhinitis, allograft rejection, alpha-1- antitrypsin deficiency, amyotrophic lateral sclerosis, anemia, angina pectoris, anterior horn cell degeneration, anti cd3
5 therapy, antiphospholipid syndrome, anti-receptor hypersensitivity reactions, aortic and peripheral aneurysms, aortic dissection, arterial hypertension, arteriosclerosis, arteriovenous fistula, ataxia, atrial fibrillation (sustained or paroxysmal), atrial flutter, atrioventricular block, B cell lymphoma, bone graft rejection, bone marrow transplant (BMT) rejection, bundle branch block, Burkitt's lymphoma, Burns, cardiac arrhythmias, cardiac stun syndrome, cardiac tumors, cardiomyopathy,
10 cardiopulmonary bypass inflammation response, cartilage transplant rejection, cerebellar cortical degenerations, cerebellar disorders, chaotic or multifocal atrial tachycardia, chemotherapy associated disorders, chronic myelocytic leukemia (CML), chronic alcoholism, chronic inflammatory pathologies, chronic lymphocytic leukemia (CLL), chronic obstructive pulmonary disease (COPD), chronic salicylate intoxication, colorectal carcinoma, congestive heart failure,
15 conjunctivitis, contact dermatitis, cor pulmonale, coronary artery disease, Creutzfeldt-Jakob disease, culture negative sepsis, cystic fibrosis, cytokine therapy associated disorders, Dementia pugilistica, demyelinating diseases, dengue hemorrhagic fever, dermatitis, dermatologic conditions, diabetes, diabetes mellitus, diabetic atherosclerotic disease, Diffuse Lewy body disease, dilated congestive cardiomyopathy, disorders of the basal ganglia, Down's Syndrome in
20 middle age, drug- induced movement disorders induced by drugs which block CNS dopamine receptors, drug sensitivity, eczema, encephalomyelitis, endocarditis, endocrinopathy, epiglottitis, epstein-barr virus infection, erythromelalgia, extrapyramidal and cerebellar disorders, familial hematophagocytic lymphohistiocytosis, fetal thymus implant rejection, Friedreich's ataxia, functional peripheral arterial disorders, fungal sepsis, gas gangrene, gastric ulcer, glomerular
25 nephritis, graft rejection of any organ or tissue, gram negative sepsis, gram positive sepsis, granulomas due to intracellular organisms, hairy cell leukemia, Hallerorden-Spatz disease, hashimoto's thyroiditis, hay fever, heart transplant rejection, hemachromatosis, hemodialysis, hemolytic uremic syndrome/thrombolytic thrombocytopenic purpura, hemorrhage, hepatitis (A), His bundle arrhythmias, HIV infection/HIV neuropathy, Hodgkin's disease, hyperkinetic
30 movement disorders, hypersensitivity reactions, hypersensitivity pneumonitis, hypertension, hypokinetic movement disorders, hypothalamic-pituitary-adrenal axis evaluation, idiopathic Addison's disease, idiopathic pulmonary fibrosis, antibody mediated cytotoxicity, Asthenia, infantile spinal muscular atrophy, inflammation of the aorta, influenza a, ionizing radiation exposure, iridocyclitis/uveitis/optic neuritis, ischemia- reperfusion injury, ischemic stroke,
35 juvenile rheumatoid arthritis, juvenile spinal muscular atrophy, Kaposi's sarcoma, kidney transplant rejection, legionella, leishmaniasis, leprosy, lesions of the corticospinal system, lipedema, liver transplant rejection, lymphedema, malaria, malignant Lymphoma, malignant

histiocytosis, malignant melanoma, meningitis, meningococemia, metabolic/idiopathic diseases, migraine headache, mitochondrial multi.system disorder, mixed connective tissue disease, monoclonal gammopathy, multiple myeloma, multiple systems degenerations (Mencel Dejerine-Thomas Shi-Drager and Machado-Joseph), myasthenia gravis, mycobacterium avium
5 intracellulare, mycobacterium tuberculosis, myelodysplastic syndrome, myocardial infarction, myocardial ischemic disorders, nasopharyngeal carcinoma, neonatal chronic lung disease, nephritis, nephrosis, neurodegenerative diseases, neurogenic I muscular atrophies, neutropenic fever, non- hodgkins lymphoma, occlusion of the abdominal aorta and its branches, occlusive arterial disorders, okt3 therapy, orchitis/epididymitis, orchitis/vasectomy reversal procedures,
10 organomegaly, osteoporosis, pancreas transplant rejection, pancreatic carcinoma, paraneoplastic syndrome/hypercalcemia of malignancy, parathyroid transplant rejection, pelvic inflammatory disease, perennial rhinitis, pericardial disease, peripheral atherosclerotic disease, peripheral vascular disorders, peritonitis, pernicious anemia, pneumocystis carinii pneumonia, pneumonia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy,
15 and skin changes syndrome), post perfusion syndrome, post pump syndrome, post-MI cardiomyopathy syndrome, preeclampsia, Progressive supranucleo Palsy, primary pulmonary hypertension, radiation therapy, Raynaud's phenomenon and disease, Raynaud's disease, Refsum's disease, regular narrow QRS tachycardia, renovascular hypertension, reperfusion injury, restrictive cardiomyopathy, sarcomas, scleroderma, senile chorea, Senile Dementia of Lewy body type,
20 seronegative arthropathies, shock, sickle cell anemia, skin allograft rejection, skin changes syndrome, small bowel transplant rejection, solid tumors, specific arrhythmias, spinal ataxia, spinocerebellar degenerations, streptococcal myositis, structural lesions of the cerebellum, Subacute sclerosing panencephalitis, Syncope, syphilis of the cardiovascular system, systemic anaphalaxis, systemic inflammatory response syndrome, systemic onset juvenile rheumatoid
25 arthritis, T-cell or FAB ALL, Telangiectasia, thromboangitis obliterans, thrombocytopenia, toxicity, transplants, trauma/hemorrhage, type III hypersensitivity reactions, type IV hypersensitivity, unstable angina, uremia, urosepsis, urticaria, valvular heart diseases, varicose veins, ,vasculitis, venous diseases, venous thrombosis, ventricular fibrillation, viral and fungal infections, vital encephalitis/aseptic meningitis, vital-associated hemaphagocytic syndrome,
30 Wernicke- Korsakoff syndrome, Wilson's disease, xenograft rejection of any organ or tissue, acute coronary syndromes, acute idiopathic polyneuritis, acute inflammatory demyelinating polyradiculoneuropathy, acute ischemia, adult Still's disease, alopecia areata, anaphylaxis, anti-phospholipid antibody syndrome, aplastic anemia, arteriosclerosis, atopic eczema, atopic dermatitis, autoimmune dermatitis, autoimmune disorder associated with streptococcus infection,
35 autoimmune enteropathy, autoimmune hearing loss, autoimmune lymphoproliferative syndrome (ALPS), autoimmune myocarditis, autoimmune premature ovarian failure, blepharitis, bronchiectasis, bullous pemphigoid, cardiovascular disease, catastrophic antiphospholipid

syndrome, celiac disease, cervical spondylosis, chronic ischemia, cicatricial pemphigoid,
 clinically isolated syndrome (cis) with risk for multiple sclerosis, conjunctivitis, childhood onset
 psychiatric disorder, chronic obstructive pulmonary disease (COPD), dacryocystitis,
 dermatomyositis, diabetic retinopathy, diabetes mellitus, disk herniation, disk prolaps, drug
 5 induced immune hemolytic anemia, endocarditis, endometriosis, endophthalmitis, episcleritis,
 erythema multiforme, erythema multiforme major, gestational pemphigoid, Guillain-Barré
 syndrome (GBS), hay fever, Hughes syndrome, idiopathic Parkinson's disease, idiopathic
 interstitial pneumonia, IgE-mediated allergy, immune hemolytic anemia, inclusion body myositis,
 infectious ocular inflammatory disease, inflammatory demyelinating disease, inflammatory heart
 10 disease, inflammatory kidney disease, IPF/UIP, iritis, keratitis, keratoconjunctivitis sicca, Kussmaul
 disease or Kussmaul-Meier disease, Landry's paralysis, Langerhan's cell histiocytosis, livedo
 reticularis, macular degeneration, microscopic polyangiitis, morbus bechtereov, motor neuron
 disorders, mucous membrane pemphigoid, multiple organ failure, myasthenia gravis,
 myelodysplastic syndrome, myocarditis, nerve root disorders, neuropathy, non-A non-B hepatitis,
 15 optic neuritis, osteolysis, ovarian cancer, pauciarticular JRA, peripheral artery occlusive disease
 (PAOD), peripheral vascular disease (PVD), peripheral artery, disease (PAD), phlebitis,
 polyarteritis nodosa (or periarteritis nodosa), polychondritis, polymyalgia rheumatica, poliosis,
 polyarticular JRA, polyendocrine deficiency syndrome, polymyositis, polymyalgia rheumatica
 (PMR), post-pump syndrome, primary Parkinsonism, prostate and rectal cancer and
 20 hematopoietic malignancies (leukemia and lymphoma), prostatitis, pure red cell aplasia, primary
 adrenal insufficiency, recurrent neuromyelitis optica, restenosis, rheumatic heart disease, sapho
 (synovitis, acne, pustulosis, hyperostosis, and osteitis), scleroderma, secondary amyloidosis,
 shock lung, scleritis, sciatica, secondary adrenal insufficiency, silicone associated connective
 tissue disease, sneddon-wilkinson dermatosis, spondilitis ankylosans, Stevens-Johnson syndrome
 25 (SJS), systemic inflammatory response syndrome, temporal arteritis, toxoplasmic retinitis, toxic
 epidermal necrolysis, transverse myelitis, TRAPS (tumor necrosis factor receptor, type 1 allergic
 reaction, type II diabetes, urticaria, usual interstitial pneumonia (UIP), vasculitis, vernal
 conjunctivitis, viral retinitis, Vogt-Koyanagi-Harada syndrome (VKH syndrome), wet macular
 degeneration, wound healing, yersinia and salmonella associated arthropathy.

30 In an embodiment, diseases that can be treated or diagnosed with the compositions and
 methods of the invention include, but are not limited to, primary and metastatic cancers, including
 carcinomas of breast, colon, rectum, lung, oropharynx, hypopharynx, esophagus, stomach,
 pancreas, liver, gallbladder and bile ducts, small intestine, urinary tract (including kidney, bladder
 and urothelium), female genital tract (including cervix, uterus, and ovaries as well as
 35 choriocarcinoma and gestational trophoblastic disease), male genital tract (including prostate,
 seminal vesicles, testes and germ cell tumors), endocrine glands (including the thyroid, adrenal,

and pituitary glands), and skin, as well as hemangiomas, melanomas, sarcomas (including those arising from bone and soft tissues as well as Kaposi's sarcoma), tumors of the brain, nerves, eyes, and meninges (including astrocytomas, gliomas, glioblastomas, retinoblastomas, neuromas, neuroblastomas, Schwannomas, and meningiomas), solid tumors arising from hematopoietic malignancies such as leukemias, and lymphomas (both Hodgkin's and non-Hodgkin's lymphomas).

In an embodiment, the antibodies of the invention or antigen-binding portions thereof, are used to treat cancer or in the prevention of metastases from the tumors described herein either when used alone or in combination with radiotherapy and/or other chemotherapeutic agents.

In another aspect the invention provides a method of treating a patient suffering from a disorder comprising the step of administering any one of the binding proteins disclosed herein before, concurrent, or after the administration of a second agent, as discussed herein. In a particular embodiment the second agent is selected from the group consisting of budenoside, epidermal growth factor, corticosteroids, cyclosporin, sulfasalazine, aminosalicylates, 6-mercaptapurine, azathioprine, metronidazole, lipoxigenase inhibitors, mesalamine, olsalazine, balsalazide, antioxidants, thromboxane inhibitors, IL-1 receptor antagonists, anti-IL-1 β mAbs, anti-IL-6 or IL-6 receptor mAbs, growth factors, elastase inhibitors, pyridinyl-imidazole compounds, antibodies or agonists of TNF, LT, IL-1, IL-2, IL-6, IL-7, IL-8, IL-12, IL-13, IL-15, IL-16, IL-18, IL-23, EMAP-II, GM-CSF, FGF, and PDGF, antibodies of CD2, CD3, CD4, CD8, CD-19, CD25, CD28, CD30, CD40, CD45, CD69, CD90 or their ligands, methotrexate, cyclosporin, FK506, rapamycin, mycophenolate mofetil, leflunomide, NSAIDs, ibuprofen, corticosteroids, prednisolone, phosphodiesterase inhibitors, adenosine agonists, antithrombotic agents, complement inhibitors, adrenergic agents, IRAK, NIK, IKK, p38, MAP kinase inhibitors, IL-1 β converting enzyme inhibitors, TNF α converting enzyme inhibitors, T-cell signalling inhibitors, metalloproteinase inhibitors, sulfasalazine, azathioprine, 6-mercaptapurines, angiotensin converting enzyme inhibitors, soluble cytokine receptors, soluble p55 TNF receptor, soluble p75 TNF receptor, sIL-1RI, sIL-1RII, sIL-6R, antiinflammatory cytokines, IL-4, IL-10, IL-11, IL-13 and TGF β .

In a particular embodiment the pharmaceutical compositions disclosed herein are administered to the patient by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal,

intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

One aspect of the invention provides at least one anti-idiotypic antibody to at least one binding protein of the present invention. The anti-idiotypic antibody includes any protein or peptide
5 containing molecule that comprises at least a portion of an immunoglobulin molecule such as, but not limited to, at least one complementarily determining region (CDR) of a heavy or light chain or a ligand binding portion thereof, a heavy chain or light chain variable region, a heavy chain or light chain constant region, a framework region, or any portion thereof, that can be incorporated into a binding protein of the present invention.

10

Brief Description of the Drawings

Figure 1A is a schematic representation of Dual Variable Domain (DVD)-Ig constructs and shows the strategy for generation of a DVD-Ig from two parent antibodies;

Figure 1B, is a schematic representation of constructs DVD1-Ig, DVD2-Ig, and two chimeric mono-specific antibodies from hybridoma clones 2D13.E3 (anti-IL-1 α) and 13F5.G5 (anti-
15 IL-1 β).

Detailed Description of the Invention

This invention pertains to multivalent and/or multispecific binding proteins capable of binding two or more antigens. Specifically, the invention relates to dual variable domain immunoglobulins (DVD-Ig), and pharmaceutical compositions thereof, as well as nucleic acids,
20 recombinant expression vectors and host cells for making such DVD-Igs. Methods of using the DVD-Igs of the invention to detect specific antigens, either in vitro or in vivo are also encompassed by the invention.

Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary
25 skill in the art. The meaning and scope of the terms should be clear, however, in the event of any latent ambiguity, definitions provided herein take precedent over any dictionary or extrinsic definition. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. In this application, the use of "or" means "and/or" unless stated otherwise. Furthermore, the use of the term "including", as well as other forms,
30 such as "includes" and "included", is not limiting. Also, terms such as "element" or "component" encompass both elements and components comprising one unit and elements and components that comprise more than one subunit unless specifically stated otherwise.

Generally, nomenclatures used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid

chemistry and hybridization described herein are those well known and commonly used in the art. The methods and techniques of the present invention are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless
5 otherwise indicated. Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein. The nomenclatures used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques are
10 used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

That the present invention may be more readily understood, select terms are defined below.

The term "polypeptide" as used herein, refers to any polymeric chain of amino acids. The
15 terms "peptide" and "protein" are used interchangeably with the term polypeptide and also refer to a polymeric chain of amino acids. The term "polypeptide" encompasses native or artificial proteins, protein fragments and polypeptide analogs of a protein sequence. A polypeptide may be monomeric or polymeric. Use of "polypeptide" herein is intended to encompass polypeptide and fragments and variants (including fragments of variants) thereof, unless otherwise contradicted by
20 context. For an antigenic polypeptide, a fragment of polypeptide optionally contains at least one contiguous or nonlinear epitope of polypeptide. The precise boundaries of the at least one epitope fragment can be confirmed using ordinary skill in the art. The fragment comprises at least about 5 contiguous amino acids, such as at least about 10 contiguous amino acids, at least about 15 contiguous amino acids, or at least about 20 contiguous amino acids. A variant of polypeptide is
25 as described herein.

The term "isolated protein" or "isolated polypeptide" is a protein or polypeptide that by virtue of its origin or source of derivation is not associated with naturally associated components that accompany it in its native state; is substantially free of other proteins from the same species; is expressed by a cell from a different species; or does not occur in nature. Thus, a polypeptide
30 that is chemically synthesized or synthesized in a cellular system different from the cell from which it naturally originates will be "isolated" from its naturally associated components. A protein may also be rendered substantially free of naturally associated components by isolation, using protein purification techniques well known in the art.

The term "recovering" as used herein, refers to the process of rendering a chemical species such as a polypeptide substantially free of naturally associated components by isolation, e.g., using protein purification techniques well known in the art.

5 "Biological activity" as used herein, refers to any one or more inherent biological properties of a molecule (whether present naturally as found in vivo, or provided or enabled by recombinant means). Biological properties include but are not limited to binding receptor; induction of cell proliferation, inhibiting cell growth, inductions of other cytokines, induction of apoptosis, and enzymatic activity. Biological activity also includes activity of an Ig molecule.

10 The terms "specific binding" or "specifically binding", as used herein, in reference to the interaction of an antibody, a protein, or a peptide with a second chemical species, mean that the interaction is dependent upon the presence of a particular structure (e.g., an antigenic determinant or epitope) on the chemical species; for example, an antibody recognizes and binds to a specific protein structure rather than to proteins generally. If an antibody is specific for epitope "A", the presence of a molecule containing epitope A (or free, unlabeled A), in a reaction containing
15 labeled "A" and the antibody, will reduce the amount of labeled A bound to the antibody.

The term "antibody", as used herein, broadly refers to any immunoglobulin (Ig) molecule comprised of four polypeptide chains, two heavy (H) chains and two light (L) chains, or any functional fragment, mutant, variant, or derivation thereof, which retains the essential epitope binding features of an Ig molecule. Such mutant, variant, or derivative antibody formats are
20 known in the art. Nonlimiting embodiments of which are discussed below.

In a full-length antibody, each heavy chain is comprised of a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, CH1, CH2 and CH3. Each light chain is comprised of a light chain variable region (abbreviated herein as LCVR or VL) and a light chain
25 constant region. The light chain constant region is comprised of one domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3,
30 FR4. Immunoglobulin molecules can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG 1, IgG2, IgG 3, IgG4, IgA1 and IgA2) or subclass.

The term "Fc region" is used to define the C-terminal region of an immunoglobulin heavy chain, which may be generated by papain digestion of an intact antibody. The Fc region may be a native sequence Fc region or a variant Fc region. The Fc region of an immunoglobulin generally
35 comprises two constant domains, a CH2 domain and a CH3 domain, and optionally comprises a

CH4 domain. Replacements of amino acid residues in the Fc portion to alter antibody effector function are known in the art (Winter, *et al.* US Patent Nos 5,648,260 and 5,624,821). The Fc portion of an antibody mediates several important effector functions e.g., cytokine induction, ADCC, phagocytosis, complement dependent cytotoxicity (CDC) and half-life/ clearance rate of antibody and antigen-antibody complexes. In some cases these effector functions are desirable for therapeutic antibody but in other cases might be unnecessary or even deleterious, depending on the therapeutic objectives. Certain human IgG isotypes, particularly IgG1 and IgG3, mediate ADCC and CDC via binding to FcγRs and complement C1q, respectively. Neonatal Fc receptors (FcRn) are the critical components determining the circulating half-life of antibodies. In still another embodiment at least one amino acid residue is replaced in the constant region of the antibody, for example the Fc region of the antibody, such that effector functions of the antibody are altered. The dimerization of two identical heavy chains of an immunoglobulin is mediated by the dimerization of CH3 domains and is stabilized by the disulfide bonds within the hinge region (Huber et al. *Nature*; 264: 415-20; Thies et al 1999 *J Mol Biol*; 293: 67-79.). Mutation of cysteine residues within the hinge regions to prevent heavy chain-heavy chain disulfide bonds will destabilize dimeration of CH3 domains. Residues responsible for CH3 dimerization have been identified (Dall'Acqua 1998 *Biochemistry* 37: 9266-73.). Therefore, it is possible to generate a monovalent half-Ig. Interestingly, these monovalent half Ig molecules have been found in nature for both IgG and IgA subclasses (Seligman 1978 *Ann Immunol* 129: 855-70; Biewenga et al 1983 *Clin Exp Immunol* 51: 395-400). The stoichiometry of FcRn: Ig Fc region has been determined to be 2:1 (West et al .2000 *Biochemistry* 39: 9698-708), and half Fc is sufficient for mediating FcRn binding (Kim et al 1994 *Eur J Immunol*; 24: 542-548.). Mutations to disrupt the dimerization of CH3 domain may not have greater adverse effect on its FcRn binding as the residues important for CH3 dimerization are located on the inner interface of CH3 b sheet structure, whereas the region responsible for FcRn binding is located on the outside interface of CH2-CH3 domains. However the half Ig molecule may have certain advantage in tissue penetration due to its smaller size than that of a regular antibody. In one embodiment at least one amino acid residue is replaced in the constant region of the binding protein of the invention, for example the Fc region, such that the dimerization of the heavy chains is disrupted, resulting in half DVD Ig molecules. The anti-inflammatory activity of IgG is completely dependent on sialylation of the N-linked glycan of the IgG Fc fragment. The precise glycan requirements for anti-inflammatory activity has been determined, such that an appropriate IgG1 Fc fragment can be created, thereby generating a fully recombinant, sialylated IgG1 Fc with greatly enhanced potency (Anthony, R.M., et al. (2008) *Science* 320:373-376).

35 The term "antigen-binding portion" of an antibody (or simply "antibody portion"), as used herein, refers to one or more fragments of an antibody that retain the ability to specifically bind to

an antigen. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Such antibody embodiments may also be bispecific, dual specific, or multi-specific formats; specifically binding to two or more different antigens.

Examples of binding fragments encompassed within the term "antigen-binding portion" of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab')₂ fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward *et al.*, (1989) *Nature* 341:544-546, Winter *et al.*, PCT publication WO 90/05144 A1 herein incorporated by reference), which comprises a single variable domain; and (vi) an isolated complementarity determining region (CDR). Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); see *e.g.*, Bird *et al.* (1988) *Science* 242:423-426; and Huston *et al.* (1988) *Proc. Natl. Acad. Sci. USA* 85:5879-5883). Such single chain antibodies are also intended to be encompassed within the term "antigen-binding portion" of an antibody. Other forms of single chain antibodies, such as diabodies are also encompassed. Diabodies are bivalent, bispecific antibodies in which VH and VL domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites (see *e.g.*, Holliger, P., *et al.* (1993) *Proc. Natl. Acad. Sci. USA* 90:6444-6448; Poljak, R.J., *et al.* (1994) *Structure* 2:1121-1123). Such antibody binding portions are known in the art (Kontermann and Dubel eds., *Antibody Engineering* (2001) Springer-Verlag, New York. 790 pp. (ISBN 3-540-41354-5). In addition single chain antibodies also include "linear antibodies" comprising a pair of tandem Fv segments (VH-CH1-VH-CH1) which, together with complementary light chain polypeptides, form a pair of antigen binding regions (Zapata *et al.* *Protein Eng.* 8(10):1057-1062 (1995); and US Patent No. 5,641,870).

The term "multivalent binding protein" is used throughout this specification to denote a binding protein comprising two or more antigen binding sites. In an embodiment, the multivalent binding protein is engineered to have the three or more antigen binding sites, and is generally not a naturally occurring antibody. The term "multispecific binding protein" refers to a binding protein capable of binding two or more related or unrelated targets. Dual variable domain (DVD) binding proteins of the invention comprise two or more antigen binding sites and are tetravalent or multivalent binding proteins. DVDs may be monospecific, *i.e.*, capable of binding one antigen or multispecific, *i.e.* capable of binding two or more antigens. DVD binding proteins comprising

two heavy chain DVD polypeptides and two light chain DVD polypeptides are referred to as DVD-Ig. Each half of a DVD-Ig comprises a heavy chain DVD polypeptide, and a light chain DVD polypeptide, and two antigen binding sites. Each binding site comprises a heavy chain variable domain and a light chain variable domain with a total of 6 CDRs involved in antigen binding per antigen binding site.

The term "bispecific antibody", as used herein, refers to full-length antibodies that are generated by quadroma technology (see Milstein, C. and A.C. Cuello, *Nature*, 1983. 305(5934): p. 537-40), by chemical conjugation of two different monoclonal antibodies (see Staerz, U.D., et al., *Nature*, 1985. 314(6012): p. 628-31), or by knob-into-hole or similar approaches which introduces mutations in the Fc region (see Holliger, P., T. Prospero, and G. Winter, *Proc Natl Acad Sci U S A*, 1993. 90(14): p. 6444-8.18), resulting in multiple different immunoglobulin species of which only one is the functional bispecific antibody. By molecular function, a bispecific antibody binds one antigen (or epitope) on one of its two binding arms (one pair of HC/LC), and binds a different antigen (or epitope) on its second arm (a different pair of HC/LC). By this definition, a bispecific antibody has two distinct antigen binding arms (in both specificity and CDR sequences), and is monovalent for each antigen it binds to.

The term "dual-specific antibody", as used herein, refers to full-length antibodies that can bind two different antigens (or epitopes) in each of its two binding arms (a pair of HC/LC) (see PCT publication WO 02/02773). Accordingly a dual-specific binding protein has two identical antigen binding arms, with identical specificity and identical CDR sequences, and is bivalent for each antigen it binds to.

A "functional antigen binding site" of a binding protein is one that is capable of binding a target antigen. The antigen binding affinity of the antigen binding site is not necessarily as strong as the parent antibody from which the antigen binding site is derived, but the ability to bind antigen must be measurable using any one of a variety of methods known for evaluating antibody binding to an antigen. Moreover, the antigen binding affinity of each of the antigen binding sites of a multivalent antibody herein need not be quantitatively the same.

The term "cytokine" is a generic term for proteins released by one cell population, which act on another cell population as intercellular mediators. Examples of such cytokines are lymphokines, monokines, and traditional polypeptide hormones. Included among the cytokines are growth hormone such as human growth hormone, N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; relaxin; prorelaxin; glycoprotein hormones such as follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), and luteinizing hormone (LH); hepatic growth factor; fibroblast growth factor; prolactin; placental lactogen; tumor necrosis factor-alpha and - beta; mullerian-inhibiting substance; mouse

gonadotropin-associated peptide; inhibin; activin; vascular endothelial growth factor; integrin; thrombopoietin (TPO); nerve growth factors such as NGF-alpha; platelet-growth factor; placental growth factor, transforming growth factors (TGFs) such as TGF- alpha and TGF-beta; insulin-like growth factor-1 and -11; erythropoietin (EPO); osteoinductive factors; interferons such as
 5 interferon-alpha, -beta and -gamma colony stimulating factors (CSFs) such as macrophage-CSF (M-CSF); granulocyte macrophage-CSF (GM-CSF); and granulocyte-CSF (G-CSF); interleukins (ILs) such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-18, IL-21, IL-22, IL-23, IL-33; a tumor necrosis factor such as TNF-alpha or TNF-beta; and other polypeptide factors including LIF and kit ligand (KL). As used herein, the term
 10 cytokine includes proteins from natural sources or from recombinant cell culture and biologically active equivalents of the native sequence cytokines.

The term "linker" is used to denote polypeptides comprising two or more amino acid residues joined by peptide bonds and are used to link one or more antigen binding portions. Such linker polypeptides are well known in the art (see *e.g.*, Holliger, P., *et al.* (1993) *Proc. Natl. Acad. Sci. USA* 90:6444-6448; Poljak, R.J., *et al.* (1994) *Structure* 2:1121-1123). Exemplary linkers
 15 include, but are not limited to, AKTTPKLEEGEFSEAR (SEQ ID NO: 1); AKTTPKLEEGEFSEARV (SEQ ID NO: 2); AKTTPKLGG (SEQ ID NO: 3); SAKTTPKLGG (SEQ ID NO: 4); SAKTTP (SEQ ID NO: 5); RADAAP (SEQ ID NO: 6); RADAAPTVS (SEQ ID NO: 7); RADAAAAGGPGS (SEQ ID NO: 8); RADAAA(G₄S)₄ (SEQ ID NO: 9);
 20 SAKTTPKLEEGEFSEARV (SEQ ID NO: 10); ADAAP (SEQ ID NO: 11); ADAAPTVSIFPP (SEQ ID NO: 12); TVAAP (SEQ ID NO: 13); TVAAPSVFIFPP (SEQ ID NO: 14); QPKAAP (SEQ ID NO: 15); QPKAAPSVTLFPP (SEQ ID NO: 16); AKTTPP (SEQ ID NO: 17); AKTTPPSVTPLAP (SEQ ID NO: 18); AKTTAP (SEQ ID NO: 19); AKTTAPSVYPLAP (SEQ ID NO: 20); ASTKGP (SEQ ID NO: 21); ASTKGPSVFPLAP (SEQ ID NO: 22),
 25 GGGGSGGGGSGGGGS (SEQ ID NO: 23); GENKVEYAPALMALS (SEQ ID NO: 24); GPAKELTPLKEAKVS (SEQ ID NO: 25); GHEAAAVMQVQPAS (SEQ ID NO: 26).

An "immunoglobulin constant domain" refers to a heavy or light chain constant domain. Human IgG heavy chain and light chain constant domain amino acid sequences are known in the art.

30 The term "monoclonal antibody" or "mAb" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigen. Furthermore, in contrast to polyclonal antibody preparations that typically include
 35 different antibodies directed against different determinants (epitopes), each mAb is directed

against a single determinant on the antigen. The modifier "monoclonal" is not to be construed as requiring production of the antibody by any particular method.

The term "human antibody", as used herein, is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The human antibodies of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), for example in the CDRs and in particular CDR3. However, the term "human antibody", as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.

The term "recombinant human antibody", as used herein, is intended to include all human antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell (described further in Section II C, below), antibodies isolated from a recombinant, combinatorial human antibody library (Hoogenboom H.R. (1997) *TIB Tech.* 15:62-70; Azzazy H., and Highsmith W.E. (2002) *Clin. Biochem.* 35:425-445; Gavilondo J.V., and Larrick J.W. (2002) *BioTechniques* 29:128-145; Hoogenboom H., and Chames P. (2000) *Immunology Today* 21:371-378), antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (see, Taylor, L. D., et al. (1992) *Nucl. Acids Res.* 20:6287-6295; Kellermann S-A. and Green L.L. (2002) *Current Opinion in Biotechnology* 13:593-597; Little M. et al. (2000) *Immunology Today* 21:364-370) or antibodies prepared, expressed, created or isolated by any other means that involves splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences. In certain embodiments, however, such recombinant human antibodies are subjected to in vitro mutagenesis (or, when an animal transgenic for human Ig sequences is used, in vivo somatic mutagenesis) and thus the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germline VH and VL sequences, may not naturally exist within the human antibody germline repertoire in vivo.

An "affinity matured" antibody is an antibody with one or more alterations in one or more CDRs thereof which result an improvement in the affinity of the antibody for antigen, compared to a parent antibody which does not possess those alteration(s). Exemplary affinity matured antibodies will have nanomolar or even picomolar affinities for the target antigen. Affinity matured antibodies are produced by procedures known in the art. Marks et al. *BidlTechnology* 10:779-783 (1992) describes affinity maturation by VH and VL domain shuffling. Random mutagenesis of CDR and/or framework residues is described by: Barbas et al. *Proc Nat. Acad.*

Sci, USA 91:3809-3813 (1994); Schier et al. Gene 169:147- 155 (1995); Yelton et al. J. Immunol. 155:1994-2004 (1995); Jackson et al., J. Immunol. 154(7):3310-9 (1995); Hawkins et al, J. Mol. BioL 226:889-896 (1992) and selective mutation at selective mutagenesis positions, contact or hypermutation positions with an activity enhancing amino acid residue as described in US patent
5 US 6914128B1.

The term "chimeric antibody" refers to antibodies which comprise heavy and light chain variable region sequences from one species and constant region sequences from another species, such as antibodies having murine heavy and light chain variable regions linked to human constant regions.

10 The term "CDR-grafted antibody" refers to antibodies which comprise heavy and light chain variable region sequences from one species but in which the sequences of one or more of the CDR regions of VH and/or VL are replaced with CDR sequences of another species, such as antibodies having murine heavy and light chain variable regions in which one or more of the murine CDRs (e.g., CDR3) has been replaced with human CDR sequences.

15 The term "humanized antibody" refers to antibodies which comprise heavy and light chain variable region sequences from a non-human species (e.g., a mouse) but in which at least a portion of the VH and/or VL sequence has been altered to be more "human-like", i.e., more similar to human germline variable sequences. One type of humanized antibody is a CDR-grafted antibody, in which human CDR sequences are introduced into non-human VH and VL sequences
20 to replace the corresponding nonhuman CDR sequences. Also "humanized antibody" is an antibody or a variant, derivative, analog or fragment thereof which immunospecifically binds to an antigen of interest and which comprises a framework (FR) region having substantially the amino acid sequence of a human antibody and a complementary determining region (CDR) having substantially the amino acid sequence of a non-human antibody. As used herein, the term
25 "substantially" in the context of a CDR refers to a CDR having an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or at least 99% identical to the amino acid sequence of a non-human antibody CDR. A humanized antibody comprises substantially all of at least one, and typically two, variable domains (Fab, Fab', F(ab')₂, FabC, Fv) in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin (i.e.,
30 donor antibody) and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. In an embodiment, a humanized antibody also comprises at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. In some embodiments, a humanized antibody contains both the light chain as well as at least the variable domain of a heavy chain. The antibody also may include the CH1,
35 hinge, CH2, CH3, and CH4 regions of the heavy chain. In some embodiments, a humanized antibody only contains a humanized light chain. In some embodiments, a humanized antibody

only contains a humanized heavy chain. In specific embodiments, a humanized antibody only contains a humanized variable domain of a light chain and/or humanized heavy chain.

The terms "Kabat numbering", "Kabat definitions" and "Kabat labeling" are used interchangeably herein. These terms, which are recognized in the art, refer to a system of numbering amino acid residues which are more variable (*i.e.* hypervariable) than other amino acid residues in the heavy and light chain variable regions of an antibody, or an antigen binding portion thereof (Kabat *et al.* (1971) *Ann. NY Acad. Sci.* 190:382-391 and, Kabat, E.A., *et al.* (1991) *Sequences of Proteins of Immunological Interest, Fifth Edition*, U.S. Department of Health and Human Services, NIH Publication No. 91-3242). For the heavy chain variable region, the hypervariable region ranges from amino acid positions 31 to 35 for CDR1, amino acid positions 50 to 65 for CDR2, and amino acid positions 95 to 102 for CDR3. For the light chain variable region, the hypervariable region ranges from amino acid positions 24 to 34 for CDR1, amino acid positions 50 to 56 for CDR2, and amino acid positions 89 to 97 for CDR3.

As used herein, the term "CDR" refers to the complementarity determining region within antibody variable sequences. There are three CDRs in each of the variable regions of the heavy chain and the light chain, which are designated CDR1, CDR2 and CDR3, for each of the variable regions. The term "CDR set" as used herein refers to a group of three CDRs that occur in a single variable region capable of binding the antigen. The exact boundaries of these CDRs have been defined differently according to different systems. The system described by Kabat (Kabat *et al.*, *Sequences of Proteins of Immunological Interest* (National Institutes of Health, Bethesda, Md. (1987) and (1991)) not only provides an unambiguous residue numbering system applicable to any variable region of an antibody, but also provides precise residue boundaries defining the three CDRs. These CDRs may be referred to as Kabat CDRs. Chothia and coworkers (Chothia & Lesk, *J. Mol. Biol.* 196:901-917 (1987) and Chothia *et al.*, *Nature* 342:877-883 (1989)) found that certain sub- portions within Kabat CDRs adopt nearly identical peptide backbone conformations, despite having great diversity at the level of amino acid sequence. These sub-portions were designated as L1, L2 and L3 or H1, H2 and H3 where the "L" and the "H" designates the light chain and the heavy chains regions, respectively. These regions may be referred to as Chothia CDRs, which have boundaries that overlap with Kabat CDRs. Other boundaries defining CDRs overlapping with the Kabat CDRs have been described by Padlan (*FASEB J.* 9:133-139 (1995)) and MacCallum (*J Mol Biol* 262(5):732-45 (1996)). Still other CDR boundary definitions may not strictly follow one of the herein systems, but will nonetheless overlap with the Kabat CDRs, although they may be shortened or lengthened in light of prediction or experimental findings that particular residues or groups of residues or even entire CDRs do not significantly impact antigen binding. The methods used herein may utilize CDRs defined according to any of these systems, although certain embodiments use Kabat or Chothia defined CDRs.

As used herein, the term "framework" or "framework sequence" refers to the remaining sequences of a variable region minus the CDRs. Because the exact definition of a CDR sequence can be determined by different systems, the meaning of a framework sequence is subject to correspondingly different interpretations. The six CDRs (CDR-L1, -L2, and -L3 of light chain and CDR-H1, -H2, and -H3 of heavy chain) also divide the framework regions on the light chain and the heavy chain into four sub-regions (FR1, FR2, FR3 and FR4) on each chain, in which CDR1 is positioned between FR1 and FR2, CDR2 between FR2 and FR3, and CDR3 between FR3 and FR4. Without specifying the particular sub-regions as FR1, FR2, FR3 or FR4, a framework region, as referred by others, represents the combined FR's within the variable region of a single, naturally occurring immunoglobulin chain. As used herein, a FR represents one of the four sub-regions, and FRs represents two or more of the four sub- regions constituting a framework region.

As used herein, the term "germline antibody gene" or "gene fragment" refers to an immunoglobulin sequence encoded by non- lymphoid cells that have not undergone the maturation process that leads to genetic rearrangement and mutation for expression of a particular immunoglobulin. (See, e.g., Shapiro et al., *Crit. Rev. Immunol.* 22(3): 183-200 (2002); Marchalonis et al., *Adv Exp Med Biol.* 484:13-30 (2001)). One of the advantages provided by various embodiments of the present invention stems from the recognition that germline antibody genes are more likely than mature antibody genes to conserve essential amino acid sequence structures characteristic of individuals in the species, hence less likely to be recognized as from a foreign source when used therapeutically in that species.

As used herein, the term "neutralizing" refers to counteracting the biological activity of an antigen when a binding protein specifically binds the antigen. In an embodiment, the neutralizing binding protein binds the cytokine and reduces its biological activity by at least about 20%, 40%, 60%, 80%, 85% or more.

The term "activity" includes activities such as the binding specificity and affinity of a DVD-Ig for two or more antigens.

The term "epitope" includes any polypeptide determinant capable of specific binding to an immunoglobulin or T-cell receptor. In certain embodiments, epitope determinants include chemically active surface groupings of molecules such as amino acids, sugar side chains, phosphoryl, or sulfonyl, and, in certain embodiments, may have specific three dimensional structural characteristics, and/or specific charge characteristics. An epitope is a region of an antigen that is bound by an antibody. In certain embodiments, an antibody is said to specifically bind an antigen when it recognizes its target antigen in a complex mixture of proteins and/or macromolecules. Antibodies are said to "bind to the same epitope" if the antibodies cross-compete (one prevents the binding or modulating effect of the other). In addition structural


definitions of epitopes (overlapping, similar, identical) are informative, but functional definitions are often more relevant as they encompass structural (binding) and functional (modulation, competition) parameters.

The term "surface plasmon resonance", as used herein, refers to an optical phenomenon that allows for the analysis of real-time biospecific interactions by detection of alterations in protein concentrations within a biosensor matrix, for example using the BIAcore® system (BIAcore International AB, a GE Healthcare company, Uppsala, Sweden and Piscataway, NJ). For further descriptions, see Jönsson, U., *et al.* (1993) *Ann. Biol. Clin.* 51:19-26; Jönsson, U., *et al.* (1991) *Biotechniques* 11:620-627; Johnson, B., *et al.* (1995) *J. Mol. Recognit.* 8:125-131; and Johnson, B., *et al.* (1991) *Anal. Biochem.* 198:268-277.

The term " K_{on} ", as used herein, is intended to refer to the on rate constant for association of a binding protein (e.g., an antibody) to the antigen to form the, e.g., antibody/antigen complex as is known in the art. The " K_{on} " also is known by the terms "association rate constant", or " k_a ", as used interchangeably herein. This value indicating the binding rate of an antibody to its target antigen or the rate of complex formation between an antibody and antigen also is shown by the equation below:



The term " K_{off} ", as used herein, is intended to refer to the off rate constant for dissociation, or "dissociation rate constant", of a binding protein (e.g., an antibody) from the, e.g., antibody/antigen complex as is known in the art. This value indicates the dissociation rate of an antibody from its target antigen or separation of Ab-Ag complex over time into free antibody and antigen as shown by the equation below:



The term " K_D " as used herein, is intended to refer to the "equilibrium dissociation constant", and refers to the value obtained in a titration measurement at equilibrium, or by dividing the dissociation rate constant (k_{off}) by the association rate constant (k_{on}). The association rate constant, the dissociation rate constant and the equilibrium dissociation constant are used to represent the binding affinity of an antibody to an antigen. Methods for determining association and dissociation rate constants are well known in the art. Using fluorescence-based techniques offers high sensitivity and the ability to examine samples in physiological buffers at equilibrium. Other experimental approaches and instruments such as a BIAcore® (biomolecular interaction analysis) assay can be used (e.g., instrument available from BIAcore International AB, a GE Healthcare company, Uppsala, Sweden). Additionally, a KinExA® (Kinetic Exclusion Assay) assay, available from Savidyne Instruments (Boise, Idaho) can also be used.

“Label” and “detectable label” mean a moiety attached to a specific binding partner, such as an antibody or an analyte, e.g., to render the reaction between members of a specific binding pair, such as an antibody and an analyte, detectable, and the specific binding partner, e.g., antibody or analyte, so labeled is referred to as “detectably labeled.” Thus, the term “labeled binding protein” as used herein, refers to a protein with a label incorporated that provides for the identification of the binding protein. In an embodiment, the label is a detectable marker that can produce a signal that is detectable by visual or instrumental means, e.g., incorporation of a radiolabeled amino acid or attachment to a polypeptide of biotinyl moieties that can be detected by marked avidin (e.g., streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or colorimetric methods). Examples of labels for polypeptides include, but are not limited to, the following: radioisotopes or radionuclides (e.g., ^3H , ^{14}C , ^{35}S , ^{90}Y , ^{99}Tc , ^{111}In , ^{125}I , ^{131}I , ^{177}Lu , ^{166}Ho , or ^{153}Sm); chromogens, fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), enzymatic labels (e.g., horseradish peroxidase, luciferase, alkaline phosphatase); chemiluminescent markers; biotinyl groups; predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags); and magnetic agents, such as gadolinium chelates. Representative examples of labels commonly employed for immunoassays include moieties that produce light, e.g., acridinium compounds, and moieties that produce fluorescence, e.g., fluorescein. Other labels are described herein. In this regard, the moiety itself may not be detectably labeled but may become detectable upon reaction with yet another moiety. Use of “detectably labeled” is intended to encompass the latter type of detectable labeling.

The term “conjugate” refers to a binding protein, such as an antibody, chemically linked to a second chemical moiety, such as a therapeutic or cytotoxic agent. The term “agent” is used herein to denote a chemical compound, a mixture of chemical compounds, a biological macromolecule, or an extract made from biological materials. In an embodiment, the therapeutic or cytotoxic agents include, but are not limited to, pertussis toxin, taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. When employed in the context of an immunoassay, the conjugate antibody may be a detectably labeled antibody used as the detection antibody.

The terms “crystal” and “crystallized” as used herein, refer to a binding protein (e.g., an antibody), or antigen binding portion thereof, that exists in the form of a crystal. Crystals are one form of the solid state of matter, which is distinct from other forms such as the amorphous solid state or the liquid crystalline state. Crystals are composed of regular, repeating, three-

dimensional arrays of atoms, ions, molecules (e.g., proteins such as antibodies), or molecular assemblies (e.g., antigen/antibody complexes). These three-dimensional arrays are arranged according to specific mathematical relationships that are well-understood in the field. The fundamental unit, or building block, that is repeated in a crystal is called the asymmetric unit.

5 Repetition of the asymmetric unit in an arrangement that conforms to a given, well-defined crystallographic symmetry provides the "unit cell" of the crystal. Repetition of the unit cell by regular translations in all three dimensions provides the crystal. See Giege, R. and Ducruix, A. Barrett, *Crystallization of Nucleic Acids and Proteins, a Practical Approach*, 2nd ea., pp. 20 1-16, Oxford University Press, New York, New York, (1999)."

10 The term "polynucleotide" means a polymeric form of two or more nucleotides, either ribonucleotides or deoxynucleotides or a modified form of either type of nucleotide. The term includes single and double stranded forms of DNA.

The term "isolated polynucleotide" shall mean a polynucleotide (e.g., of genomic, cDNA, or synthetic origin, or some combination thereof) that, by virtue of its origin, the "isolated
15 polynucleotide" is not associated with all or a portion of a polynucleotide with which the "isolated polynucleotide" is found in nature; is operably linked to a polynucleotide that it is not linked to in nature; or does not occur in nature as part of a larger sequence.

The term "vector", is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to
20 a circular double stranded DNA loop into which additional DNA segments may be ligated. Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) can be integrated into
25 the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply, "expression vectors"). In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification,
30 "plasmid" and "vector" may be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The term "operably linked" refers to a juxtaposition wherein the components described
35 are in a relationship permitting them to function in their intended manner. A control sequence

"operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences. "Operably linked" sequences include both expression control sequences that are contiguous with the gene of interest and expression control sequences that act in *trans* or at a distance to control the gene of interest.

5 The term "expression control sequence" as used herein refers to polynucleotide sequences which are necessary to effect the expression and processing of coding sequences to which they are ligated. Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance

10 translation efficiency (i.e., Kozak consensus sequence); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence; in eukaryotes, generally, such control sequences include promoters and transcription termination sequence. The

15 term "control sequences" is intended to include components whose presence is essential for expression and processing, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.

"Transformation", refers to any process by which exogenous DNA enters a host cell. Transformation may occur under natural or artificial conditions using various methods well

20 known in the art. Transformation may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method is selected based on the host cell being transformed and may include, but is not limited to, viral infection, electroporation, lipofection, and particle bombardment. Such "transformed" cells include stably transformed cells in which the inserted DNA is capable of replication either as an autonomously

25 replicating plasmid or as part of the host chromosome. They also include cells which transiently express the inserted DNA or RNA for limited periods of time.

The term "recombinant host cell" (or simply "host cell"), is intended to refer to a cell into which exogenous DNA has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell, but, to the progeny of such a cell. Because certain

30 modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein. In an embodiment, host cells include prokaryotic and eukaryotic cells selected from any of the Kingdoms of life. In another

embodiment, eukaryotic cells include protist, fungal, plant and animal cells. In another

35 embodiment, host cells include but are not limited to the prokaryotic cell line E.Coli; mammalian

cell lines CHO, HEK 293, COS, NS0, SP2 and PER.C6; the insect cell line Sf9; and the fungal cell *Saccharomyces cerevisiae*.

Standard techniques may be used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection). Enzymatic reactions and purification techniques may be performed according to manufacturer's specifications or as commonly accomplished in the art or as described herein. The foregoing techniques and procedures may be generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. See e.g., Sambrook et al. *Molecular Cloning: A Laboratory Manual* (2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)), which is incorporated herein by reference for any purpose.

“Transgenic organism”, as known in the art, refers to an organism having cells that contain a transgene, wherein the transgene introduced into the organism (or an ancestor of the organism) expresses a polypeptide not naturally expressed in the organism. A “transgene” is a DNA construct, which is stably and operably integrated into the genome of a cell from which a transgenic organism develops, directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic organism.

The term “regulate” and “modulate” are used interchangeably, and, as used herein, refers to a change or an alteration in the activity of a molecule of interest (e.g., the biological activity of a cytokine). Modulation may be an increase or a decrease in the magnitude of a certain activity or function of the molecule of interest. Exemplary activities and functions of a molecule include, but are not limited to, binding characteristics, enzymatic activity, cell receptor activation, and signal transduction.

Correspondingly, the term “modulator” is a compound capable of changing or altering an activity or function of a molecule of interest (e.g., the biological activity of a cytokine). For example, a modulator may cause an increase or decrease in the magnitude of a certain activity or function of a molecule compared to the magnitude of the activity or function observed in the absence of the modulator. In certain embodiments, a modulator is an inhibitor, which decreases the magnitude of at least one activity or function of a molecule. Exemplary inhibitors include, but are not limited to, proteins, peptides, antibodies, peptibodies, carbohydrates or small organic molecules. Peptibodies are described, e.g., in WO01/83525.

The term “agonist”, refers to a modulator that, when contacted with a molecule of interest, causes an increase in the magnitude of a certain activity or function of the molecule compared to the magnitude of the activity or function observed in the absence of the agonist. Particular

agonists of interest may include, but are not limited to, polypeptides, nucleic acids, carbohydrates, or any other molecules that bind to the antigen.

5 The term "antagonist" or "inhibitor", refer to a modulator that, when contacted with a molecule of interest causes a decrease in the magnitude of a certain activity or function of the molecule compared to the magnitude of the activity or function observed in the absence of the antagonist. Particular antagonists of interest include those that block or modulate the biological or immunological activity of of the antigen. Antagonists and inhibitors of antigens may include, but are not limited to, proteins, nucleic acids, carbohydrates, or any other molecules, which bind to the antigen.

10 As used herein, the term "effective amount" refers to the amount of a therapy which is sufficient to reduce or ameliorate the severity and/or duration of a disorder or one or more symptoms thereof, prevent the advancement of a disorder, cause regression of a disorder, prevent the recurrence, development, onset or progression of one or more symptoms associated with a disorder, detect a disorder, or enhance or improve the prophylactic or therapeutic effect(s) of
15 another therapy (e.g., prophylactic or therapeutic agent).

"Patient" and "subject" may be used interchangeably herein to refer to an animal, such as a mammal, including a primate (for example, a human, a monkey, and a chimpanzee), a non-primate (for example, a cow, a pig, a camel, a llama, a horse, a goat, a rabbit, a sheep, a hamster, a guinea pig, a cat, a dog, a rat, a mouse, a whale), a bird (e.g., a duck or a goose), and a shark.
20 Preferably, the patient or subject is a human, such as a human being treated or assessed for a disease, disorder or condition, a human at risk for a disease, disorder or condition, a human having a disease, disorder or condition, and/or human being treated for a disease, disorder or condition.

The term "sample", as used herein, is used in its broadest sense. A "biological sample", as
25 used herein, includes, but is not limited to, any quantity of a substance from a living thing or formerly living thing. Such living things include, but are not limited to, humans, mice, rats, monkeys, dogs, rabbits and other animals. Such substances include, but are not limited to, blood, (e.g., whole blood), plasma, serum, urine, amniotic fluid, synovial fluid, endothelial cells, leukocytes, monocytes, other cells, organs, tissues, bone marrow, lymph nodes and spleen.

30 "Component," "components," and "at least one component," refer generally to a capture antibody, a detection or conjugate antibody, a control, a calibrator, a series of calibrators, a sensitivity panel, a container, a buffer, a diluent, a salt, an enzyme, a co-factor for an enzyme, a detection reagent, a pretreatment reagent/solution, a substrate (e.g., as a solution), a stop solution, and the like that can be included in a kit for assay of a test sample, such as a patient urine, serum
35 or plasma sample, in accordance with the methods described herein and other methods known in

the art. Thus, in the context of the present disclosure, “at least one component,” “component,” and “components” can include a polypeptide or other analyte as above, such as a composition comprising an analyte such as polypeptide, which is optionally immobilized on a solid support, such as by binding to an anti-analyte (e.g., anti-polypeptide) antibody. Some components can be
5 in solution or lyophilized for reconstitution for use in an assay.

“Control” refers to a composition known to not analyte (“negative control”) or to contain analyte (“positive control”). A positive control can comprise a known concentration of analyte. “Control,” “positive control,” and “calibrator” may be used interchangeably herein to refer to a composition comprising a known concentration of analyte. A “positive control” can be used to
10 establish assay performance characteristics and is a useful indicator of the integrity of reagents (e.g., analytes).

“Predetermined cutoff” and “predetermined level” refer generally to an assay cutoff value that is used to assess diagnostic/prognostic/therapeutic efficacy results by comparing the assay results against the predetermined cutoff/level, where the predetermined cutoff/level already has
15 been linked or associated with various clinical parameters (e.g., severity of disease, progression/nonprogression/improvement, etc.). While the present disclosure may provide exemplary predetermined levels, it is well-known that cutoff values may vary depending on the nature of the immunoassay (e.g., antibodies employed, etc.). It further is well within the ordinary skill of one in the art to adapt the disclosure herein for other immunoassays to obtain
20 immunoassay-specific cutoff values for those other immunoassays based on this disclosure. Whereas the precise value of the predetermined cutoff/level may vary between assays, correlations as described herein (if any) should be generally applicable.

“Pretreatment reagent,” e.g., lysis, precipitation and/or solubilization reagent, as used in a diagnostic assay as described herein is one that lyses any cells and/or solubilizes any analyte that
25 is/are present in a test sample. Pretreatment is not necessary for all samples, as described further herein. Among other things, solubilizing the analyte (e.g., polypeptide of interest) may entail release of the analyte from any endogenous binding proteins present in the sample. A pretreatment reagent may be homogeneous (not requiring a separation step) or heterogeneous (requiring a separation step). With use of a heterogeneous pretreatment reagent there is removal
30 of any precipitated analyte binding proteins from the test sample prior to proceeding to the next step of the assay.

“Quality control reagents” in the context of immunoassays and kits described herein, include, but are not limited to, calibrators, controls, and sensitivity panels. A “calibrator” or “standard” typically is used (e.g., one or more, such as a plurality) in order to establish calibration
35 (standard) curves for interpolation of the concentration of an analyte, such as an antibody or an analyte. Alternatively, a single calibrator, which is near a predetermined positive/negative cutoff,

can be used. Multiple calibrators (i.e., more than one calibrator or a varying amount of calibrator(s)) can be used in conjunction so as to comprise a “sensitivity panel.”

“Risk” refers to the possibility or probability of a particular event occurring either presently or at some point in the future. “Risk stratification” refers to an array of known clinical risk factors that allows physicians to classify patients into a low, moderate, high or highest risk of developing a particular disease, disorder or condition.

“Specific” and “specificity” in the context of an interaction between members of a specific binding pair (e.g., an antigen (or fragment thereof) and an antibody (or antigenically reactive fragment thereof)) refer to the selective reactivity of the interaction. The phrase “specifically binds to” and analogous phrases refer to the ability of antibodies (or antigenically reactive fragments thereof) to bind specifically to analyte (or a fragment thereof) and not bind specifically to other entities.

“Specific binding partner” is a member of a specific binding pair. A specific binding pair comprises two different molecules, which specifically bind to each other through chemical or physical means. Therefore, in addition to antigen and antibody specific binding pairs of common immunoassays, other specific binding pairs can include biotin and avidin (or streptavidin), carbohydrates and lectins, complementary nucleotide sequences, effector and receptor molecules, cofactors and enzymes, enzyme inhibitors and enzymes, and the like. Furthermore, specific binding pairs can include members that are analogs of the original specific binding members, for example, an analyte-analog. Immunoreactive specific binding members include antigens, antigen fragments, and antibodies, including monoclonal and polyclonal antibodies as well as complexes, fragments, and variants (including fragments of variants) thereof, whether isolated or recombinantly produced.

“Variant” as used herein means a polypeptide that differs from a given polypeptide (e.g., IL-18, BNP, NGAL or HIV polypeptide or anti-polypeptide antibody) in amino acid sequence by the addition (e.g., insertion), deletion, or conservative substitution of amino acids, but that retains the biological activity of the given polypeptide (e.g., a variant IL-18 can compete with anti-IL-18 antibody for binding to IL-18). A conservative substitution of an amino acid, i.e., replacing an amino acid with a different amino acid of similar properties (e.g., hydrophilicity and degree and distribution of charged regions) is recognized in the art as typically involving a minor change. These minor changes can be identified, in part, by considering the hydropathic index of amino acids, as understood in the art (see, e.g., Kyte et al., J. Mol. Biol. 157: 105-132 (1982)). The hydropathic index of an amino acid is based on a consideration of its hydrophobicity and charge. It is known in the art that amino acids of similar hydropathic indexes can be substituted and still retain protein function. In one aspect, amino acids having hydropathic indexes of ± 2 are substituted. The hydrophilicity of amino acids also can be used to reveal substitutions that would

result in proteins retaining biological function. A consideration of the hydrophilicity of amino acids in the context of a peptide permits calculation of the greatest local average hydrophilicity of that peptide, a useful measure that has been reported to correlate well with antigenicity and immunogenicity (see, e.g., U.S. Pat. No. 4,554,101, which is incorporated herein by reference).

5 Substitution of amino acids having similar hydrophilicity values can result in peptides retaining biological activity, for example immunogenicity, as is understood in the art. In one aspect, substitutions are performed with amino acids having hydrophilicity values within ± 2 of each other. Both the hydrophobicity index and the hydrophilicity value of amino acids are influenced by the particular side chain of that amino acid. Consistent with that observation, amino acid

10 substitutions that are compatible with biological function are understood to depend on the relative similarity of the amino acids, and particularly the side chains of those amino acids, as revealed by the hydrophobicity, hydrophilicity, charge, size, and other properties. "Variant" also can be used to describe a polypeptide or fragment thereof that has been differentially processed, such as by proteolysis, phosphorylation, or other post-translational modification, yet retains its biological

15 activity or antigen reactivity, e.g., the ability to bind to IL-18. Use of "variant" herein is intended to encompass fragments of a variant unless otherwise contradicted by context.

I. Generation of DVD binding protein

The invention pertains to Dual Variable Domain binding proteins capable of binding one or more targets and methods of making the same. In an embodiment, the binding protein

20 comprises a polypeptide chain, wherein said polypeptide chain comprises VD1-(X1) n -VD2-C-(X2) n , wherein VD1 is a first variable domain, VD2 is a second variable domain, C is a constant domain, X1 represents an amino acid or polypeptide, X2 represents an Fc region and n is 0 or 1. The binding protein of the invention can be generated using various techniques. The invention provides expression vectors, host cell and methods of generating the binding protein.

25 A. Generation of parent monoclonal antibodies

The variable domains of the DVD binding protein can be obtained from parent antibodies, including polyclonal and mAbs capable of binding antigens of interest. These antibodies may be naturally occurring or may be generated by recombinant technology.

MAbs can be prepared using a wide variety of techniques known in the art including the

30 use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, mAbs can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al. , *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: *Monoclonal Antibodies and T-Cell Hybridomas* 563-681 (Elsevier, N.Y., 1981) (said references incorporated by reference in their

35 entireties). The term "monoclonal antibody" as used herein is not limited to antibodies produced

through hybridoma technology. The term "monoclonal antibody" refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced. Hybridomas are selected, cloned and further screened for desirable characteristics, including robust hybridoma growth, high antibody production and desirable antibody characteristics, as discussed in Example 1 below. Hybridomas may be cultured and expanded *in vivo* in syngeneic animals, in animals that lack an immune system, e.g., nude mice, or in cell culture *in vitro*. Methods of selecting, cloning and expanding hybridomas are well known to those of ordinary skill in the art. In a particular embodiment, the hybridomas are mouse hybridomas. In another embodiment, the hybridomas are produced in a non-human, non-mouse species such as rats, sheep, pigs, goats, cattle or horses. In another embodiment, the hybridomas are human hybridomas, in which a human non-secretory myeloma is fused with a human cell expressing an antibody capable of binding a specific antigen.

Recombinant mAbs are also generated from single, isolated lymphocytes using a procedure referred to in the art as the selected lymphocyte antibody method (SLAM), as described in U.S. Patent No. 5,627,052, PCT Publication WO 92/02551 and Babcock, J.S. *et al.* (1996) *Proc. Natl. Acad. Sci. USA* 93:7843-7848. In this method, single cells secreting antibodies of interest, e.g., lymphocytes derived from an immunized animal, are identified, and, heavy- and light-chain variable region cDNAs are rescued from the cells by reverse transcriptase-PCR and these variable regions can then be expressed, in the context of appropriate immunoglobulin constant regions (e.g., human constant regions), in mammalian host cells, such as COS or CHO cells. The host cells transfected with the amplified immunoglobulin sequences, derived from *in vivo* selected lymphocytes, can then undergo further analysis and selection *in vitro*, for example by panning the transfected cells to isolate cells expressing antibodies to the antigen of interest. The amplified immunoglobulin sequences further can be manipulated *in vitro*, such as by *in vitro* affinity maturation methods such as those described in PCT Publication WO 97/29131 and PCT Publication WO 00/56772.

Monoclonal antibodies are also produced by immunizing a non-human animal comprising some, or all, of the human immunoglobulin locus with an antigen of interest. In an embodiment, the non-human animal is a XENOMOUSE transgenic mouse, an engineered mouse strain that comprises large fragments of the human immunoglobulin loci and is deficient in mouse antibody production. See, e.g., Green et al. *Nature Genetics* 7:13-21 (1994) and United States Patents Nos. 5,916,771, 5,939,598, 5,985,615, 5,998,209, 6,075,181, 6,091,001, 6,114,598 and 6,130,364. See also WO 91/10741, published July 25, 1991, WO 94/02602, published February 3, 1994, WO 96/34096 and WO 96/33735, both published October 31, 1996, WO 98/16654, published April 23, 1998, WO 98/24893, published June 11, 1998, WO 98/50433, published November 12, 1998, WO 99/45031, published September 10, 1999, WO

99/53049, published October 21, 1999, WO 00 09560, published February 24, 2000 and WO 00/037504, published June 29, 2000. The XENOMOUSE transgenic mouse produces an adult-like human repertoire of fully human antibodies, and generates antigen-specific human monoclonal antibodies. The XENOMOUSE transgenic mouse contains approximately 80% of the human antibody repertoire through introduction of megabase sized, germline configuration YAC fragments of the human heavy chain loci and x light chain loci. See Mendez et al., *Nature Genetics* 15:146-156 (1997), Green and Jakobovits *J. Exp. Med.* 188:483-495 (1998), the disclosures of which are hereby incorporated by reference.

In vitro methods also can be used to make the parent antibodies, wherein an antibody library is screened to identify an antibody having the desired binding specificity. Methods for such screening of recombinant antibody libraries are well known in the art and include methods described in, for example, Ladner *et al.* U.S. Patent No. 5,223,409; Kang *et al.* PCT Publication No. WO 92/18619; Dower *et al.* PCT Publication No. WO 91/17271; Winter *et al.* PCT Publication No. WO 92/20791; Markland *et al.* PCT Publication No. WO 92/15679; Breitling *et al.* PCT Publication No. WO 93/01288; McCafferty *et al.* PCT Publication No. WO 92/01047; Garrard *et al.* PCT Publication No. WO 92/09690; Fuchs *et al.* (1991) *Bio/Technology* 9:1370-1372; Hay *et al.* (1992) *Hum Antibod Hybridomas* 3:81-85; Huse *et al.* (1989) *Science* 246:1275-1281; McCafferty *et al.*, *Nature* (1990) 348:552-554; Griffiths *et al.* (1993) *EMBO J* 12:725-734; Hawkins *et al.* (1992) *J Mol Biol* 226:889-896; Clackson *et al.* (1991) *Nature* 352:624-628; Gram *et al.* (1992) *PNAS* 89:3576-3580; Garrard *et al.* (1991) *Bio/Technology* 9:1373-1377; Hoogenboom *et al.* (1991) *Nuc Acid Res* 19:4133-4137; and Barbas *et al.* (1991) *PNAS* 88:7978-7982, US patent application publication 20030186374, and PCT Publication No. WO 97/29131, the contents of each of which are incorporated herein by reference.

Parent antibodies of the present invention can also be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In a particular, such phage can be utilized to display antigen-binding domains expressed from a repertoire or combinatorial antibody library (e. g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage including fd and M13 binding domains expressed from phage with Fab, Fv or disulfide stabilized Fv antibody domains recombinantly fused to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman *et al.*, *J. Immunol. Methods* 182:41-50 (1995); Ames *et al.*, *J. Immunol. Methods* 184:177-186 (1995); Kettleborough *et al.*, *Eur. J. Immunol.* 24:952-958 (1994); Persic *et al.*, *Gene* 187 9-18

(1997); Burton et al., *Advances in Immunology* 57:191-280 (1994); PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Pat. Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780, 225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.

As described in the herein references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies including human antibodies or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')₂ fragments can also be employed using methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., *BioTechniques* 12(6):864-869 (1992); and Sawai et al., *AJRI* 34:26-34 (1995); and Better et al., *Science* 240:1041-1043 (1988) (said references incorporated by reference in their entireties). Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Pat. 4,946,778 and 5,258, 498; Huston et al., *Methods in Enzymology* 203:46-88 (1991); Shu et al., *PNAS* 90:7995-7999 (1993); and Skerra et al., *Science* 240:1038-1040 (1988).

Alternative to screening of recombinant antibody libraries by phage display, other methodologies known in the art for screening large combinatorial libraries can be applied to the identification of parent antibodies. One type of alternative expression system is one in which the recombinant antibody library is expressed as RNA-protein fusions, as described in PCT Publication No. WO 98/31700 by Szostak and Roberts, and in Roberts, R.W. and Szostak, J.W. (1997) *Proc. Natl. Acad. Sci. USA* 94:12297-12302. In this system, a covalent fusion is created between an mRNA and the peptide or protein that it encodes by *in vitro* translation of synthetic mRNAs that carry puromycin, a peptidyl acceptor antibiotic, at their 3' end. Thus, a specific mRNA can be enriched from a complex mixture of mRNAs (e.g., a combinatorial library) based on the properties of the encoded peptide or protein, e.g., antibody, or portion thereof, such as binding of the antibody, or portion thereof, to the dual specificity antigen. Nucleic acid sequences encoding antibodies, or portions thereof, recovered from screening of such libraries can be expressed by recombinant means as described herein (e.g., in mammalian host cells) and, moreover, can be subjected to further affinity maturation by either additional rounds of screening of mRNA-peptide fusions in which mutations have been introduced into the originally selected sequence(s), or by other methods for affinity maturation *in vitro* of recombinant antibodies, as described herein.

In another approach the parent antibodies can also be generated using yeast display methods known in the art. In yeast display methods, genetic methods are used to tether antibody domains to the yeast cell wall and display them on the surface of yeast. In particular, such yeast can be utilized to display antigen-binding domains expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Examples of yeast display methods that can be used to make the parent antibodies include those disclosed in Wittrup, et al. U.S. Patent No. 6,699,658 incorporated herein by reference.

The antibodies described herein can be further modified to generate CDR grafted and humanized parent antibodies. CDR-grafted parent antibodies comprise heavy and light chain variable region sequences from a human antibody wherein one or more of the CDR regions of V_H and/or V_L are replaced with CDR sequences of murine antibodies capable of binding antigen of interest. A framework sequence from any human antibody may serve as the template for CDR grafting. However, straight chain replacement onto such a framework often leads to some loss of binding affinity to the antigen. The more homologous a human antibody is to the original murine antibody, the less likely the possibility that combining the murine CDRs with the human framework will introduce distortions in the CDRs that could reduce affinity. Therefore, in an embodiment, the human variable framework that is chosen to replace the murine variable framework apart from the CDRs have at least a 65% sequence identity with the murine antibody variable region framework. In an embodiment, the human and murine variable regions apart from the CDRs have at least 70% sequence identify. In a particular embodiment, that the human and murine variable regions apart from the CDRs have at least 75% sequence identity. In another embodiment, the human and murine variable regions apart from the CDRs have at least 80% sequence identity. Methods for producing such antibodies are known in the art (see EP 239,400; PCT publication WO 91/09967; U.S. Pat. Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, *Molecular Immunology* 28(4/5):489-498 (1991); Studnicka et al., *Protein Engineering* 7(6):805-814 (1994); Roguska et al., *PNAS* 91:969-973 (1994)), and chain shuffling (U.S. Pat. No. 5,565,352); and anti-idiotypic antibodies.

Humanized antibodies are antibody molecules from non-human species antibody that binds the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and framework regions from a human immunoglobulin molecule. Known human Ig sequences are disclosed, e.g., www.ncbi.nlm.nih.gov/entrez-/query.fcgi; www.atcc.org/phage/hdb.html; www.sciquest.com/; www.abcam.com/; www.antibodyresource.com/onlinecomp.html; www.public.iastate.edu/about.pedro/research_tools.html; www.mgen.uni-heidelberg.de/SD/IT/IT.html; www.whfreeman.com/immunology/CH-05/kuby05.htm; www.library.thinkquest.org/12429/Immune/Antibody.html;

www.hhmi.org/grants/lectures/1996/vlab/; www.path.cam.ac.uk/.about.mrc7/m-ikeimages.html;
www.antibodyresource.com/; mcb.harvard.edu/BioLinks/Immunology.html.www.immunologylink.com/; pathbox.wustl.edu/.about.hcenter/index.-html;
www.biotech.ufl.edu/.about.hcl/; www.pebio.com/pa/340913/340913.html ;
5 www.nal.usda.gov/awic/pubs/antibody/; www.m.ehime-u.ac.jp/.about.yasuhito-/Elisa.html;
www.biodesign.com/table.asp; www.icnet.uk/axp/facs/davies/links.html;
www.biotech.ufl.edu/.about.fccl/protocol.html; www.isac-net.org/sites_geo.html; aximtl.imt.uni-marburg.de/.about.rek/AEP-Start.html; baserv.uci.kun.nl/.about.jraats/links.html;
www.recab.uni-hd.de/immuno.bme.nwu.edu/; www.mrc-cpe.cam.ac.uk/imt-doc-public/INTRO.html; www.ibt.unam.mx/vir/V_mice.html; imgt.cnusc.fr:8104/;
10 www.biochem.ucl.ac.uk/.about.martin/abs/index.html; antibody.bath.ac.uk/;
abgen.cvm.tamu.edu/lab/wwwabgen.html; www.unizh.ch/.about.honegger/AHOseminar/Slide01.html; www.cryst.bbk.ac.uk/.about.ubcg07s/;
www.nimr.mrc.ac.uk/CC/ccaewg/ccaewg.htm; www.path.cam.ac.uk/.about.mrc7/humanisation/TAHHP.html; www.ibt.unam.mx/vir/structure/stat_aim.html;
15 www.biosci.missouri.edu/smithgp/index.html; www.cryst.bioc.cam.ac.uk/.about.fmolina/Webpages/Pept/spottech.html; www.jerini.de/fr/roducts.htm; www.patents.ibm.com/ibm.html. Kabat et al., Sequences of Proteins of Immunological Interest, U.S. Dept. Health (1983), each entirely incorporated herein by reference. Such imported sequences can be used to reduce immunogenicity
20 or reduce, enhance or modify binding, affinity, on-rate, off-rate, avidity, specificity, half-life, or any other suitable characteristic, as known in the art.

Framework residues in the human framework regions may be substituted with the corresponding residue from the CDR donor antibody to alter, e.g., improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling
25 of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al., U.S. Pat. No. 5,585,089; Riechmann et al., Nature 332:323 (1988), which are incorporated herein by reference in their entireties.) Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art.
30 Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from
35 the consensus and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved. In general, the CDR residues are directly and most

substantially involved in influencing antigen binding. Antibodies can be humanized using a variety of techniques known in the art, such as but not limited to those described in Jones et al., Nature 321:522 (1986); Verhoeyen et al., Science 239:1534 (1988)), Sims et al., J. Immunol. 151: 2296 (1993); Chothia and Lesk, J. Mol. Biol. 196:901 (1987), Carter et al., Proc. Natl. Acad. Sci. U.S.A. 89:4285 (1992); Presta et al., J. Immunol. 151:2623 (1993), Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnicka et al., Protein Engineering 7(6):805-814 (1994); Roguska. et al. , PNAS 91:969-973 (1994); PCT publication WO 91/09967, PCT/: US98/16280, US96/18978, US91/09630, US91/05939, US94/01234, GB89/01334, GB91/01134, GB92/01755; WO90/14443, WO90/14424, WO90/14430, EP 229246, EP 592,106; EP 519,596, EP 239,400, U.S. Pat. Nos. 5,565,332, 5,723,323, 5,976,862, 5,824,514, 5,817,483, 5,814,476, 5,763,192, 5,723,323, 5,766,886, 5,714,352, 6,204,023, 6,180,370, 5,693,762, 5,530,101, 5,585,089, 5,225,539; 4,816,567, each entirely incorporated herein by reference, included references cited therein.

B. Criteria for selecting parent monoclonal antibodies

An embodiment of the invention pertains to selecting parent antibodies with at least one or more properties desired in the DVD-Ig molecule. In an embodiment, the desired property is selected from one or more antibody parameters. In another embodiment, the antibody parameters are selected from the group consisting of antigen specificity, affinity to antigen, potency, biological function, epitope recognition, stability, solubility, production efficiency, immunogenicity, pharmacokinetics, bioavailability, tissue cross reactivity, and orthologous antigen binding.

B1. Affinity to Antigen

The desired affinity of a therapeutic mAb may depend upon the nature of the antigen, and the desired therapeutic end-point. In an embodiment, monoclonal antibodies have higher affinities ($K_d = 0.01 - 0.50 \text{ pM}$) when blocking a cytokine-cytokine receptor interaction as such interaction are usually high affinity interactions (e.g., $< \text{pM} - < \text{nM}$ ranges). In such instances, the mAb affinity for its target should be equal to or better than the affinity of the cytokine (ligand) for its receptor. On the other hand, mAb with lesser affinity ($> \text{nM}$ range) could be therapeutically effective e.g., in clearing circulating potentially pathogenic proteins e.g., monoclonal antibodies that bind to, sequester, and clear circulating species of A- β amyloid. In other instances, reducing the affinity of an existing high affinity mAb by site-directed mutagenesis or using a mAb with lower affinity for its target could be used to avoid potential side-effects e.g., a high affinity mAb may sequester/neutralize all of its intended target, thereby completely depleting/eliminating the function(s) of the targeted protein. In this scenario, a low affinity mAb may sequester/neutralize a fraction of the target that may be responsible for the disease symptoms (the pathological or over-

produced levels), thus allowing a fraction of the target to continue to perform its normal physiological function(s). Therefore, it may be possible to reduce the K_d to adjust dose and/or reduce side-effects. The affinity of the parental mAb might play a role in appropriately targeting cell surface molecules to achieve desired therapeutic out-come. For example, if a target is
5 expressed on cancer cells with high density and on normal cells with low density, a lower affinity mAb will bind a greater number of targets on tumor cells than normal cells, resulting in tumor cell elimination via ADCC or CDC, and therefore might have therapeutically desirable effects. Thus selecting a mAb with desired affinity may be relevant for both soluble and surface targets.

Signaling through a receptor upon interaction with its ligand may depend upon the
10 affinity of the receptor-ligand interaction. Similarly, it is conceivable that the affinity of a mAb for a surface receptor could determine the nature of intracellular signaling and whether the mAb may deliver an agonist or an antagonist signal. The affinity-based nature of mAb-mediated signaling may have an impact of its side-effect profile. Therefore, the desired affinity and desired functions of therapeutic monoclonal antibodies need to be determined carefully by in vitro and in
15 vivo experimentation.

The desired K_d of a binding protein (e.g., an antibody) may be determined experimentally depending on the desired therapeutic outcome. In an embodiment parent antibodies with affinity (K_d) for a particular antigen equal to, or better than, the desired affinity of the DVD-Ig for the same antigen are selected. The antigen binding affinity and kinetics are assessed by Biacore or
20 another similar technique. In one embodiment, each parent antibody has a dissociation constant (K_d) to its antigen selected from the group consisting of: at most about 10^{-7} M; at most about 10^{-8} M; at most about 10^{-9} M; at most about 10^{-10} M; at most about 10^{-11} M; at most about 10^{-12} M; and at most 10^{-13} M. First parent antibody from which VD1 is obtained and second parent antibody from which VD2 is obtained may have similar or different affinity (K_D) for the respective antigen.
25 Each parent antibody has an on rate constant (K_{on}) to the antigen selected from the group consisting of: at least about $10^2 M^{-1} s^{-1}$; at least about $10^3 M^{-1} s^{-1}$; at least about $10^4 M^{-1} s^{-1}$; at least about $10^5 M^{-1} s^{-1}$; and at least about $10^6 M^{-1} s^{-1}$, as measured by surface plasmon resonance. The first parent antibody from which VD1 is obtained and the second parent antibody from which VD2 is obtained may have similar or different on rate constant (K_{on}) for the respective antigen. In one
30 embodiment, each parent antibody has an off rate constant (K_{off}) to the antigen selected from the group consisting of: at most about $10^{-3} s^{-1}$; at most about $10^{-4} s^{-1}$; at most about $10^{-5} s^{-1}$; and at most about $10^{-6} s^{-1}$, as measured by surface plasmon resonance. The first parent antibody from which VD1 is obtained and the second parent antibody from which VD2 is obtained may have similar or different off rate constants (K_{off}) for the respective antigen.

35 **B2. Potency**

The desired affinity/potency of parental monoclonal antibodies will depend on the desired therapeutic outcome. For example, for receptor-ligand (R-L) interactions the affinity (kd) is equal to or better than the R-L kd (pM range). For simple clearance of a pathologic circulating protein, the kd could be in low nM range e.g., clearance of various species of circulating A- β peptide. In addition, the kd will also depend on whether the target expresses multiple copies of the same epitope e.g a mAb targeting conformational epitope in A β oligomers.

Where VDI and VD2 bind the same antigen, but distinct epitopes, the DVD-Ig will contain 4 binding sites for the same antigen, thus increasing avidity and thereby the apparent kd of the DVD-Ig. In an embodiment, parent antibodies with equal or lower kd than that desired in the DVD-Ig are chosen. The affinity considerations of a parental mAb may also depend upon whether the DVD-Ig contains four or more identical antigen binding sites (i.e; a DVD-Ig from a single mAb). In this case, the apparent kd would be greater than the mAb due to avidity. Such DVD-Igs can be employed for cross-linking surface receptor, increase neutralization potency, enhance clearance of pathological proteins etc.

In an embodiment parent antibodies with neutralization potency for specific antigen equal to or better than the desired neutralization potential of the DVD-Ig for the same antigen are selected. The neutralization potency can be assessed by a target-dependent bioassay where cells of appropriate type produce a measurable signal (i.e. proliferation or cytokine production) in response to target stimulation, and target neutralization by the mAb can reduce the signal in a dose-dependent manner.

B3. Biological functions

Monoclonal antibodies can perform potentially several functions. Some of these functions are listed in Table 1. These functions can be assessed by both in vitro assays (e.g., cell-based and biochemical assays) and in vivo animal models.

Table 1: Some Potential Applications For Therapeutic Antibodies

Target (Class)	Mechanism of Action (target)
Soluble (cytokines, other)	Neutralization of activity (e.g., a cytokine) Enhance clearance (e.g., A β oligomers) Increase half-life (e.g., GLP 1)
Cell Surface (Receptors, other)	Agonist (e.g., GLP1 R; EPO R; etc.) Antagonist (e.g., integrins; etc.) Cytotoxic (CD 20; etc.)
Protein deposits	Enhance clearance/degradation (e.g., A β plaques, amyloid deposits)

MABs with distinct functions described in the examples herein in Table 1 can be selected to achieve desired therapeutic outcomes. Two or more selected parent monoclonal antibodies can then be used in DVD-Ig format to achieve two distinct functions in a single DVD-Ig molecule. For example, a DVD-Ig can be generated by selecting a parent mAb that neutralizes function of a specific cytokine, and selecting a parent mAb that enhances clearance of a pathological protein. Similarly, we can select two parent monoclonal antibodies that recognize two different cell surface receptors, one mAb with an agonist function on one receptor and the other mAb with an antagonist function on a different receptor. These two selected monoclonal antibodies each with a distinct function can be used to construct a single DVD-Ig molecule that will possess the two distinct functions (agonist and antagonist) of the selected monoclonal antibodies in a single molecule. Similarly, two antagonistic monoclonal antibodies to cell surface receptors each blocking binding of respective receptor ligands (e.g., EGF and IGF) can be used in a DVD-Ig format. Conversely, an antagonistic anti-receptor mAb (e.g., anti-EGFR) and a neutralizing anti-soluble mediator (e.g., anti-IGF1/2) mAb can be selected to make a DVD-Ig.

15 **B4. Epitope Recognition:**

Different regions of proteins may perform different functions. For example specific regions of a cytokine interact with the cytokine receptor to bring about receptor activation whereas other regions of the protein may be required for stabilizing the cytokine. In this instance one may select a mAb that binds specifically to the receptor interacting region(s) on the cytokine and thereby block cytokine-receptor interaction. In some cases, for example certain chemokine receptors that bind multiple ligands, a mAb that binds to the epitope (region on chemokine receptor) that interacts with only one ligand can be selected. In other instances, monoclonal antibodies can bind to epitopes on a target that are not directly responsible for physiological functions of the protein, but binding of a mAb to these regions could either interfere with physiological functions (steric hindrance) or alter the conformation of the protein such that the protein cannot function (mAb to receptors with multiple ligand which alter the receptor conformation such that none of the ligand can bind). Anti-cytokine monoclonal antibodies that do not block binding of the cytokine to its receptor, but block signal transduction have also been identified (e.g., 125-2H, an anti-IL-18 mAb).

30 Examples of epitopes and mAb functions include, but are not limited to, blocking Receptor-Ligand (R-L) interaction (neutralizing mAb that binds R-interacting site); steric hindrance resulting in diminished or no R-binding. An Ab can bind the target at a site other than a receptor binding site, but still interferes with receptor binding and functions of the target by inducing conformational change and eliminate function (e.g., Xolair), binding to R but block signaling (125-2H).

In an embodiment, the parental mAb needs to target the appropriate epitope for maximum efficacy. Such epitope should be conserved in the DVD-Ig. The binding epitope of a mAb can be determined by several approaches, including co-crystallography, limited proteolysis of mAb-antigen complex plus mass spectrometric peptide mapping (Legros V. et al 2000 Protein Sci. 9:1002-10), phage displayed peptide libraries (O'Connor KH et al 2005 J Immunol Methods. 299:21-35), as well as mutagenesis (Wu C. et al . 2003 J Immunol 170:5571-7).

B5. Physicochemical and pharmaceutical properties:

Therapeutic treatment with antibodies often requires administration of high doses, often several mg/kg (due to a low potency on a mass basis as a consequence of a typically large molecular weight). In order to accommodate patient compliance and to adequately address chronic disease therapies and outpatient treatment, subcutaneous (s.c.) or intramuscular (i.m.) administration of therapeutic mAbs is desirable. For example, the maximum desirable volume for s.c. administration is ~1.0 mL, and therefore, concentrations of >100 mg/mL are desirable to limit the number of injections per dose. In an embodiment, the therapeutic antibody is administered in one dose. The development of such formulations is constrained, however, by protein-protein interactions (e.g., aggregation, which potentially increases immunogenicity risks) and by limitations during processing and delivery (e.g., viscosity). Consequently, the large quantities required for clinical efficacy and the associated development constraints limit full exploitation of the potential of antibody formulation and s.c. administration in high-dose regimens. It is apparent that the physicochemical and pharmaceutical properties of a protein molecule and the protein solution are of utmost importance, e.g., stability, solubility and viscosity features.

B5.1. Stability:

A "stable" antibody formulation is one in which the antibody therein essentially retains its physical stability and/or chemical stability and/or biological activity upon storage. Stability can be measured at a selected temperature for a selected time period. In an embodiment,, the antibody in the formulation is stable at room temperature (about 30°C) or at 40°C for at least 1 month and/or stable at about 2-8°C. for at least 1 year for at least 2 years. Furthermore, in an embodiment, the formulation is stable following freezing (to, e.g., -70°C) and thawing of the formulation, hereinafter referred to as a "freeze/thaw cycle." In another example, a "stable" formulation may be one wherein less than about 10% and less than about 5% of the protein is present as an aggregate in the formulation.

A DVD-Ig stable in vitro at various temperatures for an extended time period is desirable. One can achieve this by rapid screening of parental mAbs stable in vitro at elevated temperature, e.g., at 40°C for 2-4 weeks, and then assess stability. During storage at 2-8°C, the protein reveals stability for at least 12 months, e.g., at least 24 months. Stability (% of monomeric, intact

molecule) can be assessed using various techniques such as cation exchange chromatography, size exclusion chromatography, SDS-PAGE, as well as bioactivity testing. For a more comprehensive list of analytical techniques that may be employed to analyze covalent and conformational modifications please see Jones, A. J. S. (1993) Analytical methods for the assessment of protein formulations and delivery systems. In: Cleland, J. L.; Langer, R., editors. Formulation and delivery of peptides and proteins, 1st edition, Washington, ACS, pg. 22-45; and Pearlman, R.; Nguyen, T. H.(1990) Analysis of protein drugs. In: Lee, V. H., editor. Peptide and protein drug delivery, 1st edition, New York, Marcel Dekker, Inc., pg. 247-301.

Heterogeneity and aggregate formation: stability of the antibody may be such that the formulation may reveal less than about 10%, and, in an embodiment, less than about 5%, in another embodiment, less than about 2%, or, in an embodiment, within the range of 0.5% to 1.5% or less in the GMP antibody material that is present as aggregate. Size exclusion chromatography is a method that is sensitive, reproducible, and very robust in the detection of protein aggregates.

In addition to low aggregate levels, the antibody must, in an embodiment, be chemically stable. Chemical stability may be determined by ion exchange chromatography (e.g., cation or anion exchange chromatography), hydrophobic interaction chromatography, or other methods such as isoelectric focusing or capillary electrophoresis. For instance, chemical stability of the antibody may be such that after storage of at least 12 months at 2-8°C the peak representing unmodified antibody in a cation exchange chromatography may increase not more than 20%, in an embodiment, not more than 10%, or, in another embodiment, not more than 5% as compared to the antibody solution prior to storage testing.

In an embodiment, the parent antibodies display structural integrity; correct disulfide bond formation, and correct folding: Chemical instability due to changes in secondary or tertiary structure of an antibody may impact antibody activity. For instance, stability as indicated by activity of the antibody may be such that after storage of at least 12 months at 2-8°C the activity of the antibody may decrease not more than 50%, in an embodiment not more than 30%, or even not more than 10%, or in an embodiment not more than 5% or 1% as compared to the antibody solution prior to storage testing. Suitable antigen-binding assays can be employed to determine antibody activity.

30 **B5.2. Solubility:**

The "solubility" of a mAb correlates with the production of correctly folded, monomeric IgG. The solubility of the IgG may therefore be assessed by HPLC. For example, soluble (monomeric) IgG will give rise to a single peak on the HPLC chromatograph, whereas insoluble (e.g., multimeric and aggregated) will give rise to a plurality of peaks. A person skilled in the art will therefore be able to detect an increase or decrease in solubility of an IgG using routine HPLC

techniques. For a more comprehensive list of analytical techniques that may be employed to analyze solubility (see Jones, A. G. *Dep. Chem. Biochem. Eng., Univ. Coll. London, London, UK*. Editor(s): Shamlou, P. Ayazi. *Process. Solid-Liq. Suspensions* (1993), 93-117. Publisher: Butterworth-Heinemann, Oxford, UK and Pearlman, Rodney; Nguyen, Tue H, *Advances in Parenteral Sciences* (1990), 4 (Pept. Protein Drug Delivery), 247-301). Solubility of a therapeutic mAb is critical for formulating to high concentration often required for adequate dosing. As outlined herein, solubilities of >100 mg/mL may be required to accommodate efficient antibody dosing. For instance, antibody solubility may be not less than about 5 mg/mL in early research phase, in an embodiment not less than about 25 mg/mL in advanced process science stages, or in an embodiment not less than about 100 mg/mL, or in an embodiment not less than about 150 mg/mL. It is obvious to a person skilled in the art that the intrinsic properties of a protein molecule are important the physico-chemical properties of the protein solution, e.g., stability, solubility, viscosity. However, a person skilled in the art will appreciate that a broad variety of excipients exist that may be used as additives to beneficially impact the characteristics of the final protein formulation. These excipients may include: (i) liquid solvents, cosolvents (e.g., alcohols such as ethanol); (ii) buffering agents (e.g., phosphate, acetate, citrate, amino acid buffers); (iii) sugars or sugar alcohols (e.g., sucrose, trehalose, fructose, raffinose, mannitol, sorbitol, dextrans); (iv) surfactants (e.g., polysorbate 20, 40, 60, 80, poloxamers); (v) isotonicity modifiers (e.g., salts such as NaCl, sugars, sugar alcohols); and (vi) others (e.g., preservatives, chelating agents, antioxidants, chelating substances (e.g., EDTA), biodegradable polymers, carrier molecules (e.g., HSA, PEGs)

Viscosity is a parameter of high importance with regard to antibody manufacture and antibody processing (e.g., diafiltration/ultrafiltration), fill-finish processes (pumping aspects, filtration aspects) and delivery aspects (syringeability, sophisticated device delivery). Low viscosities enable the liquid solution of the antibody having a higher concentration. This enables the same dose may be administered in smaller volumes. Small injection volumes inhere the advantage of lower pain on injection sensations, and the solutions not necessarily have to be isotonic to reduce pain on injection in the patient. The viscosity of the antibody solution may be such that at shear rates of 100 (1/s) antibody solution viscosity is below 200 mPa s, in an embodiment below 125 mPa s, in another embodiment below 70 mPa s, and in yet another embodiment below 25 mPa s or even below 10 mPa s.

B 5.3. Production efficiency

The generation of a DVD-Ig that is efficiently expressed in mammalian cells, such as Chinese hamster ovary cells (CHO), will in an embodiment require two parental monoclonal antibodies which are themselves expressed efficiently in mammalian cells. The production yield from a stable mammalian line (i.e. CHO) should be above about 0.5g/L, in an embodiment above

about 1g/L, and in another embodiment in the range of from about 2-5 g/L or more (Kipriyanov SM, Little M. 1999 Mol Biotechnol. 12:173-201; Carroll S, Al-Rubeai M. 2004 Expert Opin Biol Ther. 4:1821-9).

5 Production of antibodies and Ig fusion proteins in mammalian cells is influenced by several factors. Engineering of the expression vector via incorporation of strong promoters, enhancers and selection markers can maximize transcription of the gene of interest from an integrated vector copy. The identification of vector integration sites that are permissive for high levels of gene transcription can augment protein expression from a vector (Wurm et al, 2004, Nature Biotechnology , 2004, Vol/Iss/Pg. 22/11 (1393-1398)). Furthermore, levels of production
10 are affected by the ratio of antibody heavy and light chains and various steps in the process of protein assembly and secretion (Jiang et al. 2006, Biotechnology Progress, Jan-Feb 2006, vol. 22, no. 1, p. 313-8).

B 6. Immunogenicity

Administration of a therapeutic mAb may results in certain incidence of an immune
15 response (ie, the formation of endogenous antibodies directed against the therapeutic mAb). Potential elements that might induce immunogenicity should be analyzed during selection of the parental monoclonal antibodies, and steps to reduce such risk can be taken to optimize the parental monoclonal antibodies prior to DVD-Ig construction. Mouse-derived antibodies have been found to be highly immunogenic in patients. The generation of chimeric antibodies
20 comprised of mouse variable and human constant regions presents a logical next step to reduce the immunogenicity of therapeutic antibodies (Morrison and Schlom, 1990). Alternatively, immunogenicity can be reduced by transferring murine CDR sequences into a human antibody framework (reshaping/CDR grafting/humanization), as described for a therapeutic antibody by Riechmann et al., 1988. Another method is referred to as “resurfacing” or “veneering”, starting
25 with the rodent variable light and heavy domains, only surface-accessible framework amino acids are altered to human ones, while the CDR and buried amino acids remain from the parental rodent antibody (Roguska et al., 1996). In another type of humanization, instead of grafting the entire CDRs, one technique grafts only the “specificity-determining regions” (SDRs), defined as the subset of CDR residues that are involved in binding of the antibody to its target (Kashmiri et al.,
30 2005). This necessitates identification of the SDRs either through analysis of available three-dimensional structures of antibody-target complexes or mutational analysis of the antibody CDR residues to determine which interact with the target. Alternatively, fully human antibodies may have reduced immunogenicity compared to murine, chimeric or humanized antibodies.

Another approach to reduce the immunogenicity of therapeutic antibodies is the
35 elimination of certain specific sequences that are predicted to be immunogenic. In one approach,

after a first generation biologic has been tested in humans and found to be unacceptably immunogenic, the B-cell epitopes can be mapped and then altered to avoid immune detection. Another approach uses methods to predict and remove potential T-cell epitopes. Computational methods have been developed to scan and to identify the peptide sequences of biologic therapeutics with the potential to bind to MHC proteins (Desmet et al., 2005). Alternatively a human dendritic cell-based method can be used to identify CD4⁺ T-cell epitopes in potential protein allergens (Stickler et al., 2005; S.L. Morrison and J. Schlom, *Important Adv. Oncol.* (1990), pp. 3-18; Riechmann, L., Clark, M., Waldmann, H. and Winter, G. "*Reshaping human antibodies for therapy.*" *Nature* (1988) 332: 323-327; Roguska-M-A, Pedersen-J-T, Henry-A-H, Searle-S-M, Roja-C-M, Avery-B, Hoffee-M, Cook-S, Lambert-J-M, Blättler-W-A, Rees-A-R, Guild-B-C. A comparison of two murine mAbs humanized by CDR-grafting and variable domain resurfacing. *Protein engineering*, {Protein-Eng}, 1996, vol. 9, p. 895-904; Kashmiri-Syed-V-S, De-Pascalis-Roberto, Gonzales-Noreen-R, Schlom-Jeffrey. SDR grafting--a new approach to antibody humanization. *Methods* (San Diego Calif.), {Methods}, May 2005, vol. 36, no. 1, p. 25-34; Desmet-Johan, Meersseman-Geert, Boutonnet-Nathalie, Pletinckx-Jurgen, De-Clercq-Krista, Debulpaep-Maja, Braeckman-Tessa, Lasters-Ignace. Anchor profiles of HLA-specific peptides: analysis by a novel affinity scoring method and experimental validation. *Proteins*, 2005, vol. 58, p. 53-69; Stickler-M-M, Estell-D-A, Harding-F-A. CD4⁺ T-cell epitope determination using unexposed human donor peripheral blood mononuclear cells. *Journal of immunotherapy* 2000, vol. 23, p. 654-60.)

B 7. In vivo efficacy

To generate a DVD-Ig molecule with desired in vivo efficacy, it is important to generate and select mAbs with similarly desired in vivo efficacy when given in combination. However, in some instances the DVD-Ig may exhibit in vivo efficacy that cannot be achieved with the combination of two separate mAbs. For instance, a DVD-Ig may bring two targets in close proximity leading to an activity that cannot be achieved with the combination of two separate mAbs. Additional desirable biological functions are described herein in section **B 3**. Parent antibodies with characteristics desirable in the DVD-Ig molecule may be selected based on factors such as pharmacokinetic t_{1/2}; tissue distribution; soluble versus cell surface targets; and target concentration- soluble/density –surface.

B 8. In vivo tissue distribution

To generate a DVD-Ig molecule with desired in vivo tissue distribution, in an embodiment parent mAbs with similar desired in vivo tissue distribution profile must be selected. Alternatively, based on the mechanism of the dual-specific targeting strategy, it may at other times not be required to select parent mAbs with the similarly desired in vivo tissue distribution

when given in combination. For instance, in the case of a DVD-Ig in which one binding component targets the DVD-Ig to a specific site thereby bringing the second binding component to the same target site. For example, one binding specificity of a DVD-Ig could target pancreas (islet cells) and the other specificity could bring GLP1 to the pancreas to induce insulin.

5 **B 9. Isotype:**

To generate a DVD-Ig molecule with desired properties including, but not limited to, Isotype, Effector functions and the circulating half-life, in an embodiment parent mAbs with appropriate Fc-effector functions depending on the therapeutic utility and the desired therapeutic end-point are selected. There are five main heavy-chain classes or isotypes some of which have
10 several sub-types and these determine the effector functions of an antibody molecule. These effector functions reside in the hinge region, CH2 and CH3 domains of the antibody molecule. However, residues in other parts of an antibody molecule may have effects on effector functions as well. The hinge region Fc-effector functions include: (i) antibody-dependent cellular cytotoxicity, (ii) complement (C1q) binding, activation and complement-dependent cytotoxicity
15 (CDC), (iii) phagocytosis/clearance of antigen-antibody complexes, and (iv) cytokine release in some instances. These Fc-effector functions of an antibody molecule are mediated through the interaction of the Fc-region with a set of class-specific cell surface receptors. Antibodies of the IgG1 isotype are most active while IgG2 and IgG4 having minimal or no effector functions. The effector functions of the IgG antibodies are mediated through interactions with three structurally
20 homologous cellular Fc receptor types (and sub-types) (FcγR1, FcγR2 and FcγR3). These effector functions of an IgG1 can be eliminated by mutating specific amino acid residues in the lower hinge region (e.g., L234A, L235A) that are required for FcγR and C1q binding. Amino acid residues in the Fc region, in particular the CH2-CH3 domains, also determine the circulating half-life of the antibody molecule. This Fc function is mediated through the binding of the Fc-region to
25 the neonatal Fc receptor (FcRn) which is responsible for recycling of antibody molecules from the acidic lysosomes back to the general circulation.

Whether a mAb should have an active or an inactive isotype will depend on the desired therapeutic end-point for an antibody. Some examples of usage of isotypes and desired therapeutic outcome are listed below:

- 30 a) If the desired end-point is functional neutralization of a soluble cytokine then an inactive isotype may be used;
- b) If the desired out-come is clearance of a pathological protein an active isotype may be used;
- c) If the desired out-come is clearance of protein aggregates an active isotype may be used;

- d) If the desired outcome is to antagonize a surface receptor an inactive isotype is used (Tysabri, IgG4; OKT3, mutated IgG1);
- e) If the desired outcome is to eliminate target cells an active isotype is used (Herceptin, IgG1 (and with enhanced effector functions); and
- 5 f) If the desired outcome is to clear proteins from circulation without entering the CNS an IgM isotype may be used (e.g., clearing circulating Ab peptide species).

The Fc effector functions of a parental mAb can be determined by various in vitro methods well known in the art.

As discussed, the selection of isotype, and thereby the effector functions will depend upon
 10 the desired therapeutic end-point. In cases where simple neutralization of a circulating target is desired, for example blocking receptor-ligand interactions, the effector functions may not be required. In such instances isotypes or mutations in the Fc-region of an antibody that eliminate effector functions are desirable. In other instances where elimination of target cells is the therapeutic end-point, for example elimination of tumor cells, isotypes or mutations or de-
 15 fucosylation in the Fc-region that enhance effector functions are desirable (Presta GL, *Adv. Drug Delivery Rev.* 58:640-656, 2006; Satoh M., Iida S., Shitara K. *Expert Opinion Biol. Ther.* 6:1161-1173, 2006). Similarly, depending up on the therapeutic utility, the circulating half-life of an antibody molecule can be reduced/prolonged by modulating antibody-FcRn interactions by introducing specific mutations in the Fc region (Dall'Acqua WF, Kiener PA, Wu H. *J. Biol. Chem.* 281:23514-23524, 2006; Petkova SB., Akilesh S., Sproule TJ. et al. *Internat. Immunol.* 18:1759-1769, 2006; Vaccaro C., Bawdon R., Wanjie S et al. *PNAS* 103:18709-18714, 2007).

The published information on the various residues that influence the different effector functions of a normal therapeutic mAb may need to be confirmed for DVD-Ig. It may be possible that in a DVD-Ig format additional (different) Fc-region residues, other than those identified for
 25 the modulation of monoclonal antibody effector functions, may be important.

Overall, the decision as to which Fc-effector functions (isotype) will be critical in the final DVD-Ig format will depend up on the disease indication, therapeutic target, desired therapeutic end-point and safety considerations. Listed below are exemplary appropriate heavy chain and light chain constant regions including, but not limited to:

- 30
- IgG1 – allotype: G1mz
 - IgG1 mutant – A234, A235
 - IgG2 – allotype: G2m(n-)
 - Kappa – Km3

- Lambda

Fc Receptor and C1q Studies: The possibility of unwanted antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) by antibody complexing to any overexpressed target on cell membranes can be abrogated by the (for example, 5 L234A, L235A) hinge-region mutations. These substituted amino acids, present in the IgG1 hinge region of mAb, are expected to result in diminished binding of mAb to human Fc receptors (but not FcRn), as FcγR binding is thought to occur within overlapping sites on the IgG1 hinge region. This feature of mAb may lead to an improved safety profile over antibodies containing a wild-type IgG. Binding of mAb to human Fc receptors can be determined by flow cytometry 10 experiments using cell lines (e.g., THP-1, K562) and an engineered CHO cell line that expresses FcγRIIb (or other FcγRs). Compared to IgG1 control monoclonal antibodies, mAb show reduced binding to FcγRI and FcγRIIa whereas binding to FcγRIIb is unaffected. The binding and activation of C1q by antigen/IgG immune complexes triggers the classical complement cascade with consequent inflammatory and/or immunoregulatory responses. The C1q binding site on 15 IgGs has been localized to residues within the IgG hinge region. C1q binding to increasing concentrations of mAb was assessed by C1q ELISA. The results demonstrate that mAb is unable to bind to C1q, as expected when compared to the binding of a wildtype control IgG1. Overall, the L234A, L235A hinge region mutation abolishes binding of mAb to FcγRI, FcγRIIa and C1q but does not impact the interaction of mAb with FcγRIIb. This data suggests that in vivo, mAb 20 with mutant Fc will interact normally with the inhibitory FcγRIIb but will likely fail to interact with the activating FcγRI and FcγRIIa receptors or C1q.

Human FcRn binding: The neonatal receptor (FcRn) is responsible for transport of IgG across the placenta and to control the catabolic half-life of the IgG molecules. It might be desirable to increase the terminal half-life of an antibody to improve efficacy, to reduce the dose 25 or frequency of administration, or to improve localization to the target. Alternatively, it might be advantageous to do the converse that is, to decrease the terminal half-life of an antibody to reduce whole body exposure or to improve the target-to-non-target binding ratios. Tailoring the interaction between IgG and its salvage receptor, FcRn, offers a way to increase or decrease the terminal half-life of IgG. Proteins in the circulation, including IgG, are taken up in the fluid phase 30 through micropinocytosis by certain cells, such as those of the vascular endothelia. IgG can bind FcRn in endosomes under slightly acidic conditions (pH 6.0–6.5) and can recycle to the cell surface, where it is released under almost neutral conditions (pH 7.0–7.4). Mapping of the Fc-region-binding site on FcRn80, 16, 17 showed that two histidine residues that are conserved across species, His310 and His435, are responsible for the pH dependence of this interaction. 35 Using phage-display technology, a mouse Fc-region mutation that increases binding to FcRn and extends the half-life of mouse IgG was identified (see Victor, G. et al.; Nature Biotechnology

(1997), 15(7), 637-640). Fc-region mutations that increase the binding affinity of human IgG for FcRn at pH 6.0, but not at pH 7.4, have also been identified (see Dall'Acqua William F, et al., Journal of Immunology (2002), 169(9), 5171-80). Moreover, in one case, a similar pH-dependent increase in binding (up to 27-fold) was also observed for rhesus FcRn, and this resulted in a
5 twofold increase in serum half-life in rhesus monkeys compared with the parent IgG (see Hinton, Paul R. et al., Journal of Biological Chemistry (2004), 279(8), 6213-6216). These findings indicate that it is feasible to extend the plasma half-life of antibody therapeutics by tailoring the interaction of the Fc region with FcRn. Conversely, Fc-region mutations that attenuate interaction with FcRn can reduce antibody half-life.

10 **B.10 Pharmacokinetics (PK):**

To generate a DVD-Ig molecule with desired pharmacokinetic profile, in an embodiment parent mAbs with the similarly desired pharmacokinetic profile are selected. One consideration is that immunogenic response to monoclonal antibodies (ie, HAHA, human anti-human antibody response; HACA, human anti-chimeric antibody response) further complicates the
15 pharmacokinetics of these therapeutic agents. In an embodiment, monoclonal antibodies with minimal or no immunogenicity are used for constructing DVD-Ig molecules such that the resulting DVD-Igs will also have minimal or no immunogenicity. Some of the factors that determine the PK of a mAb include, but are not limited to, Intrinsic properties of the mAb (VH amino acid sequence); immunogenicity; FcRn binding and Fc functions.

20 The PK profile of selected parental monoclonal antibodies can be easily determined in rodents as the PK profile in rodents correlates well with (or closely predicts) the PK profile of monoclonal antibodies in cynomolgus monkey and humans. The PK profile is determined as described in Example section 1.2.2.3.A.

After the parental monoclonal antibodies with desired PK characteristics (and other desired
25 functional properties as discussed herein) are selected, the DVD-Ig is constructed. As the DVD-Ig molecules contain two antigen-binding domains from two parental monoclonal antibodies, the PK properties of the DVD-Ig are assessed as well. Therefore, while determining the PK properties of the DVD-Ig, PK assays may be employed that determine the PK profile based on functionality of both antigen-binding domains derived from the 2 parent monoclonal antibodies. The PK profile of
30 a DVD-Ig can be determined as described in Example 1.2.2.3.A. Additional factors that may impact the PK profile of DVD-Ig include the antigen-binding domain (CDR) orientation; Linker size; and Fc / FcRn interactions. PK characteristics of parent antibodies can be evaluated by assessing the following parameters: absorption, distribution, metabolism and excretion.

Absorption: To date, administration of therapeutic monoclonal antibodies is via
35 parenteral routes (e.g., intravenous [IV], subcutaneous [SC], or intramuscular [IM]). Absorption

of a mAb into the systemic circulation following either SC or IM administration from the interstitial space is primarily through the lymphatic pathway. Saturable, presystemic, proteolytic degradation may result in variable absolute bioavailability following extravascular administration. Usually, increases in absolute bioavailability with increasing doses of monoclonal antibodies may
5 be observed due to saturated proteolytic capacity at higher doses. The absorption process for a mAb is usually quite slow as the lymph fluid drains slowly into the vascular system, and the duration of absorption may occur over hours to several days. The absolute bioavailability of monoclonal antibodies following SC administration generally ranges from 50% to 100%.

Distribution: Following IV administration, monoclonal antibodies usually follow a
10 biphasic serum (or plasma) concentration-time profile, beginning with a rapid distribution phase, followed by a slow elimination phase. In general, a biexponential pharmacokinetic model best describes this kind of pharmacokinetic profile. The volume of distribution in the central compartment (V_c) for a mAb is usually equal to or slightly larger than the plasma volume (2-3 liters). A distinct biphasic pattern in serum (plasma) concentration versus time profile may not be
15 apparent with other parenteral routes of administration, such as IM or SC, because the distribution phase of the serum (plasma) concentration-time curve is masked by the long absorption portion. Many factors, including physicochemical properties, site-specific and target-oriented receptor mediated uptake, binding capacity of tissue, and mAb dose can influence biodistribution of a mAb. Some of these factors can contribute to nonlinearity in biodistribution for a mAb.

Metabolism and Excretion: Due to the molecular size, intact monoclonal antibodies are
20 not excreted into the urine via kidney. They are primarily inactivated by metabolism (e.g., catabolism). For IgG-based therapeutic monoclonal antibodies, half-lives typically ranges from hours or 1-2 days to over 20 days. The elimination of a mAb can be affected by many factors, including, but not limited to, affinity for the FcRn receptor, immunogenicity of the mAb, the
25 degree of glycosylation of the mAb, the susceptibility for the mAb to proteolysis, and receptor-mediated elimination.

B.11 Tissue cross-reactivity pattern on human and tox species:

Identical staining pattern suggests that potential human toxicity can be evaluated in tox species. Tox species are those animal in which unrelated toxicity is studied.

30 The individual antibodies are selected to meet two criteria. (1) Tissue staining appropriate for the known expression of the antibody target. (2) Similar staining pattern between human and tox species tissues from the same organ.

Criterion 1: Immunizations and/or antibody selections typically employ recombinant or synthesized antigens (proteins, carbohydrates or other molecules). Binding to the natural
35 counterpart and counterscreen against unrelated antigens are often part of the screening funnel for

therapeutic antibodies. However, screening against a multitude of antigens is often unpractical. Therefore tissue cross-reactivity studies with human tissues from all major organs serve to rule out unwanted binding of the antibody to any unrelated antigens.

Criterion 2: Comparative tissue cross reactivity studies with human and tox species tissues (cynomolgus monkey, dog, possibly rodents and others, the same 36 or 37 tissues are being tested as in the human study) help to validate the selection of a tox species. In the typical tissue cross-reactivity studies on frozen tissues sections therapeutic antibodies may demonstrate the expected binding to the known antigen and/or to a lesser degree binding to tissues based either on low level interactions (unspecific binding, low level binding to similar antigens, low level charge based interactions etc.). In any case the most relevant toxicology animal species is the one with the highest degree of coincidence of binding to human and animal tissue.

Tissue cross reactivity studies follow the appropriate regulatory guidelines including EC CPMP Guideline III/5271/94 "Production and quality control of mAbs" and the 1997 US FDA/CBER "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use". . Cryosections (5 μ m) of human tissues obtained at autopsy or biopsy were fixed and dried on object glass. The peroxidase staining of tissue sections was performed, using the avidin-biotin system. FDA's Guidance "*Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use*". Relevant references include Clarke J 2004, Boon L. 2002a, Boon L 2002b, Ryan A 1999.

Tissue cross reactivity studies are often done in two stages, with the first stage including cryosections of 32 tissues (typically: Adrenal Gland, Gastrointestinal Tract, Prostate, Bladder, Heart, Skeletal Muscle, Blood Cells, Kidney, Skin, Bone Marrow, Liver, Spinal Cord, Breast, Lung, Spleen, Cerebellum, Lymph Node, Testes, Cerebral Cortex, Ovary, Thymus, Colon, Pancreas, Thyroid, Endothelium, Parathyroid, Ureter, Eye, Pituitary, Uterus, Fallopian Tube and Placenta) from one human donor. In the second phase a full cross reactivity study is performed with up to 38 tissues (including adrenal, blood, blood vessel, bone marrow, cerebellum, cerebrum, cervix, esophagus, eye, heart, kidney, large intestine, liver, lung, lymph node, breast mammary gland, ovary, oviduct, pancreas, parathyroid, peripheral nerve, pituitary, placenta, prostate, salivary gland, skin, small intestine, spinal cord, spleen, stomach, striated muscle, testis, thymus, thyroid, tonsil, ureter, urinary bladder, and uterus) from 3 unrelated adults. Studies are done typically at minimally two dose levels.

The therapeutic antibody (i.e. test article) and isotype matched control antibody may be biotinylated for avidin-biotin complex (ABC) detection; other detection methods may include tertiary antibody detection for a FITC (or otherwise) labeled test article, or precomplexing with a labeled anti-human IgG for an unlabeled test article.

Briefly, cryosections (about 5 μm) of human tissues obtained at autopsy or biopsy are fixed and dried on object glass. The peroxidase staining of tissue sections is performed, using the avidin-biotin system. First (in case of a precomplexing detection system), the test article is incubated with the secondary biotinylated anti-human IgG and developed into immune complex.

5 The immune complex at the final concentrations of 2 and 10 $\mu\text{g}/\text{mL}$ of test article is added onto tissue sections on object glass and then the tissue sections were reacted for 30 minutes with a avidin-biotin-peroxidase kit. Subsequently, DAB (3,3'-diaminobenzidine), a substrate for the peroxidase reaction, was applied for 4 minutes for tissue staining. Antigen-Sepharose beads are used as positive control tissue sections.

10 Any specific staining is judged to be either an expected (e.g., consistent with antigen expression) or unexpected reactivity based upon known expression of the target antigen in question. Any staining judged specific is scored for intensity and frequency. Antigen or serum competition or blocking studies can assist further in determining whether observed staining is specific or nonspecific.

15 If two selected antibodies are found to meet the selection criteria – appropriate tissue staining, matching staining between human and toxicology animal specific tissue – they can be selected for DVD-Ig generation.

The tissue cross reactivity study has to be repeated with the final DVD-Ig construct, but while these studies follow the same protocol as outline herein, they are more complex to evaluate
20 because any binding can come from any of the two parent antibodies, and any unexplained binding needs to be confirmed with complex antigen competition studies.

It is readily apparent that the complex undertaking of tissue crossreactivity studies with a multispecific molecule like a DVD-Ig is greatly simplified if the two parental antibodies are selected for (1) lack of unexpected tissue cross reactivity findings and (2) for appropriate
25 similarity of tissue cross reactivity findings between the corresponding human and toxicology animal species tissues.

B.12 Specificity and selectivity:

To generate a DVD-Ig molecule with desired specificity and selectivity, one needs to generate and select parent mAbs with the similarly desired specificity and selectivity profile.

30 Binding studies for specificity and selectivity with a DVD-Ig can be complex due to the four or more binding sites, two each for each antigen. Briefly, binding studies using ELISA, BIAcore. KinExA or other interaction studies with a DVD-Ig need to monitor the binding of one, two or more antigens to the DVD-Ig molecule. While BIAcore technology can resolve the sequential, independent binding of multiple antigens, more traditional methods including ELISA

or more modern techniques like KinExA cannot. Therefore careful characterization of each parent antibody is critical. After each individual antibody has been characterized for specificity, confirmation of specificity retention of the individual binding sites in the DVD-Ig molecule is greatly simplified.

5 It is readily apparent that the complex undertaking of determining the specificity of a DVD-Ig is greatly simplified if the two parental antibodies are selected for specificity prior to being combined into a DVD-Ig.

 Antigen-antibody interaction studies can take many forms, including many classical protein protein interaction studies, including ELISA (Enzyme linked immunosorbent assay), Mass
10 spectrometry, chemical cross linking, SEC with light scattering, equilibrium dialysis, gel permeation, ultrafiltration, gel chromatography, large-zone analytical SEC, micropreparative ultracentrifugation (sedimentation equilibrium), spectroscopic methods, titration microcalorimetry, sedimentation equilibrium (in analytical ultracentrifuge), sedimentation velocity (in analytical centrifuge), surface plasmon resonance (including BIAcore). Relevant
15 references include "Current Protocols in Protein Science", John E. Coligan, Ben M. Dunn, David W. Speicher, Paul T. Wingfield (eds.) Volume 3, chapters 19 and 20, published by John Wiley & Sons Inc., and references included therein and "Current Protocols in Immunology", John E. Coligan, Barbara E. Bierer, David H. Margulies, Ethan M. Shevach, Warren Strober (eds.) published by John Wiley & Sons Inc and relevant references included therein.

20 Cytokine Release in Whole Blood: The interaction of mAb with human blood cells can be investigated by a cytokine release assay (Wing, M. G. Therapeutic Immunology (1995), 2(4), 183-190; "Current Protocols in Pharmacology", S.J. Enna, Michael Williams, John W. Ferkany, Terry Kenakin, Paul Moser, (eds.) published by John Wiley & Sons Inc; Madhusudan, S. Clinical Cancer Research (2004), 10(19), 6528-6534; Cox, J. Methods (2006), 38(4), 274-282; Choi, I.
25 European Journal of Immunology (2001), 31(1), 94-106). Briefly, various concentrations of mAb are incubated with human whole blood for 24 hours. The concentration tested should cover a wide range including final concentrations mimicking typical blood levels in patients (including but not limited to 100 ng/ml – 100µg/ml). Following the incubation, supernatants and cell lysates were
30 analyzed for the presence of IL-1R α , TNF- α , IL-1b, IL-6 and IL-8. Cytokine concentration profiles generated for mAb were compared to profiles produced by a negative human IgG control and a positive LPS or PHA control. The cytokine profile displayed by mAb from both cell supernatants and cell lysates was comparable to control human IgG. In an embodiment, the monoclonal antibody does not interact with human blood cells to spontaneously release inflammatory cytokines.

Cytokine release studies for a DVD-Ig are complex due to the four or more binding sites, two each for each antigen. Briefly, cytokine release studies as described herein measure the effect of the whole DVD-Ig molecule on whole blood or other cell systems, but can resolve which portion of the molecule causes cytokine release. Once cytokine release has been detected, the purity of the DVD-Ig preparation has to be ascertained, because some co-purifying cellular components can cause cytokine release on their own. If purity is not the issue, fragmentation of DVD-Ig (including but not limited to removal of Fc portion, separation of binding sites etc.), binding site mutagenesis or other methods may need to be employed to deconvolute any observations. It is readily apparent that this complex undertaking is greatly simplified if the two parental antibodies are selected for lack of cytokine release prior to being combined into a DVD-Ig.

B.13 Cross reactivity to other species for toxicological studies:

In an embodiment, the individual antibodies selected with sufficient cross-reactivity to appropriate tox species, for example, cynomolgus monkey. Parental antibodies need to bind to orthologous species target (i.e. cynomolgus monkey) and elicit appropriate response (modulation, neutralization, activation). In an embodiment, the cross-reactivity (affinity/potency) to orthologous species target should be within 10-fold of the human target. In practice, the parental antibodies are evaluated for multiple species, including mouse, rat, dog, monkey (and other non-human primates), as well as disease model species (i.e. sheep for asthma model). The acceptable cross-reactivity to tox species from the parental monoclonal antibodies allows future toxicology studies of DVD-Ig-Ig in the same species. For that reason, the two parental monoclonal antibodies should have acceptable cross-reactivity for a common tox species therefore allowing toxicology studies of DVD-Ig in the same species.

Parent mAbs may be selected from various mAbs capable of binding specific targets and well known in the art. These include, but are not limited to anti-TNF antibody (US Patent No. 6,258,562), anti-IL-12 and/or anti-IL-12p40 antibody (US Patent No. 6,914,128); anti-IL-18 antibody (US 2005/0147610 A1), anti-C5, anti-CBL, anti-CD147, anti-gp120, anti-VLA-4, anti-CD11a, anti-CD18, anti-VEGF, anti-CD40L, anti CD-40 (e.g., see WO2007124299) anti-Id, anti-ICAM-1, anti-CXCL13, anti-CD2, anti-EGFR, anti-TGF-beta 2, anti-HGF, anti-cMet, anti DLL-4, anti-NPR1, anti-PLGF, anti-ErbB3, anti-E-selectin, anti-Fact VII, anti-Her2/neu, anti-F gp, anti-CD11/18, anti-CD14, anti-ICAM-3, anti-RON, anti CD-19, anti-CD80 (e.g., see WO2003039486, anti-CD4, anti-CD3, anti-CD23, anti-beta2-integrin, anti-alpha4beta7, anti-CD52, anti-HLA DR, anti-CD22 (e.g., see US Patent NO: 5,789,554), anti-CD20, anti-MIF, anti-CD64 (FcR), anti-TCR alpha beta, anti-CD2, anti-Hep B, anti-CA 125, anti-EpCAM, anti-gp120, anti-CMV, anti-gpIIbIIIa, anti-IgE, anti-CD25, anti-CD33, anti-HLA, anti-IGF1,2, anti IGFR, anti-VNRintegrin, anti-IL-1alpha, anti-IL-1beta, anti-IL-1 receptor, anti-IL-2 receptor, anti-IL-4,

anti-IL-4 receptor, anti-IL5, anti-IL-5 receptor, anti-IL-6, anti-IL-8, anti-IL-9, anti-IL-13, anti-IL-13 receptor, anti-IL-17, and anti-IL-23 (see Presta LG. 2005 Selection, design, and engineering of therapeutic antibodies *J Allergy Clin Immunol.* 116:731-6 and <http://www.path.cam.ac.uk/~mrc7/humanisation/antibodies.html>).

5 Parent mAbs may also be selected from various therapeutic antibodies approved for use, in clinical trials, or in development for clinical use. Such therapeutic antibodies include, but are not limited to, rituximab (Rituxan®, IDEC/Genentech/Roche) (see for example U. S. Pat. No. 5,736,137), a chimeric anti-CD20 antibody approved to treat Non-Hodgkin's lymphoma; HuMax-CD20, an anti-CD20 currently being developed by Genmab, an anti-CD20 antibody
10 described in U.S. Pat. No. 5, 500,362, AME-133 (Applied Molecular Evolution), hA20 (Immunomedics, Inc.), HumaLYM (Intracel), and PRO70769 (PCT/US2003/040426, entitled "Immunoglobulin Variants and Uses Thereof"), trastuzumab (Herceptin®, Genentech) (see for example U.S. Pat. No. 5,677,171), a humanized anti- Her2/neu antibody approved to treat breast cancer; pertuzumab (rhuMab-2C4, Omnitarg®), currently being developed by Genentech; an
15 anti-Her2 antibody described in U.S. Pat. No. 4,753,894; cetuximab (Erbix®, Imclone) (U.S. Pat. No. 4,943,533; PCT WO 96/40210), a chimeric anti-EGFR antibody in clinical trials for a variety of cancers; ABX-EGF (U.S. Pat. No. 6,235,883), currently being developed by Abgenix-Immunex-Amgen; HuMax- EGFr (U.S. Ser. No. 10/172,317), currently being developed by
20 Genmab; 425, EMD55900, EMD62000, and EMD72000 (Merck KGaA) (U.S. Pat. No. 5,558,864; Murthy et al. 1987, *Arch Biochem Biophys.* 252(2):549-60; Rodeck et al., 1987, *J Cell Biochem.* 35(4):315-20; Kettleborough et al., 1991, *Protein Eng.* 4(7):773-83); ICR62 (Institute of Cancer Research) (PCT WO 95/20045; Modjtahedi et al., 1993, *J. Cell Biophys.* 1993, 22(1-3):129-46; Modjtahedi et al., 1993, *Br J Cancer.* 1993, 67(2):247-53; Modjtahedi et al, 1996, *Br J Cancer,* 73(2):228-35; Modjtahedi et al, 2003, *Int J Cancer,* 105(2):273-80);
25 TheraCIM hR3 (YM Biosciences, Canada and Centro de Immunologia Molecular, Cuba (U.S. Pat. No. 5,891,996; U.S. Pat. No. 6,506, 883; Mateo et al, 1997, *Immunotechnology,* 3(1):71-81); mAb-806 (Ludwig Institute for Cancer Research, Memorial Sloan-Kettering) (Jungbluth et al. 2003, *Proc Natl Acad Sci USA.* 100(2):639-44); KSB-102 (KS Biomedix); MR1-1 (IVAX, National Cancer Institute) (PCT WO 0162931A2); and SC100 (Scancell) (PCT WO 01/88138);
30 alemtuzumab (Campath®, Millenium), a humanized mAb currently approved for treatment of B-cell chronic lymphocytic leukemia; muromonab-CD3 (Orthoclone OKT3®), an anti-CD3 antibody developed by Ortho Biotech/Johnson & Johnson, ibritumomab tiuxetan (Zevalin®), an anti-CD20 antibody developed by IDEC/Schering AG, gemtuzumab ozogamicin (Mylotarg®), an anti-CD33 (p67 protein) antibody developed by Celltech/Wyeth, alefacept (Amevive®), an
35 anti-LFA-3 Fc fusion developed by Biogen), abciximab (ReoPro®), developed by Centocor/Lilly, basiliximab (Simulect®), developed by Novartis, palivizumab (Synagis®),

developed by Medimmune, infliximab (Remicade®), an anti-TNFalpha antibody developed by Centocor, adalimumab (Humira®), an anti-TNFalpha antibody developed by Abbott, Humicade®, an anti-TNFalpha antibody developed by Celltech, golimumab (CNTO-148), a fully human TNF antibody developed by Centocor, etanercept (Enbrel®), an p75 TNF receptor Fc fusion developed by Immunex/Amgen, lenercept, an p55TNF receptor Fc fusion previously developed by Roche, ABX-CBL, an anti-CD147 antibody being developed by Abgenix, ABX-IL8, an anti-IL8 antibody being developed by Abgenix, ABX-MA1, an anti-MUC18 antibody being developed by Abgenix, Pemtumomab (R1549, 90Y-muHMFG1), an anti-MUC1 in development by Antisoma, Therex (R1550), an anti-MUC1 antibody being developed by Antisoma, AngioMab (AS1405), being developed by Antisoma, HuBC-1, being developed by Antisoma, Thioplatin (AS1407) being developed by Antisoma, Antegren® (natalizumab), an anti-alpha-4-beta-1 (VLA-4) and alpha-4-beta-7 antibody being developed by Biogen, VLA-1 mAb, an anti-VLA-1 integrin antibody being developed by Biogen, LTBR mAb, an anti-lymphotoxin beta receptor (LTBR) antibody being developed by Biogen, CAT-152, an anti-TGF-β2 antibody being developed by Cambridge Antibody Technology, ABT 874 (J695), an anti-IL-12 p40 antibody being developed by Abbott, CAT-192, an anti-TGFβ1 antibody being developed by Cambridge Antibody Technology and Genzyme, CAT-213, an anti-Eotaxin1 antibody being developed by Cambridge Antibody Technology, LymphoStat-B® an anti-Blyss antibody being developed by Cambridge Antibody Technology and Human Genome Sciences Inc., TRAIL-R1 mAb, an anti-TRAIL-R1 antibody being developed by Cambridge Antibody Technology and Human Genome Sciences, Inc., Avastin® bevacizumab, rhuMab-VEGF), an anti-VEGF antibody being developed by Genentech, an anti-HER receptor family antibody being developed by Genentech, Anti-Tissue Factor (ATF), an anti-Tissue Factor antibody being developed by Genentech, Xolair® (Omalizumab), an anti-IgE antibody being developed by Genentech, Raptiva® (Efalizumab), an anti-CD11a antibody being developed by Genentech and Xoma, MLN-02 Antibody (formerly LDP-02), being developed by Genentech and Millenium Pharmaceuticals, HuMax CD4, an anti-CD4 antibody being developed by Genmab, HuMax-IL15, an anti-IL15 antibody being developed by Genmab and Amgen, HuMax-Inflam, being developed by Genmab and Medarex, HuMax-Cancer, an anti-Heparanase I antibody being developed by Genmab and Medarex and Oxford GcoSciences, HuMax-Lymphoma, being developed by Genmab and Amgen, HuMax-TAC, being developed by Genmab, IDEC-131, and anti-CD40L antibody being developed by IDEC Pharmaceuticals, IDEC-151 (Clenoliximab), an anti-CD4 antibody being developed by IDEC Pharmaceuticals, IDEC-114, an anti-CD80 antibody being developed by IDEC Pharmaceuticals, IDEC-152, an anti-CD23 being developed by IDEC Pharmaceuticals, anti-macrophage migration factor (MIF) antibodies being developed by IDEC Pharmaceuticals, BEC2, an anti-idiotypic antibody being developed by Imclone, IMC-1C11, an anti-KDR antibody being developed by Imclone, DC101, an anti-flk-1 antibody being

developed by Imclone, anti-VE cadherin antibodies being developed by Imclone, CEA-Cide®
 (labetuzumab), an anti-carcinoembryonic antigen (CEA) antibody being developed by
 Immunomedics, LymphoCide® (Epratuzumab), an anti-CD22 antibody being developed by
 Immunomedics, AFP-Cide, being developed by Immunomedics, MyelomaCide, being developed
 5 by Immunomedics, LkoCide, being developed by Immunomedics, ProstaCide, being developed
 by Immunomedics, MDX-010, an anti-CTLA4 antibody being developed by Medarex, MDX-
 060, an anti-CD30 antibody being developed by Medarex, MDX-070 being developed by
 Medarex, MDX-018 being developed by Medarex, Osidem® (IDM-1), and anti-Her2 antibody
 being developed by Medarex and Immuno-Designed Molecules, HuMax®-CD4, an anti-CD4
 10 antibody being developed by Medarex and Genmab, HuMax-IL15, an anti-IL15 antibody being
 developed by Medarex and Genmab, CNTO 148, an anti-TNF α antibody being developed by
 Medarex and Centocor/J&J, CNTO 1275, an anti-cytokine antibody being developed by
 Centocor/J&J, MOR101 and MOR102, anti-intercellular adhesion molecule-1 (ICAM-1) (CD54)
 antibodies being developed by MorphoSys, MOR201, an anti-fibroblast growth factor receptor 3
 15 (FGFR-3) antibody being developed by MorphoSys, Nuvion® (visilizumab), an anti-CD3
 antibody being developed by Protein Design Labs, HuZAF®, an anti-gamma interferon antibody
 being developed by Protein Design Labs, Anti- α 5 β 1 Integrin, being developed by Protein
 Design Labs, anti-IL-12, being developed by Protein Design Labs, ING-1, an anti-Ep-CAM
 antibody being developed by Xoma, Xolair® (Omalizumab) a humanized anti-IgE antibody
 20 developed by Genentech and Novartis, and MLN01, an anti-Beta2 integrin antibody being
 developed by Xoma, all of the herein-cited references in this paragraph are expressly
 incorporated herein by reference. In another embodiment, the therapeutics include KRN330
 (Kirin); huA33 antibody (A33, Ludwig Institute for Cancer Research); CNTO 95 (alpha V
 integrins, Centocor); MEDI-522 (alpha V β 3 integrin, Medimmune); volociximab (alpha V β 1
 25 integrin, Biogen/PDL); Human mAb 216 (B cell glycosolated epitope, NCI); BiTE MT103
 (bispecific CD19 x CD3, Medimmune); 4G7xH22 (Bispecific BcellxFcgammaR1,
 Medarex/Merck KGa); rM28 (Bispecific CD28 x MAPG, US Patent No. EP1444268); MDX447
 (EMD 82633) (Bispecific CD64 x EGFR, Medarex); Catumaxomab (removab) (Bispecific
 EpCAM x anti-CD3, Trion/Fres); Ertumaxomab (bispecific HER2/CD3, Fresenius Biotech);
 30 oregovomab (OvaRex) (CA-125, ViRexx); Rencarex® (WX G250) (carbonic anhydrase IX,
 Wilex); CNTO 888 (CCL2, Centocor); TRC105 (CD105 (endoglin), Tracon); BMS-663513
 (CD137 agonist, Bristol Myers Squibb); MDX-1342 (CD19, Medarex); Siplizumab (MEDI-507)
 (CD2, Medimmune); Ofatumumab (Humax-CD20) (CD20, Genmab); Rituximab (Rituxan)
 (CD20, Genentech); veltuzumab (hA20) (CD20, Immunomedics); Epratuzumab (CD22,
 35 Amgen); lumiliximab (IDEC 152) (CD23, Biogen); muromonab-CD3 (CD3, Ortho); HuM291
 (CD3 fc receptor, PDL Biopharma); HeFi-1, CD30, NCI); MDX-060 (CD30, Medarex); MDX-
 1401 (CD30, Medarex); SGN-30 (CD30, Seattle Genentics); SGN-33 (Lintuzumab) (CD33,

Seattle Genentics); Zanolimumab (HuMax-CD4) (CD4, Genmab); HCD122 (CD40, Novartis); SGN-40 (CD40, Seattle Genentics); Campath1h (Alemtuzumab) (CD52, Genzyme); MDX-1411 (CD70, Medarex); hLL1 (EPB-1) (CD74.38, Immunomedics); Galiximab (IDEC-144) (CD80, Biogen); MT293 (TRC093/D93) (cleaved collagen, Tracon); HuLuc63 (CS1, PDL Pharma);
 5 ipilimumab (MDX-010) (CTLA4, Bristol Myers Squibb); Tremelimumab (Ticilimumab, CP-675,2) (CTLA4, Pfizer); HGS-ETR1 (Mapatumumab) (DR4 TRAIL-R1 agonist, Human Genome Science /Glaxo Smith Kline); AMG-655 (DR5, Amgen); Apomab (DR5, Genentech); CS-1008 (DR5, Daiichi Sankyo); HGS-ETR2 (lexatumumab) (DR5 TRAIL-R2 agonist, HGS); Cetuximab (Erbix) (EGFR, Imclone); IMC-11F8, (EGFR, Imclone); Nimotuzumab (EGFR, YM Bio); Panitumumab (Vectabix) (EGFR, Amgen); Zalutumumab (HuMaxEGFr) (EGFR, Genmab); CDX-110 (EGFRvIII, AVANT Immunotherapeutics); adecatumumab (MT201) (Epcam, Merck); edrecolomab (Panorex, 17-1A) (Epcam, Glaxo/Centocor); MORAb-003 (folate receptor a, Morphotech); KW-2871 (ganglioside GD3, Kyowa); MORAb-009 (GP-9, Morphotech); CDX-1307 (MDX-1307) (hCGb, Celldex); Trastuzumab (Herceptin) (HER2, 15 Celldex); Pertuzumab (rhuMab 2C4) (HER2 (DI), Genentech); apolizumab (HLA-DR beta chain, PDL Pharma); AMG-479 (IGF-1R, Amgen); anti-IGF-1R R1507 (IGF1-R, Roche); CP 751871 (IGF1-R, Pfizer); IMC-A12 (IGF1-R, Imclone); BIIB022 (IGF-1R, Biogen); Mik-beta-1 (IL-2Rb (CD122), Hoffman LaRoche); CNTO 328 (IL6, Centocor); Anti-KIR (1-7F9) (Killer cell Ig-like Receptor (KIR), Novo); Hu3S193 (Lewis (y), Wyeth, Ludwig Institute of Cancer 20 Research); hCBE-11 (LTβR, Biogen); HuHMFG1 (MUC1, Antisoma/NCI); RAV12 (N-linked carbohydrate epitope, Raven); CAL (parathyroid hormone-related protein (PTH-rP), University of California); CT-011 (PD1, CureTech); MDX-1106 (ono-4538) (PD1, Medarex/Ono); MAb CT-011 (PD1, Curetech); IMC-3G3 (PDGFRa, Imclone); bavituximab (phosphatidylserine, Peregrine); huJ591 (PSMA, Cornell Research Foundation); muJ591 (PSMA, Cornell Research 25 Foundation); GC1008 (TGFb (pan) inhibitor (IgG4), Genzyme); Infliximab (Remicade) (TNFα, Centocor); A27.15 (transferrin receptor, Salk Institute, INSERN WO 2005/111082); E2.3 (transferrin receptor, Salk Institute); Bevacizumab (Avastin) (VEGF, Genentech); HuMV833 (VEGF, Tsukuba Research Lab-WO/2000/034337, University of Texas); IMC-18F1 (VEGFR1, Imclone); IMC-1121 (VEGFR2, Imclone).

30 B. Construction of DVD molecules:

The dual variable domain immunoglobulin (DVD-Ig) molecule is designed such that two different light chain variable domains (VL) from the two different parent monoclonal antibodies are linked in tandem directly or via a short linker by recombinant DNA techniques, followed by the light chain constant domain. Similarly, the heavy chain comprises two different heavy chain 35 variable domains (VH) linked in tandem, followed by the constant domain CH1 and Fc region (Fig.1A).

The variable domains can be obtained using recombinant DNA techniques from a parent antibody generated by any one of the methods described herein. In an embodiment, the variable domain is a murine heavy or light chain variable domain. In another embodiment, the variable domain is a CDR grafted or a humanized variable heavy or light chain domain. In an
5 embodiment, the variable domain is a human heavy or light chain variable domain.

In one embodiment the first and second variable domains are linked directly to each other using recombinant DNA techniques. In another embodiment the variable domains are linked via a linker sequence. In an embodiment, two variable domains are linked. Three or more variable domains may also be linked directly or via a linker sequence. The variable domains may bind the
10 same antigen or may bind different antigens. DVD molecules of the invention may include one immunoglobulin variable domain and one non- immunoglobulin variable domain such as ligand binding domain of a receptor, active domain of an enzyme. DVD molecules may also comprise 2 or more non-Ig domains.

The linker sequence may be a single amino acid or a polypeptide sequence. In an
15 embodiment, the linker sequences are selected from the group consisting of AKTTPKLEEGEFSEAR (SEQ ID NO: 1); AKTTPKLEEGEFSEARV (SEQ ID NO: 2); AKTTPKLG (SEQ ID NO: 3); SAKTTPKLG (SEQ ID NO: 4); SAKTTP (SEQ ID NO: 5); RADAAP (SEQ ID NO: 6); RADAAPT (SEQ ID NO: 7); RADAAAAGGPGS (SEQ ID NO: 8); RADAAA(G₄S)₄ (SEQ ID NO: 9); SAKTTPKLEEGEFSEARV (SEQ ID NO: 10); ADAAP
20 (SEQ ID NO: 11); ADAAPT (SEQ ID NO: 12); TVAAP (SEQ ID NO: 13); TVAAPSVFIFPP (SEQ ID NO: 14); QPKAAP (SEQ ID NO: 15); QPKAAPSVTLFPP (SEQ ID NO: 16); AKTTP (SEQ ID NO: 17); AKTTPSVTLPLAP (SEQ ID NO: 18); AKTTAP (SEQ ID NO: 19); AKTTAPSVYPLAP (SEQ ID NO: 20); ASTKGP (SEQ ID NO: 21); ASTKGPSVFPLAP (SEQ ID NO: 22); GGGGSGGGGSGGGGS (SEQ ID NO: 23);
25 GENKVEYAPALMALS (SEQ ID NO: 24); GPAKELTPLKEAKVS (SEQ ID NO: 25); GHEAAAVMQVQYPAS (SEQ ID NO: 26). The choice of linker sequences is based on crystal structure analysis of several Fab molecules. There is a natural flexible linkage between the variable domain and the CH1/CL constant domain in Fab or antibody molecular structure. This natural linkage comprises approximately 10-12 amino acid residues, contributed by 4-6 residues
30 from C-terminus of V domain and 4-6 residues from the N-terminus of CL/CH1 domain. DVD Igs of the invention were generated using N-terminal 5-6 amino acid residues, or 11-12 amino acid residues, of CL or CH1 as linker in light chain and heavy chain of DVD-Ig, respectively. The N-terminal residues of CL or CH1 domains, particularly the first 5-6 amino acid residues, adopt a loop conformation without strong secondary structures, therefore can act as flexible
35 linkers between the two variable domains. The N-terminal residues of CL or CH1 domains are

natural extension of the variable domains, as they are part of the Ig sequences, therefore minimize to a large extent any immunogenicity potentially arising from the linkers and junctions.

Other linker sequences may include any sequence of any length of CL/CH1 domain but not all residues of CL/CH1 domain; for example the first 5-12 amino acid residues of the CL/CH1 domains; the light chain linkers can be from Cκ or Cλ; and the heavy chain linkers can be derived from CH1 of any isotypes, including Cγ1, Cγ2, Cγ3, Cγ4, Cα1, Cα2, Cδ, Cε, and Cμ. Linker sequences may also be derived from other proteins such as Ig-like proteins, (e.g.TCR, FcR, KIR); G/S based sequences (e.g G4S repeats); hinge region-derived sequences; and other natural sequences from other proteins.

In an embodiment a constant domain is linked to the two linked variable domains using recombinant DNA techniques. In an embodiment, sequence comprising linked heavy chain variable domains is linked to a heavy chain constant domain and sequence comprising linked light chain variable domains is linked to a light chain constant domain. In an embodiment, the constant domains are human heavy chain constant domain and human light chain constant domain respectively. In an embodiment, the DVD heavy chain is further linked to an Fc region. The Fc region may be a native sequence Fc region, or a variant Fc region. In another embodiment, the Fc region is a human Fc region. In another embodiment the Fc region includes Fc region from IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, or IgD.

In another embodiment two heavy chain DVD polypeptides and two light chain DVD polypeptides are combined to form a DVD-Ig molecule. Table 2 lists amino acid sequences of VH and VL regions of exemplary antibodies for targets useful for treating disease, e.g., for treating cancer. In an embodiment, the invention provides a DVD comprising at least two of the VH and/or VL regions listed in Table 2, in any orientation.

Table 2: List of Amino Acid Sequences of VH and VL regions of Antibodies for Generating DVD-Igs

SEQ ID No.	ABT Unique ID	Protein region	Sequence
			1234567890123456789012345678901234567890
27	AB001VH	VH CD20	QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQT PGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAY MQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVS A

SEQ ID No.	ABT Unique ID	Protein region	Sequence
			1234567890123456789012345678901234567890
28	AB001VL	VL CD20	QIVLSQSPAILSPSPGKVTMTCRASSSVSYIHWFQQKPG SSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAE DAATYYCQWTSNPPTFGGGTKLEIKR
29	AB002VH	VH CD3 (seq. 1)	QVQLQQSGAELARPGASVKMSCASGYTFTRYTMHWVKQR PGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAY MQLSSLTSEDSAVYYCARYDDHYCLDYWGQGTTLTVSS
30	AB002VL	VL CD3 (seq. 1)	QIVLTQSPAIMASAPGKVTMTCRASSSVSYMNWYQQKSG TSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAE DAATYYCQWSSNPLTFGSGTKLEINR
31	AB003VH	VH EGFR (seq. 1)	QVQLQESGPGLVKPSSETLSLTCTVSGGSVSSGDYWTWIR QSPGKGLEWIGHIYYSGNTNYPNPSLKSRLTISIDTSKTQF SLKLSVTAADTAIYYCVRDRVTGAFDIWGQGTMTVTVSS
32	AB003VL	VL EGFR (seq. 1)	DIQMTQSPSSLSASVGDRTITCQASQDISNYLNWYQQKP GKAPKLLIYDASNLETGVPSRFSGSGSGTDFFTISSLQP EDIATYFCQHFHDLPLAFGGGKVEIKR
33	AB004VH	VH HER2 (seq. 1)	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQA PGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAY LQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTTLVTVSS
34	AB004VL	VL HER2 (seq. 1)	DIQMTQSPSSLSASVGDRTITCRASQDVNTAVAWYQQKP GKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQP EDFATYYCQHYHTPPTFGQGTKVEIKR
35	AB005VH	VH RON (seq. 1)	EVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYAMHWVRQA PGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNKNTLY LQMNSLRAEDTAVYYCARFSGWPNNYYYYGMDVWGQGTTV TVSS
36	AB005VL	VL RON (seq. 1)	DVVMTQSPPLSLPVTPEGPASISCRSSQSLLSNGFNVDW YLQKPGQSPHLLIYFGSYRASGVPDRFSGSGSGTDFTLKI SRVEAEDVGVYYCMQALQTPPWTFGQGTKEIRR
37	AB006VH	VH CD-19	QVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMNVKQR PGQGLEWIGQIWPGDGTNYNGKFKGKATLTADESSSTAY MQLSSLASEDSAVYFCARRETTTVGRYYYYAMDYWGQGTSV TVSS

SEQ ID No.	ABT Unique ID	Protein region	Sequence
			1234567890123456789012345678901234567890
38	AB006VL	VL CD-19	DILLTQTPASLAVSLGQRATISCKASQSVDYDGD SYLNWY QQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLNIH PVEKVDAATYHCQQSTEDPWTFGGGKLEIKR
39	AB007VH	VH CD-80	QVQLQESGPGLVKPKSETLSLTCVAVSGGSISSGGYWG WIRQ PPGKGLEWIGSFYSSSGNTYYNPSLKSQVTISTDTSKNQF SLKLSMTAADTAVYYCVRDRLFSVVMVYNNWFDVWGPG VLVTVSS
40	AB007VL	VL CD-80	ESALTQPPSVSGAPGQKVTISCTGSTSNIGGYDLHWYQQL PGTAPKLLIYDINKRPSGISDRFSGSKSGTAASLAITGLQ TEDEADYYCQSYDSSLNAQVFGGGTRLTVLG
41	AB008VH	VH CD-22	QVQLVQSGAEVKKPGSSVKVSKASGYTFTSYWLHWVRQA PGQGLEWIGYINPRNDYTEYNQNFKDKATITADESTNTAY MELSSLRSEDTAFYFCARRDITTFYWGQGTITVTVSS
42	AB008VL	VL CD-22	DIQLTQSPSSLSASVGDRTMCKSSQSVLYSANHKNYLA WYQQKPGKAPKLLIYWASTRESGVPDRFSGSGSGTDFTF ISSLPEDIATYYCHQYLSSWTFGGGKLEIKR
43	AB009VH	VH CD-40	QVQLVESGGGVVQGRSLRLSCAASGFTFSSYGMHWVRQA PGKGLEWVAVISYEESNRYHADSVKGRFTISRDN SKITLY LQMNSLRTEDTAVYYCARDGGIAAPGPDYWGQGTITVTVSS
44	AB009VL	VL CD-40	DIVMTQSPLSLTVPGEPAISCRSSQSLLYSNGYNYLDW YLQKPGQSPQVLISLGSNRASGVPDRFSGSGSGTDFTLKI SRVEAEDVGVYYCMQARQTPFTFGPGTKVDIR
45	AB010VH	VH IGF1,2	QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQA TGQGLEWGMWNPNSGNTGYAQKFQGRVTMTRNTSISTAY MELSSLRSEDTAVYYCARDPYYYYYGMVDVWGQGTITVTVSS
46	AB010VL	VL IGF1,2	QSVLTQPPSVSAAPGQKVTISCSGSSSNIENNHVSWYQQL PGTAPKLLIYDNNKRPSPGIPDRFSGSKSGTSATLGITGLQ TGDEADYYCETWDTLSAGRVFGGGTKLTVLG
47	AB011VH	VH IGF1R (seq. 1)	EVQLLESGGGLVQPGGSLRLSCTASGFTFSSYAMN WVRQA PGKGLEWVAISGSGGTFYADSVKGRFTISRDN SRTTLY LQMNSLRAEDTAVYYCAKDLGWSDSYYYYYGMVDVWGQGT TVTVSS

SEQ ID No.	ABT Unique ID	Protein region	Sequence 1234567890123456789012345678901234567890
48	AB011VL	VL IGF1R (seq. 1)	DIQMTQFPSSLSASVGDRVTITCRASQGIRNDLGWYQQKP GKAPKRLIYAASRLHRGVPSRFSGSGSGETFTLTISLQPE EDFATYYCLQHNSYPCSFQGTGKLEIKR
49	AB012VH	VH HGF (seq. 1)	QVQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMSWIRQA PGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLY LQMNSLRAEDTAVYYCARDEYNSGWYVLFDYWGQGLVTV SS
50	AB012VL	VL HGF (seq. 1)	DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKP GKAPNLLIYEASSLQSGVPSRFSGSGSGETFTLTISLQPE EDFATYYCQANGFPWTFGQGTGKVEIKR
51	AB013VH	VH c-MET	QVQLQQSGPELVRPGASVKWSCPASGYTFTSYWLHWVKKQ RPGQGLEWIGMIDPSNSDTRFNPPNFKDKATLNVDSSNT AYNLLSSLTSADSAVYYCATYGSYVSPLDYWGQGTSVYVS S
52	AB013VL	VL c-MET	DIMMSQSPSSLTVSVGEKVTVCKSSQSLLVTSQKNYLA WYQQKPKQSPKLLIYWASTRESGVPDRFTGSGSGETFTLT ITSVKADDLAVYYCQYYAYPWTFGDGKLEIKR
53	AB014VH	VH VEGF (seq. 1)	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWRQA PGKGLEWGWINTYTGPTYAADFRRFTFSLDTSKSTAY LQMNSLRAEDTAVYYCAKYPHYGSSHWYFDVWGQGLVTV VSS
54	AB014VL	VL VEGF (seq. 1)	DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKP GKAPKVLIIYFTSSLHSGVPSRFSGSGSGETFTLTISLQPE EDFATYYCQYSTVPWTFGQGTGKVEIKR
55	AB015VH	VH DLL-4 (seq. 1)	EVQLVESGGGLVQPGGSLRLSCAASGFTFTDNWISWVRQA PGKGLEWVGYISPNSGFTYYADSVKGRFTISADTSKNTAY LQMNSLRAEDTAVYYCARDNFGGYFDYWGQGLVTVSS
56	AB015VL	VL DLL-4 (seq. 1)	DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKP GKAPKLLIYSASFLYSGVPSRFSGSGSGETFTLTISLQPE EDFATYYCQSYTGTVTFGQGTGKVEIKR
57	AB016VH	VH NRP1 (seq. 1)	EVQLVESGGGLVQPGGSLRLSCAASGFSFSSEPISWVRQA PGKGLEWVSSITGKNGYTYADSVKGRFTISADTSKNTAY LQMNSLRAEDTAVYYCARWGKKVYGMVWGQGLVTVSS

SEQ ID No.	ABT Unique ID	Protein region	Sequence
			1234567890123456789012345678901234567890
58	AB016VL	VL NRP1 (seq. 1)	DIQMTQSPSSLSASVGDRTITCRASQSISSYLAWYQQKPGKAPKLLIYGASSRASGVPSRFSGSGSDFTLTISLQPEDFATYYCQYMSVPIITFGQGTKVEIKR
59	AB033VH	VH EGFR (seq. 2)	QVQLKQSGPGLVQPSSLSITCTVSGFSLTNYGVHWRQSPGKGLEWLGVIWGGNTDYNTPFTSRLSINKDNSKQVFFKMNSLQSNDAIYYCARALTYDYEFAYWGQGLTVSA
60	AB033VL	VL EGFR (seq. 2)	DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSDFTLSINSVESEDIADYYCQQNNWPTTFGAGTKLELKR
61	AB034VH	VH RON (seq. 2)	QVQLQESGPGLVKPSIILSLTCTVSGGSISSHYWSVWRQPPGKGLEWIGYIYYSGSTNYNPSLKSRTISVDTSKNQFSLNLSVTAADTAVYYCARIPNYYDRSGYYPGYWYFDLWGRGTLVTVSS
62	AB034VL	VL RON (seq. 2)	QAVLTQPSLSAPPASASLTCTLRSGFNVDYRISWYQQKPGSPPPQYLLRYKSDSDKQGGSGVPSRFSGSKDASANAGILLISGLQSEDEADYYCMIWHSSAWVFGGGTKLVLR
63	AB035VH	VH NRP1 (seq. 2)	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSIIPAGGYTNYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARELPYYRMSKVMQVQGGTLTVSS
64	AB035VL	VL NRP1 (seq. 2)	DIQMTQSPSSLSASVGDRTITCRASQYFSSYLAWYQQKPGKAPKLLIYGASSRASGVPSRFSGSGSDFTLTISLQPEDFATYYCQYLGSPPTFGQGTKVEIKR
65	AB039VH	VH CD3 (seq. 2)	QVQLQQSGAELARPGASVKMCKASGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYDDHYCLDYWGQGTTLTVSS
66	AB039VL	VL CD3 (seq. 2)	QIVLTQSPAISASPGKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLASGVPAPFRGSGSGTSYSLTISGMEAEAAATYYCQWSSNPPTFGSGTKLEINR

SEQ ID No.	ABT Unique ID	Protein region	Sequence
			1234567890123456789012345678901234567890
67	AB047VH	VH PLGF (seq. 1)	QVQLQQSGAELVKPGASVKISCKASGYTFTDYINWVKLA PGQGLEWIGWIYPGSGNTKYNEKFKGKATLTIDTSSSTAY MQLSSLTSEDVAVYFCVRDSPFFDYWGQGTLLTVSS
68	AB047VL	VL PLGF (seq. 1)	DIVLTQSPDSLAVSLGERVTMCKSSQSLNLSGMRKSF WYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFLT ISSVQAEDVAVYYCKQSYHLFTFGSGTKLEIKR
69	AB062VH	VH ErbB3 (seq. 1)	QVQLQQWGAGLLKPSSETLSLTCVAVYGGSFSGYYWSWIRQP PGKGLEWIGEINHSGSTNYPNPSLKRVTISVETSKNQFSL KLSSVTAADTAVYYCARDKWTWYFDLWGRGTLTVSS
70	AB062VL	VL ErbB3 (seq. 1)	DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSNRNYLA WYQQNPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFLT ISSLQAEDVAVYYCQQYYSTPRFTFGQGTKEIKR
71	AB063VH	VH ErbB3 (seq. 2)	EVQLVESGGGLVQPGGSLRLSCAASGFTFSIYSMNWVRQA PGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNKNSLY LQMNSLRDEDTAVYYCARDRGDFDAFDIWGQGTMTVTVSS
72	AB063VL	VL ErbB3 (seq. 2)	DIQMTQSPSSLSASVGRVTITCQASQDITNYLNWYQQKP GKAPKLLIYDASNLETGVPSRFSGSGSGTDFFTISSLQP EDIATYNCQQCFPIITFGQGTREIKR
73	AB067VH	VH ErbB3 (seq. 3)	EVQLLESAGGLVQPGGSLRLSCAASGFTFSHYVMAWVRQA PGKGLEWVSSISSSGWTLYADSVKGRFTISRDNKNTLY LQMNSLRADDTAVYYCTRGLKMATIFDYWGQGTLLTVSS
74	AB067VL	VL ErbB3 (seq. 3)	QSALTQPASVSGSPGQSITISCTGTSSDVGSYNVVSWYQQ HPGKAPKLLIYEVSQRPSGVSNRFSGSKGNTASLTISGL QTEDEADYCCSYAGSSIFVIFGGGTVTVLG
75	AB069VH	VH DLL4 (seq. 2)	QVQLVQSGAEVKKPGASVKISCKASGYSFTAYYIHWVKQA PGQGLEWIGYISSYNGATNYNQKFKGRVFTTDTSTSTAY MELRSLRSDDTAVYYCARDYDYGMDYWGQGTLLTVSS
76	AB069VL	VL DLL4 (seq. 2)	DIVMTQSPDSLAVSLGERATISCRASESVDNYGISFMKWF QQKPGQPPKLLIYAASNQSGVDPDRFSGSGSGTDFLTIS SLQAEDVAVYYCQKSKEVPWTFGGGTVTVLG

SEQ ID No.	ABT Unique ID	Protein region	Sequence
			1234567890123456789012345678901234567890
77	AB070VH	VH VEGF (seq. 2)	EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIHWVRQA PGKGLEWVAGITPAGGYTYADSVKGRFTISADTSKNTAY LQMNSLRAEDTAVYYCARFVFFLPYAMDYWGQGLTVTVSS
78	AB070VL	VL VEGF (seq. 2)	DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKP GKAPKLLIYASFLYSGVPSRFSGSGSGTDFTLTISLQP EDFATYYCQSQSYTTPPTFGQGTKVEIKR
79	AB071VH	VH VEGF (seq. 3)	EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIHWVRQA PGKGLEWVGAIYPYSGYTNADSVKGRFTISADTSKNTAY LQMNSLRAEDTAVYYCARWGHSTSPWAMDYWGQGLTVTVSS
80	AB071VL	VL VEGF (seq. 3)	DIQMTQSPSSLSASVGDRVTITCRASQVIRRLAWYQQKP GKAPKLLIYAASNLAGVPSRFSGSGSGTDFTLTISLQP EDFATYYCQSQSNTSPLTFGQGTKVEIKR
81	AB072VH	VH DLL4 (seq. 3)	EVQLQQSGPELVKPGASVKMCKASGYTFTSYVINWVKQK PGQGLEWIGLINPYNDGTYNEKFKVKATLTSDKSSSTAY MELSSLTSEDSAVYYCASYYYGSRYFDYWGQGTTLTVSS
82	AB072VL	VL DLL4 (seq. 3)	DIQMTQSSSYLSVSLGGRVTITCKASDHINWLAWYQQKP GNAPRLLISGATSLETGVPSRFSGSGSGKDYTLTSLQ EDVATYYCQYWSIPLTFGAGTKLELKR
83	AB073VH	VH DLL4 (seq. 4)	EVQLQQSGPELEKPGASVKISCKASGYSFTGYNMWVKQS NGKSLEWIGNIDPYFGGTNYNQKFKGKATLTVDKSSSTAY MQLKSLTSEDSAVYYCARNYDYGCGFDYWGQGTTLTVSS
84	AB073VL	VL DLL4 (seq. 4)	QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQE KPDHLFTGLIGGTNNRAPGVPARFSGSLIGDKAALTITGA QTEDEAIYFCALWYSNHWFVGGGKLTVLG
85	AB074VH	VH PLGF (seq. 2)	QVQLKQSGPGLVQPSQSLITCTVSGFSLTTYGIHWVRQS PGKGLEWLGVMWSSGGTDYDAAFISRLSISKDNSKQVFF KMNSLQANDTGIYYCARYRFYGM DYWGQGTSTVTVSS
86	AB074VL	VL PLGF (seq. 2)	AIQMTQSSSSFSVSLGDRVTITCKASEDIYNRFAWYQQKP GNAPRLLISGAASLEAGVPSRFSGSGSGQDYTLTSLQ EDVATYYCQYWPWTFVGGGKLEIKR

SEQ ID No.	ABT Unique ID	Protein region	Sequence 1234567890123456789012345678901234567890
87	AB075VH	VH IGF1R (seq. 2)	EVQLVQSGAEVKKPGSSVKVSKASGGTFSSYAISWVRQA PGQGLEWMGGI IPIFGTANYAQKFGQGRVTITADKSTSTAY MELSSLRSEDTAVYYCARAPLRFLEWSTQDHYYYYYMDVW GKGTITVTVSS
88	AB075VL	VL IGF1R (seq. 2)	SSELTQDPAVSVALGQTVRITCQGDLSRYYATWYQQKPG QAPILVIYGENKRPSGIPDRFSGSSGNTASLTITGAQAE DEADYYCKSRDGSQHLVFGGGTKLTVLG
89	AB077VH	VH IGF1R (seq. 3)	EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSFAMHWVRQA PGKGLEWISVIDTRGATYYADSVKGRFTISRDNAKNSLYL QMNSLRAEDTAVYYCARLGNFYGMVWVGQGTITVTVSS
90	AB077VL	VL IGF1R (seq. 3)	EIVLTQSPGTLSVSPGERATLSCRASQSIGSSLHWYQQKP GQAPRLLIKYASQSLSGIPDRFSGSGSGTDFTLTISRLEP EDFAVYYCHQSSRLPHTFGQGTKVEIKR
91	AB079VH	VH HGF (seq. 2)	EVQLVQSGAEVKKPGESEKISCKGSGYSFTTYMHWVRQM PGKGLEWMGEINPTNGHTNYNPSFQGVVITISADKSI STAY LQWSSSLKASDTAMYYCARNYVGSIFDYWGQGTITVTVSS
92	AB079VL	VL HGF (seq. 2)	DIQMTQSPSSLSASVGDRTITCKASENVVSYVSWYQQKP GKAPKLLIYGASNRNTGVPSRFSGSGSGTDFTLTISLQP EDFATYYCGQSYNYPYTFGQGTKLEIKR
93	AB080VH	VH HER2 (seq. 2)	EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQA PGKGLEWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLY LQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTITVTVSS
94	AB080VL	VL HER2 (seq. 2)	DIQMTQSPSSLSASVGDRTITCKASQDVSIGVAWYQQKP GKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISLQP EDFATYYCQYYIYPYTFGQGTKVEIKR

Detailed description of specific DVD-Ig molecules capable of binding specific targets, and methods of making the same, is provided in the Examples section below.

C. Production of DVD proteins

Binding proteins of the present invention may be produced by any of a number of techniques known in the art. For example, expression from host cells, wherein expression vector(s) encoding the DVD heavy and DVD light chains is (are) transfected into a host cell by standard techniques. The various forms of the term "transfection" are intended to encompass a

wide variety of techniques commonly used for the introduction of exogenous DNA into a prokaryotic or eukaryotic host cell, *e.g.*, electroporation, calcium-phosphate precipitation, DEAE-dextran transfection and the like. Although it is possible to express the DVD proteins of the invention in either prokaryotic or eukaryotic host cells, DVD proteins are expressed in eukaryotic cells, for example, mammalian host cells, because such eukaryotic cells (and in particular mammalian cells) are more likely than prokaryotic cells to assemble and secrete a properly folded and immunologically active DVD protein.

Exemplary mammalian host cells for expressing the recombinant antibodies of the invention include Chinese Hamster Ovary (CHO cells) (including dhfr- CHO cells, described in Urlaub and Chasin, (1980) *Proc. Natl. Acad. Sci. USA* 77:4216-4220, used with a DHFR selectable marker, *e.g.*, as described in R.J. Kaufman and P.A. Sharp (1982) *Mol. Biol.* 159:601-621), NS0 myeloma cells, COS cells, SP2 and PER.C6 cells. When recombinant expression vectors encoding DVD proteins are introduced into mammalian host cells, the DVD proteins are produced by culturing the host cells for a period of time sufficient to allow for expression of the DVD proteins in the host cells or secretion of the DVD proteins into the culture medium in which the host cells are grown. DVD proteins can be recovered from the culture medium using standard protein purification methods.

In an exemplary system for recombinant expression of DVD proteins of the invention, a recombinant expression vector encoding both the DVD heavy chain and the DVD light chain is introduced into dhfr- CHO cells by calcium phosphate-mediated transfection. Within the recombinant expression vector, the DVD heavy and light chain genes are each operatively linked to CMV enhancer/AdMLP promoter regulatory elements to drive high levels of transcription of the genes. The recombinant expression vector also carries a DHFR gene, which allows for selection of CHO cells that have been transfected with the vector using methotrexate selection/amplification. The selected transformant host cells are cultured to allow for expression of the DVD heavy and light chains and intact DVD protein is recovered from the culture medium. Standard molecular biology techniques are used to prepare the recombinant expression vector, transfect the host cells, select for transformants, culture the host cells and recover the DVD protein from the culture medium. Still further the invention provides a method of synthesizing a DVD protein of the invention by culturing a host cell of the invention in a suitable culture medium until a DVD protein of the invention is synthesized. The method can further comprise isolating the DVD protein from the culture medium.

An important feature of DVD-Ig is that it can be produced and purified in a similar way as a conventional antibody. The production of DVD-Ig results in a homogeneous, single major product with desired dual-specific activity, without any sequence modification of the constant region or chemical modifications of any kind. Other previously described methods to generate

“bi-specific”, “multi-specific”, and “multi-specific multivalent” full length binding proteins do not lead to a single primary product but instead lead to the intracellular or secreted production of a mixture of assembled inactive, mono-specific, multi-specific, multivalent, full length binding proteins, and multivalent full length binding proteins with combination of different binding sites.

5 As an example, based on the design described by Miller and Presta (PCT publication WO2001/077342(A1), there are 16 possible combinations of heavy and light chains. Consequently only 6.25% of protein is likely to be in the desired active form, and not as a single major product or single primary product compared to the other 15 possible combinations. Separation of the desired, fully active forms of the protein from inactive and partially active forms
10 of the protein using standard chromatography techniques, typically used in large scale manufacturing, is yet to be demonstrated.

Surprisingly the design of the “dual-specific multivalent full length binding proteins” of the present invention leads to a dual variable domain light chain and a dual variable domain heavy chain which assemble primarily to the desired “dual-specific multivalent full length binding
15 proteins”.

At least 50%, at least 75% and at least 90% of the assembled, and expressed dual variable domain immunoglobulin molecules are the desired dual-specific tetravalent protein. This aspect of the invention particularly enhances the commercial utility of the invention. Therefore, the present invention includes a method to express a dual variable domain light chain and a dual variable
20 domain heavy chain in a single cell leading to a single primary product of a “dual-specific tetravalent full length binding protein”.

The present invention provides a methods of expressing a dual variable domain light chain and a dual variable domain heavy chain in a single cell leading to a “primary product” of a “dual-specific tetravalent full length binding protein”, where the “primary product” is more than
25 50% of all assembled protein, comprising a dual variable domain light chain and a dual variable domain heavy chain.

The present invention provides methods of expressing a dual variable domain light chain and a dual variable domain heavy chain in a single cell leading to a single “primary product” of a “dual-specific tetravalent full length binding protein”, where the “primary product” is more than
30 75% of all assembled protein, comprising a dual variable domain light chain and a dual variable domain heavy chain.

The present invention provides methods of expressing a dual variable domain light chain and a dual variable domain heavy chain in a single cell leading to a single “primary product” of a “dual-specific tetravalent full length binding protein”, where the “primary product” is more than

90% of all assembled protein, comprising a dual variable domain light chain and a dual variable domain heavy chain.

II. Derivatized DVD binding proteins:

One embodiment provides a labeled binding protein wherein the binding protein of the invention is derivatized or linked to another functional molecule (e.g., another peptide or protein). For example, a labeled binding protein of the invention can be derived by functionally linking an binding protein of the invention (by chemical coupling, genetic fusion, noncovalent association or otherwise) to one or more other molecular entities, such as another antibody (e.g., a bispecific antibody or a diabody), a detectable agent, a cytotoxic agent, a pharmaceutical agent, and/or a protein or peptide that can mediate association of the binding protein with another molecule (such as a streptavidin core region or a polyhistidine tag).

Useful detectable agents with which a binding protein of the invention may be derivatized include fluorescent compounds. Exemplary fluorescent detectable agents include fluorescein, fluorescein isothiocyanate, rhodamine, 5-dimethylamine-1-naphthalenesulfonyl chloride, phycoerythrin and the like. A binding protein may also be derivatized with detectable enzymes, such as alkaline phosphatase, horseradish peroxidase, glucose oxidase and the like. When a binding protein is derivatized with a detectable enzyme, it is detected by adding additional reagents that the enzyme uses to produce a detectable reaction product. For example, when the detectable agent horseradish peroxidase is present, the addition of hydrogen peroxide and diaminobenzidine leads to a colored reaction product, which is detectable. a binding protein may also be derivatized with biotin, and detected through indirect measurement of avidin or streptavidin binding.

Another embodiment of the invention provides a crystallized binding protein and formulations and compositions comprising such crystals. In one embodiment the crystallized binding protein has a greater half-life *in vivo* than the soluble counterpart of the binding protein. In another embodiment the binding protein retains biological activity after crystallization.

Crystallized binding protein of the invention may be produced according to methods known in the art and as disclosed in WO 02072636, incorporated herein by reference.

Another embodiment of the invention provides a glycosylated binding protein wherein the antibody or antigen-binding portion thereof comprises one or more carbohydrate residues. Nascent *in vivo* protein production may undergo further processing, known as post-translational modification. In particular, sugar (glycosyl) residues may be added enzymatically, a process known as glycosylation. The resulting proteins bearing covalently linked oligosaccharide side chains are known as glycosylated proteins or glycoproteins. Antibodies are glycoproteins with one or more carbohydrate residues in the Fc domain, as well as the variable domain.

Carbohydrate residues in the Fc domain have important effect on the effector function of the Fc domain, with minimal effect on antigen binding or half-life of the antibody (R. Jefferis, *Biotechnol. Prog.* **21** (2005), pp. 11–16). In contrast, glycosylation of the variable domain may have an effect on the antigen binding activity of the antibody. Glycosylation in the variable
5 domain may have a negative effect on antibody binding affinity, likely due to steric hindrance (Co, M.S., et al., *Mol. Immunol.* (1993) 30:1361- 1367), or result in increased affinity for the antigen (Wallick, S.C., et al., *Exp. Med.* (1988) 168:1099-1109; Wright, A., et al., *EMBO J.* (1991) 10:2717 2723).

One aspect of the present invention is directed to generating glycosylation site mutants in
10 which the O- or N-linked glycosylation site of the binding protein has been mutated. One skilled in the art can generate such mutants using standard well-known technologies. Glycosylation site mutants that retain the biological activity but have increased or decreased binding activity are another object of the present invention.

In still another embodiment, the glycosylation of the antibody or antigen-binding portion
15 of the invention is modified. For example, an aglycosylated antibody can be made (i.e., the antibody lacks glycosylation). Glycosylation can be altered to, for example, increase the affinity of the antibody for antigen. Such carbohydrate modifications can be accomplished by, for example, altering one or more sites of glycosylation within the antibody sequence. For example, one or more amino acid substitutions can be made that result in elimination of one or more
20 variable region glycosylation sites to thereby eliminate glycosylation at that site. Such aglycosylation may increase the affinity of the antibody for antigen. Such an approach is described in further detail in PCT Publication WO2003016466A2, and U.S. Pat. Nos. 5,714,350 and 6,350,861, each of which is incorporated herein by reference in its entirety.

Additionally or alternatively, a modified binding protein of the invention can be made
25 that has an altered type of glycosylation, such as a hypofucosylated antibody having reduced amounts of fucosyl residues (see Kanda, Yutaka et al., *Journal of Biotechnology* (2007), 130(3), 300-310.) or an antibody having increased bisecting GlcNAc structures. Such altered glycosylation patterns have been demonstrated to increase the ADCC ability of antibodies. Such carbohydrate modifications can be accomplished by, for example, expressing the antibody in a
30 host cell with altered glycosylation machinery. Cells with altered glycosylation machinery have been described in the art and can be used as host cells in which to express recombinant antibodies of the invention to thereby produce an antibody with altered glycosylation. See, for example, Shields, R. L. et al. (2002) *J. Biol. Chem.* 277:26733-26740; Umana et al. (1999) *Nat. Biotech.* 17:176-1, as well as, European Patent No: EP 1,176,195; PCT Publications WO 03/035835; WO
35 99/54342 80, each of which is incorporated herein by reference in its entirety.

Protein glycosylation depends on the amino acid sequence of the protein of interest, as well as the host cell in which the protein is expressed. Different organisms may produce different glycosylation enzymes (eg., glycosyltransferases and glycosidases), and have different substrates (nucleotide sugars) available. Due to such factors, protein glycosylation pattern, and composition
5 of glycosyl residues, may differ depending on the host system in which the particular protein is expressed. Glycosyl residues useful in the invention may include, but are not limited to, glucose, galactose, mannose, fucose, n-acetylglucosamine and sialic acid. In an embodiment, the glycosylated binding protein comprises glycosyl residues such that the glycosylation pattern is human.

10 It is known to those skilled in the art that differing protein glycosylation may result in differing protein characteristics. For instance, the efficacy of a therapeutic protein produced in a microorganism host, such as yeast, and glycosylated utilizing the yeast endogenous pathway may be reduced compared to that of the same protein expressed in a mammalian cell, such as a CHO cell line. Such glycoproteins may also be immunogenic in humans and show reduced half-life *in*
15 *vivo* after administration. Specific receptors in humans and other animals may recognize specific glycosyl residues and promote the rapid clearance of the protein from the bloodstream. Other adverse effects may include changes in protein folding, solubility, susceptibility to proteases, trafficking, transport, compartmentalization, secretion, recognition by other proteins or factors, antigenicity, or allergenicity. Accordingly, a practitioner may choose a therapeutic protein with a
20 specific composition and pattern of glycosylation, for example glycosylation composition and pattern identical, or at least similar, to that produced in human cells or in the species-specific cells of the intended subject animal.

Expressing glycosylated proteins different from that of a host cell may be achieved by genetically modifying the host cell to express heterologous glycosylation enzymes. Using
25 techniques known in the art a practitioner may generate antibodies or antigen-binding portions thereof exhibiting human protein glycosylation. For example, yeast strains have been genetically modified to express non-naturally occurring glycosylation enzymes such that glycosylated proteins (glycoproteins) produced in these yeast strains exhibit protein glycosylation identical to that of animal cells, especially human cells (U.S patent applications 20040018590 and
30 20020137134 and PCT publication WO2005100584 A2).

In addition to the binding proteins, the present invention is also directed to anti-idiotypic (anti-Id) antibodies specific for such binding proteins of the invention. An anti-Id antibody is an antibody, which recognizes unique determinants generally associated with the antigen-binding region of another antibody. The anti-Id can be prepared by immunizing an animal with the
35 binding protein or a CDR containing region thereof. The immunized animal will recognize, and respond to the idiotypic determinants of the immunizing antibody and produce an anti-Id

antibody. It is readily apparent that it may be easier to generate anti-idiotypic antibodies to the two or more parent antibodies incorporated into a DVD-Ig molecule; and confirm binding studies by methods well recognized in the art (e.g., BIAcore, ELISA) to verify that anti-idiotypic antibodies specific for the idiotype of each parent antibody also recognize the idiotype (e.g., antigen binding site) in the context of the DVD-Ig. The anti-idiotypic antibodies specific for each of the two or more antigen binding sites of a DVD-Ig provide ideal reagents to measure DVD-Ig concentrations of a human DVD-Ig in patient serum; DVD-Ig concentration assays can be established using a "sandwich assay ELISA format" with an antibody to a first antigen binding regions coated on the solid phase (e.g., BIAcore chip, ELISA plate etc.), rinsed with rinsing buffer, incubation with the serum sample, another rinsing step and ultimately incubation with another anti-idiotypic antibody to the another antigen binding site, itself labeled with an enzyme for quantitation of the binding reaction. In an embodiment, for a DVD-Ig with more than two different binding sites, anti-idiotypic antibodies to the two outermost binding sites (most distal and proximal from the constant region) will not only help in determining the DVD-Ig concentration in human serum but also document the integrity of the molecule *in vivo*. Each anti-Id antibody may also be used as an "immunogen" to induce an immune response in yet another animal, producing a so-called anti-anti-Id antibody.

Further, it will be appreciated by one skilled in the art that a protein of interest may be expressed using a library of host cells genetically engineered to express various glycosylation enzymes, such that member host cells of the library produce the protein of interest with variant glycosylation patterns. A practitioner may then select and isolate the protein of interest with particular novel glycosylation patterns. In an embodiment, the protein having a particularly selected novel glycosylation pattern exhibits improved or altered biological properties.

III. Uses of DVD-Ig

Given their ability to bind to two or more antigens the binding proteins of the invention can be used to detect the antigens (e.g., in a biological sample, such as serum or plasma), using a conventional immunoassay, such as an enzyme linked immunosorbent assays (ELISA), an radioimmunoassay (RIA) or tissue immunohistochemistry. The DVD-Ig is directly or indirectly labeled with a detectable substance to facilitate detection of the bound or unbound antibody. Suitable detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a

luminescent material includes luminol; and examples of suitable radioactive material include ^3H , ^{14}C , ^{35}S , ^{90}Y , ^{99}Tc , ^{111}In , ^{125}I , ^{131}I , ^{177}Lu , ^{166}Ho , or ^{153}Sm .

In an embodiment, the binding proteins of the invention are capable of neutralizing the activity of the antigens both *in vitro* and *in vivo*. Accordingly, such DVD-Igs can be used to
5 inhibit antigen activity, *e.g.*, in a cell culture containing the antigens, in human subjects or in other mammalian subjects having the antigens with which a binding protein of the invention cross-reacts. In another embodiment, the invention provides a method for reducing antigen activity in a subject suffering from a disease or disorder in which the antigen activity is detrimental. A binding protein of the invention can be administered to a human subject for therapeutic purposes.

10 As used herein, the term "a disorder in which antigen activity is detrimental" is intended to include diseases and other disorders in which the presence of the antigen in a subject suffering from the disorder has been shown to be or is suspected of being either responsible for the pathophysiology of the disorder or a factor that contributes to a worsening of the disorder. Accordingly, a disorder in which antigen activity is detrimental is a disorder in which reduction of
15 antigen activity is expected to alleviate the symptoms and/or progression of the disorder. Such disorders may be evidenced, for example, by an increase in the concentration of the antigen in a biological fluid of a subject suffering from the disorder (*e.g.*, an increase in the concentration of antigen in serum, plasma, synovial fluid, *etc.* of the subject). Non-limiting examples of disorders that can be treated with the binding proteins of the invention include those disorders discussed
20 below and in the section pertaining to pharmaceutical compositions of the antibodies of the invention.

The DVD-Igs of the invention may bind one antigen or multiple antigens. Such antigens include, but are not limited to, the targets listed in the following databases, which databases are incorporated herein by reference. These target databases include those listings:

25 Therapeutic targets (<http://xin.cz3.nus.edu.sg/group/cjttd/ttd.asp>);

Cytokines and cytokine receptors (<http://www.cytokinewebfacts.com/>,
<http://www.copewithcytokines.de/cope.cgi>, and

http://cmbi.bjmu.edu.cn/cmbidata/cgf/CGF_Database/cytokine.medic.kumamoto-u.ac.jp/CFC/indexR.html);

30 Chemokines (<http://cytokine.medic.kumamoto-u.ac.jp/CFC/CK/Chemokine.html>);

Chemokine receptors and GPCRs (<http://csp.medic.kumamoto-u.ac.jp/CSP/Receptor.html>,
<http://www.gpcr.org/7tm/>);

Olfactory Receptors (<http://senselab.med.yale.edu/senselab/ORDB/default.asp>);

Receptors (<http://www.iuphar-db.org/iuphar-rd/list/index.htm>);

Cancer targets (<http://cged.hgc.jp/cgi-bin/input.cgi>);

Secreted proteins as potential antibody targets (<http://spd.cbi.pku.edu.cn/>);

Protein kinases (<http://spd.cbi.pku.edu.cn/>), and

- 5 Human CD markers (http://content.labvelocity.com/tools/6/1226/CD_table_final_locked.pdf) and (Zola H, 2005 CD molecules 2005: human cell differentiation molecules Blood, 106:3123-6).

DVD-Igs are useful as therapeutic agents to simultaneously block two different targets to enhance efficacy/safety and/or increase patient coverage. Such targets may include soluble targets (TNF) and cell surface receptor targets (VEGFR and EGFR). It can also be used to induce
10 redirected cytotoxicity between tumor cells and T cells (Her2 and CD3) for cancer therapy, or between autoreactive cell and effector cells for autoimmune disease or transplantation, or between any target cell and effector cell to eliminate disease-causing cells in any given disease.

In addition, DVD-Ig can be used to trigger receptor clustering and activation when it is designed to target two different epitopes on the same receptor. This may have benefit in making
15 agonistic and antagonistic anti-GPCR therapeutics. In this case, DVD-Ig can be used to target two different epitopes (including epitopes on both the loop regions and the extracellular domain) on one cell for clustering/signaling (two cell surface molecules) or signaling (on one molecule). Similarly, a DVD-Ig molecule can be designed to trigger CTLA-4 ligation, and a negative signal by targeting two different epitopes (or 2 copies of the same epitope) of CTLA-4 extracellular
20 domain, leading to down regulation of the immune response. CTLA-4 is a clinically validated target for therapeutic treatment of a number of immunological disorders. CTLA-4/B7 interactions negatively regulate T cell activation by attenuating cell cycle progression, IL-2 production, and proliferation of T cells following activation, and CTLA-4 (CD152) engagement can down-regulate T cell activation and promote the induction of immune tolerance. However, the strategy
25 of attenuating T cell activation by agonistic antibody engagement of CTLA-4 has been unsuccessful since CTLA-4 activation requires ligation. The molecular interaction of CTLA-4/B7 is in "skewed zipper" arrays, as demonstrated by crystal structural analysis (Stamper 2001 Nature 410:608). However none of the currently available CTLA-4 binding reagents have ligation properties, including anti-CTLA-4 mAbs. There have been several attempts to address this issue.
30 In one case, a cell member-bound single chain antibody was generated, and significantly inhibited allogeneic rejection in mice (Hwang 2002 JI 169:633). In a separate case, artificial APC surface-linked single-chain antibody to CTLA-4 was generated and demonstrated to attenuate T cell responses (Griffin 2000 JI 164:4433). In both cases, CTLA-4 ligation was achieved by closely localized member-bound antibodies in artificial systems. While these experiments provide proof-
35 of-concept for immune down-regulation by triggering CTLA-4 negative signaling, the reagents

used in these reports are not suitable for therapeutic use. To this end, CTLA-4 ligation may be achieved by using a DVD-Ig molecule, which target two different epitopes (or 2 copies of the same epitope) of CTLA-4 extracellular domain. The rationale is that the distance spanning two binding sites of an IgG, approximately 150-170Å, is too large for active ligation of CTLA-4 (30-50 Å between 2 CTLA-4 homodimer). However the distance between the two binding sites on DVD-Ig (one arm) is much shorter, also in the range of 30-50 Å, allowing proper ligation of CTLA-4.

Similarly, DVD-Ig can target two different members of a cell surface receptor complex (e.g., IL-12R alpha and beta). Furthermore, DVD-Ig can target CR1 and a soluble protein/pathogen to drive rapid clearance of the target soluble protein/pathogen.

Additionally, DVD-Igs of the invention can be employed for tissue-specific delivery (target a tissue marker and a disease mediator for enhanced local PK thus higher efficacy and/or lower toxicity), including intracellular delivery (targeting an internalizing receptor and an intracellular molecule), delivering to inside brain (targeting transferrin receptor and a CNS disease mediator for crossing the blood-brain barrier). DVD-Ig can also serve as a carrier protein to deliver an antigen to a specific location via binding to a non-neutralizing epitope of that antigen and also to increase the half-life of the antigen. Furthermore, DVD-Ig can be designed to either be physically linked to medical devices implanted into patients or target these medical devices (see Burke, Sandra E.; Kuntz, Richard E.; Schwartz, Lewis B., Zotarolimus eluting stents. Advanced Drug Delivery Reviews (2006), 58(3), 437-446; Surface coatings for biological activation and functionalization of medical devices, Hildebrand, H. F.; Blanchemain, N.; Mayer, G.; Chai, F.; Lefebvre, M.; Boschin, F., Surface and Coatings Technology (2006), 200(22-23), 6318-6324; Drug/ device combinations for local drug therapies and infection prophylaxis, Wu, Peng; Grainger, David W., Biomaterials (2006), 27(11), 2450-2467; Mediation of the cytokine network in the implantation of orthopedic devices., Marques, A. P.; Hunt, J. A.; Reis, Rui L., Biodegradable Systems in Tissue Engineering and Regenerative Medicine (2005), 377-397). Briefly, directing appropriate types of cell to the site of medical implant may promote healing and restoring normal tissue function. Alternatively, inhibition of mediators (including but not limited to cytokines), released upon device implantation by a DVD coupled to or target to a device is also provided. For example, Stents have been used for years in interventional cardiology to clear blocked arteries and to improve the flow of blood to the heart muscle. However, traditional bare metal stents have been known to cause restenosis (re-narrowing of the artery in a treated area) in some patients and can lead to blood clots. Recently, an anti-CD34 antibody coated stent has been described which reduced restenosis and prevents blood clots from occurring by capturing endothelial progenitor cells (EPC) circulating throughout the blood. Endothelial cells are cells that line blood vessels, allowing blood to flow smoothly. The EPCs adhere to the hard surface of the

stent forming a smooth layer that not only promotes healing but prevents restenosis and blood clots, complications previously associated with the use of stents (Aoji et al. 2005 J Am Coll Cardiol. 45(10):1574-9). In addition to improving outcomes for patients requiring stents, there are also implications for patients requiring cardiovascular bypass surgery. For example, a
5 prosthetic vascular conduit (artificial artery) coated with anti-EPC antibodies would eliminate the need to use arteries from patients legs or arms for bypass surgery grafts. This would reduce surgery and anesthesia times, which in turn will reduce coronary surgery deaths. DVD-Ig are designed in such a way that it binds to a cell surface marker (such as CD34) as well as a protein (or an epitope of any kind, including but not limited to proteins, lipids and polysaccharides) that
10 has been coated on the implanted device to facilitate the cell recruitment. Such approaches can also be applied to other medical implants in general. Alternatively, DVD-Igs can be coated on medical devices and upon implantation and releasing all DVDs from the device (or any other need which may require additional fresh DVD-Ig, including aging and denaturation of the already loaded DVD-Ig) the device could be reloaded by systemic administration of fresh DVD-Ig to the
15 patient, where the DVD-Ig is designed to binds to a target of interest (a cytokine, a cell surface marker (such as CD34) etc.) with one set of binding sites and to a target coated on the device (including a protein, an epitope of any kind, including but not limited to lipids, polysaccharides and polymers) with the other. This technology has the advantage of extending the usefulness of coated implants.

20 A. Use of DVD-Igs in various diseases

DVD-Ig molecules of the invention are also useful as therapeutic molecules to treat various diseases. Such DVD molecules may bind one or more targets involved in a specific disease. Examples of such targets in various diseases are described below.

1. Human Autoimmune and Inflammatory Response

25 Many proteins have been implicated in general autoimmune and inflammatory responses, including C5, CCL1 (I-309), CCL11 (eotaxin), CCL13 (mcp-4), CCL15 (MIP-1d), CCL16 (HCC-4), CCL17 (TARC), CCL18 (PARC), CCL19, CCL2 (mcp-1), CCL20 (MIP-3a), CCL21 (MIP-2), CCL23 (MPIF-1), CCL24 (MPIF-2 / eotaxin-2), CCL25 (TECK), CCL26, CCL3 (MIP-1a), CCL4 (MIP-1b), CCL5 (RANTES), CCL7 (mcp-3), CCL8 (mcp-2), CXCL1, CXCL10 (IP-10),
30 CXCL11 (I-TAC / IP-9), CXCL12 (SDF1), CXCL13, CXCL14, CXCL2, CXCL3, CXCL5 (ENA-78 / LIX), CXCL6 (GCP-2), CXCL9, IL13, IL8, CCL13 (mcp-4), CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CX3CR1, IL8RA, XCR1 (CCXCR1), IFNA2, IL10, IL13, IL17C, IL1A, IL1B, IL1F10, IL1F5, IL1F6, IL1F7, IL1F8, IL1F9, IL22, IL5, IL8, IL9, LTA, LTB, MIF, SCYE1 (endothelial Monocyte-activating cytokine), SPP1, TNF, TNFSF5,
35 IFNA2, IL10RA, IL10RB, IL13, IL13RA1, IL5RA, IL9, IL9R, ABCF1, BCL6, C3, C4A,

CEBPB, CRP, ICEBERG, IL1R1, IL1RN, IL8RB, LTB4R, TOLLIP, FADD, IRAK1, IRAK2, MYD88, NCK2, TNFAIP3, TRADD, TRAF1, TRAF2, TRAF3, TRAF4, TRAF5, TRAF6, ACVR1, ACVR1B, ACVR2, ACVR2B, ACVRL1, CD28, CD3E, CD3G, CD3Z, CD69, CD80, CD86, CNR1, CTLA4, CYSLTR1, FCER1A, FCER2, FCGR3A, GPR44, HAVCR2, OPRD1, 5 P2RX7, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, BLR1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL13, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CX3CL1, CX3CR1, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL10, CXCL11, CXCL12, CXCL13, CXCR4, GPR2, SCYE1, SDF2, XCL1, XCL2, XCR1, 10 AMH, AMHR2, BMPR1A, BMPR1B, BMPR2, C19orf10 (IL27w), CER1, CSF1, CSF2, CSF3, DKFZp451J0118, FGF2, GFI1, IFNA1, IFNB1, IFNG, IGF1, IL1A, IL1B, IL1R1, IL1R2, IL2, IL2RA, IL2RB, IL2RG, IL3, IL4, IL4R, IL5, IL5RA, IL6, IL6R, IL6ST, IL7, IL8, IL8RA, IL8RB, IL9, IL9R, IL10, IL10RA, IL10RB, IL11, IL11RA, IL12A, IL12B, IL12RB1, IL12RB2, IL13, IL13RA1, IL13RA2, IL15, IL15RA, IL16, IL17, IL17R, IL18, IL18R1, IL19, IL20, 15 KITLG, LEP, LTA, LTB, LTB4R, LTB4R2, LTBR, MIF, NPPB, PDGFB, TBX21, TDGF1, TGFA, TGFB1, TGFB111, TGFB2, TGFB3, TGFB1, TGFB1R1, TGFB1R2, TGFB1R3, TH1L, TNF, TNFRSF1A, TNFRSF1B, TNFRSF7, TNFRSF8, TNFRSF9, TNFRSF11A, TNFRSF21, TNFSF4, TNFSF5, TNFSF6, TNFSF11, VEGF, ZFPM2, and RNF110 (ZNF144). In one aspect, DVD-Igs capable of binding one or more of the targets listed herein are provided.

20 2. Asthma

Allergic asthma is characterized by the presence of eosinophilia, goblet cell metaplasia, epithelial cell alterations, airway hyperreactivity (AHR), and Th2 and Th1 cytokine expression, as well as elevated serum IgE levels. It is now widely accepted that airway inflammation is the key factor underlying the pathogenesis of asthma, involving a complex interplay of inflammatory cells 25 such as T cells, B cells, eosinophils, mast cells and macrophages, and of their secreted mediators including cytokines and chemokines. Corticosteroids are the most important anti-inflammatory treatment for asthma today, however their mechanism of action is non-specific and safety concerns exist, especially in the juvenile patient population. The development of more specific and targeted therapies is therefore warranted. There is increasing evidence that IL-13 in mice 30 mimics many of the features of asthma, including AHR, mucus hypersecretion and airway fibrosis, independently of eosinophilic inflammation (Finotto et al., *International Immunology* (2005), 17(8), 993-1007; Padilla et al., *Journal of Immunology* (2005), 174(12), 8097-8105).

IL-13 has been implicated as having a pivotal role in causing pathological responses associated with asthma. The development of anti-IL-13 mAb therapy to reduce the effects of IL- 35 13 in the lung is an exciting new approach that offers considerable promise as a novel treatment for asthma. However other mediators of differential immunological pathways are also involved in

asthma pathogenesis, and blocking these mediators, in addition to IL-13, may offer additional therapeutic benefit. Such target pairs include, but are not limited to, IL-13 and a pro-inflammatory cytokine, such as tumor necrosis factor- α (TNF- α). TNF- α may amplify the inflammatory response in asthma and may be linked to disease severity (McDonnell, et al.,
5 Progress in Respiratory Research (2001), 31(New Drugs for Asthma, Allergy and COPD), 247-250.). This suggests that blocking both IL-13 and TNF- α may have beneficial effects, particularly in severe airway disease. In another embodiment the DVD-Ig of the invention binds the targets IL-13 and TNF α and is used for treating asthma.

Animal models such as OVA-induced asthma mouse model, where both inflammation
10 and AHR can be assessed, are known in the art and may be used to determine the ability of various DVD-Ig molecules to treat asthma. Animal models for studying asthma are disclosed in Coffman, et al., Journal of Experimental Medicine (2005), 201(12), 1875-1879; Lloyd, et al., Advances in Immunology (2001), 77, 263-295; Boyce et al., Journal of Experimental Medicine (2005), 201(12), 1869-1873; and Snibson, et al., Journal of the British Society for Allergy and
15 Clinical Immunology (2005), 35(2), 146-52. In addition to routine safety assessments of these target pairs specific tests for the degree of immunosuppression may be warranted and helpful in selecting the best target pairs (see Luster et al., Toxicology (1994), 92(1-3), 229-43; Descotes, et al., Developments in biological standardization (1992), 77 99-102; Hart et al., Journal of Allergy and Clinical Immunology (2001), 108(2), 250-257).

20 Based on the rationale disclosed herein and using the same evaluation model for efficacy and safety other pairs of targets that DVD-Ig molecules can bind and be useful to treat asthma may be determined. In an embodiment, such targets include, but are not limited to, IL-13 and IL-1beta, since IL-1beta is also implicated in inflammatory response in asthma; IL-13 and cytokines and chemokines that are involved in inflammation, such as IL-13 and IL-9; IL-13 and IL-4; IL-13 and IL-5; IL-13 and IL-25; IL-13 and TARC; IL-13 and MDC; IL-13 and MIF; IL-13 and TGF- β ;
25 IL-13 and LHR agonist; IL-13 and CL25; IL-13 and SPRR2a; IL-13 and SPRR2b; and IL-13 and ADAM8. The present invention also provides DVD-Igs capable of binding one or more targets involved in asthma selected from the group consisting of CSF1 (MCSF), CSF2 (GM-CSF), CSF3 (GCSF), FGF2, IFNA1, IFNB1, IFNG, histamine and histamine receptors, IL1A, IL1B, IL2, IL3,
30 IL4, IL5, IL6, IL7, IL8, IL9, IL10, IL11, IL12A, IL12B, IL13, IL14, IL15, IL16, IL17, IL18, IL19, KITLG, PDGFB, IL2RA, IL4R, IL5RA, IL8RA, IL8RB, IL12RB1, IL12RB2, IL13RA1, IL13RA2, IL18R1, TSLP, CCL1, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL13, CCL17, CCL18, CCL19, CCL20, CCL22, CCL24, CX3CL1, CXCL1, CXCL2, CXCL3, XCL1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CX3CR1, GPR2, XCR1, FOS, GATA3, JAK1,
35 JAK3, STAT6, TBX21, TGFB1, TNF, TNFSF6, YY1, CYSLTR1, FCER1A, FCER2, LTB4R, TB4R2, LTBR, and Chitinase.

3. Rheumatoid arthritis

Rheumatoid arthritis (RA), a systemic disease, is characterized by a chronic inflammatory reaction in the synovium of joints and is associated with degeneration of cartilage and erosion of juxta-articular bone. Many pro-inflammatory cytokines including TNF, chemokines, and growth factors are expressed in diseased joints. Systemic administration of anti-TNF antibody or sTNFR fusion protein to mouse models of RA was shown to be anti-inflammatory and joint protective. Clinical investigations in which the activity of TNF in RA patients was blocked with intravenously administered infliximab (Harriman G, Harper LK, Schaible TF. 1999 Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNF α treatment. *Ann Rheum Dis* 58 Suppl 1:161-4), a chimeric anti-TNF mAb, has provided evidence that TNF regulates IL-6, IL-8, MCP-1, and VEGF production, recruitment of immune and inflammatory cells into joints, angiogenesis, and reduction of blood levels of matrix metalloproteinases-1 and -3. A better understanding of the inflammatory pathway in rheumatoid arthritis has led to identification of other therapeutic targets involved in rheumatoid arthritis. Promising treatments such as interleukin-6 antagonists (IL-6 receptor antibody MRA, developed by Chugai, Roche (see Nishimoto, Norihiro et al., *Arthritis & Rheumatism* (2004), 50(6), 1761-1769), CTLA4Ig (abatacept, Genovese Mc et al 2005 Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. *N Engl J Med*. 353:1114-23.), and anti-B cell therapy (rituximab, Okamoto H, Kamatani N. 2004 Rituximab for rheumatoid arthritis. *N Engl J Med*. 351:1909) have already been tested in randomized controlled trials over the past year. Other cytokines have been identified and have been shown to be of benefit in animal models, including interleukin-15 (therapeutic antibody HuMax-IL_15, AMG 714 see Baslund, Bo et al., *Arthritis & Rheumatism* (2005), 52(9), 2686-2692), interleukin-17, and interleukin-18, and clinical trials of these agents are currently under way. Dual-specific antibody therapy, combining anti-TNF and another mediator, has great potential in enhancing clinical efficacy and/or patient coverage. For example, blocking both TNF and VEGF can potentially eradicate inflammation and angiogenesis, both of which are involved in pathophysiology of RA. Blocking other pairs of targets involved in RA including, but not limited to, TNF and IL-18; TNF and IL-12; TNF and IL-23; TNF and IL-1 β ; TNF and MIF; TNF and IL-17; TNF and IL-15 with specific DVD Igs is also contemplated. In addition to routine safety assessments of these target pairs, specific tests for the degree of immunosuppression may be warranted and helpful in selecting the best target pairs (see Luster et al., *Toxicology* (1994), 92(1-3), 229-43; Descotes, et al., *Developments in biological standardization* (1992), 77 99-102; Hart et al., *Journal of Allergy and Clinical Immunology* (2001), 108(2), 250-257). Whether a DVD Ig molecule will be useful for the treatment of rheumatoid arthritis can be assessed using pre-clinical animal RA models such as the collagen-induced arthritis mouse model. Other useful models are also well known in the art (see Brand

DD., *Comp Med.* (2005) 55(2):114-22). Based on the cross-reactivity of the parental antibodies for human and mouse orthologues (e.g., reactivity for human and mouse TNF, human and mouse IL-15 etc.) validation studies in the mouse CIA model may be conducted with “matched surrogate antibody” derived DVD-Ig molecules; briefly, a DVD-Ig based on two (or more) mouse target specific antibodies may be matched to the extent possible to the characteristics of the parental human or humanized antibodies used for human DVD-Ig construction (similar affinity, similar neutralization potency, similar half-life etc.).

4. SLE

The immunopathogenic hallmark of SLE is the polyclonal B cell activation, which leads to hyperglobulinemia, autoantibody production and immune complex formation. The fundamental abnormality appears to be the failure of T cells to suppress the forbidden B cell clones due to generalized T cell dysregulation. In addition, B and T-cell interaction is facilitated by several cytokines such as IL-10 as well as co-stimulatory molecules such as CD40 and CD40L, B7 and CD28 and CTLA-4, which initiate the second signal. These interactions together with impaired phagocytic clearance of immune complexes and apoptotic material, perpetuate the immune response with resultant tissue injury. The following targets may be involved in SLE and can potentially be used for DVD-Ig approach for therapeutic intervention: B cell targeted therapies: CD-20, CD-22, CD-19, CD28, CD4, CD80, HLA-DRA, IL10, IL2, IL4, TNFRSF5, TNFRSF6, TNFSF5, TNFSF6, BLR1, HDAC4, HDAC5, HDAC7A, HDAC9, ICOSL, IGBP1, MS4A1, RGS1, SLA2, CD81, IFNB1, IL10, TNFRSF5, TNFRSF7, TNFSF5, AICDA, BLNK, GALNAC4S-6ST, HDAC4, HDAC5, HDAC7A, HDAC9, IL10, IL11, IL4, INHA, INHBA, KLF6, TNFRSF7, CD28, CD38, CD69, CD80, CD83, CD86, DPP4, FCER2, IL2RA, TNFRSF8, TNFSF7, CD24, CD37, CD40, CD72, CD74, CD79A, CD79B, CR2, IL1R2, ITGA2, ITGA3, MS4A1, ST6GAL1, CD1C, CHST10, HLA-A, HLA-DRA, and NT5E.; co-stimulatory signals: CTLA4 or B7.1/B7.2; inhibition of B cell survival: BlyS, BAFF; Complement inactivation: C5; Cytokine modulation: the key principle is that the net biologic response in any tissue is the result of a balance between local levels of proinflammatory or anti-inflammatory cytokines (see Sfrikakis PP et al 2005 *Curr Opin Rheumatol* 17:550-7). SLE is considered to be a Th-2 driven disease with documented elevations in serum IL-4, IL-6, IL-10. DVD Igs capable of binding one or more targets selected from the group consisting of IL-4, IL-6, IL-10, IFN- α , and TNF- α are also contemplated. Combination of targets discussed herein will enhance therapeutic efficacy for SLE which can be tested in a number of lupus preclinical models (see Peng SL (2004) *Methods Mol Med.*;102:227-72). Based on the cross-reactivity of the parental antibodies for human and mouse orthologues (e.g., reactivity for human and mouse CD20, human and mouse Interferon alpha etc.) validation studies in a mouse lupus model may be conducted with “matched surrogate antibody” derived DVD-Ig molecules; briefly, a DVD-Ig based two (or more) mouse target specific

antibodies may be matched to the extent possible to the characteristics of the parental human or humanized antibodies used for human DVD-Ig construction (similar affinity, similar neutralization potency, similar half-life etc.).

5. Multiple sclerosis

5 Multiple sclerosis (MS) is a complex human autoimmune-type disease with a predominantly unknown etiology. Immunologic destruction of myelin basic protein (MBP) throughout the nervous system is the major pathology of multiple sclerosis. MS is a disease of complex pathologies, which involves infiltration by CD4+ and CD8+ T cells and of response within the central nervous system. Expression in the CNS of cytokines, reactive nitrogen species
10 and costimulator molecules have all been described in MS. Of major consideration are immunological mechanisms that contribute to the development of autoimmunity. In particular, antigen expression, cytokine and leukocyte interactions, and regulatory T-cells, which help balance/modulate other T-cells such as Th1 and Th2 cells, are important areas for therapeutic target identification.

15 IL-12 is a proinflammatory cytokine that is produced by APC and promotes differentiation of Th1 effector cells. IL-12 is produced in the developing lesions of patients with MS as well as in EAE-affected animals. Previously it was shown that interference in IL-12 pathways effectively prevents EAE in rodents, and that in vivo neutralization of IL-12p40 using a anti-IL-12 mAb has beneficial effects in the myelin-induced EAE model in common marmosets.

20 TWEAK is a member of the TNF family, constitutively expressed in the central nervous system (CNS), with pro-inflammatory, proliferative or apoptotic effects depending upon cell types. Its receptor, Fn14, is expressed in CNS by endothelial cells, reactive astrocytes and neurons. TWEAK and Fn14 mRNA expression increased in spinal cord during experimental autoimmune encephalomyelitis (EAE). Anti-TWEAK antibody treatment in myelin
25 oligodendrocyte glycoprotein (MOG) induced EAE in C57BL/6 mice resulted in a reduction of disease severity and leukocyte infiltration when mice were treated after the priming phase.

One aspect of the invention pertains to DVD Ig molecules capable of binding one or more, for example two, targets selected from the group consisting of IL-12, TWEAK, IL-23, CXCL13, CD40, CD40L, IL-18, VEGF, VLA-4, TNF, CD45RB, CD200, IFN γ , GM-CSF,
30 FGF, C5, CD52, and CCR2. An embodiment includes a dual-specific anti-IL-12/TWEAK DVD Ig as a therapeutic agent beneficial for the treatment of MS.

Several animal models for assessing the usefulness of the DVD molecules to treat MS are known in the art (see Steinman L, et al., (2005) Trends Immunol. 26(11):565-71; Lublin FD., et al., (1985) Springer Semin Immunopathol.8(3):197-208; Genain CP, et al., (1997) J Mol Med.
35 75(3):187-97; Tuohy VK, et al., (1999) J Exp Med. 189(7):1033-42; Owens T, et al., (1995)

Neurol Clin.13(1):51-73; and 't Hart BA, et al., (2005) J Immunol 175(7):4761-8. Based on the cross-reactivity of the parental antibodies for human and animal species othologues (e.g.,reactivity for human and mouse IL-12, human and mouse TWEAK etc.) validation studies in the mouse EAE model may be conducted with “matched surrogate antibody” derived DVD-Ig molecules; briefly, a DVD-Ig based on to (or more) mouse target specific antibodies may be matched to the extent possible to the characteristics of the parental human or humanized antibodies used for human DVD-Ig construction (similar affinity, similar neutralization potency, similar half-life etc.). The same concept applies to animal models in other non-rodent species, where a “matched surrogate antibody” derived DVD-Ig would be selected for the anticipated pharmacology and possibly safety studies. In addition to routine safety assessments of these target pairs specific tests for the degree of immunosuppression may be warranted and helpful in selecting the best target pairs (see Luster et al., Toxicology (1994), 92(1-3), 229-43; Descotes, et al., Developments in biological standardization (1992), 77 99-102; Jones R. 2000 Rovelizumab (ICOS Corp). IDrugs.3(4):442-6).

15 **6. Sepsis**

The pathophysiology of sepsis is initiated by the outer membrane components of both gram-negative organisms (lipopolysaccharide [LPS], lipid A, endotoxin) and gram-positive organisms (lipoteichoic acid, peptidoglycan). These outer membrane components are able to bind to the CD14 receptor on the surface of monocytes. By virtue of the recently described toll-like receptors, a signal is then transmitted to the cell, leading to the eventual production of the proinflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 (IL-1). Overwhelming inflammatory and immune responses are essential features of septic shock and play a central part in the pathogenesis of tissue damage, multiple organ failure, and death induced by sepsis. Cytokines, especially tumor necrosis factor (TNF) and interleukin (IL-1), have been shown to be critical mediators of septic shock. These cytokines have a direct toxic effect on tissues; they also activate phospholipase A2. These and other effects lead to increased concentrations of platelet-activating factor, promotion of nitric oxide synthase activity, promotion of tissue infiltration by neutrophils, and promotion of neutrophil activity.

The treatment of sepsis and septic shock remains a clinical conundrum, and recent prospective trials with biological response modifiers (i.e. anti-TNF, anti-MIF) aimed at the inflammatory response have shown only modest clinical benefit. Recently, interest has shifted toward therapies aimed at reversing the accompanying periods of immune suppression. Studies in experimental animals and critically ill patients have demonstrated that increased apoptosis of lymphoid organs and some parenchymal tissues contribute to this immune suppression, anergy, and organ system dysfunction. During sepsis syndromes, lymphocyte apoptosis can be triggered by the absence of IL-2 or by the release of glucocorticoids, granzymes, or the so-called 'death'

cytokines: tumor necrosis factor alpha or Fas ligand. Apoptosis proceeds via auto-activation of cytosolic and/or mitochondrial caspases, which can be influenced by the pro- and anti-apoptotic members of the Bcl-2 family. In experimental animals, not only can treatment with inhibitors of apoptosis prevent lymphoid cell apoptosis; it may also improve outcome. Although clinical trials with anti-apoptotic agents remain distant due in large part to technical difficulties associated with their administration and tissue targeting, inhibition of lymphocyte apoptosis represents an attractive therapeutic target for the septic patient. Likewise, a dual-specific agent targeting both inflammatory mediator and a apoptotic mediator, may have added benefit. One aspect of the invention pertains to DVD Igs capable of binding one or more targets involved in sepsis, in an embodiment two targets, selected from the group consisting TNF, IL-1, MIF, IL-6, IL-8, IL-18, IL-12, IL-23, FasL, LPS, Toll-like receptors, TLR-4, tissue factor, MIP-2, ADORA2A, CASP1, CASP4, IL-10, IL-1B, NFKB1, PROC, TNFRSF1A, CSF3, CCR3, IL1RN, MIF, NFKB1, PTAFR, TLR2, TLR4, GPR44, HMOX1, midkine, IRAK1, NFKB2, SERPINA1, SERPINE1, and TREM1. The efficacy of such DVD Igs for sepsis can be assessed in preclinical animal models known in the art (see Buras JA, et al.,(2005) Nat Rev Drug Discov. 4(10):854-65 and Calandra T, et al., (2000) Nat Med. 6(2):164-70).

7. Neurological disorders

7.1. Neurodegenerative Diseases

Chronic neurodegenerative diseases are usually age-dependent diseases characterized by progressive loss of neuronal functions (neuronal cell death, demyelination), loss of mobility and loss of memory. Emerging knowledge of the mechanisms underlying chronic neurodegenerative diseases (e.g., Alzheimer's disease) show a complex etiology and a variety of factors have been recognized to contribute to their development and progression e.g., age, glycemic status, amyloid production and multimerization, accumulation of advanced glycation-end products (AGE) which bind to their receptor RAGE (receptor for AGE), increased brain oxidative stress, decreased cerebral blood flow, neuroinflammation including release of inflammatory cytokines and chemokines, neuronal dysfunction and microglial activation. Thus these chronic neurodegenerative diseases represent a complex interaction between multiple cell types and mediators. Treatment strategies for such diseases are limited and mostly constitute either blocking inflammatory processes with non-specific anti-inflammatory agents (e.g., corticosteroids, COX inhibitors) or agents to prevent neuron loss and/or synaptic functions. These treatments fail to stop disease progression. Recent studies suggest that more targeted therapies such as antibodies to soluble A-b peptide (including the A-b oligomeric forms) can not only help stop disease progression but may help maintain memory as well. These preliminary observations suggest that specific therapies targeting more than one disease mediator (e.g., A-b and a pro-inflammatory cytokine such as TNF) may provide even better therapeutic efficacy for

chronic neurodegenerative diseases than observed with targeting a single disease mechanism (e.g., soluble A- β alone) (see C.E. Shepherd, et al, *Neurobiol Aging*. 2005 Oct 24; Nelson RB., *Curr Pharm Des*. 2005;11:3335; William L. Klein.; *Neurochem Int*. 2002 ;41:345; Michelle C Janelins, et al., *J Neuroinflammation*. 2005 ;2:23; Soloman B., *Curr Alzheimer Res*. 2004;1:149; 5 Igor Klyubin, et al., *Nat Med*. 2005;11:556-61; Arancio O, et al., *EMBO Journal* (2004) 1-10; Bornemann KD, et al., *Am J Pathol*. 2001;158:63; Deane R, et al., *Nat Med*. 2003;9:907-13; and Eliezer Masliah, et al., *Neuron*. 2005;46:857).

The DVD-Ig molecules of the invention can bind one or more targets involved in Chronic neurodegenerative diseases such as Alzheimers. Such targets include, but are not limited to, any 10 mediator, soluble or cell surface, implicated in AD pathogenesis e.g AGE (S100 A, amphoterin), pro-inflammatory cytokines (e.g.,IL-1), chemokines (e.g.,MCP 1), molecules that inhibit nerve regeneration (e.g.,Nogo, RGM A), molecules that enhance neurite growth (neurotrophins). The efficacy of DVD-Ig molecules can be validated in pre-clinical animal models such as the transgenic mice that over-express amyloid precursor protein or RAGE and develop Alzheimer's 15 disease-like symptoms. In addition, DVD-Ig molecules can be constructed and tested for efficacy in the animal models and the best therapeutic DVD-Ig can be selected for testing in human patients. DVD-Ig molecules can also be employed for treatment of other neurodegenerative diseases such as Parkinson's disease. Alpha-Synuclein is involved in Parkinson's pathology. A DVD-Ig capable of targeting alpha-synuclein and inflammatory 20 mediators such as TNF, IL-1, MCP-1 can prove effective therapy for Parkinson's disease and are contemplated in the invention.

7.2 Neuronal Regeneration and Spinal Cord Injury

Despite an increase in knowledge of the pathologic mechanisms, spinal cord injury (SCI) is still a devastating condition and represents a medical indication characterized by a high medical 25 need. Most spinal cord injuries are contusion or compression injuries and the primary injury is usually followed by secondary injury mechanisms (inflammatory mediators e.g.,cytokines and chemokines) that worsen the initial injury and result in significant enlargement of the lesion area, sometimes more than 10-fold. These primary and secondary mechanisms in SCI are very similar to those in brain injury caused by other means e.g.,stroke. No satisfying treatment exists and high 30 dose bolus injection of methylprednisolone (MP) is the only used therapy within a narrow time window of 8 h post injury. This treatment, however, is only intended to prevent secondary injury without causing any significant functional recovery. It is heavily criticized for the lack of unequivocal efficacy and severe adverse effects, like immunosuppression with subsequent infections and severe histopathological muscle alterations. No other drugs, biologics or small 35 molecules, stimulating the endogenous regenerative potential are approved, but promising treatment principles and drug candidates have shown efficacy in animal models of SCI in recent

years. To a large extent the lack of functional recovery in human SCI is caused by factors inhibiting neurite growth, at lesion sites, in scar tissue, in myelin as well as on injury-associated cells. Such factors are the myelin-associated proteins NogoA, OMgp and MAG, RGM A, the scar-associated CSPG (Chondroitin Sulfate Proteoglycans) and inhibitory factors on reactive astrocytes (some semaphorins and ephrins). However, at the lesion site not only growth inhibitory molecules are found but also neurite growth stimulating factors like neurotrophins, laminin, L1 and others. This ensemble of neurite growth inhibitory and growth promoting molecules may explain that blocking single factors, like NogoA or RGM A, resulted in significant functional recovery in rodent SCI models, because a reduction of the inhibitory influences could shift the balance from growth inhibition to growth promotion. However, recoveries observed with blocking a single neurite outgrowth inhibitory molecule were not complete. To achieve faster and more pronounced recoveries either blocking two neurite outgrowth inhibitory molecules e.g Nogo and RGM A, or blocking an neurite outgrowth inhibitory molecule and enhancing functions of a neurite outgrowth enhancing molecule e.g Nogo and neurotrophins, or blocking a neurite outgrowth inhibitory molecule e.g., Nogo and a pro-inflammatory molecule e.g., TNF, may be desirable (see McGee AW, et al., Trends Neurosci. 2003;26:193; Marco Domeniconi, et al., J Neurol Sci. 2005;233:43; Milan Makwana1, et al., FEBS J. 2005;272:2628; Barry J. Dickson, Science. 2002;298:1959; Felicia Yu Hsuan Teng, et al., J Neurosci Res. 2005;79:273; Tara Karnezis, et al., Nature Neuroscience 2004; 7, 736; Gang Xu, et al., J. Neurochem. 2004; 91; 1018).

In one aspect, DVD-Igs capable of binding target pairs such as NgR and RGM A; NogoA and RGM A; MAG and RGM A; OMgp and RGM A; RGM A and RGM B; CSPGs and RGM A; aggrecan, midkine, neurocan, versican, phosphacan, Te38 and TNF- α ; A β globulomer-specific antibodies combined with antibodies promoting dendrite & axon sprouting are provided. Dendrite pathology is a very early sign of AD and it is known that NOGO A restricts dendrite growth. One can combine such type of ab with any of the SCI-candidate (myelin-proteins) Ab. Other DVD-Ig targets may include any combination of NgR-p75, NgR-Troy, NgR-Nogo66 (Nogo), NgR-Lingo, Lingo-Troy, Lingo-p75, MAG or Omgp. Additionally, targets may also include any mediator, soluble or cell surface, implicated in inhibition of neurite e.g Nogo, Omgp, MAG, RGM A, semaphorins, ephrins, soluble A-b, pro-inflammatory cytokines (e.g., IL-1), chemokines (e.g., MIP 1a), molecules that inhibit nerve regeneration. The efficacy of anti-nogo / anti-RGM A or similar DVD-Ig molecules can be validated in pre-clinical animal models of spinal cord injury. In addition, these DVD-Ig molecules can be constructed and tested for efficacy in the animal models and the best therapeutic DVD-Ig can be selected for testing in human patients. In addition, DVD-Ig molecules can be constructed that target two distinct ligand binding sites on a single receptor e.g., Nogo receptor which binds three ligand Nogo, Omgp, and

MAG and RAGE that binds A-b and S100 A. Furthermore, neurite outgrowth inhibitors e.g., nogo and nogo receptor, also play a role in preventing nerve regeneration in immunological diseases like multiple sclerosis. Inhibition of nogo-nogo receptor interaction has been shown to enhance recovery in animal models of multiple sclerosis. Therefore, DVD-Ig molecules that can
 5 block the function of one immune mediator eg a cytokine like IL-12 and a neurite outgrowth inhibitor molecule eg nogo or RGM may offer faster and greater efficacy than blocking either an immune or an neurite outgrowth inhibitor molecule alone.

8. Oncological disorders

Monoclonal antibody therapy has emerged as an important therapeutic modality for
 10 cancer (von Mehren M, et al 2003 Monoclonal antibody therapy for cancer. Annu Rev Med.;54:343-69). Antibodies may exert antitumor effects by inducing apoptosis, redirected cytotoxicity, interfering with ligand-receptor interactions, or preventing the expression of proteins that are critical to the neoplastic phenotype. In addition, antibodies can target components of the tumor microenvironment, perturbing vital structures such as the formation of tumor-associated
 15 vasculature. Antibodies can also target receptors whose ligands are growth factors, such as the epidermal growth factor receptor. The antibody thus inhibits natural ligands that stimulate cell growth from binding to targeted tumor cells. Alternatively, antibodies may induce an anti-idiotypic network, complement-mediated cytotoxicity, or antibody-dependent cellular cytotoxicity (ADCC). The use of dual-specific antibody that targets two separate tumor mediators will likely
 20 give additional benefit compared to a mono-specific therapy. DVD Igs capable of binding the following pairs of targets to treat oncological disease are also contemplated: IGF1 and IGF2; IGF1/2 and HER-2; VEGFR and EGFR; CD20 and CD3; CD138 and CD20; CD38 and CD20; CD38 and CD138; CD40 and CD20; CD138 and CD40; CD38 and CD40; CD-20 and CD-19; CD-20 and EGFR; CD-20 and CD-80; CD-20 and CD-22; CD-3 and HER-2; CD-3 and CD-19;
 25 EGFR and HER-2; EGFR and CD-3; EGFR and IGF1,2; EGFR and IGF1R; EGFR and RON; EGFR and HGF; EGFR and c-MET; HER-2 and IGF1,2; HER-2 and IGF1R; RON and HGF; VEGF and EGFR; VEGF and HER-2; VEGF and CD-20; VEGF and IGF1,2; VEGF and DLL4; VEGF and HGF; VEGF and RON; VEGF and NRP1; CD20 and CD3; VEGF and PLGF; DLL4 and PLGF; ErbB3 and EGFR; HGF and ErbB3, HER-2 and ErbB3; c-Met and ErbB3; HER-2 and
 30 PLGF; HER-2 and HER-2.

In another embodiment, a DVD of the invention is capable of binding VEGF and phosphatidylserine; VEGF and ErbB3; VEGF and PLGF; VEGF and ROBO4; VEGF and BSG2; VEGF and CDCP1; VEGF and ANPEP; VEGF and c-MET; HER-2 and ERB3; HER-2 and BSG2; HER-2 and CDCP1; HER-2 and ANPEP; EGFR and CD64; EGFR and BSG2; EGFR and
 35 CDCP1; EGFR and ANPEP; IGF1R and PDGFR; IGF1R and VEGF; IGF1R and CD20; CD20 and CD74; CD20 and CD30; CD20 and DR4; CD20 and VEGFR2; CD20 and CD52; CD20 and

CD4; HGF and c-MET; HGF and NRP1; HGF and phosphatidylserine; ErbB3 and IGF1R; ErbB3
 and IGF1,2; c-Met and Her-2; c-Met and NRP1; c-Met and IGF1R; IGF1,2 and PDGFR; IGF1,2
 and CD20; IGF1,2 and IGF1R; IGF2 and EGFR; IGF2 and HER2; IGF2 and CD20; IGF2 and
 VEGF; IGF2 and IGF1R; IGF1 and IGF2; PDGFRa and VEGFR2; PDGFRa and PLGF; PDGFRa
 5 and VEGF; PDGFRa and c-Met; PDGFRa and EGFR; PDGFRb and VEGFR2; PDGFRb and c-
 Met; PDGFRb and EGFR; RON and c-Met; RON and MTSP1; RON and MSP; RON and
 CDCP1; VGFR1 and PLGF; VGFR1 and RON; VGFR1 and EGFR; VEGFR2 and PLGF;
 VEGFR2 and NRP1; VEGFR2 and RON; VEGFR2 and DLL4; VEGFR2 and EGFR; VEGFR2
 and ROBO4; VEGFR2 and CD55; LPA and S1P; EPHB2 and RON; CTLA4 and VEGF; CD3
 10 and EPCAM; CD40 and IL6; CD40 and IGF; CD40 and CD56; CD40 and CD70; CD40 and
 VEGFR1; CD40 and DR5; CD40 and DR4; CD40 and APRIL; CD40 and BCMA; CD40 and
 RANKL; CD28 and MAPG; CD80 and CD40; CD80 and CD30; CD80 and CD33; CD80 and
 CD74; CD80 and CD2; CD80 and CD3; CD80 and CD19; CD80 and CD4; CD80 and CD52;
 CD80 and VEGF; CD80 and DR5; CD80 and VEGFR2; CD22 and CD20; CD22 and CD80;
 15 CD22 and CD40; CD22 and CD23; CD22 and CD33; CD22 and CD74; CD22 and CD19; CD22
 and DR5; CD22 and DR4; CD22 and VEGF; CD22 and CD52; CD30 and CD20; CD30 and
 CD22; CD30 and CD23; CD30 and CD40; CD30 and VEGF; CD30 and CD74; CD30 and CD19;
 CD30 and DR5; CD30 and DR4; CD30 and VEGFR2; CD30 and CD52; CD30 and CD4; CD138
 and RANKL; CD33 and FTL3; CD33 and VEGF; CD33 and VEGFR2; CD33 and CD44; CD33
 20 and DR4; CD33 and DR5; DR4 and CD137; DR4 and IGF1,2; DR4 and IGF1R; DR4 and DR5;
 DR5 and CD40; DR5 and CD137; DR5 and CD20; DR5 and EGFR; DR5 and IGF1,2; DR5 and
 IGFR, DR5 and HER-2, EGFR and DLL4. Other target combinations include one or more
 members of the EGF/erb-2/erb-3 family. Other targets (one or more) involved in oncological
 diseases that DVD Igs may bind include, but are not limited to those selected from the group
 25 consisting of: CD52, CD20, CD19, CD3, CD4, CD8, BMP6, IL12A, IL1A, IL1B, IL2, IL24,
 INHA, TNF, TNFSF10, BMP6, EGF, FGF1, FGF10, FGF11, FGF12, FGF13, FGF14, FGF16,
 FGF17, FGF18, FGF19, FGF2, FGF20, FGF21, FGF22, FGF23, FGF3, FGF4, FGF5, FGF6,
 FGF7, FGF8, FGF9, GRP, IGF1, IGF2, IL12A, IL1A, IL1B, IL2, INHA, TGFA, TGFB1,
 TGFB2, TGFB3, VEGF, CDK2, FGF10, FGF18, FGF2, FGF4, FGF7, IGF1R, IL2, BCL2,
 30 CD164, CDKN1A, CDKN1B, CDKN1C, CDKN2A, CDKN2B, CDKN2C, CDKN3, GNRH1,
 IGFBP6, IL1A, IL1B, ODZ1, PAWR, PLG, TGFB1I1, AR, BRCA1, CDK3, CDK4, CDK5,
 CDK6, CDK7, CDK9, E2F1, EGFR, ENO1, ERBB2, ESR1, ESR2, IGFBP3, IGFBP6, IL2,
 INSL4, MYC, NOX5, NR6A1, PAP, PCNA, PRKCQ, PRKD1, PRL, TP53, FGF22, FGF23,
 FGF9, IGFBP3, IL2, INHA, KLK6, TP53, CHGB, GNRH1, IGF1, IGF2, INHA, INSL3, INSL4,
 35 PRL, KLK6, SHBG, NR1D1, NR1H3, NR1I3, NR2F6, NR4A3, ESR1, ESR2, NR0B1, NR0B2,
 NR1D2, NR1H2, NR1H4, NR1I2, NR2C1, NR2C2, NR2E1, NR2E3, NR2F1, NR2F2, NR3C1,
 NR3C2, NR4A1, NR4A2, NR5A1, NR5A2, NR6A1, PGR, RARB, FGF1, FGF2, FGF6, KLK3,

KRT1, APOC1, BRCA1, CHGA, CHGB, CLU, COL1A1, COL6A1, EGF, ERBB2, ERK8,
 FGF1, FGF10, FGF11, FGF13, FGF14, FGF16, FGF17, FGF18, FGF2, FGF20, FGF21, FGF22,
 FGF23, FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF9, GNRH1, IGF1, IGF2, IGFBP3,
 IGFBP6, IL12A, IL1A, IL1B, IL2, IL24, INHA, INSL3, INSL4, KLK10, KLK12, KLK13,
 5 KLK14, KLK15, KLK3, KLK4, KLK5, KLK6, KLK9, MMP2, MMP9, MSMB, NTN4, ODZ1,
 PAP, PLAU, PRL, PSAP, SERPINA3, SHBG, TGFA, TIMP3, CD44, CDH1, CDH10, CDH19,
 CDH20, CDH7, CDH9, CDH1, CDH10, CDH13, CDH18, CDH19, CDH20, CDH7, CDH8,
 CDH9, ROBO2, CD44, ILK, ITGA1, APC, CD164, COL6A1, MTSS1, PAP, TGFBIII1, AGR2,
 AIG1, AKAP1, AKAP2, CANT1, CAV1, CDH12, CLDN3, CLN3, CYB5, CYC1, DAB2IP,
 10 DES, DNCL1, ELAC2, ENO2, ENO3, FASN, FLJ12584, FLJ25530, GAGEB1, GAGEC1,
 GGT1, GSTP1, HIP1, HUMCYT2A, IL29, K6HF, KAI1, KRT2A, MIB1, PART1, PATE, PCA3,
 PIAS2, PIK3CG, PPID, PRI, PSCA, SLC2A2, SLC33A1, SLC43A1, STEAP, STEAP2, TPM1,
 TPM2, TRPC6, ANGPT1, ANGPT2, ANPEP, ECGF1, EREG, FGF1, FGF2, FIGF, FLT1, JAG1,
 KDR, LAMA5, NRP1, NRP2, PGF, PLXDC1, STAB1, VEGF, VEGFC, ANGPTL3, BAI1,
 15 COL4A3, IL8, LAMA5, NRP1, NRP2, STAB1, ANGPTL4, PECAM1, PF4, PROK2,
 SERPINF1, TNFAIP2, CCL11, CCL2, CXCL1, CXCL10, CXCL3, CXCL5, CXCL6, CXCL9,
 IFNA1, IFNB1, IFNG, IL1B, IL6, MDK, EDG1, EFNA1, EFNA3, EFNB2, EGF, EPHB4,
 FGFR3, HGF, IGF1, ITGB3, PDGFA, TEK, TGFA, TGFB1, TGFB2, TGFBRI1, CCL2, CDH5,
 COL18A1, EDG1, ENG, ITGAV, ITGB3, THBS1, THBS2, BAD, BAG1, BCL2, CCNA1,
 20 CCNA2, CCND1, CCNE1, CCNE2, CDH1 (E-cadherin), CDKN1B (p27Kip1), CDKN2A
 (p16INK4a), COL6A1, CTNNB1 (b-catenin), CTSB (cathepsin B), ERBB2 (Her-2), ESR1,
 ESR2, F3 (TF), FOSL1 (FRA-1), GATA3, GSN (Gelsolin), IGFBP2, IL2RA, IL6, IL6R, IL6ST
 (glycoprotein 130), ITGA6 (a6 integrin), JUN, KLK5, KRT19, MAP2K7 (c-Jun), MKI67 (Ki-67),
 NGFB (NGF), NGFR, NME1 (NM23A), PGR, PLAU (uPA), PTEN, SERPINB5 (maspin),
 25 SERPINE1 (PAI-1), TGFA, THBS1 (thrombospondin-1), TIE (Tie-1), TNFRSF6 (Fas), TNFSF6
 (FasL), TOP2A (topoisomerase Iia), TP53, AZGP1 (zinc-a-glycoprotein), BPAG1 (plectin),
 CDKN1A (p21Wap1/Cip1), CLDN7 (claudin-7), CLU (clusterin), ERBB2 (Her-2), FGF1,
 FLRT1 (fibronectin), GABRP (GABAa), GNAS1, ID2, ITGA6 (a6 integrin), ITGB4 (b 4
 integrin), KLF5 (GC Box BP), KRT19 (Keratin 19), KRTHB6 (hair-specific type II keratin),
 30 MACMARCKS, MT3 (metallothionein-III), MUC1 (mucin), PTGS2 (COX-2), RAC2
 (p21Rac2), S100A2, SCGB1D2 (lipophilin B), SCGB2A1 (mammaglobin 2), SCGB2A2
 (mammaglobin 1), SPRR1B (Spr1), THBS1, THBS2, THBS4, and TNFAIP2 (B94), RON, c-Met,
 CD64, DLL4, PLGF, CTLA4, phosphatidylserine, ROBO4, CD80, CD22, CD40, CD23, CD28,
 CD80, CD55, CD38, CD70, CD74, CD30, CD138, CD56, CD33, CD2, CD137, DR4, DR5,
 35 RANKL, VEGFR2, PDGFR, VEGFR1, MTSP1, MSP, EPHB2, EPHA1, EPHA2, EpCAM,
 PGE2, NKG2D, LPA, SIP, APRIL, BCMA, MAPG, FLT3, PDGFR alpha, PDGFR beta, ROR1,
 PSMA, PSCA, SCD1, and CD59.

IV. Pharmaceutical Compositions

The invention also provides pharmaceutical compositions comprising a binding protein, of the invention and a pharmaceutically acceptable carrier. The pharmaceutical compositions comprising binding proteins of the invention are for use in, but not limited to, diagnosing, 5 detecting, or monitoring a disorder, in preventing, treating, managing, or ameliorating of a disorder or one or more symptoms thereof, and/or in research. In a specific embodiment, a composition comprises one or more binding proteins of the invention. In another embodiment, the pharmaceutical composition comprises one or more binding proteins of the invention and one or more prophylactic or therapeutic agents other than binding proteins of the invention for treating a 10 disorder. In an embodiment, the prophylactic or therapeutic agents known to be useful for or having been or currently being used in the prevention, treatment, management, or amelioration of a disorder or one or more symptoms thereof. In accordance with these embodiments, the composition may further comprise of a carrier, diluent or excipient.

The binding proteins of the invention can be incorporated into pharmaceutical 15 compositions suitable for administration to a subject. Typically, the pharmaceutical composition comprises a binding protein of the invention and a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. Examples of pharmaceutically acceptable carriers include 20 one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof. In some embodiments, isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride, are included in the composition. Pharmaceutically acceptable carriers may further comprise minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or 25 effectiveness of the antibody or antibody portion.

Various delivery systems are known and can be used to administer one or more antibodies of the invention or the combination of one or more antibodies of the invention and a prophylactic agent or therapeutic agent useful for preventing, managing, treating, or ameliorating a disorder or one or more symptoms thereof, e.g., encapsulation in liposomes, microparticles, microcapsules, 30 recombinant cells capable of expressing the antibody or antibody fragment, receptor-mediated endocytosis (see, e. g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)), construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of administering a prophylactic or therapeutic agent of the invention include, but are not limited to, parenteral administration (e.g., intradermal, intramuscular, intraperitoneal, intravenous and subcutaneous), epidural 35 administration, intratumoral administration, and mucosal administration (e.g., intranasal and oral routes). In addition, pulmonary administration can be employed, e.g., by use of an inhaler or

nebulizer, and formulation with an aerosolizing agent. See, e.g., U.S. Pat. Nos. 6,019,968; 5,985,320; 5,985,309; 5,934,272; 5,874,064; 5,855,913; 5,290,540; and 4,880,078; and PCT Publication Nos. WO 92/19244; WO 97/32572; WO 97/44013; WO 98/31346; and WO 99/66903, each of which is incorporated herein by reference their entireties. In one embodiment, a binding protein of the invention, combination therapy, or a composition of the invention is administered using Alkermes AIR® pulmonary drug delivery technology (Alkermes, Inc., Cambridge, Mass.). In a specific embodiment, prophylactic or therapeutic agents of the invention are administered intramuscularly, intravenously, intratumorally, orally, intranasally, pulmonary, or subcutaneously. The prophylactic or therapeutic agents may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local.

In an embodiment, specific binding of antibody-coupled carbon nanotubes (CNTs) to tumor cells in vitro, followed by their highly specific ablation with near-infrared (NIR) light can be used to target tumor cells. For example, biotinylated polar lipids can be used to prepare stable, biocompatible, noncytotoxic CNT dispersions that are then attached to one or two different neutralite avidin-derivatized DVD-Igs directed against one or more tumor antigens (e.g., CD22) (Chakravarty, P. et al. (2008) Proc. Natl. Acad. Sci. USA 105:8697-8702).

In a specific embodiment, it may be desirable to administer the prophylactic or therapeutic agents of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion, by injection, or by means of an implant, said implant being of a porous or non-porous material, including membranes and matrices, such as sialastic membranes, polymers, fibrous matrices (e.g., Tissuel®), or collagen matrices. In one embodiment, an effective amount of one or more antibodies of the invention antagonists is administered locally to the affected area to a subject to prevent, treat, manage, and/or ameliorate a disorder or a symptom thereof. In another embodiment, an effective amount of one or more antibodies of the invention is administered locally to the affected area in combination with an effective amount of one or more therapies (e. g., one or more prophylactic or therapeutic agents) other than a binding protein of the invention of a subject to prevent, treat, manage, and/or ameliorate a disorder or one or more symptoms thereof.

In another embodiment, the prophylactic or therapeutic agent can be delivered in a controlled release or sustained release system. In one embodiment, a pump may be used to achieve controlled or sustained release (see Langer, supra; Sefton, 1987, CRC Crit. Ref. Biomed. Eng. 14:20; Buchwald et al., 1980, Surgery 88:507; Saudek et al., 1989, N. Engl. J. Med. 321:574). In another embodiment, polymeric materials can be used to achieve controlled or

sustained release of the therapies of the invention (see e.g., Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Fla. (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, 1983, J., Macromol. Sci. Rev. Macromol. Chem. 23:61; see also Levy et al., 1985, Science 228:190; During et al., 1989, Ann. Neurol. 25:351; Howard et al., 1989, J. Neurosurg. 71:105); U.S. Pat. No. 5,679,377; U.S. Pat. No. 5,916,597; U. S. Pat. No. 5,912,015; U.S. Pat. No. 5,989,463; U.S. Pat. No. 5,128,326; PCT Publication No. WO 99/15154; and PCT Publication No. WO 99/20253. Examples of polymers used in sustained release formulations include, but are not limited to, poly(2-hydroxy ethyl methacrylate), poly(methyl methacrylate), poly(acrylic acid), poly(ethylene-co-vinyl acetate), poly(methacrylic acid), polyglycolides (PLG), polyanhydrides, poly(N-vinyl pyrrolidone), poly(vinyl alcohol), polyacrylamide, poly(ethylene glycol), polylactides (PLA), poly(lactide-co-glycolides) (PLGA), and polyorthoesters. In an embodiment, the polymer used in a sustained release formulation is inert, free of leachable impurities, stable on storage, sterile, and biodegradable. In yet another embodiment, a controlled or sustained release system can be placed in proximity of the prophylactic or therapeutic target, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984)).

Controlled release systems are discussed in the review by Langer (1990, Science 249:1527-1533). Any technique known to one of skill in the art can be used to produce sustained release formulations comprising one or more therapeutic agents of the invention. See, e.g., U. S. Pat. No. 4,526,938, PCT publication WO 91/05548, PCT publication WO 96/20698, Ning et al., 1996, "Intratumoral Radioimmunotherapy of a Human Colon Cancer Xenograft Using a Sustained-Release Gel," Radiotherapy & Oncology 39:179-189, Song et al., 1995, "Antibody Mediated Lung Targeting of Long-Circulating Emulsions," PDA Journal of Pharmaceutical Science & Technology 50:372-397, Cleek et al., 1997, "Biodegradable Polymeric Carriers for a bFGF Antibody for Cardiovascular Application," Pro. Int'l. Symp. Control. Rel. Bioact. Mater. 24:853-854, and Lam et al., 1997, "Microencapsulation of Recombinant Humanized Monoclonal Antibody for Local Delivery," Proc. Int'l. Symp. Control Rel. Bioact. Mater. 24:759-760, each of which is incorporated herein by reference in their entireties.

In a specific embodiment, where the composition of the invention is a nucleic acid encoding a prophylactic or therapeutic agent, the nucleic acid can be administered in vivo to promote expression of its encoded prophylactic or therapeutic agent, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by use of a retroviral vector (see U. S. Pat. No. 4,980,286), or by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox-like

peptide which is known to enter the nucleus (see, e.g., Joliot et al., 1991, Proc. Natl. Acad. Sci. USA 88:1864-1868). Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression by homologous recombination.

5 A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include, but are not limited to, parenteral, e.g., intravenous, intradermal, subcutaneous, oral, intranasal (e.g., inhalation), transdermal (e.g., topical), transmucosal, and rectal administration. In a specific embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous, subcutaneous, intramuscular, oral, intranasal, or topical administration to
10 human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection.

If the compositions of the invention are to be administered topically, the compositions can be formulated in the form of an ointment, cream, transdermal patch, lotion, gel, shampoo, spray,
15 aerosol, solution, emulsion, or other form well-known to one of skill in the art. See, e.g., Remington's Pharmaceutical Sciences and Introduction to Pharmaceutical Dosage Forms, 19th ed., Mack Pub. Co., Easton, Pa. (1995). In an embodiment, for non-sprayable topical dosage forms, viscous to semi-solid or solid forms comprising a carrier or one or more excipients compatible with topical application and having a dynamic viscosity greater than water are
20 employed. Suitable formulations include, without limitation, solutions, suspensions, emulsions, creams, ointments, powders, liniments, salves, and the like, which are, if desired, sterilized or mixed with auxiliary agents (e.g., preservatives, stabilizers, wetting agents, buffers, or salts) for influencing various properties, such as, for example, osmotic pressure. Other suitable topical dosage forms include sprayable aerosol preparations wherein the active ingredient, in an
25 embodiment, in combination with a solid or liquid inert carrier, is packaged in a mixture with a pressurized volatile (e.g., a gaseous propellant, such as freon) or in a squeeze bottle. Moisturizers or humectants can also be added to pharmaceutical compositions and dosage forms if desired. Examples of such additional ingredients are well-known in the art.

If the method of the invention comprises intranasal administration of a composition, the
30 composition can be formulated in an aerosol form, spray, mist or in the form of drops. In particular, prophylactic or therapeutic agents for use according to the present invention can be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant (e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas). In the
35 case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges (composed of, e.g., gelatin) for use in an inhaler or

insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

If the method of the invention comprises oral administration, compositions can be formulated orally in the form of tablets, capsules, cachets, gelcaps, solutions, suspensions, and the like. Tablets or capsules can be prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone, or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose, or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc, or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate). The tablets may be coated by methods well-known in the art. Liquid preparations for oral administration may take the form of, but not limited to, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives, or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol, or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavoring, coloring, and sweetening agents as appropriate. Preparations for oral administration may be suitably formulated for slow release, controlled release, or sustained release of a prophylactic or therapeutic agent(s).

The method of the invention may comprise pulmonary administration, e.g., by use of an inhaler or nebulizer, of a composition formulated with an aerosolizing agent. See, e.g., U.S. Pat. Nos. 6,019,968; 5,985,320; 5,985,309; 5,934,272; 5,874,064; 5,855,913; 5,290,540; and 4,880,078; and PCT Publication Nos. WO 92/19244; WO 97/32572; WO 97/44013; WO 98/31346; and WO 99/66903, each of which is incorporated herein by reference their entireties. In a specific embodiment, a binding protein of the invention, combination therapy, and/or composition of the invention is administered using Alkermes AIR® pulmonary drug delivery technology (Alkermes, Inc., Cambridge, Mass.).

The method of the invention may comprise administration of a composition formulated for parenteral administration by injection (e.g., by bolus injection or continuous infusion). Formulations for injection may be presented in unit dosage form (e.g., in ampoules or in multi-dose containers) with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle (e.g., sterile pyrogen-free water) before use.

The methods of the invention may additionally comprise of administration of compositions formulated as depot preparations. Such long acting formulations may be administered by implantation (e.g., subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compositions may be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives (e.g., as a sparingly soluble salt).

The methods of the invention encompass administration of compositions formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

Generally, the ingredients of compositions are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the mode of administration is infusion, composition can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the mode of administration is by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

In particular, the invention also provides that one or more of the prophylactic or therapeutic agents, or pharmaceutical compositions of the invention is packaged in a hermetically sealed container such as an ampoule or sachette indicating the quantity of the agent. In one embodiment, one or more of the prophylactic or therapeutic agents, or pharmaceutical compositions of the invention is supplied as a dry sterilized lyophilized powder or water free concentrate in a hermetically sealed container and can be reconstituted (e.g., with water or saline) to the appropriate concentration for administration to a subject. In an embodiment, one or more of the prophylactic or therapeutic agents or pharmaceutical compositions of the invention is supplied as a dry sterile lyophilized powder in a hermetically sealed container at a unit dosage of at least 5 mg, at least 10 mg, at least 15 mg, at least 25 mg, at least 35 mg, at least 45 mg, at least 50 mg, at least 75 mg, or at least 100 mg. The lyophilized prophylactic or therapeutic agents or pharmaceutical compositions of the invention should be stored at between 2° C. and 8° C. in its original container and the prophylactic or therapeutic agents, or pharmaceutical compositions of the invention should be administered within 1 week, e.g., within 5 days, within 72 hours, within 48 hours, within 24 hours, within 12 hours, within 6 hours, within 5 hours, within 3 hours, or within 1 hour after being reconstituted. In an alternative embodiment, one or more of the prophylactic or therapeutic agents or pharmaceutical compositions of the invention is supplied in liquid form in a hermetically sealed container indicating the quantity and concentration of the

agent. In an embodiment, the liquid form of the administered composition is supplied in a hermetically sealed container at least 0.25 mg/ml, at least 0.5 mg/ml, at least 1 mg/ml, at least 2.5 mg/ml, at least 5 mg/ml, at least 8 mg/ml, at least 10 mg/ml, at least 15 mg/kg, at least 25 mg/ml, at least 50 mg/ml, at least 75 mg/ml or at least 100 mg/ml. The liquid form should be stored at
5 between 2° C. and 8° C. in its original container.

The binding proteins of the invention can be incorporated into a pharmaceutical composition suitable for parenteral administration. In an embodiment, the antibody or antibody-
10 portions will be prepared as an injectable solution containing 0.1-250 mg/ml binding protein. The injectable solution can be composed of either a liquid or lyophilized dosage form in a flint or amber vial, ampule or pre-filled syringe. The buffer can be L-histidine (1-50 mM), optimally 5-10mM, at pH 5.0 to 7.0 (optimally pH 6.0). Other suitable buffers include but are not limited to, sodium succinate, sodium citrate, sodium phosphate or potassium phosphate. Sodium chloride can be used to modify the toxicity of the solution at a concentration of 0-300 mM (optimally 150 mM for a liquid dosage form). Cryoprotectants can be included for a lyophilized dosage form,
15 principally 0-10% sucrose (optimally 0.5-1.0%). Other suitable cryoprotectants include trehalose and lactose. Bulking agents can be included for a lyophilized dosage form, principally 1-10% mannitol (optimally 2-4%). Stabilizers can be used in both liquid and lyophilized dosage forms, principally 1-50 mM L-Methionine (optimally 5-10 mM). Other suitable bulking agents include glycine, arginine, can be included as 0-0.05% polysorbate-80 (optimally 0.005-0.01%).
20 Additional surfactants include but are not limited to polysorbate 20 and BRIJ surfactants. The pharmaceutical composition comprising the binding proteins of the invention prepared as an injectable solution for parenteral administration, can further comprise an agent useful as an adjuvant, such as those used to increase the absorption, or dispersion of a therapeutic protein (e.g., antibody). A particularly useful adjuvant is hyaluronidase, such as Hylenex® (recombinant
25 human hyaluronidase). Addition of hyaluronidase in the injectable solution improves human bioavailability following parenteral administration, particularly subcutaneous administration. It also allows for greater injection site volumes (i.e. greater than 1 ml) with less pain and discomfort, and minimum incidence of injection site reactions. (see WO2004078140, and US2006104968 incorporated herein by reference).

30 The compositions of this invention may be in a variety of forms. These include, for example, liquid, semi-solid and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories. The form chosen depends on the intended mode of administration and therapeutic application. Typical compositions are in the form of injectable or infusible solutions, such as
35 compositions similar to those used for passive immunization of humans with other antibodies. The chosen mode of administration is parenteral (e.g., intravenous, subcutaneous, intraperitoneal,

intramuscular). In an embodiment, the antibody is administered by intravenous infusion or injection. In another embodiment, the antibody is administered by intramuscular or subcutaneous injection.

Therapeutic compositions typically must be sterile and stable under the conditions of
5 manufacture and storage. The composition can be formulated as a solution, microemulsion, dispersion, liposome, or other ordered structure suitable to high drug concentration. Sterile injectable solutions can be prepared by incorporating the active compound (*i.e.*, antibody or antibody portion) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated herein, as required, followed by filtered sterilization. Generally, dispersions
10 are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated herein. In the case of sterile, lyophilized powders for the preparation of sterile injectable solutions, the methods of preparation are vacuum drying and spray-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. The proper
15 fluidity of a solution can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prolonged absorption of injectable compositions can be brought about by including, in the composition, an agent that delays absorption, for example, monostearate salts and gelatin.

The binding proteins of the present invention can be administered by a variety of methods
20 known in the art, although for many therapeutic applications, in an embodiment, the route/mode of administration is subcutaneous injection, intravenous injection or infusion. As will be appreciated by the skilled artisan, the route and/or mode of administration will vary depending upon the desired results. In certain embodiments, the active compound may be prepared with a carrier that will protect the compound against rapid release, such as a controlled release formulation, including
25 implants, transdermal patches, and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Many methods for the preparation of such formulations are patented or generally known to those skilled in the art. See, *e.g.*, *Sustained and Controlled Release Drug Delivery Systems*, J.R. Robinson, ed., Marcel Dekker, Inc., New York,
30 1978.

In certain embodiments, a binding protein of the invention may be orally administered, for example, with an inert diluent or an assimilable edible carrier. The compound (and other ingredients, if desired) may also be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the subject's diet. For oral therapeutic administration,
35 the compounds may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. To administer

a compound of the invention by other than parenteral administration, it may be necessary to coat the compound with, or co-administer the compound with, a material to prevent its inactivation.

Supplementary active compounds can also be incorporated into the compositions. In certain embodiments, a binding protein of the invention is coformulated with and/or
5 coadministered with one or more additional therapeutic agents that are useful for treating disorders with binding protein of the invention. For example, a binding protein of the invention may be coformulated and/or coadministered with one or more additional antibodies that bind other targets (*e.g.*, antibodies that bind other cytokines or that bind cell surface molecules).
Furthermore, one or more antibodies of the invention may be used in combination with two or
10 more of the foregoing therapeutic agents. Such combination therapies may advantageously utilize lower dosages of the administered therapeutic agents, thus avoiding possible toxicities or complications associated with the various monotherapies.

In certain embodiments, a binding protein is linked to a half-life extending vehicle known in the art. Such vehicles include, but are not limited to, the Fc domain, polyethylene
15 glycol, and dextran. Such vehicles are described, *e.g.*, in U.S. Application Serial No. 09/428,082 and published PCT Application No. WO 99/25044, which are hereby incorporated by reference for any purpose.

In a specific embodiment, nucleic acid sequences encoding a binding protein of the invention or another prophylactic or therapeutic agent of the invention are administered to treat,
20 prevent, manage, or ameliorate a disorder or one or more symptoms thereof by way of gene therapy. Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic acid. In this embodiment of the invention, the nucleic acids produce their encoded antibody or prophylactic or therapeutic agent of the invention that mediates a prophylactic or therapeutic effect.

Any of the methods for gene therapy available in the art can be used according to the
25 present invention. For general reviews of the methods of gene therapy, see Goldspiel et al., 1993, *Clinical Pharmacy* 12:488-505; Wu and Wu, 1991, *Biotherapy* 3:87-95; Tolstoshev, 1993, *Ann. Rev. Pharmacol. Toxicol.* 32:573-596; Mulligan, *Science* 260:926-932 (1993); and Morgan and Anderson, 1993, *Ann. Rev. Biochem.* 62:191-217; May, 1993, *TIBTECH* 11(5):155-215.
30 Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, NY (1993); and Kriegler, *Gene Transfer and Expression, A Laboratory Manual*, Stockton Press, NY (1990). Detailed description of various methods of gene therapy are disclosed in US20050042664 A1 which is incorporated herein by reference.

The binding proteins of the invention are useful in treating various diseases wherein the targets that are recognized by the binding proteins are detrimental. Such diseases include, but are not limited to, rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis, septic arthritis, Lyme arthritis, psoriatic arthritis, reactive arthritis, spondyloarthropathy, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, inflammatory bowel disease, insulin dependent diabetes mellitus, thyroiditis, asthma, allergic diseases, psoriasis, dermatitis scleroderma, graft versus host disease, organ transplant rejection, acute or chronic immune disease associated with organ transplantation, sarcoidosis, atherosclerosis, disseminated intravascular coagulation, Kawasaki's disease, Grave's disease, nephrotic syndrome, chronic fatigue syndrome, Wegener's granulomatosis, Henoch-Schoenlein purpura, microscopic vasculitis of the kidneys, chronic active hepatitis, uveitis, septic shock, toxic shock syndrome, sepsis syndrome, cachexia, infectious diseases, parasitic diseases, acquired immunodeficiency syndrome, acute transverse myelitis, Huntington's chorea, Parkinson's disease, Alzheimer's disease, stroke, primary biliary cirrhosis, hemolytic anemia, malignancies, heart failure, myocardial infarction, Addison's disease, sporadic, polyglandular deficiency type I and polyglandular deficiency type II, Schmidt's syndrome, adult (acute) respiratory distress syndrome, alopecia, alopecia areata, seronegative arthropathy, arthropathy, Reiter's disease, psoriatic arthropathy, ulcerative colitic arthropathy, enteropathic synovitis, chlamydia, yersinia and salmonella associated arthropathy, spondyloarthropathy, atheromatous disease/arteriosclerosis, atopic allergy, autoimmune bullous disease, pemphigus vulgaris, pemphigus foliaceus, pemphigoid, linear IgA disease, autoimmune haemolytic anaemia, Coombs positive haemolytic anaemia, acquired pernicious anaemia, juvenile pernicious anaemia, myalgic encephalitis/Royal Free Disease, chronic mucocutaneous candidiasis, giant cell arteritis, primary sclerosing hepatitis, cryptogenic autoimmune hepatitis, Acquired Immunodeficiency Disease Syndrome, Acquired Immunodeficiency Related Diseases, Hepatitis B, Hepatitis C, common varied immunodeficiency (common variable hypogammaglobulinaemia), dilated cardiomyopathy, female infertility, ovarian failure, premature ovarian failure, fibrotic lung disease, cryptogenic fibrosing alveolitis, post-inflammatory interstitial lung disease, interstitial pneumonitis, connective tissue disease associated interstitial lung disease, mixed connective tissue disease associated lung disease, systemic sclerosis associated interstitial lung disease, rheumatoid arthritis associated interstitial lung disease, systemic lupus erythematosus associated lung disease, dermatomyositis/polymyositis associated lung disease, Sjögren's disease associated lung disease, ankylosing spondylitis associated lung disease, vasculitic diffuse lung disease, haemosiderosis associated lung disease, drug-induced interstitial lung disease, fibrosis, radiation fibrosis, bronchiolitis obliterans, chronic eosinophilic pneumonia, lymphocytic infiltrative lung disease, postinfectious interstitial lung disease, gouty arthritis, autoimmune hepatitis, type-1 autoimmune hepatitis (classical autoimmune or lupoid hepatitis), type-2 autoimmune hepatitis (anti-LKM antibody hepatitis), autoimmune mediated

hypoglycaemia, type B insulin resistance with acanthosis nigricans, hypoparathyroidism, acute immune disease associated with organ transplantation, chronic immune disease associated with organ transplantation, osteoarthritis, primary sclerosing cholangitis, psoriasis type 1, psoriasis type 2, idiopathic leucopaenia, autoimmune neutropaenia, renal disease NOS,

5 glomerulonephritides, microscopic vasculitis of the kidneys, lyme disease, discoid lupus erythematosus, male infertility idiopathic or NOS, sperm autoimmunity, multiple sclerosis (all subtypes), sympathetic ophthalmia, pulmonary hypertension secondary to connective tissue disease, Goodpasture's syndrome, pulmonary manifestation of polyarteritis nodosa, acute rheumatic fever, rheumatoid spondylitis, Still's disease, systemic sclerosis, Sjögren's syndrome,

10 Takayasu's disease/arteritis, autoimmune thrombocytopenia, idiopathic thrombocytopenia, autoimmune thyroid disease, hyperthyroidism, goitrous autoimmune hypothyroidism (Hashimoto's disease), atrophic autoimmune hypothyroidism, primary myxoedema, phacogenic uveitis, primary vasculitis, vitiligo acute liver disease, chronic liver diseases, alcoholic cirrhosis, alcohol-induced liver injury, choleostasis, idiosyncratic liver disease, Drug-Induced hepatitis,

15 Non-alcoholic Steatohepatitis, allergy and asthma, group B streptococci (GBS) infection, mental disorders (*e.g.*, depression and schizophrenia), Th2 Type and Th1 Type mediated diseases, acute and chronic pain (different forms of pain), and cancers such as lung, breast, stomach, bladder, colon, pancreas, ovarian, prostate and rectal cancer and hematopoietic malignancies (leukemia and lymphoma), Abetalipoproteinemia, Acrocyanosis, acute and chronic parasitic or infectious

20 processes, acute leukemia, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), acute or chronic bacterial infection, acute pancreatitis, acute renal failure, adenocarcinomas, aerial ectopic beats, AIDS dementia complex, alcohol-induced hepatitis, allergic conjunctivitis, allergic contact dermatitis, allergic rhinitis, allograft rejection, alpha-1- antitrypsin deficiency, amyotrophic lateral sclerosis, anemia, angina pectoris, anterior horn cell degeneration, anti cd3

25 therapy, antiphospholipid syndrome, anti-receptor hypersensitivity reactions, aortic and peripheral aneurysms, aortic dissection, arterial hypertension, arteriosclerosis, arteriovenous fistula, ataxia, atrial fibrillation (sustained or paroxysmal), atrial flutter, atrioventricular block, B cell lymphoma, bone graft rejection, bone marrow transplant (BMT) rejection, bundle branch block, Burkitt's lymphoma, Burns, cardiac arrhythmias, cardiac stun syndrome, cardiac tumors,

30 cardiomyopathy, cardiopulmonary bypass inflammation response, cartilage transplant rejection, cerebellar cortical degenerations, cerebellar disorders, chaotic or multifocal atrial tachycardia, chemotherapy associated disorders, chronic myelocytic leukemia (CML), chronic alcoholism, chronic inflammatory pathologies, chronic lymphocytic leukemia (CLL), chronic obstructive pulmonary disease (COPD), chronic salicylate intoxication, colorectal carcinoma, congestive

35 heart failure, conjunctivitis, contact dermatitis, cor pulmonale, coronary artery disease, Creutzfeldt-Jakob disease, culture negative sepsis, cystic fibrosis, cytokine therapy associated disorders, Dementia pugilistica, demyelinating diseases, dengue hemorrhagic fever, dermatitis,

dermatologic conditions, diabetes, diabetes mellitus, diabetic atherosclerotic disease, Diffuse
Lewy body disease, dilated congestive cardiomyopathy, disorders of the basal ganglia, Down's
Syndrome in middle age, drug- induced movement disorders induced by drugs which block CNS
dopamine receptors, drug sensitivity, eczema, encephalomyelitis, endocarditis, endocrinopathy,
5 epiglottitis, epstein-barr virus infection, erythromelalgia, extrapyramidal and cerebellar disorders,
familial hematomphagocytic lymphohistiocytosis, fetal thymus implant rejection, Friedreich's
ataxia, functional peripheral arterial disorders, fungal sepsis, gas gangrene, gastric ulcer,
glomerular nephritis, graft rejection of any organ or tissue, gram negative sepsis, gram positive
sepsis, granulomas due to intracellular organisms, hairy cell leukemia, Hallerorden-Spatz
10 disease, hashimoto's thyroiditis, hay fever, heart transplant rejection, hemachromatosis,
hemodialysis, hemolytic uremic syndrome/thrombolytic thrombocytopenic purpura, hemorrhage,
hepatitis (A), His bundle arrhythmias, HIV infection/HIV neuropathy, Hodgkin's disease,
hyperkinetic movement disorders, hypersensitivity reactions, hypersensitivity pneumonitis,
hypertension, hypokinetic movement disorders, hypothalamic-pituitary-adrenal axis evaluation,
15 idiopathic Addison's disease, idiopathic pulmonary fibrosis, antibody mediated cytotoxicity,
Asthenia, infantile spinal muscular atrophy, inflammation of the aorta, influenza a, ionizing
radiation exposure, iridocyclitis/uveitis/optic neuritis, ischemia- reperfusion injury, ischemic
stroke, juvenile rheumatoid arthritis, juvenile spinal muscular atrophy, Kaposi's sarcoma, kidney
transplant rejection, legionella, leishmaniasis, leprosy, lesions of the corticospinal system,
20 lipedema, liver transplant rejection, lymphedema, malaria, malignant Lymphoma, malignant
histiocytosis, malignant melanoma, meningitis, meningococemia, metabolic/idiopathic, migraine
headache, mitochondrial multi.system disorder, mixed connective tissue disease, monoclonal
gammopathy, multiple myeloma, multiple systems degenerations (Mencel Dejerine- Thomas Shi-
Drager and Machado-Joseph), myasthenia gravis, mycobacterium avium intracellulare,
25 mycobacterium tuberculosis, myelodysplastic syndrome, myocardial infarction, myocardial
ischemic disorders, nasopharyngeal carcinoma, neonatal chronic lung disease, nephritis,
nephrosis, neurodegenerative diseases, neurogenic I muscular atrophies , neutropenic fever, non-
hodgkins lymphoma, occlusion of the abdominal aorta and its branches, occlusive arterial
disorders, okt3 therapy, orchitis/epididymitis, orchitis/vasectomy reversal procedures,
30 organomegaly, osteoporosis, pancreas transplant rejection, pancreatic carcinoma, paraneoplastic
syndrome/hypercalcemia of malignancy, parathyroid transplant rejection, pelvic inflammatory
disease, perennial rhinitis, pericardial disease, peripheral atherosclerotic disease, peripheral
vascular disorders, peritonitis, pernicious anemia, pneumocystis carinii pneumonia, pneumonia,
POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy,
35 and skin changes syndrome), post perfusion syndrome, post pump syndrome, post-MI cardiomy
syndrome, preeclampsia, Progressive supranucleo Palsy, primary pulmonary hypertension,
radiation therapy, Raynaud's phenomenon and disease, Raynoud's disease, Refsum's disease,

regular narrow QRS tachycardia, renovascular hypertension, reperfusion injury, restrictive cardiomyopathy, sarcomas, scleroderma, senile chorea, Senile Dementia of Lewy body type, seronegative arthropathies, shock, sickle cell anemia, skin allograft rejection, skin changes syndrome, small bowel transplant rejection, solid tumors, specific arrhythmias, spinal ataxia, spinocerebellar degenerations, streptococcal myositis, structural lesions of the cerebellum, Subacute sclerosing panencephalitis, Syncope, syphilis of the cardiovascular system, systemic anaphalaxis, systemic inflammatory response syndrome, systemic onset juvenile rheumatoid arthritis, T-cell or FAB ALL, Telangiectasia, thromboangitis obliterans, thrombocytopenia, toxicity, transplants, trauma/hemorrhage, type III hypersensitivity reactions, type IV hypersensitivity, unstable angina, uremia, urosepsis, urticaria, valvular heart diseases, varicose veins, vasculitis, venous diseases, venous thrombosis, ventricular fibrillation, viral and fungal infections, viral encephalitis/aseptic meningitis, viral-associated hemaphagocytic syndrome, Wernicke- Korsakoff syndrome, Wilson's disease, xenograft rejection of any organ or tissue. (see Peritt et al. PCT publication No. WO2002097048A2, Leonard et al., PCT publication No. WO9524918 A1, and Salfeld et al., PCT publication No. WO00/56772A1).

The binding proteins of the invention can be used to treat humans suffering from autoimmune diseases, in particular those associated with inflammation, including, rheumatoid arthritis, spondylitis, allergy, autoimmune diabetes, autoimmune uveitis. In an embodiment, the binding proteins of the invention or antigen-binding portions thereof, are used to treat rheumatoid arthritis, Crohn's disease, multiple sclerosis, insulin dependent diabetes mellitus and psoriasis.

In an embodiment, diseases that can be treated or diagnosed with the compositions and methods of the invention include, but are not limited to, primary and metastatic cancers, including carcinomas of breast, colon, rectum, lung, oropharynx, hypopharynx, esophagus, stomach, pancreas, liver, gallbladder and bile ducts, small intestine, urinary tract (including kidney, bladder and urothelium), female genital tract (including cervix, uterus, and ovaries as well as choriocarcinoma and gestational trophoblastic disease), male genital tract (including prostate, seminal vesicles, testes and germ cell tumors), endocrine glands (including the thyroid, adrenal, and pituitary glands), and skin, as well as hemangiomas, melanomas, sarcomas (including those arising from bone and soft tissues as well as Kaposi's sarcoma), tumors of the brain, nerves, eyes, and meninges (including astrocytomas, gliomas, glioblastomas, retinoblastomas, neuromas, neuroblastomas, Schwannomas, and meningiomas), solid tumors arising from hematopoietic malignancies such as leukemias, and lymphomas (both Hodgkin's and non-Hodgkin's lymphomas).

In an embodiment, the antibodies of the invention or antigen-binding portions thereof, are used to treat cancer or in the prevention of metastases from the tumors described herein either when used alone or in combination with radiotherapy and/or other chemotherapeutic agents.

The antibodies of the invention, or antigen binding portions thereof, may be combined with agents that include but are not limited to, antineoplastic agents, radiotherapy, chemotherapy such as DNA alkylating agents, cisplatin, carboplatin, anti-tubulin agents, paclitaxel, docetaxel, taxol, doxorubicin, gemcitabine, gemzar, anthracyclines, adriamycin, topoisomerase I inhibitors, 5 topoisomerase II inhibitors, 5-fluorouracil (5-FU), leucovorin, irinotecan, receptor tyrosine kinase inhibitors (e.g., erlotinib, gefitinib), COX-2 inhibitors (e.g., celecoxib), kinase inhibitors, and siRNAs.

A binding protein of the invention also can be administered with one or more additional therapeutic agents useful in the treatment of various diseases.

10 A binding protein of the invention can be used alone or in combination to treat such diseases. It should be understood that the binding proteins can be used alone or in combination with an additional agent, e.g., a therapeutic agent, said additional agent being selected by the skilled artisan for its intended purpose. For example, the additional agent can be a therapeutic agent art-recognized as being useful to treat the disease or condition being treated by the antibody 15 of the present invention. The additional agent also can be an agent that imparts a beneficial attribute to the therapeutic composition e.g., an agent which effects the viscosity of the composition.

It should further be understood that the combinations which are to be included within this invention are those combinations useful for their intended purpose. The agents set forth below are 20 illustrative for purposes and not intended to be limited. The combinations, which are part of this invention, can be the antibodies of the present invention and at least one additional agent selected from the lists below. The combination can also include more than one additional agent, e.g., two or three additional agents if the combination is such that the formed composition can perform its intended function.

25 Combinations to treat autoimmune and inflammatory diseases are non-steroidal anti-inflammatory drug(s) also referred to as NSAIDS which include drugs like ibuprofen. Other combinations are corticosteroids including prednisolone; the well known side-effects of steroid use can be reduced or even eliminated by tapering the steroid dose required when treating patients in combination with the DVD Igs of this invention. Non-limiting examples of therapeutic agents 30 for rheumatoid arthritis with which an antibody, or antibody portion, of the invention can be combined include the following: cytokine suppressive anti-inflammatory drug(s) (CSAIDs); antibodies to or antagonists of other human cytokines or growth factors, for example, TNF, LT, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-15, IL-16, IL-18, IL-21, IL-23, interferons, EMAP-II, GM-CSF, FGF, and PDGF. Binding proteins of the invention, or antigen binding 35 portions thereof, can be combined with antibodies to cell surface molecules such as CD2, CD3,

CD4, CD8, CD25, CD28, CD30, CD40, CD45, CD69, CD80 (B7.1), CD86 (B7.2), CD90, CTLA or their ligands including CD154 (gp39 or CD40L).

Combinations of therapeutic agents may interfere at different points in the autoimmune and subsequent inflammatory cascade; examples include TNF antagonists like chimeric, 5 humanized or human TNF antibodies, ADALIMUMAB, (PCT Publication No. WO 97/29131), CA2 (RemicadeTM), CDP 571, and soluble p55 or p75 TNF receptors, derivatives, thereof, (p75TNFR1gG (EnbrelTM) or p55TNFR1gG (Lenercept)), and also TNF α converting enzyme (TACE) inhibitors; similarly IL-1 inhibitors (Interleukin-1-converting enzyme inhibitors, IL-1RA etc.) may be effective for the same reason. Other combinations include Interleukin 11. Yet 10 another combination include key players of the autoimmune response which may act parallel to, dependent on or in concert with IL-12 function; especially are IL-18 antagonists including IL-18 antibodies or soluble IL-18 receptors, or IL-18 binding proteins. It has been shown that IL-12 and IL-18 have overlapping but distinct functions and a combination of antagonists to both may be most effective. Yet another combination are non-depleting anti-CD4 inhibitors. Yet other 15 combinations include antagonists of the co-stimulatory pathway CD80 (B7.1) or CD86 (B7.2) including antibodies, soluble receptors or antagonistic ligands.

The binding proteins of the invention may also be combined with agents, such as methotrexate, 6-MP, azathioprine sulphasalazine, mesalazine, olsalazine 20 chloroquine/hydroxychloroquine, pencillamine, aurothiomalate (intramuscular and oral), azathioprine, cochlincine, corticosteroids (oral, inhaled and local injection), beta-2 adrenoreceptor agonists (salbutamol, terbutaline, salmeteral), xanthines (theophylline, aminophylline), cromoglycate, nedocromil, ketotifen, ipratropium and oxitropium, cyclosporin, FK506, rapamycin, mycophenolate mofetil, leflunomide, NSAIDs, for example, ibuprofen, corticosteroids such as prednisolone, phosphodiesterase inhibitors, adenosine agonists, antithrombotic agents, 25 complement inhibitors, adrenergic agents, agents which interfere with signalling by proinflammatory cytokines such as TNF- α or IL-1 (e.g., IRAK, NIK, IKK, p38 or MAP kinase inhibitors), IL-1 β converting enzyme inhibitors, TNF α converting enzyme (TACE) inhibitors, T-cell signalling inhibitors such as kinase inhibitors, metalloproteinase inhibitors, sulfasalazine, azathioprine, 6-mercaptopurines, angiotensin converting enzyme inhibitors, soluble cytokine 30 receptors and derivatives thereof (e.g., soluble p55 or p75 TNF receptors and the derivatives p75TNFR1gG (EnbrelTM) and p55TNFR1gG (Lenercept)), sIL-1RI, sIL-1RII, sIL-6R), antiinflammatory cytokines (e.g., IL-4, IL-10, IL-11, IL-13 and TGF β), celecoxib, folic acid, hydroxychloroquine sulfate, rofecoxib, etanercept, infliximab, naproxen, valdecoxib, sulfasalazine, methylprednisolone, meloxicam, methylprednisolone acetate, gold sodium 35 thiomalate, aspirin, triamcinolone acetonide, propoxyphene napsylate/apap, folate, nabumetone, diclofenac, piroxicam, etodolac, diclofenac sodium, oxaprozin, oxycodone hcl, hydrocodone

bitartrate/apap, diclofenac sodium/misoprostol, fentanyl, anakinra, human recombinant, tramadol hcl, salsalate, sulindac, cyanocobalamin/fa/pyridoxine, acetaminophen, alendronate sodium, prednisolone, morphine sulfate, lidocaine hydrochloride, indomethacin, glucosamine sulf/chondroitin, amitriptyline hcl, sulfadiazine, oxycodone hcl/acetaminophen, olopatadine hcl, misoprostol, naproxen sodium, omeprazole, cyclophosphamide, rituximab, IL-1 TRAP, MRA, 5 CTLA4-IG, IL-18 BP, anti-IL-18, Anti-IL15, BIRB-796, SCIO-469, VX-702, AMG-548, VX-740, Roflumilast, IC-485, CDC-801, and Mesopram. Combinations include methotrexate or leflunomide and in moderate or severe rheumatoid arthritis cases, cyclosporine.

Nonlimiting additional agents which can also be used in combination with a binding 10 protein to treat rheumatoid arthritis include, but are not limited to, the following: non-steroidal anti-inflammatory drug(s) (NSAIDs); cytokine suppressive anti-inflammatory drug(s) (CSAIDs); CDP-571/BAY-10-3356 (humanized anti-TNF α antibody; Celltech/Bayer); cA2/infliximab (chimeric anti-TNF α antibody; Centocor); 75 kdTNFR-IgG/etanercept (75 kD TNF receptor-IgG fusion protein; Immunex; see *e.g.*, *Arthritis & Rheumatism* (1994) Vol. 37, S295; *J. Invest. Med.* 15 (1996) Vol. 44, 235A); 55 kdTNF-IgG (55 kD TNF receptor-IgG fusion protein; Hoffmann-LaRoche); IDEC-CE9.1/SB 210396 (non-depleting primatized anti-CD4 antibody; IDEC/SmithKline; see *e.g.*, *Arthritis & Rheumatism* (1995) Vol. 38, S185); DAB 486-IL-2 and/or DAB 389-IL-2 (IL-2 fusion proteins; Seragen; see *e.g.*, *Arthritis & Rheumatism* (1993) Vol. 36, 1223); Anti-Tac (humanized anti-IL-2R α ; Protein Design Labs/Roche); IL-4 (anti-inflammatory 20 cytokine; DNAX/Schering); IL-10 (SCH 52000; recombinant IL-10, anti-inflammatory cytokine; DNAX/Schering); IL-4; IL-10 and/or IL-4 agonists (*e.g.*, agonist antibodies); IL-1RA (IL-1 receptor antagonist; Synergen/Amgen); anakinra (Kineret[®]/Amgen); TNF-bp/s-TNF (soluble TNF binding protein; see *e.g.*, *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S284; *Amer. J. Physiol. - Heart and Circulatory Physiology* (1995) Vol. 268, pp. 37-42); R973401 25 (phosphodiesterase Type IV inhibitor; see *e.g.*, *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S282); MK-966 (COX-2 Inhibitor; see *e.g.*, *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S81); Iloprost (see *e.g.*, *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S82); methotrexate; thalidomide (see *e.g.*, *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S282) and thalidomide-related drugs (*e.g.*, Celgen); leflunomide (anti- 30 inflammatory and cytokine inhibitor; see *e.g.*, *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S131; *Inflammation Research* (1996) Vol. 45, pp. 103-107); tranexamic acid (inhibitor of plasminogen activation; see *e.g.*, *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S284); T-614 (cytokine inhibitor; see *e.g.*, *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S282); prostaglandin E1 (see *e.g.*, *Arthritis & Rheumatism* (1996) Vol. 39, 35 No. 9 (supplement), S282); Tenidap (non-steroidal anti-inflammatory drug; see *e.g.*, *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S280); Naproxen (non-steroidal anti-

inflammatory drug; see *e.g.*, *Neuro Report* (1996) Vol. 7, pp. 1209-1213); Meloxicam (non-steroidal anti-inflammatory drug); Ibuprofen (non-steroidal anti-inflammatory drug); Piroxicam (non-steroidal anti-inflammatory drug); Diclofenac (non-steroidal anti-inflammatory drug); Indomethacin (non-steroidal anti-inflammatory drug); Sulfasalazine (see *e.g.*, *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S281); Azathioprine (see *e.g.*, *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S281); ICE inhibitor (inhibitor of the enzyme interleukin-1 β converting enzyme); zap-70 and/or lck inhibitor (inhibitor of the tyrosine kinase zap-70 or lck); VEGF inhibitor and/or VEGF-R inhibitor (inhibitors of vascular endothelial cell growth factor or vascular endothelial cell growth factor receptor; inhibitors of angiogenesis); corticosteroid anti-inflammatory drugs (*e.g.*, SB203580); TNF-convertase inhibitors; anti-IL-12 antibodies; anti-IL-18 antibodies; interleukin-11 (see *e.g.*, *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S296); interleukin-13 (see *e.g.*, *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S308); interleukin -17 inhibitors (see *e.g.*, *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S120); gold; penicillamine; chloroquine; chlorambucil; hydroxychloroquine; cyclosporine; cyclophosphamide; total lymphoid irradiation; anti-thymocyte globulin; anti-CD4 antibodies; CD5-toxins; orally-administered peptides and collagen; lobenzarit disodium; Cytokine Regulating Agents (CRAs) HP228 and HP466 (Houghten Pharmaceuticals, Inc.); ICAM-1 antisense phosphorothioate oligo-deoxynucleotides (ISIS 2302; Isis Pharmaceuticals, Inc.); soluble complement receptor 1 (TP10; T Cell Sciences, Inc.); prednisone; orgotein; glycosaminoglycan polysulphate; minocycline; anti-IL2R antibodies; marine and botanical lipids (fish and plant seed fatty acids; see *e.g.*, DeLuca *et al.* (1995) *Rheum. Dis. Clin. North Am.* 21:759-777); auranofin; phenylbutazone; meclofenamic acid; flufenamic acid; intravenous immune globulin; zileuton; azaribine; mycophenolic acid (RS-61443); tacrolimus (FK-506); sirolimus (rapamycin); amiprilose (therafectin); cladribine (2-chlorodeoxyadenosine); methotrexate; bcl-2 inhibitors (see Bruncko, Milan *et al.*, *Journal of Medicinal Chemistry* (2007), 50(4), 641-662); antivirals and immune modulating agents.

In one embodiment, the binding protein or antigen-binding portion thereof, is administered in combination with one of the following agents for the treatment of rheumatoid arthritis: small molecule inhibitor of KDR, small molecule inhibitor of Tie-2; methotrexate; prednisone; celecoxib; folic acid; hydroxychloroquine sulfate; rofecoxib; etanercept; infliximab; leflunomide; naproxen; valdecoxib; sulfasalazine; methylprednisolone; ibuprofen; meloxicam; methylprednisolone acetate; gold sodium thiomalate; aspirin; azathioprine; triamcinolone acetate; propoxyphene napsylate/apap; folate; nabumetone; diclofenac; piroxicam; etodolac; diclofenac sodium; oxaprozin; oxycodone hcl; hydrocodone bitartrate/apap; diclofenac sodium/misoprostol; fentanyl; anakinra, human recombinant; tramadol hcl; salsalate; sulindac; cyanocobalamin/fa/pyridoxine; acetaminophen; alendronate sodium; prednisolone; morphine

sulfate; lidocaine hydrochloride; indomethacin; glucosamine sulfate/chondroitin; cyclosporine; amitriptyline hcl; sulfadiazine; oxycodone hcl/acetaminophen; olopatadine hcl; misoprostol; naproxen sodium; omeprazole; mycophenolate mofetil; cyclophosphamide; rituximab; IL-1 TRAP; MRA; CTLA4-IG; IL-18 BP; IL-12/23; anti-IL 18; anti-IL 15; BIRB-796; SCIO-469; 5 VX-702; AMG-548; VX-740; Roflumilast; IC-485; CDC-801; and mesopram.

Non-limiting examples of therapeutic agents for inflammatory bowel disease with which a binding protein of the invention can be combined include the following: budesonide; epidermal growth factor; corticosteroids; cyclosporin, sulfasalazine; aminosaliclates; 6-mercaptopurine; azathioprine; metronidazole; lipoxygenase inhibitors; mesalamine; olsalazine; balsalazide; 10 antioxidants; thromboxane inhibitors; IL-1 receptor antagonists; anti-IL-1 β mAbs; anti-IL-6 mAbs; growth factors; elastase inhibitors; pyridinyl-imidazole compounds; antibodies to or antagonists of other human cytokines or growth factors, for example, TNF, LT, IL-1, IL-2, IL-6, IL-7, IL-8, IL-15, IL-16, IL-17, IL-18, EMAP-II, GM-CSF, FGF, and PDGF. Antibodies of the invention, or antigen binding portions thereof, can be combined with antibodies to cell surface 15 molecules such as CD2, CD3, CD4, CD8, CD25, CD28, CD30, CD40, CD45, CD69, CD90 or their ligands. The antibodies of the invention, or antigen binding portions thereof, may also be combined with agents, such as methotrexate, cyclosporin, FK506, rapamycin, mycophenolate mofetil, leflunomide, NSAIDs, for example, ibuprofen, corticosteroids such as prednisolone, phosphodiesterase inhibitors, adenosine agonists, antithrombotic agents, complement inhibitors, 20 adrenergic agents, agents which interfere with signalling by proinflammatory cytokines such as TNF α or IL-1 (e.g., IRAK, NIK, IKK, p38 or MAP kinase inhibitors), IL-1 β converting enzyme inhibitors, TNF α converting enzyme inhibitors, T-cell signalling inhibitors such as kinase inhibitors, metalloproteinase inhibitors, sulfasalazine, azathioprine, 6-mercaptopurines, angiotensin converting enzyme inhibitors, soluble cytokine receptors and derivatives thereof (e.g., soluble p55 or p75 TNF receptors, sIL-1RI, sIL-1RII, sIL-6R) and antiinflammatory 25 cytokines (e.g., IL-4, IL-10, IL-11, IL-13 and TGF β) and bcl-2 inhibitors.

Examples of therapeutic agents for Crohn's disease in which a binding protein can be combined include the following: TNF antagonists, for example, anti-TNF antibodies, ADALIMUMAB (PCT Publication No. WO 97/29131; HUMIRA), CA2 (REMICADE), CDP 30 571, TNFR-Ig constructs, (p75TNFRIG (ENBREL) and p55TNFRIG (LENERCEPT)) inhibitors and PDE4 inhibitors. Antibodies of the invention, or antigen binding portions thereof, can be combined with corticosteroids, for example, budesonide and dexamethasone. Binding proteins of the invention or antigen binding portions thereof, may also be combined with agents such as sulfasalazine, 5-aminosalicylic acid and olsalazine, and agents which interfere with 35 synthesis or action of proinflammatory cytokines such as IL-1, for example, IL-1 β converting enzyme inhibitors and IL-1ra. Antibodies of the invention or antigen binding portion thereof may

also be used with T cell signaling inhibitors, for example, tyrosine kinase inhibitors 6-
mercaptapurines. Binding proteins of the invention, or antigen binding portions thereof, can be
combined with IL-11. Binding proteins of the invention, or antigen binding portions thereof, can
be combined with mesalamine, prednisone, azathioprine, mercaptopurine, infliximab,
5 methylprednisolone sodium succinate, diphenoxylate/atrop sulfate, loperamide hydrochloride,
methotrexate, omeprazole, folate, ciprofloxacin/dextrose-water, hydrocodone bitartrate/apap,
tetracycline hydrochloride, fluocinonide, metronidazole, thimerosal/boric acid,
cholestyramine/sucrose, ciprofloxacin hydrochloride, hyoscyamine sulfate, meperidine
hydrochloride, midazolam hydrochloride, oxycodone hcl/acetaminophen, promethazine
10 hydrochloride, sodium phosphate, sulfamethoxazole/trimethoprim, celecoxib, polycarbophil,
propoxyphene napsylate, hydrocortisone, multivitamins, balsalazide disodium, codeine
phosphate/apap, colesevelam hcl, cyanocobalamin, folic acid, levofloxacin, methylprednisolone,
natalizumab and interferon-gamma

Non-limiting examples of therapeutic agents for multiple sclerosis with which binding
15 proteins of the invention can be combined include the following: corticosteroids; prednisolone;
methylprednisolone; azathioprine; cyclophosphamide; cyclosporine; methotrexate; 4-
aminopyridine; tizanidine; interferon- β 1a (AVONEX; Biogen); interferon- β 1b (BETASERON;
Chiron/Berlex); interferon α -n3) (Interferon Sciences/Fujimoto), interferon- α (Alfa
Wassermann/J&J), interferon β 1A-IF (Serono/Inhale Therapeutics), Peginterferon α 2b
20 (Enzon/Schering-Plough), Copolymer 1 (Cop-1; COPAXONE; Teva Pharmaceutical Industries,
Inc.); hyperbaric oxygen; intravenous immunoglobulin; clabribine; antibodies to or antagonists of
other human cytokines or growth factors and their receptors, for example, TNF, LT, IL-1, IL-2,
IL-6, IL-7, IL-8, IL-23, IL-15, IL-16, IL-18, EMAP-II, GM-CSF, FGF, and PDGF. Binding
proteins of the invention can be combined with antibodies to cell surface molecules such as CD2,
25 CD3, CD4, CD8, CD19, CD20, CD25, CD28, CD30, CD40, CD45, CD69, CD80, CD86, CD90
or their ligands. Binding proteins of the invention, may also be combined with agents, such as
methotrexate, cyclosporine, FK506, rapamycin, mycophenolate mofetil, leflunomide, NSAIDs,
for example, ibuprofen, corticosteroids such as prednisolone, phosphodiesterase inhibitors,
adenosine agonists, antithrombotic agents, complement inhibitors, adrenergic agents, agents
30 which interfere with signalling by proinflammatory cytokines such as TNF α or IL-1 (e.g., IRAK,
NIK, IKK, p38 or MAP kinase inhibitors), IL-1 β converting enzyme inhibitors, TACE inhibitors,
T-cell signaling inhibitors such as kinase inhibitors, metalloproteinase inhibitors, sulfasalazine,
azathioprine, 6-mercaptapurines, angiotensin converting enzyme inhibitors, soluble cytokine
receptors and derivatives thereof (e.g., soluble p55 or p75 TNF receptors, sIL-1RI, sIL-1RII, sIL-
35 6R), antiinflammatory cytokines (e.g., IL-4, IL-10, IL-13 and TGF β) and bcl-2 inhibitors.

Examples of therapeutic agents for multiple sclerosis in which binding proteins of the invention can be combined include interferon- β , for example, IFN β 1a and IFN β 1b; copaxone, corticosteroids, caspase inhibitors, for example inhibitors of caspase-1, IL-1 inhibitors, TNF inhibitors, and antibodies to CD40 ligand and CD80.

5 The binding proteins of the invention, may also be combined with agents, such as alemtuzumab, dronabinol, Unimed, daclizumab, mitoxantrone, xaliproden hydrochloride, fampridine, glatiramer acetate, natalizumab, sinnabidol, a-immunokine NNSO3, ABR-215062, Anergix.MS, chemokine receptor antagonists, BBR-2778, calagualine, CPI-1189, LEM (liposome encapsulated mitoxantrone), THC.CBD (cannabinoid agonist) MBP-8298, mesopram 10 (PDE4 inhibitor), MNA-715, anti-IL-6 receptor antibody, neurovax, pirfenidone allopurinol 1258 (RDP-1258), sTNF-R1, talampanel, teriflunomide, TGF-beta2, tiplimotide, VLA-4 antagonists (for example, TR-14035, VLA4 Ultrahaler, Antegran-ELAN/Biogen), interferon gamma antagonists, IL-4 agonists.

Non-limiting examples of therapeutic agents for Angina with which binding proteins of 15 the invention can be combined include the following: aspirin, nitroglycerin, isosorbide mononitrate, metoprolol succinate, atenolol, metoprolol tartrate, amlodipine besylate, diltiazem hydrochloride, isosorbide dinitrate, clopidogrel bisulfate, nifedipine, atorvastatin calcium, potassium chloride, furosemide, simvastatin, verapamil hcl, digoxin, propranolol hydrochloride, carvedilol, lisinopril, spironolactone, hydrochlorothiazide, enalapril maleate, nadolol, ramipril, 20 enoxaparin sodium, heparin sodium, valsartan, sotalol hydrochloride, fenofibrate, ezetimibe, bumetanide, losartan potassium, lisinopril/hydrochlorothiazide, felodipine, captopril, bisoprolol fumarate.

Non-limiting examples of therapeutic agents for Ankylosing Spondylitis with which 25 binding proteins of the invention can be combined include the following: ibuprofen, diclofenac and misoprostol, naproxen, meloxicam, indomethacin, diclofenac, celecoxib, rofecoxib, Sulfasalazine, Methotrexate, azathioprine, minocyclin, prednisone, etanercept, infliximab.

Non-limiting examples of therapeutic agents for Asthma with which binding proteins of 30 the invention can be combined include the following: albuterol, salmeterol/fluticasone, montelukast sodium, fluticasone propionate, budesonide, prednisone, salmeterol xinafoate, levalbuterol hcl, albuterol sulfate/ipratropium, prednisolone sodium phosphate, triamcinolone acetate, beclomethasone dipropionate, ipratropium bromide, azithromycin, pirbuterol acetate, prednisolone, theophylline anhydrous, methylprednisolone sodium succinate, clarithromycin, 35 zafirlukast, formoterol fumarate, influenza virus vaccine, methylprednisolone, amoxicillin trihydrate, flunisolide, allergy injection, cromolyn sodium, fexofenadine hydrochloride, flunisolide/menthol, amoxicillin/clavulanate, levofloxacin, inhaler assist device, guaifenesin,

dexamethasone sodium phosphate, moxifloxacin hcl, doxycycline hyclate, guaifenesin/d-methorphan, p-ephedrine/cod/chlorphenir, gatifloxacin, cetirizine hydrochloride, mometasone furoate, salmeterol xinafoate, benzonatate, cephalixin, pe/hydrocodone/chlorphenir, cetirizine hcl/pseudoephed, phenylephrine/cod/promethazine, codeine/promethazine, cefprozil,
5 dexamethasone, guaifenesin/pseudoephedrine, chlorpheniramine/hydrocodone, nedocromil sodium, terbutaline sulfate, epinephrine, methylprednisolone, metaproterenol sulfate.

Non-limiting examples of therapeutic agents for COPD with which binding proteins of the invention can be combined include the following: albuterol sulfate/ipratropium, ipratropium bromide, salmeterol/fluticasone, albuterol, salmeterol xinafoate, fluticasone propionate,
10 prednisone, theophylline anhydrous, methylprednisolone sodium succinate, montelukast sodium, budesonide, formoterol fumarate, triamcinolone acetonide, levofloxacin, guaifenesin, azithromycin, beclomethasone dipropionate, levalbuterol hcl, flunisolide, ceftriaxone sodium, amoxicillin trihydrate, gatifloxacin, zafirlukast, amoxicillin/clavulanate, flunisolide/menthol, chlorpheniramine/hydrocodone, metaproterenol sulfate, methylprednisolone, mometasone furoate,
15 p-ephedrine/cod/chlorphenir, pirbuterol acetate, p-ephedrine/loratadine, terbutaline sulfate, tiotropium bromide, (R,R)-formoterol, TgAAT, Cilomilast, Roflumilast.

Non-limiting examples of therapeutic agents for HCV with which binding proteins of the invention can be combined include the following: Interferon-alpha-2a, Interferon-alpha-2b, Interferon-alpha con1, Interferon-alpha-n1, Pegylated interferon-alpha-2a, Pegylated interferon-alpha-2b, ribavirin, Peginterferon alfa-2b + ribavirin, Ursodeoxycholic Acid, Glycyrrhizic Acid,
20 Thymalfasin, Maxamine, VX-497 and any compounds that are used to treat HCV through intervention with the following targets: HCV polymerase, HCV protease, HCV helicase, HCV IRES (internal ribosome entry site).

Non-limiting examples of therapeutic agents for Idiopathic Pulmonary Fibrosis with
25 which binding proteins of the invention can be combined include the following: prednisone, azathioprine, albuterol, colchicine, albuterol sulfate, digoxin, gamma interferon, methylprednisolone sod succ, lorazepam, furosemide, lisinopril, nitroglycerin, spironolactone, cyclophosphamide, ipratropium bromide, actinomycin d, alteplase, fluticasone propionate, levofloxacin, metaproterenol sulfate, morphine sulfate, oxycodone hcl, potassium chloride,
30 triamcinolone acetonide, tacrolimus anhydrous, calcium, interferon-alpha, methotrexate, mycophenolate mofetil, Interferon-gamma-1 β .

Non-limiting examples of therapeutic agents for Myocardial Infarction with which binding proteins of the invention can be combined include the following: aspirin, nitroglycerin, metoprolol tartrate, enoxaparin sodium, heparin sodium, clopidogrel bisulfate, carvedilol,
35 atenolol, morphine sulfate, metoprolol succinate, warfarin sodium, lisinopril, isosorbide

- mononitrate, digoxin, furosemide, simvastatin, ramipril, tenecteplase, enalapril maleate, torsemide, retavase, losartan potassium, quinapril hcl/mag carb, bumetanide, alteplase, enalaprilat, amiodarone hydrochloride, tirofiban hcl m-hydrate, diltiazem hydrochloride, captopril, irbesartan, valsartan, propranolol hydrochloride, fosinopril sodium, lidocaine hydrochloride, eptifibatide,
- 5 cefazolin sodium, atropine sulfate, aminocaproic acid, spironolactone, interferon, sotalol hydrochloride, potassium chloride, docusate sodium, dobutamine hcl, alprazolam, pravastatin sodium, atorvastatin calcium, midazolam hydrochloride, meperidine hydrochloride, isosorbide dinitrate, epinephrine, dopamine hydrochloride, bivalirudin, rosuvastatin, ezetimibe/simvastatin, avasimibe, cariporide.
- 10 Non-limiting examples of therapeutic agents for Psoriasis with which binding proteins of the invention can be combined include the following: small molecule inhibitor of KDR, small molecule inhibitor of Tie-2, calcipotriene, clobetasol propionate, triamcinolone acetate, halobetasol propionate, tazarotene, methotrexate, fluocinonide, betamethasone diprop augmented, fluocinolone acetate, acitretin, tar shampoo, betamethasone valerate, mometasone furoate,
- 15 ketoconazole, pramoxine/fluocinolone, hydrocortisone valerate, flurandrenolide, urea, betamethasone, clobetasol propionate/emoll, fluticasone propionate, azithromycin, hydrocortisone, moisturizing formula, folic acid, desonide, pimecrolimus, coal tar, diflorasone diacetate, etanercept folate, lactic acid, methoxsalen, hc/bismuth subgal/znox/resor, methylprednisolone acetate, prednisone, sunscreen, halcinonide, salicylic acid, anthralin,
- 20 clocortolone pivalate, coal extract, coal tar/salicylic acid, coal tar/salicylic acid/sulfur, desoximetasone, diazepam, emollient, fluocinonide/emollient, mineral oil/castor oil/na lact, mineral oil/peanut oil, petroleum/isopropyl myristate, psoralen, salicylic acid, soap/tribromsalan, thimerosal/boric acid, celecoxib, infliximab, cyclosporine, alefacept, efalizumab, tacrolimus, pimecrolimus, PUVA, UVB, sulfasalazine.
- 25 Non-limiting examples of therapeutic agents for Psoriatic Arthritis with which binding proteins of the invention can be combined include the following: methotrexate, etanercept, rofecoxib, celecoxib, folic acid, sulfasalazine, naproxen, leflunomide, methylprednisolone acetate, indomethacin, hydroxychloroquine sulfate, prednisone, sulindac, betamethasone diprop augmented, infliximab, methotrexate, folate, triamcinolone acetate, diclofenac,
- 30 dimethylsulfoxide, piroxicam, diclofenac sodium, ketoprofen, meloxicam, methylprednisolone, nabumetone, tolmetin sodium, calcipotriene, cyclosporine, diclofenac sodium/misoprostol, fluocinonide, glucosamine sulfate, gold sodium thiomalate, hydrocodone bitartrate/apap, ibuprofen, risedronate sodium, sulfadiazine, thioguanine, valdecoxib, alefacept, efalizumab and bcl-2 inhibitors.

Non-limiting examples of therapeutic agents for Restenosis with which binding proteins of the invention can be combined include the following: sirolimus, paclitaxel, everolimus, tacrolimus, Zotarolimus, acetaminophen.

Non-limiting examples of therapeutic agents for Sciatica with which binding proteins of the invention can be combined include the following: hydrocodone bitartrate/apap, rofecoxib, cyclobenzaprine hcl, methylprednisolone, naproxen, ibuprofen, oxycodone hcl/acetaminophen, celecoxib, valdecoxib, methylprednisolone acetate, prednisone, codeine phosphate/apap, tramadol hcl/acetaminophen, metaxalone, meloxicam, methocarbamol, lidocaine hydrochloride, diclofenac sodium, gabapentin, dexamethasone, carisoprodol, ketorolac tromethamine, indomethacin, acetaminophen, diazepam, nabumetone, oxycodone hcl, tizanidine hcl, diclofenac sodium/misoprostol, propoxyphene napsylate/apap, asa/oxycod/oxycodone ter, ibuprofen/hydrocodone bit, tramadol hcl, etodolac, propoxyphene hcl, amitriptyline hcl, carisoprodol/codeine phos/asa, morphine sulfate, multivitamins, naproxen sodium, orphenadrine citrate, temazepam.

Examples of therapeutic agents for SLE (Lupus) in which binding proteins of the invention can be combined include the following: NSAIDS, for example, diclofenac, naproxen, ibuprofen, piroxicam, indomethacin; COX2 inhibitors, for example, Celecoxib, rofecoxib, valdecoxib; anti-malarials, for example, hydroxychloroquine; Steroids, for example, prednisone, prednisolone, budesonide, dexamethasone; Cytotoxics, for example, azathioprine, cyclophosphamide, mycophenolate mofetil, methotrexate; inhibitors of PDE4 or purine synthesis inhibitor, for example Cellcept. Binding proteins of the invention, may also be combined with agents such as sulfasalazine, 5-aminosalicylic acid, olsalazine, Imuran and agents which interfere with synthesis, production or action of proinflammatory cytokines such as IL-1, for example, caspase inhibitors like IL-1 β converting enzyme inhibitors and IL-1ra. Binding proteins of the invention may also be used with T cell signaling inhibitors, for example, tyrosine kinase inhibitors; or molecules that target T cell activation molecules, for example, CTLA-4-IgG or anti-B7 family antibodies, anti-PD-1 family antibodies. Binding proteins of the invention, can be combined with IL-11 or anti-cytokine antibodies, for example, fonotolizumab (anti-IFN γ antibody), or anti-receptor antibodies, for example, anti-IL-6 receptor antibody and antibodies to B-cell surface molecules. Antibodies of the invention or antigen binding portion thereof may also be used with LJP 394 (abetimus), agents that deplete or inactivate B-cells, for example, Rituximab (anti-CD20 antibody), lymphostat-B (anti-BlyS antibody), TNF antagonists, for example, anti-TNF antibodies, Adalimumab (PCT Publication No. WO 97/29131; HUMIRA), CA2 (REMICADE), CDP 571, TNFR-Ig constructs, (p75TNFR-IgG (ENBREL)¹ and p55TNFR-IgG (LENERCEPT)) and bcl-2 inhibitors, because bcl-2 overexpression in transgenic mice has been demonstrated to cause a lupus like phenotype (see Marquina, Regina et al., Journal

of Immunology (2004), 172(11), 7177-7185), therefore inhibition is expected to have therapeutic effects.

The pharmaceutical compositions of the invention may include a "therapeutically effective amount" or a "prophylactically effective amount" of a binding protein of the invention.

5 A "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result. A therapeutically effective amount of the binding protein may be determined by a person skilled in the art and may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the binding protein to elicit a desired response in the individual. A therapeutically effective amount is

10 also one in which any toxic or detrimental effects of the antibody, or antibody portion, are outweighed by the therapeutically beneficial effects. A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically

15 effective amount.

Dosage regimens may be adjusted to provide the optimum desired response (*e.g.*, a therapeutic or prophylactic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is especially advantageous

20 to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the

25 invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic or prophylactic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.

An exemplary, non-limiting range for a therapeutically or prophylactically effective

30 amount of a binding protein of the invention is 0.1-20 mg/kg, for example, 1-10 mg/kg. It is to be noted that dosage values may vary with the type and severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that dosage ranges set

35 forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.

It will be readily apparent to those skilled in the art that other suitable modifications and adaptations of the methods of the invention described herein are obvious and may be made using suitable equivalents without departing from the scope of the invention or the embodiments disclosed herein. Having now described the present invention in detail, the same will be more clearly understood by reference to the following examples, which are included for purposes of illustration only and are not intended to be limiting of the invention.

V. Diagnostics

The disclosure herein also provides diagnostic applications. This is further elucidated below.

I. Method of Assay

The present disclosure also provides a method for determining the presence, amount or concentration of an analyte (or a fragment thereof) in a test sample using at least one DVD-Ig as described herein. Any suitable assay as is known in the art can be used in the method. Examples include, but are not limited to, immunoassay, such as sandwich immunoassay (e.g., monoclonal, polyclonal and/or DVD-Ig sandwich immunoassays or any variation thereof (e.g., monoclonal/DVD-Ig, DVD-Ig/polyclonal, etc.), including radioisotope detection (radioimmunoassay (RIA)) and enzyme detection (enzyme immunoassay (EIA) or enzyme-linked immunosorbent assay (ELISA) (e.g., Quantikine ELISA assays, R&D Systems, Minneapolis, MN)), competitive inhibition immunoassay (e.g., forward and reverse), fluorescence polarization immunoassay (FPIA), enzyme multiplied immunoassay technique (EMIT), bioluminescence resonance energy transfer (BRET), and homogeneous chemiluminescent assay, etc. In a SELDI-based immunoassay, a capture reagent that specifically binds an analyte (or a fragment thereof) of interest is attached to the surface of a mass spectrometry probe, such as a pre-activated protein chip array. The analyte (or a fragment thereof) is then specifically captured on the biochip, and the captured analyte (or a fragment thereof) is detected by mass spectrometry. Alternatively, the analyte (or a fragment thereof) can be eluted from the capture reagent and detected by traditional MALDI (matrix-assisted laser desorption/ionization) or by SELDI. A chemiluminescent microparticle immunoassay, in particular one employing the ARCHITECT® automated analyzer (Abbott Laboratories, Abbott Park, IL), is an example of a preferred immunoassay.

Methods well-known in the art for collecting, handling and processing urine, blood, serum and plasma, and other body fluids, are used in the practice of the present disclosure, for instance, when a DVD-Ig as described herein is employed as an immunodiagnostic reagent and/or in an analyte immunoassay kit. The test sample can comprise further moieties in addition to the analyte of interest, such as antibodies, antigens, haptens, hormones, drugs, enzymes, receptors, proteins, peptides, polypeptides, oligonucleotides and/or polynucleotides. For example, the sample can be a whole blood sample obtained from a subject. It can be necessary or desired that a test sample, particularly whole blood, be treated prior to immunoassay as described herein, e.g.,

with a pretreatment reagent. Even in cases where pretreatment is not necessary (e.g., most urine samples), pretreatment optionally can be done (e.g., as part of a regimen on a commercial platform).

The pretreatment reagent can be any reagent appropriate for use with the immunoassay and kits of the invention. The pretreatment optionally comprises: (a) one or more solvents (e.g., 5 methanol and ethylene glycol) and optionally, salt, (b) one or more solvents and salt, and optionally, detergent, (c) detergent, or (d) detergent and salt. Pretreatment reagents are known in the art, and such pretreatment can be employed, e.g., as used for assays on Abbott TDx, AxSYM®, and ARCHITECT® analyzers (Abbott Laboratories, Abbott Park, IL), as described in 10 the literature (see, e.g., Yatscoff et al., *Abbott TDx Monoclonal Antibody Assay Evaluated for Measuring Cyclosporine in Whole Blood*, *Clin. Chem.* 36: 1969-1973 (1990), and Wallemacq et al., *Evaluation of the New AxSYM Cyclosporine Assay: Comparison with TDx Monoclonal Whole Blood and EMIT Cyclosporine Assays*, *Clin. Chem.* 45: 432-435 (1999)), and/or as commercially available. Additionally, pretreatment can be done as described in Abbott's U.S. 15 Pat. No. 5,135,875, European Pat. Pub. No. 0 471 293, U.S Provisional Pat. App. 60/878,017, filed December 29, 2006, and U.S. Pat. App. Pub. No. 2008/0020401 (incorporated by reference in its entirety for its teachings regarding pretreatment). The pretreatment reagent can be a heterogeneous agent or a homogeneous agent.

With use of a heterogeneous pretreatment reagent, the pretreatment reagent precipitates 20 analyte binding protein (e.g., protein that can bind to an analyte or a fragment thereof) present in the sample. Such a pretreatment step comprises removing any analyte binding protein by separating from the precipitated analyte binding protein the supernatant of the mixture formed by addition of the pretreatment agent to sample. In such an assay, the supernatant of the mixture 25 absent any binding protein is used in the assay, proceeding directly to the antibody capture step.

With use of a homogeneous pretreatment reagent there is no such separation step. The 25 entire mixture of test sample and pretreatment reagent are contacted with a labeled specific binding partner for analyte (or a fragment thereof), such as a labeled anti-analyte antibody (or an antigenically reactive fragment thereof). The pretreatment reagent employed for such an assay typically is diluted in the pretreated test sample mixture, either before or during capture by the 30 first specific binding partner. Despite such dilution, a certain amount of the pretreatment reagent is still present (or remains) in the test sample mixture during capture. According to the invention, the labeled specific binding partner can be a DVD-Ig (or a fragment, a variant, or a fragment of a variant thereof).

In a heterogeneous format, after the test sample is obtained from a subject, a first mixture 35 is prepared. The mixture contains the test sample being assessed for an analyte (or a fragment

thereof) and a first specific binding partner, wherein the first specific binding partner and any analyte contained in the test sample form a first specific binding partner-analyte complex.

Preferably, the first specific binding partner is an anti-analyte antibody or a fragment thereof. The first specific binding partner can be a DVD-Ig (or a fragment, a variant, or a fragment of a variant thereof) as described herein. The order in which the test sample and the first specific binding partner are added to form the mixture is not critical. Preferably, the first specific binding partner is immobilized on a solid phase. The solid phase used in the immunoassay (for the first specific binding partner and, optionally, the second specific binding partner) can be any solid phase known in the art, such as, but not limited to, a magnetic particle, a bead, a test tube, a microtiter plate, a cuvette, a membrane, a scaffolding molecule, a film, a filter paper, a disc and a chip.

After the mixture containing the first specific binding partner-analyte complex is formed, any unbound analyte is removed from the complex using any technique known in the art. For example, the unbound analyte can be removed by washing. Desirably, however, the first specific binding partner is present in excess of any analyte present in the test sample, such that all analyte that is present in the test sample is bound by the first specific binding partner.

After any unbound analyte is removed, a second specific binding partner is added to the mixture to form a first specific binding partner-analyte-second specific binding partner complex. The second specific binding partner is preferably an anti-analyte antibody that binds to an epitope on analyte that differs from the epitope on analyte bound by the first specific binding partner. Moreover, also preferably, the second specific binding partner is labeled with or contains a detectable label as described above. The second specific binding partner can be a DVD-Ig (or a fragment, a variant, or a fragment of a variant thereof) as described herein.

Any suitable detectable label as is known in the art can be used. For example, the detectable label can be a radioactive label (such as ^3H , ^{125}I , ^{35}S , ^{14}C , ^{32}P , and ^{33}P), an enzymatic label (such as horseradish peroxidase, alkaline peroxidase, glucose 6-phosphate dehydrogenase, and the like), a chemiluminescent label (such as acridinium esters, thioesters, or sulfonamides; luminol, isoluminol, phenanthridinium esters, and the like), a fluorescent label (such as fluorescein (e.g., 5-fluorescein, 6-carboxyfluorescein, 3'6-carboxyfluorescein, 5(6)-carboxyfluorescein, 6-hexachloro-fluorescein, 6-tetrachlorofluorescein, fluorescein isothiocyanate, and the like)), rhodamine, phycobiliproteins, R-phycoerythrin, quantum dots (e.g., zinc sulfide-capped cadmium selenide), a thermometric label, or an immuno-polymerase chain reaction label. An introduction to labels, labeling procedures and detection of labels is found in Polak and Van Noorden, *Introduction to Immunocytochemistry*, 2nd ed., Springer Verlag, N.Y. (1997), and in Haugland, *Handbook of Fluorescent Probes and Research Chemicals* (1996), which is a combined handbook and catalogue published by Molecular Probes, Inc., Eugene, Oregon. A fluorescent label can be used in FPIA (see, e.g., U.S. Patent Nos. 5,593,896, 5,573,904, 5,496,925, 5,359,093, and 5,352,803, which are hereby incorporated by reference in

their entireties). An acridinium compound can be used as a detectable label in a homogeneous or heterogeneous chemiluminescent assay (see, e.g., Adamczyk et al., *Bioorg. Med. Chem. Lett.* 16: 1324-1328 (2006); Adamczyk et al., *Bioorg. Med. Chem. Lett.* 4: 2313-2317 (2004); Adamczyk et al., *Bioorg. Med. Chem. Lett.* 14: 3917-3921 (2004); and Adamczyk et al., *Org. Lett.* 5: 3779-3782 (2003)).

A preferred acridinium compound is an acridinium-9-carboxamide. Methods for preparing acridinium 9-carboxamides are described in Mattingly, *J. Biolumin. Chemilumin.* 6: 107-114 (1991); Adamczyk et al., *J. Org. Chem.* 63: 5636-5639 (1998); Adamczyk et al., *Tetrahedron* 55: 10899-10914 (1999); Adamczyk et al., *Org. Lett.* 1: 779-781 (1999); Adamczyk et al., *Bioconjugate Chem.* 11: 714-724 (2000); Mattingly et al., In *Luminescence Biotechnology: Instruments and Applications*; Dyke, K. V. Ed.; CRC Press: Boca Raton, pp. 77-105 (2002); Adamczyk et al., *Org. Lett.* 5: 3779-3782 (2003); and U.S. Pat. Nos. 5,468,646, 5,543,524 and 5,783,699 (each of which is incorporated herein by reference in its entirety for its teachings regarding same). Another preferred acridinium compound is an acridinium-9-carboxylate aryl ester. An example of an acridinium-9-carboxylate aryl ester is 10-methyl-9-(phenoxyacetyl)acridinium fluorosulfonate (available from Cayman Chemical, Ann Arbor, MI). Methods for preparing acridinium 9-carboxylate aryl esters are described in McCapra et al., *Photochem. Photobiol.* 4: 1111-21 (1965); Razavi et al., *Luminescence* 15: 245-249 (2000); Razavi et al., *Luminescence* 15: 239-244 (2000); and U.S. Patent No. 5,241,070 (each of which is incorporated herein by reference in its entirety for its teachings regarding same). Further details regarding acridinium-9-carboxylate aryl ester and its use are set forth in US 2008-0248493.

Chemiluminescent assays (e.g., using acridinium as described above or other chemiluminescent agents) can be performed in accordance with the methods described in Adamczyk et al., *Anal. Chim. Acta* 579(1): 61-67 (2006). While any suitable assay format can be used, a microplate chemiluminometer (Mithras LB-940, Berthold Technologies U.S.A., LLC, Oak Ridge, TN) enables the assay of multiple samples of small volumes rapidly.

The order in which the test sample and the specific binding partner(s) are added to form the mixture for chemiluminescent assay is not critical. If the first specific binding partner is detectably labeled with a chemiluminescent agent such as an acridinium compound, detectably labeled first specific binding partner-analyte complexes form. Alternatively, if a second specific binding partner is used and the second specific binding partner is detectably labeled with a chemiluminescent agent such as an acridinium compound, detectably labeled first specific binding partner-analyte-second specific binding partner complexes form. Any unbound specific binding partner, whether labeled or unlabeled, can be removed from the mixture using any technique known in the art, such as washing.

Hydrogen peroxide can be generated *in situ* in the mixture or provided or supplied to the mixture (e.g., the source of the hydrogen peroxide being one or more buffers or other solutions

that are known to contain hydrogen peroxide) before, simultaneously with, or after the addition of an above-described acridinium compound. Hydrogen peroxide can be generated *in situ* in a number of ways such as would be apparent to one skilled in the art.

Upon the simultaneous or subsequent addition of at least one basic solution to the sample, a detectable signal, namely, a chemiluminescent signal, indicative of the presence of analyte is generated. The basic solution contains at least one base and has a pH greater than or equal to 10, preferably, greater than or equal to 12. Examples of basic solutions include, but are not limited to, sodium hydroxide, potassium hydroxide, calcium hydroxide, ammonium hydroxide, magnesium hydroxide, sodium carbonate, sodium bicarbonate, calcium hydroxide, calcium carbonate, and calcium bicarbonate. The amount of basic solution added to the sample depends on the concentration of the basic solution. Based on the concentration of the basic solution used, one skilled in the art can easily determine the amount of basic solution to add to the sample.

The chemiluminescent signal that is generated can be detected using routine techniques known to those skilled in the art. Based on the intensity of the signal generated, the amount of analyte in the sample can be quantified. Specifically, the amount of analyte in the sample is proportional to the intensity of the signal generated. The amount of analyte present can be quantified by comparing the amount of light generated to a standard curve for analyte or by comparison to a reference standard. The standard curve can be generated using serial dilutions or solutions of known concentrations of analyte by mass spectroscopy, gravimetric methods, and other techniques known in the art. While the above is described with emphasis on use of an acridinium compound as the chemiluminescent agent, one of ordinary skill in the art can readily adapt this description for use of other chemiluminescent agents.

Analyte immunoassays generally can be conducted using any format known in the art, such as, but not limited to, a sandwich format. Specifically, in one immunoassay format, at least two antibodies are employed to separate and quantify analyte, such as human analyte, or a fragment thereof in a sample. More specifically, the at least two antibodies bind to different epitopes on an analyte (or a fragment thereof) forming an immune complex, which is referred to as a "sandwich." Generally, in the immunoassays one or more antibodies can be used to capture the analyte (or a fragment thereof) in the test sample (these antibodies are frequently referred to as a "capture" antibody or "capture" antibodies) and one or more antibodies can be used to bind a detectable (namely, quantifiable) label to the sandwich (these antibodies are frequently referred to as the "detection antibody," the "detection antibodies," the "conjugate," or the "conjugates"). Thus, in the context of a sandwich immunoassay format, a DVD-Ig (or a fragment, a variant, or a fragment of a variant thereof) as described herein can be used as a capture antibody, a detection antibody, or both. For example, one DVD-Ig having a domain that can bind a first epitope on an analyte (or a fragment thereof) can be used as a capture antibody and/or another DVD-Ig having a

domain that can bind a second epitope on an analyte (or a fragment thereof) can be used as a detection antibody. In this regard, a DVD-Ig having a first domain that can bind a first epitope on an analyte (or a fragment thereof) and a second domain that can bind a second epitope on an analyte (or a fragment thereof) can be used as a capture antibody and/or a detection antibody.

5 Alternatively, one DVD-Ig having a first domain that can bind an epitope on a first analyte (or a fragment thereof) and a second domain that can bind an epitope on a second analyte (or a fragment thereof) can be used as a capture antibody and/or a detection antibody to detect, and optionally quantify, two or more analytes. In the event that an analyte can be present in a sample in more than one form, such as a monomeric form and a dimeric/multimeric form, which can be

10 homomeric or heteromeric, one DVD-Ig having a domain that can bind an epitope that is only exposed on the monomeric form and another DVD-Ig having a domain that can bind an epitope on a different part of a dimeric/multimeric form can be used as capture antibodies and/or detection antibodies, thereby enabling the detection, and optional quantification, of different forms of a given analyte. Furthermore, employing DVD-Igs with differential affinities within a single DVD-

15 Ig and/or between DVD-Igs can provide an avidity advantage. In the context of immunoassays as described herein, it generally may be helpful or desired to incorporate one or more linkers within the structure of a DVD-Ig. When present, optimally the linker should be of sufficient length and structural flexibility to enable binding of an epitope by the inner domains as well as binding of another epitope by the outer domains. In this regard, if a DVD-Ig can bind two different analytes

20 and one analyte is larger than the other, desirably the larger analyte is bound by the outer domains.

Generally speaking, a sample being tested for (for example, suspected of containing) analyte (or a fragment thereof) can be contacted with at least one capture antibody (or antibodies) and at least one detection antibody (which can be a second detection antibody or a third detection

25 antibody or even a successively numbered antibody, e.g., as where the capture and/or detection antibody comprise multiple antibodies) either simultaneously or sequentially and in any order. For example, the test sample can be first contacted with at least one capture antibody and then (sequentially) with at least one detection antibody. Alternatively, the test sample can be first contacted with at least one detection antibody and then (sequentially) with at least one capture

30 antibody. In yet another alternative, the test sample can be contacted simultaneously with a capture antibody and a detection antibody.

In the sandwich assay format, a sample suspected of containing analyte (or a fragment thereof) is first brought into contact with at least one first capture antibody under conditions that allow the formation of a first antibody/analyte complex. If more than one capture antibody is

35 used, a first capture antibody/analyte complex comprising two or more capture antibodies is formed. In a sandwich assay, the antibodies, i.e., preferably, the at least one capture antibody, are

used in molar excess amounts of the maximum amount of analyte (or a fragment thereof) expected in the test sample. For example, from about 5 μg to about 1 mg of antibody per mL of buffer (e.g., microparticle coating buffer) can be used.

Competitive inhibition immunoassays, which are often used to measure small analytes because binding by only one antibody is required, comprise sequential and classic formats. In a sequential competitive inhibition immunoassay a capture antibody to an analyte of interest is coated onto a well of a microtiter plate or other solid support. When the sample containing the analyte of interest is added to the well, the analyte of interest binds to the capture antibody. After washing, a known amount of labeled (e.g., biotin or horseradish peroxidase (HRP)) analyte is added to the well. A substrate for an enzymatic label is necessary to generate a signal. An example of a suitable substrate for HRP is 3,3',5,5'-tetramethylbenzidine (TMB). After washing, the signal generated by the labeled analyte is measured and is inversely proportional to the amount of analyte in the sample. In a classic competitive inhibition immunoassay an antibody to an analyte of interest is coated onto a solid support (e.g., a well of a microtiter plate). However, unlike the sequential competitive inhibition immunoassay, the sample and the labeled analyte are added to the well at the same time. Any analyte in the sample competes with labeled analyte for binding to the capture antibody. After washing, the signal generated by the labeled analyte is measured and is inversely proportional to the amount of analyte in the sample.

Optionally, prior to contacting the test sample with the at least one capture antibody (for example, the first capture antibody), the at least one capture antibody can be bound to a solid support, which facilitates the separation of the first antibody/analyte (or a fragment thereof) complex from the test sample. The substrate to which the capture antibody is bound can be any suitable solid support or solid phase that facilitates separation of the capture antibody-analyte complex from the sample.

Examples include a well of a plate, such as a microtiter plate, a test tube, a porous gel (e.g., silica gel, agarose, dextran, or gelatin), a polymeric film (e.g., polyacrylamide), beads (e.g., polystyrene beads or magnetic beads), a strip of a filter/membrane (e.g., nitrocellulose or nylon), microparticles (e.g., latex particles, magnetizable microparticles (e.g., microparticles having ferric oxide or chromium oxide cores and homo- or hetero-polymeric coats and radii of about 1-10 microns). The substrate can comprise a suitable porous material with a suitable surface affinity to bind antigens and sufficient porosity to allow access by detection antibodies. A microporous material is generally preferred, although a gelatinous material in a hydrated state can be used. Such porous substrates are preferably in the form of sheets having a thickness of about 0.01 to about 0.5 mm, preferably about 0.1 mm. While the pore size may vary quite a bit, preferably the pore size is from about 0.025 to about 15 microns, more preferably from about 0.15 to about 15 microns. The surface of such substrates can be activated by chemical processes that cause

covalent linkage of an antibody to the substrate. Irreversible binding, generally by adsorption through hydrophobic forces, of the antigen or the antibody to the substrate results; alternatively, a chemical coupling agent or other means can be used to bind covalently the antibody to the substrate, provided that such binding does not interfere with the ability of the antibody to bind to
5 analyte. Alternatively, the antibody can be bound with microparticles, which have been previously coated with streptavidin (e.g., DYNAL® Magnetic Beads, Invitrogen, Carlsbad, CA) or biotin (e.g., using Power-Bind™-SA-MP streptavidin-coated microparticles (Seradyn, Indianapolis, IN)) or anti-species-specific monoclonal antibodies. If necessary, the substrate can be derivatized to allow reactivity with various functional groups on the antibody. Such
10 derivatization requires the use of certain coupling agents, examples of which include, but are not limited to, maleic anhydride, N-hydroxysuccinimide, and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide. If desired, one or more capture reagents, such as antibodies (or fragments thereof), each of which is specific for analyte(s) can be attached to solid phases in different physical or addressable locations (e.g., such as in a biochip configuration (see, e.g., U.S. Pat. No. 6,225,047;
15 Int'l Pat. App. Pub. No. WO 99/51773; U.S. Pat. No. 6,329,209; Int'l Pat. App. Pub. No. WO 00/56934, and U.S. Pat. No. 5,242,828). If the capture reagent is attached to a mass spectrometry probe as the solid support, the amount of analyte bound to the probe can be detected by laser desorption ionization mass spectrometry. Alternatively, a single column can be packed with different beads, which are derivatized with the one or more capture reagents, thereby capturing
20 the analyte in a single place (see, antibody-derivatized, bead-based technologies, e.g., the xMAP technology of Luminex (Austin, TX)).

After the test sample being assayed for analyte (or a fragment thereof) is brought into contact with the at least one capture antibody (for example, the first capture antibody), the mixture is incubated in order to allow for the formation of a first antibody (or multiple antibody)-analyte
25 (or a fragment thereof) complex. The incubation can be carried out at a pH of from about 4.5 to about 10.0, at a temperature of from about 2°C to about 45°C, and for a period from at least about one (1) minute to about eighteen (18) hours, preferably from about 1 to about 24 minutes, most preferably for about 4 to about 18 minutes. The immunoassay described herein can be conducted in one step (meaning the test sample, at least one capture antibody and at
30 least one detection antibody are all added sequentially or simultaneously to a reaction vessel) or in more than one step, such as two steps, three steps, etc.

After formation of the (first or multiple) capture antibody/analyte (or a fragment thereof) complex, the complex is then contacted with at least one detection antibody under conditions which allow for the formation of a (first or multiple) capture antibody/analyte (or a fragment
35 thereof)/second detection antibody complex). While captioned for clarity as the "second" antibody (e.g., second detection antibody), in fact, where multiple antibodies are used for capture and/or detection, the at least one detection antibody can be the second, third, fourth, etc.

antibodies used in the immunoassay. If the capture antibody/analyte (or a fragment thereof) complex is contacted with more than one detection antibody, then a (first or multiple) capture antibody/analyte (or a fragment thereof)/(multiple) detection antibody complex is formed. As with the capture antibody (e.g., the first capture antibody), when the at least one (e.g., second and
5 any subsequent) detection antibody is brought into contact with the capture antibody/analyte (or a fragment thereof) complex, a period of incubation under conditions similar to those described above is required for the formation of the (first or multiple) capture antibody/analyte (or a fragment thereof)/(second or multiple) detection antibody complex. Preferably, at least one detection antibody contains a detectable label. The detectable label can be bound to the at least
10 one detection antibody (e.g., the second detection antibody) prior to, simultaneously with, or after the formation of the (first or multiple) capture antibody/analyte (or a fragment thereof)/(second or multiple) detection antibody complex. Any detectable label known in the art can be used (see discussion above, including of the Polak and Van Noorden (1997) and Haugland (1996) references).

15 The detectable label can be bound to the antibodies either directly or through a coupling agent. An example of a coupling agent that can be used is EDAC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide, hydrochloride), which is commercially available from Sigma-Aldrich, St. Louis, MO. Other coupling agents that can be used are known in the art. Methods for binding a detectable label to an antibody are known in the art. Additionally, many
20 detectable labels can be purchased or synthesized that already contain end groups that facilitate the coupling of the detectable label to the antibody, such as CPSP-Acridium Ester (i.e., 9-[N-tosyl-N-(3-carboxypropyl)]-10-(3-sulfopropyl)acridinium carboxamide) or SPSP-Acridium Ester (i.e., N10-(3-sulfopropyl)-N-(3-sulfopropyl)-acridinium-9-carboxamide).

The (first or multiple) capture antibody/analyte/(second or multiple) detection antibody
25 complex can be, but does not have to be, separated from the remainder of the test sample prior to quantification of the label. For example, if the at least one capture antibody (e.g., the first capture antibody) is bound to a solid support, such as a well or a bead, separation can be accomplished by removing the fluid (of the test sample) from contact with the solid support. Alternatively, if the at least first capture antibody is bound to a solid support, it can be simultaneously contacted with the
30 analyte-containing sample and the at least one second detection antibody to form a first (multiple) antibody/analyte/second (multiple) antibody complex, followed by removal of the fluid (test sample) from contact with the solid support. If the at least one first capture antibody is not bound to a solid support, then the (first or multiple) capture antibody/analyte/(second or multiple) detection antibody complex does not have to be removed from the test sample for quantification
35 of the amount of the label.

After formation of the labeled capture antibody/analyte/detection antibody complex (e.g., the first capture antibody/analyte/second detection antibody complex), the amount of label in the complex is quantified using techniques known in the art. For example, if an enzymatic label is used, the labeled complex is reacted with a substrate for the label that gives a quantifiable reaction
5 such as the development of color. If the label is a radioactive label, the label is quantified using appropriate means, such as a scintillation counter. If the label is a fluorescent label, the label is quantified by stimulating the label with a light of one color (which is known as the “excitation wavelength”) and detecting another color (which is known as the “emission wavelength”) that is emitted by the label in response to the stimulation. If the label is a chemiluminescent label, the
10 label is quantified by detecting the light emitted either visually or by using luminometers, x-ray film, high speed photographic film, a CCD camera, etc. Once the amount of the label in the complex has been quantified, the concentration of analyte or a fragment thereof in the test sample is determined by appropriate means, such as by use of a standard curve that has been generated using serial dilutions of analyte or a fragment thereof of known concentration. Other than using
15 serial dilutions of analyte or a fragment thereof, the standard curve can be generated gravimetrically, by mass spectroscopy and by other techniques known in the art.

In a chemiluminescent microparticle assay employing the ARCHITECT® analyzer, the conjugate diluent pH should be about 6.0 +/- 0.2, the microparticle coating buffer should be maintained at about room temperature (i.e., at from about 17 to about 27 °C), the microparticle
20 coating buffer pH should be about 6.5 +/- 0.2, and the microparticle diluent pH should be about 7.8 +/- 0.2. Solids preferably are less than about 0.2%, such as less than about 0.15%, less than about 0.14%, less than about 0.13%, less than about 0.12%, or less than about 0.11%, such as about 0.10%.

FPIAs are based on competitive binding immunoassay principles. A fluorescently labeled
25 compound, when excited by a linearly polarized light, will emit fluorescence having a degree of polarization inversely proportional to its rate of rotation. When a fluorescently labeled tracer-antibody complex is excited by a linearly polarized light, the emitted light remains highly polarized because the fluorophore is constrained from rotating between the time light is absorbed and the time light is emitted. When a “free” tracer compound (i.e., a compound that is not bound
30 to an antibody) is excited by linearly polarized light, its rotation is much faster than the corresponding tracer-antibody conjugate produced in a competitive binding immunoassay. FPIAs are advantageous over RIAs inasmuch as there are no radioactive substances requiring special handling and disposal. In addition, FPIAs are homogeneous assays that can be easily and rapidly performed.

35 In view of the above, a method of determining the presence, amount, or concentration of analyte (or a fragment thereof) in a test sample is provided. The method comprises assaying the test sample for an analyte (or a fragment thereof) by an assay (i) employing (i') at least one of an

antibody, a fragment of an antibody that can bind to an analyte, a variant of an antibody that can bind to an analyte, a fragment of a variant of an antibody that can bind to an analyte, and a DVD-Ig (or a fragment, a variant, or a fragment of a variant thereof) that can bind to an analyte, and (ii') at least one detectable label and (ii) comprising comparing a signal generated by the detectable label as a direct or indirect indication of the presence, amount or concentration of analyte (or a fragment thereof) in the test sample to a signal generated as a direct or indirect indication of the presence, amount or concentration of analyte (or a fragment thereof) in a control or calibrator. The calibrator is optionally part of a series of calibrators, in which each of the calibrators differs from the other calibrators by the concentration of analyte.

10 The method can comprise (i) contacting the test sample with at least one first specific binding partner for analyte (or a fragment thereof) selected from the group consisting of an antibody, a fragment of an antibody that can bind to an analyte, a variant of an antibody that can bind to an analyte, a fragment of a variant of an antibody that can bind to an analyte, and a DVD-Ig (or a fragment, a variant, or a fragment of a variant thereof) that can bind to an analyte so as to form a first specific binding partner/analyte (or fragment thereof) complex, (ii) contacting the first specific binding partner/analyte (or fragment thereof) complex with at least one second specific binding partner for analyte (or fragment thereof) selected from the group consisting of a detectably labeled anti-analyte antibody, a detectably labeled fragment of an anti-analyte antibody that can bind to analyte, a detectably labeled variant of an anti-analyte antibody that can bind to analyte, a detectably labeled fragment of a variant of an anti-analyte antibody that can bind to analyte, and a detectably labeled DVD-Ig (or a fragment, a variant, or a fragment of a variant thereof) so as to form a first specific binding partner/analyte (or fragment thereof)/second specific binding partner complex, and (iii) determining the presence, amount or concentration of analyte in the test sample by detecting or measuring the signal generated by the detectable label in the first specific binding partner/analyte (or fragment thereof)/second specific binding partner complex formed in (ii). A method in which at least one first specific binding partner for analyte (or a fragment thereof) and/or at least one second specific binding partner for analyte (or a fragment thereof) is a DVD-Ig (or a fragment, a variant, or a fragment of a variant thereof) as described herein can be preferred.

30 Alternatively, the method can comprise contacting the test sample with at least one first specific binding partner for analyte (or a fragment thereof) selected from the group consisting of an antibody, a fragment of an antibody that can bind to an analyte, a variant of an antibody that can bind to an analyte, a fragment of a variant of an antibody that can bind to an analyte, and a DVD-Ig (or a fragment, a variant, or a fragment of a variant thereof) and simultaneously or sequentially, in either order, contacting the test sample with at least one second specific binding partner, which can compete with analyte (or a fragment thereof) for binding to the at least one first specific binding partner and which is selected from the group consisting of a detectably

labeled analyte, a detectably labeled fragment of analyte that can bind to the first specific binding partner, a detectably labeled variant of analyte that can bind to the first specific binding partner, and a detectably labeled fragment of a variant of analyte that can bind to the first specific binding partner. Any analyte (or a fragment thereof) present in the test sample and the at least one second
5 specific binding partner compete with each other to form a first specific binding partner/analyte (or fragment thereof) complex and a first specific binding partner/second specific binding partner complex, respectively. The method further comprises determining the presence, amount or concentration of analyte in the test sample by detecting or measuring the signal generated by the detectable label in the first specific binding partner/second specific binding partner complex
10 formed in (ii), wherein the signal generated by the detectable label in the first specific binding partner/second specific binding partner complex is inversely proportional to the amount or concentration of analyte in the test sample.

The above methods can further comprise diagnosing, prognosticating, or assessing the efficacy of a therapeutic/prophylactic treatment of a patient from whom the test sample was
15 obtained. If the method further comprises assessing the efficacy of a therapeutic/prophylactic treatment of the patient from whom the test sample was obtained, the method optionally further comprises modifying the therapeutic/prophylactic treatment of the patient as needed to improve efficacy. The method can be adapted for use in an automated system or a semi-automated system.

With regard to the methods of assay (and kit therefor), it may be possible to employ
20 commercially available anti-analyte antibodies or methods for production of anti-analyte as described in the literature. Commercial supplies of various antibodies include, but are not limited to, Santa Cruz Biotechnology Inc. (Santa Cruz, CA), GenWay Biotech, Inc. (San Diego, CA), and R&D Systems (RDS; Minneapolis, MN).

Generally, a predetermined level can be employed as a benchmark against which to assess
25 results obtained upon assaying a test sample for analyte or a fragment thereof, e.g., for detecting disease or risk of disease. Generally, in making such a comparison, the predetermined level is obtained by running a particular assay a sufficient number of times and under appropriate conditions such that a linkage or association of analyte presence, amount or concentration with a particular stage or endpoint of a disease, disorder or condition or with particular clinical indicia
30 can be made. Typically, the predetermined level is obtained with assays of reference subjects (or populations of subjects). The analyte measured can include fragments thereof, degradation products thereof, and/or enzymatic cleavage products thereof.

In particular, with respect to a predetermined level as employed for monitoring disease
35 progression and/or treatment, the amount or concentration of analyte or a fragment thereof may be “unchanged,” “favorable” (or “favorably altered”), or “unfavorable” (or “unfavorably altered”). “Elevated” or “increased” refers to an amount or a concentration in a test sample that is higher

than a typical or normal level or range (e.g., predetermined level), or is higher than another reference level or range (e.g., earlier or baseline sample). The term “lowered” or “reduced” refers to an amount or a concentration in a test sample that is lower than a typical or normal level or range (e.g., predetermined level), or is lower than another reference level or range (e.g., earlier or baseline sample). The term “altered” refers to an amount or a concentration in a sample that is altered (increased or decreased) over a typical or normal level or range (e.g., predetermined level), or over another reference level or range (e.g., earlier or baseline sample).

The typical or normal level or range for analyte is defined in accordance with standard practice. Because the levels of analyte in some instances will be very low, a so-called altered level or alteration can be considered to have occurred when there is any net change as compared to the typical or normal level or range, or reference level or range, that cannot be explained by experimental error or sample variation. Thus, the level measured in a particular sample will be compared with the level or range of levels determined in similar samples from a so-called normal subject. In this context, a “normal subject” is an individual with no detectable disease, for example, and a “normal” (sometimes termed “control”) patient or population is/are one(s) that exhibit(s) no detectable disease, respectively, for example. Furthermore, given that analyte is not routinely found at a high level in the majority of the human population, a “normal subject” can be considered an individual with no substantial detectable increased or elevated amount or concentration of analyte, and a “normal” (sometimes termed “control”) patient or population is/are one(s) that exhibit(s) no substantial detectable increased or elevated amount or concentration of analyte. An “apparently normal subject” is one in which analyte has not yet been or currently is being assessed. The level of an analyte is said to be “elevated” when the analyte is normally undetectable (e.g., the normal level is zero, or within a range of from about 25 to about 75 percentiles of normal populations), but is detected in a test sample, as well as when the analyte is present in the test sample at a higher than normal level. Thus, *inter alia*, the disclosure provides a method of screening for a subject having, or at risk of having, a particular disease, disorder, or condition. The method of assay can also involve the assay of other markers and the like.

Accordingly, the methods described herein also can be used to determine whether or not a subject has or is at risk of developing a given disease, disorder or condition. Specifically, such a method can comprise the steps of:

- (a) determining the concentration or amount in a test sample from a subject of analyte (or a fragment thereof) (e.g., using the methods described herein, or methods known in the art); and
- (b) comparing the concentration or amount of analyte (or a fragment thereof) determined in step (a) with a predetermined level, wherein, if the concentration or amount of analyte determined in step (a) is favorable with respect to a predetermined level, then the subject is

determined not to have or be at risk for a given disease, disorder or condition. However, if the concentration or amount of analyte determined in step (a) is unfavorable with respect to the predetermined level, then the subject is determined to have or be at risk for a given disease, disorder or condition.

5 Additionally, provided herein is method of monitoring the progression of disease in a subject. Optimally the method comprising the steps of:

(a) determining the concentration or amount in a test sample from a subject of analyte;

(b) determining the concentration or amount in a later test sample from the subject of analyte; and

10 (c) comparing the concentration or amount of analyte as determined in step (b) with the concentration or amount of analyte determined in step (a), wherein if the concentration or amount determined in step (b) is unchanged or is unfavorable when compared to the concentration or amount of analyte determined in step (a), then the disease in the subject is determined to have continued, progressed or worsened. By comparison, if the concentration or amount of analyte as
15 determined in step (b) is favorable when compared to the concentration or amount of analyte as determined in step (a), then the disease in the subject is determined to have discontinued, regressed or improved.

 Optionally, the method further comprises comparing the concentration or amount of analyte as determined in step (b), for example, with a predetermined level. Further, optionally the
20 method comprises treating the subject with one or more pharmaceutical compositions for a period of time if the comparison shows that the concentration or amount of analyte as determined in step (b), for example, is unfavorably altered with respect to the predetermined level.

 Still further, the methods can be used to monitor treatment in a subject receiving treatment with one or more pharmaceutical compositions. Specifically, such methods involve
25 providing a first test sample from a subject before the subject has been administered one or more pharmaceutical compositions. Next, the concentration or amount in a first test sample from a subject of analyte is determined (e.g., using the methods described herein or as known in the art). After the concentration or amount of analyte is determined, optionally the concentration or amount of analyte is then compared with a predetermined level. If the concentration or amount of
30 analyte as determined in the first test sample is lower than the predetermined level, then the subject is not treated with one or more pharmaceutical compositions. However, if the concentration or amount of analyte as determined in the first test sample is higher than the predetermined level, then the subject is treated with one or more pharmaceutical compositions for a period of time. The period of time that the subject is treated with the one or more
35 pharmaceutical compositions can be determined by one skilled in the art (for example, the period of time can be from about seven (7) days to about two years, preferably from about fourteen (14) days to about one (1) year).

During the course of treatment with the one or more pharmaceutical compositions, second and subsequent test samples are then obtained from the subject. The number of test samples and the time in which said test samples are obtained from the subject are not critical. For example, a second test sample could be obtained seven (7) days after the subject is first administered the one or more pharmaceutical compositions, a third test sample could be obtained two (2) weeks after the subject is first administered the one or more pharmaceutical compositions, a fourth test sample could be obtained three (3) weeks after the subject is first administered the one or more pharmaceutical compositions, a fifth test sample could be obtained four (4) weeks after the subject is first administered the one or more pharmaceutical compositions, etc.

After each second or subsequent test sample is obtained from the subject, the concentration or amount of analyte is determined in the second or subsequent test sample is determined (e.g., using the methods described herein or as known in the art). The concentration or amount of analyte as determined in each of the second and subsequent test samples is then compared with the concentration or amount of analyte as determined in the first test sample (e.g., the test sample that was originally optionally compared to the predetermined level). If the concentration or amount of analyte as determined in step (c) is favorable when compared to the concentration or amount of analyte as determined in step (a), then the disease in the subject is determined to have discontinued, regressed or improved, and the subject should continue to be administered the one or pharmaceutical compositions of step (b). However, if the concentration or amount determined in step (c) is unchanged or is unfavorable when compared to the concentration or amount of analyte as determined in step (a), then the disease in the subject is determined to have continued, progressed or worsened, and the subject should be treated with a higher concentration of the one or more pharmaceutical compositions administered to the subject in step (b) or the subject should be treated with one or more pharmaceutical compositions that are different from the one or more pharmaceutical compositions administered to the subject in step (b). Specifically, the subject can be treated with one or more pharmaceutical compositions that are different from the one or more pharmaceutical compositions that the subject had previously received to decrease or lower said subject's analyte level.

Generally, for assays in which repeat testing may be done (e.g., monitoring disease progression and/or response to treatment), a second or subsequent test sample is obtained at a period in time after the first test sample has been obtained from the subject. Specifically, a second test sample from the subject can be obtained minutes, hours, days, weeks or years after the first test sample has been obtained from the subject. For example, the second test sample can be obtained from the subject at a time period of about 1 minute, about 5 minutes, about 10 minutes, about 15 minutes, about 30 minutes, about 45 minutes, about 60 minutes, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours,

about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 17 weeks, about 18 weeks, about 19 weeks, about 20 weeks, about 21 weeks, about 22 weeks, about 23 weeks, about 24 weeks, about 25 weeks, about 26 weeks, about 27 weeks, about 28 weeks, about 29 weeks, about 30 weeks, about 31 weeks, about 32 weeks, about 33 weeks, about 34 weeks, about 35 weeks, about 36 weeks, about 37 weeks, about 38 weeks, about 39 weeks, about 40 weeks, about 41 weeks, about 42 weeks, about 43 weeks, about 44 weeks, about 45 weeks, about 46 weeks, about 47 weeks, about 48 weeks, about 49 weeks, about 50 weeks, about 51 weeks, about 52 weeks, about 1.5 years, about 2 years, about 2.5 years, about 3.0 years, about 3.5 years, about 4.0 years, about 4.5 years, about 5.0 years, about 5.5 years, about 6.0 years, about 6.5 years, about 7.0 years, about 7.5 years, about 8.0 years, about 8.5 years, about 9.0 years, about 9.5 years or about 10.0 years after the first test sample from the subject is obtained.

When used to monitor disease progression, the above assay can be used to monitor the progression of disease in subjects suffering from acute conditions. Acute conditions, also known as critical care conditions, refer to acute, life-threatening diseases or other critical medical conditions involving, for example, the cardiovascular system or excretory system. Typically, critical care conditions refer to those conditions requiring acute medical intervention in a hospital-based setting (including, but not limited to, the emergency room, intensive care unit, trauma center, or other emergent care setting) or administration by a paramedic or other field-based medical personnel. For critical care conditions, repeat monitoring is generally done within a shorter time frame, namely, minutes, hours or days (e.g., about 1 minute, about 5 minutes, about 10 minutes, about 15 minutes, about 30 minutes, about 45 minutes, about 60 minutes, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days or about 7 days), and the initial assay likewise is generally done within a shorter timeframe, e.g., about minutes, hours or days of the onset of the disease or condition.

The assays also can be used to monitor the progression of disease in subjects suffering from chronic or non-acute conditions. Non-critical care or, non-acute conditions, refers to conditions other than acute, life-threatening disease or other critical medical conditions involving, for example, the cardiovascular system and/or excretory system. Typically, non-acute conditions

include those of longer-term or chronic duration. For non-acute conditions, repeat monitoring generally is done with a longer timeframe, e.g., hours, days, weeks, months or years (e.g., about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 17 weeks, about 18 weeks, about 19 weeks, about 20 weeks, about 21 weeks, about 22 weeks, about 23 weeks, about 24 weeks, about 25 weeks, about 26 weeks, about 27 weeks, about 28 weeks, about 29 weeks, about 30 weeks, about 31 weeks, about 32 weeks, about 33 weeks, about 34 weeks, about 35 weeks, about 36 weeks, about 37 weeks, about 38 weeks, about 39 weeks, about 40 weeks, about 41 weeks, about 42 weeks, about 43 weeks, about 44 weeks, about 45 weeks, about 46 weeks, about 47 weeks, about 48 weeks, about 49 weeks, about 50 weeks, about 51 weeks, about 52 weeks, about 1.5 years, about 2 years, about 2.5 years, about 3.0 years, about 3.5 years, about 4.0 years, about 4.5 years, about 5.0 years, about 5.5 years, about 6.0 years, about 6.5 years, about 7.0 years, about 7.5 years, about 8.0 years, about 8.5 years, about 9.0 years, about 9.5 years or about 10.0 years), and the initial assay likewise generally is done within a longer time frame, e.g., about hours, days, months or years of the onset of the disease or condition.

Furthermore, the above assays can be performed using a first test sample obtained from a subject where the first test sample is obtained from one source, such as urine, serum or plasma. Optionally, the above assays can then be repeated using a second test sample obtained from the subject where the second test sample is obtained from another source. For example, if the first test sample was obtained from urine, the second test sample can be obtained from serum or plasma. The results obtained from the assays using the first test sample and the second test sample can be compared. The comparison can be used to assess the status of a disease or condition in the subject.

Moreover, the present disclosure also relates to methods of determining whether a subject predisposed to or suffering from a given disease, disorder or condition will benefit from treatment. In particular, the disclosure relates to analyte companion diagnostic methods and products. Thus, the method of "monitoring the treatment of disease in a subject" as described herein further optimally also can encompass selecting or identifying candidates for therapy.

Thus, in particular embodiments, the disclosure also provides a method of determining whether a subject having, or at risk for, a given disease, disorder or condition is a candidate for

therapy. Generally, the subject is one who has experienced some symptom of a given disease, disorder or condition or who has actually been diagnosed as having, or being at risk for, a given disease, disorder or condition, and/or who demonstrates an unfavorable concentration or amount of analyte or a fragment thereof, as described herein.

5 The method optionally comprises an assay as described herein, where analyte is assessed before and following treatment of a subject with one or more pharmaceutical compositions (e.g., particularly with a pharmaceutical related to a mechanism of action involving analyte), with immunosuppressive therapy, or by immunoabsorption therapy, or where analyte is assessed following such treatment and the concentration or the amount of analyte is compared against a
10 predetermined level. An unfavorable concentration or amount of analyte observed following treatment confirms that the subject will not benefit from receiving further or continued treatment, whereas a favorable concentration or amount of analyte observed following treatment confirms that the subject will benefit from receiving further or continued treatment. This confirmation assists with management of clinical studies, and provision of improved patient care.

15 It goes without saying that, while certain embodiments herein are advantageous when employed to assess a given disease, disorder or condition as discussed herein, the assays and kits can be employed to assess analyte in other diseases, disorders and conditions. The method of assay can also involve the assay of other markers and the like.

 The method of assay also can be used to identify a compound that ameliorates a given
20 disease, disorder or condition. For example, a cell that expresses analyte can be contacted with a candidate compound. The level of expression of analyte in the cell contacted with the compound can be compared to that in a control cell using the method of assay described herein.

II. Kit

25 A kit for assaying a test sample for the presence, amount or concentration of an analyte (or a fragment thereof) in a test sample is also provided. The kit comprises at least one component for assaying the test sample for the analyte (or a fragment thereof) and instructions for assaying the test sample for the analyte (or a fragment thereof). The at least one component for assaying the test sample for the analyte (or a fragment thereof) can include a composition
30 comprising an anti-analyte DVD-Ig (or a fragment, a variant, or a fragment of a variant thereof), which is optionally immobilized on a solid phase.

 The kit can comprise at least one component for assaying the test sample for an analyte by immunoassay, e.g., chemiluminescent microparticle immunoassay, and instructions for assaying the test sample for an analyte by immunoassay, e.g., chemiluminescent microparticle
35 immunoassay. For example, the kit can comprise at least one specific binding partner for an analyte, such as an anti-analyte, monoclonal/polyclonal antibody (or a fragment thereof that can bind to the analyte, a variant thereof that can bind to the analyte, or a fragment of a variant that

can bind to the analyte) or an anti-analyte DVD-Ig (or a fragment, a variant, or a fragment of a variant thereof), either of which can be detectably labeled. Alternatively or additionally, the kit can comprise detectably labeled analyte (or a fragment thereof that can bind to an anti-analyte, monoclonal/polyclonal antibody or an anti-analyte DVD-Ig (or a fragment, a variant, or a fragment of a variant thereof)), which can compete with any analyte in a test sample for binding to an anti-analyte, monoclonal/polyclonal antibody (or a fragment thereof that can bind to the analyte, a variant thereof that can bind to the analyte, or a fragment of a variant that can bind to the analyte) or an anti-analyte DVD-Ig (or a fragment, a variant, or a fragment of a variant thereof), either of which can be immobilized on a solid support. The kit can comprise a calibrator or control, e.g., isolated or purified analyte. The kit can comprise at least one container (e.g., tube, microtiter plates or strips, which can be already coated with a first specific binding partner, for example) for conducting the assay, and/or a buffer, such as an assay buffer or a wash buffer, either one of which can be provided as a concentrated solution, a substrate solution for the detectable label (e.g., an enzymatic label), or a stop solution. Preferably, the kit comprises all components, i.e., reagents, standards, buffers, diluents, etc., which are necessary to perform the assay. The instructions can be in paper form or computer-readable form, such as a disk, CD, DVD, or the like.

Any antibodies, such as an anti-analyte antibody or an anti-analyte DVD-Ig, or tracer can incorporate a detectable label as described herein, such as a fluorophore, a radioactive moiety, an enzyme, a biotin/avidin label, a chromophore, a chemiluminescent label, or the like, or the kit can include reagents for carrying out detectable labeling. The antibodies, calibrators and/or controls can be provided in separate containers or pre-dispensed into an appropriate assay format, for example, into microtiter plates.

Optionally, the kit includes quality control components (for example, sensitivity panels, calibrators, and positive controls). Preparation of quality control reagents is well-known in the art and is described on insert sheets for a variety of immunodiagnostic products. Sensitivity panel members optionally are used to establish assay performance characteristics, and further optionally are useful indicators of the integrity of the immunoassay kit reagents, and the standardization of assays.

The kit can also optionally include other reagents required to conduct a diagnostic assay or facilitate quality control evaluations, such as buffers, salts, enzymes, enzyme co-factors, enzyme substrates, detection reagents, and the like. Other components, such as buffers and solutions for the isolation and/or treatment of a test sample (e.g., pretreatment reagents), also can be included in the kit. The kit can additionally include one or more other controls. One or more of the components of the kit can be lyophilized, in which case the kit can further comprise reagents suitable for the reconstitution of the lyophilized components.

The various components of the kit optionally are provided in suitable containers as necessary, e.g., a microtiter plate. The kit can further include containers for holding or storing a sample (e.g., a container or cartridge for a urine sample). Where appropriate, the kit optionally also can contain reaction vessels, mixing vessels, and other components that facilitate the preparation of reagents or the test sample. The kit can also include one or more instruments for assisting with obtaining a test sample, such as a syringe, pipette, forceps, measured spoon, or the like.

If the detectable label is at least one acridinium compound, the kit can comprise at least one acridinium-9-carboxamide, at least one acridinium-9-carboxylate aryl ester, or any combination thereof. If the detectable label is at least one acridinium compound, the kit also can comprise a source of hydrogen peroxide, such as a buffer, a solution, and/or at least one basic solution. If desired, the kit can contain a solid phase, such as a magnetic particle, bead, test tube, microtiter plate, cuvette, membrane, scaffolding molecule, film, filter paper, disc or chip.

15 **III. Adaptation of Kit and Method**

The kit (or components thereof), as well as the method of determining the presence, amount or concentration of an analyte in a test sample by an assay, such as an immunoassay as described herein, can be adapted for use in a variety of automated and semi-automated systems (including those wherein the solid phase comprises a microparticle), as described, e.g., in U.S. Patent Nos. 5,089,424 and 5,006,309, and as commercially marketed, e.g., by Abbott Laboratories (Abbott Park, IL) as ARCHITECT®.

Some of the differences between an automated or semi-automated system as compared to a non-automated system (e.g., ELISA) include the substrate to which the first specific binding partner (e.g., an anti-analyte, monoclonal/polyclonal antibody (or a fragment thereof, a variant thereof, or a fragment of a variant thereof) or an anti-analyte DVD-Ig (or a fragment thereof, a variant thereof, or a fragment of a variant thereof) is attached; either way, sandwich formation and analyte reactivity can be impacted), and the length and timing of the capture, detection and/or any optional wash steps. Whereas a non-automated format, such as an ELISA, may require a relatively longer incubation time with sample and capture reagent (e.g., about 2 hours), an automated or semi-automated format (e.g., ARCHITECT®, Abbott Laboratories) may have a relatively shorter incubation time (e.g., approximately 18 minutes for ARCHITECT®). Similarly, whereas a non-automated format, such as an ELISA, may incubate a detection antibody, such as the conjugate reagent, for a relatively longer incubation time (e.g., about 2 hours), an automated or semi-automated format (e.g., ARCHITECT®) may have a relatively shorter incubation time (e.g., approximately 4 minutes for the ARCHITECT®).

Other platforms available from Abbott Laboratories include, but are not limited to, AxSYM®, IMx® (see, e.g., U.S. Pat. No. 5,294,404, which is hereby incorporated by reference in its entirety), PRISM®, EIA (bead), and Quantum™ II, as well as other platforms. Additionally, the assays, kits and kit components can be employed in other formats, for example, on
5 electrochemical or other hand-held or point-of-care assay systems. The present disclosure is, for example, applicable to the commercial Abbott Point of Care (i-STAT®, Abbott Laboratories) electrochemical immunoassay system that performs sandwich immunoassays. Immunosensors and their methods of manufacture and operation in single-use test devices are described, for example in, U.S. Patent No. 5,063,081, U.S. Pat. App. Pub. No. 2003/0170881, U.S. Pat. App.
10 Pub. No. 2004/0018577, U.S. Pat. App. Pub. No. 2005/0054078, and U.S. Pat. App. Pub. No. 2006/0160164, which are incorporated in their entireties by reference for their teachings regarding same.

In particular, with regard to the adaptation of an analyte assay to the I-STAT® system, the following configuration is preferred. A microfabricated silicon chip is manufactured with a
15 pair of gold amperometric working electrodes and a silver-silver chloride reference electrode. On one of the working electrodes, polystyrene beads (0.2 mm diameter) with immobilized anti-analyte, monoclonal/polyclonal antibody (or a fragment thereof, a variant thereof, or a fragment of a variant thereof) or anti-analyte DVD-Ig (or a fragment thereof, a variant thereof, or a fragment of a variant thereof), are adhered to a polymer coating of patterned polyvinyl alcohol
20 over the electrode. This chip is assembled into an I-STAT® cartridge with a fluidics format suitable for immunoassay. On a portion of the wall of the sample-holding chamber of the cartridge there is a layer comprising a specific binding partner for an analyte, such as an anti-analyte, monoclonal/polyclonal antibody (or a fragment thereof, a variant thereof, or a fragment of a variant thereof that can bind the analyte) or an anti-analyte DVD-Ig (or a fragment thereof, a
25 variant thereof, or a fragment of a variant thereof that can bind the analyte), either of which can be detectably labeled. Within the fluid pouch of the cartridge is an aqueous reagent that includes p-aminophenol phosphate.

In operation, a sample suspected of containing an analyte is added to the holding chamber of the test cartridge, and the cartridge is inserted into the I-STAT® reader. After the specific
30 binding partner for an analyte has dissolved into the sample, a pump element within the cartridge forces the sample into a conduit containing the chip. Here it is oscillated to promote formation of the sandwich. In the penultimate step of the assay, fluid is forced out of the pouch and into the conduit to wash the sample off the chip and into a waste chamber. In the final step of the assay, the alkaline phosphatase label reacts with p-aminophenol phosphate to cleave the phosphate group
35 and permit the liberated p-aminophenol to be electrochemically oxidized at the working electrode. Based on the measured current, the reader is able to calculate the amount of analyte in the sample by means of an embedded algorithm and factory-determined calibration curve.

It further goes without saying that the methods and kits as described herein necessarily encompass other reagents and methods for carrying out the immunoassay. For instance, encompassed are various buffers such as are known in the art and/or which can be readily prepared or optimized to be employed, e.g., for washing, as a conjugate diluent, microparticle diluent, and/or as a calibrator diluent. An exemplary conjugate diluent is ARCHITECT® conjugate diluent employed in certain kits (Abbott Laboratories, Abbott Park, IL) and containing 2-(N-morpholino)ethanesulfonic acid (MES), a salt, a protein blocker, an antimicrobial agent, and a detergent. An exemplary calibrator diluent is ARCHITECT® human calibrator diluent employed in certain kits (Abbott Laboratories, Abbott Park, IL), which comprises a buffer containing MES, other salt, a protein blocker, and an antimicrobial agent. Additionally, as described in U.S. Patent Application No. 61/142,048 filed December 31, 2008, improved signal generation may be obtained, e.g., in an I-Stat cartridge format, using a nucleic acid sequence linked to the signal antibody as a signal amplifier.

EXAMPLIFICATION

Example 1: Design, Construction, and Analysis of a DVD-Ig

Example 1.1: Assays Used to Identify and Characterize Parent Antibodies and DVD-Ig

The following assays were used throughout the Examples to identify and characterize parent antibodies and DVD-Ig, unless otherwise stated.

Example 1.1.1: Assays Used To Determine Binding and Affinity of Parent Antibodies and DVD-Ig for Their Target Antigen(s)

Example 1.1.1A: Direct Bind ELISA

Enzyme Linked Immunosorbent Assays to screen for antibodies that bind a desired target antigen were performed as follows. High bind ELISA plates (Corning Costar # 3369, Acton, MA) were coated with 100 μ L/well of 10 μ g/ml of desired target antigen (R&D Systems, Minneapolis, MN) or desired target antigen extra-cellular domain / FC fusion protein (R&D Systems, Minneapolis, MN) or monoclonal mouse anti-polyHistidine antibody (R&D Systems # MAB050, Minneapolis, MN) in phosphate buffered saline (10X PBS, Abbott Bioresearch Center, Media Prep# MPS-073, Worcester, MA) overnight at 4°C. Plates were washed four times with PBS containing 0.02% Tween 20. Plates were blocked by the addition of 300 μ L/well blocking solution (non-fat dry milk powder, various retail suppliers, diluted to 2% in PBS) for 1/2 hour at room temperature. Plates were washed four times after blocking with PBS containing 0.02% Tween 20.

Alternatively, one hundred microliters per well of 10 µg/ml of Histidine (His) tagged desired target antigen (R&D Systems, Minneapolis, MN) was added to ELISA plates coated with monoclonal mouse anti-polyHistidine antibody as described above and incubated for 1 hour at room temperature. Wells were washed four times with PBS containing 0.02% Tween 20.

5 One hundred microliters of antibody or DVD-Ig preparations diluted in blocking solution as described above was added to the desired target antigen plate or desired target antigen / FC fusion plate or the anti-polyHistidine antibody / His tagged desired target antigen plate prepared as described above and incubated for 1 hour at room temperature. Wells are washed four times with PBS containing 0.02% Tween 20.

10 One hundred microliters of 10ng/mL goat anti-human IgG –FC specific HRP conjugated antibody (Southern Biotech # 2040-05, Birmingham, AL) was added to each well of the desired target antigen plate or anti-polyHistidine antibody / Histidine tagged desired target antigen plate. Alternatively, one hundred microliters of 10 ng/mL goat anti-human IgG –kappa light chain specific HRP conjugated antibody (Southern Biotech # 2060-05 Birmingham, AL) was added to
15 each well of the desired target antigen / FC fusion plate and incubated for 1 hour at room temperature. Plates were washed 4 times with PBS containing 0.02% Tween 20.

One hundred microliters of enhanced TMB solution (Neogen Corp. #308177, K Blue, Lexington, KY) was added to each well and incubated for 10 minutes at room temperature. The reaction was stopped by the addition of 50 µL 1N sulphuric acid. Plates were read
20 spectrophotometrically at a wavelength of 450 nm.

Table 3 contains a list of the antigens used in the Direct Bind Assay.

Table 4 contains the binding data expressed as EC50 in nM for those antibodies and DVD-Ig constructs tested in the Direct Bind ELISA assay.

In the Direct Bind ELISA, binding was sometimes not observed, probably because the
25 antibody binding site on the target antigen was either “masked” or the antigen is “distorted” when coated to the plastic surface. The inability of a DVD-Ig to bind its target may also be due to steric limitation imposed on DVD-Ig by the Direct Bind ELISA format. The parent antibodies and DVD-Igs that did not bind in the Direct Bind ELISA format bound to target antigen in other ELISA formats, such as FACS, Biacore or bioassay. Non-binding of a DVD-Ig was also restored
30 by adjusting the linker length between the two variable domains of the DVD-Ig, as shown previously.

Table 3: Antigens Used in Direct Bind ELISA

Assay	Antigen	Vendor Designation	Vendor	Catalog #
CD-22	CD22/FC	Siglec-2 ECD/FC chimera	R&D	1968-SL-050
CD-40	CD40/FC	CD40 ECD/FC chimera-His tag	R&D	1493-CD-050

CD-80	CD80/FC	B7-1 ECD/FC chimera	R&D	140-B1-100
DLL4	DLL4	DLL4 ECD/His tag	R&D	1506-D4-050
EGFR	EGFR/FC	EGFR ECD/FC chimera	R&D	344-ER-050
HER-2	HER-2/FC	ErbB2 ECD/FC chimera-His tag	R&D	1129-ER-050
HGF	HGF	HGF-His tag	R&D	294-HG-025
IGF1	IGF1	IGF-I	R&D	291-G1-050
IGF2	IGF2	IGF-2	R&D	292-G2-050
IGF1R	IGF1R	IGF1R ECD	R&D	391-GR-050
NRP1	NRP1	Neuropilin-1 Npn-1-His tag	R&D	3870-N1-025
PlGF	PlGF	Placental GF	R&D	264-PG-050
RON	RON	MSP Receptor ECD-His tag	R&D	1947-MS-050
VEGF	VEGF	VEGF 1-165 aa	R&D	293-VE-010
ErbB3	ErbB3	ErbB3 ECD/FC Chimera-His tag	R&D	348-RB-050

ECD = Extracellular Domain

/FC chimera = antigen/IgG FC domain fusion protein

Table 4: Direct Bind ELISA Of Parent Antibodies And DVD-Ig Constructs

5

Parent Antibody or DVD-Ig ID	N-terminal Variable Domain (VD)	C-terminal Variable Domain (VD)	Direct Bind ELISA N-terminal VD EC50 (nM)	Direct Bind ELISA C-terminal VD EC50 (nM)
AB006	CD-19		0.04	
AB001	CD-20			
DVD001	CD-20	CD-19		12.93
DVD002	CD-19	CD-20	0.07	
AB007	CD-80		0.77	
AB001	CD-20			
DVD005	CD-20	CD-80		9.77
DVD006	CD-80	CD-20	1.09	
AB008	CD-22		3.44	
AB001	CD-20			
DVD007	CD-20	CD-22		30.54
DVD008	CD-22	CD-20	4.79	
AB009	CD-40		0.99	
AB001	CD-20			
DVD009	CD-20	CD-40		3.55
DVD010	CD-40	CD-20	0.82	
AB002	CD-3			
AB004	HER-2		0.15	
DVD011	CD-3	HER-2		6.63
DVD012	HER-2	CD-3	1.24	
AB002	CD-3			
AB006	CD-19		0.14	
DVD013	CD-3	CD-19		7.29
DVD014	CD-19	CD-3	0.12	
AB033	EGFR		0.66	
AB004	HER-2		1.9	

DVD015	EGFR	HER-2	0.41	148.48
DVD016	HER-2	EGFR	1.25	5.23
AB002	CD-3			
AB033	EGFR		0.28	
DVD017	EGFR	CD-3	0.3	
DVD018	CD-3	EGFR		1.93
AB033	EGFR		0.27	
AB011	IGF1R		0.28	
DVD021	EGFR	IGF1R	0.33	134.95
DVD022	IGF1R	EGFR	0.26	0.74
AB005	RON		0.26	
AB033	EGFR		0.28	
DVD023	EGFR	RON	0.23	40.18
DVD024	RON	EGFR	0.54	1.87
AB033	EGFR		0.27	
AB012	HGF		0.22	
DVD025	EGFR	HGF	0.31	251.45
DVD026	HGF	EGFR	0.33	7.89
AB004	HER-2		0.44	
AB010	IGF1,2		4.77/10.02	
DVD029	HER-2	IGF1/IGF2	1226.04	229.33/206.12
DVD030	IGF1/IGF2	HER-2	1.75/5.49	10.65
AB004	HER-2		0.15	
AB011	IGF1R		0.28	
DVD031	HER-2	IGF1R	0.28	171.04
DVD032	IGF1R	HER-2	0.16	11.03
AB005	RON		0.21	
AB012	HGF		0.19	
DVD033	RON	HGF	0.22	11.95
DVD034	HGF	RON	0.27	116.46
AB014	VEGF		0.87	
AB033	EGFR		0.28	
DVD035	VEGF	EGFR	0.74	1.24
DVD036	EGFR	VEGF	0.18	336.13
AB014	VEGF		2.71	
AB004	HER-2		0.15	
DVD037	VEGF	HER-2	1.86	1.44
DVD038	HER-2	VEGF	0.66	106.77
AB001	CD-20			
AB014	VEGF		2.71	
DVD039	VEGF	CD-20	1.27	
DVD040	CD-20	VEGF		71.18
AB014	VEGF		0.87	
AB010	IGF1,2		4.77/18.13	
DVD041	VEGF	IGF1/IGF2	0.68	381.18/7335.24
DVD042	IGF1/IGF2	VEGF	2.54/17.62	42.3
AB015	DLL-4		0.31	
AB014	VEGF		2.71	
DVD043	VEGF	DLL4	28.25	2.12
DVD044	DLL4	VEGF	0.53	10.88

AB014	VEGF		2.95	
AB012	HGF		0.19	
DVD045	VEGF	HGF	2.87	184.53
DVD046	HGF	VEGF	0.5	46.3
AB005	RON		0.26	
AB014	VEGF		2.95	
DVD047	VEGF	RON	19.2	94.82
DVD048	RON	VEGF	0.46	42.95
AB014	VEGF		2.95	
AB016	NRP1		0.58	
DVD049	VEGF	NRP1	1.71	0.5
DVD050	NRP1	VEGF	0.46	219.02
AB015	DLL-4		0.31	
AB047	PIGF		0.2	
DVD257	DLL4	PIGF	0.28	2
DVD258	PIGF	DLL4	0.08	2.3
AB014	VEGF		1.09	
AB047	PIGF		0.2	
DVD259	VEGF	PIGF	0.79	1.3
DVD260	PIGF	VEGF	0.12	19.06
AB062	ErbB3		1.93	
AB033	EGFR		0.68	
DVD299	ErbB3	EGFR	1.96	17.38
DVD300	EGFR	ErbB3	0.49	7633.3
AB063	ErbB3		0.28	
AB033	EGFR		0.68	
DVD305	ErbB3	EGFR	0.44	24.39
DVD306	EGFR	ErbB3	0.36	150.92

Binding of all DVD-Ig constructs was maintained and comparable to that of parent antibodies. All N-terminal variable domains bound with a similar high affinity as the parent antibody as well as the C-terminal variable domains of DVD-Ig constructs DVD009, DVD016, DVD018, DVD022, DVD024, DVD035, DVD37, DVD043, DVD044, DVD49, DVD257, DVD258 and DVD259.

Tables 5 and 6 contain VEGF Direct Bind ELISA data for three VEGF parent antibodies and 96 DVD-Ig constructs with either C-terminal (C-term.) or N-terminal (N-term.) variable domains derived from the variable domains of the parent VEGF Reference Antibodies (Ref. Ab.) AB014 - VEGF (seq. 1), AB071 - VEGF (seq. 2) and AB070 - VEGF (seq. 3). These variable domains are paired with four DLL-4 variable domains derived from four DLL-4 Ref. Ab. (AB015 – DLL-4 (seq.1), AB069– DLL-4 (seq.2), AB073– DLL-4 (seq.3), and AB072 – DLL-4 (seq.4). The DVD-Ig variable domains are connected by 2 linker lengths (Short and Long in either the heavy chain (HC linker) and/or light chain (LC linker), resulting in four possible linker combinations: Short-Short, Long-Long, Short-Long and Long-Short. The combination of these 5 factors (3 VEGF sequences x 2 Orientations x 2 HC Linkers x 2 LC Linkers x 4 DLL-4 sequences) results in the full factorial experiment of 96 DVDs.

Table 5: Direct Bind ELISA Of 96 DVD Constructs With Various VEGF Sequences, Orientations And Linker Length Combinations To VEGF

DVD ID	Sequence ID	Position	HC Linker	LC Linker	Other DVD Domain	DVD VEGF EC50 (nM)	Ref. Ab. ID	RefAb VEGF EC50 (nM)
DVD043	VEGF (Seq. 1)	N-term.	Short	Short	DLL4 (seq. 1)	1.25	AB014	2.36
DVD044	VEGF (Seq. 1)	C-term.	Short	Short	DLL4 (seq. 1)	407.52	AB014	2.36
DVD469	VEGF (Seq. 1)	C-term.	Long	Long	DLL4 (seq. 1)	1262.59	AB014	2.36
DVD470	VEGF (Seq. 1)	N-term.	Long	Long	DLL4 (seq. 1)	1.87	AB014	2.36
DVD475	VEGF (Seq. 1)	C-term.	Long	Short	DLL4 (seq. 1)	19.17	AB014	1.51
DVD476	VEGF (Seq. 1)	N-term.	Long	Short	DLL4 (seq. 1)	0.55	AB014	1.51
DVD481	VEGF (Seq. 1)	C-term.	Short	Long	DLL4 (seq. 1)	150.24	AB014	1.51
DVD482	VEGF (Seq. 1)	N-term.	Short	Long	DLL4 (seq. 1)	1.30	AB014	1.51
DVD467	VEGF (Seq. 2)	C-term.	Short	Short	DLL4 (seq. 1)	1805.23	AB071	60.82
DVD468	VEGF (Seq. 2)	N-term.	Short	Short	DLL4 (seq. 1)	25.55	AB071	60.82
DVD473	VEGF (Seq. 2)	C-term.	Long	Long	DLL4 (seq. 1)	388.01	AB071	60.82
DVD474	VEGF (Seq. 2)	N-term.	Long	Long	DLL4 (seq. 1)	17.93	AB071	60.82
DVD479	VEGF (Seq. 2)	C-term.	Long	Short	DLL4 (seq. 1)	455.50	AB071	68.55
DVD480	VEGF (Seq. 2)	N-term.	Long	Short	DLL4 (seq. 1)	22.98	AB071	68.55
DVD485	VEGF (Seq. 2)	C-term.	Short	Long	DLL4 (seq. 1)	121.21	AB071	68.55
DVD486	VEGF (Seq. 2)	N-term.	Short	Long	DLL4 (seq. 1)	27.96	AB071	68.55
DVD465	VEGF (Seq. 3)	C-term.	Short	Short	DLL4 (seq. 1)	396.45	AB070	1.82
DVD466	VEGF (Seq. 3)	N-term.	Short	Short	DLL4 (seq. 1)	2.61	AB070	1.82
DVD471	VEGF (Seq. 3)	C-term.	Long	Long	DLL4 (seq. 1)	30.05	AB070	1.82
DVD472	VEGF (Seq. 3)	N-term.	Long	Long	DLL4 (seq. 1)	9.22	AB070	1.82
DVD477	VEGF (Seq. 3)	C-term.	Long	Short	DLL4 (seq. 1)	41.66	AB070	3.59
DVD478	VEGF (Seq. 3)	N-term.	Long	Short	DLL4 (seq. 1)	2.72	AB070	3.59
DVD483	VEGF (Seq. 3)	C-term.	Short	Long	DLL4 (seq. 1)	46.09	AB070	3.59
DVD484	VEGF (Seq. 3)	N-term.	Short	Long	DLL4 (seq. 1)	4.84	AB070	3.59
DVD441	VEGF (Seq. 1)	C-term.	Short	Short	DLL4 (seq. 2)	247.99	AB014	1.52
DVD442	VEGF (Seq. 1)	N-term.	Short	Short	DLL4 (seq. 2)	0.59	AB014	1.52
DVD447	VEGF (Seq. 1)	C-term.	Long	Long	DLL4 (seq. 2)	5.05	AB014	1.52
DVD448	VEGF (Seq. 1)	N-term.	Long	Long	DLL4 (seq. 2)	1.59	AB014	1.52
DVD453	VEGF (Seq. 1)	C-term.	Long	Short	DLL4 (seq. 2)	35.28	AB014	1.50
DVD454	VEGF (Seq. 1)	N-term.	Long	Short	DLL4 (seq. 2)	1.43	AB014	1.50
DVD459	VEGF (Seq. 1)	C-term.	Short	Long	DLL4 (seq. 2)	6.17	AB014	1.50
DVD460	VEGF (Seq. 1)	N-term.	Short	Long	DLL4 (seq. 2)	0.94	AB014	1.50
DVD445	VEGF (Seq. 2)	C-term.	Short	Short	DLL4 (seq. 2)	14482.02	AB071	48.07
DVD446	VEGF (Seq. 2)	N-term.	Short	Short	DLL4 (seq. 2)	14.38	AB071	48.07
DVD451	VEGF (Seq. 2)	C-term.	Long	Long	DLL4 (seq. 2)	2404.95	AB071	48.07
DVD452	VEGF (Seq. 2)	N-term.	Long	Long	DLL4 (seq. 2)	17.75	AB071	48.07
DVD457	VEGF (Seq. 2)	C-term.	Long	Short	DLL4 (seq. 2)	1475.74	AB071	40.24
DVD458	VEGF (Seq. 2)	N-term.	Long	Short	DLL4 (seq. 2)	21.51	AB071	40.24
DVD463	VEGF (Seq. 2)	C-term.	Short	Long	DLL4 (seq. 2)	1730.97	AB071	40.24
DVD464	VEGF (Seq. 2)	N-term.	Short	Long	DLL4 (seq. 2)	19.31	AB071	40.24
DVD443	VEGF (Seq. 3)	C-term.	Short	Short	DLL4 (seq. 2)	610.53	AB070	1.05
DVD444	VEGF (Seq. 3)	N-term.	Short	Short	DLL4 (seq. 2)	2.44	AB070	1.05
DVD449	VEGF (Seq. 3)	C-term.	Long	Long	DLL4 (seq. 2)	15.61	AB070	1.05
DVD450	VEGF (Seq. 3)	N-term.	Long	Long	DLL4 (seq. 2)	12.06	AB070	1.05
DVD455	VEGF (Seq. 3)	C-term.	Long	Short	DLL4 (seq. 2)	26.71	AB070	1.11

DVD456	VEGF (Seq. 3)	N-term.	Long	Short	DLL4 (seq. 2)	1.63	AB070	1.11
DVD461	VEGF (Seq. 3)	C-term.	Short	Long	DLL4 (seq. 2)	10.44	AB070	1.11
DVD462	VEGF (Seq. 3)	N-term.	Short	Long	DLL4 (seq. 2)	8.00	AB070	1.11
DVD511	VEGF (Seq. 1)	C-term.	Short	Short	DLL4 (seq. 3)	35.11	AB014	0.75
DVD512	VEGF (Seq. 1)	N-term.	Short	Short	DLL4 (seq. 3)	0.71	AB014	0.75
DVD517	VEGF (Seq. 1)	C-term.	Long	Long	DLL4 (seq. 3)	9.78	AB014	0.75
DVD518	VEGF (Seq. 1)	N-term.	Long	Long	DLL4 (seq. 3)	162.44	AB014	0.75
DVD523	VEGF (Seq. 1)	C-term.	Long	Short	DLL4 (seq. 3)	9.67	AB014	0.49
DVD524	VEGF (Seq. 1)	N-term.	Long	Short	DLL4 (seq. 3)	0.30	AB014	0.49
DVD529	VEGF (Seq. 1)	C-term.	Short	Long	DLL4 (seq. 3)	2.64	AB014	0.49
DVD530	VEGF (Seq. 1)	N-term.	Short	Long	DLL4 (seq. 3)	0.79	AB014	0.49
DVD515	VEGF (Seq. 2)	C-term.	Short	Short	DLL4 (seq. 3)	3015.10	AB071	35.19
DVD516	VEGF (Seq. 2)	N-term.	Short	Short	DLL4 (seq. 3)	24.65	AB071	35.19
DVD521	VEGF (Seq. 2)	C-term.	Long	Long	DLL4 (seq. 3)	654.85	AB071	35.19
DVD522	VEGF (Seq. 2)	N-term.	Long	Long	DLL4 (seq. 3)	23.53	AB071	35.19
DVD527	VEGF (Seq. 2)	C-term.	Long	Short	DLL4 (seq. 3)	2380.25	AB071	52.97
DVD528	VEGF (Seq. 2)	N-term.	Long	Short	DLL4 (seq. 3)	27.69	AB071	52.97
DVD533	VEGF (Seq. 2)	C-term.	Short	Long	DLL4 (seq. 3)	1260.61	AB071	52.97
DVD534	VEGF (Seq. 2)	N-term.	Short	Long	DLL4 (seq. 3)	23.61	AB071	52.97
DVD513	VEGF (Seq. 3)	C-term.	Short	Short	DLL4 (seq. 3)	58.54	AB070	0.97
DVD514	VEGF (Seq. 3)	N-term.	Short	Short	DLL4 (seq. 3)	67.41	AB070	0.97
DVD519	VEGF (Seq. 3)	C-term.	Long	Long	DLL4 (seq. 3)	77.17	AB070	0.97
DVD520	VEGF (Seq. 3)	N-term.	Long	Long	DLL4 (seq. 3)	247.74	AB070	0.97
DVD525	VEGF (Seq. 3)	C-term.	Long	Short	DLL4 (seq. 3)	21.79	AB070	1.42
DVD526	VEGF (Seq. 3)	N-term.	Long	Short	DLL4 (seq. 3)	96.22	AB070	1.42
DVD531	VEGF (Seq. 3)	C-term.	Short	Long	DLL4 (seq. 3)	60.39	AB070	1.42
DVD532	VEGF (Seq. 3)	N-term.	Short	Long	DLL4 (seq. 3)	28.91	AB070	1.42
DVD487	VEGF (Seq. 1)	C-term.	Short	Short	DLL4 (seq. 4)	39.78	AB014	1.61
DVD488	VEGF (Seq. 1)	N-term.	Short	Short	DLL4 (seq. 4)	4.98	AB014	1.61
DVD493	VEGF (Seq. 1)	C-term.	Long	Long	DLL4 (seq. 4)	2.26	AB014	1.61
DVD494	VEGF (Seq. 1)	N-term.	Long	Long	DLL4 (seq. 4)	712.21	AB014	1.61
DVD499	VEGF (Seq. 1)	C-term.	Long	Short	DLL4 (seq. 4)	5.07	AB014	1.41
DVD500	VEGF (Seq. 1)	N-term.	Long	Short	DLL4 (seq. 4)	5.28	AB014	1.41
DVD505	VEGF (Seq. 1)	C-term.	Short	Long	DLL4 (seq. 4)	1.27	AB014	1.41
DVD506	VEGF (Seq. 1)	N-term.	Short	Long	DLL4 (seq. 4)	1.84	AB014	1.41
DVD491	VEGF (Seq. 2)	C-term.	Short	Short	DLL4 (seq. 4)	1249.97	AB071	45.67
DVD492	VEGF (Seq. 2)	N-term.	Short	Short	DLL4 (seq. 4)	8.42	AB071	45.67
DVD497	VEGF (Seq. 2)	C-term.	Long	Long	DLL4 (seq. 4)	858.21	AB071	45.67
DVD498	VEGF (Seq. 2)	N-term.	Long	Long	DLL4 (seq. 4)	30.61	AB071	45.67
DVD503	VEGF (Seq. 2)	C-term.	Long	Short	DLL4 (seq. 4)	429.96	AB071	37.84
DVD504	VEGF (Seq. 2)	N-term.	Long	Short	DLL4 (seq. 4)	16.74	AB071	37.84
DVD509	VEGF (Seq. 2)	C-term.	Short	Long	DLL4 (seq. 4)	121.28	AB071	37.84
DVD510	VEGF (Seq. 2)	N-term.	Short	Long	DLL4 (seq. 4)	23.89	AB071	37.84
DVD489	VEGF (Seq. 3)	C-term.	Short	Short	DLL4 (seq. 4)	180.95	AB070	2.80
DVD490	VEGF (Seq. 3)	N-term.	Short	Short	DLL4 (seq. 4)	6.70	AB070	2.80
DVD495	VEGF (Seq. 3)	C-term.	Long	Long	DLL4 (seq. 4)	69.95	AB070	2.80
DVD496	VEGF (Seq. 3)	N-term.	Long	Long	DLL4 (seq. 4)	107.87	AB070	2.80
DVD501	VEGF (Seq. 3)	C-term.	Long	Short	DLL4 (seq. 4)	45.16	AB070	2.44
DVD502	VEGF (Seq. 3)	N-term.	Long	Short	DLL4 (seq. 4)	3.25	AB070	2.44
DVD507	VEGF (Seq. 3)	C-term.	Short	Long	DLL4 (seq. 4)	34.85	AB070	2.44
DVD508	VEGF (Seq. 3)	N-term.	Short	Long	DLL4 (seq. 4)	7.88	AB070	2.44

Binding of all DVD-Ig constructs to VEGF was maintained and comparable to that of parent antibodies. All N-terminal variable domains bound with a similar high affinity as the parent antibody. Some specific combinations of linker length in the heavy chain and light chain improved the binding affinity of the C-terminal domains comparable to the parent antibody.

- 5 Specifically there is a statistically significant ($p=0.019$) improvement in affinity of the C-terminal domain with a long linker rather than a short linker in the light chain.

Table 6: Direct Bind ELISA Of 96 DVD-Ig Constructs With Various DLL4 Sequences, Orientations And Linker Length Combinations To DLL

DVD-Ig ID	Sequence ID	Orien-tation	HC linker	LC linker	Other DVD-Ig Variable Domain	DVD-Ig DLL4 EC50 (nM)	Ref. Ab. ID	Ref.Ab. DLL4 EC50 (nM)
DVD043	DLL4 (Seq. 1)	C-term.	Short	Short	VEGF (Seq. 1)	0.67	AB015	1.39
DVD044	DLL4 (Seq. 1)	N-term.	Short	Short	VEGF (Seq. 1)	0.25	AB015	1.39
DVD469	DLL4 (Seq. 1)	N-term.	Long	Long	VEGF (Seq. 1)	2.78	AB015	1.39
DVD470	DLL4 (Seq. 1)	C-term.	Long	Long	VEGF (Seq. 1)	0.19	AB015	1.39
DVD475	DLL4 (Seq. 1)	N-term.	Long	Short	VEGF (Seq. 1)	0.23	AB015	1.23
DVD476	DLL4 (Seq. 1)	C-term.	Long	Short	VEGF (Seq. 1)	0.30	AB015	1.23
DVD481	DLL4 (Seq. 1)	N-term.	Short	Long	VEGF (Seq. 1)	3.30	AB015	1.23
DVD482	DLL4 (Seq. 1)	C-term.	Short	Long	VEGF (Seq. 1)	0.36	AB015	1.23
DVD441	DLL4 (Seq. 4)	N-term.	Short	Short	VEGF (Seq. 1)	0.04	AB069	0.10
DVD442	DLL4 (Seq. 4)	C-term.	Short	Short	VEGF (Seq. 1)	10.55	AB069	0.10
DVD447	DLL4 (Seq. 4)	N-term.	Long	Long	VEGF (Seq. 1)	0.12	AB069	0.10
DVD448	DLL4 (Seq. 4)	C-term.	Long	Long	VEGF (Seq. 1)	0.41	AB069	0.10
DVD453	DLL4 (Seq. 4)	N-term.	Long	Short	VEGF (Seq. 1)	0.09	AB069	0.04
DVD454	DLL4 (Seq. 4)	C-term.	Long	Short	VEGF (Seq. 1)	1.01	AB069	0.04
DVD459	DLL4 (Seq. 4)	N-term.	Short	Long	VEGF (Seq. 1)	0.26	AB069	0.04
DVD460	DLL4 (Seq. 4)	C-term.	Short	Long	VEGF (Seq. 1)	0.64	AB069	0.04
DVD511	DLL4 (Seq. 2)	N-term.	Short	Short	VEGF (Seq. 1)	0.10	AB073	0.08
DVD512	DLL4 (Seq. 2)	C-term.	Short	Short	VEGF (Seq. 1)	1.71	AB073	0.08
DVD517	DLL4 (Seq. 2)	N-term.	Long	Long	VEGF (Seq. 1)	0.10	AB073	0.08
DVD518	DLL4 (Seq. 2)	C-term.	Long	Long	VEGF (Seq. 1)	5.90	AB073	0.08
DVD523	DLL4 (Seq. 2)	N-term.	Long	Short	VEGF (Seq. 1)	0.09	AB073	0.03
DVD524	DLL4 (Seq. 2)	C-term.	Long	Short	VEGF (Seq. 1)	0.22	AB073	0.03
DVD529	DLL4 (Seq. 2)	N-term.	Short	Long	VEGF (Seq. 1)	0.10	AB073	0.03
DVD530	DLL4 (Seq. 2)	C-term.	Short	Long	VEGF (Seq. 1)	0.22	AB073	0.03
DVD487	DLL4 (Seq. 3)	N-term.	Short	Short	VEGF (Seq. 1)	0.14	AB072	1.29
DVD488	DLL4 (Seq. 3)	C-term.	Short	Short	VEGF (Seq. 1)	1.84	AB072	1.29
DVD493	DLL4 (Seq. 3)	N-term.	Long	Long	VEGF (Seq. 1)	0.06	AB072	1.29
DVD494	DLL4 (Seq. 3)	C-term.	Long	Long	VEGF (Seq. 1)	39.48	AB072	1.29
DVD499	DLL4 (Seq. 3)	N-term.	Long	Short	VEGF (Seq. 1)	0.09	AB072	0.70
DVD500	DLL4 (Seq. 3)	C-term.	Long	Short	VEGF (Seq. 1)	0.57	AB072	0.70

DVD-Ig ID	Sequence ID	Orien- tation	HC linker	LC linker	Other DVD- Ig Variable Domain	DVD-Ig DLL4 EC50 (nM)	Ref. Ab. ID	Ref.Ab. DLL4 EC50 (nM)
DVD505	DLL4 (Seq. 3)	N-term.	Short	Long	VEGF (Seq. 1)	0.09	AB072	0.70
DVD506	DLL4 (Seq. 3)	C-term.	Short	Long	VEGF (Seq. 1)	0.32	AB072	0.70
DVD467	DLL4 (Seq. 1)	N-term.	Short	Short	VEGF (Seq. 2)	0.54	AB015	0.30
DVD468	DLL4 (Seq. 1)	C-term.	Short	Short	VEGF (Seq. 2)	2.28	AB015	0.30
DVD473	DLL4 (Seq. 1)	N-term.	Long	Long	VEGF (Seq. 2)	1.80	AB015	0.30
DVD474	DLL4 (Seq. 1)	C-term.	Long	Long	VEGF (Seq. 2)	0.57	AB015	0.30
DVD479	DLL4 (Seq. 1)	N-term.	Long	Short	VEGF (Seq. 2)	1.69	AB015	0.28
DVD480	DLL4 (Seq. 1)	C-term.	Long	Short	VEGF (Seq. 2)	0.60	AB015	0.28
DVD485	DLL4 (Seq. 1)	N-term.	Short	Long	VEGF (Seq. 2)	1.41	AB015	0.28
DVD486	DLL4 (Seq. 1)	C-term.	Short	Long	VEGF (Seq. 2)	0.59	AB015	0.28
DVD445	DLL4 (Seq. 4)	N-term.	Short	Short	VEGF (Seq. 2)	0.17	AB069	0.20
DVD446	DLL4 (Seq. 4)	C-term.	Short	Short	VEGF (Seq. 2)	13.92	AB069	0.20
DVD451	DLL4 (Seq. 4)	N-term.	Long	Long	VEGF (Seq. 2)	0.40	AB069	0.20
DVD452	DLL4 (Seq. 4)	C-term.	Long	Long	VEGF (Seq. 2)	0.34	AB069	0.20
DVD457	DLL4 (Seq. 4)	N-term.	Long	Short	VEGF (Seq. 2)	0.13	AB069	0.21
DVD458	DLL4 (Seq. 4)	C-term.	Long	Short	VEGF (Seq. 2)	1.54	AB069	0.21
DVD463	DLL4 (Seq. 4)	N-term.	Short	Long	VEGF (Seq. 2)	0.50	AB069	0.21
DVD464	DLL4 (Seq. 4)	C-term.	Short	Long	VEGF (Seq. 2)	0.80	AB069	0.21
DVD515	DLL4 (Seq. 2)	N-term.	Short	Short	VEGF (Seq. 2)	0.20	AB073	0.11
DVD516	DLL4 (Seq. 2)	C-term.	Short	Short	VEGF (Seq. 2)	4.33	AB073	0.11
DVD521	DLL4 (Seq. 2)	N-term.	Long	Long	VEGF (Seq. 2)	0.26	AB073	0.11
DVD522	DLL4 (Seq. 2)	C-term.	Long	Long	VEGF (Seq. 2)	0.48	AB073	0.11
DVD527	DLL4 (Seq. 2)	N-term.	Long	Short	VEGF (Seq. 2)	0.20	AB073	0.11
DVD528	DLL4 (Seq. 2)	C-term.	Long	Short	VEGF (Seq. 2)	0.81	AB073	0.11
DVD533	DLL4 (Seq. 2)	N-term.	Short	Long	VEGF (Seq. 2)	0.25	AB073	0.11
DVD534	DLL4 (Seq. 2)	C-term.	Short	Long	VEGF (Seq. 2)	0.47	AB073	0.11
DVD491	DLL4 (Seq. 3)	N-term.	Short	Short	VEGF (Seq. 2)	0.39	AB072	1.99
DVD492	DLL4 (Seq. 3)	C-term.	Short	Short	VEGF (Seq. 2)	1.77	AB072	1.99
DVD497	DLL4 (Seq. 3)	N-term.	Long	Long	VEGF (Seq. 2)	0.53	AB072	1.99
DVD498	DLL4 (Seq. 3)	C-term.	Long	Long	VEGF (Seq. 2)	0.45	AB072	1.99
DVD503	DLL4 (Seq. 3)	N-term.	Long	Short	VEGF (Seq. 2)	0.33	AB072	1.85
DVD504	DLL4 (Seq. 3)	C-term.	Long	Short	VEGF (Seq. 2)	0.53	AB072	1.85
DVD509	DLL4 (Seq. 3)	N-term.	Short	Long	VEGF (Seq. 2)	0.21	AB072	1.85
DVD510	DLL4 (Seq. 3)	C-term.	Short	Long	VEGF (Seq. 2)	0.42	AB072	1.85
DVD465	DLL4 (Seq. 1)	N-term.	Short	Short	VEGF (Seq.3)	0.57	AB015	0.60
DVD466	DLL4 (Seq. 1)	C-term.	Short	Short	VEGF (Seq.3)	19.84	AB015	0.60
DVD471	DLL4 (Seq. 1)	N-term.	Long	Long	VEGF (Seq.3)	0.89	AB015	0.60
DVD472	DLL4 (Seq. 1)	C-term.	Long	Long	VEGF (Seq.3)	2.78	AB015	0.60
DVD477	DLL4 (Seq. 1)	N-term.	Long	Short	VEGF (Seq.3)	0.69	AB015	0.58
DVD478	DLL4 (Seq. 1)	C-term.	Long	Short	VEGF (Seq.3)	2.53	AB015	0.58

DVD-Ig ID	Sequence ID	Orientation	HC linker	LC linker	Other DVD-Ig Variable Domain	DVD-Ig DLL4 EC50 (nM)	Ref. Ab. ID	Ref.Ab. DLL4 EC50 (nM)
DVD483	DLL4 (Seq. 1)	N-term.	Short	Long	VEGF (Seq.3)	0.63	AB015	0.58
DVD484	DLL4 (Seq. 1)	C-term.	Short	Long	VEGF (Seq.3)	1.75	AB015	0.58
DVD443	DLL4 (Seq. 4)	N-term.	Short	Short	VEGF (Seq.3)	0.20	AB069	0.23
DVD444	DLL4 (Seq. 4)	C-term.	Short	Short	VEGF (Seq.3)	30.54	AB069	0.23
DVD449	DLL4 (Seq. 4)	N-term.	Long	Long	VEGF (Seq.3)	0.36	AB069	0.23
DVD450	DLL4 (Seq. 4)	C-term.	Long	Long	VEGF (Seq.3)	1.99	AB069	0.23
DVD455	DLL4 (Seq. 4)	N-term.	Long	Short	VEGF (Seq.3)	0.24	AB069	0.24
DVD456	DLL4 (Seq. 4)	C-term.	Long	Short	VEGF (Seq.3)	2.48	AB069	0.24
DVD461	DLL4 (Seq. 4)	N-term.	Short	Long	VEGF (Seq.3)	0.52	AB069	0.24
DVD462	DLL4 (Seq. 4)	C-term.	Short	Long	VEGF (Seq.3)	7.99	AB069	0.24
DVD513	DLL4 (Seq. 2)	N-term.	Short	Short	VEGF (Seq.3)	0.66	AB073	0.22
DVD514	DLL4 (Seq. 2)	C-term.	Short	Short	VEGF (Seq.3)	21.05	AB073	0.22
DVD519	DLL4 (Seq. 2)	N-term.	Long	Long	VEGF (Seq.3)	1.53	AB073	0.22
DVD520	DLL4 (Seq. 2)	C-term.	Long	Long	VEGF (Seq.3)	17.34	AB073	0.22
DVD525	DLL4 (Seq. 2)	N-term.	Long	Short	VEGF (Seq.3)	1.00	AB073	0.21
DVD526	DLL4 (Seq. 2)	C-term.	Long	Short	VEGF (Seq.3)	1.57	AB073	0.21
DVD531	DLL4 (Seq. 2)	N-term.	Short	Long	VEGF (Seq.3)	0.57	AB073	0.21
DVD532	DLL4 (Seq. 2)	C-term.	Short	Long	VEGF (Seq.3)	1.43	AB073	0.21
DVD489	DLL4 (Seq. 3)	N-term.	Short	Short	VEGF (Seq.3)	0.62	AB072	63.43
DVD490	DLL4 (Seq. 3)	C-term.	Short	Short	VEGF (Seq.3)	9.27	AB072	63.43
DVD495	DLL4 (Seq. 3)	N-term.	Long	Long	VEGF (Seq.3)	0.33	AB072	63.43
DVD496	DLL4 (Seq. 3)	C-term.	Long	Long	VEGF (Seq.3)	5.59	AB072	63.43
DVD501	DLL4 (Seq. 3)	N-term.	Long	Short	VEGF (Seq.3)	0.18	AB072	63.24
DVD502	DLL4 (Seq. 3)	C-term.	Long	Short	VEGF (Seq.3)	3.17	AB072	63.24
DVD507	DLL4 (Seq. 3)	N-term.	Short	Long	VEGF (Seq.3)	0.71	AB072	63.24
DVD508	DLL4 (Seq. 3)	C-term.	Short	Long	VEGF (Seq.3)	0.61	AB072	63.24

Binding of all DVD-Ig constructs to DLL4 was maintained and comparable to that of parent antibodies. All N-terminal variable domains bound with a similar high affinity as the parent antibody. Some specific combinations of linker length in the heavy chain and light chain improved the binding affinity of the C-terminal domains comparable to the parent antibody. Specifically there is a trend for improvement in the affinity of the C-terminal domain with a long linker in the light chain and/or heavy chain rather than a short linker in both the light and heavy chain.

Example 1.1.1.B: Capture ELISA - VEGF

ELISA plates (Nunc, MaxiSorp, Rochester, NY) were incubated overnight at 4°C with anti-human Fc antibody (5 µg/ml in PBS, Jackson ImmunoResearch, West Grove, PA). Plates

were washed three times in washing buffer (PBS containing 0.05% Tween 20), and blocked for 1 hour at 25°C in blocking buffer (PBS containing 1% BSA). Wells were washed three times, and serial dilutions of each antibody or DVD-Ig in PBS containing 0.1% BSA were added to the wells and incubated at 25°C for 1 hour. The wells were washed three times, and biotinylated VEGF (2nM) was added to the plates and incubated for 1 hour at 25°C. The wells were washed three times, and then incubated for 1 hour at 25°C with streptavidin-HRP (KPL #474-3000, Gaithersburg, MD). The wells were washed three times, and 100 µl of ULTRA-TMB ELISA (Pierce, Rockford, IL) were added per well. Following color development the reaction was stopped with 1N HCL and absorbance at 450nm was measured. VEGF capture ELISA data is shown in Table 7.

10 **Example 1.1.1.C: IgG-Fc Capture ELISA - RON**

96-well Nunc-Immuno plates were coated with 2µg/mL goat-anti-human IgG Fc specific antibody (Jackson ImmunoResearch # 109-055-098, West Grove, PA, 50µL/well) in PBS (Gibco #10010-023 from Invitrogen, Grand Island, NY), and incubated overnight at 4°C. Plates were washed three times with washing buffer (PBS, 0.05% Tween 20) and subsequently blocked with 100µL/well of blocking buffer (PBS, 2% BSA) for one hour at room temperature. Plates were washed three times and incubated with 50µL/well of a 1µg/mL solution of the appropriate antibody or DVD-Ig for one hour at room temperature. After the one hour incubation, the plates were washed three times and incubated with 50µL/well of his-tagged, recombinant RON protein (R&D Systems # 1947-MS, Minneapolis, MN, 1000nM to 0nM final dose range) for one hour at room temperature. Plates were washed three times, and 50µL/well of a rabbit-anti-His tag-HRP antibody (Abcam ab1187, Cambridge, MA, diluted at 1:10,000 in 2% BSA/PBS solution) was added and plates were incubated at room temperature for one hour. After the final wash, 50µl/well of TMB substrate (Pierce #34028, Rockford, IL) was added, and the reaction was terminated after five minutes using 50µl/well of 2N H2SO4. The absorbance was read at 450 nm (Spectra Max Plus plate reader, Molecular Devices, Sunnyvale, CA). EC50s were calculated in GraphPad Prism 4.03. RON capture ELISA data is shown in Table 7.

Example 1.1.1.D: Capture ELISA - IGF1,2

96-well Nunc-Immuno plates were coated with 5 µg/ml antibody against human IgG (Fcγ fragment specific, Jackson ImmunoResearch, West Grove, PA, #109-005-098, 100 µl/well) in D-PBS (Gibco #14190, San Diego, CA) and incubated overnight at 4 oC. ELISA plates were washed three times in wash buffer (PBS, 0.05% Tween 20) and then blocked with 200 µl/well blocking buffer (D-PBS, 1% BSA) for 1 hour at 25 oC. Plates were then washed and incubated with 100 µl/well antibodies or DVD-Igs (0.01µg/mL -100 µg/mL in blocking buffer) for 1 hour at 37 oC. Plates were then washed three times and incubated with biotin-labeled human IGF1 or IGF2 (0.02 nM -100 nM dose range in blocking buffer, 100µl/well) for 1 hour at 37 oC. Plates

were washed three times and incubated with streptavidin conjugated with HRP (KPL #474-3000, Gaithersburg, MD, 1:10,000 dilution in blocking buffer, 100 µl/well) for 1 hour at 25 oC. After the final wash, plates were incubated with 100 µl/well ELISA substrate (1-Step Ultra TMB-ELISA, Pierce #340280, Rockford, IL). The reaction was stopped after 5 minutes at 25 oC with 100 µl/well 2N H2SO4 and the absorbance was read at 450 nm. IGF1,2 capture ELISA data is shown in Table 7.

Example 1.1.1.E: Capture ELISA – DLL4

96-well Nunc-Immuno plates (#439454, Rochester, NY) were coated with 5 µ g/ml antibody against human IgG (Fc fragment specific, Jackson ImmunoResearch, West Grove, PA #109-005-098, 100 µ l/well) in D-PBS (Gibco #14190, Grand Island, NY) and incubated overnight at 4 oC. ELISA plates were washed three times with wash buffer (PBS, 0.05% Tween 20) and then blocked with 200 µl/well blocking buffer (D-PBS, 1% BSA, 1 mM CaCl2, 0.05% Tween 20) for 1 hour at 25 oC. Plates were washed three times and incubated with 100 µ l/ well DLL4 antibodies (0.0001-100 nM, 10-fold serial dilution in blocking buffer) for 1 hour at 25oC, and then washed again three times. Plates containing captured DLL4 Ab were incubated with biotin-labeled human DLL4 extracellular domain (10 nM in blocking buffer, 100 µl/well) for 1 hour at 25oC, washed three times, and incubated with streptavidin conjugated with HRP (KPL #474-3000C, washed three times, and incubated with streptavidin conjugated with HRP (KPL #474-3000, Gaithersburg, MD, 1:10,000 dilution in blocking buffer, 100 µl/well) for 1 hour at 25 oC. After the final wash, plates were incubated with 100 µl/well ELISA substrate (1-Step Ultra TMB-ELISA, Pierce #340280, Rockford, IL). The reaction was stopped after 2 minutes at 25 oC with 100 µl/well 2N H2SO4 and the absorbance was read at 450 nm. DLL4 capture ELISA data is shown in Table 7.

Example 1.1.1.F: Capture ELISA – ErbB3 or EGFR

96-well ELISA plates were coated with goat anti-human IgG Fc (Jackson Immunoresearch, PA) at a concentration of 33 nM, and incubated overnight at 4°C. The plates were washed with PBS containing 0.05% Tween 20 three times and blocked with 200 µl/well of 1%BSA/PBS for 1 hour at room temperature. Fifty µl of 5 nM DVD-Ig or antibody were added to each well and incubated for 1 hour at room temperature. The plates were washed, and then incubated with 50µl/well of biotinylated ErbB3 or biotinylated EGFR at various concentrations for 1 hour at room temperature. The plates were washed again and then incubated with 50 µl/well of streptavidin- conjugated HRP (KPL #474-3000, Protein Research Products, MD) and incubated for 1 hour at room temperature. The wells were washed three times, and 100µl of ULTRA-TMB ELISA (Pierce, Rockford, IL) were added per well. Following color development, the reaction was stopped with 1N HCL and absorbance at 450nm was measured.

Table 7 contains the affinity, expressed as EC50 in nM, of parent antibodies and DVD-Ig constructs in the VEGF, RON, EGFR, IGFR, IGF-1,2, HER-2, DLL4, and ErbB3.

Table 7: VEGF, RON, EGFR, ErbB3, IGFR, IGF-1,2, DLL4 and HER-2 Antigen Capture ELISA of Parent Antibodies and DVD-Ig Constructs

Parent Antibody or DVD-Ig ID	N-terminal Variable Domain	C-terminal Variable Domain	N-terminal Ag binding in Capture ELISA (EC50, nM)	C-terminal Ag binding in Capture ELISA (EC50, nM)
AB004	HER-2		0.4	
AB010	IGF1,2		4.8, 10	
DVD029	HER-2	IGF1,2		229, 206
DVD030	IGF1,2	HER-2	1.8, 5.5	10.7
AB033	EGFR		0.3	
AB011	IGF1R		0.3	
DVD021	EGFR	IGF1R	0.3	135
DVD022	IGF1R	EGFR	0.3	0.7
AB005	RON		1.6	
DVD024	RON	EGFR	1.96	
DVD023	EGFR	RON		>100
AB004	HER-2		0.2	
AB011	IGF1R		0.3	
DVD031	HER-2	IGF1R	0.3	171
DVD032	IGF1R	HER-2	0.2	11
AB005	RON		0.7	
AB012	HGF			
DVD033	RON	HGF	2.5	
DVD034	HGF	RON		
AB014	VEGF		0.24	
DVD035	VEGF	EGFR	0.24	

AB014	VEGF		0.24	
DVD038	HER-2	VEGF		2.00
AB014	VEGF		0.9	
AB010	IGF1,2		4.8, 18.1	
DVD041	VEGF	IGF1,2	0.7	381, 7335
DVD042	IGF1,2	VEGF	2.5, 17.6	42.3
AB015	DLL-4		0.03	
AB014	VEGF		0.24	
DVD044	DLL4	VEGF	0.06	4.20
DVD043	VEGF	DLL4	0.20	0.50
AB014	VEGF		0.24	
AB012	HGF			
DVD045	VEGF	HGF	0.29	>100
AB005	RON		1.3	
AB014	VEGF		0.24	
DVD048	RON	VEGF	2.7	3.60
DVD047	VEGF	RON	0.36	>100
AB014	VEGF		0.24	
DVD049	VEGF	NRP1	4.80	
DVD050	NRP1	VEGF		2.30
AB014	VEGF		0.53	
DVD260	PlGF	VEGF		1.70
AB062	ErbB3		0.26	
DVD299	ErbB3	EGFR	0.32	>10.0
AB063	ErbB3		0.67	
AB033	EGFR			
DVD305	ErbB3	EGFR	1.16	
DVD306	EGFR	ErbB3		>10.0

Binding of all DVD-Ig constructs to soluble antigen was maintained and comparable to parent antibodies. All N-terminal variable domains bound with a similar high affinity as to the parent antibody as well as the C-terminal variable domains of DVD022, DVD038, DVD043, DVD048, DVD50 and DVD260.

Example 1.1.1.G: Affinity Determination using BIACORE technology

Table 8: Reagent Used in Biacore Analyses

Assay	Antigen	Vendor Designation	Vendor	Catalog #
DLL4	DLL4	DLL ECD His tag	R&D	1506-D4-050
EGFR	EGFR	EGFR ECD	R&D	1095-ER
HER-2	HER-2/FC	ErbB2/FC chimera-His tag	R&D	1129-ER-050
HGF	HGF	HGF	R&D	294-HG-025
IGF1	IGF1	IGF-1	R&D	291-G1-050
IGF2	IGF2	IGF-2	R&D	292-G2-050
IGF1R	IGF1R	IGF1R ECD	R&D	391-GR-050
NRP1	NRP1	Neuropilin-1 Npn-1-His tag	R&D	3870-N1-025

PIGF	PIGF	Placental GF	R&D	264-PG-050
RON	RON	MSP Receptor ECD-His tag	R&D	1947-MS-050
VEGF	VEGF	VEGF	R&D	293-VE-010
ErbB3	ErbB3	ErbB3/FC Chimera-His tag	R&D	348-RB

ECD = Extracellular Domain

/FC = antigen/IgG FC domain fusion protein

BIACORE Methods:

5 The BIACORE assay (Biacore, Inc, Piscataway, NJ) determines the affinity of antibodies or DVD-Ig with kinetic measurements of on-rate and off-rate constants. Binding of antibodies or DVD-Ig to a target antigen (for example, a purified recombinant target antigen) is determined by surface plasmon resonance-based measurements with a Biacore® 1000 or 3000 instrument (Biacore® AB, Uppsala, Sweden) using running HBS-EP (10 mM HEPES [pH 7.4], 150 mM

10 NaCl, 3 mM EDTA, and 0.005% surfactant P20) at 25° C. All chemicals are obtained from Biacore® AB (Uppsala, Sweden) or otherwise from a different source as described in the text. For example, approximately 5000 RU of goat anti-mouse IgG, (Fc γ), fragment specific polyclonal antibody (Pierce Biotechnology Inc, Rockford, IL) diluted in 10 mM sodium acetate (pH 4.5) is directly immobilized across a CM5 research grade biosensor chip using a standard amine

15 coupling kit according to manufacturer's instructions and procedures at 25 μ g/ml. Unreacted moieties on the biosensor surface are blocked with ethanolamine. Modified carboxymethyl dextran surface in flowcell 2 and 4 is used as a reaction surface. Unmodified carboxymethyl dextran without goat anti-mouse IgG in flow cell 1 and 3 is used as the reference surface. For kinetic analysis, rate equations derived from the 1:1 Langmuir binding model are fitted

20 simultaneously to association and dissociation phases of all eight injections (using global fit analysis) with the use of Biaevaluation 4.0.1 software. Purified antibodies or DVD-Ig are diluted in HEPES-buffered saline for capture across goat anti-mouse IgG specific reaction surfaces. Antibodies or DVD-Ig to be captured as a ligand (25 μ g/ml) are injected over reaction matrices at a flow rate of 5 μ l/min. The association and dissociation rate constants, k_{on} ($M^{-1}s^{-1}$) and k_{off} (s^{-1})

25 are determined under a continuous flow rate of 25 μ l/min. Rate constants are derived by making kinetic binding measurements at different antigen concentrations ranging from 10 – 200 nM. The equilibrium dissociation constant (M) of the reaction between antibodies or DVD-Igs and the target antigen is then calculated from the kinetic rate constants by the following formula: $K_D = k_{off}/k_{on}$. Binding is recorded as a function of time and kinetic rate constants are calculated. In this

30 assay, on-rates as fast as $10^6 M^{-1}s^{-1}$ and off-rates as slow as $10^{-6} s^{-1}$ can be measured.

Table 9: BIACORE Analysis of Parental Antibodies and DVD Constructs

Parent Antibody	N-Terminal	C-Terminal	k_{on}	k_{off}	K_D
-----------------	------------	------------	----------	-----------	-------

			(M-1s-1)	(s-1)	(M)
AB011	IGF1R		7.32E+04	6.21E-05	8.48E-10
DVD021	EGFR		1.22E+06	1.80E-03	1.47E-9
DVD021		IGF1R			
DVD022	IGF1R		1.06E+05	8.25E-05	7.78E-10
DVD022		EGFR	8.03E+04	2.26E-04	2.81E-9
AB004	HER-2		3.22E+05	1.28E-05	3.97E-11
AB011	IGF1R		7.32E+04	6.21E-05	8.48E-10
DVD031	HER-2		3.30E+05	7.02E-06	2.12E-11
DVD031		IGF1R			
DVD032	IGF1R		5.10E+04	4.23E-05	8.29E-10
DVD032		HER-2	1.84E+04	9.31E-06	5.05E-10
AB004	HER-2		3.22E+05	1.28E-05	3.97E-11
AB010	IGF1		3.17E+06	1.23E-03	3.88E-10
AB010	IGF2		6.47E+06	2.74E-06	4.23E-13
DVD029	HER-2		2.42E+05	9.64E-06	3.98E-11
DVD029		IGF1	6.65E+04	4.23E-04	6.36E-9
DVD029		IGF2	1.04E+05	3.15E-05	3.02E-10
DVD030	IGF1		3.96E+06	1.16E-03	2.92E-10
DVD030	IGF2		8.46E+06	1.98E-05	2.34E-12
DVD030		HER-2	1.54E+05	7.36E-04	4.77E-9
AB033	EGFR		7.93E+04	1.39E-03	1.75E-8
AB004	HER-2		3.22E+05	1.28E-05	3.97E-11
DVD015	EGFR		1.79E+06	1.96E-03	1.09E-9
DVD015		HER-2			
DVD016	HER-2		2.44E+05	4.36E-06	1.78E-11
DVD016		EGFR	2.36E+04	4.53E-04	1.92E-8
AB014	VEGF		1.47E+05	3.03E-05	2.07E-10
AB010	IGF1				
AB010	IGF2		3.35E+06	<1.00E-06	<2.99E-13
DVD041	VEGF		5.26E+05	2.39E-06	4.55E-12
DVD041		IGF1			
DVD041		IGF2	8.09E+04	<1.00E-06	<1.24E-11
DVD042	IGF1				
DVD042	IGF2		5.20E+06	5.18E-06	9.98E-13
DVD042		VEGF	3.45E+04	1.46E-05	4.21E-10
AB005	RON		3.66E+04	7.39E-04	2.02E-8
AB033	EGFR		7.93E+04	1.39E-03	1.75E-8
DVD024	RON		4.56E+04	8.52E-04	1.86E-8
DVD024		EGFR			
DVD023	EGFR		2.08E+06	2.22E-03	1.06E-9
DVD023		RON			
AB005	RON		3.66E+04	7.39E-04	2.02E-8
AB012	HGF		>1.00E+7	2.84E-04	<2.84E-11
DVD033	RON		1.56E+05	1.18E-03	7.60E-09
DVD033		HGF	2.97E+05	9.20E-05	3.10E-10
DVD034	HGF		3.05E+06	6.55E-05	2.15E-11
DVD034		RON			
AB005	RON		3.66E+04	7.39E-04	2.01E-8
AB014	VEGF		3.06E+05	3.99E-06	1.30E-11
DVD048	RON				

Parent Antibody or DVD-Ig ID	N-Terminal Variable Domain (VD)	C-Terminal Variable Domain (VD)	k_{on} (M ⁻¹ s ⁻¹)	k_{off} (s ⁻¹)	K_D (M)
DVD048		VEGF	3.85E+04	4.50E-05	1.17E-9
DVD047	VEGF		3.46E+05	2.79E-05	8.06E-11
DVD047		RON			
AB015		DLL-4	4.00E+05	1.66E-04	4.14E-10
AB014		VEGF	1.47E+05	3.03E-05	2.07E-10
DVD044	DLL4		5.90E+05	2.05E-04	3.47E-10
DVD044		VEGF	3.67E+04	1.13E-05	3.08E-10
DVD043	VEGF		4.94E+05	8.26E-06	1.67E-11
DVD043		DLL4	9.37E+04	2.17E-04	2.32E-09
AB015		DLL-4			
AB047		PlGF	3.80E+06	1.08E-04	2.84E-11
DVD257	DLL4		8.35E+05	1.96E-04	2.34E-10
DVD257		PlGF	3.02E+05	1.11E-04	3.67E-10
DVD258	PlGF		>1.00E+07	2.54E-03	<2.54E-10
DVD258		DLL4			
AB014		VEGF	1.47E+05	3.03E-05	2.07E-10
AB033		EGFR	8.85E+05	1.23E-03	1.39E-09
DVD035	VEGF		2.25E+05	1.73E-05	8.23E-11
DVD035		EGFR			
DVD036	EGFR		1.21E+06	1.57E-03	1.30E-09
DVD036		VEGF	4.80E+04	3.19E-04	6.65E-09
AB014		VEGF	3.07E+05	3.39E-05	1.06E-11
AB004		HER-2	3.02E+05	1.03E-05	3.40E-11
DVD037	VEGF		4.45E+05	<1.00E-06	<2.25E-12
DVD037		HER-2	7.61E+03	2.83E-06	3.72E-10
DVD038	HER-2		1.95E+05	4.81E-06	2.47E-11
DVD038		VEGF	3.67E+04	<1.00E-06	<2.27E-11
AB014		VEGF	1.47E+05	3.03E-05	2.07E-10
AB012		HGF	>1.00E+7	2.84E-04	<2.84E-11
DVD045	VEGF		2.01E+05	3.05E-06	1.52E-11
DVD045		HGF	1.84E+05	1.66E-04	9.01E-10
DVD046	HGF		>1.00E+7	2.36E-04	<2.36E-11
DVD046		VEGF			
AB014		VEGF	3.06E+05	3.99E-06	1.30E-11
AB016		NRP1	1.47E+05	3.90E-04	2.67E-9
DVD049	VEGF				
DVD049		NRP1	1.42E+05	1.81E-04	1.28E-9
DVD050	NRP1		1.82E+05	2.61E-04	1.440E-9
DVD050		VEGF	1.82E+05	2.61E-04	1.440E-9
AB014		VEGF	3.07E+05	3.39E-05	1.06E-10
AB047		PlGF	3.80E+06	1.08E-04	2.85E-11
DVD259	VEGF		5.02E+05	2.06E-05	4.12E-11
DVD259		PlGF	2.99E+05	9.87E-05	3.30E-10
DVD260	PlGF		4.27E+06	5.14E-05	1.20E-11
DVD260		VEGF	4.99E+04	2.05E-05	4.11E-10
AB033		EGFR	8.85E+05	1.23E-03	1.39E-09
AB012		HGF	>1.00E+7	2.84E-04	<2.84E-11

Parent Antibody or DVD-Ig ID	N-Terminal Variable Domain (VD)	C-Terminal Variable Domain (VD)	k_{on} (M ⁻¹ s ⁻¹)	k_{off} (s ⁻¹)	K_D (M)
DVD025	EGFR		7.31E+05	1.44E-03	1.98E-09
DVD025		HGF	3.05E+05	2.28E-04	7.46E-10
DVD026	HGF		4.19E+06	6.67E-05	1.59E-11
DVD026		EGFR			
AB062		ErbB3	8.66E+04	1.17E-04	1.360E-9
AB033		EGFR	7.93E+04	1.39E-03	1.75E-8
DVD299	ErbB3		1.95E+05	1.60E-04	8.20E-10
DVD299		EGFR	3.26E+04	4.48E-04	1.37E-8
DVD300	EGFR		1.52E+06	1.69E-03	1.11E-9
DVD300		ErbB3			
AB063		ErbB3	1.17E+06	1.75E-04	1.50 E-10
AB033		EGFR	7.93E+04	1.39E-03	1.75 E-8
DVD305	ErbB3		2.27E+06	1.37E-04	6.03E-11
DVD305		EGFR	3.99E+04	3.17E-04	7.940 E-9
DVD306	EGFR		1.82E+06	1.86E-03	1.020 E-9
DVD306		ErbB3			

Binding of all DVD-Ig constructs characterized by Biacore technology was maintained and comparable to that of parent antibodies. All N-terminal variable domains bound with a similar high affinity as the parent antibody as well as the C-terminal variable domains of DVD-Ig constructs DVD022, DVD016, DVD042, DVD 044, DVD043, DVD038, DVD049, DVD260, DVD299, and DVD305.

Example 1.1.2: Assays Used To Determine the Functional Activity Of Parent Antibodies And DVD-Ig

Example 1.1.2.A: Cytokine Bioassay

The ability of an anti-cytokine or an anti-growth factor parent antibody or DVD-Ig containing anti-cytokine or anti-growth factor sequences to inhibit or neutralize a target cytokine or growth factor bioactivity is analyzed by determining the inhibitory potential of the antibody or DVD-Ig. For example, the ability of an anti-IL-4 antibody to inhibit IL-4 mediated IgE production may be used. For example, human naive B cells are isolated from peripheral blood, respectively, buffy coats by Ficoll-paque density centrifugation, followed by magnetic separation with MACS beads (Miltenyi Biotec, Bergisch Gladbach, Germany) specific for human sIgD FITC labeled goat F(ab)₂ antibodies followed by anti-FITC MACS beads. Magnetically sorted naive B cells are adjusted to 3×10^5 cells per ml in XV15 and plated out in 100 μ l per well of 96-well plates in a 6 x 6 array in the center of the plate, surrounded by PBS filled wells during the 10 days of culture at 37° C in the presence of 5% CO₂. One plate each is prepared per antibody to be tested, consisting of 3 wells each of un-induced and induced controls and quintuplicate repeats of antibody titrations starting at 7 μ g/ml and running in 3-fold dilution down to 29 ng/ml final

concentrations added in 50 μ l four times concentrated pre-dilution. To induce IgE production, rhIL-4 at 20 ng/ml plus anti-CD40 monoclonal antibody (Novartis, Basel, Switzerland) at 0.5 μ g/ml final concentrations in 50 μ l each are added to each well, and IgE concentrations are determined at the end of the culture period by a standard sandwich ELISA method.

5 **Example 1.1.2.B: Cytokine Release Assay**

The ability of a parent antibody or DVD-Ig to cause cytokine release is analyzed. Peripheral blood is withdrawn from three healthy donors by venipuncture into heparized vacutainer tubes. Whole blood is diluted 1:5 with RPMI-1640 medium and placed in 24-well tissue culture plates at 0.5 mL per well. The anti-cytokine antibodies (e.g., anti-IL-4) are diluted
10 into RPMI-1640 and placed in the plates at 0.5 mL/well to give final concentrations of 200, 100, 50, 10, and 1 μ g/mL. The final dilution of whole blood in the culture plates is 1:10. LPS and PHA are added to separate wells at 2 μ g/mL and 5 μ g/mL final concentration as a positive control for cytokine release. Polyclonal human IgG is used as negative control antibody. The experiment is performed in duplicate. Plates are incubated at 37°C at 5% CO₂. Twenty-four hours later the
15 contents of the wells are transferred into test tubes and spun for 5 minutes at 1200 rpm. Cell-free supernatants are collected and frozen for cytokine assays. Cells left over on the plates and in the tubes are lysed with 0.5 mL of lysis solution, and placed at -20°C and thawed. 0.5 mL of medium is added (to bring the volume to the same level as the cell-free supernatant samples) and the cell preparations are collected and frozen for cytokine assays. Cell-free supernatants and cell lysates
20 are assayed for cytokine levels by ELISA, for example, for levels of IL-8, IL-6, IL-1 β , IL-1RA, or TNF- α .

Example 1.1.2.C: Cytokine Cross-Reactivity Study

The ability of an anti-cytokine parent antibody or DVD-Ig directed to a cytokine(s) of interest to cross react with other cytokines is analyzed. Parent antibodies or DVD-Ig are
25 immobilized on a Biacore biosensor matrix. An anti-human Fc mAb is covalently linked via free amine groups to the dextran matrix by first activating carboxyl groups on the matrix with 100mM N-hydroxysuccinimide (NHS) and 400mM N-Ethyl-N'-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC). Approximately 50 μ L of each antibody or DVD-Ig preparation at a concentration of 25 μ g/mL, diluted in sodium acetate, pH 4.5, is injected across the activated
30 biosensor and free amines on the protein are bound directly to the activated carboxyl groups. Typically, 5000 Resonance Units (RU's) are immobilized. Unreacted matrix EDC-esters are deactivated by an injection of 1 M ethanolamine. A second flow cell is prepared as a reference standard by immobilizing human IgG1/K using the standard amine coupling kit. SPR measurements are performed using the CM biosensor chip. All antigens to be analyzed on the
35 biosensor surface are diluted in HBS-EP running buffer containing 0.01% P20.

To examine the cytokine binding specificity, excess cytokine of interest (100nM, e.g., soluble recombinant human) is injected across the anti-cytokine parent antibody or DVD-Ig immobilized biosensor surface (5 minute contact time). Before injection of the cytokine of interest and immediately afterward, HBS-EP buffer alone flows through each flow cell. The net difference in the signals between the baseline and the point corresponding to approximately 30 seconds after completion of cytokine injection are taken to represent the final binding value. Again, the response is measured in Resonance Units. Biosensor matrices are regenerated using 10mM HCl before injection of the next sample where a binding event is observed, otherwise running buffer was injected over the matrices. Human cytokines (e.g., IL-1 α , IL-1 β , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-22, IL-23, IL-27, TNF- α , TNF- β , and IFN- γ , for example) are also simultaneously injected over the immobilized mouse IgG1/K reference surface to record any nonspecific binding background. By preparing a reference and reaction surface, Biacore can automatically subtract the reference surface data from the reaction surface data in order to eliminate the majority of the refractive index change and injection noise. Thus, it is possible to ascertain the true binding response attributed to an anti-cytokine antibody or DVD-Ig binding reaction.

When a cytokine of interest is injected across immobilized anti-cytokine antibody, significant binding is observed. 10mM HCl regeneration completely removes all non-covalently associated proteins. Examination of the sensorgram shows that immobilized anti-cytokine antibody or DVD-Ig binding to soluble cytokine is strong and robust. After confirming the expected result with the cytokine of interest, the panel of remaining recombinant human cytokines is tested, for each antibody or DVD-Ig separately. The amount of anti-cytokine antibody or DVD-Ig bound or unbound cytokine for each injection cycle is recorded. The results from three independent experiments are used to determine the specificity profile of each antibody or DVD-Ig. Antibodies or DVD-Ig with the expected binding to the cytokine of interest and no binding to any other cytokine are selected.

Example 1.1.2.D: Tissue Cross Reactivity

Tissue cross reactivity studies are done in three stages, with the first stage including cryosections of 32 tissues, second stage including up to 38 tissues, and the 3rd stage including additional tissues from 3 unrelated adults as described below. Studies are done typically at two dose levels.

Stage 1: Cryosections (about 5 μ m) of human tissues (32 tissues (typically: Adrenal Gland, Gastrointestinal Tract, Prostate, Bladder, Heart, Skeletal Muscle, Blood Cells, Kidney, Skin, Bone Marrow, Liver, Spinal Cord, Breast, Lung, Spleen, Cerebellum, Lymph Node, Testes, Cerebral Cortex, Ovary, Thymus, Colon, Pancreas, Thyroid, Endothelium,

Parathyroid, Ureter, Eye, Pituitary, Uterus, Fallopian Tube and Placenta) from one human donor obtained at autopsy or biopsy) are fixed and dried on object glass. The peroxidase staining of tissue sections is performed, using the avidin-biotin system.

Stage 2: Cryosections (about 5 μm) of human tissues 38 tissues (including adrenal, blood, blood vessel, bone marrow, cerebellum, cerebrum, cervix, esophagus, eye, heart, kidney, large intestine, liver, lung, lymph node, breast mammary gland, ovary, oviduct, pancreas, parathyroid, peripheral nerve, pituitary, placenta, prostate, salivary gland, skin, small intestine, spinal cord, spleen, stomach, striated muscle, testis, thymus, thyroid, tonsil, ureter, urinary bladder, and uterus) from 3 unrelated adults obtained at autopsy or biopsy) are fixed and dried on object glass. The peroxidase staining of tissue sections is performed, using the avidin-biotin system.

Stage 3: Cryosections (about 5 μm) of cynomolgus monkey tissues (38 tissues (including adrenal, blood, blood vessel, bone marrow, cerebellum, cerebrum, cervix, esophagus, eye, heart, kidney, large intestine, liver, lung, lymph node, breast mammary gland, ovary, oviduct, pancreas, parathyroid, peripheral nerve, pituitary, placenta, prostate, salivary gland, skin, small intestine, spinal cord, spleen, stomach, striated muscle, testis, thymus, thyroid, tonsil, ureter, urinary bladder, and uterus) from 3 unrelated adult monkeys obtained at autopsy or biopsy) are fixed and dried on object glass. The peroxidase staining of tissue sections is performed, using the avidin-biotin system.

The antibody or DVD-Ig is incubated with the secondary biotinylated anti-human IgG and developed into immune complex. The immune complex at the final concentrations of 2 and 10 $\mu\text{g}/\text{mL}$ of antibody or DVD-Ig is added onto tissue sections on object glass and then the tissue sections are reacted for 30 minutes with a avidin-biotin-peroxidase kit. Subsequently, DAB (3,3'-diaminobenzidine), a substrate for the peroxidase reaction, is applied for 4 minutes for tissue staining. Antigen-Sepharose beads are used as positive control tissue sections. Target antigen and human serum blocking studies serve as additional controls. The immune complex at the final concentrations of 2 and 10 $\mu\text{g}/\text{mL}$ of antibody or DVD-Ig is pre-incubated with target antigen (final concentration of 100 $\mu\text{g}/\text{ml}$) or human serum (final concentration 10%) for 30 minutes, and then added onto the tissue sections on object glass and then the tissue sections are reacted for 30 minutes with a avidin-biotin-peroxidase kit. Subsequently, DAB (3,3'-diaminobenzidine), a substrate for the peroxidase reaction, is applied for 4 minutes for tissue staining.

Any specific staining is judged to be either an expected (e.g., consistent with antigen expression) or unexpected reactivity based upon known expression of the target antigen in question. Any staining judged specific is scored for intensity and frequency. The tissue staining between stage 2 (human tissue) and stage 3 (cynomolgus monkey tissue) is either judged to be similar or different.

Example 1.1.2.E: Inhibition of HUVEC Proliferation/Survival by VEGF Parent Antibody and DVD-Ig Constructs

Prior to plating for the assay, normal human umbilical vascular endothelial cells or HUVEC (passage 2-6) were maintained in EBM-2 (Lonza-Clonetics, Walkersville, MD) supplemented with EGM-2 SingleQuots (Lonza-Clonetics, Walkersville, MD, #CC-4176). HUVEC cells were plated at 10,000 cells/well on collagen coated black 96-well plates in (100µl) EMB-2 with 0.1% FBS in the absence of growth factors. The following day the media was replaced with 0.1% FBS in the absence of growth factors. The following day the media was replaced with 100µl of EMB-2 (without growth factors or serum) and incubated for four hours prior to the addition of VEGF and antibodies/DVD-Igs. Anti-VEGF monoclonal antibodies or DVD-Igs (at final concentrations of 67 nM, 6.7 nM and 0.67 nM) were diluted in EMB-2 with 0.1% BSA and were pre-incubated with recombinant human VEGF₁₆₅ (50ng/ml) for 1 hour at 25°C in 50µl. Antibody/DVD-Ig and VEGF mixtures were then added to the cells (50µl), and the plates were incubated at 37 °C in a humidified, 5% CO₂ atmosphere for 72 hours. Cell survival/proliferation was measured indirectly by assessing ATP levels using an ATPlite kit (Perkin Elmer, Waltham, MA) according to the manufacturer's instructions. Table 10 provides the data showing inhibition of HUVEC proliferation/survival.

Table 10: Inhibition Of HUVEC Proliferation/Survival By VEGF Parent Antibody And DVD-Ig Constructs

Parent Antibody or DVD-Ig ID	N-terminal Variable Domain (VD)	C-terminal Variable Domain (VD)	N-terminal VD inhibition of HUVEC proliferation (% inhibition at 67, 6.7 and 0.67nM Ab/DVD-Ig)	C-terminal VD inhibition of HUVEC proliferation (% inhibition at 67, 6.7 and 0.67nM Ab/DVD-Ig)
AB014	VEGF		67nM=98%, 6.7nM=91%, 0.67nM=12%	
DVD038	HER-2	VEGF		67nM=45%, 6.7nM=-18%, 0.67nM=-22%
AB014	VEGF		67nM=98%, 6.7nM=91%, 0.67nM=12%	
DVD044	DLL4	VEGF		67nM=99%, 6.7nM=19%, 0.67nM=6%
DVD043	VEGF	DLL4	67nM=89%, 6.7nM=51%, 0.67nM=-22%	
AB014	VEGF		67nM=97%, 6.7nM=91%, 0.67nM=62%	
DVD048	RON	VEGF		67nM=91%, 6.7nM=88%, 0.67nM=62%

DVD047	VEGF	RON	67nM=65%, 6.7nM=31%, 0.67nM=-5%	
AB014	VEGF		67nM=97%, 6.7nM=91%, 0.67nM=62%	
DVD049	VEGF	NRP1	67nM=108%, 6.7nM=86%, 0.67nM=43%	
DVD050	NRP1	VEGF		67nM=103%, 6.7nM=74%, 0.67nM=15%
AB014	VEGF		67nM=98%, 6.7nM=91%, 0.67nM=12%	
DVD260	PIGF	VEGF		67nM=51%, 6.7nM=7%, 0.67nM=-16%

All DVD-Igs containing VDs from AB014 inhibited HUVEC cell proliferation caused by VEGF. DVD044, DVD048, DVD040 DVD050 inhibited HUVEC cell proliferation by > 90% at 67nM concentration of DVD-Igs.

5 **Example 1.1.2.F: Tumor Cell Growth Inhibitory Effect of IGF1,2 Monoclonal Antibodies or DVD-Igs In Vitro.**

IGF1,2 monoclonal antibodies or DVD-Igs diluted in D-PBS-BSA (Dulbecco's phosphate buffered saline with 0.1%BSA) 20 μ L were added to human tumor cells at final concentrations of 0.01 μ g/mL-100 μ g/mL in 200 μ L. The plates were incubated at 37 °C in a humidified, 5% CO₂ atmosphere for three days. The number of live cells in each well was quantified using MTS reagents according to the manufacturer's instructions (Promega, Madison, WI) to determine the percent of tumor growth inhibition. Wells without antibody treatment were used as controls of 0% inhibition whereas wells without cells were considered to show 100% inhibition.

10 **Table 11: H929, IGFR Line Proliferation Inhibition Assay With IGF1R and IGF1,2 Parent Antibodies and DVD-Ig Constructs**

Parent Antibody or DVD-Ig ID	N-terminal Variable Domain (VD)	C-terminal Variable Domain (VD)	N-terminal VD Proliferation Inhibition Cellular Assay IC50 nM (H929, IGF1R line)	C-terminal VD Proliferation Inhibition Cellular Assay IC50 nM (H929, IGF1R line)
AB033	EGFR		>67 (5% max)	
AB004	HER-2		>67 (10% max)	
DVD015	EGFR	HER-2	> 50 (20% max)	
DVD016	HER-2	EGFR		> 50 (15% max)
AB033	EGFR		> 67 (5% max)	
AB011	IGF1R		0.1 (65% max)	
DVD021	EGFR	IGF1R		> 50 (10% max)
DVD022	IGF1R	EGFR	0.05 (70% max)	
AB004	HER-2		> 67 (10% max)	

Parent Antibody or DVD-Ig ID	N-terminal Variable Domain (VD)	C-terminal Variable Domain (VD)	N-terminal VD Proliferation Inhibition Cellular Assay IC50 nM (H929, IGF1R line)	C-terminal VD Proliferation Inhibition Cellular Assay IC50 nM (H929, IGF1R line)
AB010	IGF1,2		1.6 (70% max)	
DVD029	HER-2	IGF1,2		6.8 (40% max)
DVD030	IGF1,2	HER-2	0.8 (70% max)	
AB004	HER-2		> 67 (10%)	
AB011	IGF1R		0.1 (65% max)	
DVD031	HER-2	IGF1R		> 50 (10% max)
DVD032	IGF1R	HER-2	0.1 (60% max)	

All DVD-Igs containing VDs from AB033, AB004, AB011, or AB010 in either the N-terminal or C-terminal position showed inhibition in the A431 cell proliferation assay.

Example 1.1.2.G: Growth Inhibitory Effect of an EGFR Monoclonal Antibody or DVD-Igs In Vitro

EGFR monoclonal antibodies or DVD-Igs diluted in D-PBS-BSA (Dulbecco's phosphate buffered saline with 0.1%BSA) 20 μ L were added to human tumor cells at final concentrations of 0.01 μ g/mL-100 μ g/mL in 180 μ L. The plates were incubated at 37 °C in a humidified, 5% CO₂ atmosphere for 3 days. The number of live cells in each well was quantified using MTS reagents according to the manufacturer's instructions (Promega, Madison, WI) to determine the percent of tumor growth inhibition. Wells without antibody treatment were used as controls of 0% inhibition whereas wells without cells were considered to show 100% inhibition.

Table 12: A431, EGFR Cell Line Proliferation Inhibition Assay With EGFR Parent Antibodies And DVD-Ig Constructs

Parent Antibody or DVD-Ig ID	N-terminal Variable Domain (VD)	C-terminal Variable Domain (VD)	N-terminal VD Proliferation Inhibition Cellular Assay IC50 nM (A431, EGFR line)	C-terminal VD Proliferation Inhibition Cellular Assay IC50 nM (A431 EGFR line)
AB033	EGFR		1.0 (65% max)	
AB004	HER-2		> 67 (10% max)	
DVD015	EGFR	HER-2	1.7 (65% max)	
DVD016	HER-2	EGFR		5.4 (80% max)
AB033	EGFR		1.0 (65% max)	
AB011	IGF1R		> 67 (5% max)	
DVD021	EGFR	IGF1R	1.5 (50% max)	
DVD022	IGF1R	EGFR		3.4 (65% max)
AB004	HER-2		> 67 (10% max)	
AB010	IGF1,2		> 67 (10% max)	

Parent Antibody or DVD-Ig ID	N-terminal Variable Domain (VD)	C-terminal Variable Domain (VD)	N-terminal VD Proliferation Inhibition Cellular Assay IC50 nM (A431, EGFR line)	C-terminal VD Proliferation Inhibition Cellular Assay IC50 nM (A431 EGFR line)
DVD029	HER-2	IGF1,2	> 50 (10% max)	
DVD030	IGF1,2	HER-2	> 50 (10% max)	
AB004	HER-2		> 67 (10% max)	
AB011	IGF1R		> 67 (5% max)	
DVD031	HER-2	IGF1R	> 50 (10% max)	
DVD032	IGF1R	HER-2	> 50 (10% max)	
AB014	VEGF		> 67 (0%)	
AB010	IGF1,2		>67 (10% max)	
DVD041	VEGF	IGF1,2	> 50 (0%)	

All DVD-Igs containing VDs from AB033, AB004, AB011, AB010, AB014 in either N-terminal or C-terminal position showed inhibition of A431 cell proliferation assay.

Table 13: GEO, EGFR/IGF1R Cell Line Proliferation Inhibition Assay With EGFR, IGF1R And IGF1,2 Parent Antibodies And DVD-Ig Constructs

5

Parent Antibody or DVD-Ig ID	N-terminal Variable Domain (VD)	C-terminal Variable Domain (VD)	N-terminal Proliferation Inhibition Cellular Assay IC50 nM (GEO, EGFR/ IGF1R line)	C-terminal Proliferation Inhibition Cellular Assay IC50 nM (GEO, EGFR/ IGF1R line)
AB033	EGFR		0.2 (60% max)	
AB004	HER-2		> 67 (15% max)	
DVD015	EGFR	HER-2	13 (60% max)	
DVD016	HER-2	EGFR		10 (40% max)
AB033	EGFR		0.2 (60% max)	
AB011	IGF1R		> 67 (15% max)	
DVD021	EGFR	IGF1R	0.32 (60% max)	0.32 (60% max)
DVD022	IGF1R	EGFR	3.0 (40% max)	3.0 (40% max)
AB004	HER-2		> 67 (15% max)	
AB010	IGF1,2		20% at 67 nM	
DVD029	HER-2	IGF1,2	> 50 (10% max)	> 50 (10% max)
DVD030	IGF1,2	HER-2	> 50 (10% max)	> 50 (10% max)
AB004	HER-2		> 67 (15% max)	
AB011	IGF1R		> 67 (15% max)	
DVD031	HER-2	IGF1R	> 50 (10% max)	> 50 (10% max)
DVD032	IGF1R	HER-2	> 50 (10% max)	> 50 (10% max)

All DVD-Igs containing VDs from AB033, AB004, AB011, AB010, AB014 in either N-terminal or C-terminal position showed inhibition of GEO cell proliferation assay.

Example 1.1.2.H Tumor Cell Growth Inhibitory Effect of HER2 Parent Antibody or DVD-Ig Constructs *In Vitro*

10

HER2 monoclonal antibody or DVD-Igs diluted in D-PBS-BSA (Dulbecco's phosphate buffered saline with 0.1% BSA) 20 μ L were added to HER2-expressing human tumor cells (BT474) at final concentrations of 0.01 μ g/mL-100 μ g/mL (180 μ L). The plates were incubated at 37 °C in a humidified, 5% CO₂ atmosphere for three days. The number of live cells in each well was quantified using MTS reagents according to the manufacturer's instructions (Promega, Madison, WI) to determine the percent of tumor growth inhibition. Wells without antibody treatment were used as controls of 0% inhibition whereas wells without cells were considered to show 100% inhibition.

10 **Table 14: BT474, Erb2(Her-2) Cell Line Proliferation Inhibition Assay With Anti-Her-2 Parent Antibodies And DVD-Ig Constructs**

Parent Antibody or DVD-Ig ID	N-terminal Variable Domain (VD)	C-terminal Variable Domain (VD)	N-terminal VD Proliferation Inhibition Cellular Assay IC50 nM (BT474, ErbB2 line)	C-terminal VD Proliferation Inhibition Cellular Assay IC50 nM (BT474, ErbB2 line)
AB004	HER-2		0.9	
DVD015	EGFR	HER-2		> 50
DVD016	HER-2	EGFR	1.7	
AB004	HER-2		0.9	
DVD029	HER-2	IGF1,2	2.7	
DVD030	IGF1,2	HER-2		> 50
AB004	HER-2		0.9	
DVD031	HER-2	IGF1R	2.2	
DVD032	IGF1R	HER-2		> 50

All DVD-Igs containing VD from AB004 in either N-terminal or C-terminal position showed inhibition in the BT474 cell proliferation assay.

15 **Example 1.1.2.I: Inhibition Of Recombinant DLL4-Dependent Increase Of Svegfr1 (Sflt1) In Eahy.926 Cells By DLL4 Parent Antibody And DVD-Ig Constructs**

96-well tissue culture plates were coated with 100 μ l/well human DLL4 extracellular domain at 5 μ g/ml in D-PBS (Gibco #14190, Grand Island, NY) and incubated overnight at 4 °C. Plates were washed once with D-PBS and 4000 EA.hy926 cells/well were seeded in the absence or presence of antibodies or DVD-Igs. Cell proliferation was measured four days later using the CyQUANT Cell Proliferation Assay Kit (Invitrogen, #C35007, Eugene, OR). sVEGFR1 expression in the conditioned media was detected by an ELISA kit per the manufacturer's recommendations (R&D Systems #DVR100B, Minneapolis, MN). Levels of sVEGFR1 were normalized to the RFU determined by CyQUANT assay to account for differences in cell proliferation.

20

25

Table 15: Inhibition Of DLL4-Dependent Increase Of Svegfr1 (Sflt1) In Eahy.926 Cells By DLL4 Parent Antibodies Or DVD-Ig Constructs

Parent Antibody or DVD-Ig ID	N-terminal Variable Domain (VD)	C-terminal Variable Domain (VD)	N-terminal VD Soluble Flt1 Assay (% of Neutralization @ nM Ab)	C-terminal VD Soluble Flt1 Assay (% of Neutralization @ nM Ab)
AB015	DLL-4		75.2% @9.2 nM, 78.7% @27.7 nM, 86.6% @83.3 nM	
DVD044	DLL4	VEGF	39.8% @9.2 nM, 76.2% @27.7 nM, 79.9% @83.3 nM	
DVD043	VEGF	DLL4		1.1% @9.2 nM, 50.3% @27.7 nM, 57.9% @83.3 nM

5 DVD-Igs containing VD from AB015 in either N-terminal or C-terminal position showed dose-dependent inhibition of sFLT release induced by DLL4 from Eahy.926 cells.

Example 1.1.2.J: Tumoricidal Effect of A Parent or DVD-Ig Antibody In Vitro

Parent antibodies or DVD-Ig that bind to target antigens on tumor cells may be analyzed for tumoricidal activity. Briefly, parent antibodies or DVD-Ig are diluted in D-PBS-BSA (Dulbecco's phosphate buffered saline with 0.1%BSA) and added to human tumor cells at final concentrations of 0.01 µg/mL to 100 µg/mL 200µL. The plates are incubated at 37 °C in a humidified, 5% CO₂ atmosphere for 3 days. The number of live cells in each well is quantified using MTS reagents according to the manufacturer's instructions (Promega, Madison, WI) to determine the percent of tumor growth inhibition. Wells without antibody treatment are used as controls of 0% inhibition whereas wells without cells were considered to show 100% inhibition.

For assessment of apoptosis, caspase-3 activation was determined by the following protocol: antibody-treated cells in 96 well plates are lysed in 120 µl of 1x lysis buffer (1.67mM Hepes, pH 7.4, 7mM KCl, 0.83mM MgCl₂, 0.11mM EDTA, 0.11mM EGTA, 0.57% CHAPS, 1mM DTT, 1x protease inhibitor cocktail tablet; EDTA-free; Roche Pharmaceuticals, Nutley, NJ) at room temperature with shaking for 20 minutes. After cell lysis, 80 µl of a caspase-3 reaction buffer (48mM Hepes, pH 7.5, 252mM sucrose, 0.1% CHAPS, 4mM DTT, and 20 µM Ac-DEVD-AMC substrate; Biomol Research Labs, Inc., Plymouth Meeting, PA) is added and the plates are incubated for 2 hours at 37°C. The plates are read on a 1420 VICTOR Multilabel Counter (Perkin Elmer Life Sciences, Downers Grove, IL) using the following settings: excitation= 360/40, emission= 460/40. An increase of fluorescence units from antibody-treated cells relative to the isotype antibody control-treated cells is indicative of apoptosis.

Example 1.1.2.K: Inhibition of U87-MG Tumor Cell Proliferation by HGF Parent Antibody and DVD-Ig Constructs

U87-MG human glioma tumor cells were plated at 2,000 cells/well in 100 μ l in 96-well dishes in RPMI medium supplemented with 5% fetal bovine serum, and incubated at 37°C, 5% CO₂ overnight. The following day the cells were treated with serial dilutions of antibody or DVD-Igs (0.013 nM to 133 nM dose range), and incubated at 37 °C in a humidified, 5% CO₂ atmosphere for 5 days. Cell survival/proliferation was measured indirectly by assessing ATP levels using an ATPlite kit (Perkin Elmer, Waltham, MA) according to the manufacturer's instructions.

10 **Table 16: U87-MG Tumor Proliferation Inhibition by anti-HGF Parent Antibody and DVD-Ig Constructs**

Parent Antibody or DVD-Ig ID	N-terminal Variable Domain (VD)	C-terminal Variable Domain (VD)	N-terminal VD inhibition of U87MG proliferation (EC50)	C-terminal VD inhibition of U87MG proliferation (EC50)
AB012	HGF		12	
DVD025	EGFR	HGF		>200
AB012	HGF		12	
DVD033	RON	HGF		>200
DVD034	HGF	RON	136	
AB012	HGF		12	
DVD045	VEGF	HGF		>200
AB008	CD22		>200	

DVD-Igs containing a VD from AB012 in the C-terminal position or N-terminal position inhibited U87-MG tumor cell proliferation.

15 **Example 1.1.2.L: Inhibition of RON Interaction with MSP1 by RON Parent Antibody and DVD-Ig Constructs *In Vitro***

96-well plates were coated with 50 μ l/well of an anti-MSP α chain antibody (R&D Systems #MAB352, Minneapolis, MN, 2 μ g/mL), and plates were incubated overnight at 4°C. Plates were washed three times in wash buffer (PBS containing 0.05% Tween 20), and subsequently blocked with 100 μ l/well of blocking buffer (PBS containing 2% BSA) for one hour at 25°C. Plates were then washed three times, and incubated with 50 μ l/well of a 10nM solution of recombinant human MSP1 (R&D Systems #352-MS, Minneapolis, MN) for one hour at 25°C. During plate incubation, serial 10-fold dilutions of the antibodies to be tested (0nM to 1000nM dose range) were pre-incubated with 10nM recombinant His-RON partial ECD (R&D Systems #1947-MS, Minneapolis, MN) at 25°C for one hour. Plates incubated with recombinant human MSP1 were washed three times, and 50 μ l/well of the antibody/His-RON complexes were then

added in triplicate. Following a one hour incubation at 25°C, the plates were then washed, and 50µl/well of a TMB substrate (Pierce #34028, Rockford, IL) were added and incubated for five minutes at 25°C. The reaction was terminated after five minutes using 50µl/well of 2N H₂SO₄. The absorbance was read at 450 nm (Spectra Max Plus plate reader, Molecular Devices, Sunnyvale, CA). EC50s were calculated in GraphPad Prism 4.03. The results are provided in Table 17 below.

Example 1.1.2.M: VEGF Parent Antibody and DVD-Ig Constructs Prevent VEGF₁₆₅ Interaction with VEGFR1

ELISA plates (Nunc, MaxiSorp, Rochester, NY) were incubated overnight at 4°C with 100 µl PBS containing recombinant VEGFR1 extra-cellular domain-Fc fusion protein (5µg/ml, R&D systems, Minneapolis, MN). Plates were washed three times in washing buffer (PBS containing 0.05% Tween 20), and blocked for 1 hour at 25°C in blocking buffer (PBS containing 1% BSA). Serial dilutions of each antibody/DVD-Ig in PBS containing 0.1% BSA were incubated with 50µl of 2nM biotinylated VEGF for 1 hour at 25°C. The antibody/DVD-Ig-biotinylated VEGF mixtures (100µl) were then added to the VEGFR1-Fc coated wells and incubated at 25°C for 10 minutes. The wells were washed three times, and then incubated for 1 hour at 25°C with 100µl of streptavidin-HRP (KPL #474-3000, Gaithersburg, MD). The wells were washed three times, and 100µl of ULTRA-TMB ELISA (Pierce, Rockford, IL) were added per well. Following color development the reaction was stopped with 1N HCL and absorbance at 450nm was measured. The results are provided in Table 17 below.

Example 1.1.2.N: Inhibition of DLL4 Interaction with Notch-1 by DLL4 Parent Antibody and DVD-Ig Constructs In Vitro

96-well Nunc-Immuno plates (Nunc, #439454, Rochester, NY) were coated with 16 nM human Notch-1 (R&D Systems #3647-TK, Minneapolis, MN, 100 µl/well in D-PBS) and incubated overnight at 4°C. Plates were then washed once with wash buffer (PBS, 0.05% Tween 20) and blocked with 200 µl/well blocking buffer (D-PBS, 1% BSA, 1 mM CaCl₂, 0.05% Tween 20) for 1 hour at 25°C. While blocking, 300 µl biotin labeled human DLL4 extracellular domain (14 nM) was mixed with antibody or DVD-Ig (3.4 pM-66 nM, 3-fold serial dilution in blocking buffer) for 1 hour at 25°C. Assay plates were washed after blocking, and incubated with DLL4 antibody or DVD-Ig mixtures (100 µl/well, 1 hour at 25°C). Plates were washed again and 100 µl/well streptavidin conjugated with HRP (KPL #474-3000, Gaithersburg, MD, diluted 1:10,000 in blocking buffer) was added for 1 hour at 25°C. After a final wash, plates were developed using 100 µl/well substrate (1-Step Ultra TMB-ELISA, Pierce #340280, Rockford, IL), and the reaction was stopped after a 10-20 minute incubation at 25°C using 100 µl/well 2N H₂SO₄, and the absorbance was read at 450 nm. The results are provided in Table 17 below.

Example 1.1.2.O: Inhibition of HGF Interaction with c-Met by HGF Parent Antibody and DVD-Ig Constructs

ELISA plates (Nunc, MaxiSorp) were coated with 100 μ l/well of recombinant human HGF (2 μ g/ml of HGF in PBS, R&D systems) overnight at 4°C. Serial dilutions of each antibody/DVD-Ig and 2nM soluble c-Met Fc fusion (R&D systems) (50 μ l), were co-incubated and added to HGF coated wells. c-Met binding was detected with biotinylated anti-c-Met (BAF358, R&D Systems) and 100 μ l of streptavidin-HRP (KPL). The wells were washed three times in PBST (PBS containing 0.05% Tween 20), and 100 μ l of ULTRA-TMB ELISA (Pierce) were added per well. Following color development the reaction was stopped with 1N HCL and absorbance at 450nm was measured. The data were evaluated by calculating the percentage inhibition compared with the maximal signal (control antibody or no antibody added) and the IC₅₀ values were calculated.

The following table contains the affinity data, expressed as IC₅₀ in nM, of parent antibodies and DVD-Ig constructs in the ligand-receptor binding competition ELISA assays for RON, VEGF, DLL4, and HGF as described above.

Table 17: Inhibition Of Ligand-Receptor Interaction With RON, VEGF DLL4, And HGF Parent Antibodies And DVD-Ig Constructs *In Vitro*

Parent Antibody or DVD-Ig ID	N-terminal Variable Domain (VD)	C-terminal Variable Domain (VD)	N-terminal VD Ligand-Receptor Binding Competition Assay (IC ₅₀ , nM)	C-terminal VD Ligand-Receptor Binding Competition Assay (IC ₅₀ , nM)
AB005	RON		8.1	
DVD024	RON	EGFR	9.6	
DVD023	EGFR	RON		
AB005	RON		0.32	
DVD033	RON	HGF	**0.0000097	
DVD034	HGF	RON		
AB014	VEGF		21.40	
DVD035	VEGF	EGFR	23.90	
AB014	VEGF		21.40	
DVD038	HER-2	VEGF		73.00
AB015	DLL-4		0.37	
AB014	VEGF		21.4	
DVD044	DLL4	VEGF	0.50	143
DVD043	VEGF	DLL4	24.1	13.10
AB005	RON		0.1	
AB014	VEGF		21.4	
DVD048	RON	VEGF	0.1127	114
DVD047	VEGF	RON	30.5	21.28

AB014	VEGF		21.40
DVD050	NRP1	VEGF	79.00
AB015	DLL-4		0.4
DVD257	DLL4	PIGF	0.38
DVD258	PIGF	DLL4	17.47
AB014	VEGF		21.40
DVD260	PIGF	VEGF	13.00
AB012	HGF		0.18
DVD025	EGFR	HGF	>100
AB012	HGF		0.18
DVD045	VEGF	HGF	>100
AB012	HGF		0.18
DVD033	RON	HGF	8.7
DVD034	HGF	RON	0.34

All DVD-Igs containing VD from AB005, AB015, AB015, AB012, in either N-terminal or C-terminal positions showed inhibition of ligand to their respective receptors. The N-terminal domain of DVD-Ig blocked ligand-receptor interaction as well as parent antibody.

5 **Example 1.1.2.P: Inhibition of IGF-Induced IGFR Phosphorylation by Parent Antibodies or DVD-Ig Constructs *In Vitro***

Human carcinoma cells were plated in 96-well plates at 40,000 cells/well in 180µl serum-free medium (DMEM+ 0.1% BSA), and incubated overnight at 37°C, 5% CO₂. Costar EIA plates (Lowell, MA) were coated with 100 µl/well of IGFR capture Ab (R&D Systems cat #MAB391,
 10 Minneapolis, MN, 4µg/ml final concentration), and incubated overnight at room temperature while shaking. The following day, IGFR antibody-coated ELISA plates were washed (three times with PBST = 0.05% Tween 20 in PBS, pH 7.2 - 7.4), and 200µl blocking solution was added (1% BSA, 0.05% NaN₃ in PBS, pH 7.2 - 7.4.) to block for 2 hours at room temperature on a rocker. Human tumor cells were co-incubated with antibodies or DVD-Igs and IGF ligand. IGF1,2
 15 monoclonal antibodies or DVD-Igs diluted in D-PBS-BSA (Dulbecco's phosphate buffered saline with 0.1%BSA) were added to human carcinoma cells at final concentrations of 0.01 µg/mL-100 µg/mL. Growth factors (IGF1 and IGF2) were simultaneously added to the cells at concentrations of 1-100ng/mL (200µL), and cells were incubated at 37°C in a humidified, 5% CO₂ atmosphere for 1 hour. Cells were lysed in 120µl/well of cold cell extraction buffer (10 mM Tris, pH 7.4, 100
 20 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 1 mM sodium orthovanadate, 1% Triton X-100, 10% Glycerol, 0.1% SDS, and protease inhibitor cocktail), and incubated at 4°C for 20 minutes with shaking. Cell lysates (100µl) were added to the ELISA plate, and incubated overnight at 4°C with gentle shaking. The following day, ELISA plates were washed, and 100 µl/well of pTyr-HRP detection Ab was added (p-IGF1R ELISA kit, R&D System # DYC1770,
 25 Minneapolis, MN), and plates were incubated for 2 hours at 25⁰C in the dark. Plates were

developed to determine phospho-IGF1R per the manufacturer's instructions. Results are shown in Tables 18 and 19.

5 **Table 18: Inhibition Of IGF1R Phosphorylation By IGF1 With Anti-IGF1,2 Parent Antibodies Or DVD-Ig Constructs**

Parent Antibody or DVD-Ig ID	N-terminal Variable Domain (VD)	C-terminal Variable Domain (VD)	N-terminal VD pIGF1R Cellular Assay (hIGF1 Neutralization IC50 nM)	C-terminal VD pIGF1R Cellular Assay (hIGF1 Neutralization IC50 nM)
AB010	IGF1,2		1.7	
DVD029	HER-2	IGF1,2		14.22 (40% max)
DVD030	IGF1,2	HER-2	1.9	
AB010	IGF1,2		1.7	
DVD041	VEGF	IGF1,2		16.8 (40% max)
DVD042	IGF1,2	VEGF	1.8	

DVD-Igs containing the VD from AB010 in either the N-terminal or the C-terminal position showed inhibition of IGF1-induced IGF1R receptor phosphorylation. The VD of AB010 in N-terminal position of DVD-Ig blocked receptor phosphorylation as well as parent antibody AB010.

10 **Table 19: Inhibition Of IGF1R Phosphorylation By IGF2 With Anti-IGF1,2 Parent Antibodies Or DVD-Ig Constructs**

Parent Antibody or DVD-Ig ID	N-terminal Variable Domain (VD)	C-terminal Variable Domain (VD)	N-terminal VD pIGFR1 Cellular Assay (IGF2 induced IC50 nM)	C-terminal VD pIGFR1 Cellular Assay (IGF2 induced IC50 nM)
AB010	IGF1,2		0.3	
DVD029	HER-2	IGF1,2	ND	1.9
DVD030	IGF1,2	HER-2	0.4	ND
AB010	IGF1,2		0.3	
DVD041	VEGF	IGF1,2	ND	1.5
DVD042	IGF1,2	VEGF	0.3	ND

DVD-Igs containing the VD from AB010 in either the N-terminal or the C-terminal position showed inhibition of IGF2-induced IGF1R receptor phosphorylation. The VD of AB010 in the N-terminal position of DVD-Ig blocked receptor phosphorylation as well as parent antibody AB010.

Example 1.1.2.Q: Inhibition Of HGF-Mediated Phosphorylation Of Akt By HGF Parent Antibody And DVD-Ig Constructs

H1299 non-small cell lung tumor cells were plated at 20,000 cells/well (100 μ l total volume) in 96-well plates and serum starved for 18 hours at 37°C, 5% CO₂. Anti-HGF
 5 monoclonal antibodies or DVD-Igs (final concentrations of 67 nM, 6.7 nM, and 0.67 nM) were diluted in Dulbecco's Minimal Essential Media containing 0.1% BSA and were pre-incubated with recombinant human HGF (50ng/ml) in 50 μ l for 1 hour at 25°C. These antibody/DVD-Ig and HGF mixtures (50 μ l) were then added to the cells, and the plates were incubated at 37°C in a humidified, 5% CO₂ atmosphere for approximately 15 minutes. The cells were then fixed by
 10 adding an equal volume of 7.6% formaldehyde to each well and the plates were incubated for 15 minutes at 25°C. Following fixation, the cells were washed five times in PBS containing 0.1% Triton X-100. The cells were then treated with 150 μ l of LI-COR Odyssey Blocking Buffer (Li-Cor Biosciences, Lincoln, NE) per well, and incubated for 90 minutes at room temperature with moderate shaking. The blocking buffer was removed and the cells were incubated at 4°C
 15 overnight with primary antibody diluted in blocking buffer (1:300 dilution Phospho Ser473-Akt, Cell Signaling Technology #4060, Boston, MA). The wells were then washed five times with PBS containing 0.1% Tween 20, and then incubated with secondary antibody (1:400 dilution of an anti-rabbit IRDye™ 680CW LI-COR (Li-Cor Biosciences, Lincoln, NE) in 1XPBS with 0.2% Tween 20) for 1 hour at 25°C. The cells were washed five times with PBS containing 0.1% Tween
 20 20, and imaged using an Odyssey Infrared Imaging System.

Table 20: Inhibition Of HGF-Mediated Phosphorylation Of Akt By HGF Parent Antibody And DVD-Ig Constructs

Parent Antibody or DVD-Ig ID	N-terminal Variable Domain (VD)	C-terminal Variable Domain (VD)	N-Terminal VD Inhibition Of Akt Phosphorylation (% Inhibition At 67, 6.7 And 0.67nM Ab/DVD)	C-Terminal VD Inhibition Of Akt Phosphorylation (% Inhibition At 67, 6.7 And 0.67nm Ab/DVD)
AB012	HGF		67nM=106%, 6.7nM=110%, 0.67nM=79%	
DVD033	RON	HGF		67nM=95%, 6.7nM=91%, 0.67nM=24%
DVD034	HGF	RON	67nM=111%, 6.7nM=105%, 0.67nM=99%	
AB012	HGF		67nM=106%, 6.7nM=110%, 0.67nM=79%	
DVD045	VEGF	HGF		67nM=64%, 6.7nM=-2%, 0.67nM=-15%
AB008	CD22		67nM=8%, 6.7nM=-13%	

DVD-Igs containing the VD from AB012 in either the N-terminal or the C-terminal position showed good inhibition of HGF-induced Akt phosphorylation. The VD of AB012 in the N-terminal position of DVD-Ig blocked Akt phosphorylation as well as parent antibody AB012.

Example 1.1.2.R: Inhibition Of VEGFR2 (KDR) Phosphorylation By VEGF Parent

5 **Antibody And DVD-Ig Constructs**

NIH3T3 cells expressing human VEGFR2 (KDR) were plated at 20,000 cells/well (100 μ l) in 96-well plates in DMEM supplemented with 10% FBS. The following day, the cells were washed twice with DMEM and serum-starved for three hours in DMEM without FBS. Anti-VEGF parent antibody or DVD-Igs (at final concentrations of 67 nM, 6.7 nM and 0.67 nM) 10 diluted in DMEM with 0.1%BSA were pre-incubated with recombinant human VEGF₁₆₅ (50ng/ml) for 1 hour at 25°C. These antibody/DVD-Ig and VEGF mixtures were then added to the cells, and the plates were incubated at 37°C in a humidified, 5% CO₂ atmosphere for 10 minutes. Cells were washed twice with ice cold PBS and lysed by addition of 100 μ l/ well of Cell Lysis Buffer (Cell Signaling, Boston, MA) supplemented with 0.1% NP40. Duplicate samples were 15 pooled and 170 μ l was added to wells of ELISA plates previously coated with anti-VEGFR2 antibody (R&D systems, AF357, Minneapolis, MN) and incubated at 25°C with gentle shaking for two hours. The wells were washed five times with washing buffer (PBS containing 0.05% Tween 20), and incubated with 50 μ l of of 1:2000 dilution of biotinylated anti-phosphotyrosine antibody (4G10; Millipore, Billerica, MA) for 1 hour at 25°C. The wells were washed five times 20 with PBS containing 0.05% Tween 20, and then incubated for 1 hour at 25°C with streptavidin-HRP (KPL #474-3000, Gaithersburg, MD). The wells were washed three times with streptavidin-HRP (KPL #474-3000, Gaithersburg, MD)). The wells were washed three times with PBS containing 0.05% Tween 20, and 100 μ l of ULTRA-TMB ELISA (Pierce, Rockford, IL) were added per well. Following color development the reaction was stopped with 1N HCL and 25 absorbance at 450nm was measured. The results are shown in Table 21.

Table 21: Inhibition Of VEGFR2 (KDR) Phosphorylation By VEGF Parent Antibodies Or DVD-Ig Constructs

Parent Antibody or DVD-Ig ID	C-terminal Variable Domain (VD)	N-terminal Variable Domain (VD)	N-Terminal VD Inhibition Of Pkdr (EC50)	C-Terminal VD Inhibition Of Pkdr (EC50)
AB014	VEGF		0.45	
DVD044	DLL4	VEGF		10.40
DVD043	VEGF	DLL4	0.54	
AB014	VEGF		0.45	
DVD048	RON	VEGF		31.80
DVD047	VEGF	RON	0.47	

DVD-Igs containing the VD from AB014 in either N-terminal or the C-terminal position showed good inhibition of VEGF-induced KDR phosphorylation. The VD of AB014 in the N-terminal position of DVD-Ig blocked KDR phosphorylation as well as parent antibody AB014.

5 **Example 1.1.2.S: Inhibition Of EGF-Induced EGFR Phosphorylation By EGFR Parent Antibody Or DVD-Ig Constructs *In Vitro***

EGFR monoclonal antibodies or DVD-Igs diluted in D-PBS-BSA (Dulbecco's phosphate buffered saline with 0.1%BSA) were added to human carcinoma cells at final concentrations of 0.01 µg/mL-100 µg/mL (180µL). The plates were incubated at 37 °C in a humidified, 5% CO₂ atmosphere for 1 hour. Growth factors (EGF) at a final concentration of 1-100ng/mL (20µL) were added to the cells for 5-15 minutes to stimulate receptor (EGFR) autophosphorylation. Wells without antibody treatment were used as controls of 0% inhibition whereas wells without growth factor stimulation were considered to show 100% inhibition. Cell lysates were made by incubation with cell extraction buffer (10 mM Tris, pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 1 mM sodium orthovanadate, 1% Triton X-100, 10% Glycerol, 0.1% SDS, and protease inhibitor cocktail). Phospho-EGFR in these cell lysates was determined using the p-EGFR ELISA kit from R&D Systems (#DYC1095, Minneapolis, MN) according to the manufacturer's instructions. Results are shown in Tables 22 and 23.

20 **Table 22: Inhibition Of EGF-Induced EGFR Phosphorylation By Anti-EGFR Parent Antibodies And DVD-Ig Constructs**

Parent Antibody or DVD-Ig ID	N-terminal Variable Domain (VD)	C-terminal Variable Domain (VD)	N-terminal VD pEGFR Cellular Assay (EGF induced IC50 nM)	C-terminal VD pEGFR Cellular Assay (EGF induced IC50 nM)
AB033	EGFR		7.3	
DVD015	EGFR	HER-2	7.9	
DVD016	HER-2	EGFR		>50 (10 % max)
AB033	EGFR		7.3	
DVD021	EGFR	IGF1R	7.7	
DVD022	IGF1R	EGFR		> 50 (20% max)

DVD-Igs containing the VD from AB033 in either the N-terminal or the C-terminal position showed good inhibition of EGF-induced EGFR phosphorylation. The VD of AB033 in the N-terminal position of DVD-Ig (DVD015, DVD021) blocked EGFR phosphorylation as well as parent antibody AB033.

25 **Table 23: Inhibition Of EGF-Induced EGFR Phosphorylation By Anti-EGFR Parent Antibodies And DVD-Ig Constructs**

Parent Antibody or DVD-Ig ID	N-terminal Variable Domain (VD)	C-terminal Variable Domain (VD)	N-Terminal Cellular Assay, Inhibition Of EGF-Induced phEGFR (IC50, nM)	C-Terminal Cellular Assay, Inhibition Of EGF-Induced phEGFR (IC50, nM)
AB033	EGFR		0.35	
DVD024	RON	EGFR	ND	7.143
DVD023	EGFR	RON	0.54	ND

DVD-Igs containing the VD from AB033 in either the N-terminal or the C-terminal position showed good inhibition of EGF-induced EGFR phosphorylation. The VD of AB033 in the N-terminal position of DVD-Ig (DVD023) blocked EGFR phosphorylation as well as parent antibody AB033.

Example 1.1.2.T: Inhibition Of MSP1-Induced ERK1/2 And AKT Phosphorylation *In Vitro* By Parent RON Antibody And DVD-Ig Constructs

Sub-confluent DU145 colon tumor cells grown in 10% FBS/Minimal Essential Medium were trypsinized and seeded into 6-well tissue culture plates (0.25 x 10⁶ cells/ 2ml final volume), and incubated at 37⁰C, 5% CO₂ for 18-24 hours. After incubation, the cells were washed twice with 1X D-PBS and starved overnight in serum-free medium. The next day, cells were incubated with 900μl of serum-free media containing 1μM of monoclonal antibodies or DVD-Igs for 1 hour at 37⁰C. Following antibody incubation, cells were then treated with 13nM MSP1 (37⁰C, 30 minutes). Cells were washed twice with ice-cold D-PBS and harvested in 150μl Cell Extraction Buffer (Biosource International, Carlsbad, CA) containing 100μl of HALT[®] phosphatase inhibitor cocktail (Thermo Scientific, Rockford, IL), one Complete[®] EDTA-free protease inhibitor tablet (1 tablet/10ml, Roche Diagnostic, Mannheim, Germany), and PMSF. Cell lysates were incubated on ice for 30 minutes with intermittent vortexing, pre-cleared by centrifugation (10 min, 14,000 RPM, 4⁰C), and processed for Western blot analysis. A total of 15μg of cell lysate was resolved by SDS-PAGE on a 4-12% NuPage Bis-Tris Gel with 1X MOPS running buffer (Invitrogen, Carlsbad, CA). Proteins were transferred onto a nitrocellulose membrane (Invitrogen, Carlsbad, CA), and blocked in 5% nonfat milk in TBS-T (1X TBS/0.1% Tween 20) for 1 hour at room temperature. After blocking, membranes were incubated overnight at 4⁰C with a 1:1000 dilution of either a rabbit polyclonal phospho-p44/42 MAPK (Thr²⁰²/Tyr²⁰⁴) antibody (Cell Signaling, Danvers, MA) or a rabbit monoclonal phospho-AKT (Ser⁴⁷³) antibody (Cell Signaling, Danvers, MA). Blots were washed three times (1X TBS-T, 15 minutes), and incubated for 1 hour at room temperature with a 1:5000 dilution of anti-rabbit IgG, HRP-conjugated secondary goat antibody (Jackson ImmunoResearch, West Grove, PA) in a 5% nonfat milk/ TBS-T solution. The blots were washed three times (1X TBS-T, 15 min), and peroxidase conjugated

secondary antibody was activated by a 5 min. incubation with SuperSignal West Dura Luminol/Enhancer Solution[®] (Millipore, Temecula, CA), and chemiluminescence was detected and quantified with a Luminescent Image Analyzer LAS-3000 (FUJIFilm, Tokyo, Japan). Band density was determined using MultiGauge Software (FUJIFilm, Tokyo, Japan) and the total chemiluminescent signal was quantified for each band. To determine total ERK1/2 and AKT levels, membranes were stripped for 15 minute with 1X Reblot Plus Strong Solution[®] (Thermo Scientific, Rockford, IL) and reprobred with a 1:1000 dilution of either a rabbit polyclonal p44/42 MAPK antibody (Cell Signaling, Danvers, MA) or a rabbit monoclonal AKT antibody (Cell Signaling, Danvers, MA), and processed as described above for phospho-antibodies. Ph-ERK and ph-Akt levels were standardized to total ERK or total Akt, respectively.

Table 24: Inhibition Of MSP1-Induced ERK1/2 Phosphorylation By RON Parent Antibodies Or DVD-Ig Constructs

Parent Antibody or DVD-Ig ID	N-terminal Variable Domain (VD)	C-terminal Variable Domain (VD)	N-Terminal VD Cellular Assay, Inhibition Of RON-Induced phERK1/2 (% of neutralization @ nM Ab)	C-Terminal VD Cellular Assay, Inhibition Of RON-Induced phERK1/2 (% of neutralization @ nM Ab)
AB005	RON		80% at 1000nM	
DVD024	RON	EGFR	97% at 1000nM	
AB005	RON		80% at 1000nM	
DVD033	RON	HGF	60% at 1000nM	

DVD-Igs containing the VD from AB005 in the N-terminal position showed excellent inhibition of MSP1-induced ERK1/2 phosphorylation. The inhibition profile of DVD024 and DVD033 was similar to the inhibition profile of parent antibody AB005.

Example 1.1.2.U: Efficacy Of A DVD-Ig On The Growth Of Human Carcinoma Subcutaneous Flank Xenografts

A-431 human epidermoid carcinoma cells were grown *in vitro* to 99% viability, 85% confluence in tissue culture flasks. SCID female mice (Charles Rivers Labs, Wilmington, MA) at 19-25 grams were injected subcutaneously into the right flank with 1×10^6 human tumor cells (1:1 matrigel) on study day 0. Administration (IP, QD, 3x/ week) of human IgG control or DVD-Ig was initiated after mice were size matched into groups of mice with mean tumor volumes of approximately 200 to 320 mm³. The tumors were measured twice a week starting on approximately day 10 post tumor cell injection

Reduction in tumor volume was seen in animals administered EGFR + IGF1/2 DVD Ig relative to tumors in animals that received only control IgG. For two different EGFR + IGF1/2

DVD Ig constructs, %TGIs were 69 and 64 as measured four days after the end of the 3 week dosing phase.

Example 1.1.2.V: Binding of Monoclonal Antibodies to the Surface of Human Tumor Cell Lines as Assessed by Flow Cytometry

5 Stable cell lines overexpressing a cell-surface antigen of interest or human tumor cell lines were harvested from tissue culture flasks and resuspended in phosphate buffered saline (PBS) containing 5% fetal bovine serum (PBS/FBS). Prior to staining, human tumor cells were incubated on ice with (100 μ l) human IgG at 5 μ g/ml in PBS/FCS. 1-5 x 10⁵ cells were incubated with antibody or DVD-Ig (2 μ g/mL) in PBS/FBS for 30-60 minutes on ice. Cells were washed
10 twice and 100 μ l of F(ab')₂ goat anti human IgG, Fc γ - phycoerythrin (1:200 dilution in PBS) (Jackson ImmunoResearch, West Grove, PA, Cat.#109-116-170) was added. After 30 minutes incubation on ice, cells were washed twice and resuspended in PBS/FBS. Fluorescence was measured using a Becton Dickinson FACSCalibur (Becton Dickinson, San Jose, CA).

Table 25 shows the FACS data for the DVD-Ig constructs. The geometric mean is the n
15 root of the multiplication product of n fluorescent signals (a₁ x a₂ x a₃...a_n). With log-transformed data the geometric mean is used to normalize the weighting of the data distribution. The following table contains the FACS geometric mean of parent antibodies and DVD-Ig constructs.

Table 25: Fluorescent Activated Cell Sorting of DVD-Ig Constructs

Parent Antibody or DVD-Ig ID	N-terminal Variable Domain (VD)	C-terminal Variable Domain (VD)	FACS Geometric Mean N-terminal	FACS Geometric Mean C-terminal
AB006	CD-19		979	
AB001	CD-20			
DVD001	CD-20	CD-19		161
DVD002	CD-19	CD-20	1102	
AB001	CD-20		95.8	
AB002	CD-3		461	
DVD003	CD-20	CD-3	45.9	5.7
DVD004	CD-3	CD-20	673	3.59
AB007	CD-80		25.4	
AB001	CD-20			
DVD005	CD-20	CD-80		6
DVD006	CD-80	CD-20	70.7	
AB002	CD-3		897	
AB004	HER-2		27.7	
DVD011	CD-3	HER-2	1096	3.39
DVD012	HER-2	CD-3	7.14	41.6
AB002	CD-3		461/897	

Parent Antibody or DVD-Ig ID	N-terminal Variable Domain (VD)	C-terminal Variable Domain (VD)	FACS Geometric Mean N-terminal	FACS Geometric Mean C-terminal
AB006	CD-19		661/989	
DVD013	CD-3	CD-19	417	103
DVD014	CD-19	CD-3	1090	23.3
AB033	EGFR		955.4	
AB004	HER-2		24.77	
DVD015	EGFR	HER-2	1006.4	200.07
DVD016	HER-2	EGFR	75.67	384.4
AB033	EGFR		955.4	
AB011	IGF1R		1684.5	
DVD021	EGFR	IGF1R	888.4	733.5
DVD022	IGF1R	EGFR	2016.5	411.4
AB005	RON		54.46	
AB033	EGFR		955.4	
DVD024	RON	EGFR	0.38	309.4
DVD023	EGFR	RON	1001.4	164.96
AB033	EGFR		955.4	
AB012	HGF			
DVD025	EGFR	HGF	1045.4	
DVD026	HGF	EGFR		143.4
AB004	HER-2		24.77	
AB010	IGF1,2			
DVD029	HER-2	IGF1,2	22.37	
DVD030	IGF1,2	HER-2		0.23
AB004	HER-2		24.77	
AB011	IGF1R		1684.5	
DVD031	HER-2	IGF1R	4.99	24.7
DVD032	IGF1R	HER-2	34.6	4.9
AB005	RON		54.46	
AB012	HGF			
DVD033	RON	HGF	6.46	
DVD034	HGF	RON		0.39
AB014	VEGF			
AB033	EGFR		955.4	
DVD035	VEGF	EGFR		162.4
DVD036	EGFR	VEGF	1081.4	
AB014	VEGF			
AB004	HER-2		24.77	
DVD037	VEGF	HER-2		1.03
DVD038	HER-2	VEGF	7.47	
AB015	DLL-4		308.27	
AB014	VEGF			
DVD044	DLL4	VEGF	297.27	
DVD043	VEGF	DLL4		68.37
AB014	VEGF			

Parent Antibody or DVD-Ig ID	N-terminal Variable Domain (VD)	C-terminal Variable Domain (VD)	FACS Geometric Mean N-terminal	FACS Geometric Mean C-terminal
AB012	HGF			
DVD045	VEGF	HGF		
DVD046	HGF	VEGF		
AB005	RON		54.46	
AB014	VEGF			
DVD048	RON	VEGF	29.86	
DVD047	VEGF	RON		0.51
AB014	VEGF			
AB016	NRP1		338.4	
DVD049	VEGF	NRP1		352.4
DVD050	NRP1	VEGF	336.4	
AB015	DLL-4		308.27	
AB047	PIGF			
DVD257	DLL4	PIGF	274.27	
DVD258	PIGF	DLL4		5.57

All DVDs showed binding to their cell surface targets. The N-terminal domains of DVDs bound their targets on the cell surface as well as or better than the parent antibody. Binding can be restored or improved by adjusting linker length.

5 **Example 1.1.2.W: Binding of Parent EGFR Antibody and DVD-Ig Constructs to the Surface of Human Tumor Cell Lines as Assessed by Flow Cytometry**

Stable cell lines overexpressing cell-surface EGFR or human tumor cell lines were harvested from tissue culture flasks and resuspended in Dulbecco's phosphate buffered saline (DPBS) containing 1% fetal calf serum (DPBS/FCS). 1-5 x10⁵ cells were incubated with 100μL antibodies or DVD-Igs (10ug/mL) in DPBS/FCS for 30-60 minutes on ice. Cells were washed twice and 50μl of goat anti-human IgG-phycoerythrin (1:50 dilution in DPBS/BSA) (Southern Biotech Associates, Birmingham, AL cat#2040-09) was added. After 30-45 minutes incubation on ice, cells were washed twice and resuspended in 125uL/well 1% formaldehyde in DPBS/FCS. Fluorescence was measured using a Becton Dickinson LSRII (Becton Dickinson, San Jose, CA).

15 **Table 26: Binding Affinity of anti-EGFR Parent Antibodies and DVD-Ig Constructs to A431, EGFR Cell Line by FACS**

Parent Antibody or DVD-Ig ID	N-terminal Variable Domain (VD)	C-terminal Variable Domain (VD)	N-terminal VD Ag binding A431 FACS (EC50, nM)	C-terminal VD Ag binding A431 FACS (EC50, nM)
AB005	RON			
AB033	EGFR		4.2	

DVD024	RON	EGFR	ND	25.43
DVD023	EGFR	RON	5.38	ND

All DVDs bound to their cell surface targets. The N-terminal domains of DVDs bound their targets on the cell surface as well as the parent antibody.

5 **Table 27: Binding Affinity of anti-EGFR Parent Antibodies and DVD-Ig Constructs to BAFvar3 Cell Line by FACS**

Parent Antibody or DVD-Ig ID	N-terminal Variable Domain (VD)	C-terminal Variable Domain (VD)	N-terminal VD Ag binding BAFvar3 FACS (EC50, nM)	C-terminalVD Ag binding BAFvar3 FACS (EC50, nM)
AB005	RON			
AB033	EGFR		0.5	
DVD024	RON	EGFR	ND	17.8
DVD023	EGFR	RON	0.6	ND

10 All DVDs bound to their cell surface targets. The N-terminal domains of DVDs bound their targets on the cell surface as well as the parent antibody.

Example 1.2: Generation Of Parent Monoclonal Antibodies to a Human Antigen of Interest

Parent mouse mAbs able to bind to and neutralize a human antigen of interest and a variant thereof are obtained as follows:

Example 1.2.A: Immunization Of Mice With a Human Antigen of Interest

15 Twenty micrograms of recombinant purified human antigen (e.g., IGF1,2) mixed with complete Freund's adjuvant or Immuneeasy adjuvant (Qiagen, Valencia, CA) is injected subcutaneously into five 6-8 week-old Balb/C, five C57B/6 mice, and five AJ mice on Day 1. On days 24, 38, and 49, twenty micrograms of recombinant purified human antigen variant mixed with incomplete Freund's adjuvant or Immuneeasy adjuvant is injected subcutaneously into the
20 same mice. On day 84 or day 112 or day 144, mice are injected intravenously with 1 µg recombinant purified human antigen of interest.

Example 1.2.B: Generation of a Hybridoma

25 Splenocytes obtained from the immunized mice described in Example 1.2.A are fused with SP2/O-Ag-14 cells at a ratio of 5:1 according to the established method described in Kohler, G. and Milstein (1975) Nature, 256:495 to generate hybridomas. Fusion products are plated in selection media containing azaserine and hypoxanthine in 96-well plates at a density of 2.5×10^6 spleen cells per well. Seven to ten days post fusion, macroscopic hybridoma colonies are

observed. Supernatant from each well containing hybridoma colonies is tested by ELISA for the presence of antibody to the antigen of interest (as described in Example 1.1.1.A). Supernatants displaying antigen-specific activity are then tested for activity (as described in the assays of Example 1.1.2), for example, the ability to neutralize the antigen of interest in a bioassay such as that described in Example 1.1.2.I).

Example 1.2.C: Identification And Characterization Of Parent Monoclonal Antibodies to a Human Target Antigen of Interest

Example 1.2.C.1: Analyzing Parent Monoclonal Antibody Neutralizing Activity

Hybridoma supernatants are assayed for the presence of parent antibodies that bind an antigen of interest, generated according to Examples 1.2.A and 1.2.B, and are also capable of binding a variant of the antigen of interest ("antigen variant"). Supernatants with antibodies positive in both assays are then tested for their antigen neutralization potency, for example, in the cytokine bioassay of Example 1.1.2.I. The hybridomas producing antibodies with IC₅₀ values in the bioassay less than 1000pM, in an embodiment, less than 100pM are scaled up and cloned by limiting dilution. Hybridoma cells are expanded into media containing 10% low IgG fetal bovine serum (Hyclone #SH30151, Logan, UT). On average, 250 mL of each hybridoma supernatant (derived from a clonal population) is harvested, concentrated and purified by protein A affinity chromatography, as described in Harlow, E. and Lane, D. 1988 "Antibodies: A Laboratory Manual". The ability of purified mAbs to inhibit the activity of its target antigen is determined, for example, using the cytokine bioassay as described in Example 1.1.2.I).

Example 1.2.C.2: Analyzing Parent Monoclonal Antibody Cross-Reactivity To Cynomolgus Target Antigen Of Interest

To determine whether the selected mAbs described herein recognize cynomolgus antigen of interest, BIACORE analysis is conducted as described herein (Example 1.1.1.G) using recombinant cynomolgus target antigen. In addition, neutralization potencies of mAbs against recombinant cynomolgus antigen of interest may also be measured in the cytokine bioassay (Example 1.1.2.I). MAbs with good cyno cross-reactivity (in an embodiment, within 5-fold of reactivity for human antigen) are selected for future characterization.

Example 1.2.D: Determination Of The Amino Acid Sequence Of The Variable Region For Each Murine Anti-Human Monoclonal Antibody

Isolation of the cDNAs, expression and characterization of the recombinant anti-human mouse mAbs is conducted as follows. For each amino acid sequence determination, approximately 1×10^6 hybridoma cells are isolated by centrifugation and processed to isolate total RNA with Trizol (Gibco BRL/Invitrogen, Carlsbad, CA.) following manufacturer's instructions.

Total RNA is subjected to first strand DNA synthesis using the SuperScript First-Strand Synthesis System (Invitrogen, Carlsbad, CA) per the manufacturer's instructions. Oligo(dT) is used to prime first-strand synthesis to select for poly(A)+ RNA. The first-strand cDNA product is then amplified by PCR with primers designed for amplification of murine immunoglobulin variable regions (Ig-Primer Sets, Novagen, Madison, WI). PCR products are resolved on an agarose gel, excised, purified, and then subcloned with the TOPO Cloning kit into pCR2.1-TOPO vector (Invitrogen, Carlsbad, CA) and transformed into TOP10 chemically competent E. coli (Invitrogen, Carlsbad, CA). Colony PCR is performed on the transformants to identify clones containing insert. Plasmid DNA is isolated from clones containing insert using a QIAprep Miniprep kit (Qiagen, Valencia, CA). Inserts in the plasmids are sequenced on both strands to determine the variable heavy or variable light chain DNA sequences using M13 forward and M13 reverse primers (Fermentas Life Sciences, Hanover MD). Variable heavy and variable light chain sequences of the mAbs are identified. In an embodiment, the selection criteria for a panel of lead mAbs for next step development (humanization) includes the following:

- 15 ▪ The antibody does not contain any N-linked glycosylation sites (NXS), except from the standard one in CH2
- The antibody does not contain any extra cysteines in addition to the normal cysteines in every antibody
- The antibody sequence is aligned with the closest human germline sequences for VH and VL and any unusual amino acids should be checked for occurrence in other natural human antibodies
- 20 ▪ N-terminal Glutamine (Q) is changed to Glutamic acid (E) if it does not affect the activity of the antibody. This will reduce heterogeneity due to cyclization of Q
- Efficient signal sequence cleavage is confirmed by Mass Spectrophotometry. This can be done with COS cell or 293 cell material
- 25 ▪ The protein sequence is checked for the risk of deamidation of Asn that could result in loss of activity
- The antibody has a low level of aggregation
- The antibody has solubility >5-10 mg/ml (in research phase); >25 mg/ml
- 30 ▪ The antibody has a normal size (5-6 nm) by Dynamic Light Scattering (DLS)
- The antibody has a low charge heterogeneity
- The antibody lacks cytokine release (see Example 1.1.2.B)
- The antibody has specificity for the intended cytokine (see Example 1.1.2.C)
- The antibody lacks unexpected tissue cross reactivity (see Example 1.1.2.D)
- 35 ▪ The antibody has similarity between human and cynomolgus tissue cross reactivity (see Example 1.1.2.D)

Example 1.2.2: Recombinant Humanized Parent Antibodies**Example 1.2.2.1: Construction And Expression Of Recombinant Chimeric Anti Human Parent Antibodies**

5 The DNA encoding the heavy chain constant region of murine anti-human parent mAbs is replaced by a cDNA fragment encoding the human IgG1 constant region containing 2 hinge-region amino acid mutations by homologous recombination in bacteria. These mutations are a leucine to alanine change at position 234 (EU numbering) and a leucine to alanine change at position 235 (Lund et al., 1991, J. Immunol., 147:2657). The light chain constant region of each of these antibodies is replaced by a human kappa constant region. Full-length chimeric antibodies
10 are transiently expressed in COS cells by co-transfection of chimeric heavy and light chain cDNAs ligated into the pBOS expression plasmid (Mizushima and Nagata, Nucleic Acids Research 1990, Vol 18, pg 5322). Cell supernatants containing recombinant chimeric antibody are purified by Protein A Sepharose chromatography and bound antibody is eluted by addition of acid buffer. Antibodies are neutralized and dialyzed into PBS.

15 The heavy chain cDNA encoding a chimeric mAb is co-transfected with its chimeric light chain cDNA (both ligated in the pBOS vector) into COS cells. Cell supernatant containing recombinant chimeric antibody is purified by Protein A Sepharose chromatography and bound antibody is eluted by addition of acid buffer. Antibodies are neutralized and dialyzed into PBS.

The purified chimeric anti-human parent mAbs are then tested for their ability to bind (by
20 Biacore) and for functional activity, e.g., to inhibit the cytokine induced production of IgE as described in Examples 1.1.1.G and 1.1.2.B. Chimeric mAbs that maintain the activity of the parent hybridoma mAbs are selected for future development.

Example 1.2.2.2: Construction And Expression Of Humanized Anti Human Parent Antibodies**25 Example 1.2.2.2.A: Selection Of Human Antibody Frameworks**

Each murine variable heavy and variable light chain gene sequence is separately aligned against 44 human immunoglobulin germline variable heavy chain or 46 germline variable light chain sequences (derived from NCBI Ig Blast website at <http://www.ncbi.nlm.nih.gov/igblast/retrieveig.html>.) using Vector NTI software.

30 Humanization is based on amino acid sequence homology, CDR cluster analysis, frequency of use among expressed human antibodies, and available information on the crystal structures of human antibodies. Taking into account possible effects on antibody binding, VH-VL pairing, and other factors, murine residues are mutated to human residues where murine and human framework residues are different, with a few exceptions. Additional humanization

strategies are designed based on an analysis of human germline antibody sequences, or a subgroup thereof, that possessed a high degree of homology, i.e., sequence similarity, to the actual amino acid sequence of the murine antibody variable regions.

Homology modeling is used to identify residues unique to the murine antibody sequences that are predicted to be critical to the structure of the antibody combining site, the CDRs. Homology modeling is a computational method whereby approximate three dimensional coordinates are generated for a protein. The source of initial coordinates and guidance for their further refinement is a second protein, the reference protein, for which the three dimensional coordinates are known and the sequence of which is related to the sequence of the first protein. The relationship among the sequences of the two proteins is used to generate a correspondence between the reference protein and the protein for which coordinates are desired, the target protein. The primary sequences of the reference and target proteins are aligned with coordinates of identical portions of the two proteins transferred directly from the reference protein to the target protein. Coordinates for mismatched portions of the two proteins, e.g., from residue mutations, insertions, or deletions, are constructed from generic structural templates and energy refined to insure consistency with the already transferred model coordinates. This computational protein structure may be further refined or employed directly in modeling studies. The quality of the model structure is determined by the accuracy of the contention that the reference and target proteins are related and the precision with which the sequence alignment is constructed.

For the murine mAbs, a combination of BLAST searching and visual inspection is used to identify suitable reference structures. Sequence identity of 25% between the reference and target amino acid sequences is considered the minimum necessary to attempt a homology modeling exercise. Sequence alignments are constructed manually and model coordinates are generated with the program Jackal (see Petrey, D. et al. (2003) Proteins 53 (Suppl. 6): 430–435).

The primary sequences of the murine and human framework regions of the selected antibodies share significant identity. Residue positions that differ are candidates for inclusion of the murine residue in the humanized sequence in order to retain the observed binding potency of the murine antibody. A list of framework residues that differ between the human and murine sequences is constructed manually. Table 28 shows the framework sequences chosen for this study.

Table 28: Sequence Of Human IgG Heavy Chain Constant Domain And Light Chain Constant Domain

Protein	SEQ ID NO	Sequence
		12345678901234567890123456789012345678901
Wild type hIgG1 constant region	95	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPQAVLQSSGLYSLSSVVTVPSSSLGTQTYI

		CNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE LL GGPSV FLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNWYVDG VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGIFYPSDIAVEWESNGQPENNYKTPPVLDSDGSF FLYSKLTVDKSRWQQGNVFSVCSVMHEALHNHYTQKSLSLSP GK
Mutant hIgG1 constant region	96	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI CNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE AA GGPSV FLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNWYVDG VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGIFYPSDIAVEWESNGQPENNYKTPPVLDSDGSF FLYSKLTVDKSRWQQGNVFSVCSVMHEALHNHYTQKSLSLSP GK
Ig kappa constant region	SEQ ID NO. : 97	TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWK VDNALQSGNSQESVTEQDSKDSTYLSLSSTLTLTKADYEEKHK VYACEVTHQGLSSPVTKSFNRGEC
Ig Lambda constant region	SEQ ID NO. : 98	QPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAW KADSSPVKAGVETTPSKQSNNKYAASSYLSLTPEQWKSRR SYSCQVTHEGSTVEKTVAPTECS

The likelihood that a given framework residue would impact the binding properties of the antibody depends on its proximity to the CDR residues. Therefore, using the model structures, the residues that differ between the murine and human sequences are ranked according to their distance from any atom in the CDRs. Those residues that fell within 4.5 Å of any CDR atom are identified as most important and are recommended to be candidates for retention of the murine residue in the humanized antibody (i.e., back mutation).

In silico constructed humanized antibodies are constructed using oligonucleotides. For each variable region cDNA, 6 oligonucleotides of 60-80 nucleotides each are designed to overlap each other by 20 nucleotides at the 5' and/or 3' end of each oligonucleotide. In an annealing reaction, all 6 oligonucleotides are combined, boiled, and annealed in the presence of dNTPs. DNA polymerase I, Large (Klenow) fragment (New England Biolabs #M0210, Beverly, MA.) is added to fill-in the approximately 40bp gaps between the overlapping oligonucleotides. PCR is performed to amplify the entire variable region gene using two outermost primers containing overhanging sequences complementary to the multiple cloning site in a modified pBOS vector (Mizushima, S. and Nagata, S. (1990) Nucleic Acids Res. 18: 17). The PCR products derived from each cDNA assembly are separated on an agarose gel and the band corresponding to the predicted variable region cDNA size is excised and purified. The variable heavy region is inserted in-frame onto a cDNA fragment encoding the human IgG1 constant region containing 2 hinge-region amino acid mutations by homologous recombination in bacteria. These mutations are a leucine to alanine change at position 234 (EU numbering) and a leucine to alanine change at position 235 (Lund et al. (1991) J. Immunol. 147:2657). The variable light chain region is inserted in-frame with the human kappa constant region by homologous recombination. Bacterial colonies are isolated and plasmid DNA extracted. cDNA inserts are sequenced in their entirety.

Correct humanized heavy and light chains corresponding to each antibody are co-transfected into COS cells to transiently produce full-length humanized anti-human antibodies. Cell supernatants containing recombinant chimeric antibody are purified by Protein A Sepharose chromatography and bound antibody is eluted by addition of acid buffer. Antibodies are neutralized and dialyzed into PBS.

Example 1.2.2.3: Characterization Of Humanized Antibodies

The ability of purified humanized antibodies to inhibit a functional activity is determined, e.g., using the cytokine bioassay as described in Examples 1.1.2.A. The binding affinities of the humanized antibodies to recombinant human antigen are determined using surface plasmon resonance (Biacore®) measurement as described in Example 1.1.1.B. The IC₅₀ values from the bioassays and the affinity of the humanized antibodies are ranked. The humanized mAbs that fully maintain the activity of the parent hybridoma mAbs are selected as candidates for future development. The top 2-3 most favorable humanized mAbs are further characterized.

Example 1.2.2.3.A: Pharmacokinetic Analysis Of Humanized Antibodies

Pharmacokinetic studies are carried out in Sprague-Dawley rats and cynomolgus monkeys. Male and female rats and cynomolgus monkeys are dosed intravenously or subcutaneously with a single dose of 4mg/kg mAb and samples are analyzed using antigen capture ELISA, and pharmacokinetic parameters are determined by noncompartmental analysis. Briefly, ELISA plates are coated with goat anti-biotin antibody (5 mg/ml, 4°C, overnight), blocked with Superblock (Pierce), and incubated with biotinylated human antigen at 50 ng/ml in 10% Superblock TTBS at room temperature for 2 hours. Serum samples are serially diluted (0.5% serum, 10% Superblock in TTBS) and incubated on the plate for 30 minutes at room temperature. Detection is carried out with HRP-labeled goat anti human antibody and concentrations are determined with the help of standard curves using the four parameter logistic fit. Values for the pharmacokinetic parameters are determined by non-compartmental model using WinNonlin software (Pharsight Corporation, Mountain View, CA). Humanized mAbs with good pharmacokinetics profile (T_{1/2} is 8-13 days or better, with low clearance and excellent bioavailability 50-100%) are selected.

Example 1.2.2.3.B: Physicochemical And In Vitro Stability Analysis Of Humanized Monoclonal Antibodies

Size exclusion chromatography

Antibodies are diluted to 2.5 mg/mL with water and 20 mL is analyzed on a Shimadzu HPLC system using a TSK gel G3000 SWXL column (Tosoh Bioscience, cat# k5539-05k).

Samples are eluted from the column with 211 mM sodium sulfate, 92 mM sodium phosphate, pH 7.0, at a flow rate of 0.3 mL/minutes. The HPLC system operating conditions are the following:

	Mobile phase:	211 mM Na ₂ SO ₄ , 92 mM Na ₂ HPO ₄ *7H ₂ O, pH 7.0
	Gradient:	Isocratic
5	Flow rate:	0.3 mL/minute
	Detector wavelength:	280 nm
	Autosampler cooler temp:	4°C
	Column oven temperature:	Ambient
	Run time:	50 minutes

10 Table 29 contains purity data of parent antibodies and DVD-Ig constructs expressed as percent monomer (unaggregated protein of the expected molecular weight) as determined by the above protocol.

Table 29: Purity of Parent Antibodies and DVD-Ig Constructs as Determined by Size Exclusion Chromatography

15

Parent Antibody or DVD-Ig ID	N-terminal Variable Domain (VD)	C-terminal Variable Domain (VD)	% Monomer (purity)
AB033	EGFR		99.75
AB004	HER-2		95.6
DVD015	EGFR	HER-2	96.98
DVD016	HER-2	EGFR	93.41
AB033	EGFR		99.75
AB011	IGF1R		98.23
DVD021	EGFR	IGF1R	99.25
DVD022	IGF1R	EGFR	99.53
AB005	RON		79.34
AB033	EGFR		99.75
DVD024	RON	EGFR	96.86
DVD023	EGFR	RON	97.27
AB033	EGFR		99.75
AB012	HGF		98.97
DVD025	EGFR	HGF	99.21
DVD026	HGF	EGFR	99.48
AB004	HER-2		95.6
AB010	IGF1,2		93.2
DVD029	HER-2	IGF1,2	88.2
DVD030	IGF1,2	HER-2	96.9
AB004	HER-2		95.6
AB011	IGF1R		98.23
DVD031	HER-2	IGF1R	94.53
DVD032	IGF1R	HER-2	98.1
AB005	RON		79.34
AB012	HGF		98.97
DVD033	RON	HGF	100

DVD034	HGF	RON	100
AB014	VEGF		97.81
AB033	EGFR		99.75
DVD035	VEGF	EGFR	97.7
DVD036	EGFR	VEGF	99.36
AB014	VEGF		97.81
AB004	HER-2		95.6
DVD037	VEGF	HER-2	45.4
DVD038	HER-2	VEGF	96.9
AB014	VEGF		97.81
AB010	IGF1,2		93.2
DVD041	VEGF	IGF1,2	94.7
DVD042	IGF1,2	VEGF	92.4
AB015	DLL-4		97.52
AB014	VEGF		97.81
DVD044	DLL4	VEGF	48.66
DVD043	VEGF	DLL4	96.72
AB014	VEGF		97.81
AB012	HGF		98.97
DVD045	VEGF	HGF	97.88
DVD046	HGF	VEGF	98.14
AB005	RON		79.34
AB014	VEGF		97.81
DVD048	RON	VEGF	100
DVD047	VEGF	RON	100
AB014	VEGF		97.81
AB016	NRP1		93.54
DVD049	VEGF	NRP1	97.74
DVD050	NRP1	VEGF	98.59
AB015	DLL-4		97.52
AB047	PlGF		99.47
DVD257	DLL4	PlGF	83.8
DVD258	PlGF	DLL4	100
AB014	VEGF		97.81
AB047	PlGF		99.47
DVD259	VEGF	PlGF	90.61
DVD260	PlGF	VEGF	98.57
AB062	ErbB3		100
AB033	EGFR		99.75
DVD299	ErbB3	EGFR	98.8
DVD300	EGFR	ErbB3	100
AB063	ErbB3		96
AB033	EGFR		99.75
DVD305	ErbB3	EGFR	83.8
DVD306	EGFR	ErbB3	100

DVD-Igs showed an excellent SEC profile with most DVD-Ig showing >90% monomer. This DVD-Ig profile is similar to that observed for parent antibodies.

SDS-PAGE

Antibodies are analyzed by sodium dodecyl sulfate - polyacrylamide gel electrophoresis (SDS-PAGE) under both reducing and non-reducing conditions. Adalimumab lot AFP04C is used as a control. For reducing conditions, the samples are mixed 1:1 with 2X tris glycine SDS-PAGE sample buffer (Invitrogen, cat# LC2676, lot# 1323208) with 100 mM DTT, and heated at 60°C for 30 minutes. For non-reducing conditions, the samples are mixed 1:1 with sample buffer and heated at 100°C for 5 minutes. The reduced samples (10 mg per lane) are loaded on a 12% pre-cast tris-glycine gel (Invitrogen, cat# EC6005box, lot# 6111021), and the non-reduced samples (10 mg per lane) are loaded on an 8%-16% pre-cast tris-glycine gel (Invitrogen, cat# EC6045box, lot# 6111021). SeeBlue Plus 2 (Invitrogen, cat#LC5925, lot# 1351542) is used as a molecular weight marker. The gels are run in a XCell SureLock mini cell gel box (Invitrogen, cat# EI0001) and the proteins are separated by first applying a voltage of 75 to stack the samples in the gel, followed by a constant voltage of 125 until the dye front reached the bottom of the gel. The running buffer used is 1X tris glycine SDS buffer, prepared from a 10X tris glycine SDS buffer (ABC, MPS-79-080106). The gels are stained overnight with colloidal blue stain (Invitrogen cat# 46-7015, 46-7016) and destained with Milli-Q water until the background is clear. The stained gels are then scanned using an Epson Expression scanner (model 1680, S/N DASX003641).

Sedimentation Velocity Analysis

Antibodies are loaded into the sample chamber of each of three standard two-sector carbon epon centerpieces. These centerpieces have a 1.2 cm optical path length and are built with sapphire windows. PBS is used for a reference buffer and each chamber contained 140 μ L. All samples are examined simultaneously using a 4-hole (AN-60Ti) rotor in a Beckman ProteomeLab XL-I analytical ultracentrifuge (serial # PL106C01).

Run conditions are programmed and centrifuge control is performed using ProteomeLab (v5.6). The samples and rotor are allowed to thermally equilibrate for one hour prior to analysis (20.0 \pm 0.1 °C). Confirmation of proper cell loading is performed at 3000 rpm and a single scan is recorded for each cell. The sedimentation velocity conditions are the following:

Sample Cell Volume: 420 μ L
Reference Cell Volume: 420 μ L
Temperature: 20°C
Rotor Speed: 35,000 rpm
Time: 8:00 hours
UV Wavelength: 280 nm
Radial Step Size: 0.003 cm
Data Collection: One data point per step without signal averaging.

Total Number of Scans: 100

LC-MS molecular weight measurement of intact antibodies

Molecular weight of intact antibodies are analyzed by LC-MS. Each antibody is diluted to approximately 1 mg/mL with water. An 1100 HPLC (Agilent) system with a protein microtrap (Michrom Bioresources, Inc, cat# 004/25109/03) is used to desalt and introduce 5 mg of the sample into an API Qstar pulsar i mass spectrometer (Applied Biosystems). A short gradient is used to elute the samples. The gradient is run with mobile phase A (0.08% FA, 0.02% TFA in HPLC water) and mobile phase B (0.08% FA and 0.02% TFA in acetonitrile) at a flow rate of 50 mL/minute. The mass spectrometer is operated at 4.5 kvolts spray voltage with a scan range from 2000 to 3500 mass to charge ratio.

LC-MS molecular weight measurement of antibody light and heavy chains

Molecular weight measurement of antibody light chain (LC), heavy chain (HC) and deglycosylated HC are analyzed by LC-MS. Antibody is diluted to 1 mg/mL with water and the sample is reduced to LC and HC with a final concentration of 10 mM DTT for 30 minutes at 37°C. To deglycosylate the antibody, 100 mg of the antibody is incubated with 2 mL of PNGase F, 5 mL of 10% N-octylglucoside in a total volume of 100 mL overnight at 37 °C. After deglycosylation the sample is reduced with a final concentration of 10 mM DTT for 30 minutes at 37°C. An Agilent 1100 HPLC system with a C4 column (Vydac, cat# 214TP5115, S/N 060206537204069) is used to desalt and introduce the sample (5 mg) into an API Qstar pulsar i mass spectrometer (Applied Biosystems). A short gradient is used to elute the sample. The gradient is run with mobile phase A (0.08% FA, 0.02% TFA in HPLC water) and mobile phase B (0.08% FA and 0.02% TFA in acetonitrile) at a flow rate of 50 mL/minute. The mass spectrometer is operated at 4.5 kvolts spray voltage with a scan range from 800 to 3500 mass to charge ratio.

Peptide mapping

Antibody is denatured for 15 minutes at room temperature with a final concentration of 6 M guanidine hydrochloride in 75 mM ammonium bicarbonate. The denatured samples are reduced with a final concentration of 10 mM DTT at 37°C for 60 minutes, followed by alkylation with 50 mM iodoacetic acid (IAA) in the dark at 37°C for 30 minutes. Following alkylation, the sample is dialyzed overnight against four liters of 10 mM ammonium bicarbonate at 4°C. The dialyzed sample is diluted to 1 mg/mL with 10 mM ammonium bicarbonate, pH 7.8 and 100 mg of antibody is either digested with trypsin (Promega, cat# V5111) or Lys-C (Roche, cat# 11 047 825 001) at a 1:20 (w/w) trypsin/Lys-C:antibody ratio at 37°C for 4 hrs. Digests are quenched with 1 mL of 1 N HCl. For peptide mapping with mass spectrometer detection, 40 mL of the digests are separated by reverse phase high performance liquid chromatography (RPHPLC) on a

C18 column (Vydac, cat# 218TP51, S/N NE9606 10.3.5) with an Agilent 1100 HPLC system. The peptide separation is run with a gradient using mobile phase A (0.02% TFA and 0.08% FA in HPLC grade water) and mobile phase B (0.02% TFA and 0.08% FA in acetonitrile) at a flow rate of 50 mL/minutes. The API QSTAR Pulsar i mass spectrometer is operated in positive mode at 4.5 kvolts spray voltage and a scan range from 800 to 2500 mass to charge ratio.

Disulfide Bond Mapping

To denature the antibody, 100 mL of the antibody is mixed with 300 mL of 8 M guanidine HCl in 100 mM ammonium bicarbonate. The pH is checked to ensure that it is between 7 and 8 and the samples are denatured for 15 minutes at room temperature in a final concentration of 6 M guanidine HCl. A portion of the denatured sample (100 mL) is diluted to 600 mL with Milli-Q water to give a final guanidine-HCl concentration of 1 M. The sample (220 mg) is digested with either trypsin (Promega, cat # V5111, lot# 22265901) or Lys-C (Roche, cat# 11047825001, lot# 12808000) at a 1:50 trypsin or 1:50 Lys-C: antibody (w/w) ratios (4.4 mg enzyme: 220 mg sample) at 37°C for approximately 16 hours. An additional 5 mg of trypsin or Lys-C is added to the samples and digestion is allowed to proceed for an additional 2 hours at 37°C. Digestions are stopped by adding 1 mL of TFA to each sample. Digested samples are separated by RPHPLC using a C18 column (Vydac, cat# 218TP51 S/N NE020630-4-1A) on an Agilent HPLC system. The separation is run with the same gradient used for peptide mapping using mobile phase A (0.02% TFA and 0.08% FA in HPLC grade water) and mobile phase B (0.02% TFA and 0.08% FA in acetonitrile) at a flow rate of 50 mL/minute. The HPLC operating conditions are the same as those used for peptide mapping. The API QSTAR Pulsar i mass spectrometer is operated in positive mode at 4.5 kvolts spray voltage and a scan range from 800 to 2500 mass-to-charge ratio. Disulfide bonds are assigned by matching the observed MWs of peptides with the predicted MWs of tryptic or Lys-C peptides linked by disulfide bonds.

Free sulfhydryl determination

The method used to quantify free cysteines in an antibody is based on the reaction of Ellman's reagent, 5,5'-dithio-bis (2-nitrobenzoic acid) (DTNB), with sulfhydryl groups (SH) which gives rise to a characteristic chromophoric product, 5-thio-(2-nitrobenzoic acid) (TNB). The reaction is illustrated in the formula:



The absorbance of the TNB⁻ is measured at 412 nm using a Cary 50 spectrophotometer. An absorbance curve is plotted using dilutions of 2 mercaptoethanol (b-ME) as the free SH standard and the concentrations of the free sulfhydryl groups in the protein are determined from absorbance at 412 nm of the sample.

The b-ME standard stock is prepared by a serial dilution of 14.2 M b-ME with HPLC grade water to a final concentration of 0.142 mM. Then standards in triplicate for each concentration are prepared. Antibody is concentrated to 10 mg/mL using an amicon ultra 10,000 MWCO centrifugal filter (Millipore, cat# UFC801096, lot# L3KN5251) and the buffer is changed to the formulation buffer used for adalimumab (5.57 mM sodium phosphate monobasic, 8.69 mM sodium phosphate dibasic, 106.69 mM NaCl, 1.07 mM sodium citrate, 6.45 mM citric acid, 66.68 mM mannitol, pH 5.2, 0.1% (w/v) Tween). The samples are mixed on a shaker at room temperature for 20 minutes. Then 180 mL of 100 mM Tris buffer, pH 8.1 is added to each sample and standard followed by the addition of 300 mL of 2 mM DTNB in 10 mM phosphate buffer, pH 8.1. After thorough mixing, the samples and standards are measured for absorption at 412 nm on a Cary 50 spectrophotometer. The standard curve is obtained by plotting the amount of free SH and OD₄₁₂ nm of the b-ME standards. Free SH content of samples are calculated based on this curve after subtraction of the blank.

Weak Cation Exchange Chromatography

Antibody is diluted to 1 mg/mL with 10 mM sodium phosphate, pH 6.0. Charge heterogeneity is analyzed using a Shimadzu HPLC system with a WCX-10 ProPac analytical column (Dionex, cat# 054993, S/N 02722). The samples are loaded on the column in 80% mobile phase A (10 mM sodium phosphate, pH 6.0) and 20% mobile phase B (10 mM sodium phosphate, 500 mM NaCl, pH 6.0) and eluted at a flow rate of 1.0 mL/minute.

20 Oligosaccharide Profiling

Oligosaccharides released after PNGase F treatment of antibody are derivatized with 2-aminobenzamide (2-AB) labeling reagent. The fluorescent-labeled oligosaccharides are separated by normal phase high performance liquid chromatography (NPHPLC) and the different forms of oligosaccharides are characterized based on retention time comparison with known standards.

The antibody is first digested with PNGaseF to cleave N-linked oligosaccharides from the Fc portion of the heavy chain. The antibody (200 mg) is placed in a 500 mL Eppendorf tube along with 2 mL PNGase F and 3 mL of 10% N-octylglucoside. Phosphate buffered saline is added to bring the final volume to 60 mL. The sample is incubated overnight at 37°C in an Eppendorf thermomixer set at 700 RPM. Adalimumab lot AFP04C is also digested with PNGase F as a control.

After PNGase F treatment, the samples are incubated at 95°C for 5 minutes in an Eppendorf thermomixer set at 750 RPM to precipitate out the proteins, then the samples are placed in an Eppendorf centrifuge for 2 minutes at 10,000 RPM to spin down the precipitated proteins. The supernatant containing the oligosaccharides are transferred to a 500 mL Eppendorf tube and dried in a speed-vac at 65°C.

The oligosaccharides are labeled with 2AB using a 2AB labeling kit purchased from Prozyme (cat# GKK-404, lot# 132026). The labeling reagent is prepared according to the manufacturer's instructions. Acetic acid (150 mL, provided in kit) is added to the DMSO vial (provided in kit) and mixed by pipeting the solution up and down several times. The acetic acid/DMSO mixture (100 mL) is transferred to a vial of 2-AB dye (just prior to use) and mixed
5 until the dye is fully dissolved. The dye solution is then added to a vial of reductant (provided in kit) and mixed well (labeling reagent). The labeling reagent (5 mL) is added to each dried oligosaccharide sample vial, and mixed thoroughly. The reaction vials are placed in an Eppendorf thermomixer set at 65°C and 700-800 RPM for 2 hours of reaction.

10 After the labeling reaction, the excess fluorescent dye is removed using GlycoClean S Cartridges from Prozyme (cat# GKI-4726). Prior to adding the samples, the cartridges are washed with 1 mL of milli-Q water followed with 5 washes of 1 mL 30% acetic acid solution. Just prior to adding the samples, 1 mL of acetonitrile (Burdick and Jackson, cat# AH015-4) is added to the cartridges.

15 After all of the acetonitrile passed through the cartridge, the sample is spotted onto the center of the freshly washed disc and allowed to adsorb onto the disc for 10 minutes. The disc is washed with 1 mL of acetonitrile followed by five washes of 1 mL of 96% acetonitrile. The cartridges are placed over a 1.5 mL Eppendorf tube and the 2-AB labeled oligosaccharides are eluted with 3 washes (400 µL each wash) of milli Q water.

20 The oligosaccharides are separated using a Glycosep N HPLC (cat# GKI-4728) column connected to a Shimadzu HPLC system. The Shimadzu HPLC system consisted of a system controller, degasser, binary pumps, autosampler with a sample cooler, and a fluorescent detector.

Stability at Elevated Temperatures

The buffer of antibody is either 5.57 mM sodium phosphate monobasic, 8.69 mM sodium phosphate dibasic, 106.69 mM NaCl, 1.07 mM sodium citrate, 6.45 mM citric acid, 66.68 mM mannitol, 0.1% (w/v) Tween, pH 5.2; or 10 mM histidine, 10 mM methionine, 4% mannitol, pH 5.9 using Amicon ultra centrifugal filters. The final concentration of the antibodies is adjusted to 2 mg/mL with the appropriate buffers. The antibody solutions are then filter sterilized and 0.25 mL aliquots are prepared under sterile conditions. The aliquots are left at either -80°C, 5°C, 25°C, or
30 40°C for 1, 2 or 3 weeks. At the end of the incubation period, the samples are analyzed by size exclusion chromatography and SDS-PAGE.

The stability samples are analyzed by SDS-PAGE under both reducing and non-reducing conditions. The procedure used is the same as described herein. The gels are stained overnight with colloidal blue stain (Invitrogen cat# 46-7015, 46-7016) and destained with Milli-Q water
35 until the background is clear. The stained gels are then scanned using an Epson Expression

scanner (model 1680, S/N DASX003641). To obtain more sensitivity, the same gels are silver stained using silver staining kit (Owl Scientific) and the recommended procedures given by the manufacturer is used.

Example 1.2.2.3.C: Efficacy Of A Humanized Monoclonal Antibody By Itself Or In Combination With Chemotherapy On The Growth Of Human Carcinoma Xenografts

Human cancer cells are grown *in vitro* to 99% viability, 85% confluence in tissue culture flasks. SCID female or male mice (Charles Rivers Labs) at 19-25 grams, are ear tagged and shaved. Mice are then inoculated subcutaneously into the right flank with 0.2 ml of 2×10^6 human tumor cells (1:1 matrigel) on study day 0. Administration (IP, Q3D/ week) of vehicle (PBS), humanized antibody, and/or chemotherapy is initiated after mice are size matched into separate cages of mice with mean tumor volumes of approximately 150 to 200 mm³. The tumors are measured by a pair of calipers twice a week starting on approximately day 10 post inoculation and the tumor volumes calculated according to the formula $V = L \times W^2/2$ (V: volume, mm³; L: length, mm; W: width, mm). Reduction in tumor volume is seen in animals treated with mAb alone or in combination with chemotherapy relative to tumors in animals that received only vehicle or an isotype control mAb.

Example 1.2.2.3.D: FACS Based Redirected Cytotoxicity (rCTL) Assay

Human CD3+ T cells were isolated from previously frozen isolated peripheral blood mononuclear cells (PBMC) by a negative selection enrichment column (R&D Systems, Minneapolis, MN; Cat.#HTCC-525). T cells were stimulated for 4 days in flasks (vent cap, Corning, Acton, MA) coated with 10µg/mL anti-CD3 (OKT-3, eBioscience, Inc., San Diego, CA) and 2µg/mL anti-CD28 (CD28.2, eBioscience, Inc., San Diego, CA) in D-PBS (Invitrogen, Carlsbad, CA) and cultured in 30U/mL IL-2 (Roche) in complete RPMI 1640 media (Invitrogen, Carlsbad, CA) with L-glutamine, 55mM β-ME, Pen/Strep, 10% FBS). T cells were then rested overnight in 30U/mL IL-2 before using in assay. DoHH2 or Raji target cells were labeled with PKH26 (Sigma-Aldrich, St. Louis, MO) according to manufacturer's instructions. RPMI 1640 media (no phenol, Invitrogen, Carlsbad, CA) containing L-glutamine and 10% FBS (Hyclone, Logan, UT) was used throughout the rCTL assay. (See Dreier *et al.* (2002) Int J Cancer 100:690).

Effector T cells (E) and targets (T) were plated at a final cell concentration of 10^5 and 10^4 cells/well in 96-well plates (Costar #3799, Acton, MA), respectively to give an E:T ratio of 10:1. DVD-Ig molecules were diluted to obtain concentration-dependent titration curves. After an overnight incubation cells are pelleted and washed with D-PBS once before resuspending in FACS buffer containing 0.1% BSA (Invitrogen, Carlsbad, CA), 0.1% sodium azide and 0.5µg/mL propidium iodide (BD) in D-PBS. FACS data was collected on a FACS Canto II machine (Becton Dickinson, San Jose, CA) and analyzed in Flowjo (Treestar). The percent live targets in

the DVD-Ig treated samples divided by the percent total targets (control, no treatment) was calculated to determine percent specific lysis. IC50s were calculated in Prism (Graphpad).

The CD3 / CD 19 DVD-Ig (AB sequence IDs, AB002 + AB006; Example 2.7) was tested in the redirected toxicity assay for tumor cell killing. This DVD-Ig showed in vitro tumor killing with an IC50 = 5.0 pM. A CD3 / CD20 DVD-Ig was also tested for redirected toxicity and showed in vitro tumor killing with an IC50 = 325pM. The sequence of this CD3 / CD20 DVD-Ig was disclosed in US Patent Application Serial No. 20070071675.

Example 1.4: Generation of a DVD-Ig

DVD-Ig molecules capable of binding two antigens are constructed using two parent monoclonal antibodies, one against human antigen A, and the other against human antigen B, selected as described herein.

Example 1.4.1: Generation Of A DVD-Ig Having Two Linker Lengths

A constant region containing μ 1 Fc with mutations at 234, and 235 to eliminate ADCC/CDC effector functions is used. Four different anti-A/B DVD-Ig constructs are generated: 2 with short linker and 2 with long linker, each in two different domain orientations: V_A-V_B-C and V_B-V_A-C (see Table 30). The linker sequences, derived from the N-terminal sequence of human C1/Ck or CH1 domain, are as follows:

For DVDAB constructs:

light chain (if anti-A has λ):Short linker: QPKAAP; Long linker: QPKAAPSVTLFPP

light chain (if anti-A has κ):Short linker: TVAAP ; Long linker: TVAAPSVFIFPP

heavy chain (γ 1): Short linker: ASTKGP; Long linker: ASTKGPSVFPLAP

For DVDBA constructs:

light chain (if anti-B has λ):Short linker: QPKAAP; Long linker: QPKAAPSVTLFPP

light chain (if anti-B has κ):Short linker: TVAAP ; Long linker: TVAAPSVFIFPP

heavy chain (γ 1): Short linker: ASTKGP; Long linker: ASTKGPSVFPLAP

Heavy and light chain constructs are subcloned into the pBOS expression vector, and expressed in COS cells, followed by purification by Protein A chromatography. The purified materials are subjected to SDS-PAGE and SEC analysis.

Table 30 describes the heavy chain and light chain constructs used to express each anti-A/B DVD-Ig protein.

Table 30: Anti-A/B DVD-Ig Constructs

DVD-Ig protein	Heavy chain construct	Light chain construct
----------------	-----------------------	-----------------------

DVD-Ig protein	Heavy chain construct	Light chain construct
DVDABSL	DVDABHC-SL	DVDABLC-SL
DVDABLL	DVDABHC-LL	DVDABLC-LL
DVDBASL	DVDBAHC-SL	DVDBALC-SL
DVDBALL	DVDBAHC-LL	DVDBALC-LL

Example 1.4.2: Molecular cloning of DNA constructs for DVDABSL and DVDABLL:

To generate heavy chain constructs DVDABHC-LL and DVDABHC-SL, VH domain of A antibody is PCR amplified using specific primers (3' primers contain short/long liner sequence for SL/LL constructs, respectively); meanwhile VH domain of B antibody is amplified using specific primers (5' primers contains short/long liner sequence for SL/LL constructs, respectively). Both PCR reactions are performed according to standard PCR techniques and procedures. The two PCR products are gel-purified, and used together as overlapping template for the subsequent overlapping PCR reaction. The overlapping PCR products are subcloned into Srf I and Sal I double digested pBOS-hC γ 1,z non-a mammalian expression vector (Abbott) by using standard homologous recombination approach.

To generate light chain constructs DVDABLC-LL and DVDABLC-SL, VL domain of A antibody is PCR amplified using specific primers (3' primers contain short/long liner sequence for SL/LL constructs, respectively); meanwhile VL domain of B antibody is amplified using specific primers (5' primers contains short/long liner sequence for SL/LL constructs, respectively). Both PCR reactions are performed according to standard PCR techniques and procedures. The two PCR products are gel-purified, and used together as overlapping template for the subsequent overlapping PCR reaction using standard PCR conditions. The overlapping PCR products are subcloned into Srf I and Not I double digested pBOS-hCk mammalian expression vector (Abbott) by using standard homologous recombination approach. Similar approach has been used to generate DVDBASL and DVDBALL as described below:

Example 1.4.3: Molecular cloning of DNA constructs for DVDBASL and DVDBALL

To generate heavy chain constructs DVDBAHC-LL and DVDBAHC-SL, VH domain of antibody B is PCR amplified using specific primers (3' primers contain short/long liner sequence for SL/LL constructs, respectively); meanwhile VH domain of antibody A is amplified using specific primers (5' primers contains short/long liner sequence for SL/LL constructs, respectively). Both PCR reactions are performed according to standard PCR techniques and procedures. The two PCR products are gel-purified, and used together as overlapping template

for the subsequent overlapping PCR reaction using standard PCR conditions. The overlapping PCR products are subcloned into Srf I and Sal I double digested pBOS-hC γ 1,z non-a mammalian expression vector (Abbott) by using standard homologous recombination approach.

To generate light chain constructs DVDBALC-LL and DVDBALC-SL, VL domain of antibody B is PCR amplified using specific primers (3' primers contain short/long liner sequence for SL/LL constructs, respectively); meanwhile VL domain of antibody A is amplified using specific primers (5' primers contains short/long liner sequence for SL/LL constructs, respectively). Both PCR reactions are performed according to standard PCR techniques and procedures. The two PCR products are gel-purified, and used together as overlapping template for the subsequent overlapping PCR reaction using standard PCR conditions. The overlapping PCR products are subcloned into Srf I and Not I double digested pBOS-hCk mammalian expression vector (Abbott) by using standard homologous recombination approach.

Example 1.4.4: Construction and Expression of Additional DVD-Ig

Example 1.4.4.1: Preparation of DVD-Ig vector constructs

Parent antibody amino acid sequences for specific antibodies, which recognize specific antigens or epitopes thereof, for incorporation into a DVD-Ig can be obtained by preparation of hybridomas as described above or can be obtained by sequencing known antibody proteins or nucleic acids. In addition, known sequences can be obtained from the literature. The sequences can be used to synthesize nucleic acids using standard DNA synthesis or amplification technologies and assembling the desired antibody fragments into expression vectors, using standard recombinant DNA technology, for expression in cells.

For example, nucleic acid codons were determined from amino acids sequences and oligonucleotide DNA was synthesized by Blue Heron Biotechnology, Inc. (www.blueheronbio.com) Bothell, WA USA. The oligonucleotides were assembled into 300-2,000 base pair double-stranded DNA fragments, cloned into a plasmid vector and sequence-verified. Cloned fragments were assembled using an enzymatic process to yield the complete gene and subcloned into an expression vector. (See 7,306,914; 7,297,541; 7,279,159; 7,150,969; 20080115243; 20080102475; 20080081379; 20080075690; 20080063780; 20080050506; 20080038777; 20080022422; 20070289033; 20070287170; 20070254338; 20070243194; 20070225227; 20070207171; 20070150976; 20070135620; 20070128190; 20070104722; 20070092484; 20070037196; 20070028321; 20060172404; 20060162026; 20060153791; 20030215458; 20030157643).

A group of pHybE vectors (US Patent Application Serial No. 61/021,282) were used for parental antibody and DVD-Ig cloning. V1, derived from pJP183; pHybE-hC γ 1,z,non-a V2, was used for cloning of antibody and DVD heavy chains with a wildtype constant region. V2, derived

from pJP191; pHybE-hCk V2, was used for cloning of antibody and DVD light chains with a kappa constant region. V3, derived from pJP192; pHybE-hCl V2, was used for cloning of antibody and DVDs light chains with a lambda constant region. V4, built with a lambda signal peptide and a kappa constant region, was used for cloning of DVD light chains with a lambda-kappa hybrid V domain. V5, built with a kappa signal peptide and a lambda constant region, was used for cloning of DVD light chains with a kappa-lambda hybrid V domain. V7, derived from pJP183; pHybE-hCg1,z,non-a V2, was used for cloning of antibody and DVD heavy chains with a (234,235 AA) mutant constant region.

Referring to Table 31, a number of vectors were used in the cloning of the parent antibodies and DVD-Ig VH and VL chains.

Table 31: Vectors Used to Clone Parent Antibodies and DVD-Igs

ID	Heavy chain vector	Light chain vector
AB001	V1	V2
AB002	V1	V2
AB003	V1	V2
AB004	V1	V2
AB005	V1	V2
AB006	V1	V2
AB007	V1	V3
AB008	V1	V2
AB009	V1	V2
AB010	V1	V3
AB011	V1	V2
AB012	V1	V2
AB013	V1	V2
AB014	V1	V2
AB015	V1	V2
AB016	V1	V2
AB033	V1	V2
AB034	V1	V2
AB035	V1	V2
AB039	V1	V2
AB047	V1	V2
AB062	V1	V2
AB063	V1	V2
AB067	V7	V3
AB069	V1	V2
AB070	V1	V2
AB071	V7	V2
AB072	V1	V2
AB073	V1	V3
AB074	V1	V2
AB075	V1	V3

AB077	V1	V2
AB079	V1	V2
AB080	V1	V2
DVD001	V1	V2
DVD002	V1	V2
DVD003	V1	V2
DVD004	V1	V2
DVD005	V1	V5
DVD006	V1	V4
DVD007	V1	V2
DVD008	V1	V2
DVD009	V1	V2
DVD010	V1	V2
DVD011	V1	V2
DVD012	V1	V2
DVD013	V1	V2
DVD014	V1	V2
DVD015	V1	V2
DVD016	V1	V2
DVD017	V1	V2
DVD018	V1	V2
DVD019	V1	V5
DVD020	V1	V4
DVD021	V1	V2
DVD022	V1	V2
DVD023	V1	V2
DVD024	V1	V2
DVD025	V1	V2
DVD026	V1	V2
DVD027	V1	V2
DVD028	V1	V2
DVD029	V1	V5
DVD030	V1	V4
DVD031	V1	V2
DVD032	V1	V2
DVD033	V1	V2
DVD034	V1	V2
DVD035	V1	V2
DVD036	V1	V2
DVD037	V1	V2
DVD038	V1	V2
DVD039	V1	V2
DVD040	V1	V2
DVD041	V1	V5
DVD042	V1	V4
DVD043	V1	V2
DVD044	V1	V2
DVD045	V1	V2

DVD046	V1	V2
DVD047	V1	V2
DVD048	V1	V2
DVD049	V1	V2
DVD050	V1	V2
DVD073	V1	V2
DVD074	V1	V2
DVD075	V1	V2
DVD076	V1	V2
DVD077	V1	V2
DVD078	V1	V2
DVD079	V1	V2
DVD080	V1	V2
DVD081	V1	V2
DVD082	V1	V2
DVD083	V1	V2
DVD084	V1	V2
DVD085	V1	V2
DVD086	V1	V2
DVD087	V1	V2
DVD088	V1	V2
DVD089	V1	V2
DVD090	V1	V2
DVD091	V1	V2
DVD092	V1	V2
DVD093	V1	V2
DVD094	V1	V2
DVD107	V1	V2
DVD108	V1	V2
DVD131	V1	V2
DVD132	V1	V2
DVD135	V1	V2
DVD136	V1	V2
DVD137	V1	V2
DVD138	V1	V2
DVD139	V1	V2
DVD140	V1	V2
DVD141	V1	V2
DVD142	V1	V2
DVD143	V1	V2
DVD144	V1	V2
DVD257	V1	V2
DVD258	V1	V2
DVD259	V1	V2
DVD260	V1	V2
DVD299	V1	V2
DVD300	V1	V2
DVD301	V1	V2

DVD302	V1	V2
DVD303	V1	V2
DVD304	V1	V2
DVD305	V1	V2
DVD306	V1	V2
DVD307	V1	V2
DVD308	V1	V2
DVD309	V1	V2
DVD310	V1	V2
DVD385	V1	V2
DVD386	V1	V2
DVD387	V7	V2
DVD388	V1	V2
DVD389	V1	V2
DVD390	V1	V2
DVD391	V7	V2
DVD392	V1	V2
DVD393	V1	V2
DVD394	V1	V2
DVD395	V1	V2
DVD396	V1	V2
DVD397	V1	V2
DVD398	V1	V2
DVD399	V1	V2
DVD400	V1	V2
DVD401	V1	V2
DVD402	V1	V2
DVD403	V1	V2
DVD404	V1	V2
DVD405	V1	V2
DVD406	V1	V2
DVD407	V1	V2
DVD408	V1	V2
DVD409	V1	V4
DVD410	V1	V5
DVD411	V1	V4
DVD412	V1	V5
DVD413	V1	V4
DVD414	V7	V5
DVD415	V1	V4
DVD416	V1	V5
DVD417	V1	V4
DVD418	V7	V5
DVD419	V1	V4
DVD420	V1	V5
DVD421	V1	V4
DVD422	V1	V5
DVD423	V1	V4

DVD424	V1	V5
DVD441	V1	V2
DVD442	V1	V2
DVD443	V1	V2
DVD444	V1	V2
DVD445	V1	V2
DVD446	V1	V2
DVD447	V1	V2
DVD448	V1	V2
DVD449	V1	V2
DVD450	V1	V2
DVD451	V7	V2
DVD452	V7	V2
DVD453	V1	V2
DVD454	V1	V2
DVD455	V1	V2
DVD456	V1	V2
DVD457	V7	V2
DVD458	V7	V2
DVD459	V1	V2
DVD460	V1	V2
DVD461	V1	V2
DVD462	V1	V2
DVD463	V1	V2
DVD464	V1	V2
DVD465	V1	V2
DVD466	V1	V2
DVD467	V1	V2
DVD468	V1	V2
DVD469	V1	V2
DVD470	V1	V2
DVD471	V7	V2
DVD472	V1	V2
DVD473	V1	V2
DVD474	V1	V2
DVD475	V1	V2
DVD476	V1	V2
DVD477	V7	V2
DVD478	V1	V2
DVD479	V1	V2
DVD480	V1	V2
DVD481	V1	V2
DVD482	V1	V2
DVD483	V1	V2
DVD484	V1	V2
DVD485	V1	V2
DVD486	V1	V2
DVD487	V1	V2

DVD488	V1	V2
DVD489	V7	V2
DVD490	V1	V2
DVD491	V1	V2
DVD492	V1	V2
DVD493	V1	V2
DVD494	V1	V2
DVD495	V1	V2
DVD496	V1	V2
DVD497	V1	V2
DVD498	V1	V2
DVD499	V1	V2
DVD500	V1	V2
DVD501	V1	V2
DVD502	V1	V2
DVD503	V1	V2
DVD504	V1	V2
DVD505	V1	V2
DVD506	V1	V2
DVD507	V7	V2
DVD508	V1	V2
DVD509	V1	V2
DVD510	V1	V2
DVD511	V1	V4
DVD512	V7	V5
DVD513	V1	V4
DVD514	V1	V5
DVD515	V1	V4
DVD516	V1	V5
DVD517	V1	V4
DVD518	V1	V5
DVD519	V1	V4
DVD520	V1	V5
DVD521	V7	V4
DVD522	V7	V5
DVD523	V1	V4
DVD524	V1	V5
DVD525	V1	V4
DVD526	V1	V5
DVD527	V1	V4
DVD528	V1	V5
DVD529	V1	V4
DVD530	V7	V5
DVD531	V1	V4
DVD532	V1	V5
DVD533	V7	V4
DVD534	V7	V5
DVD535	V1	V2

DVD536	V1	V2
DVD537	V1	V2
DVD538	V1	V2
DVD539	V1	V2
DVD540	V1	V2
DVD541	V1	V2
DVD542	V1	V2
DVD543	V1	V2
DVD544	V1	V2
DVD545	V1	V2
DVD546	V1	V2
DVD547	V1	V2
DVD548	V1	V2
DVD549	V1	V2
DVD550	V1	V2
DVD551	V1	V2
DVD552	V1	V2
DVD553	V1	V2
DVD554	V1	V2
DVD555	V1	V2
DVD556	V1	V2
DVD557	V1	V2
DVD558	V1	V2
DVD559	V1	V2
DVD560	V1	V2
DVD561	V1	V2
DVD562	V1	V2
DVD563	V1	V2
DVD564	V1	V2
DVD565	V1	V2
DVD566	V1	V2
DVD567	V1	V2
DVD568	V1	V2
DVD569	V1	V2
DVD570	V1	V2
DVD571	V1	V2
DVD572	V1	V2
DVD573	V1	V2
DVD574	V1	V2
DVD575	V1	V2
DVD576	V1	V2
DVD577	V1	V2
DVD578	V1	V2
DVD579	V1	V2
DVD580	V1	V2
DVD581	V1	V2
DVD582	V1	V2
DVD583	V1	V2

DVD584	V1	V2
DVD585	V1	V2
DVD586	V1	V2
DVD587	V1	V2
DVD588	V1	V2
DVD589	V1	V2
DVD590	V1	V2
DVD591	V1	V2
DVD592	V1	V2
DVD593	V1	V2
DVD594	V1	V2
DVD595	V1	V2
DVD596	V1	V2
DVD597	V1	V2
DVD598	V1	V2
DVD599	V1	V2
DVD600	V1	V2
DVD601	V1	V2
DVD602	V1	V2
DVD603	V1	V4
DVD604	V1	V5
DVD605	V1	V4
DVD606	V1	V5
DVD607	V1	V4
DVD608	V1	V5
DVD609	V1	V4
DVD610	V1	V5
DVD611	V1	V2
DVD612	V1	V2
DVD613	V1	V2
DVD614	V1	V2
DVD615	V1	V2
DVD616	V1	V2
DVD625	V1	V2
DVD626	V1	V2
DVD627	V1	V2
DVD628	V1	V2
DVD629	V1	V2
DVD630	V1	V2
DVD631	V1	V2
DVD632	V1	V2
DVD641	V1	V2
DVD642	V1	V2
DVD643	V1	V2
DVD644	V1	V2
DVD645	V1	V2
DVD646	V1	V2
DVD647	V1	V2

DVD648	V1	V2
DVD649	V1	V2
DVD650	V1	V2
DVD651	V1	V2
DVD652	V1	V2
DVD653	V1	V2
DVD654	V1	V2
DVD655	V1	V2
DVD656	V1	V2
DVD657	V1	V2
DVD658	V1	V2
DVD659	V1	V2
DVD660	V1	V2
DVD661	V1	V2
DVD662	V1	V2
DVD663	V1	V2
DVD664	V1	V2
DVD665	V1	V2
DVD666	V1	V2
DVD667	V1	V2
DVD668	V1	V2
DVD669	V1	V2
DVD670	V1	V2
DVD671	V1	V2
DVD672	V1	V2
DVD673	V1	V2
DVD674	V1	V2
DVD675	V1	V2
DVD676	V1	V2
DVD677	V1	V2
DVD678	V1	V2
DVD679	V1	V2
DVD680	V1	V2
DVD681	V1	V2
DVD682	V1	V2
DVD683	V1	V2
DVD684	V1	V2
DVD685	V1	V2
DVD686	V1	V2
DVD687	V1	V2
DVD688	V1	V2
DVD689	V1	V2
DVD690	V1	V2
DVD691	V1	V2
DVD692	V1	V2
DVD693	V1	V2
DVD694	V1	V2
DVD709	V1	V2

DVD710	V1	V2
DVD711	V1	V2
DVD712	V1	V2

Example 1.4.4.2: Transfection And Expression In 293 Cells

The DVD-Ig vector constructs are transfected into 293 cells for production of DVD-Ig protein. The 293 transient transfection procedure used is a modification of the methods published in Durocher et al. (2002) Nucleic Acids Res. 30(2):E9 and Pham et al. (2005) Biotech. Bioengineering 90(3):332-44. Reagents that were used in the transfection included:

- HEK 293-6E cells (human embryonic kidney cell line stably expressing EBNA1; obtained from National Research Council Canada) cultured in disposable Erlenmeyer flasks in a humidified incubator set at 130 rpm, 37°C and 5% CO₂.
- Culture medium: FreeStyle 293 Expression Medium (Invitrogen 12338-018) plus 25 µg/mL Geneticin (G418) (Invitrogen 10131-027) and 0.1% Pluronic F-68 (Invitrogen 24040-032).
- Transfection medium: FreeStyle 293 Expression Medium plus 10 mM HEPES (Invitrogen 15630-080).
- Polyethylenimine (PEI) stock: 1 mg/mL sterile stock solution, pH 7.0, prepared with linear 25kDa PEI (Polysciences) and stored at less than -15°C.
- Tryptone Feed Medium: 5% w/v sterile stock of Tryptone N1 (Organotechnie, 19554) in FreeStyle 293 Expression Medium.

Cell preparation for transfection: Approximately 2 - 4 hours prior to transfection, HEK 293-6E cells are harvested by centrifugation and resuspended in culture medium at a cell density of approximately 1 million viable cells per mL. For each transfection, 40 mL of the cell suspension is transferred into a disposable 250-mL Erlenmeyer flask and incubated for 2 - 4 hours.

Transfection: The transfection medium and PEI stock are prewarmed to room temperature (RT). For each transfection, 25µg of plasmid DNA and 50µg of polyethylenimine (PEI) are combined in 5 mL of transfection medium and incubated for 15 – 20 minutes at RT to allow the DNA:PEI complexes to form. For the BR3-Ig transfections, 25µg of BR3-Ig plasmid is used per transfection. Each 5-mL DNA:PEI complex mixture is added to a 40-mL culture prepared previously and returned to the humidified incubator set at 130 rpm, 37°C and 5% CO₂. After 20-28 hours, 5 mL of Tryptone Feed Medium is added to each transfection and the cultures are continued for six days.

Table 32 contains the yield data for parent antibodies or DVD-Ig constructs expressed as milligrams per liter in 293 cells.

Table 32: Transient Expression in Yields of Parent Antibodies and DVD-Ig Constructs in 293 Cells

Parent Antibody or DVD-Ig ID	N-terminal Variable Domain (VD)	C-terminal Variable Domain (VD)	Expression Yield (mg/L)
AB006	CD-19		9.4
AB001	CD-20		90.2
DVD001	CD-20	CD-19	5.8
DVD002	CD-19	CD-20	2.4
AB001	CD-20		90.2
AB002	CD-3		67.2
DVD003	CD-20	CD-3	4.2
DVD004	CD-3	CD-20	7.4
AB007	CD-80		9.6
AB001	CD-20		90.2
DVD005	CD-20	CD-80	35.4
DVD006	CD-80	CD-20	43.4
AB008	CD-22		50
AB001	CD-20		90.2
DVD007	CD-20	CD-22	0.8
DVD008	CD-22	CD-20	0.22
AB009	CD-40		36.6
AB001	CD-20		90.2
DVD009	CD-20	CD-40	2.6
DVD010	CD-40	CD-20	8
AB002	CD-3		67.2
AB004	HER-2		108.2
DVD011	CD-3	HER-2	30.6
DVD012	HER-2	CD-3	74
AB002	CD-3		67.2
AB006	CD-19		9.4
DVD013	CD-3	CD-19	12.4
DVD014	CD-19	CD-3	7.2
AB033	EGFR		44.4
AB004	HER-2		108.2
DVD015	EGFR	HER-2	42.2
DVD016	HER-2	EGFR	17
AB002	CD-3		67.2
AB033	EGFR		44.4
DVD017	EGFR	CD-3	9.6
DVD018	CD-3	EGFR	4
AB033	EGFR		44.4
AB011	IGF1R		28.5
DVD021	EGFR	IGF1R	10.4
DVD022	IGF1R	EGFR	17.8

AB005	RON		67.4
AB033	EGFR		44.4
DVD024	RON	EGFR	19.2
DVD023	EGFR	RON	17.8
AB033	EGFR		44.4
AB012	HGF		22.8
DVD025	EGFR	HGF	5.8
DVD026	HGF	EGFR	2.2
AB004	HER-2		108.2
AB010	IGF1,2		38.6
DVD029	HER-2	IGF1,2	74.4
DVD030	IGF1,2	HER-2	26.8
AB004	HER-2		108.2
AB011	IGF1R		28.5
DVD031	HER-2	IGF1R	95
DVD032	IGF1R	HER-2	41.4
AB005	RON		67.4
AB012	HGF		22.8
DVD033	RON	HGF	29.4
DVD034	HGF	RON	7.8
AB014	VEGF		52.4
AB033	EGFR		44.4
DVD035	VEGF	EGFR	6.4
DVD036	EGFR	VEGF	5.4
AB014	VEGF		52.4
AB004	HER-2		108.2
DVD037	VEGF	HER-2	43.4
DVD038	HER-2	VEGF	41.2
AB001	CD-20		57
AB014	VEGF		52.4
DVD039	VEGF	CD-20	0.22
DVD040	CD-20	VEGF	0.48
AB014	VEGF		52.4
AB010	IGF1,2		38.6
DVD041	VEGF	IGF1,2	39.4
DVD042	IGF1,2	VEGF	8.8
AB015	DLL-4		57.6
AB014	VEGF		52.4
DVD044	DLL4	VEGF	5.4
DVD043	VEGF	DLL4	17.4
AB014	VEGF		52.4
AB012	HGF		22.8
DVD045	VEGF	HGF	4
DVD046	HGF	VEGF	1.4
AB005	RON		67.4
AB014	VEGF		52.4
DVD048	RON	VEGF	14
DVD047	VEGF	RON	18
AB014	VEGF		52.4
AB016	NRP1		114.6
DVD049	VEGF	NRP1	13

DVD050	NRP1	VEGF	27.2
AB015	DLL-4		57.6
AB047	PIGF		23.6
DVD257	DLL4	PIGF	31.2
DVD258	PIGF	DLL4	21
AB014	VEGF		52.4
AB047	PIGF		23.6
DVD259	VEGF	PIGF	2.2
DVD260	PIGF	VEGF	7.8
AB062	ErbB3		24.6
AB033	EGFR		44.4
DVD299	ErbB3	EGFR	4.2
DVD300	EGFR	ErbB3	1.6
AB063	ErbB3		37.8
AB033	EGFR		44.4
DVD305	ErbB3	EGFR	5.6
DVD306	EGFR	ErbB3	11.2

All DVDs expressed well in 293 cells. DVDs could be easily purified over a protein A column. In most cases >5 mg/L purified DVD-Ig could be obtained easily from supernatants of 293 cells.

5 **Example 1.4.5: Characterization and lead selection of A/B DVD-Igs**

The binding affinities of anti-A/B DVD-Igs are analyzed on Biacore against both protein A and protein B. The tetravalent property of the DVD-Ig is examined by multiple binding studies on Biacore. Meanwhile, the neutralization potency of the DVD-Igs for protein A and protein B are assessed by bioassays, respectively, as described herein. The DVD-Ig molecules that best
 10 retain the affinity and potency of the original parent mAbs are selected for in-depth physicochemical and bio-analytical (rat PK) characterizations as described herein for each mAb. Based on the collection of analyses, the final lead DVD-Ig is advanced into CHO stable cell line development, and the CHO-derived material is employed in stability, pharmacokinetic and efficacy studies in cynomolgus monkey, and preformulation activities.

15 **Example 2: Generation and Characterization of Dual Variable Domain Immunoglobulins (DVD-Ig)**

Dual variable domain immunoglobulins (DVD-Ig) using parent antibodies with known amino acid sequences were generated by synthesizing polynucleotide fragments encoding DVD-Ig variable heavy and DVD-Ig variable light chain sequences and cloning the fragments into a
 20 pHybC-D2 vector according to Example 1.4.4.1. The DVD-Ig constructs were cloned into and expressed in 293 cells as described in Example 1,4.4.2. The DVD-Ig protein was purified according to standard methods. Functional characteristics were determined according to the

methods described in Example 1.1.1 and 1.1.2 as indicated. DVD-Ig VH and VL chains for the DVD-Igs of the invention are provided below.

5

Example 2.1: Generation of CD-20 and CD-19 DVD-Igs

Table 33

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
99	DVD001H	AB001VH	AB006VH	QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMH WVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATL TADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGD WYFNVWGAGTTVTVSA ASTRGP QVQLQQSGAELVR PGSSVKISCKASGYAFSSYWMNWVKQRPQGLEWI GQIWPQDGDNTYNGKFKGKATLTADESSSTAYMQL SSLASEDSAVYFCARRETTTVGRYYYAMDYWGQGT SVTVSS
100	DVD001L	AB001VL	AB006VL	QIVLSQSPAILSPSPGKVTMTCRASSSVSYIHWF QQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSY SLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEI KR TVAAP DILLTQTPASLAVSLGQRATISCKASQS VDYDGDSYLNWYQQIPGQPPKLLIYDASNLVSGIP PRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTED PWTFGGGTKLEIKR
101	DVD002H	AB006VH	AB001VH	QVQLQQSGAELVVRPGSSVKISCKASGYAFSSYWMN WVKQRPQGLEWIGQIWPQDGDNTYNGKFKGKATL TADESSSTAYMQLSSLASEDSAVYFCARRETTTVG RYYYAMDYWGQGTSTVTVSS ASTRGP QVQLQQPGAEL LVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGL EWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAY MQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGT TVTVSA
102	DVD002L	AB006VL	AB001VL	DILLTQTPASLAVSLGQRATISCKASQSDYDGDS YLNWYQQIPGQPPKLLIYDASNLVSGIPPRFSGSG SGTDFTLNIHPVEKVDAATYHCQQSTEDPWTFGGG TKLEIKR TVAAP QIVLSQSPAILSPSPGKVTMTC RASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVP VRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSN PPTFGGGTKLEIKR

Example 2.2: Generation of CD-20 and CD-3 (seq. 1) DVD-Igs

Table 34

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
103	DVD003H	AB001VH	AB002VH	QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMH WVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATL TADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGD WYFNVWGAGTTVTVSA ASTKGP QVQLQQSGAELAR PGASVKMSCKASGYTFTRYTMHWVKQRPQGLEWI GYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQL SSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVS S
104	DVD003L	AB001VL	AB002VL	QIVLSQSPAILSPSPGKVTMTCRASSSVSYIHWF QQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSY SLTISRVEAEDAATYYCQQWTSNPPTFGGKLEI KR TVAAP QIVLTQSPAIMSASPGEKVTMTCRASSS VSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSG SGSGTSYSLTISRVEAEDAATYYCQQWSSNPLTFG SGTKLEINR
105	DVD004H	AB002VH	AB001VH	QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMH WVKQRPQGQLEWIGYINPSRGYTNYNQKFKDKATL TTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYC LDYWGQGTTLTVSS ASTKGP QVQLQQPGAELVKPG ASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGA IYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSS LTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVS A
106	DVD004L	AB002VL	AB001VL	QIVLTQSPAIMSASPGEKVTMTCRASSSVSYMNWY QQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSY SLTISRVEAEDAATYYCQQWSSNPLTFGSGTKLEI NR TVAAP QIVLSQSPAILSPSPGKVTMTCRASSS VSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSG SGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFG GGTKLEIKR

Example 2.3: Generation of CD-20 and CD-80 DVD-Igs

Table 35

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
107	DVD005H	AB001VH	AB007VH	QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMH WVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATL TADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGD WYFNVWGAGTTVTVSA ASTKGP QVQLQESGPGLVK PSETLSLTCAVSGGSIISGGYGWGWRQPPGKGLEW IGSFYSSSGNTYYNPSLKSQVTTISDTSKNQFSLK LNSMTAADTAVYYCVRDRLFSVVGMYNNWFDVWG PGVLVTVSS
108	DVD005L	AB001VL	AB007VL	QIVLSQSPAILSPSPGKVTMTCRASSSVSYIHWF QQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSY SLTISRVEAEDAATYYCQQTWSNPPTFGGGTKLEI KR TVAAP ESALTQPPSVSGAPGQKVTISCTGSTSN IGGYDLHWYQQLPGTAPKLLIYDINKRPSGISDRF SGSKSGTAAASLAITGLQTEDEADYYCQSYDSSLNA QVFGGGTRLTVLG
109	DVD006H	AB007VH	AB001VH	QVQLQESGPGPLVKPSETLSLTCAVSGGSIISGGYGW GWIRQPPGKGLEWIGSFYSSSGNTYYNPSLKSQVT ISTDTSKNQFSLKLNMTAADTAVYYCVRDRLFSV VGMVYNNWFDVWGPVGLVTVSS ASTKGP QVQLQQP GAELVKPGASVKMSCKASGYTFTSYNMHWKQTPG RGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSS TAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWG AGTTVTVSA
110	DVD006L	AB007VL	AB001VL	ESALTQPPSVSGAPGQKVTISCTGSTSNIGGYDLH WYQQLPGTAPKLLIYDINKRPSGISDRFSGSKSGT AASLAITGLQTEDEADYYCQSYDSSLNAQVFGGGT RLTVLGG QPKAAP QIVLSQSPAILSPSPGKVTMT CRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVP VRFSGSGSGTSYSLTISRVEAEDAATYYCQQTWSN PPTFGGGTKLEIKR

Example 2.4: Generation of CD-20 and CD-22 DVD-Igs

Table 36

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
111	DVD007H	AB001VH	AB008VH	QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMH WVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATL TADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGD WYFNVWGAGTTVTVSA ASTKGP QVQLVQSGAEVKK PGSSVKVSKASGYTFTSYWLHWVRQAPGGLEWI GYINPRNDYTEYNQNFKDKATITADESTNTAYMEL SSLRSEDTAFYFCARRDITTFYWGQGTITVTVSS
112	DVD007L	AB001VL	AB008VL	QIVLSQSPAILSPSPGKVTMTCRASSSVSYIHWF QQKPGSSPKPIYATSNLASGVPVRFSGSGSGTSY SLTISRVEAEDAATYYCQWTSNPPTFGGGTKLEI KR TVAAP DIQLTQSPSSLSASVGDRTVMSCKSSQS VLYSANHKNYLAWYQQKPGKAPKLLIYWASTRESG VPSRFSGSGSGTDFTFTISSLQPEDATYYCHQYL SSWTFGGGTKLEIKR
113	DVD008H	AB008VH	AB001VH	QVQLVQSGAEVKKPGSSVKVSKASGYTFTSYWLH WVRQAPGGLEWIGYINPRNDYTEYNQNFKDKATI TADESTNTAYMELSSLRSEDTAFYFCARRDITTFY WGQGTITVTVSS ASTKGP QVQLQQPGAELVKPGASV KMSCKASGYTFTSYNMHWKQTPGRGLEWIGAIYP GNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLT EDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSA
114	DVD008L	AB008VL	AB001VL	DIQLTQSPSSLSASVGDRTVMSCKSSQSVLYSANH KNYLAWYQQKPGKAPKLLIYWASTRESGVPVSRFSG SGSGTDFTFTISSLQPEDATYYCHQYLSSWTFGG GTKLEIKR TVAAP QIVLSQSPAILSPSPGKVTMT CRASSSVSYIHWFQQKPGSSPKPIYATSNLASGV PVRFSGSGSGTSYSLTISRVEAEDAATYYCQWTS NPPTFGGGTKLEIKR

Example 2.5: Generation of CD-20 and CD-40 DVD-Igs

Table 37

SEQ ID No.	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				123456789 0 123456789 0 123456789 0 12345
115	DVD009H	AB001VH	AB009VH	QVQLQQPGAELVKPGASVKMCKASGYTFTSYNMH WVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATL TADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGD WYFNVWGAGTTVTVSA ASTKGP QVQLVESGGGVVQ PGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWV AVISYEESNRYHADSVKGRFTISRDNKITYLQMN NSLRTEDEVAVYYCARDGGIAAPGPDYWGQGLTVV SS
116	DVD009L	AB001VL	AB009VL	QIVLSQSPAILSPSPGKVTMTCRASSSVSYIHW QQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSY SLTISRVEAEDAATYYCQWTSNPPTFGGGTKLEI KRTVAAPDIVMTQSPLSLTVPGEPAISCRSSQS LLYSNGYNYLDWYLQKPGQSPQVLISLGSNRASGV PDRFSGSGSGTDFTLKI SRVEAEDVGVYYCMQARQ TPPTFGPGTKVDIRR
117	DVD010H	AB009VH	AB001VH	QVQLVESGGGVVQ PGRSLRLSCAASGFTFSSYGMH WVRQAPGKGLEWVAVISYEESNRYHADSVKGRFTI SRDNKITYLQMNLSLRTEDEVAVYYCARDGGIAAP GPDYWGQGLTVTVSS ASTKGP QVQLQQPGAELVKP GASVKMCKASGYTFTSYNMHWVKQTPGRGLEWIG AIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLS SLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTV SA
118	DVD010L	AB009VL	AB001VL	DIVMTQSPLSLTVPGEPAISCRSSQSLLYSNGY NYLDWYLQKPGQSPQVLISLGSNRASGVPDRFSGS GSGTDFTLKI SRVEAEDVGVYYCMQARQTPPTFGP GTKVDIRR TVAAP QIVLSQSPAILSPSPGKVTMT CRASSSVSYIHWVQQKPGSSPKPWIYATSNLASGV PVRFSGSGSGTSYSLTISRVEAEDAATYYCQWTS NPPTFGGGTKLEIKR

Example 2.6: Generation of CD-3 (seq. 1) and HER-2 (seq. 1) DVD-Igs

Table 38

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
119	DVD011H	AB002VH	AB004VH	QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMH WVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATL TTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYC LDYWGQGTTLTVSS ASTKGP EVQLVESGGGLVQPG GSLRLSCAASGFNIKDTYIHWVRQAPGKLEWVAR IYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNS LRAEDTAVYYCSRWGGDGFYAMDYWGQGTTLTVSS
120	DVD011L	AB002VL	AB004VL	QIVLTQSPA IMSASPGEKVTMTCRASSSVSYMNWY QQKSGTSPKRWIYDTSKVASGVPYRFSGSGSTSY SLTISSMEAEADAATYYCQQWSSNPLTFGSGTKLEI NR TVAAP DIQMTQSPSSLSASVGDRTVITCRASQD VNTAVAWYQQKPGKAPKLLIYSASFYSGVPSRFS GSRSGTDFTLTISLQPEDFATYYCQHYTTPPTF GQGTKVEIKR
121	DVD012H	AB004VH	AB002VH	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIH WVRQAPGKLEWVARIYPTNGYTRYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFY AMDYWGQGTTLTVSS ASTKGP QVQLQQSGAELARP GASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIG YINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLS SLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSS
122	DVD012L	AB004VL	AB002VL	DIQMTQSPSSLSASVGDRTVITCRASQDVNTAVAW YQQKPGKAPKLLIYSASFYSGVPSRFSGSRSGTD FTLTISLQPEDFATYYCQHYTTPPTFGQGTKVE IKR TVAAP QIVLTQSPA IMSASPGEKVTMTCRASS SVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFS GSGSTSYSLTISSMEAEADAATYYCQQWSSNPLTF GSGTKLEINR

Example 2.7: Generation of CD-3 (seq. 1) and CD-19 DVD-Igs

Table 39

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
123	DVD013H	AB002VH	AB006VH	QVQLQQSGAELARPGASVKMCKASGYTFTRYTMH WVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATL TTDKSSSTAYMQLSSLTSEDSAVYYCARYDDHYC LDYWGQGTTLTVSS ASTKGP QVQLQQSGAELVRPG SSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQ IWPGDGDTNYNGKFKGKATLTADESSSTAYMQLSS LASEDSAVYFCARRETTTVGRYYYAMDYWGQGTSV TVSS
124	DVD013L	AB002VL	AB006VL	QIVLTQSPAIMASAPGKVTMTCRASSSVSYMNWY QQKSGTSPKRWIYDTSKVASGVPYRFGSGSGTSY SLTISSMEAEADAATYYCQWSSNPLTFGSGTKLEI NR TVAAP DILLTQTPASLAVSLGQRATISCKASQS VDYDGDSYLNWYQQIPGQPPKLLIYDASNLVSGIP PRFGSGSGTDFTLNIHPVEKVDAAATYHCQQSTED PWTFGGGTKLEIKR
125	DVD014H	AB006VH	AB002VH	QVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMN WVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATL TADESSSTAYMQLSSLASEDSAVYFCARRETTTVG RYYYAMDYWGQGTSVTVSS ASTKGP QVQLQQSGAE LARPGASVKMCKASGYTFTRYTMHWVKQRPGQL EWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAY MQLSSLTSEDSAVYYCARYDDHYCLDYWGQGTTL TVSS
126	DVD014L	AB006VL	AB002VL	DILLTQTPASLAVSLGQRATISCKASQVDYDGDS YLNWYQQIPGQPPKLLIYDASNLVSGIPPRFGSGG SGTDFTLNIHPVEKVDAAATYHCQQSTEDPWTFGGG TKLEIKR TVAAP QIVLTQSPAIMASAPGKVTMT CRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVP YRFGSGSGTSYSLTISSMEAEADAATYYCQWSSN PLTFGSGTKLEINR

Example 2.8: Generation of EGFR (seq. 2) and HER-2 (seq. 1) DVD-Igs

Table 40

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
127	DVD015H	AB033VH	AB004VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTNYGVH WVRQSPGKGLEWLGVIWISGGNTDYNTPFTRLSIN KDNSKSQVFFKMNSLQSNDAIYYCARALTYDYDYE FAYWGQGLVTVSA ASTKGP EVQLVESGGGLVQPG GSLRLSCAASGFNIKDTYIHWVRQAPGKLEWVAR IYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNS LRAEDTAVYYCSRWGGDGFYAMDYWGQGLVTVSS
128	DVD015L	AB033VL	AB004VL	DILLTQSPVILSVSPGERVVFSCRASQSIGTNIHW YQRTNGSPRLLIKYASESISGIPSRFSGSGSGTD FTLSINSVESEDIADYYCQNNWPTTFGAGTKLE LKR TVAAP DIQMTQSPSSLSASVGDVITCRASQ DVNTAVAWYQQKPKAPKLLIYSASFYSGVPSRF SGSRSGTDFTLTISLQPEDFATYYCQQHYTTPPT FGQGTKVEIKR
129	DVD016H	AB004VH	AB033VH	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIH WVRQAPGKLEWVARIYPTNGYTRYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFY AMDYWGQGLVTVSS ASTKGP QVQLKQSGPGLVQ PSQSLITCTVSGFSLTNYGVHWRQSPGKLEWLG VIWISGGNTDYNTPFTRLSINKDNSKSQVFFKMNS LQSNDAIYYCARALTYDYEFAYWGQGLVTVSA
130	DVD016L	AB004VL	AB033VL	DIQMTQSPSSLSASVGDVITCRASQDVNTAVAW YQQKPKAPKLLIYSASFYSGVPSRFSGSRSGTD FTLTISLQPEDFATYYCQQHYTTPPTFGQGTKVE IKR TVAAP DILLTQSPVILSVSPGERVVFSCRASQ SIGTNIHWYQRTNGSPRLLIKYASESISGIPSRF SGSGSGTDFTLSINSVESEDIADYYCQNNWPTT FGAGTKLELKR

Example 2.9: Generation of EGFR (seq. 2) and CD-3 (seq. 1) DVD-Igs

Table 41

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
131	DVD017H	AB033VH	AB002VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTNYGVH WVRQSPGKGLEWLGVIWGGNTDYNTPFTRSRLSIN KDNSKSQVFFKMNSLQSNDAIYYCARALTYDYDYE FAYWGQGLVTVSA ASTKGP QVQLQSGAELARPG ASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGY INPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSS LTSSEDSAVYYCARYDDHYCLDYWGQGLTTLTVSS
132	DVD017L	VD033VL	AB002VL	DILLTQSPVILSVSPGERVFSFSCRASQSIGTNIHW YQRTNGSPRLLIKYASESISGIPSRFSGSGSGTD FTLSINSVESEDIADYYCQNNNWPTTFGAGTKLE LKR TVAAP QIVLTQSPAIMSASPGEKVTMTCRASS SVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFS GSGSGTSYSLTISSMEADAATYYCQWSSNPLTF GSGTKLEINR
133	DVD018H	AB002VH	AB033VH	QVQLQSGAELARPGASVKMSCKASGYTFTRYTMH WVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATL TTDKSSSTAYMQLSSLTSSEDSAVYYCARYDDHYC LDYWGQGLTTLTVSS ASTKGP QVQLKQSGPGLVQPS QSLITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVI WGGNTDYNTPFTRSRLSINKDNSKSQVFFKMNSL QSNDAIYYCARALTYDYEFAYWGQGLVTVSA
134	DVD018L	AB002VL	AB033VL	QIVLTQSPAIMSASPGEKVTMTCRASSSVSYMNWY QQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSY SLTISSMEADAATYYCQWSSNPLTFGSGTKLEI NR TVAAP DILLTQSPVILSVSPGERVFSFSCRASQS IGTNIHWYQRTNGSPRLLIKYASESISGIPSRFS GSGSGTDFTLINSVESEDIADYYCQNNNWPTTF GAGTKLELKR

Example 2.10: Generation of EGFR (seq. 2) and IGF1,2 DVD-Igs

Table 42

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				123456789 0 123456789 0 123456789 0 12345
135	DVD019H	AB033VH	AB010VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTNYGVH WVRQSPGKGLEWLGVIWISGGNTDYNTPFTRLSIN KDNSKQVFFKMNSLQSNDAIYYCARALTYDYDYE FAYWGGTLVTVSA ASTKGP QVQLVQSGAEVKKPG ASVKVSKASGYFTSYDINWVRQATGQGLEWMGW MNPNSGNTGYAQKFGQGRVTMTRNTSISTAYMELSS LRSEDTAVYYCARDPYYYYGMDVWVGQGTIVTVSS
136	DVD019L	AB033VL	AB010VL	DILLTQSPVILSVSPGERVFSFCRASQSIGTNIHW YQRTNGSPRLLIKYASESISGIPSRFSGSGSGTD FTLSINSVESEDIADYYCQQNNWPTTFGAGTKLE LKR TVAAP QSVLTQPPSVSAAPGQKVTISCSGSSS NIENNHVSWYQQLPGTAPKLLIYDNNKRPSGIPDR FSGSKSGTSATLGITGLQTGDEADYYCETWDTLSL AGRVFGGGTKLTVLG
137	DVD020H	AB010VH	AB033VH	QVQLVQSGAEVKKPGASVKVSKASGYFTSYDIN WVRQATGQGLEWMGMNPNSGNTGYAQKFGQGRVTM TRNTSISTAYMELSSLRSEDTAVYYCARDPYYYY GMDVWVGQGTIVTVSS ASTKGP QVQLKQSGPGLVQ PSQSLITCTVSGFSLTNYGVHWRQSPGKLEWLG VIWISGGNTDYNTPFTRLSINKDNSKQVFFKMNS LQSNDAIYYCARALTYDYEFAYWGGTLVTVSA
138	DVD020L	AB010VL	AB033VL	QSVLTQPPSVSAAPGQKVTISCSGSSSNIENNHVS WYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGT SATLGITGLQTGDEADYYCETWDTLSAGRVFGGG TKLTVLG QPKAAP DILLTQSPVILSVSPGERVFS FCRASQSIGTNIHWYQRTNGSPRLLIKYASESISG IPSRFSGSGSGTDFTLINSVESEDIADYYCQQNN NWPTTFGAGTKLELKR

Example 2.11: Generation of EGFR (seq. 2) and IGF1R (seq. 1) DVD-Igs with Linker Set 1

Table 43

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
139	DVD021H	AB033VH	AB011VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTNYGVH WVRQSPGKGLEWLGVIWISGGNTDYNTPFTRSLSIN KDNSKSQVFFKMNSLQSNDAIYYCARALTYDYDYE FAYWGQGLVTVSA ASTKGP EVQLLESGGGLVQPG GSLRLSCTASGFTFSSYAMNWRQAPGKGLEWVSA ISGSGGTFYADSVKGRFTISRDNRTTLYLQMNS LRAEDTAVYYCAKDLGWSDSYYYYYGMVWVWGQGT TVVSS
140	DVD021L	AB033VL	AB011VL	DILLTQSPVILSVSPGERVVFSCRASQSIGTNIHW YQRTNGSPRLLIKYASESISGIPSRFSGSGSGTD FTLSINSVESEDIADYYCQNNNWPTTFGAGTKLE LKR TVAAP DIQMTQFPSSLSASVGDVRTITCRASQ GIRNDLGWYQQKPKAPKRLIYAASRLHRGVPSRF SGSGSGTEFTLTISLQPEDFATYYCLQHNSYPCS FGQGTKLEIKR
141	DVD022H	AB011VH	AB033VH	EVQLLESGGGLVQPGGSLRLSCTASGFTFSSYAMN WVRQAPGKGLEWVSAISGSGGTFYADSVKGRFTI SRDNRTTLYLQMNSLRAEDTAVYYCAKDLGWSDS YYYYYGMVWVWGQGTTVTVSS ASTKGP QVQLKQSGP GLVQPSQSLITCTVSGFSLTNYGVHWRQSPGK LEWLGVIWISGGNTDYNTPFTRSLSINKDNSKSQV FKMNSLQSNDAIYYCARALTYDYDYEFAWYWGQGL TVVSA
142	DVD022L	AB011VL	AB033VL	DIQMTQFPSSLSASVGDVRTITCRASQGIRNDLGW YQQKPKAPKRLIYAASRLHRGVPSRFSGSGSGTE FTLTISLQPEDFATYYCLQHNSYPCSFQGTKLE IKR TVAAP DILLTQSPVILSVSPGERVVFSCRASQ SIGTNIHWYQRTNGSPRLLIKYASESISGIPSRF SGSGSGTDFTLINSVESEDIADYYCQNNNWPTT FGAGTKLELKR

Example 2.12: Generation of EGFR (seq. 2) and IGF1R (seq. 1) DVD-Igs with Linker Set 2

Table 44

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
143	DVD611H	AB011VH	AB033VH	EVQLLESQGGGLVQPGGSLRLSCTASGFTFSSYAMN WVRQAPGKGLEWVSAISGSGGTTYADSVKGRFTI SRDNSRTTLYLQMNSLRAEDTAVYYCAKDLGWSDS YYYYYGMVDVWGQGTITVTVSS ASTKGPSVFPLAP QV QLKQSGPGLVQPSQSLITCTVSGFSLTNYGVHWV RQSPGKGLEWLGVIWSSGNTDYNTPFSTRLSINKD NSKSKVFFKMNLSQSDNTAIYYCARALTYDYEFAY YWGQGTITVTVSA
144	DVD611L	AB011VL	AB033VL	DIQMTQFPSSLSASVGDRTVITCRASQGIKNDLQW YQQKPGKAPKRLIYAASRLHRGVPSRFGSGSGGTE FTLTISSLPEDFATYYCLQHNYSYPCSFQGGTKLE IKR TVAAPSVFI FPDILITQSPVILSVSPGERV FSCRASQSIGTNIHWYQRTNGSPRLLIKYASESI SGIPSRFGSGSGGTDFTLSINSVESEDIADYYCQQ NNNWPTTFGAGTKLELKR
145	DVD612H	AB033VH	AB011VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTNYGVH WVRQSPGKGLEWLGVIWSSGNTDYNTPFSTRLSIN KDNSKSKVFFKMNLSQSDNTAIYYCARALTYDYE FAYWGQGTITVTVSA ASTKGPSVFPLAP EVQLLESG GGLVQPGGSLRLSCTASGFTFSSYAMNWRQAPGK GLEWVSAISGSGGTTYADSVKGRFTISRDNSTT LYLQMNSLRAEDTAVYYCAKDLGWSDSYYYYYGM VDVWGQGTITVTVSS
146	DVD612L	AB033VL	AB011VL	DILITQSPVILSVSPGERVDFSCRASQSIGTNIHW YQRTNGSPRLLIKYASEISGIPSRFGSGSGGTD FTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLE LKR TVAAPSVFI FPDILITQSPVILSVSPGERV ITCRASQGIKNDLQWYQQKPGKAPKRLIYAASRLH RGVPSRFGSGSGGTEFTLTISSLPEDFATYYCLQ HNSYPCSFQGGTKLEIKR

Example 2.13: Generation of EGFR (seq. 2) and IGF1R (seq. 1) DVD-Igs with Linker Set 3

Table 45

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
147	DVD613H	AB011VH	AB033VH	EVQLLESGGGLVQPGGSLRLSCTASGFTFSSYAMN WVRQAPGKGLEWVSAISGSGGTTYADSVKGRFTI SRDNSRTTLYLQMNSLRAEDTAVYYCAKDLGWSDS YYYYYGM DVWGQGT TVTVSS ASTKGPSVFPLAP QV QLKQSGPGLVQPSQSL SITCTVSGFSLTNYGVHWV RQSPGKGLEWLGVIWSSGNTDYNTPFSTRLSINKD NSKSKVFFKMNLSQSNDAIYYCARALTYDYEFAY YWGQGT TVTVSA
148	DVD613L	AB011VL	AB033VL	DIQMTQFPSSLSASVGDRTVITCRASQGIRNDLW YQKPGKAPKRLIYAASRLHRGVPSRFSGSGSGTE FTLTISLQPEDFATYYCLQHNSYPCSFQGGTKLE IKR TVAAP DILLTQSPVILSVSPGERVVFSCRASQ SIGTNIHWYQRTNGSPRLLIKYASESISGIPSRF SGSGSGTEFTLTISLQPEDFATYYCLQHNSYPCSF FGAGTKLEIKR
149	DVD614H	AB033VH	AB011VH	QVQLKQSGPGLVQPSQSL SITCTVSGFSLTNYGVH WVRQSPGKGLEWLGVIWSSGNTDYNTPFSTRLSIN KDNSKSKVFFKMNLSQSNDAIYYCARALTYDYEFAY YWGQGT TVTVSA ASTKGPSVFPLAP EVQLLES GGLVQPGGSLRLSCTASGFTFSSYAMNWRQAPGK GLEWVSAISGSGGTTYADSVKGRFTISRDNSTT LYLQMNSLRAEDTAVYYCAKDLGWSDSYYYYYGM DVWGQGT TVTVSS
150	DVD614L	AB033VL	AB011VL	DILLTQSPVILSVSPGERVVFSCRASQSIGTNIHW YQRTNGSPRLLIKYASESISGIPSRFSGSGSGTD FTLTISLQPEDFATYYCLQHNSYPCSFQGGTKLE IKR TVAAP DIQMTQFPSSLSASVGDRTVITCRASQ GIRNDLWYQKPGKAPKRLIYAASRLHRGVPSRF SGSGSGTEFTLTISLQPEDFATYYCLQHNSYPCSF FGAGTKLEIKR

Example 2.14: Generation of EGFR (seq. 2) and IGF1R (seq. 1) DVD-Igs with Linker Set 4

Table 46

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
151	DVD615H	AB011VH	AB033VH	EVQLLESGGGLVQPGGSLRLSCTASGFTFSSYAMN WVRQAPGKGLEWVSAISGSGGTTFYADSVKGRFTI SRDNSRTTLYLQMNSLRAEDTAVYYCAKDLGWSDS YYYYYGMVDVWGQGTITVTVSS ASTKGP QVQLKQSGP GLVQPSQSLITCTVSGFSLTNYGVHWRQSPGKG LEWLGVIWISGGNTDYNTPFSTRLSINKDNSKQVVF FKMNSLQSNDAIYYCARALTYDYEFAYWGQGT LTVVSA
152	DVD615L	AB011VL	AB033VL	DIQMTQFPSSLSASVGDRTITCRASQGIRNDLW YQQKPGKAPKRLIYAASRLHRGVPSRFGSGSGTE FTLTISLQPEDFATYYCLQHNSYPCSFQGGTKLE IKR TVAAPSVFI FPDILLTQSPVILSVSPGERV SFSCRASQSIGTNIHWYQRTNGSPRLLIKYASESI SGIPSRFGSGSGTDFTLINSVESEDIADYYCQ NNNWPTTFGAGTKLELKR
153	DVD616H	AB033VH	AB011VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTNYGVH WVRQSPGKGLEWLGVIWISGGNTDYNTPFSTRLSIN KDNSKQVVFVKMNSLQSNDAIYYCARALTYDY EFAYWGQGTITVTVSA ASTKGP EVQLLESGGGLVQPG GSLRLSCTASGFTFSSYAMNWRQAPGKGLEWVSA ISGSGGTTFYADSVKGRFTISRDNSTTLYLQMNS LRAEDTAVYYCAKDLGWSDSYYYYYGMVDVWGQGT ITVTVSS
154	DVD616L	AB033VL	AB011VL	DILLTQSPVILSVSPGERVFSFSCRASQSIGTNIHW YQRTNGSPRLLIKYASEISGIPSRFGSGSGTD FTLSINSVESEDIADYYCQNNNWPTTFGAGTKLE LKR TVAAPSVFI FPDILLTQSPVILSVSPGERV ITCRASQIRNDLWYQQKPGKAPKRLIYAASRLH RGVPSRFGSGSGTEFTLTISLQPEDFATYYCLQ HNSYPCSFQGGTKLEIKR

Example 2.15: Generation of EGFR (seq. 2) and IGF1R (seq. 2) DVD-Igs with Linker Set 1

Table 47

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
155	DVD603H	AB075VH	AB033VH	EVQLVQSGAEVKKPGSSVKVSKASGGTFSSYAIS WVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTI TADKSTSTAYMELSSLRSEDTAVYYCARAPLRFLE WSTQDHYYYYYMDVWGKGTITVTVSS ASTKGP QVQL KQSGPGLVQPSQSLITCTVSGFSLTNYGVHWVRQ SPGKGLEWLGVIWISGGNTDYNTPFTRSLSINKDNS KSQVFFKMNSLQSNDAIYYCARALTYDYEFAYW GGTTLVTVSA
156	DVD603L	AB075VL	AB033VL	SSELTQDPAVSVALGQTVRITCQGDSLRSYYATWY QQKPGQAPILVIYGENKRPSGIPDRFSGSSSGNTA SLTITGAQAEDAEDYYCKSRDGSQHLVFGGGTKL TVLG QPKAAP DILLTQSPVILSVSPGERVFSFCRA SQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPS RFGSGSGTDFTLINSVESEDIADYYCQNNNWP TTFGAGTKLELKR
157	DVD604H	AB033VH	AB075VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTNYGVH WVRQSPGKGLEWLGVIWISGGNTDYNTPFTRSLSIN KDNSKSQVFFKMNSLQSNDAIYYCARALTYDYE FAYWGGTTLVTVSA ASTKGPE VQLVQSGAEVKKPG SSVKVSKASGGTFSSYAISWVRQAPGQGLEWMGG IIPIFGTANYAQKFQGRVTITADKSTSTAYMELSS LRSEDTAVYYCARAPLRFLEWSTQDHYYYYYMDVW GKGTITVTVSS
158	DVD604L	AB033VL	AB075VL	DILLTQSPVILSVSPGERVFSFCRASQSIGTNIHW YQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTD FTLSINSVESEDIADYYCQNNNWP TTFGAGTKLE LKR TVAAP SSELTQDPAVSVALGQTVRITCQGDSL RSYYATWYQQKPGQAPILVIYGENKRPSGIPDRFS GSSSGNTASLTITGAQAEDAEDYYCKSRDGSQHL VFGGGTKLTVLG

Example 2.16: Generation of EGFR (seq. 2) and IGF1R (seq. 2) DVD-Igs with Linker Set 2

Table 48

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
159	DVD605H	AB075VH	AB033VH	EVQLVQSGAEVKKKPGSSVKVSKASGGTFSSYAIS WVRQAPGQGLEWMGGIIPIFGTANYAQKFGGRVTI TADKSTSTAYMELSSLRSEDVAVYYCARAPLRFLE WSTQDHYYYYYMDVWGKGTITVTVSS ASTKGPSVFP LAPQVQLKQSGPGLVQPSQSLITCTVSGFSLTNY GVHWVRQSPGKLEWLGVIWSSGNTDYNTPFPSRL SINKDNKSKQVFFKMNLSLQSNDAIYYCARALTY DYEFAYWGQGLTVTSA
160	DVD605L	AB075VL	AB033VL	SSELTQDPAVSVALGQTVRITCQGDSLRSYYATWY QQKPGQAPILVIYGENKRPSGIPDRFSGSSSGNTA SLTITGAQAEDEADYYCKSRDGSQHLVFGGGTKL TVLG QPKAAPSVTLFPP DILLTQSPVILSVSPGER VSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASE SISGIPSRFSGSGSDFTLSINSVESEDIADYYC QQNNNWPTTFGAGTKLELKR
161	DVD606H	AB033VH	AB075VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTNYGVH WVRQSPGKLEWLGVIWSSGNTDYNTPFPSRLSIN KDNKSKQVFFKMNLSLQSNDAIYYCARALTYDY FAYWGQGLTVTSA ASTKGPSVFP LAPQVQLVQSG AEVKKPGSSVKVSKASGGTFSSYAISWVRQAPGQ GLEWMGGIIPIFGTANYAQKFGGRVTITADKSTST AYMELSSLRSEDVAVYYCARAPLRFLEWSTQDHYY YYYYMDVWGKGTITVTVSS
162	DVD606L	AB033VL	AB075VL	DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHW YQQRTNGSPRLLIKYASESISGIPSRFSGSGSD FTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLE LKR TVAAPSVFI FPSSSELTQDPAVSVALGQTVRI TCQGDSLRSYYATWYQQKPGQAPILVIYGENKRPS GIPDRFSGSSSGNTASLTITGAQAEDEADYYCKSR DGSQHLVFGGGTKLTVLG

Example 2.17: Generation of EGFR (seq. 2) and IGF1R (seq. 2) DVD-Igs with Linker Set 3

Table 49

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
163	DVD607H	AB075VH	AB033VH	EVQLVQSGAEVKKKPGSSVKVCKASGGTFSSYAIS WVRQAPGQGLEWMGGIIPIFGTANYAQKFGGRVTI TADKSTSTAYMELSSLRSEDVAVYYCARAPLRFLE WSTQDHYYYYYMDVWGKGTITVTVSS ASTKGPSVFPLAP LAPQVQLKQSGPGLVQPSQSLSI TCTVSGFSLTNY GVHWVRQSPGKGLEWLGVIWGGNTDYNTPFPSRL SINKDNKSKQVFFKMNLSLQSNDAIYYCARALTY DYEFAYWGQGLTVTSA
164	DVD607L	AB075VL	AB033VL	SSELTQDPAVSVALGQTVRITCQGDSLRSYYATWY QQKPGQAPILVIYGENKRPSGIPDRFSGSSSGNTA SLTITGAQAEDEADYYCKSRDGSQHLVFGGGTKL TVLG QPKAAP DILLTQSPVILSVSPGERVFSFCRA SISGIPRFSFGSGGTDFTLSINSVESEDIADYYCQNNNWP TTFGAGTKLELKR
165	DVD608H	AB033VH	AB075VH	QVQLKQSGPGLVQPSQSLSI TCTVSGFSLTNYGVH WVRQSPGKGLEWLGVIWGGNTDYNTPFPSRLSIN KDNKSKQVFFKMNLSLQSNDAIYYCARALTYDY FAYWGQGLTVTSA ASTKGPSVFPLAP EVQLVQSG AEVKKPGSSVKVCKASGGTFSSYAISWVRQAPGQ GLEWMGGIIPIFGTANYAQKFGGRVTITADKSTST AYMELSSLRSEDVAVYYCARAPLRFLEWSTQDHYY YYYYMDVWGKGTITVTVSS
166	DVD608L	AB033VL	AB075VL	DILLTQSPVILSVSPGERVFSFCRASQSIGTNIHW YQQRNGSPRLLIKYASESISGIPSRFSGSGGTD FTLSINSVESEDIADYYCQNNNWP TTFGAGTKLE LKR TVAAP SSELTQDPAVSVALGQTVRITCQGDSL RSYYATWYQQKPGQAPILVIYGENKRPSGIPDRFS GSSSGNTASLTITGAQAEDEADYYCKSRDGSQHL VFGGGTKLTVLG

Example 2.18: Generation of EGFR (seq. 2) and IGF1R (seq. 2) DVD-Igs with Linker Set 4

Table 50

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
167	DVD609H	AB075VH	AB033VH	EVQLVQSGAEVKKKPGSSVKVSKASGGTFSSYAIS WVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTI TADKSTSTAYMELSSLRSEDVAVYYCARAPLRFLE WSTQDHYYYYYMDVWGKGTITVTVSS ASTKGP QVQL KQSGPGLVQPSQSLITCTVSGFSLTNYGVHWVRQ SPGKGLEWLGVIWISGGNTDYNTPFPSRLSINKDNS KSQVFFKMNSLQSNDAIYYCARALTYDYEFAYW GGTTLVTVSA
168	DVD609L	AB075VL	AB033VL	SSELTQDPAVSVALGQTVRITCQGDSLRSYYATWY QQKPGQAPILVIYGENKRPSGIPDRFSGSSSGNTA SLTITGAQAEDEADYYCKSRDGSQHLVFGGGTKL TVLG QPKAAPSVTLFPP DILLTQSPVILSVSPGER VSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASE SISGIPSRFSGSGGTDFTLSINSVESEDIADYYC QQNNNWPTTFGAGTKLELKR
169	DVD610H	AB033VH	AB075VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTNYGVH WVRQSPGKGLEWLGVIWISGGNTDYNTPFPSRLSIN KDNSKSQVFFKMNSLQSNDAIYYCARALTYDYEF FAYWGGTTLVTVSA ASTKGPE VQLVQSGAEVKKPG SSVKVSKASGGTFSSYAISWVRQAPGQGLEWMGG IIPIFGTANYAQKFQGRVTITADKSTSTAYMELSS LRSEDVAVYYCARAPLRFLEWSTQDHYYYYYMDVW GKGTITVTVSS
170	DVD610L	AB033VL	AB075VL	DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHW YQQRTNGSPRLLIKYASESISGIPSRFSGSGGTD FTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLE LKR TVAAPSVFI FPSSSELTQDPAVSVALGQTVRI TCQGDSLRSYYATWYQQKPGQAPILVIYGENKRPS GIPDRFSGSSSGNTASLTITGAQAEDEADYYCKSR DGSQHLVFGGGTKLTVLG

Example 2.19: Generation of EGFR (seq. 2) and IGF1R (seq. 3) DVD-Igs with Linker Set 1

Table 51

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
171	DVD625H	AB077VH	AB033VH	EVQLVQSGGGLVVKPGGSLRLSCAASGFTFSSFAMH WVRQAPGKGLEWISVIDTRGATYYADSVKGRFTIS RDNAKNSLYLQMNSLRAEDTAVYYCARLGNFYYGM DVWGQGT TVTVSS ASTKGP QVQLKQSGPGLVQPSQ SLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVI WSGGNTDYNTPFTSRLSINKDNSKQVFFKMNSLQ SNDTAYYCARALTYDYEFAYWGQGLTVTVA
172	DVD625L	AB077VL	AB033VL	EIVLTQSPGTL SVSPGERATL SCRASQSIGSSLHW YQQKPGQAPRLLIKYASQSLSGIPDRFSGSGSGTD FTLTISRLEPEDFAVYYCHQSSRLPHTFGQGTKVE IKR TVAAP DILLTQSPVILSVSPGERV SP FCRASQ SIGTNIHWYQRTNGSPRLLIKYASESISGIPSRF SGSGSGTDFTLSINSVESEDIADYYCQNNNWPTT FGAGTKLELKR
173	DVD626H	AB033VH	AB077VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTNYGVH WVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSIN KDNSKQVFFKMNSLQSNDAIYYCARALTYDYDYE FAYWGQGLTVTVA ASTKGP EVQLVQSGGGLVVKPG GSLRLSCAASGFTFSSFAMHWVRQAPGKGLEWISV IDTRGATYYADSVKGRFTISRDNKNSLYLQMNSL RAEDTAVYYCARLGNFYYGMDVWGQGT TVTVSS
174	DVD626L	AB033VL	AB077VL	DILLTQSPVILSVSPGERV SP FCRASQSIGTNIHW YQRTNGSPRLLIKYASESISGIPSRFSGSGSGTD FTLSINSVESEDIADYYCQNNNWPTT FGAGTKLE LKR TVAAP EIVLTQSPGTL SVSPGERATL SCRASQ SIGSSLHWYQKPGQAPRLLIKYASQSLSGIPDRF SGSGSGTDFTLTISRLEPEDFAVYYCHQSSRLPHT FGQGTKVEIKR

Example 2.20: Generation of EGFR (seq. 2) and IGF1R (seq. 3) DVD-Igs with Linker Set 2

Table 52

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
175	DVD627H	AB077VH	AB033VH	EVQLVQSGGGLVKGPGSLRLSCAASGFTFSSFAMH WVRQAPGKLEWISVIDTRGATYYADSVKGRFTIS RDNAKNSLYLQMNSLRAEDTAVYYCARLGNFYFGM DVWGQGTITVTVSS ASTKGPSVFPLAP QVQLKQSGP GLVQPSQSLISITCTVSGFSLTNYGVHWRQSPGKG LEWLGVIWSSGNTDYNTPFSTRLSINKDNSKQVVF FKMNSLQSNDAIYYCARALTYDYEFAYWGQGT LTVVSA
176	DVD627L	AB077VL	AB033VL	EIVLTQSPGTLSPGERATLSCRASQSIGSSSLHW YQQKPGQAPRLLIKYASQSLSGIPDRFSGSGSGTD FTLTISRLEPEDFAVYYCHQSSRLPHTFGQGTKVE IKR TVAAPSVFI FPDILITQSPVILSVSPGERV FSCRASQSIGTNIHWYQRTNGSPRLLIKYASESI SGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQ QNNWPTTFGAGTKLELKR
177	DVD628H	AB033VH	AB077VH	QVQLKQSGPGLVQPSQSLISITCTVSGFSLTNYGVH WVRQSPGKLEWLGVIWSSGNTDYNTPFSTRLSIN KDNSKQVVFVKMNSLQSNDAIYYCARALTYDYEF FAYWGQGTITVTVSA ASTKGPSVFPLAP EVQLVQSG GGLVKGPGSLRLSCAASGFTFSSFAMHWRQAPGK GLEWISVIDTRGATYYADSVKGRFTISRDNKNSL YLQMNSLRAEDTAVYYCARLGNFYFGMDVWGQGT ITVTVSS
178	DVD628L	AB033VL	AB077VL	DILITQSPVILSVSPGERVVFSCRASQSIGTNIHW YQRTNGSPRLLIKYASEISGIPSRFSGSGSGTD FTLSINSVESEDIADYYCQNNWPTTFGAGTKLE LKR TVAAPSVFI FPPEIVLTQSPGTLSPGERAT LSCRASQSIGSSSLHWYQQKPGQAPRLLIKYASQSL SGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCHQ SSRLPHTFGQGTKVEIKR

Example 2.21: Generation of EGFR (seq. 2) and IGF1R (seq. 3) DVD-Igs with Linker Set 3

Table 53

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
179	DVD629H	AB077VH	AB033VH	EVQLVQSGGGLVKGPGSLRLSCAASGFTFSSFAMH WVRQAPGKGLEWISVIDTRGATYYADSVKGRFTIS RDNAKNSLYLQMNSLRAEDTAVYYCARLGNFYFGM DVWGQGTFTVTVSS ASTKGPSVFPLAP QVQLKQSGP GLVQPSQSLISITCTVSGFSLTNYGVHWRQSPGKG LEWLGVIWSSGNTDYNTPFSTRLSINKDNSKQVVF FKMNSLQSNDAIYYCARALTYDYEFAYWGQGT LTVVSA
180	DVD629L	AB077VL	AB033VL	EIVLTQSPGTLSVSPGERATLSCRASQSIGSSSLHW YQQKPGQAPRLLIKYASQSLSGIPDRFSGSGSGTD FTLTISRLEPEDFAVYYCHQSSRLPHTFGQGTKE IKR TVAAP DILLTQSPVILSVSPGERVDFSCRASQ SIGTNIHWYQQRNGSPRLLIKYASESISGIPSRF SGSGSGTDFTLTINSVESEDIADYYCQNNNWPTT FGAGTKLELKR
181	DVD630H	AB033VH	AB077VH	QVQLKQSGPGLVQPSQSLISITCTVSGFSLTNYGVH WVRQSPGKGLEWLGVIWSSGNTDYNTPFSTRLSIN KDNSKQVFFKMNLSQSNDAIYYCARALTYDYEF FAYWGQGTFTVTVSS ASTKGPSVFPLAP EVQLVQSG GGLVKGPGSLRLSCAASGFTFSSFAMHWRQAPGK GLEWISVIDTRGATYYADSVKGRFTISRDNKNSL YLQMNSLRAEDTAVYYCARLGNFYFGMDVWGQGT FTVSS
182	DVD630L	AB033VL	AB077VL	DILLTQSPVILSVSPGERVDFSCRASQSIGTNIHW YQQRNGSPRLLIKYASESISGIPSRFSGSGSGTD FTLINSVESEDIADYYCQNNNWPTTFGAGTKLE LKR TVAAP EIVLTQSPGTLSVSPGERATLSCRASQ SIGSSSLHWYQQKPGQAPRLLIKYASQSLSGIPDRF SGSGSGTDFTLTISRLEPEDFAVYYCHQSSRLPHT FGQGTKEIKR

Example 2.22: Generation of EGFR (seq. 2) and IGF1R (seq. 3) DVD-Igs with Linker Set 4

Table 54

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
183	DVD631H	AB077VH	AB033VH	EVQLVQSGGGLVKKPGGSLRLSCAASGFTFSSFAMH WVRQAPGKGLEWISVIDTRGATYYADSVKGRFTIS RDNAKNSLYLQMNSLRAEDTAVYYCARLGNFYYGM DVWGQGT T V T V S S ASTKGP QVQLKQSGPGLVQPSQ SLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVI WSGGNTDYNT PFTSRLSINKDNSKQVFFKMNSLQ SNDTAYYCARALTYDYEFAYWGQGT L V T V S A
184	DVD631L	AB077VL	AB033VL	EIVLTQSPGTLSPGERATLSCRASQSIGSSLHW YQQKPGQAPRLLIKYASQSLSGIPDRFSGSGSGTD FTLTISRLEPEDFAVYYCHQSSRLPHTFGQGTKVE IKR TVAAPSVFIFPP DILLTQSPVILSVSPGERVS FSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESI SGIPSRFSGSGSGTDFTLINSVESEDIADYYCQQ NNNWPTTFGAGTKLELKR
185	DVD632H	AB033VH	AB077VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTNYGVH WVRQSPGKGLEWLGVIWSGGNTDYNT PFTSRLSIN KDNSKQVFFKMNSLQSNDAIYYCARALTYDYDYE FAYWGQGT L V T V S A ASTKGP EVQLVQSGGGLVKKPG GSLRLSCAASGFTFSSFAMHWVRQAPGKGLEWISV IDTRGATYYADSVKGRFTISRDNKNSLYLQMNSL RAEDTAVYYCARLGNFYYGMDVWGQGT T V T V S S
186	DVD632L	AB033VL	AB077VL	DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHW YQQRTNGSPRLLIKYASEISGIPSRFSGSGSGTD FTLINSVESEDIADYYCQQNNNWPTTFGAGTKLE LKR TVAAPSVFIFPPE I V L T Q S P G T L S V S P G E R A T L S C R A S Q S I G S S L H W Y Q Q K P G Q A P R L L I K Y A S Q S L S G I P D R F S G S G S G T D F T L T I S R L E P E D F A V Y Y C H Q S S R L P H T F G Q G T K V E I K R

Example 2.23: Generation of EGFR (seq. 2) and RON (seq. 1) DVD-Igs with Linker Set 1

Table 55

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
187	DVD023H	AB033VH	AB005VH	QVQLKQSGPGLVQPSSLSITCTVSGFSLTNYGVH WVRQSPGKLEWLGVIWGGNTDYNTPFTSRLSIN KDNSKQVFFKMNSLQSNDAIYYCARALTYDYDYE FAYWGGTLVTVSA ASTKGP EVQLVQSGGGLVKPG GSLRLSCAASGFTFSSYAMHWVRQAPGKLEWVAV ISYDGSNKYYADSVKGRFTISRDNKNTLYLQMNS LRAEDTAVYYCARFSGWPNNYYYYGMDVWGGQTTV TVSS
188	DVD023L	AB033VL	AB005VL	DILLTQSPVILSVSPGERVFSFCRASQSIGTNIHW YQRTNGSPRLLIKYASESISGIPSRFSGSGSGTD FTLSINSVESEDIADYYCQQNNWPTTFGAGTKLE LKR TVAAP DVVMTQSPLSLPVTPGEPASISCRSSQ SLLHNSGFNYVDWYLQKPGQSPHLLIYFGSYRASG VPDRFSGSGSGTDFTLTKISRVEAEDVGVYYCMQAL QTPPWTFGQGTKEIRR
189	DVD024H	AB005VH	AB033VH	EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYAMH WVRQAPGKLEWVAVISYDGSNKYYADSVKGRFTI SRDNKNTLYLQMNSLRAEDTAVYYCARFSGWPNN YYYYGMDVWGGQTTVTVSS ASTKGP QVQLKQSGPG LVQPSQSLITCTVSGFSLTNYGVHWVRQSPGKGL EWLGVIWGGNTDYNTPFTSRLSINKDNSKQVFF KMNSLQSNDAIYYCARALTYDYEFAYWGGTLV TVSA
190	DVD024L	AB005VL	AB033VL	DVVMTQSPLSLPVTPGEPASISCRSSQSLHNSGF NYVDWYLQKPGQSPHLLIYFGSYRASGVPDRFSGS GSGTDFTLTKISRVEAEDVGVYYCMQALQTPPWTFG QGTKEIRR TVAAP DILLTQSPVILSVSPGERVFS SCRASQSIGTNIHWYQRTNGSPRLLIKYASESIS GIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQN NNWPTTFGAGTKLELKR

Example 2.24: Generation of EGFR (seq. 2) and RON (seq. 1) DVD-Igs with Linker Set 2

Table 56

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
191	DVD535H	AB005VH	AB033VH	EVQLVQSGGGLVKKPGGSLRLSCAASGFTFSSYAMH WVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARFSGWPNN YYYYGMDVWGQGTTVTVSS ASTKGPSVFPLAPQVQ LKQSGPGLVQPSQSLITCTVSGFSLTNYGVHWVR QSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDN SKSQVFFKMNLSQSDTAIYYCARALTYDYEFAY WGQGTTLVTVSA
192	DVD535L	AB005VL	AB033VL	DVVMTQSPLSLPVTPGEPASISCRSSQSLLSNGF NYVDWYLQKPGQSPHLLIYFGSYRASGVPDRFSGS GSGTDFTLKISRVEAEDVGVYVYCMQALQTPPWTFG QGTKEIIR TVAAPSVFI FPPDILLTQSPVILSVS PGERVFSFSCRASQSIGTNIHWYQQRTNGSPRLLIK YASESISGIPSRFSGSGSGTDFTLINSVSESDIA DYCQNNNWPTTFGAGTKLELKR
193	DVD536H	AB033VH	AB005VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTNYGVH WVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSIN KDNSKQVFFKMNLSQSDTAIYYCARALTYDYDYE FAYWGQGTTLVTVSA ASTKGPSVFPLAPEVQLVQSG GGLVKKPGGSLRLSCAASGFTFSSYAMHWVRQAPGK GLEWVAVISYDGSNKYYADSVKGRFTISRDNKNT LYLQMNSLRAEDTAVYYCARFSGWPNYYYYGMDV WGQGTTLVTVSS
194	DVD536L	AB033VL	AB005VL	DILLTQSPVILSVSPGERVFSFSCRASQSIGTNIHW YQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTD FTLSINSVSESDIADYDQNNNWPTTFGAGTKLE LKR TVAAPSVFI FPPDVVMTQSPLSLPVTPGEPAS ISCRSSQSLLSNGFNKYVDWYLQKPGQSPHLLIYF GSYRASGVPDRFSGSGSGTDFTLKISRVEAEDVGV YVYCMQALQTPPWTFGQGTKEIIR

Example 2.25: Generation of EGFR (seq. 2) and RON (seq. 1) DVD-Igs with Linker Set 3

Table 57

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
195	DVD537H	AB005VH	AB033VH	EVQLVQSGGGLVKGPGSLRLSCAASGFTFSSYAMH WVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARFSGWPNN YYYYGMDVWGQGTTVTVSS ASTKGPSVFPLAP QVQ LKQSGPGLVQPSQSLITCTVSGFSLTNYGVHWVR QSPGKGLEWLGVIWSSGNTDYNTPFTSRLSINKDN SKSQVFFKMNLSQSDTAIYYCARALTYDYEFAY WGQGTTLVTVSA
196	DVD537L	AB005VL	AB033VL	DVVMTQSPLSLPVTPGEPASISCRSSQSLHNSGF NYVDWYLQKPGQSPHLLIYFGSYRASGVPDRFSGS GGSDFTLTKISRVEAEDVGVYVYCMQALQTPPWTFG QGTKVEIRR TVAAP DILLTQSPVILSVSPGERVVF SCRASQSIGTNIHWYQQRNGSPRLLIKYASESIS GIPSRFSGSGSDFTLINSVESEDIADYYCQQN NNWPTTFGAGTKLELKR
197	DVD538H	AB033VH	AB005VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTNYGVH WVRQSPGKGLEWLGVIWSSGNTDYNTPFTSRLSIN KDNSKQVFFKMNLSQSDTAIYYCARALTYDYE FAYWGQGTTLVTVS AASTKGPSVFPLAP EVQLVQSG GGLVKGPGSLRLSCAASGFTFSSYAMHWVRQAPGK GLEWVAVISYDGSNKYYADSVKGRFTISRDNKNT LYLQMNSLRAEDTAVYYCARFSGWPNNYYYYGMDV WGQGTTLVTVSS
198	DVD538L	AB033VL	AB005VL	DILLTQSPVILSVSPGERVVFSCRASQSIGTNIHW YQQRNGSPRLLIKYASESISGIPSRFSGSGSD FTLINSVESEDIADYYCQQNNWPTTFGAGTKLE LKR TVAAP DVVMTQSPLSLPVTPGEPASISCRSSQ SLHNSGFNYVDWYLQKPGQSPHLLIYFGSYRASG VPDRFSGSGSDFTLTKISRVEAEDVGVYVYCMQAL QTPPWTFGQGTKVEIRR

Example 2.26: Generation of EGFR (seq. 2) and RON (seq. 1) DVD-Igs with Linker Set 4

Table 58

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
199	DVD539H	AB005VH	AB033VH	EVQLVQSGGGLVVKPGGSLRLSCAASGFTFSSYAMH WVRQAPGKLEWVAVISYDGSNKYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARFSGWPN YYYYGMDVWGQGTTVTVSS ASTKGP QVQLKQSGPG LVQPSQSLSI TCTVSGFSLTNYGVHWVRQSPGKGL EWLGVISGGNTDYNTPFTSRLSINKDNSKQVFF KMNSLQSNDAIYYCARALTYDYEFAYWGQGTLV TVSA
200	DVD539L	AB005VL	AB033VL	DVVMTQSPVLSLPTVTPGEPASISCRSSQSLLSNGF NYVDWYLQKPGQSPHLLIYFGSYRASGVPDRFSGS GSGTDFTLKISRVEAEDVGVYVYCMQALQTPPWTFG QGTKVEIRR TVAAPSVFI FPPDILLTQSPVILSVS PGERVDFSCRASQSIGTNIHWYQQRTNGSPRLLIK YASESISGIPSRFSGSGSGTDFTLINSVSESDIA DYQCQNNNWPTTFGAGTKLELKR
201	DVD540H	AB033VH	AB005VH	QVQLKQSGPGLVQPSQSLSI TCTVSGFSLTNYGVH WVRQSPGKLEWLVISGGNTDYNTPFTSRLSIN KDNSKQVFFKMNSLQSNDAIYYCARALTYDYEF FAYWGQGTLVTVSA ASTKGP EVQLVQSGGGLVVKPG GSLRLSCAASGFTFSSYAMHWVRQAPGKLEWVAV ISYDGSNKYYADSVKGRFTISRDNKNTLYLQMNS LRAEDTAVYYCARFSGWPNYYYYGMDVWGQGTTV TVSS
202	DVD540L	AB033VL	AB005VL	DILLTQSPVILSVSPGERVDFSCRASQSIGTNIHW YQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTD FTLSINSVSESDIADYQCQNNNWPTTFGAGTKLE LKR TVAAPSVFI FPPDVVMTQSPVLSLPTVTPGEPAS ISCRSSQSLLSNGFNHYVDWYLQKPGQSPHLLIYF GSYRASGVPDRFSGSGSGTDFTLKISRVEAEDVGV YYCMQALQTPPWTFGQGTKVEIRR

Example 2.27: Generation of EGFR (seq. 2) and HGF (seq. 1) DVD-Igs

Table 59

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
203	DVD025H	AB033VH	AB012VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTNYGVH WVRQSPGKGLEWLGVIWISGGNTDYNTPFTRSLSIN KDNSKSQVFFKMNSLQSNDAIYYCARALTYDYDYE FAYWGQGLVTVSSA ASTKGP QVQLVESGGGLVKPG GSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSY ISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNS LRAEDTAVYYCARDEYNSGWYVLFYWGQGLVTV SS
204	DVD025L	AB033VL	AB012VL	DILLTQSPVILSVSPGERVSVFSCRASQSIGTNIHW YQRTNGSPRLLIKYASESISGIPSRFSGSGSGTD FTLSINSVESEDIADYYCQNNNWPTTFGAGTKLE LKR TVAAP DIQMTQSPSSVSASVGDRTITCRASQ GISSWLAWYQQKPGKAPNLLIYEASSLQSGVPSRF GGSGSGTDFLTITISLQPEDFATYYCQANGFPWT FGQGTKVEIKR
205	DVD026H	AB012VH	AB033VH	QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMS WIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRAEDTAVYYCARDEYNSGW YVLFYWGQGLVTVSS ASTKGP QVQLKQSGPGLV QPSQSLITCTVSGFSLTNYGVHWVRQSPGKLEW LGVIWISGGNTDYNTPFTRSLSINKDNSKSQVFFKM NSLQSNDAIYYCARALTYDYEFAYWGQGLVTV SA
206	DVD026L	AB012VL	AB033VL	DIQMTQSPSSVSASVGDRTITCRASQGISSWLAW YQQKPGKAPNLLIYEASSLQSGVPSRFSGSGSGTD FTLTITISLQPEDFATYYCQANGFPWTFGQGTKVE IKR TVAAP DILLTQSPVILSVSPGERVSVFSCRASQ SIGTNIHWYQRTNGSPRLLIKYASESISGIPSRF SGSGSGTDFLTLSINSVESEDIADYYCQNNNWPTT FGAGTKLELKR

Example 2.28: Generation of EGFR (seq. 2) and c-MET DVD-Igs

Table 60

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
207	DVD027H	AB033VH	AB013VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTNYGVH WVRQSPGKLEWLGVIWISGNTDYNTPFTRSLSIN KDNSKSQVFFKMNSLQSNDAIYYCARALTYDYDYE FAYWGQGLVTVSA ASTKGP QVQLQSGPELVRPG ASVKWSCPASGYTFTSYWLHWVKKQRPQGLEWIG MIDPSNSDTRFNPPNFKDKATLNVDRSSNTAYNLL SSLTSADSAVYYCATYGSYVSPLDYWGQGTSVVYS S
208	DVD027L	AB033VL	AB013VL	DILLTQSPVILSVSPGERVFSFCRASQSIGTNIHW YQRTNGSPRLLIKYASESISGIPSRFSGSGSGTD FTLSINSVESEDIADYYCQNNNWPFTTFGAGTKLE LKR TVAAP DIMMSQSPSSLTVSVGEKVTVSKSSQ SLLVTSSQKNYLAWYQKPKQSPKLLIYWASTRES GVPDRFTGSGSGTDFTLITSVKADDLAVYYCQY YAYPWTFGDGKLEIKR
209	DVD028H	AB013VH	AB033VH	QVQLQSGPELVRPGASVKWSCPASGYTFTSYWLH WVKKQRPQGLEWIGMIDPSNSDTRFNPPNFKDKA TLNVDRSSNTAYNLLSSLTSADSAVYYCATYGSYV SPLDYWGQGTSVVYSS ASTKGP QVQLKQSGPGLVQ PSQSLITCTVSGFSLTNYGVHWRQSPGKLEWLG VIWISGNTDYNTPFTRSLSINKDNSKSQVFFKMN SLQSNDAIYYCARALTYDYEFAYWGQGLVTVS A
210	DVD028L	AB013VL	AB033VL	DIMMSQSPSSLTVSVGEKVTVSKSSQSLVTSSQ KNYLAWYQKPKQSPKLLIYWASTRESGVPDRFTG SGSGTDFTLITSVKADDLAVYYCQYYAYPWTFG DGKLEIKR TVAAP DILLTQSPVILSVSPGERVFS SCRASQSIGTNIHWYQRTNGSPRLLIKYASESIS GIPSRFSGSGSGTDFTLSINSVESEDIADYYCQ NNWPFTTFGAGTKLELKR

Example 2.29: Generation of HER-2 (seq. 1) and IGF1,2 DVD-Igs

Table 61

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
211	DVD029H	AB004VH	AB010VH	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTTLVTVSS ASTKGP QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPNVSGNTGYAQKFKQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCARDPYYYYYGMVWVGQGTTVTVSS
212	DVD029L	AB004VL	AB010VL	DIQMTQSPSSLSASVGDRTVITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFYSGVPSRFSGSRSGTDFLTISLQPEDFATYYCQQHYTTPPTFGQGTKVEIKR TVAAP QSVLTQPPSVSAAPGQKVTISCSGSSSNIENNHVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCETWDTLSAGRVEFGGKTLTVLG
213	DVD030H	AB010VH	AB004VH	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPNVSGNTGYAQKFKQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCARDPYYYYYGMVWVGQGTTLVTVSS ASTKGP EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNLSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTTLVTVSS
214	DVD030L	AB010VL	AB004VL	QSVLTQPPSVSAAPGQKVTISCSGSSSNIENNHVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCETWDTLSAGRVEFGGKTLTVLG QPKAAP DIQMTQSPSSLSASVGDRTVITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFYSGVPSRFSGSRSGTDFLTISLQPEDFATYYCQQHYTTPPTFGQGTKVEIKR

Example 2.30: Generation of HER-2 (seq. 1) and IGF1R DVD-Igs

Table 62

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
215	DVD031H	AB004VH	AB011VH	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGLVTVSS ASTKGPEVQLVESGGGLVQPGGSLRLSCTASGFTFSSYAMNWVRQAPGKGLEWVS AISGSGGTFYADSVKGRFTISRDNSTRITLYLQMN SLRAEDTAVYYCAKDLGWSDSYGGMDVWGQGLVTVSS
216	DVD031L	AB004VL	AB011VL	DIQMTQSPSSLSASVGRVITTCRASQDVNTAVAWYQQKPGKAPKLLIYSASFYSGVPSRFSGSRSGTDFLTISLQPEDFATYYCQQHYTTPPTFGQGTKVEIKR TVAAP DIQMTQSPSSLSASVGRVITTCRASQ GIRNDLGWYQQKPGKAPKRLIYAASRLHRGVPSRFSGSGGTEFTLTISLQPEDFATYYCLQHNSYPCSEFGQGTKLEIKR
217	DVD032H	AB011VH	AB004VH	EVQLLESVGGGLVQPGGSLRLSCTASGFTFSSYAMNWVRQAPGKGLEWVS AISGSGGTFYADSVKGRFTISRDNSTRITLYLQMN SLRAEDTAVYYCAKDLGWSDSYGGMDVWGQGLVTVSS ASTKGPEVQLVESGGGLVQPGGSLRLS CAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGLVTVSS
218	DVD032L	AB011VL	AB004VL	DIQMTQSPSSLSASVGRVITTCRASQGIRNDLGWYQQKPGKAPKRLIYAASRLHRGVPSRFSGSGGTEFTLTISLQPEDFATYYCLQHNSYPCSEFGQGTKLEIKR TVAAP DIQMTQSPSSLSASVGRVITTCRASQ DVNTAVAWYQQKPGKAPKLLIYSASFYSGVPSRFSGSRSGTDFLTISLQPEDFATYYCQQHYTTPPTFGQGTKVEIKR

Example 2.31: Generation of RON (seq. 1) and HGF(seq. 1) DVD-Igs

Table 63

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
219	DVD033H	AB005VH	AB012VH	EVQLVQSGGGLVVKPGGSLRLSCAASGFTFSSYAMH WVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARFSGWPNN YYYYGMDVWGQGT T V T V S S ASTKGP QVQLVESGGG LVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGL EWSYISSSGSTIYYADSVKGRFTISRDNKNSLY LQMNSLRAEDTAVYYCARDEYNSGWYVLFDYWGQG TLVTVSS
220	DVD033L	AB005VL	AB012VL	DVVMTQSPSLPVP T P G E P A S I S C R S S Q S L L H S N G F NYVDWYLQKPGQSPHLLIYFGSYRASGVPDRFSGS GGSDFTLTKISRVEAEDVGVYYCMQALQTPPWTFG QGTKVEIRR TVAAP DIQMTQSPSSVSASVGDRTI TCRASQGISSWLAWYQKPGKAPNLLIYEASSLQS GVPSRFGSGSGSDFTLTISLQPEDFATYYCQQA NGFPWTFGQGTKVEIKR
221	DVD034H	AB012VH	AB005VH	QVQLVESGGGLVVKPGGSLRLSCAASGFTFSDYYMS WIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTI SRDNKNSLYLQMNSLRAEDTAVYYCARDEYNSGW YVLFDYWGQGT T V T V S S ASTKGP EVQLVQSGGGLV KPGGSLRLSCAASGFTFSSYAMHWVRQAPGKGLEW VAVISYDGSNKYYADSVKGRFTISRDNKNTLYLQ MNSLRAEDTAVYYCARFSGWPNNYYYYGMDVWGQ T T V T V S S
222	DVD034L	AB012VL	AB005VL	DIQMTQSPSSVSASVGDRTITCRASQGISSWLAW YQKPGKAPNLLIYEASSLQSGVPSRFGSGSGSD FTLTISLQPEDFATYYCQANGFPWTFGQGTKVE IKR TVAAP DVVMTQSPSLPVP T P G E P A S I S C R S S Q SLLHNSGFNYVDWYLQKPGQSPHLLIYFGSYRASG VPDRFSGSGSDFTLTKISRVEAEDVGVYYCMQAL QTPPWTFGQGTKVEIRR

Example 2.32: Generation of VEGF (seq. 1) and EGFR (seq. 2) DVD-Igs

Table 64

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
223	DVD035H	AB014VH	AB033VH	EVQLVESGGGLVQPGGSLRLSCAASGYTFITNYGMN WVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTF SLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYS SHWYFDVWGQGTTLVTVSS ASTKGP QVQLKQSGPGL VQPSQSLITCTVSGFSLTNYGVHWVRQSPGKGLE WLGVIWGGNTDYNTPFTRLSINKDNSKQVFFK MNSLQSNDAIYYCARALTYDYEFAYWGQGTTLVT VSA
224	DVD035L	AB014VL	AB033VL	DIQMTQSPSSLSASVGDRTVITCSASQDISNYLNW YQQKPGKAPKVLIIYFTSSLSHSGVPSRFSGSGGTD FTLTISLQPEDFATYYCQQYSTVPWTFGQGTKVE IKR TVAAP DILLTQSPVILSVSPGERVVFSCRASQ SIGTNIHWYQQRNGSPRLLIKYASESISGIPSRF SGSGGTDFTLISINSVESEDIADYYCQQNNWPTT FGAGTKLELKR
225	DVD036H	AB033VH	AB014VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTNYGVH WVRQSPGKGLEWLGVIWGGNTDYNTPFTRLSIN KDNSKQVFFKMNSLQSNDAIYYCARALTYDYDYE FAYWGQGTTLVTVSS ASTKGP EVQLVESGGGLVQPG GSLRLSCAASGYTFITNYGMNWRQAPGKLEWVGW INTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNS LRAEDTAVYYCAKYPHYYS SHWYFDVWGQGTTLVT VSS
226	DVD036L	AB033VL	AB014VL	DILLTQSPVILSVSPGERVVFSCRASQSIGTNIHW YQQRNGSPRLLIKYASESISGIPSRFSGSGGTD FTLISINSVESEDIADYYCQQNNWPTT FGAGTKLE LKR TVAAP DIQMTQSPSSLSASVGDRTVITCSASQ DISNYLNWYQQKPGKAPKVLIIYFTSSLSHSGVPSRF SGSGGTDFTLTISLQPEDFATYYCQQYSTVPWT FGQGTKVEIKR

Example 2.33: Generation of VEGF (seq. 1) and HER-2 (seq. 1) DVD-Igs

Table 65

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
227	DVD037H	AB014VH	AB004VH	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMN WVRQAPGKGLEWVGWINTYTGEPYAAEFKRRFTF SLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYS SHWYFDVWGQGLTVTVSS ASTKGPE VQLVESGGGL VQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLE WVARIYPTNGYTRYADSVKGRFTISADTSKNTAYL QMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGLTV TVSS
228	DVD037L	AB014VL	AB004VL	DIQMTQSPSSLSASVGRVTITCSASQDISNYLNW YQKPGKAPKVLITYFTSSLHSGVPSRFSGSGTD FTLTISLQPEDFATYYCQQYSTVPWTFGQGTKVE IKR TVAAP DIQMTQSPSSLSASVGRVTITCRASQ DVNTAVAWYQKPGKAPKLLIYSASFLYSGVPSRF SGSRSGTDFTLTISLQPEDFATYYCQQHYTTPPT FGQGTKVEIKR
229	DVD038H	AB004VH	AB014VH	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYI HWVRQAPGKLEWVARIYPTNGYTRYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFY AMDYWGQGLTVTVSS ASTKGPE VQLVESGGGLVQ PGGSLRLSCAASGYTFTNYGMNHWVRQAPGKLEWVG WINTYTGEPYAAEFKRRFTFSLDTSKSTAYLQMN SLRAEDTAVYYCAKYPHYYSWYFDVWGQGLTV TVSS
230	DVD038L	AB004VL	AB014VL	DIQMTQSPSSLSASVGRVTITCRASQDVNTAVAW YQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTD FTLTISLQPEDFATYYCQQHYTTPPTFGQGTKVE IKR TVAAP DIQMTQSPSSLSASVGRVTITCSASQ DISNYLNWYQKPGKAPKVLITYFTSSLHSGVPSRF SGSGTDFTLTISLQPEDFATYYCQQYSTVPWT FGQGTKVEIKR

Example 2.34: Generation of VEGF (seq. 1) and CD-20 DVD-Igs

Table 66

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
231	DVD039H	AB014VH	AB001VH	EVQLVESGGGLVQPGGSLRLSCAASGYFTFTNYGMN WVRQAPGKGLEWVGWINTYTGEPYAADFKRRFTF SLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYS SHWYFDVWQGQTLVTVSS ASTKGP QVQLQPGAE LVPKPGASVKMSCKASGYFTFTSYNMHWVKQTPGRGLE WIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYM QLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTT VTVSA
232	DVD039L	AB014VL	AB001VL	DIQMTQSPSSLSASVGDRTITCSASQDISNYLNW YQQKPGKAPKVLITYFTSSLHSGVPSRFSGSGSGTD FTLTISLQPEDFATYYCQQYSTVPWTFGQGTKVE IKR TVAAP QIVLSQSPAILSPSPGKVTMTCRASS SVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRF SGSGTSLTISRVEAEDAATYYCQQWTSNPPTF GGGKLEIKR
233	DVD040H	AB001VH	AB014VH	QVQLQPGAEELVKPGASVKMSCKASGYFTFTSYNMH WVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATL TADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGD WYFNVWGAGTTVTVSA ASTKGP EVQLVESGGGLVQ PGGSLRLSCAASGYFTFTNYGMNWRQAPGKLEWV GWINTYTGEPYAADFKRRFTFSLDTSKSTAYLQM NSLRAEDTAVYYCAKYPHYYS SHWYFDVWQGQTL VTVSS
234	DVD040L	AB001VL	AB014VL	QIVLSQSPAILSPSPGKVTMTCRASSSVSYIHW FQQKPGSSPKPWIYATSNLASGVPVRFSGSGT SYSLTISRVEAEDAATYYCQQWTSNPPTFGGKLEI KR TVAAP DIQMTQSPSSLSASVGDRTITCSASQD ISNYLNWYQQKPGKAPKVLITYFTSSLHSGVPSRFS GSGGTDFTLTISLQPEDFATYYCQQYSTVPWTF GQGTKVEIKR

Example 2.35: Generation of VEGF (seq. 1) and IGF1,2 DVD-Igs

Table 67

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
235	DVD041H	AB014VH	AB010VH	EVQLVESGGGLVQPGGSLRLSCAASGYFTFTNYGMN WVRQAPGKGLEWVGWINTYTGEPYAAEFKRRFTF SLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYS SHWYFDVWGQGTLLVTVSS ASTKGP QVQLVQSGAEV KPGASVKVCKASGYFTFTSYDINWVRQATGQGLE WMGWMNPNNGTGYAQKFQGRVTMTRNTSISTAYM ELSSLRSEDTAVYYCARDPYYYYYGMVWVGQGTTV TVSS
236	DVD041L	AB014VL	AB010VL	DIQMTQSPSSLSASVGDRTVITCSASQDISNYLNW YQQKPGKAPKVLIIYFTSSLSHSGVPSRFSGSGSD FTLTISLQPEDFATYYCQQYSTVFWTFGQGTKVE IKR TVAAP QSVLTQPPSVSAAPGQKVTISCSGSSS NIENNHVSWYQQLPGTAPKLLIYDNNKRPSGIPDR FSGSKSGTSATLGITGLQTGDEADYYCETWDTLS AGRVFGGGKLTVLG
237	DVD042H	AB010VH	AB014VH	QVQLVQSGAEVKKPGASVKVCKASGYFTFTSYDIN WVRQATGQGLEWGMNPNNGTGYAQKFQGRVTM TRNTSISTAYMELSSLRSEDTAVYYCARDPYYYYY GMDVWGQGTTVTVSS ASTKGP EVQLVESGGGLVQ GGSLRLSCAASGYFTFTNYGMNWRQAPGKLEWVG WINTYTGEPYAAEFKRRFTFSLDTSKSTAYLQMN SLRAEDTAVYYCAKYPHYYS SHWYFDVWGQGTLLV TVSS
238	DVD042L	AB010VL	AB014VL	QSVLTQPPSVSAAPGQKVTISCSGSSSNIENNHV SWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGT SATLGITGLQTGDEADYYCETWDTLSAGRVFGGG TKLTVL QPKAAP DIQMTQSPSSLSASVGDRTVIT CSASQDISNYLNWYQQKPGKAPKVLIIYFTSSLSH SGVPSRFSGSGSDFTLTISLQPEDFATYYCQQYS TVPWTFGQGTKVEIKR

Example 2.36: Generation of VEGF (seq. 1) and DLL4 (seq. 1) DVD-Igs

Table 68

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
239	DVD043H	AB014VH	AB015VH	EVQLVESGGGLVQPGGSLRLSCAASGYFTFTNYGMN WVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTF SLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYS SHWYFDVWGQGTLLVTVSS ASTKGP EVQLVESGGGL VQPGGSLRLSCAASGFTFTDNWISWVRQAPGKGLE WVGYISPNISGFTYYADSVKGRFTISADTSKNTAYL QMNSLRAEDTAVYYCARDNFGGYFDYWGQGTLLVTV SS
240	DVD043L	AB014VL	AB015VL	DIQMTQSPSSLSASVGDRTVITCSASQDISNYLNW YQQKPGKAPKVLITYFTSSLHSGVPSRFSGSGSGTD FTLTISLQPEDFATYYCQQYSTVFPWTFGQGTKVE IKR TVAAP DIQMTQSPSSLSASVGDRTVITCRASQ DVSTAVAWYQQKPGKAPKLLIYSASFYSGVPSRF SGSGSGTDFTLTISLQPEDFATYYCQQSYTGTV TFGQGTKVEIKR
241	DVD044H	AB015VH	AB014VH	EVQLVESGGGLVQPGGSLRLSCAASGFTFTDNWIS WVRQAPGKGLEWVGYISPNISGFTYYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARDNFGGYF DYWGQGTLLVTVSS ASTKGP EVQLVESGGGLVQPGG SLRLSCAASGYFTFTNYGMNWRQAPGKGLEWVGWI NTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSL RAEDTAVYYCAKYPHYYSWYFDVWGQGTLLVTV SS
242	DVD044L	AB015VL	AB014VL	DIQMTQSPSSLSASVGDRTVITCRASQDVSTAVAW YQQKPGKAPKLLIYSASFYSGVPSRFSGSGSGTD FTLTISLQPEDFATYYCQQSYTGTVTFGQGTKV EIKR TVAAP DIQMTQSPSSLSASVGDRTVITCSAS QDISNYLNWYQQKPGKAPKVLITYFTSSLHSGVPSR FSGSGSGTDFTLTISLQPEDFATYYCQQYSTVFPW TFGQGTKVEIKR

Example 2.37: Generation of VEGF (seq. 1) and HGF (seq. 1) DVD-Igs with Linker Set 1

Table 69

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
243	DVD045H	AB014VH	AB012VH	EVQLVESGGGLVQPGGSLRLSCAASGYTFITNYGMN WVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTF SLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYHYS SHWYFDVWGQGT LVTVSS ASTKGP QVQLVESGGGL VKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLE WVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYL QMNSLRAEDTAVYYCARDEYNSGWVFLFDYWGQGT LVTVSS
244	DVD045L	AB014VL	AB012VL	DIQMTQSPSSLSASVGRVTITCSASQDISNYLNW YQQKPGKAPKVLIIYFTSSLSHSGVPSRFGSGSGTD FTLTISLQPEDFATYYCQQYSTVPWTFGQGTKVE IKR TVAAP DIQMTQSPSSVSASVGRVTITCRASQ GISSWLAWYQQKPGKAPNLLIYEASSLQSGVPSRF GGSGSGTDFLTITISLQPEDFATYYCQQANGFPWT FGQGTKVEIKR
245	DVD046H	AB012VH	AB014VH	QVQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMS WIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRAEDTAVYYCARDEYNSGW YVFLFDYWGQGT LVTVSS ASTKGP EVQLVESGGGLV QPGGSLRLSCAASGYTFITNYGMNWRQAPGKGLEW VGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQ MNSLRAEDTAVYYCAKYPHYHYS SHWYFDVWGQGT LVTVSS
246	DVD046L	AB012VL	AB014VL	DIQMTQSPSSVSASVGRVTITCRASQGISSWLAW YQQKPGKAPNLLIYEASSLQSGVPSRFGSGSGTD FTLTISLQPEDFATYYCQQANGFPWTFGQGTKVE IKR TVAAP DIQMTQSPSSLSASVGRVTITCSASQ DISNYLNWYQQKPGKAPKVLIIYFTSSLSHSGVPSRF SGSGSGTDFLTITISLQPEDFATYYCQQYSTVPWT FGQGTKVEIKR

Example 2.38: Generation of VEGF (seq. 1) and HGF (seq. 1) DVD-Igs with Linker Set 2

Table 70

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
247	DVD641H	AB012VH	AB014VH	QVQLVESGGGLV K PGGSLRLS CAASGFTFSDYYMS WIRQAPGK GLEWVSYISSSGSTIYYADSVKGRFTI SRDNAKNSLYLQ MNSLRAEDTAVYYCARDEYNSGW YVLFDYWGQ QTLVTVSSASTKGPSVFPLAP EVQLV ESGGGLVQ PGGSLRLS CAASGY FTNYGMN WVRQA PGK GLEWGWINTYTG EP TYAADFKRRFTFSLDTS KSTAYLQ MNSLRAEDTAVYYCAKYPHYGSSHWYF DVWGQ QTLVTVSS
248	DVD641L	AB012VL	AB014VL	DIQMTQSPSSVSASV GDRVTITCRASQGISSW LAW YQ QKPGKAPNLLIYEAS LQSGVPSR FGSGSGTD FTLTISS LQPEDFATYYCQ ANGFP WTFGQGTKVE IKR TVAAPSVFI FPDIQMTQSPSSLSASV GDRVT ITCSASQDISNYLNWYQ KPGKAPKVL IYFTSS LH SGVPSR FGSGSGTDFTLTISS LQPEDFATYYC Q YSTVP WTFGQGTKVEIKR
249	DVD642H	AB014VH	AB012VH	EVQLVESGGGLVQ PGGSLRLS CAASGY FTNYGMN WVRQAPGK GLEWGWINTYTG EP TYAADFKRRFTF SLDT SKSTAYLQ MNSLRAEDTAVYY CAKYPHYGS SHWYFDVWGQ QTLVTVSSASTKGPSVFPLAP QVQL VESGGGLV KPGGSLRLS CAASG FTFSDYYMSWIRQ APGK GLEWVSYISSSGSTIYYADSVKGRFTISRDN AKNSLYLQ MNSLRAEDTAVYYCARDEYNSGWYVLF DYWGQ QTLVTVSS
250	DVD642L	AB014VL	AB012VL	DIQMTQSPSSLSASV GDRVTITCSASQDISNYLNW YQ QKPGKAPKVL IYFTSS LHSGVPSR FGSGSG TD FTLTISS LQPEDFATYYCQ YSTVP WTFGQGTKVE IKR TVAAPSVFI FPDIQMTQSPSSVSASV GDRVT ITCRASQGISS WLAWYQ KPGKAPNLLIYEAS LQ SGVPSR FGSGSGTDFTLTISS LQPEDFATYYC Q ANGFP WTFGQGTKVEIKR

Example 2.39: Generation of VEGF (seq. 1) and HGF (seq. 1) DVD-Igs with Linker Set 3

Table 71

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
251	DVD647H	AB012VH	AB014VH	QVQLVESGGGLV ^K PGGSLRLS ^{CAASGFTFSDYYMS} WIRQAPGK ^G LEWVSYI ^{SSSGSTIYYADSVKGRFTI} SRDNAKNSLYLQ ^{MNSLRAEDTAVYYCARDEYNSGW} YVLF ^{DYWGQGT} LVTVSS ASTKGPSVFPLAP EVQLV ESGGGLV ^Q PGGSLRLS ^{CAASGYFTFTNYGMNWRQA} PGK ^G LEWGWINTY ^{TGPTYAADFKRRFTFSLDTS} KSTAYLQ ^{MNSLRAEDTAVYYCAKYPHYGSSHWYF} DVWGQGT ^{LVTVSS}
252	DVD647L	AB012VL	AB014VL	DIQMTQSPSSVSASV ^{GDRVTITCRASQGISSWLAW} YQ ^Q KPGKAPNLLI ^{YEASSLQSGVPSRFGSGSGTD} FTLT ^{ISSLPEDFATYYCQANGFPWTFGQGTKVE} IKR TVAAP DIQMTQSPSSLSASV ^{GDRVTITCSASQ} DISNYLNWYQ ^Q KPGKAPK ^{VLIYFTSSLHSGVPSRF} SGSGSGTD ^{FTLTISSLPEDFATYYCQYSTVPWT} FGQGTKVEIKR
253	DVD648H	AB014VH	AB012VH	EVQLVESGGGLV ^Q PGGSLRLS ^{CAASGYFTFTNYGMN} WVRQAPGK ^G LEWGWINTY ^{TGPTYAADFKRRFTF} SLDTSK ^{STAYLQMNLSLRAEDTAVYYCAKYPHYGS} SHWYFDVW ^{GQGT} LVTVSS ASTKGPSVFPLAP QVQL VESGGGLV ^K PGGSLRLS ^{CAASGFTFSDYYMSWIRQ} APGK ^G LEWVSYI ^{SSSGSTIYYADSVKGRFTISRDN} AKNSLYLQ ^{MNSLRAEDTAVYYCARDEYNSGWYVLF} DYWGQGT ^{LVTVSS}
254	DVD648L	AB014VL	AB012VL	DIQMTQSPSSLSASV ^{GDRVTITCSASQDISNYLNW} YQ ^Q KPGKAPK ^{VLIYFTSSLHSGVPSRFGSGSGTD} FTLT ^{ISSLPEDFATYYCQYSTVPWTFGQGTKVE} IKR TVAAP DIQMTQSPSSVSASV ^{GDRVTITCRASQ} GISSWLAWYQ ^Q KPGKAPNLLI ^{YEASSLQSGVPSRF} GGSGSGTD ^{FTLTISSLPEDFATYYCQANGFPWT} FGQGTKVEIKR

Example 2.40: Generation of VEGF (seq. 1) and HGF (seq. 1) DVD-Igs with Linker Set 4

Table 72

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
255	DVD653H	AB012VH	AB014VH	QVQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMS WIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRAEDTAVYYCARDEYNSGW YVLFDYWGQGTLLVTVSS ASTKGP EVQLVESGGGLV QPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEW VGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQ MNSLRAEDTAVYYCAKYPHYGSSHWYFDVWGQGT LVTVSS
256	DVD653L	AB012VL	AB014VL	DIQMTQSPSSVSASVGDRTVITCRASQGISSWLAW YQQKPGKAPNLLIYEASLQSGVPSRFGSGSGTD FTLTISLQPEDFATYYCQQANGFPWTFGQGTKVE IKR TVAAPSVFIFPP DIQMTQSPSSLSASVGDRTV ITCSASQDISNYLNWYQQKPGKAPKVLITYFTSSLH SGVPSRFGSGSGTDFTLTISLQPEDFATYYCQQ YSTVPWTFGQGTKVEIKR
257	DVD654H	AB014VH	AB012VH	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMN WVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTF SLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYGS SHWYFDVWGQGTLLVTVSS ASTKGP QVQLVESGGGL VQPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLE WVSYISSSGSTIYYADSVKGRFTISRDNKNSLYL QMNSLRAEDTAVYYCARDEYNSGWYVLFDYWGQGT LVTVSS
258	DVD654L	AB014VL	AB012VL	DIQMTQSPSSLSASVGDRTVITCSASQDISNYLNW YQQKPGKAPKVLITYFTSSLHSGVPSRFGSGSGTD FTLTISLQPEDFATYYCQQYSTVPWTFGQGTKVE IKR TVAAPSVFIFPP DIQMTQSPSSVSASVGDRTV ITCRASQGISSWLAWYQQKPGKAPNLLIYEASLQ SGVPSRFGSGSGTDFTLTISLQPEDFATYYCQQ ANGFPWTFGQGTKVEIKR

Example 2.41: Generation of VEGF (seq. 1) and RON (seq. 1) DVD-Igs

Table 73

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
259	DVD047H	AB014VL	AB005VH	EVQLVESGGGLVQPGGSLRLSCAASGYFTFTNYGMN WVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTF SLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYS SHWYFDVWGQGTTLVTVSS ASTKGPE VQLVQSGGGL VKPGGSLRLSCAASGFTFSSYAMHWVRQAPGKGLE WVAVISYDGSNKYYADSVKGRFTISRDNKNTLYL QMNSLRAEDTAVYYCARFSGWPNYYYYGMDVWGQ GTTVTVSS
260	DVD047L	AB014VH	AB005VL	DIQMTQSPSSLSASVGDRTITCSASQDISNYLNW YQKPGKAPKVLITYFTSSLHSGVPSRFGSGSGTD FTLTISLQPEDFATYYCQQYSTVPWTFGQGTKVE IKR TVAAP DVVMTQSPPLSLPVTGPGEPAISCRSSQ SLLHNGFNVDWYLQKPGQSPHLLIYFGSYRASG VPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQAL QTPPWTFGQGTKVEIRR
261	DVD048H	AB005VH	AB014VL	EVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYAMH WVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTI SRDNKNTLYLQMNSLRAEDTAVYYCARFSGWPN YYYYGMDVWGQGTTLVTVSS ASTKGPE VQLVESGGG LVQPGGSLRLSCAASGYFTFTNYGMNHWVRQAPGKGL EWWGINTYTGEPTYAADFKRRFTFSLDTSKSTAY LQMNSLRAEDTAVYYCAKYPHYYS SHWYFDVWGQ GTLVTVSS
262	DVD048L	AB005VL	AB014VH	DVVMTQSPPLSLPVTGPGEPAISCRSSQ SLLHNGFNVDWYLQKPGQSPHLLIYFGSYRASG VPDRFSGSGSGTDFTLTISLQPEDFATYYCQQY STVPWTFGQGTKVEIKR GGTDFTLKISRVEAEDVGVYYCMQALQTPPWTFG QGTKVEIRR TVAAP DIQMTQSPSSLSASVGDRTI TCSASQDISNYLNWYQKPGKAPKVLITYFTSSLH S GVPSRFGSGSGTDFTLTISLQPEDFATYYCQQY

Example 2.42: Generation of VEGF (seq. 1) and NRP1 (seq. 1) DVD-Igs

Table 74

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
263	DVD049H	AB014VH	AB016VH	EVQLVESGGGLVQPGGSLRLSCAASGYFTNRYGMN WVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTF SLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYS SHWYFDVWGQGTTLVTVSS ASTKGPE VQLVESGGGL VQPGGSLRLSCAASGFSFSSEPISWVRQAPGKGLE WVSSITGKNGYTYADSVKGRFTISADTSKNTAYL QMNSLRAEDTAVYYCARWGKKVYGMVWGQGTTLV VSS
264	DVD049L	AB014VL	AB016VL	DIQMTQSPSSLSASVGRVTITCSASQDISNYLNW YQQKPGKAPKVLIIYFTSSSLHSGVPSRFSGSGGTD FTLTISLQPEDFATYYCQQYSTVPWTFGQGTKVE IKR TVAAP DIQMTQSPSSLSASVGRVTITCRASQ SISSYLAWYQQKPGKAPKLLIYGASSRASGVPSRF SGSGGTDFTLTISLQPEDFATYYCQQYMSVPIT FGQGTKVEIKR
265	DVD050H	AB016VH	AB014VH	EVQLVESGGGLVQPGGSLRLSCAASGFSFSSEPI WVRQAPGKGLEWVSSITGKNGYTYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARWGKKVY MDVWGQGTTLVTVSS ASTKGPE VQLVESGGGLVQPG GSLRLSCAASGYFTNRYGMNWRQAPGKGLEWVGW INTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNS LRAEDTAVYYCAKYPHYYS SHWYFDVWGQGTTLVTVSS
266	DVD050L	AB016VL	AB014VL	DIQMTQSPSSLSASVGRVTITCRASQSISSYLAW YQQKPGKAPKLLIYGASSRASGVPSRFSGSGGTD FTLTISLQPEDFATYYCQQYMSVPITFGQGTKVE IKR TVAAP DIQMTQSPSSLSASVGRVTITCSASQ DISNYLNWYQQKPGKAPKVLIIYFTSSSLHSGVPSRF SGSGGTDFTLTISLQPEDFATYYCQQYSTVPWT FGQGTKVEIKR

Example 2.43: Generation of HGF (seq. 1) and RON (seq. 2) DVD-Igs

Table 75

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
267	DVD073H	AB034VH	AB012VH	QVQLQESGPGLVKPS EILSLTCTVSGGSISSHYWS WVRQPPGKGLEWIGYIYSGSTNYNPSLKSRVTIS VDTSKNQFSLNLSVTAADTAVYYCARI PNYYDRS GYYPGYWYFDLWGRGTLVTVSS ASTKGP QVQLVES GGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPG KGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKN SLYLQMNSLRAEDTAVYYCARDEYNSGWYVLFDYW GGTLVTVSS
268	DVD073L	AB034VL	AB012VL	QAVLTQPSSLSAPPGASASLTCTLRSGFNVDYSYRI SWYQQKPGSPPQYLLRYKSDSDKQQGSGVPSRFGS SKDASANAGILLISGLQSEDEADYYCMIWHSSAWV FGGTKLTVLR TVAAP DIQMTQSPSSVSASVGD RVTITCRASQGISSWLAWYQQKPGKAPNLLIYEASSL QSGVPSRFGGSGSDFTLTISLQPEDFATYYCQ QANGFPWTFGQGTKVEIKR
269	DVD074H	AB012VH	AB034VH	QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMS WIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRAEDTAVYYCARDEYNSGW YVLFDYWGQGLTVTVSS ASTKGP QVQLQESGPGLV KPSEILSLTCTVSGGSISSHYWSWVRQPPGKGLEW IGYIYSGSTNYNPSLKSRVTISVDTSKNQFSLNL SSVTAADTAVYYCARI PNYYDRSGYYPGYWYFDLW GRGTLVTVSS
270	DVD074L	AB012VL	AB034VL	DIQMTQSPSSVSASVGD RVTITCRASQGISSWLAW YQQKPGKAPNLLIYEASSLQSGVPSRFGGSGSD FTLTISLQPEDFATYYCQANGFPWTFGQGTKVE IKR TVAAP QAVLTQPSSLSAPPGASASLTCTLRSG FNVDYSYRISWYQQKPGSPPQYLLRYKSDSDKQQGS GVPSRFGSGKDASANAGILLISGLQSEDEADYYCM IWHSSAWVFGGTKLTVLR

Example 2.44: Generation of EGFR (seq. 2) and RON (seq. 2) DVD-Igs

Table 76

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
271	DVD075H	AB034VH	AB033VH	QVQLQESGPGLVKPS EILSLTCTVSGGSISSHYWS WVRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTIS VDTSKNQFSLNLS SVTAADTAVYYCARIPNYYDRS GYYPGYWYFDLWGRGTLTVSS ASTKGP QVQLKQS GPGLVQPSQSL SITCTVSGFSLTNYGVHWVRQSPG KGLEWLGVIWGGNTDYNTPF TSRLSINKDNSKSQ VFFKMNSLQSNDAIYYCARALTYDYEFAYWGQG TLTVSA
272	DVD075L	AB034VL	AB033VL	QAVLTQPSSLSAPPGASASLTCTLRSGFNVD SYRI SWYQQKPGSPPQYLLRYKSDSDKQQGSGVPSRFSG SKDASANAGILLISGLQSEDEADYYCMIWHSSAWV FGGGTKLTVLR TVAAP DILLTQSPVILSVSPGERV SFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASES ISGIPSRFSGSGGTDFTLSINSVESEDIADYYCQ QNNNWPTTFGAGTKLELKR
273	DVD076H	AB033VH	AB034VH	QVQLKQSGPGLVQPSQSL SITCTVSGFSLTNYGVH WVRQSPGKGLEWLGVIWGGNTDYNTPF TSRLSIN KDNSKSQVFFKMNSLQSNDAIYYCARALTYDYE FAYWGQGT LTVSA ASTKGP QVQLQESGPGLVKPS EILSLTCTVSGGSISSHYWSWVRQPPGKLEWIGY IYYSGSTNYNPSLKSRVTISVDTSKNQFSLNLSV TAADTAVYYCARIPNYYDRSGYYPGYWYFDLWGRG TLTVSS
274	DVD076L	AB033VL	AB034VL	DILLTQSPVILSVSPGERV SFSCRASQSIGTNIHW YQQRTNGSPRLLIKYASESISGIPSRFSGSGGTD FTLSINSVESEDIADYYCQNNNWPTTFGAGTKLE LKR TVAAP QAVLTQPSSLSAPPGASASLTCTLRSG FNVD SYRISWYQQKPGSPPQYLLRYKSDSDKQQGS GVPSRFSGSKDASANAGILLISGLQSEDEADYYCM IWHSSAWVFGGGTKLTVLR

Example 2.45: Generation of VEGF (seq. 1) and RON (seq. 2) DVD-Igs

Table 77

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				123456789 0 123456789 0 123456789 0 12345
275	DVD077H	AB034VH	AB014VH	QVQLQESGPGLVKPSKSEILSLTCTVSGGSISSHYWS WVRQPPGKGLEWIGYIYYSGSTNYNPSLKRVTIS VDTSKNQFSLNLSVTAADTAVYYCARI PNYYDRS GYYPGYWYFDLWGRGTLVTVSS ASTKGP EVQLVES GGGLVQPGGSLRLSCAASGYFTFTNYGMNWVRQAPG KGLEWVGWINTYTGEPYAADFKRRFTFSLDTSKS TAYLQMNSLRAEDTAVYYCAKYPHYGSSHWYFDV WQGGLVTVSS
276	DVD077L	AB034VL	AB014VL	QAVLTQPSSLSAPPGASASLTCTLRSGFNVDYSYRI SWYQQKPGSPPQYLLRYKSDSDKQQGSGVPSRFSG SKDASANAGILLISGLQSEDEADYYCMIWHSSAWV FGGKTLTVLR TVAAP DIQMTQSPSSLSASVGD TITCSASQDISNYLNWYQQKPGKAPKVLIIYFTSSL HSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQ QYSTVPWTFGQGTKVEIKR
277	DVD078H	AB014VH	AB034VH	EVQLVESGGGLVQPGGSLRLSCAASGYFTFTNYGMN WVRQAPGKGLEWVGWINTYTGEPYAADFKRRFTF SLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYGSS SHWYFDVWQGGLVTVSS ASTKGP QVQLQESGPG LVKPSKSEILSLTCTVSGGSISSHYWSWVRQPPGKLE WIGYIYYSGSTNYNPSLKRVTISVDTSKNQFSLN LSSVTAADTAVYYCARI PNYYDRSGYYPGYWYFDL WGRGTLVTVSS
278	DVD078L	AB014VL	AB034VL	DIQMTQSPSSLSASVGDRTITCSASQDISNYLNW YQQKPGKAPKVLIIYFTSSLHSGVPSRFSGSGSGT DFTLTISLQPEDFATYYCQYSTVPWTFGQGTKVE IKR TVAAP QAVLTQPSSLSAPPGASASLTCTLRSG FNVDYSYRISWYQQKPGSPPQYLLRYKSDSDKQQGS GVPSRFSGSKDASANAGILLISGLQSEDEADYYCM IWHSSAWVFGGKTLTVLR

Example 2.46: Generation of EGFR (seq. 1) and HER-2 (seq. 1) DVD-Igs

Table 78

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
279	DVD079H	AB003VH	AB004VH	QVQLQESGPGLVKPSSETLSLTCTVSGGSVSSGDYY WTWIRQSPGKGLEWIGHIYYSGNTNYPNPSLKSRLT ISIDTSKTQFSLKLSVTAADTAIYYCVRDRVGTGA FDIWGQGTMTVTVSS ASTKGP EVQLVESGGGLVQPG GSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVAR IYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNS LRAEDTAVYYCSRWGGDGFYAMDYWGQGLTVTVSS
280	DVD079L	AB003VL	AB004VL	DIQMTQSPSSLSASVGDRTITCQASQDISNYLNW YQQKPGKAPKLLIYDASNLETGVPSRFSGSGSDT FTFTISLQPEDIATYFCQHFHDLPLAFGGGKVE IKR TVAAP DIQMTQSPSSLSASVGDRTITCRASQ DVNTAVAWYQQKPGKAPKLLIYSASFYSGVPSRF SGSRSGTDFTLTISLQPEDFATYYCQQHYTTPPT FGGQTKVEIKR
281	DVD080H	AB004VH	AB003VH	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIH WVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFY AMDYWGQGLTVTVSS ASTKGP QVQLQESGPGLVK SETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEW IGHIYYSGNTNYPNPSLKSRLTISIDTSKTQFSLK SSVTAADTAIYYCVRDRVGTGAFDIWGQGTMTVTVSS
282	DVD080L	AB004VL	AB003VL	DIQMTQSPSSLSASVGDRTITCRASQDVNTAVAW YQQKPGKAPKLLIYSASFYSGVPSRFSGSRSGTD FTLTISLQPEDFATYYCQQHYTTPPTFGGQTKVE IKR TVAAP DIQMTQSPSSLSASVGDRTITCQASQ DISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRF SGSGSGTDFTFTISLQPEDIATYFCQHFHDLPLA FGGQTKVEIKR

Example 2.47: Generation of EGFR (seq. 1) and CD3 (seq. 1) DVD-Iggs

Table 79

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
283	DVD081H	AB003VH	AB002VH	QVQLQESGPGLVKPSSETLSLTCTVSGGSVSSGDYY WTWIRQSPGKGLEWIGHIYYSGNTNYPNPSLKSRLT ISIDTSKTQFSLKLSVTAADTAIYYCVRDRVTGA FDIWGQGTMTVTVSS ASTKGP QVQLQESGAELARPG ASVKMSCKASGYTFTRYTMHWKQRPGQGLEWIGY INPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSS LTSSEDSAVYYCARYDDHYCLDYWGQGTTLTVSS
284	DVD081L	AB003VL	AB002VL	DIQMTQSPSSLSASVGRVITTCQASQDISNYLNW YQQKPGKAPKLLIYDASNLETGVPSPRFSGSGGTD FTFTISSLPEDIATYFCQHFHDLPLAFGGGKVE IKR TVAAP QIVLTQSPAIMSASPGEKVTMTCRASS SVSYMNWYQQKSGTSPKRWIYDTSKVASGVPRFS GSGSGTSYSLTISSEAEADAATYYCQWSSNPLTF GGGKLEINR
285	DVD082H	AB002VH	AB003VH	QVQLQESGAELARPGASVKMSCKASGYTFTRYTMH WVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATL TTDKSSSTAYMQLSSLTSSEDSAVYYCARYDDHYC LDYWGQGTTLTVSS ASTKGP QVQLQESGPGLVKPS ETLSLTCTVSGGSVSSGDYYWTWIRQSPGKLEWI GHIYYSGNTNYPNPSLKSRLTISIDTSKTQFSLKLS SVTAADTAIYYCVRDRVTGAFDIWGQGTMTVTVSS
286	DVD082L	AB002VL	AB003VL	QIVLTQSPAIMSASPGEKVTMTCRASSSVSYMNWY QQKSGTSPKRWIYDTSKVASGVPRFSGSGSGTSY SLTISSEAEADAATYYCQWSSNPLTFGGGKLEI NR TVAAP DIQMTQSPSSLSASVGRVITTCQASQD ISNYLNWYQQKPGKAPKLLIYDASNLETGVPSPRFS GSGSGTDFFTISSLPEDIATYFCQHFHDLPLAF GGGKVEIKR

Example 2.48: Generation of EGFR (seq. 1) and IGF1R DVD-Igs

Table 80

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
287	DVD083H	AB003VH	AB011VH	QVQLQESGPGLVKPSSETLSLTCTVSGGSVSSGDYY WTWIRQSPGKGLEWIGHIYYSGNTNYPNPSLKSRLT ISIDTSKTQFSLKLSVTAADTAIYYCVRDRVTGA FDIWGQGTMTVTVSS ASTKGP EVQLLESGGGLVQPG GSLRLSCTASGFTFSSYAMNWRQAPGKGLEWVSA ISGSGGTFYADSVKGRFTISRDNSTRITLYLQMNS LRAEDTAVYYCAKDLGWSDSYYYYYGMVWVGQGT TVTVSS
288	DVD083L	AB003VL	AB011VL	DIQMTQSPSSLSASVGDRTVITCQASQDISNYLNW YQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTD FTFTISLQPEDIATYFCQHFHDLPLAFGGGKVE IKR TVAAP DIQMTQSPSSLSASVGDRTVITCRASQ GIRNDLGWYQQKPGKAPKRLIYAASRLHRGVPSRF SGSGSGTEFTLTISLQPEDFATYYCLQHNSYPCS FGGQTKLEIKR
289	DVD084H	AB011VH	AB003VH	EVQLLESGGGLVQPGGSLRLSCTASGFTFSSYAMN WVRQAPGKGLEWVSAISGSGGTFYADSVKGRFTI SRDNSTRITLYLQMNLSLRAEDTAVYYCAKDLGWS DSYYYYYGMVWVGQGTTVTVSS ASTKGP QVQLQESGP GLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPG KGLEWIGHIYYSGNTNYPNPSLKSRLTISIDTSKTQ FSLKLSVTAADTAIYYCVRDRVTGAFDIWGQGT MTVTVSS
290	DVD084L	AB011VL	AB003VL	DIQMTQSPSSLSASVGDRTVITCRASQGIRNDLGW YQQKPGKAPKRLIYAASRLHRGVPSRFSGSGSGTE FTLTISLQPEDFATYYCLQHNSYPCSFQGGTKLE IKR TVAAP DIQMTQSPSSLSASVGDRTVITCQASQ DISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRF SGSGSGTDFTFTISLQPEDIATYFCQHFHDLPLA FGGQTKLEIKR

Example 2.49: Generation of EGFR (seq. 1) and RON (seq. 1) DVD-Igs

Table 81

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
291	DVD085H	AB003VH	AB005VH	QVQLQESGPGLVKPSSETLSLTCTVSGGSVSSGDYY WTWIRQSPGKGLEWIGHIYYSGNTNYPNPSLKSRLT ISIDTSKTQFSLKLSVTAADTAIYYCVRDRVTGA FDIWGQGTMTVTVSS ASTKGP EVQLVQSGGGLVKPG GSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAV ISYDGSNKYYADSVKGRFTISRDN SKNTLYLQMNS LRAEDTAVYYCARFSGWPNNYYYYGMDVWGQGTTV TVSS
292	DVD085L	AB003VL	AB005VL	DIQMTQSPSSLSASVGDRTITCQASQDISNYLNW YQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTD FTFTISLQPEDIATYFCQHFHDLPLAFGGGTKVE IKR TVAAP DVVMTQSPSLPVTGPGEPAISCRSSQ SLLHNSGFNYVDWYLQKPGQSPHLLIYFGSYRASG VPDRFSGSGSGTDFTLTKISRVEAEDVGVYYCMQAL QTPPWTFGQGTKEIRR
293	DVD086H	AB005VH	AB003VH	EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYAMH WVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTI SRDN SKNTLYLQMNSLRAEDTAVYYCARFSGWPNN YYYYGMDVWGQGTTVTVSS ASTKGP QVQLQESGPG LVKPSSETLSLTCTVSGGSVSSGDYYWTWIRQSPGK GLEWIGHIYYSGNTNYPNPSLKSRLTISIDTSKTQF SLKLSVTAADTAIYYCVRDRVTGAFDIWGQGTMTV TVSS
294	DVD086L	AB005VL	AB003VL	DVVMTQSPSLPVTGPGEPAISCRSSQ SLLHNSGF NYVDWYLQKPGQSPHLLIYFGSYRASGVPDRFSGS GSGTDFTLTKISRVEAEDVGVYYCMQALQTPPWTFG QGTKEIRR TVAAP DIQMTQSPSSLSASVGDRTI TCQASQDISNYLNWYQKPGKAPKLLIYDASNLET GVPSRFSGSGSGTDFTFTISLQPEDIATYFCQHF HDLPLAFGGGTKVEIKR

Example 2.50: Generation of EGFR (seq. 1) and RON (seq. 2) DVD-Igs

Table 82

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
295	DVD087H	AB003VH	AB034VH	QVQLQESGPGLVKPSSETLSLTCTVSGGSVSSGDYY WTWIRQSPGKGLEWIGHIYYSGNTNYPNPSLKSRLT ISIDTSKTQFSLKLSVTAADTAIYYCVRDRVTGA FDIWGQGTMTVTVSS ASTKGP QVQLQESGPGLVKPS EILSLTCTVSGGSISSHYWSWVRPPGKGLEWIGY IYYSGSTNYPNPSLKSRLTISVDTSKNQFSLNLSV TAADTAVYYCARI PNYYDRSGYYPGYWYFDLWGRG TLTVTVSS
296	DVD087L	AB003VL	AB034VL	DIQMTQSPSSLSASVGDRTVITCQASQDISNYLNW YQQKPGKAPKLLIYDASNLETGVPFRFSGSGSGTD FTFTISSLPEDIATYFCQHFHDLPLAFGGGKVE IKR TVAAP QAVLTQPSLSAPPASASLTCTLRSG FNVDSYRISWYQQKPGSPPQYLLRYKSDSDKQQGS GVPSRFSGSKDASANAGILLISGLQSEDEADYYCM IWHSSAWVFGGGTKLTVLR
297	DVD088H	AB034VH	AB003VH	QVQLQESGPGLVKPSSEILSLTCTVSGGSISSHYWS WVRPPGKGLEWIGYIYYSGSTNYPNPSLKSRLTIS VDTSKNQFSLNLSVTAADTAVYYCARI PNYYDRS GYYPGYWYFDLWGRGTLTVTVSS ASTKGP QVQLQES GPGLVKPSSETLSLTCTVSGGSVSSGDYYWTWIRQ SPGKGLEWIGHIYYSGNTNYPNPSLKSRLTISIDTSK TQFSLKLSVTAADTAIYYCVRDRVTGAFDIWGQG TMVTVSS
298	DVD088L	AB034VL	AB003VL	QAVLTQPSLSAPPASASLTCTLRSGFNVDSYRI SWYQQKPGSPPQYLLRYKSDSDKQQGSVPSRFSG SKDASANAGILLISGLQSEDEADYYCMIWHSSAWV FGGGTKLTVLR TVAAP DIQMTQSPSSLSASVGDRT VITCQASQDISNYLNWYQQKPGKAPKLLIYDASNL ETGVPFRFSGSGSGTDFTFTISSLPEDIATYFCQ HFHDLPLAFGGGKVEIKR

Example 2.51: Generation of EGFR (seq. 1) and HGF (seq. 1) DVD-Igs

Table 83

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
299	DVD089H	AB003VH	AB012VH	QVQLQESGPGLVKPSSETLSLTCTVSGGSVSSGDYY WTWIRQSPGKGLEWIGHIYYSGNTNYPNPSLKSRLT ISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGA FDIWGQGTMTVTVSS ASTKGP QVQLVESGGGLVKPG GSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSY ISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNS LRAEDTAVYYCARDEYNSGWYVLFDYWGQGLTVT VSS
300	DVD089L	AB003VL	AB012VL	DIQMTQSPSSLSASVGDRTVITCQASQDISNYLNW YQQKPGKAPKLLIYDASNLETGVPSRFGSGSGTD FTFTISSLPEDIATYFCQHFHDLPLAFGGGKVE IKR TVAAP DIQMTQSPSSVSASVGDRTVITCRASQ GISSWLAWYQQKPGKAPNLLIYEASSLQSGVPSRF GGSGSGTDFTLTISSLPEDFATYYCQANGFPWT FGGKVEIKR
301	DVD090H	AB012VH	AB003VH	QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMS WIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRAEDTAVYYCARDEYNSGW YVLFDYWGQGLTVTVSS ASTKGP QVQLQESGPGLV KPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGL EWIGHIYYSGNTNYPNPSLKSRLTISIDTSKTQFSL KLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMTV VSS
302	DVD090L	AB012VL	AB003VL	DIQMTQSPSSVSASVGDRTVITCRASQGISSWLAW YQQKPGKAPNLLIYEASSLQSGVPSRFGSGSGTD FTLTISSLPEDFATYYCQANGFPWTFGGKVE IKR TVAAP DIQMTQSPSSLSASVGDRTVITCQASQ DISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRF SGSGSGTDFTFTISSLPEDIATYFCQHFHDLPLA FGGKVEIKR

Example 2.52: Generation of EGFR (seq. 1) and c-MET DVD-Igs

Table 84

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
303	DVD091H	AB003VH	AB013VH	QVQLQESGPGLVKPSSETLSLTCTVSGGSVSSGDYY WTWIRQSPGKGLEWIGHIYYSGNTNYPNPSLKSRLT ISIDTSKTQFSLKLVSSVTAADTAIYYCVRDRVTGA FDIWGQGTMTVTVSS ASTKGP QVQLQQSGPELVRPG ASVKWSCPASGYTFTSYWLHWVKKQRPQGQLEWIG MIDPSNSDTRFNPPNFKDKATLNVDRSSNTAYNLL SSLTSADSAVYYCATYGSYVSPLDYWGQGTSVVYS S
304	DVD091L	AB003VL	AB013VL	DIQMTQSPSSLSASVGDRTITCQASQDISNYLNW YQKPGKAPKLLIYDASNLETGVPSRFGSGSGTD FTFTISLQPEDIAITYFCQHFHDLPLAFGGGKVE IKR TVAAP DIMMSQSPSSLTVSVGEKVTVSCKSSQ SLLVTSSQKNYLAWYQQKPKQSPKLLIYWASTRES GVPDRFTGSGSGTDFTLTITSVKADDLAVYYCQY YAYPWTFGDGTKLEIKR
305	DVD092H	AB013VH	AB003VH	QVQLQQSGPELVRPGASVKWSCPASGYTFTSYWLH WVKKQRPQGQLEWIGMIDPSNSDTRFNPPNFKDKA TLNVDRSSNTAYNLLSSLTSADSAVYYCATYGSYV SPLDYWGQGTSVVYVSS ASTKGP QVQLQESGPGLVK PSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLE WIGHIYYSGNTNYPNPSLKSRLTISIDTSKTQFSLK LSSVTAADTAIYYCVRDRVTGAFDIWGQGTMTVTV S
306	DVD092L	AB013VL	AB003VL	DIMMSQSPSSLTVSVGEKVTVSCKSSQSLLVTSSQ KNYLAWYQQKPKQSPKLLIYWASTRESGVPDRFTG SGSGTDFTLTITSVKADDLAVYYCQYYAYPWTFG DGTKLEIKR TVAAP DIQMTQSPSSLSASVGDRTI TCQASQDISNYLNWYQKPGKAPKLLIYDASNLET GVPSRFGSGSGTDFTFTISLQPEDIAITYFCQHF HDLPLAFGGGKVEIKR

Example 2.53: Generation of EGFR (seq. 1) and VEGF (seq. 1) DVD-Igs

Table 85

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
307	DVD093H	AB003VH	AB014VH	QVQLQESGPGLVKPSSETLSLTCTVSGGSVSSGDYY WTWIRQSPGKGLEWIGHIYYSGNTNYPNPSLKSRLT ISIDTSKTQFSLKLSVTAADTAIYYCVRDRVTGA FDIWGQGTMTVTVSS ASTKGP EVQLVESGGGLVQPG GSLRLSCAASGYFTFTNYGMNWRQAPGKGLEWVGW INTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNS LRAEDTAVYYCAKYPHYYSSSHWFYDVGQGTTLVT VSS
308	DVD093L	AB003VL	AB014VL	DIQMTQSPSSLSASVGDRTVITCQASQDISNYLNW YQQKPGKAPKLLIYDASNLETGVPSRFSGSGGTD FTFTISSLPEDIATYFCQHFHDLPLAFGGGKVE IKR TVAAP DIQMTQSPSSLSASVGDRTVITCSAQ DISNYLNWYQQKPGKAPKVLIIYFTSSLHSGVPSRF SGSGGTDFTLTISSLQPEDFATYYCQYSTVPWT FGGKVEIKR
309	DVD094H	AB014VH	AB003VH	EVQLVESGGGLVQPGGSLRLSCAASGYFTFTNYGMN WRQAPGKGLEWGWINTYTGEPTYAADFKRRFTF SLDTSKSTAYLQMNLSLRAEDTAVYYCAKYPHYYS SHWFYDVGQGTTLVTVSS ASTKGP QVQLQESGPG LVKPSSETLSLTCTVSGGSVSSGDYYWTWIRQSPGK LEWIGHIYYSGNTNYPNPSLKSRLTISIDTSKTQFS LKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMTV VSS
310	DVD094L	AB014VL	AB003VL	DIQMTQSPSSLSASVGDRTVITCSAQDISNYLNW YQQKPGKAPKVLIIYFTSSLHSGVPSRFSGSGGTD FTLTISSLQPEDFATYYCQYSTVPWTFGGKVE IKR TVAAP DIQMTQSPSSLSASVGDRTVITCQASQ DISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRF SGSGGTDFTFTISSLPEDIATYFCQHFHDLPLA FGGKVEIKR

Example 2.54: Generation of NRP1 (seq. 2) and VEGF (seq. 1) DVD-Igs

Table 86

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
311	DVD107H	AB035VH	AB014VH	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMS WVRQAPGKGLEWVWVSI SPAGGYTNYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARELPYYRM SKVMDVQGQGT LVTVSS ASTKGP EVQLVESGGGLV QPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEW VGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQ MNSLRAEDTAVYYCAKYPHYGSSHWYFDVWVGQGT LVTVSS
312	DVD107L	AB035VL	AB014VL	DIQMTQSPSSLSASVGDRTVITCRASQYFSSYLAW YQQKPGKAPKLLIYGASSRASGVPSRFSGSGSGTD FTLTISLQPEDFATYYCQQLYLGSPPTFGQGTKVE IKR TVAAP DIQMTQSPSSLSASVGDRTVITCSASQ DISNYLNWYQQKPGKAPKVLIIYFTSSLHSGVPSRF SGSGSGTDFTLTISLQPEDFATYYCQYSTVPWT FGQGTKVEIKR
313	DVD108H	AB014VH	AB035VH	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMN WVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTF SLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYGSS SHWYFDVWVGQGT LVTVSS ASTKGP EVQLVESGGGL VQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLE WVSI SPAGGYTNYADSVKGRFTI SADTSKNTAYL QMNSLRAEDTAVYYCARELPYYRMSKVMDVQGQGT LVTVSS
314	DVD108L	AB014VL	AB035VL	DIQMTQSPSSLSASVGDRTVITCSASQDISNYLNW YQQKPGKAPKVLIIYFTSSLHSGVPSRFSGSGSGTD FTLTISLQPEDFATYYCQYSTVPWTFGQGTKVE IKR TVAAP DIQMTQSPSSLSASVGDRTVITCRASQ YFSSYLAWYQQKPGKAPKLLIYGASSRASGVPSRF SGSGSGTDFTLTISLQPEDFATYYCQQLYLGSPPT FGQGTKVEIKR

Example 2.55: Generation of CD3 (seq. 2) and CD-20 DVD-Igs

Table 87

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
315	DVD131H	AB039VH	AB001VH	QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMH WVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATL TTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYC LDYWGQGTTLTVSS ASTKGP QVQLQQPGAELVKPG ASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGA IYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSS LTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVS A
316	DVD131L	AB039VL	AB001VL	QIVLTQSPA IMSASPGEKVTMTCSASSSVSYMNWY QQKSGTSPKRWIYDTSKLAGVPAHFRGSGSGTSY SLTISGMEAEADAATYYCQWSSNPFTFGSGTKLEI NR TVAAP QIVLSQSPAILSPSPGEKVTMTCRASSS VSYIHWFQQKPGSSPKPIYATSNLASGVVFRFSG SGSGTSYSLTISRVEAEADAATYYCQWTSNPPTFG GGTKLEIKR
317	DVD132H	AB001VH	AB039VH	QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMH WVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATL TADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGD WYFNVWGAGTTVTVS ASTKGP QVQLQQSGAELAR PGASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWI GYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQL SSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVS S
318	DVD132L	AB001VL	AB039VL	QIVLSQSPAILSPSPGEKVTMTCRASSSVSYIHWF QQKPGSSPKPIYATSNLASGVVFRFSGSGSGTSY SLTISRVEAEADAATYYCQWTSNPPTFGGGTKLEI KR TVAAP QIVLTQSPA IMSASPGEKVTMTCSASSS VSYMNWYQQKSGTSPKRWIYDTSKLAGVPAHFRG SGSGTSYSLTISGMEAEADAATYYCQWSSNPPTFG SGTKLEINR

Example 2.56: Generation of CD-3 (seq. 2) and HER-2 (seq. 1) DVD-Igs

Table 88

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
319	DVD135H	AB039VH	AB004VH	QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMH WVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATL TTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYC LDYWGQGTTLTVSS ASTKGP EVQLVESGGGLVQPG GSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVAR IYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNS LRAEDTAVYYCSRWGGDGFYAMDYWGQGTTLTVSS
320	DVD135L	AB039VL	AB004VL	QIVLTQSPA IMSASPGEKVTMTCSASSSVSYMNWY QQKSGTSPKRWIYDTSKLAGVPAHFRGSGSGTSY SLTISGMEAEADAATYYCQQWSSNPFTFGSGTKLEI NR TVAAP DIQMTQSPSSLSASVGDRTITCRASQD VNTAVAWYQQKPGKAPKLLIYSASFYSGVPSRFS GSRSGTDFTLTISLQPEDFATYYCQHYTTPPTF GQGTKVEIKR
321	DVD136H	AB004VH	AB039VH	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIH WVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFY AMDYWGQGTTLTVSS ASTKGP QVQLQQSGAELARP GASVKMSCKASGYTFTRYTMHWVKRPGQGLEWIG YINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLS SLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSS
322	DVD136L	AB004VL	AB039VL	DIQMTQSPSSLSASVGDRTITCRASQDVNTAVAW YQQKPGKAPKLLIYSASFYSGVPSRFSGSRSGTD FTLTISLQPEDFATYYCQHYTTPPTFGQGTKVE IKR TVAAP QIVLTQSPA IMSASPGEKVTMTCSASS SVSYMNWYQQKSGTSPKRWIYDTSKLAGVPAHFR GSGSGTSYSLTISGMEAEADAATYYCQQWSSNPFTF GSGTKLEINR

Example 2.57: Generation of CD-3 (seq. 2) and CD-19 DVD-Igs

Table 89

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
323	DVD137H	AB039VH	AB006VH	QVQLQQSGAELARPGASVKMCKASGYTFTRYTMH WVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATL TTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYC LDYWGQGTTLTVSS ASTKGP QVQLQQSGAELVRPG SSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQ IWPGDGDTNYNGKFKGKATLTADESSSTAYMQLSS LASEDSAVYFCARRETTTVGRYYYAMDYWGQGTSV TVSS
324	DVD137L	AB039VL	AB006VL	QIVLTQSPAIMASAPGKVTMTCSASSSVSYMNWY QQKSGTSPKRWIYDTSKLAGVPAHFRGSGSGTSY SLTISGMEAEADAATYYCQQWSSNPFTFGSGTKLEI NR TVAAP DILLTQTPASLAVSLGQRATISCKASQS VDYDGDSYLNWYQQIPGQPPKLLIYDASNLVSGIP PRFSGSGSGTDFTLNIHPVEKVDAAATYHCQQSTED PWTFGGGTKLEIKR
325	DVD138H	AB006VH	AB039VH	QVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMN WVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATL TADESSSTAYMQLSSLASEDSAVYFCARRETTTVG RYYYAMDYWGQGTSVTVSS ASTKGP QVQLQQSGAE LARPGASVKMCKASGYTFTRYTMHWVKQRPGQGL EWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAY MQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTL TVSS
326	DVD138L	AB006VL	AB039VL	DILLTQTPASLAVSLGQRATISCKASQSDYDGDS YLNWYQQIPGQPPKLLIYDASNLVSGIPPRFSGSG SGTDFTLNIHPVEKVDAAATYHCQQSTEDPWTFGGG TKLEIKR TVAAP QIVLTQSPAIMASAPGKVTMT SASSSVSYMNWYQQKSGTSPKRWIYDTSKLAGVPA AHFRGSGSGTSYSLTISGMEAEADAATYYCQQWSSN PFTFGSGTKLEINR

Example 2.58: Generation of CD-3 (seq. 2) and EGFR (seq. 2) DVD-Igs

Table 90

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
327	DVD139H	AB039VH	AB033VH	QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMH WVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATL TTDKSSSTAYMQLSSLTSEDSAVYYCARYDDHYC LDYWGQGTTLTVSS ASTKGP QVQLKQSGPGLVQPS QSLSICTVSGFSLTNYGVHWRQSPGKLEWLGV IWSGGNTDYNTPFTSRLSINKDNSKQVFFKMNSL QSNDAIYYCARALTYDYEFAYWGQGTTLTVSA
328	DVD139L	AB039VL	AB033VL	QIVLTQSPA IMSASPGEKVTMTCSASSSVSYMNWY QQKSGTSPKRWIYDTSKLAGVPAHFRGSGSGTSY SLTISGMEAEADAATYYCQWSSNPFTFGSGTKLEI NR TVAAP DILLTQSPVILSVSPGERVVSFSCRASQS IGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFS GSGSGTDFTLINSVESEDIADYYCQNNNWPTTF GAGTKLELKR
329	DVD140H	AB033VH	AB039VH	QVQLKQSGPGLVQPSQSLSICTVSGFSLTNYGVH WVRQSPGKLEWLGVIWSGGNTDYNTPFTSRLSIN KDNSKQVFFKMNSLQSNDAIYYCARALTYDYEFAYWGQGTTLTVSA ASTKGP QVQLQQSGAELARPG ASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGY INPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSS LTSEDSAVYYCARYDDHYCLDYWGQGTTLTVSS
330	DVD140L	AB033VL	AB039VL	DILLTQSPVILSVSPGERVVSFSCRASQSIGTNIHW YQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTD FTLSINSVESEDIADYYCQNNNWPTTFGAGTKLE LKR TVAAP QIVLTQSPA IMSASPGEKVTMTCSASS SVSYMNWYQQKSGTSPKRWIYDTSKLAGVPAHFR GSGSGTSYSLTISGMEAEADAATYYCQWSSNPFTF GSGTKLEINR

Example 2.59: Generation of CD-3 (seq. 2) and EGFR (seq. 1) DVD-Igs

Table 91

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				123456789 0 123456789 0 123456789 0 12345
331	DVD141H	AB039VH	AB003VH	QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMH WVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATL TTDKSSSTAYMQLSSLTSEDSAVYYCARYDDHYC LDYWGQGTTLTVSS ASTKGP QVQLQESGPGLVKPS ETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWI GHIYYSGNTNYPNPSLKSRLTISIDTSKTQFSLKLS SVTAADTAIYYCVRDRVTGAFDIWGQGTMTVTVSS
332	DVD141L	AB039VL	AB003VL	QIVLTQSPA IMSASPGEKVTMTCSASSSVSYMNWY QQKSGTSPKRWIYDTSKLAGVPAHFRGSGSGTSY SLTISGMEAEADAATYYCQQWSSNPFTFGSGTKLEI NR TVAAP DIQMTQSPSSLSASVGDVRTITCQASQD ISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFS GSGSGTDFFTF TISSLPEDIATYFCQHFHDLPLAF GGGTKVEIKR
333	DVD142H	AB003VH	AB039VH	QVQLQESGPGLVKPSSETLSLTCTVSGGSVSSGDYY WTWIRQSPGKGLEWIGHIYYSGNTNYPNPSLKSRLT ISIDTSKTQFSLKLSVTAADTAIYYCVRDRVTGA FDIWGQGTMTVTVSS ASTKGP QVQLQQSGAELARPG ASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGY INPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSS LTSEDSAVYYCARYDDHYCLDYWGQGTTLTVSS
334	DVD142L	AB003VL	AB039VL	DIQMTQSPSSLSASVGDVRTITCQASQDISNYLNW YQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTD FTFTISSLPEDIATYFCQHFHDLPLAFGGGTKVE IKR TVAAP QIVLTQSPA IMSASPGEKVTMTCSASS SVSYMNWYQQKSGTSPKRWIYDTSKLAGVPAHFR GSGSGTSYSLTISGMEAEADAATYYCQQWSSNPFTF GSGTKLEINR

Example 2.60: Generation of EGFR (seq. 1) and IGF1,2 DVD-Igs

Table 92

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				123456789 0 123456789 0 123456789 0 12345
335	DVD143H	AB003VH	AB010VH	QVQLQESGPGLVKPSSETLSLTCTVSGGSVSSGDYY WTWIRQSPGKGLEWIGHIYYSGNTNYPNPSLKSRLT ISIDTSKTQFSLKLVSSVTAADTAIYYCVRDRVTGA FDIWGQGTMTVTVSS ASTKGP QVQLVQSGAEVKKPG ASVKVSKASGYTFTSYDINWVRQATGQGLEWMGW MNPNSGNTGYAQKFGQGRVTMTRNTSISTAYMELSS LRSEDTAVYYCARDPYYYYGMDVWVGQGTIVTVSS
336	DVD143L	AB003VL	AB010VL	DIQMTQSPSSLSASVGDRTITCQASQDISNYLNW YQQKPGKAPKLLIYDASNLETGVPSPRFSGSGSGTD FTFTISLQPEDIAFYFCQHFHDLPLAFGGGKVE IKR TVAAP QSVLTQPPSVSAAPGQKVTISCSGSSS NIENNHVSWYQQLPGTAPKLLIYDNNKRPSGIPDR FSGSKSGTSATLGITGLQTGDEADYYCETWDTLSL AGRVFGGGTKLTVLG
337	DVD144H	AB010VH	AB003VH	QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDIN WVRQATGQGLEWMGMNPNSGNTGYAQKFGQGRVTM TRNTSISTAYMELSSLRSEDTAVYYCARDPYYYY GMDVWVGQGTIVTVSS ASTKGP QVQLQESGPGLVK SETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEW IGHIYYSGNTNYPNPSLKSRLTISIDTSKTQFSLK SSVTAADTAIYYCVRDRVTGAFDIWGQGTMTVTVSS
338	DVD144L	AB010VL	AB003VL	QSVLTQPPSVSAAPGQKVTISCSGSSSNIENNHV SWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGT SATLGITGLQTGDEADYYCETWDTLSLQPEDIAFYFCQHF DKLTVL QPKAAP DIQMTQSPSSLSASVGDRTIT CQASQDISNYLNWYQQKPGKAPKLLIYDASNLETG VPSRFSGSGSGTDFFTFTISLQPEDIAFYFCQHF DLPLAFGGGKVEIKR

Example 2.61: Generation of DLL-4 (seq. 1) and PLGF (seq. 1) DVD-Igs

Table 93

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
339	VD257H	AB015VH	AB047VH	EVQLVESGGGLVQPGGSLRLSCAASGFTFTDNWIS WVRQAPGKGLEWVGYISPNNGFTYYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARDNFGGYF DYWGQGTLLTVSS ASTKGP QVQLQQSGAELVKPGA SVKISCKASGYFTDYYINWVKLAPGQGLEWIGWI YPGSGNTKYNEKFKGKATLTIDTSSSTAYMQLSSL TSEDVAVYFCVRDSPFFDYWGQGTLLTVSS
340	VD257L	AB015VL	AB047VL	DIQMTQSPSSLSASVGDRTITCRASQDVSTAVAW YQQKPKGKAPKLLIYSASFLYSGVPSRFSGSGSGTD FTLTISLQPEDFATYYCQQSYTGTVTFGQGTKV EIKR TVAAP DIVLTQSPDLSAVSLGERVTMCKSS QSLNSGMRKSFLLAWYQQKPGQSPKLLIYWASTRE SGVPDRFTGSGSGTDFTLTISVQAEDVAVYYCKQ SYHLFTFGSGTKLEIKR
341	VD258H	AB047VH	AB015VH	QVQLQQSGAELVKPGASVKISCKASGYFTDYYIN WVKLAPGQGLEWIGWIYPGSGNTKYNEKFKGKATL TIDTSSSTAYMQLSSLTSEDVAVYFCVRDSPFFDY WGQGTLLTVSS ASTKGP EVQLVESGGGLVQPGGSL RLSCAASGFTFTDNWISWVRQAPGKGLEWVGYISP NSGFTYYADSVKGRFTISADTSKNTAYLQMNSLRA EDTAVYYCARDNFGGYFDYWGQGTLLTVSS
342	VD258L	AB047VL	AB015VL	DIVLTQSPDLSAVSLGERVTMCKSSQSLNSGMR KSFLLAWYQQKPGQSPKLLIYWASTRESGVPDRFTG SGSGTDFTLTISVQAEDVAVYYCKQSYHLFTFGS GTKLEIKR TVAAP DIQMTQSPSSLSASVGDRTIT CRASQDVSTAVAWYQQKPKGKAPKLLIYSASFLYSG VPSRFSGSGSGTDFTLTISLQPEDFATYYCQQS YTGTVTFGQGTKVEIKR

Example 2.62: Generation of VEGF (seq. 1) and PLGF (seq. 1) DVD-Igs with Linker Set 1

Table 94

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
343	VD259H	AB014VH	AB047VH	EVQLVESGGGLVQPGGSLRLSCAASGYFTFTNYGMN WVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTF SLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYS SHWYFDVWGQGTLLTVVSS ASTKGP QVQLQQSGAEL VKPGASVKISCKASGYFTFDYYINWVKLAPGQGLE WIGWIYPGSGNTKYNEKFKGKATLTIDTSSSTAYM QLSSLTSEDVAVYFCVRDSPFFFDYWGQGTLLTVSS
344	VD259L	AB014VL	AB047VL	DIQMTQSPSSLSASVGDRTITCSASQDISNYLNW YQQKPKGKAPKVLIIYFTSSLHSGVPSRFSGSGSGTD FTLTISLQPEDFATYYCQQYSTVPWTFGQGTKVE IKR TVAAP DIVLTQSPDSLAVSLGERVTMNCSSQ SLLNSGMRKSFLLAWYQQKPGQSPKLLIYWASTRES GVPDRFTGSGSGTDFTLTISVQAEDVAVYYCKQS YHLFTFGSGTKLEIKR
345	VD260H	AB047VH	AB014VH	QVQLQQSGAELVKPGASVKISCKASGYFTFDYYIN WVKLAPGQGLEWIGWIYPGSGNTKYNEKFKGKATL TIDTSSSTAYMQLSSLTSEDVAVYFCVRDSPFFDY WGQGTLLTVVSS ASTKGP EVQLVESGGGLVQPGGSL RLSCAASGYFTFTNYGMNWRQAPGKGLEWVGWINT YTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRA EDTAVYYCAKYPHYYSWYFDVWGQGTLLTVVSS
346	VD260L	AB047VL	AB014VL	DIVLTQSPDSLAVSLGERVTMNCSSQSLLNSGMR KSFLLAWYQQKPGQSPKLLIYWASTRESGVPDRFTG SGSGTDFTLTISVQAEDVAVYYCKQSYHLFTFGS GTKLEIKR TVAAP DIQMTQSPSSLSASVGDRTIT CSASQDISNYLNWYQQKPKGKAPKVLIIYFTSSLHSG VPSRFSGSGSGTDFTLTISLQPEDFATYYCQQYS TVPWTFGQGTKVEIKR

Example 2.63: Generation of VEGF (seq. 1) and PLGF (seq. 1) DVD-Igs with Linker Set 2

Table 95

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
347	DVD579H	AB047VH	AB014VH	QVQLQQSGAELVKPGASVKISCKASGYTFTDYYINWVKLAPGGGLEWIGWIYPGSGNTKYNEKFKGKATLTIDTSSSTAYMQLSSLTSEDVAVYFCVRDSPFFDYWGQGTLLTVSS ASTKGPSVFPLAP EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWGWINTYTGPEPTAAADFRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYHGGSSHWYFDVWGQGTLLTVSS
348	DVD579L	AB047VL	AB014VL	DIVLTQSPDLSLAVSLGERVTMNCSSQSLNSGMRKSLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISVQAEDVAVYYCKQSYHLFTFGSGTKLEIKR TVAAPSVFIFPP DIQMTQSPSSLSASVGDRTVITCSASQDISNYLNWYQQKPGKAPKVLIIYFTSSSLHSGVPSRFRSGSGTDFTLTISLQPEDFATYYCQQYSTVPWTFGQGTKEIKR
349	DVD580H	AB014VH	AB047VH	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWGWINTYTGPEPTAAADFRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYHGGSSHWYFDVWGQGTLLTVSS ASTKGPSVFPLAP QVQLQQSGAELVKPGASVKISCKASGYTFTDYYINWVKLAPGGGLEWIGWIYPGSGNTKYNEKFKGKATLTIDTSSSTAYMQLSSLTSEDVAVYFCVRDSPFFDYWGQGTLLTVSS
350	DVD580L	AB014VL	AB047VL	DIQMTQSPSSLSASVGDRTVITCSASQDISNYLNWYQQKPGKAPKVLIIYFTSSSLHSGVPSRFRSGSGTDFTLTISLQPEDFATYYCQQYSTVPWTFGQGTKEIKR TVAAPSVFIFPP DIVLTQSPDLSLAVSLGERVTMNCSSQSLNSGMRKSLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISVQAEDVAVYYCKQSYHLFTFGSGTKLEIKR

Example 2.64: Generation of VEGF (seq. 1) and PLGF (seq. 1) DVD-Igs with Linker Set 3

Table 96

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
351	DVD587VH	AB047VH	AB014VH	QVQLQQSGAELVKPGASVKISCKASGYTFTDYYINWVKLAPGGGLEWIGWIYPGSGNTKYNEKFKGKATLTIDTSSSTAYMQLSSLTSEDVAVYFCVRDSPFFDYWGQGTLLTVSS ASTKGPSVFPLAP EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSSHWYFDVWGQGTLLTVSS
352	DVD587VL	AB047VL	AB014VL	DIVLTQSPDLSAVSLGERVTMNCSSQSLNSGMRKSLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFLTISSVQAEDVAVYYCKQSYHLFTFGSGTKLEIKR TVAAP DIQMTQSPSSLSASVGDRTITCSASQDISNYLNWYQQKPGKAPKVLIIYFTSSLHSGVPSRFGSGSGTDFLTISLQPEDFATYYCQQYSTVPWTFGQGTKVEIKR
353	DVD588VH	AB014VH	AB047VH	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLLTVSS ASTKGPSVFPLAP QVQLQQSGAELVKPGASVKISCKASGYTFTDYYINWVKLAPGGGLEWIGWIYPGSGNTKYNEKFKGKATLTIDTSSSTAYMQLSSLTSEDVAVYFCVRDSPFFDYWGQGTLLTVSS
354	DVD588VL	AB014VL	AB047VL	DIQMTQSPSSLSASVGDRTITCSASQDISNYLNWYQQKPGKAPKVLIIYFTSSLHSGVPSRFGSGSGTDFLTISLQPEDFATYYCQQYSTVPWTFGQGTKVEIKR TVAAP DIVLTQSPDLSAVSLGERVTMNCSSQSLNSGMRKSLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFLTISSVQAEDVAVYYCKQSYHLFTFGSGTKLEIKR

Example 2.65: Generation of VEGF (seq. 1) and PLGF (seq. 1) DVD-Igs with Linker Set 4

Table 97

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
355	DVD595VH	AB047VH	AB014VH	QVQLQQSGAELVKPGASVKISCKASGYTFTDYYINWVKLAPGQGLEWIGWIYPGSGNTKYNEKFKGKATLTIDTSSSTAYMQLSSLTSEDVAVYFCVRDSPFFDYWGQGTLLTVSS ASTKGP EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWFYFDVWGQGTLLTVSS
356	DVD595VL	AB047VL	AB014VL	DIVLTQSPDLSLAVSLGERVTMNCSSQSLNSGMRKSLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISVQAEDVAVYYCKQSYHLFTFGSGTKLEIKR TVAAPSVFI FPDIQMTQSPSSLSASV GDRVTITCSASQDISNYLNWYQQKPGKAPKVLIIYFTSSSLHSGVPSRFRSGSGTDFTLTISLQPEDFATYYCQQYSTVPWTFGQGTKVEIKR
357	DVD596VH	AB014VH	AB047VH	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYS SHWYFDVWGQGTLLTVSS ASTKGP QVQLQQSGAELVKPGASVKISCKASGYTFTDYYINWVKLAPGQGLEWIGWIYPGSGNTKYNEKFKGKATLTIDTSSSTAYMQLSSLTSEDVAVYFCVRDSPFFDYWGQGTLLTVSS
358	DVD596VL	AB014VL	AB047VL	DIQMTQSPSSLSASV GDRVTITCSASQDISNYLNWYQQKPGKAPKVLIIYFTSSSLHSGVPSRFRSGSGTDFTLTISLQPEDFATYYCQQYSTVPWTFGQGTKVEIKR TVAAPSVFI FPDIVLTQSPDLSLAVSLGERVTMNCSSQSLNSGMRKSLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISVQAEDVA VYYCKQSYHLFTFGSGTKLEIKR

Example 2.66: Generation of EGFR (seq. 2) and ErbB3 (seq. 1) DVD-Igs with Linker Set 1

Table 98

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
359	VD299H	AB062VH	AB033VH	QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWS WIRQPPGKGLEWIGEINHSGSTNYNPSLKRVTIS VETSKNQFSLKLSSVTAADTAVYYCARDKWTWYFD LWGRGTLTVSS ASTKGP QVQLKQSGPGLVQPSQS LSITCTVSGFSLTNYGVHWRQSPGKLEWLGVIW SGGNTDYNTPFTRSLSINKDNSKQVFFKMNSLQS NDTAYYCARALTYDYEFAYWGQGLTVTVSA
360	VD299L	AB062VL	AB033VL	DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSN RNYLAWYQQNPGQPPKLLIYWASTRESGVPDRFSG SGSGTDFTLTISLQAEDVAVYYCQYYSTPRTFG QGTKVEIKR TVAAP DILLTQSPVILSVSPGERVSF SCRASQSIGTNIHWYQRTNGSPRLLIKYASESIS GIPSRFSGSGSGTDFTLINSVESEDIADYYCQQN NNWPTTFGAGTKLELKR
361	VD300H	AB033VH	AB062VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTNYGVH WVRQSPGKLEWLGVIWGGNTDYNTPFTRSLSIN KDNSKQVFFKMNSLQSNDTAYYCARALTYDYEFAYWGQGLTVTVSA ASTKGP QVQLQQWGAGLLKPS ETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGE INHSGSTNYNPSLKRVTISVETSKNQFSLKLSSV TAADTAVYYCARDKWTWYFDLWGRGTLTVSS
362	VD300L	AB033VL	AB062VL	DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHW YQRTNGSPRLLIKYASESISGIPSRFSGSGSGTD FTLSINSVESEDIADYYCQQNNWPTTFGAGTKLE LKR TVAAP DIEMTQSPDSLAVSLGERATINCRSSQ SVLYSSSNRNYLAWYQQNPGQPPKLLIYWASTRES GVPDRFSGSGSGTDFTLTISLQAEDVAVYYCQY YSTPRTFGQGTKVEIKR

Example 2.67: Generation of EGFR (seq. 2) and ErbB3 (seq. 1) DVD-Igs with Linker Set 2

Table 99

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
363	DVD385H	AB062	AB033	QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWS WIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTIS VETSKNQFSLKLSSVTAADTAVYYCARDKWTWYFD LWGRGTLVTVSS ASTKGPSVFPLAP QVQLKQSGPG LVQPSQSLSICTVSGFSLTNYGVHWRQSPGKGL EWLGVIWSGGNTDYNTPFTSRLSINKDNSKSVFF KMNSLQSNDAIYYCARALTYDYEFAYWGQGLTV TVSA
364	DVD385L	AB062	AB033	DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSN RNYLAWYQQNPGQPPKLLIYWASTRESGVPDRFSG SGSGTDFTLTISLQAEDVAVYYCQQYYSTPRTFG QGTKVEIKR TVAAPSVFIFPP DILLTQSPVILSVS PGERVFSFCRASQSIGTNIHWYQQRTNGSPRLLIK YASESISGIPSRFSGSGTDFTLINSVSESDIA DYCQQNNNWPTTFGAGTKLELKR
365	DVD386H	AB033	AB062	QVQLKQSGPGLVQPSQSLSICTVSGFSLTNYGVH WVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSIN KDNSKSVFFKMNSLQSNDAIYYCARALTYDYEF FAYWGQGLVTVSA ASTKGPSVFPLAP QVQLQQWG AGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGK GLEWIGEINHSGSTNYNPSLKSRVTISVETSKNQF SLKLSSVTAADTAVYYCARDKWTWYFDLWGRGTLV TVSS
366	DVD386L	AB033	AB062	DILLTQSPVILSVSPGERVFSFCRASQSIGTNIHW YQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTD FTLSINSVSESDIADYICQQNNNWPTTFGAGTKLE LKR TVAAPSVFIFPP DIEMTQSPDSLAVSLGERAT INCRSSQSVLYSSSNRNYLAWYQQNPGQPPKLLIY WASTRESGVPDRFSGSGSGTDFTLTISLQAEDVA VYYCQQYYSTPRTFGQGTKVEIKR

Example 2.68: Generation of EGFR (seq. 2) and ErbB3 (seq. 1) DVD-Igs with Linker Set 3

Table 100

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
367	DVD389H	AB062	AB033	QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWS WIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTIS VETSKNQFSLKLSSVTAADTAVYYCARDKWTWYFD LWGRGTLVTVSS ASTKGPSVFPLAP QVQLKQSGPG LVQPSQSLSICTVSGFSLTNYGVHWVRQSPGKGL EWLGVIWSGGNTDYNTPFTSRLSINKDNSKQVFF KMNSLQSNDAIYYCARALTYDYEFAYWGQGLV TVSA
368	DVD389L	AB062	AB033	DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSN RNYLAWYQQNPGQPPKLLIYWASTRESGVPDRFSG SGSGTDFTLTISLQAEDVAVYYCQQYYSTPRTFG QGTKVEIKR TVAAP DILLTQSPVILSVSPGERVSF SCRASQSIGTNIHWYQQRNGSPRLLIKYASESIS GIPSRFSGSGSGTDFTLINSVESEDIADYYCQQN NNWPTTFGAGTKLELKR
369	DVD390H	AB033	AB062	QVQLKQSGPGLVQPSQSLSICTVSGFSLTNYGVH WVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSIN KDNSKQVFFKMNSLQSNDAIYYCARALTYDYEF FAYWGQGLVTVSA ASTKGPSVFPLAP QVQLQQWG AGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGK GLEWIGEINHSGSTNYNPSLKSRVTISVETSKNQF SLKLSSVTAADTAVYYCARDKWTWYFDLWGRGTLV TVSS
370	DVD390L	AB033	AB062	DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHW YQQRNGSPRLLIKYASESISGIPSRFSGSGSGTD FTLSINSVESEDIADYYCQQNNWPTTFGAGTKLE LKRTVAAPDIEMTQSPDSLAVSLGERATINCRSSQ SVLYSSSNRNYLAWYQQNPGQPPKLLIYWASTRES GVPDRFSGSGSGTDFTLTISLQAEDVAVYYCQY YSTPRTFGQGTKVEIKR

Example 2.69: Generation of EGFR (seq. 2) and ErbB3 (seq. 1) DVD-Igs with Linker Set 4

Table 101

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
371	DVD393H	AB062	AB033	QVQLQQWGAGLLKPSSETLSLTCAVYGGSFSGYYWS WIRQPPGKGLEWIGEINHSGSTNYNPSLKSRTVIS VETSKNQFSLKLSSVTAADTAVYYCARDKWTWYFD LWGRGTLTVSS ASTKGP QVQLKQSGPGLVQPSQS LSITCTVSGFSLTNYGVHWRQSPGKLEWLGVIW SGGNTDYNTPFTSRLSINKDNSKQVFFKMNSLQS NDTAYYCARALTYDYEFAYWGQGLTVTVA
372	DVD393L	AB062	AB033	DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSN RNYLAWYQQNPGQPPKLLIYWASTRESGVPDRFSG SGSGTDFTLTISSLQAEDVAVYYCQYYSTPRTFG QGTKVEIKR TVAAPSVFI FPDILLTQSPVILSVS PGERVVFSCRASQSIGTNIHWYQQRTNGSPRLLIK YASESISGIPSRFSGSGSGTDFTLINSINVESEDIA DYCQNNWPTTFGAGTKLELKR
373	DVD394H	AB033	AB062	QVQLKQSGPGLVQPSQSLITCTVSGFSLTNYGVH WVRQSPGKLEWLGVIWGGNTDYNTPFTSRLSIN KDNSKQVFFKMNSLQSNNTAYYCARALTYDYEFAYWGQGLTVTVA ASTKGP QVQLQQWGAGLLKPS ETLSLTCAVYGGSFSGYYWSWIRQPPGKLEWIGE INHSGSTNYNPSLKSRTISVETSKNQFSLKLSSV TAADTAVYYCARDKWTWYFDLWGRGTLTVSS
374	DVD394L	AB033	AB062	DILLTQSPVILSVSPGERVVFSCRASQSIGTNIHW YQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTD FTLSINVESEDIADYICQNNWPTTFGAGTKLE LKR TVAAPSVFI FPDIEMTQSPDSLAVSLGERAT INCRSSQSVLYSSSNRNYLAWYQQNPGQPPKLLIY WASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVA VYYCQYYSTPRTFGQGTKVEIKR

Example 2.70: Generation of EGFR (seq. 1) and ErbB3 (seq. 1) DVD-Igs

Table 102

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
375	DVD301H	AB062VH	AB003VH	QVQLQQWGAGLLKPSETLSLTCVAVYGGSFSGYYWS WIRQPPGKGLEWIGEINHSGSTNYNPSLKSRTIS VETSKNQFSLKLSSVTAADTAVYYCARDKWTWYFD LWGRGTLTVSS ASTKGP QVQLQESGPGLVKPS ETLSLTCVAVYGGSFSGYYWWTWIRQSPGKLEWIGH IYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSV TAADTAIYYCVRDRVTGAFDIWGQGTMTVSS
376	DVD301L	AB062VL	AB003VL	DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSN RNYLAWYQQNPGQPPKLLIYWASTRESGVPDRFSG SGSGTDFTLTISSLQAEDVAVYYCQYYSTPRTFG QGTKVEIKR TVAAP DIQMTQSPSSLSASVGDRTI TCQASQDISNYLNWYQKPGKAPKLLIYDASNLET GVPSRFSGSGSGTDFFTISSLPEDIATYFCQHF DHLPLAFGGGKTKVEIKR
377	DVD302H	AB003VH	AB062VH	QVQLQESGPGLVKPSSETLSLTCVAVYGGSFSGYY WWTWIRQSPGKLEWIGHIYSGNTNYNPSLKSRLT ISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGA FDIWGQGTMTVSS ASTKGP QVQLQQWGAGLLKPS ETLSLTCVAVYGGSFSGYYWSWIRQPPGKLEWIGE INHSGSTNYNPSLKSRTISVETSKNQFSLKLSSV TAADTAVYYCARDKWTWYFDLWGRGTLTVSS
378	DVD302L	AB003VL	AB062VL	DIQMTQSPSSLSASVGDRTITCQASQDISNYLNW YQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTD FTFTISSLPEDIATYFCQHFHDHLPLAFGGGKTKVE IKR TVAAP DIEMTQSPDSLAVSLGERATINCRSSQ SVLYSSNRNYLAWYQQNPGQPPKLLIYWASTRES GVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQY YSTPRTFGQGTKVEIKR

Example 2.71: Generation of HGF (seq. 1) and ErbB3 (seq. 1) DVD-Igs

Table 103

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
379	DVD303H	AB062VH	AB012VH	QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWS WIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTIS VETSKNQFSLKLSVTAADTAVYYCARDKWTWYFD LWGRGTLVTVSS ASTKGP QVQLVESGGGLVKGPGS LRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYIS SSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLR AEDTAVYYCARDEYNSGWYVLFDYWGQGLTVTVSS
380	DVD303L	AB062VL	AB012VL	DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSN RNYLAWYQQNPGQPPKLLIYWASTRESGVPDRFSG SGSGTDFTLTISLQAEADVAVYYCQYYSTPRTEFG QGKVEIKR TVAAP DIQMTQSPSSVSASVGDRTI TCRASQGISSWLAWYQQKPGKAPNLLIYEASSLQS GVPSRFGSGSGTDFTLTISLQPEDFATYYCQQA NGFPWTFGQGTKVEIKR
381	DVD304H	AB012VH	AB062VH	QVQLVESGGGLVKGPGSLRLSCAASGFTFSDYYMS WIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRAEDTAVYYCARDEYNSGW YVLFDYWGQGLTVTVSS ASTKGP QVQLQQWGAGLL KPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEW IGEINHSGSTNYNPSLKSRVTISVETSKNQFSLKLS SVTAADTAVYYCARDKWTWYFDLWGRGTLVTVSS
382	DVD304L	AB012VL	AB062VL	DIQMTQSPSSVSASVGDRTITCRASQGISSWLAW YQQKPGKAPNLLIYEASSLQSGVPSRFGSGSGTD FTLTISLQPEDFATYYCQANGFPWTFGQGTKVEI IKR TVAAP DIEMTQSPDSLAVSLGERATINCRSSQ SVLYSSNRNYLAWYQQNPGQPPKLLIYWASTRES GVPDRFSGSGSGTDFTLTISLQAEADVAVYYCQY YSTPRTEFGQGTKVEIKR

Example 2.72: Generation of EGFR (seq. 2) and ErbB3 (seq. 2) DVD-Igs with Linker Set 1

Table 104

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
383	DVD305H	AB063VH	AB033VH	EVQLVESGGGLVQPGGSLRLSCAASGFTFSIYSMN WVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRDEDTAVYYCARDRGDFDA FDIWGQGTMTVSS ASTKGP QVQLKQSGPGLVQPS QSLITCTVSGFSLTNYGVHWVRQSPGKLEWLGV IWSGGNTDYNTPFTSRLSINKDNSKSVFFKMNSL QSNDAIYYCARALTYDYEFAYWGQGLVTVSA
384	DVD305L	AB063VL	AB033VL	DIQMTQSPSSLSASVGDRTITCQASQDITNYLNW YQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTD FTFTISSLQPEDIATYNCQQCFPIITFGQGRLE IKR TVAAP DILLTQSPVILSVSPGERVSPFCRASQ SIGTNIHWYQRTNGSPRLLIKYASESISGIPSRF SGSGSGTDFTLSINSVESEDIADYYCQNNWPTT FGAGTKLELKR
385	DVD306H	AB033VH	AB063VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTNYGVH WVRQSPGKLEWLGVIWSGGNTDYNTPFTSRLSIN KDNSKSVFFKMNSLQSNDAIYYCARALTYDYEFAYWGQGLVTVSA ASTKGP EVQLVESGGGLVQPG GSLRLSCAASGFTFSIYSMNWVRQAPGKLEWVSY ISSSSSTIYYADSVKGRFTISRDNALNSLYLQMNS LRDEDTAVYYCARDRGDFDAFDIWGQGTMTVSS
386	DVD306L	AB033VL	AB063VL	DILLTQSPVILSVSPGERVSPFCRASQSIGTNIHW YQRTNGSPRLLIKYASESISGIPSRFSGSGSGTD FTLSINSVESEDIADYYCQNNWPTTFGAGTKLE LKR TVAAP DIQMTQSPSSLSASVGDRTITCQASQ DITNYLNWYQQKPGKAPKLLIYDASNLETGVPSRF SGSGSGTDFTFTISSLQPEDIATYNCQQCFPIIT FGQGRLEIKR

Example 2.73: Generation of EGFR (seq. 2) and ErbB3 (seq. 2) DVD-Igs with Linker Set 2

Table 105

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
387	DVD397H	AB063	AB033	EVQLVESGGGLVQPGGSLRLSCAASGFTFSIYSMN WVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRDEDTAVYYCARDRGDFDA FDIWGQGTMTVSS ASTKGPSVFPLAP QVQLKQSG PGLVQPSQSLITCTVSGFSLTNYGVHWVRQSPGK GLEWLGVIWSSGNTDYNTPFTSRLSINKDNSKQV FFKMNSLQSNDAIYYCARALTYDYEFAYWGQGT LVTVSA
388	DVD397L	AB063	AB033	DIQMTQSPSSLSASVGDRTVITCQASQDITNYLNW YQQKPGKAPKLLIYDASNLETGVPSRFGSGSGTD FTFTISLQPEDIAATYNCQQCENFPITFGQGRLE IKR TVAAPSVFI FPDILLTQSPVILSVSPGERVS FSCRASQSIGTNIHWYQRTNGSPRLLIKYASESI SGIPSRFGSGSGTDFTLSINSVESEDIADYYCQQ NNNWPTTFGAGTKLELKR
389	DVD398H	AB033	AB063	QVQLKQSGPGLVQPSQSLITCTVSGFSLTNYGVH WVRQSPGKGLEWLGVIWSSGNTDYNTPFTSRLSIN KDNSKQVFFKMNSLQSNDAIYYCARALTYDYEF FAYWGQGTMTVSA ASTKGPSVFPLAP EVQLVESG GGLVQPGGSLRLSCAASGFTFSIYSMNWVRQAPGK GLEWVSYISSSSSTIYYADSVKGRFTISRDNKNS LYLQMNSLRDEDTAVYYCARDRGDFDAFDIWGQGT MTVSS
390	DVD398L	AB033	AB063	DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHW YQRTNGSPRLLIKYASEISGIPSRFGSGSGTD FTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLE LKR TVAAPSVFI FPDILLTQSPSSLSASVGDRTV ITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLE TGVPSRFGSGSGTDFTFTISLQPEDIAATYNCQQ CENFPITFGQGRLEIKR

Example 2.74: Generation of EGFR (seq. 2) and ErbB3 (seq. 2) DVD-Igs with Linker Set 3

Table 106

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
391	DVD401H	AB063	AB033	EVQLVESGGGLVQPGGSLRLSCAASGFTFSIYSMN WVRQAPGKGLEWVSYISSSSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRDEDTAVYYCARDRGDFDA FDIWGQGTMTVSS ASTKGPSVFPLAP QVQLKQSG PGLVQPSQSLITCTVSGFSLTNYGVHWVRQSPGK GLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKQV FFKMNSLQSNDAIYYCARALTYDYEFAYWGQGT LVTVSA
392	DVD401L	AB063	AB033	DIQMTQSPSSLSASVGDRTVITCQASQDITNYLNW YQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTD FTFTISSLQPEDIATYNCQQCENFPITFGQGRLE IKR TVAAP DILLTQSPVILSVSPGERVVFSCRASQ SIGTNIHWYQQRNGSPRLLIKYASESISGIPSRF SGSGSGTDFTLINSVESEDIADYYCQNNNWPTT FGAGTKLELKR
393	DVD402H	AB033	AB063	QVQLKQSGPGLVQPSQSLITCTVSGFSLTNYGVH WVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSIN KDNSKQVFFKMNSLQSNDAIYYCARALTYDYE FAYWGQGTMTVSA ASTKGPSVFPLAP EVQLVESG GGLVQPGGSLRLSCAASGFTFSIYSMNWVRQAPGK GLEWVSYISSSSTIYYADSVKGRFTISRDNKNS LYLQMNSLRDEDTAVYYCARDRGDFDAFDIWGQGT MTVSS
394	DVD402L	AB033	AB063	DILLTQSPVILSVSPGERVVFSCRASQSIGTNIHW YQQRNGSPRLLIKYASESISGIPSRFSGSGSGTD FTLSINSVESEDIADYYCQNNNWPTTFFGAGTKLE LKR TVAAP DIQMTQSPSSLSASVGDRTVITCQASQ DITNYLNWYQQKPGKAPKLLIYDASNLETGVPSRF SGSGSGTDFFTFTISSLQPEDIATYNCQQCENFPIT FGQGRLEIKR

Example 2.75: Generation of EGFR (seq. 2) and ErbB3 (seq. 2) DVD-Igs with Linker Set 4

Table 107

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
395	DVD405H	AB063	AB033	EVQLVESGGGLVQPGGSLRLSCAASGFTFSIYSMN WVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRDEDTAVYYCARDRGDFDA FDIWGQGTMTVSS ASTKGP QVQLKQSGPGLVQPS QSLSI TCTVSGFSLTNYGVHWVRQSPGKLEWLGV IWSGGNTDYNTPFTSRLSINKDNSKSVFFKMNSL QSNDAIYYCARALTYDYEFAYWGQGLVTVSA
396	DVD405L	AB063	AB033	DIQMTQSPSSLSASVGDRTITCQASQDITNYLNW YQQKPGKAPKLLIYDASNLETGVPSRFRSGSGSGTD FTFTISSLPEDIATYNCQQCENFPITFGQGRLE IKR TVAAPSVFI FPP DILLTQSPVILSVSPGERVS FSCRASQSIGTNIHWYQRTNGSPRLLIKYASESI SGIPSRFRSGSGSGTDFTLSINSVESEDIADYYCQQ NNNWPTTFGAGTKLELKR
397	DVD406H	AB033	AB063	QVQLKQSGPGLVQPSQSLSI TCTVSGFSLTNYGVH WVRQSPGKLEWLGVIWSGGNTDYNTPFTSRLSIN KDNSKSVFFKMNSLQSNDAIYYCARALTYDYEFAYWGQGLVTVSA ASTKGP EVQLVESGGGLVQPG GSLRLSCAASGFTFSIYSMNWVRQAPGKLEWVSY ISSSSSTIYYADSVKGRFTISRDNALNSLYLQMNS LRDEDTAVYYCARDRGDFDAFDIWGQGTMTVSS
398	DVD406L	AB033	AB063	DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHW YQRTNGSPRLLIKYASESISGIPSRFRSGSGSGTD FTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLE LKR TVAAPSVFI FPP DIQMTQSPSSLSASVGDRTI ITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLE TGVPSRFRSGSGSGTDFTFTISSLPEDIATYNCQQ CENFPITFGQGRLEIKR

Example 2.76: Generation of EGFR (seq. 1) and ErbB3 (seq. 2) DVD-Igs

Table 108

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
399	DVD307H	AB063VH	AB003VH	EVQLVESGGGLVQPGGSLRLSCAASGFTFSIYSMN WVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRDEDTAVYYCARDRGDFDA FDIWGQGTMTVTVSS ASTKGP QVQLQESGPGLVKPS ETLSLTCTVSGGSVSSGDYYWTWIRQSPGKLEWI GHIYYSGNTNYPNPSLKSRLTISIDTSKTQFSLKLS SVTAADTAIYYCVRDRVTGAFDIWGQGTMTVTVSS
400	DVD307L	AB063VL	AB003VL	DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNW YQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTD FTFTISSLQPEDIATYNCQQCFNFPITFGQGRLE IKR TVAAP DIQMTQSPSSLSASVGDRVTITCQASQ DITNYLNWYQQKPGKAPKLLIYDASNLETGVPSRF SGSGSGTDFTFTISSLQPEDIATYFCQHFHDLPLA FGGKTKVEIKR
401	DVD308H	AB003VH	AB063VH	QVQLQESGPGLVKPSSETLSLTCTVSGGSVSSGDYY WTWIRQSPGKLEWIGHIYYSGNTNYPNPSLKSRLT ISIDTSKTQFSLKLSVTAADTAIYYCVRDRVTGA FDIWGQGTMTVTVSS ASTKGP EVQLVESGGGLVQPG GSLRLSCAASGFTFSIYSMNWVRQAPGKLEWVSY ISSSSSTIYYADSVKGRFTISRDNANSLYLQMNS LRDEDTAVYYCARDRGDFDAFDIWGQGTMTVTVSS
402	DVD308L	AB003VL	AB063VL	DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNW YQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTD FTFTISSLQPEDIATYFCQHFHDLPLAFGGKTKVE IKR TVAAP DIQMTQSPSSLSASVGDRVTITCQASQ DITNYLNWYQQKPGKAPKLLIYDASNLETGVPSRF SGSGSGTDFTFTISSLQPEDIATYNCQQCFNFPIT FGQGRLEIKR

Example 2.77: Generation of HGF (seq. 1) and ErbB3 (seq. 2) DVD-Igs

Table 109

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
403	DVD309H	AB063VH	AB012VH	EVQLVESGGGLVQPGGSLRLSCAASGFTFSIYSMN WVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRDEDTAVYYCARDRGDFDA FDIWGQGTMTVTVSS ASTKGP QVQLVESGGGLV KPGGSLRLSCAASGFTFSDIYMSWIRQAPGKGLEWVSY ISSSGSTIYYADSVKGRFTISRDNKNSLYLQMNS LRAEDTAVYYCARDEYNSGWYVLFDYWGQGLTVT VSS
404	DVD309L	AB063VL	AB012VL	DIQMTQSPSSLSASVGDRTVITCQASQDITNYLNW YQQKPGKAPKLLIYDASNLETGVPSRFSGSGS GTDFTFTISLQPEDIATYNCQCENFPITFGQGR LEIKR TVAAP DIQMTQSPSSVSASVGDRTVITCRASQ GISSWLAWYQQKPGKAPNLLIYEASSLQSGVPSRF GGSGSGLTFTLTISSLQPEDFATYYCQANGFPWT FGQGTKVEIKR
405	DVD310H	AB012VH	AB063VH	QVQLVESGGGLVQPGGSLRLSCAASGFTFSDIYMS WIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRAEDTAVYYCARDEYNSGW YVLFDYWGQGLTVTVSS ASTKGP EVQLVESGGGLV QPGGSLRLSCAASGFTFSIYSMNWVRQAPGKGLEW VSYISSSSSTIYYADSVKGRFTISRDNKNSLYLQ MNSLRDEDTAVYYCARDRGDFDAFDIWGQGTMTV VSS
406	DVD310L	AB012VL	AB063VL	DIQMTQSPSSVSASVGDRTVITCRASQGISSWLAW YQQKPGKAPNLLIYEASSLQSGVPSRFGSGS GTDFTLTISSLQPEDFATYYCQANGFPWTFGQGR LEIKR TVAAP DIQMTQSPSSLSASVGDRTVITCQASQ DITNYLNWYQQKPGKAPKLLIYDASNLETGVPSRF SGSGSGLTFTFTISLQPEDIATYNCQCENFPIT FGQGRLEIKR

Example 2.78: Generation of VEGF (seq. 1) and DLL4 (seq. 2) DVD-Igs with Linker Set 1

Table 110

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
407	DVD441H	AB069	AB014	QVQLVQSGAEVKKPGASVKISCKASGYSFTAYYIH WVKQAPGQGLEWIGYISSYNGATNYNQKFKGRVTF TTDTSTSTAYMELRSLRSDDTAVYYCARDYDYDVG MDYWGQGLTQVSS ASTKGP EVQLVESGGGLVQPG GSLRLSCAASGYFTFTNYGMNWRQAPGKGLEWVGV INTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNS LRAEDTAVYYCAKYPHYGSSHWYFDVWGQGLTQV VSS
408	DVD441L	AB069	AB014	DIVMTQSPDSLAVSLGERATISCRASESDNYGIS FMKWFQQKPGQPPKLLIYAASNQSGVDRFSGSG SGTDFTLTISLQAEDVAVYYCQQSKEVPWTFGGG TKVEIKR TVAAP DIQMTQSPSSLSASVGDRTITC SASQDISNYLNWYQQKPGKAPKVLIIYFTSSLHSGV PSRFGSGSGTDFTLTISLQPEDFATYYCQQYST VPWTFGGGKVEIKR
409	DVD442H	AB014	AB069	EVQLVESGGGLVQPGGSLRLSCAASGYFTFTNYGMN WVRQAPGKGLEWGWINTYTGEPTYAADFKRRFTF SLDTSKSTAYLQMNLSLRAEDTAVYYCAKYPHYGS SHWYFDVWGQGLTQVSS ASTKGP QVQLVQSGAEV KKPGASVKISCKASGYSFTAYYIHWVKQAPGQGLE WIGYISSYNGATNYNQKFKGRVTFTTDTSTSTAYM ELRSLRSDDTAVYYCARDYDYDVGMDYWGQGLTQV VSS
410	DVD442L	AB014	AB069	DIQMTQSPSSLSASVGDRTITCSASQDISNYLNW YQQKPGKAPKVLIIYFTSSLHSGVPSRFGSGSGTD FTLTISLQPEDFATYYCQQYSTVPWTFGGGKVE IKR TVAAP DIVMTQSPDSLAVSLGERATISCRASE SDNYGISFMKWFQQKPGQPPKLLIYAASNQSGV PDRFGSGSGTDFTLTISLQAEDVAVYYCQQSKE VPWTFGGGKVEIKR

Example 2.79: Generation of VEGF (seq. 1) and DLL4 (seq. 2) DVD-Igs with Linker Set 2

Table 111

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
411	DVD447H	AB069	AB014	QVQLVQSGAEVKKPGASVKISCKASGYSFTAYYIH WVKQAPGQGLEWIGYISSYNGATNYNQKFKGRVTF TTDTSTSTAYMELRSLRSDDTAVYYCARDYDYDVG MDYWGQGLVTVVSS ASTKGPSVFPLAP EVQLVESG GGLVQPGGSLRLSCAASGYTFTNYGMNWRQAPGK GLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKST AYLQMNSLRAEDTAVYYCAKYPHYGSSHWFYFDVW GQGLVTVVSS
412	DVD447L	AB069	AB014	DIVMTQSPDSLAVSLGERATISCRASESDNYGIS FMKWFQKPGQPPKLLIYAASNQGSVDRFSGSG SGTDFTLTISSLQAEDVAVYYCQQSKEVPWTFGGG TKVEIKR TVAAPSVFIFPP DIQMTQSPSSLSASVG DRVTITCSASQDISNYLNWYQKPGKAPKVLIIYFT SSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATY YCQQYSTVPWTFGQGTKVEIKR
413	DVD448H	AB014	AB069	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMN WVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTF SLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYGS SHWFYFDVWGQGLVTVVSS ASTKGPSVFPLAP QVQL VQSGAEVKKPGASVKISCKASGYSFTAYYIHWVKQ APGQGLEWIGYISSYNGATNYNQKFKGRVTFTTDT STSTAYMELRSLRSDDTAVYYCARDYDYDVGMDYW GQGLVTVVSS
414	DVD448L	AB014	AB069	DIQMTQSPSSLSASVGRVITCSASQDISNYLNW YQKPGKAPKVLIIYFTSSLHSGVPSRFSGSGSGTD FTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVE IKR TVAAPSVFIFPP DIVMTQSPDSLAVSLGERAT ISCRASESDNYGISFMKWFQKPGQPPKLLIYAA SNQGSVDRFSGSGSGTDFTLTISSLQAEDVAVY YCQQSKEVPWTFGGGTKVEIKR

Example 2.80: Generation of VEGF (seq. 1) and DLL4 (seq. 2) DVD-Igs with Linker Set 3

Table 112

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
415	DVD453H	AB069	AB014	QVQLVQSGAEVKKPGASVKISCKASGYSFTAYYIH WVKQAPGQGLEWIGYISSYNGATNYNQKFKGRVTF TTDTSTSTAYMELRSLRSDDTAVYYCARDYDYDVG MDYWGQGLVTVVSS ASTKGPSVFPLAP EVQLVESG GGLVQPGGSLRLSCAASGYFTFTNYGMNWRQAPGK GLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKST AYLQMNSLRAEDTAVYYCAKYPHYGSSHWFYFDVW GQGLVTVVSS
416	DVD453L	AB069	AB014	DIVMTQSPDSLAVSLGERATISCRASESDNYGIS FMKWFQQKPGQPPKLLIYAASNQSGVDRFSGSG SGTDFTLTISLQAEDVAVYYCQQSKEVPWTFGGG TKVEIKR TVAAP DIQMTQSPSSLSASVGRVTITC SASQDISNYLNWYQQKPGKAPKVLIIYFTSSLHSGV PSRFGSGSGTDFTLTISLQPEDFATYYCQYST VPWTFGGGKVEIKR
417	DVD454H	AB014	AB069	EVQLVESGGGLVQPGGSLRLSCAASGYFTFTNYGMN WVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTF SLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYGS SHWFYFDVWGQGLVTVVSS ASTKGPSVFPLAP QVQL VQSGAEVKKPGASVKISCKASGYSFTAYYIHWVKQ APGQGLEWIGYISSYNGATNYNQKFKGRVTFTTDT STSTAYMELRSLRSDDTAVYYCARDYDYDVGMDYW GQGLVTVVSS
418	DVD454L	AB014	AB069	DIQMTQSPSSLSASVGRVTITCSASQDISNYLNW YQQKPGKAPKVLIIYFTSSLHSGVPSRFGSGSGTD FTLTISLQPEDFATYYCQYSTVPWTFGGGKVE IKR TVAAP DIVMTQSPDSLAVSLGERATISCRASE SDNYGISFMKWFQQKPGQPPKLLIYAASNQSGV PDRFGSGSGTDFTLTISLQAEDVAVYYCQQSKE VPWTFGGGKVEIKR

Example 2.81: Generation of VEGF (seq. 1) and DLL4 (seq. 2) DVD-Igs with Linker Set 4

Table 113

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
419	DVD459H	AB069	AB014	QVQLVQSGAEVKKPGASVKISCKASGYSFTAYYIH WVKQAPGQGLEWIGYISSYNGATNYNQKFKGRVTF TTDTSTSTAYMELRSLRSDDTAVYYCARDYDYG MDYWGQGLVTVSS ASTKGP EVQLVESGGGLVQPG GSLRLSCAASGYFTFTNYGMNWRQAPGKGLEWVGW INTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNS LRAEDTAVYYCAKYPHYYSSSHWFYDVGQGLVTV VSS
420	DVD459L	AB069	AB014	DIVMTQSPDSLAVSLGERATISCRASESDNYGIS FMKWFQKPGQPPKLLIYAASNQGSVDRFSGSG SGTDFTLTISLQAEADVAVYYCQKSKEVPWTFGGG TKVEIKR TVAAPSVFIFPP DIQMTQSPSSLSASVG DRVTITCSASQDISNYLNWYQKPKGKAPKVLIIYFT SSLHSGVPSRFSGSGSGTDFTLTISLQPEDFATY YCOQYSTVPWTFGGGKVEIKR
421	DVD460H	AB014	AB069	EVQLVESGGGLVQPGGSLRLSCAASGYFTFTNYGMN WVRQAPGKGLEWGWINTYTGEPTYAADFKRRFTF SLDTSKSTAYLQMNLSLRAEDTAVYYCAKYPHYYS SHWFYDVGQGLVTVSS ASTKGP QVQLVQSGAEV KKPGASVKISCKASGYSFTAYYIHWVKQAPGQGLE WIGYISSYNGATNYNQKFKGRVTFTTDTSTSTAYM ELRSLRSDDTAVYYCARDYDYGMDYWGQGLVTV VSS
422	DVD460L	AB014	AB069	DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNW YQKPKGKAPKVLIIYFTSSLHSGVPSRFSGSGSGTD FTLTISLQPEDFATYCOQYSTVPWTFGGGKVE IKR TVAAPSVFIFPP DIVMTQSPDSLAVSLGERAT ISCRASESDNYGISFMKWFQKPGQPPKLLIYAA SNQGSVDRFSGSGSGTDFTLTISLQAEADVAVY YCOQKSKEVPWTFGGGKVEIKR

Example 2.82: Generation of VEGF (seq. 2) and DLL4 (seq. 2) DVD-Igs with Linker Set 1

Table 114

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
423	DVD443H	AB069	AB070	QVQLVQSGAEVKKPGASVKISCKASGYSFTAYYIH WVKQAPGQGLEWIGYISSYNGATNYNQKFKGRVTF TTDTSTSTAYMELRLSRSDDTAVYYCARDYDYDVG MDYWGQGLVTVSS ASTKGP EVQLVESGGGLVQPG GSLRLSCAASGFTISDYWIHWVRQAPGKGLEWVAG ITPAGGYTYADSVKGRFTISADTSKNTAYLQMNS LRAEDTAVYYCARFVFFFLPYAMDYWGQGLVTVSS
424	DVD443L	AB069	AB070	DIVMTQSPDSLAVSLGERATISCRASESVDNYGIS FMKWFQKPGQPPKLLIYAASNQGSVDRFSGSG SGTDFTLTISLQAEADVAVYYCQQSKEVPWTFGGG TKVEIKR TVAAP DIQMTQSPSSLSASVGDRTITC RASQDVSTAVAWYQKPGKAPKLLIYASFLYSGV PSRFSGSGSGTDFTLTISLQPEDFATYYCQSYT TPPTFGQGTKVEIKR
425	DVD444H	AB070	AB069	EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIH WVRQAPGKGLEWVAGITPAGGYTYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARFVFFFLPY AMDYWGQGLVTVSS ASTKGP QVQLVQSGAEVKKP GASVKISCKASGYSFTAYYIHWKQAPGQGLEWIG YISSYNGATNYNQKFKGRVFTTDTSTSTAYMELR SLRSDDTAVYYCARDYDYDVGMDYWGQGLVTVSS
426	DVD444L	AB070	AB069	DIQMTQSPSSLSASVGDRTITCRASQDVSTAVAW YQKPGKAPKLLIYASFLYSGVPSRFSGSGSGTD FTLTISLQPEDFATYYCQSYTTPPTFGQGTKVE IKR TVAAP DIVMTQSPDSLAVSLGERATISCRASE SVDNYGISFMKWFQKPGQPPKLLIYAASNQGSV PDRFSGSGSGTDFTLTISLQAEADVAVYYCQQSKE VPWTFGGGTKVEIKR

Example 2.83: Generation of VEGF (seq. 2) and DLL4 (seq. 2) DVD-Igs with Linker Set 2

Table 115

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
427	DVD449H	AB069	AB070	QVQLVQSGAEVKKPGASVKISCKASGYSFTAYYIH WVKQAPGQGLEWIGYISSYNGATNYNQKFKGRVTF TTDTSTSTAYMELRSLRSDDTAVYYCARDYDYDVG MDYWGQGLVTVSS ASTKGPSVFPLAP EVQLVESG GGLVQPGGSLRLSCAASGFTISDYWIHWVRQAPGK GLEWVAGITPAGGYTYADSVKGRFTISADTSKNT AYLQMNSLRAEDTAVYYCARFVFFLPYAMDYWGQG TLVTVSS
428	DVD449L	AB069	AB070	DIVMTQSPDSLAVSLGERATISCRASESDNYGIS FMKWFQQKPGQPPKLLIYAASNQGSVDRFSGSG SGTDFTLTISLQAEADVAVYYCQQSKEVPWTFGGG TKVEIKR TVAAPSVFIFPP DIQMTQSPSSLSASVG DRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSA SFLYSGVPSRFSGSGSGTDFTLTISLQPEDFATY YCQQSYTTPPTFGQGTKVEIKR
429	DVD450H	AB070	AB069	EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIH WVRQAPGKGLEWVAGITPAGGYTYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPY AMDYWGQGLVTVSS ASTKGPSVFPLAP QVQLVQS GAEVKKPGASVKISCKASGYSFTAYYIHWVKQAPG QGLEWIGYISSYNGATNYNQKFKGRVTFTTDTSTS TAYMELRSLRSDDTAVYYCARDYDYDVGMDYWGQG TLVTVSS
430	DVD450L	AB070	AB069	DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAW YQQKPGKAPKLLIYASFLYSGVPSRFSGSGSGTD FTLTISLQPEDFATYYCQQSYTTPPTFGQGTKVE IKR TVAAPSVFIFPP DIVMTQSPDSLAVSLGERAT ISCRASESDNYGISFMKWFQQKPGQPPKLLIYAA SNQGSVDRFSGSGSGTDFTLTISLQAEADVAVY YCQQSKEVPWTFGGGTKVEIKR

Example 2.84: Generation of VEGF (seq. 2) and DLL4 (seq. 2) DVD-Igs with Linker Set 3

Table 116

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
431	DVD455H	AB069	AB070	QVQLVQSGAEVKKPGASVKISCKASGYSFTAYYIH WVKQAPGQGLEWIGYISSYNGATNYNQKFKGRVTF TTDTSTSTAYMELRSLRSDDTAVYYCARDYDYDVG MDYWGQGLVTVSS ASTKGPSVFPLAP EVQLVESG GGLVQPGGSLRLSCAASGFTISDYWIHWVRQAPGK GLEWVAGITPAGGYTYADSVKGRFTISADTSKNT AYLQMNSLRAEDTAVYYCARFVFFLPYAMDYWGQG TLVTVSS
432	DVD455L	AB069	AB070	DIVMTQSPDSLAVSLGERATISCRASESDNYGIS FMKWFQQKPGQPPKLLIYAASNQSGVDRFSGSG SGTDFTLTISLQAEDVAVYYCQQSKEVPWTFGGG TKVEIKR TVAAP DIQMTQSPSSLSASVGRVTITC RASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGV PSRFGSGSGTDFTLTISLQPEDFATYYCQQSYT TPPTFGQGTKVEIKR
433	DVD456H	AB070	AB069	EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIH WVRQAPGKGLEWVAGITPAGGYTYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPY AMDYWGQGLVTVSS ASTKGPSVFPLAP QVQLVQS GAEVKKPGASVKISCKASGYSFTAYYIHWKQAPG QGLEWIGYISSYNGATNYNQKFKGRVTFTTDTSTS TAYMELRSLRSDDTAVYYCARDYDYDVGMDYWGQG TLVTVSS
434	DVD456L	AB070	AB069	DIQMTQSPSSLSASVGRVTITCRASQDVSTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFGSGSGTD FTLTISLQPEDFATYYCQQSYTTPPTFGQGTKVE IKR TVAAP DIVMTQSPDSLAVSLGERATISCRASE SDNYGISFMKWFQQKPGQPPKLLIYAASNQSGV PDRFSGSGSGTDFTLTISLQAEDVAVYYCQQSKE VPWTFGGGTKVEIKR

Example 2.85: Generation of VEGF (seq. 2) and DLL4 (seq. 2) DVD-Igs with Linker Set 4

Table 117

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
435	DVD461H	AB069	AB070	QVQLVQSGAEVKKKPGASVKISCKASGYSFTAYYIH WVKQAPGQGLEWIGYISSYNGATNYNQKFKGRVTF TTDTSTSTAYMELRSLRSDDTAVYYCARDYDYG MDYWGQGLVTVSS ASTKGP EVQLVESGGGLVQPG GSLRLSCAASGFTISDYWIHWVRQAPGKLEWVAG ITPAGGYTYADSVKGRFTISADTSKNTAYLQMNS LRAEDTAVYYCARFVFFLPYAMDYWGQGLVTVSS
436	DVD461L	AB069	AB070	DIVMTQSPDSLAVSLGERATISCRASESDNYGIS FMKWFQKPGQPPKLLIYAASNQSGVDRFSGSG SGTDFTLTISLQAEADVAVYYCQQSKEVPWTFGGG TKVEIKR TVAAPSVFI FPDIQMTQSPSSLSASVG DRVTITCRASQDVSTAVAWYQKPGKAPKLLIYSA SFLYSGVPSRFSGSGSGTDFTLTISLQPEDFATY YCQQSYTTPPTFGQGTKVEIKR
437	DVD462H	AB070	AB069	EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIH WVRQAPGKLEWVAGITPAGGYTYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPY AMDYWGQGLVTVSS ASTKGP QVQLVQSGAEVKKP GASVKISCKASGYSFTAYYIHWKQAPGQGLEWIG YISSYNGATNYNQKFKGRVTFDTSTSTAYMELR SLRSDDTAVYYCARDYDYGMDYWGQGLVTVSS
438	DVD462L	AB070	AB069	DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAW YQKPGKAPKLLIYASFLYSGVPSRFSGSGSGTD FTLTISLQPEDFATYICQQSYTTPPTFGQGTKVE IKR TVAAPSVFI FPDIQMTQSPDSLAVSLGERAT ISCRASESDNYGISFMKWFQKPGQPPKLLIYAA SNQSGVDRFSGSGSGTDFTLTISLQAEADVAVY YCQQSKEVPWTFGGGTKVEIKR

Example 2.86: Generation of VEGF (seq. 3) and DLL4 (seq. 2) DVD-Igs with Linker Set 1

Table 118

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
439	DVD445H	AB069	AB071	QVQLVQSGAEVKKPGASVKISCKASGYSFTAYYIH WVKQAPGQGLEWIGYISSYNGATNYNQKFKGRVTF TTDTSTSTAYMELRSLRSDDTAVYYCARDYDYG MDYWGQGLVTVVSS ASTKGP EVQLVESGGGLVQPG GSLRLSCAASGFTINASWIHWVRQAPGKGLEWVGA IYPYSGYTNADSVKGRFTISADTSKNTAYLQMNS LRAEDTAVYYCARWGHSTSPWAMDYWGQGLVTVS S
440	DVD445L	AB069	AB071	DIVMTQSPDSLAVSLGERATISCRASESDNYGIS FMKWFQQKPGQPPKLLIYAASNQSGVDRFSGSG SGTDFTLTISLQAEDVAVYYCQQSKEVPWTFGGG TKVEIKR TVAAP DIQMTQSPSSLSASVGRVTITC RASQVIRRLAWYQQKPGKAPKLLIYAASNLAGV PSRFGSGSGTDFTLTISLQPEDFATYYCQQSNT SPLTFGGQGTKVEIKR
441	DVD446H	AB071	AB069	EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIH WVRQAPGKGLEWGA IYPYSGYTNADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSP WAMDYWGQGLVTVVSS ASTKGP QVQLVQSGAEVKK PGASVKISCKASGYSFTAYYIHWVKQAPGQGLEWI GYISSYNGATNYNQKFKGRVTF TTDTSTSTAYMEL RSLRSDDTAVYYCARDYDYGMDYWGQGLVTVS S
442	DVD446L	AB071	AB069	DIQMTQSPSSLSASVGRVTITCRASQVIRRLAW YQQKPGKAPKLLIYAASNLAGVPSRFGSGSGTD FTLTISLQPEDFATYYCQQSNTSPLTFGGQGTKVE IKR TVAAP DIVMTQSPDSLAVSLGERATISCRASE SDNYGISFMKWFQQKPGQPPKLLIYAASNQSGV PDRFSGSGSGTDFTLTISLQAEDVAVYYCQQSKE VPWTFGGGQGTKVEIKR

Example 2.87: Generation of VEGF (seq. 3) and DLL4 (seq. 2) DVD-Igs with Linker Set 2

Table 119

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
443	DVD451H	AB069	AB071	QVQLVQSGAEVKKPGASVKISCKASGYSFTAYYIH WVKQAPGQGLEWIGYISSYNGATNYNQKFKGRVTF TTDTSTSTAYMELRSLRSDDTAVYYCARDYDYDVG MDYWGQGLTVTVSS ASTKGPSVFPLAP EVQLVESG GGLVQPGGSLRLSCAASGFTINASWIHWVRQAPGK GLEWVGAIYPYSGYTNYADSVKGRFTISADTSKNT AYLQMNSLRAEDTAVYYCARWGHSTSPWAMDYWGQ GTLTVTVSS
444	DVD451L	AB069	AB071	DIVMTQSPDSLAVSLGERATISCRASESDNYGIS FMKWFQQKPGQPPKLLIYAASNQGSVDRFSGSG SGTDFTLTISLQAEDVAVYYCQQSKEVPWTFGGG TKVEIKR TVAAPSVFI FPDIQMTQSPSSLSASVG DRVTITCRASQVIRRLAWYQQKPGKAPKLLIYAA SNLASGVPSRFSGSGSGTDFTLTISLQPEDFATY YCQQSNTSPLTFGQGTKVEIKR
445	DVD452H	AB071	AB069	EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIH WVRQAPGKGLEWVGAIYPYSGYTNYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSP WAMDYWGQGLTVTVSS ASTKGPSVFPLAP QVQLVQ SGAEVKKPGASVKISCKASGYSFTAYYIHWVKQAP GQGLEWIGYISSYNGATNYNQKFKGRVTFTTDTST STAYMELRSLRSDDTAVYYCARDYDYDVGMDYWGQ GTLTVTVSS
446	DVD452L	AB071	AB069	DIQMTQSPSSLSASVGRVTITCRASQVIRRLAW YQQKPGKAPKLLIYAASNLASGVPSRFSGSGSGTD FTLTISLQPEDFATYICQQSNTSPLTFGQGTKVE IKR TVAAPSVFI FPDIQMTQSPDSLAVSLGERAT ISCRASESDNYGISFMKWFQQKPGQPPKLLIYAA SNQGSVDRFSGSGSGTDFTLTISLQAEDVAVY YCQQSKEVPWTFGGGTKVEIKR

Example 2.88: Generation of VEGF (seq. 3) and DLL4 (seq. 2) DVD-Igs with Linker Set 3

Table 120

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
447	DVD457H	AB069	AB071	QVQLVQSGAEVKKPGASVKISCKASGYSFTAYYIH WVKQAPGQGLEWIGYISSYNGATNYNQKFKGRVTF TTDTSTSTAYMELRSLRSDDTAVYYCARDYDYDVG MDYWGQGLVTVSS ASTKGPSVFPLAP EVQLVESG GGLVQPGGSLRLSCAASGFTINASWIHWVRQAPGK GLEWVGAIYPYSGYTNYADSVKGRFTISADTSKNT AYLQMNSLRAEDTAVYYCARWGHSTSPWAMDYWGQ GTLVTVSS
448	DVD457L	AB069	AB071	DIVMTQSPDSLAVSLGERATISCRASESDNYGIS FMKWFQQKPGQPPKLLIYAASNQSGVDRFSGSG SGTDFTLTISSLQAEDVAVYYCQQSKEVPWTFGGG TKVEIKR TVAAPD IQMTQSPSSLSASVGRVTITC RASQVIRRLAWYQQKPGKAPKLLIYAASNLAGV PSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNT SPLTFGGGTKEIKR
449	DVD458H	AB071	AB069	EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIH WVRQAPGKGLEWVGAIYPYSGYTNYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSP WAMDYWGQGLVTVSS ASTKGPSVFPLAP QVQLVQ SGAEVKKPGASVKISCKASGYSFTAYYIHWVKQAP GQGLEWIGYISSYNGATNYNQKFKGRVTFTTDTST STAYMELRSLRSDDTAVYYCARDYDYDVGMDYWGQ GTLVTVSS
450	DVD458L	AB071	AB069	DIQMTQSPSSLSASVGRVTITCRASQVIRRLAW YQQKPGKAPKLLIYAASNLAGVPSRFSGSGSGTD FTLTISSLQPEDFATYYCQQSNTSPLTFGGGTKEI IKR TVAAP DIVMTQSPDSLAVSLGERATISCRASE SDNYGISFMKWFQQKPGQPPKLLIYAASNQSGV PDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKE VPWTFGGGTKEIKR

Example 2.89: Generation of VEGF (seq. 3) and DLL4 (seq. 2) DVD-Igs with Linker Set 4

Table 121

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
451	DVD463H	AB069	AB071	QVQLVQSGAEVKKPGASVKISCKASGYSTAYYIH WVKQAPGQGLEWIGYISSYNGATNYNQKFKGRVTF TTDTSTSTAYMELRSLRSDDTAVYYCARDYDYG MDYWGQGLVTVSS ASTKGP EVQLVESGGGLVQPG GSLRLSCAASGFTINASWIHWVRQAPGKLEWVGA IYPYSGYTNADSVKGRFTISADTSKNTAYLQMNS LRAEDTAVYYCARWGHSTSPWAMDYWGQGLVTVS S
452	DVD463L	AB069	AB071	DIVMTQSPDSLAVSLGERATISCRASEVDNYGIS FMKWFQKPGQPPKLLIYAASNQGSVDRFSGSG SGTDFTLTISLQAEADVAVYYCQQSKEVPWTFGGG TKVEIKR TVAAPSVFIFPP DIQMTQSPSSLSASV DRVTITCRASQVIRRLAWYQQKPGKAPKLLIYAA SNLASGVPSRFSGSGSGTDFTLTISLQPEDFATY YCQQSNTSPLTFGQGTKVEIKR
453	DVD464H	AB071	AB069	EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIH WVRQAPGKLEWGA IYPYSGYTNADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSP WAMDYWGQGLVTVSS ASTKGP QVQLVQSGAEVKK PGASVKISCKASGYSTAYYIHWVKQAPGQGLEWI GYISSYNGATNYNQKFKGRVTFDTSTSTAYMEL RSLRSDDTAVYYCARDYDYGMDYWGQGLVTVS S
454	DVD464L	AB071	AB069	DIQMTQSPSSLSASVDRVTITCRASQVIRRLAW YQQKPGKAPKLLIYAASNLASGVPSRFSGSGSGTD FTLTISLQPEDFATY YCQQSNTSPLTFGQGTKVE IKR TVAAPSVFIFPP DIVMTQSPDSLAVSLGERAT ISCRASEVDNYGISFMKWFQKPGQPPKLLIYAA SNQGSVDRFSGSGSGTDFTLTISLQAEADVAVY YCQQSKEVPWTFGGGTKVEIKR

Example 2.90: Generation of VEGF (seq. 2) and DLL4 (seq. 1) DVD-Igs with Linker Set 1

Table 122

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
455	DVD465H	AB015	AB070	EVQLVESGGGLVQPGGSLRLSCAASGFTFTDNWIS WVRQAPGKGLEWVGYSIPNSGFTYYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARDNFGGYF DYWGQGTTLVTVSS ASTKGPEV QLVESGGGLVQPGG SLRLSCAASGFTISDYWIHWVRQAPGKGLEWVAGI TPAGGYTYADSVKGRFTISADTSKNTAYLQMNSL RAEDTAVYYCARVFFFLPYAMDYWGQGTTLVTVSS
456	DVD465L	AB015	AB070	DIQMTQSPSSLSASVGDRTITCRASQDVSTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTD FTLTISLQPEDFATYYCQQSYTGTVTFGQGTKV EIKR TVAAP DIQMTQSPSSLSASVGDRTITCRAS QDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSR FSGSGSGTDFTLTISLQPEDFATYYCQQSYTTPP TFGQGTKVEIKR
457	DVD466H	AB070	AB015	EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIH WVRQAPGKGLEWVAGITPAGGYTYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARVFFFLPY AMDYWGQGTTLVTVSS ASTKGPEV QLVESGGGLVQ GGSLRLSCAASGFTFTDNWISWVRQAPGKGLEWVG YISIPNSGFTYYADSVKGRFTISADTSKNTAYLQMN SLRAEDTAVYYCARDNFGGYFDYWGQGTTLVTVSS
458	DVD466L	AB070	AB015	DIQMTQSPSSLSASVGDRTITCRASQDVSTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTD FTLTISLQPEDFATYYCQQSYTTPPTFGQGTKVE IKR TVAAP DIQMTQSPSSLSASVGDRTITCRASQ DVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRF SGSGSGTDFTLTISLQPEDFATYYCQQSYTGTV TFGQGTKVEIKR

Example 2.91: Generation of VEGF (seq. 2) and DLL4 (seq. 1) DVD-Igs with Linker Set 2

Table 123

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
459	DVD471H	AB015	AB070	EVQLVESGGGLVQPGGSLRLSCAASGFTFTDNWISWVRQAPGKGLEWVGYISPNNGFTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDNFGGYFDYWGQGT LVTVSS ASTKGPSVFPLAP EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIHWVRQAPGKGLEWVAGITPAGGYTYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPYAMDYWGQGT LVTVSS
460	DVD471L	AB015	AB070	DIQMTQSPSSLSASVGDRTVITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQSYTGTVTFTFGQGTKVEIKR TVAAPSVFIFPP DIQMTQSPSSLSASVGDRTVITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQSYTTPPTFGQGTKVEIKR
461	DVD472H	AB070	AB015	EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIHWVRQAPGKGLEWVAGITPAGGYTYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPYAMDYWGQGT LVTVSS ASTKGPSVFPLAP EVQLVESGGGLVQPGGSLRLSCAASGFTFTDNWISWVRQAPGKGLEWVGYISPNNGFTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDNFGGYFDYWGQGT LVTVSS
462	DVD472L	AB070	AB015	DIQMTQSPSSLSASVGDRTVITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQSYTGTVTFTFGQGTKVEIKR TVAAPSVFIFPP DIQMTQSPSSLSASVGDRTVITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQSYTGTVTFTFGQGTKVEIKR

Example 2.92: Generation of VEGF (seq. 2) and DLL4 (seq. 1) DVD-Igs with Linker Set 3

Table 125

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
463	DVD477H	AB015	AB070	EVQLVESGGGLVQPGGSLRLSCAASGFTFTDNWISWVRQAPGKGLEWVGYISPNNGFTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDNFGGYFDYWGQGT LVTVSS ASTKGPSVFPLAP EVQLVESGGLVQPGGSLRLSCAASGFTISDYWIHWVRQAPGKGLEWVAGITPAGGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPYAMDYWGQGT LVTVSS
464	DVD477L	AB015	AB070	DIQMTQSPSSLSASVGDRTVITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFYLYSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQSYTGTVTFTFGQGTKVEIKR TVAAP DIQMTQSPSSLSASVGDRTVITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFYLYSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQSYTTPPTFGQGTKVEIKR
465	DVD478H	AB070	AB015	EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIHWVRQAPGKGLEWVAGITPAGGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPYAMDYWGQGT LVTVSS ASTKGPSVFPLAP EVQLVESGGGLVQPGGSLRLSCAASGFTFTDNWISWVRQAPGKGLEWVGYISPNNGFTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDNFGGYFDYWGQGT LVTVSS
466	DVD478L	AB070	AB015	DIQMTQSPSSLSASVGDRTVITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFYLYSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQSYTTPPTFGQGTKVEIKR TVAAP DIQMTQSPSSLSASVGDRTVITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFYLYSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQSYTGTVFTFGQGTKVEIKR

Example 2.93: Generation of VEGF (seq. 2) and DLL4 (seq. 1) DVD-Igs with Linker Set 4

Table 126

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
467	DVD483H	AB015	AB070	EVQLVESGGGLVQPGGSLRLSCAASGFTFTDNWIS WVRQAPGKGLEWVGYISPNNGFTYYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARDNFGGYF DYWGQGTTLVTVSS ASTKGPEVQLVESGGGLVQPGG SLRLSCAASGFTISDYWIHWVRQAPGKGLEWVAGI TPAGGYTYADSVKGRFTISADTSKNTAYLQMNSL RAEDTAVYYCARVFFFLPYAMDYWGQGTTLVTVSS
468	DVD483L	AB015	AB070	DIQMTQSPSSLSASVGDRTITCRASQDVSTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFRSGSGGTD FTLTISLQPEDFATYYCQSYTGTVTFGQGTKV EIKR TVAAPSVFIFPP DIQMTQSPSSLSASVGDRT TITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFL YSGVPSRFRSGSGGTDFTLTISLQPEDFATYYCQ QSYTTPPTFGQGTKVEIKR
469	DVD484H	AB070	AB015	EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIH WVRQAPGKGLEWVAGITPAGGYTYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARVFFFLPY AMDYWGQGTTLVTVSS ASTKGPEVQLVESGGGLVQPG GGSLRLSCAASGFTFTDNWISWVRQAPGKGLEWV YISPNNGFTYYADSVKGRFTISADTSKNTAYLQMN SLRAEDTAVYYCARDNFGGYFDYWGQGTTLVTVSS
470	DVD484L	AB070	AB015	DIQMTQSPSSLSASVGDRTITCRASQDVSTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFRSGSGGTD FTLTISLQPEDFATYYCQSYTTPPTFGQGTKVE IKR TVAAPSVFIFPP DIQMTQSPSSLSASVGDRT ITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLY SGVPSRFRSGSGGTDFTLTISLQPEDFATYYCQ QSYTGTVTFGQGTKVEIKR

Example 2.94: Generation of VEGF (seq. 3) and DLL4 (seq. 1) DVD-Igs with Linker Set 1

Table 127

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
471	DVD467H	AB015	AB071	EVQLVESGGGLVQPGGSLRLSCAASGFTFTDNWIS WVRQAPGKGLEWVGAIYSPNSGFTYYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARDNFGGYF DYWGQGTLLVTVSS ASTKGPE VQLVESGGGLVQPGG SLRLSCAASGFTINASWIHWVRQAPGKGLEWVGAI YPYSGYTNYADSVKGRFTISADTSKNTAYLQMNSL RAEDTAVYYCARWGHSTSPWAMDYWGQGTLLVTVSS
472	DVD467L	AB015	AB071	DIQMTQSPSSLSASVGDRTITCRASQDVSTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTD FTLTISLQPEDFATYYCQQSYTGTVTFGQGTKV EIKR TVAAP DIQMTQSPSSLSASVGDRTITCRAS QVIRRLAWYQQKPGKAPKLLIYAASNLASGVPSR FSGSGSGTDFTLTISLQPEDFATYYCQQSNTSPL TFGQGTKVEIKR
473	DVD468H	AB071	AB015	EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIH WVRQAPGKGLEWVGAIYPYSGYTNYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSP WAMDYWGQGTLLVTVSS ASTKGPE VQLVESGGGLVQ PGGSLRLSCAASGFTFTDNWISWVRQAPGKGLEWV GYISPNSTGFTYYADSVKGRFTISADTSKNTAYLQM NSLRAEDTAVYYCARDNFGGYFDYWGQGTLLVTVSS
474	DVD468L	AB071	AB015	DIQMTQSPSSLSASVGDRTITCRASQVIRRLAW YQQKPGKAPKLLIYAASNLASGVPSRFSGSGSGTD FTLTISLQPEDFATYYCQQSNTSPLTFGQGTKVE IKR TVAAP DIQMTQSPSSLSASVGDRTITCRASQ DVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRF SGSGSGTDFTLTISLQPEDFATYYCQQSYTGTV TFGQGTKVEIKR

Example 2.95: Generation of VEGF (seq. 3) and DLL4 (seq. 1) DVD-Igs with Linker Set 2

Table 128

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
475	DVD473H	AB015	AB071	EVQLVESGGGLVQPGGSLRLSCAASGFTFTDNWIS WVRQAPGKGLEWVGYSIPNSGFTYYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARDNFGGYF DYWGQGTLLVTVSS ASTKGPSVFPLAP EVQLVESGG GLVQPGGSLRLSCAASGFTINASWIHWVRQAPGKG LEWVGAIYPYSGYTNADSVKGRFTISADTSKNTA YLQMNSLRAEDTAVYYCARWGHSTSPWAMDYWGQG TLTVSS
476	DVD473L	AB015	AB071	DIQMTQSPSSLSASVGDRTITCRASQDVSTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFRSGSGGTD FTLTISLQPEDFATYYCQQSYTGTVTFGQGTKV EIKR TVAAPSVFIFPP DIQMTQSPSSLSASVGDRT TITCRASQVIRRLAWYQQKPGKAPKLLIYAASNL ASGVPSRFRSGSGGTDFTLTISLQPEDFATYYCQ QSNTSPLTFGQGTKVEIKR
477	DVD474H	AB071	AB015	EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIH WVRQAPGKGLEWVGAIYPYSGYTNADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSP WAMDYWGQGTLLVTVSS ASTKGPSVFPLAP EVQLVE SGGGLVQPGGSLRLSCAASGFTFTDNWISWVRQAP GKGLEWVGYSIPNSGFTYYADSVKGRFTISADTSK NTAYLQMNSLRAEDTAVYYCARDNFGGYFDYWGQG TLTVSS
478	DVD474L	AB071	AB015	DIQMTQSPSSLSASVGDRTITCRASQVIRRLAW YQQKPGKAPKLLIYAASNLASGVPSRFRSGSGGTD FTLTISLQPEDFATYYCQSNTSPLTFGQGTKVE IKR TVAAPSVFIFPP DIQMTQSPSSLSASVGDRT ITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLY SGVPSRFRSGSGGTDFTLTISLQPEDFATYYCQ QSYTGTVTFGQGTKVEIKR

Example 2.96: Generation of VEGF (seq. 3) and DLL4 (seq. 1) DVD-Igs with Linker Set 3

Table 129

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
479	DVD479H	AB015	AB071	EVQLVESGGGLVQPGGSLRLSCAASGFTFTDNWIS WVRQAPGKGLEWVGYSVNSGFTYYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARDNFGGYF DYWGQGTTLVTVSS ASTKGPSVFPLAP EVQLVESGG GLVQPGGSLRLSCAASGFTINASWIHWVRQAPGKG LEWVGAIYPYSGYTNYADSVKGRFTISADTSKNTA YLQMNSLRAEDTAVYYCARWGHSTSPWAMDYWGQG TLVTVSS
480	DVD479L	AB015	AB071	DIQMTQSPSSLSASVGDRTVITCRASQDVSTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTD FTLTISSLQPEDFATYYCQQSYTGTVTFGQGTKV EIKR TVAAP DIQMTQSPSSLSASVGDRTVITCRAS QVIRRLAWYQQKPGKAPKLLIYAASNLAGVPSR FSGSGSGTDFTLTISSLQPEDFATYYCQQSNTSPL TFGQGTKVEIKR
481	DVD480H	AB071	AB015	EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIH WVRQAPGKGLEWVGAIYPYSGYTNYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSP WAMDYWGQGTTLVTVSS ASTKGPSVFPLAP EVQLVE SGGGLVQPGGSLRLSCAASGFTFTDNWISWVRQAP GKGLEWVGYSVNSGFTYYADSVKGRFTISADTSK NTAYLQMNSLRAEDTAVYYCARDNFGGYFDYWGQG TLVTVSS
482	DVD480L	AB071	AB015	DIQMTQSPSSLSASVGDRTVITCRASQVIRRLAW YQQKPGKAPKLLIYAASNLAGVPSRFSGSGSGTD FTLTISSLQPEDFATYYCQQSNTSPLTFGQGTKVE IKR TVAAP DIQMTQSPSSLSASVGDRTVITCRASQ DVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRF SGSGSGTDFTLTISSLQPEDFATYYCQQSYTGTV TFGQGTKVEIKR

Example 2.97: Generation of VEGF (seq. 3) and DLL4 (seq. 1) DVD-Igs with Linker Set 4

Table 130

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
483	DVD485H	AB015	AB071	EVQLVESGGGLVQPGGSLRLSCAASGFTFTDNWIS WVRQAPGKGLEWVGAIYISPNVSGFTYYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARDNFGGYF DYWGQGTLLVTVSS ASTKGPE EVQLVESGGGLVQPGG SLRLSCAASGFTINASWIHWVRQAPGKGLEWVGAI YPYSGYTNVADSVKGRFTISADTSKNTAYLQMNSL RAEDTAVYYCARWGHSTSPWAMDYWGQGTLLVTVSS
484	DVD485L	AB015	AB071	DIQMTQSPSSLSASVGDRTITCRASQDVSTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFRSGSGSGTD FTLTISLQPEDFATYYCQSYTGTVTFGQGTKV EIKR TVAAPSVFIFPP DIQMTQSPSSLSASVGDRT TITCRASQVIRRLAWYQQKPGKAPKLLIYAASNL ASGVPSRFRSGSGSGTDFTLTISLQPEDFATYYCQ QSNTSPLTFGQGTKVEIKR
485	DVD486H	AB071	AB015	EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIH WVRQAPGKGLEWVGAIYPYSGYTNVADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSP WAMDYWGQGTLLVTVSS ASTKGPE EVQLVESGGGLVQ PGGSLRLSCAASGFTFTDNWISWVRQAPGKGLEWV GYISPNVSGFTYYADSVKGRFTISADTSKNTAYLQM NSLRAEDTAVYYCARDNFGGYFDYWGQGTLLVTVSS
486	DVD486L	AB071	AB015	DIQMTQSPSSLSASVGDRTITCRASQVIRRLAW YQQKPGKAPKLLIYAASNLASGVPSRFRSGSGSGTD FTLTISLQPEDFATYYCQSQNTSPLTFGQGTKVE IKR TVAAPSVFIFPP DIQMTQSPSSLSASVGDRT ITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLY SGVPSRFRSGSGSGTDFTLTISLQPEDFATYYCQ QSYTGTVTFGQGTKVEIKR

Example 2.98: Generation of VEGF (seq. 1) and DLL4 (seq. 1) DVD-Igs with Linker Set 1

Table 131

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
487	DVD469H	AB015	AB014	EVQLVESGGGLVQPGGSLRLSCAASGFTFTDNWIS WVRQAPGKGLEWVGYSIPNSGFTYYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARDNFGGYF DYWGQGTLLVTVSS ASTKGPSVFPLAPEVQLVESGG GLVQPGGSLRLSCAASGYFTFTNYGMNWVRQAPGKG LEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTA YLQMNSLRAEDTAVYYCAKYPHYYGSSHWFVWVG QGTLLVTVSS
488	DVD469L	AB015	AB014	DIQMTQSPSSLSASVGDRTVITCRASQDVSTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFRSGSGSGTD FTLTISLQPEDFATYYCQQSYTGTVTFTFGQGTKV EIKR TVAAPSVFIFPP DIQMTQSPSSLSASVGDRTV TITCSASQDISNYLNWYQQKPGKAPKVLIIYFTSSL HSGVPSRFRSGSGSGTDFTLTISLQPEDFATYYCQ QYSTVPWTFGQGTKVEIKR
489	DVD470H	AB014	AB015	EVQLVESGGGLVQPGGSLRLSCAASGYFTFTNYGMN WVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTF SLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYS SHWYFDVWVGQGTLLVTVSS ASTKGPSVFPLAPEVQL VESGGGLVQPGGSLRLSCAASGFTFTDNWISWVRQ APGKGLEWVGYSIPNSGFTYYADSVKGRFTISADT SKNTAYLQMNSLRAEDTAVYYCARDNFGGYFDYWG QGTLLVTVSS
490	DVD470L	AB014	AB015	DIQMTQSPSSLSASVGDRTVITCSASQDISNYLNW YQQKPGKAPKVLIIYFTSSLHSGVPSRFRSGSGSGTD FTLTISLQPEDFATYYCQQYSTVPWTFGQGTKVE IKR TVAAPSVFIFPP DIQMTQSPSSLSASVGDRTV ITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLY SGVPSRFRSGSGSGTDFTLTISLQPEDFATYYCQ QSYTGTVTFTFGQGTKVEIKR

Example 2.99: Generation of VEGF (seq. 1) and DLL4 (seq. 1) DVD-Igs with Linker Set 2

Table 132

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
491	DVD475H	AB015	AB014	EVQLVESGGGLVQPGGSLRLSCAASGFTFTDNWIS WVRQAPGKGLEWVGYSIPNSGFTYYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARDNFGGYF DYWGQGTLLVTVSS ASTKGPSVFPLAPEVQLVESGG GLVQPGGSLRLSCAASGYFTFTNYGMNWVRQAPGKG LEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTA YLQMNSLRAEDTAVYYCAKYPHYYGSSHWFVWVG QGTLLVTVSS
492	DVD475L	AB015	AB014	DIQMTQSPSSLSASVGDRTVITCRASQDVSTAVAW YQQKPGKAPKLLIYSASFYSGVPSRFSGSGSGTD FTLTISSLQPEDFATYYCQQSYTGTVTFGQGTKV EIKR TVAAP DIQMTQSPSSLSASVGDRTVITCSAS QDISNYLNWYQQKPGKAPKVLIIYFTSSLHSGVPSR FSGSGSGTDFTLTISSLQPEDFATYYCQYSTVPW TFGQGTKVEIKR
493	DVD476H	AB014	AB015	EVQLVESGGGLVQPGGSLRLSCAASGYFTFTNYGMN WVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTF SLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYS SHWYFDVWVGQGTLLVTVSS ASTKGPSVFPLAPEVQL VESGGGLVQPGGSLRLSCAASGFTFTDNWISWVRQ APGKGLEWVGYSIPNSGFTYYADSVKGRFTISADT SKNTAYLQMNSLRAEDTAVYYCARDNFGGYFDYWG QGTLLVTVSS
494	DVD476L	AB014	AB015	DIQMTQSPSSLSASVGDRTVITCSASQDISNYLNW YQQKPGKAPKVLIIYFTSSLHSGVPSRFSGSGSGTD FTLTISSLQPEDFATYYCQYSTVPWTFGQGTKVE IKR TVAAP DIQMTQSPSSLSASVGDRTVITCRASQ DVSTAVAWYQQKPGKAPKLLIYSASFYSGVPSRF SGSGSGTDFTLTISSLQPEDFATYYCQSYTGTV TFGQGTKVEIKR

Example 2.100: Generation of VEGF (seq. 1) and DLL4 (seq. 1) DVD-Igs with Linker Set 3

Table 133

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
495	DVD481H	AB015	AB014	EVQLVESGGGLVQPGGSLRLSCAASGFTFTDNWIS WVRQAPGKGLEWVGYSIPNSGFTYYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARDNFGGYF DYWGQGTLLVTVSS ASTKGP EVQLVESGGGLVQPGG SLRLSCAASGYFTFTNYGMNWVRQAPGKGLEWVGWI NTYTGEPTYAAAFKRRFTFSLDTSKSTAYLQMNSL RAEDTAVYYCAKYPHYHGGSSHWYFDVWGQGTLLVTV SS
496	DVD481L	AB015	AB014	DIQMTQSPSSLSASVGDRTVITCRASQDVSTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTD FTLTISSLQPEDFATYYCQQSYTGTVTFTFGQGTKV EIKR TVAAPSVFIFPP DIQMTQSPSSLSASVGDRTV TITCSASQDISNYLNWYQQKPGKAPKVLIIYFTSSL HSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQ QYSTVPWTFGQGTKVEIKR
497	DVD482H	AB014	AB015	EVQLVESGGGLVQPGGSLRLSCAASGYFTFTNYGMN WVRQAPGKGLEWVGWINTYTGEPTYAAAFKRRFTF SLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYHGS SHWYFDVWGQGTLLVTVSS ASTKGP EVQLVESGGGL VQPGGSLRLSCAASGFTFTDNWISWVRQAPGKGLE WVGYSIPNSGFTYYADSVKGRFTISADTSKNTAYL QMNSLRAEDTAVYYCARDNFGGYFDYWGQGTLLVTV SS
498	DVD482L	AB014	AB015	DIQMTQSPSSLSASVGDRTVITCRASQDISNYLNW YQQKPGKAPKVLIIYFTSSLHSGVPSRFSGSGSGTD FTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVE IKR TVAAPSVFIFPP DIQMTQSPSSLSASVGDRTV ITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLY SGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQ QSYTGTVTFTFGQGTKVEIKR

Example 2.101: Generation of VEGF (seq. 1) and DLL4 (seq. 3) DVD-Igs with Linker Set 1

Table 134

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
499	DVD487H	AB072	AB014	EVQLQQSGPELVKPGASVKMSCKASGYTFTSYVINWVKQKPGQGLEWIGLINPYNDGTYNEKFKVKATLTSKSSSTAYMELSSLTSEDSAVYYCASYYYGSRYYFDYWGQGTTLTVSS ASTKGPE VQLVESGGGLVQPGSLRLSCAASGYTFTNYGMNWRQAPGKGLEWGWINTYTGEPYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYGSSHWYFDVWGQGTTLVTVSS
500	DVD487L	AB072	AB014	DIQMTQSSSYLSVSLGGRVTITCKASDHINNLAWYQKPGNAPRLLISGATSLETGVPSRFSGSGSKDYTLISITSLQTEDVATYYCQYWSIPLTFGAGTKLELKR TVAAP DIQMTQSPSSLSASVGDRTITCSASQDISNYLNWYQKPGKAPKVLIIYFTSSLHSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQYSTVPWTFGQGTKVEIKR
501	DVD488H	AB014	AB072	EVQLVESGGGLVQPGSLRLSCAASGYTFTNYGMNWRQAPGKGLEWGWINTYTGEPYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYGSSHWYFDVWGQGTTLTVSS ASTKGPE VQLQQSGPELVKPGASVKMSCKASGYTFTSYVINWVKQKPGQGLEWIGLINPYNDGTYNEKFKVKATLTSKSSSTAYMELSSLTSEDSAVYYCASYYYGSRYYFDYWGQGTTLTVSS
502	DBD488L	AB014	AB072	DIQMTQSPSSLSASVGDRTITCSASQDISNYLNWYQKPGKAPKVLIIYFTSSLHSGVPSRFSGSGSKDYTLISITSLQTEDVATYYCQYWSIPLTFGAGTKLELKR TVAAP DIQMTQSSSYLSVSLGGRVTITCKASDHINNLAWYQKPGNAPRLLISGATSLETGVPSRFSGSGSKDYTLISITSLQTEDVATYYCQYWSIPLTFGAGTKLELKR

Example 2.102: Generation of VEGF (seq. 1) and DLL4 (seq. 3) DVD-Igs with Linker Set 2

Table 135

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
503	DVD493H	AB072	AB014	EVQLQQSGPELVKPGASVKMSCKASGYTFTSYVINWVKQKPGQGLEWIGLINPYNDGTYNEKFKVKATLTSKSSSTAYMELSSLTSEDSAVYYCASYYYGSRYYFDYWGQGTTLTVSS ASTKGPSVFPLAP EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYGSSHWYFDVWGQGTTLTVSS
504	DVD493L	AB072	AB014	DIQMTQSSSYLSVSLGGRVTITCKASDHINNWLAWYQKPGNAPRLLISGATSLETGVPSRFRSGSGSKDYTLTSLQTEDVATYYCQQYWSIPLTFGAGTKLELKR TVAAPSVFIFPP DIQMTQSPSSLSASVGRVITITCSASQDISNYLNWYQQKPGKAPKVLITYFTSSLHSGVPSRFRSGSGTDFTLTISLQPEDFATYYCQYSTVPWTFGQGTKVEIKR
505	DVD494H	AB014	AB072	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYGSSHWYFDVWGQGTTLTVSS ASTKGPSVFPLAP EVQLQQSGPELVKPGASVKMSCKASGYTFTSYVINWVKQKPGQGLEWIGLINPYNDGTYNEKFKVKATLTSKSSSTAYMELSSLTSEDSAVYYCASYYYGSRYYFDYWGQGTTLTVSS
506	DVD494L	AB014	AB072	DIQMTQSPSSLSASVGRVITITCSASQDISNYLNWYQKPGKAPKVLITYFTSSLHSGVPSRFRSGSGTDFTLTISLQPEDFATYYCQYSTVPWTFGQGTKVEIKR TVAAPSVFIFPP DIQMTQSSSYLSVSLGGRVTITCKASDHINNWLAWYQKPGNAPRLLISGATSLETGVPSRFRSGSGSKDYTLTSLQTEDVATYYCQYWSIPLTFGAGTKLELKR

Example 2.103: Generation of VEGF (seq. 1) and DLL4 (seq. 3) DVD-Igs with Linker Set 3

Table 136

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
507	DVD499H	AB072	AB014	EVQLQQSGPELVKPGASVKMSCKASGYTFTSYVINWVKQKPGQGLEWIGLINPYNDGTYNEKFKVKATLTSKSSSTAYMELSSLTSEDSAVYYCASYYYGSRYYFDYWGQGTTLTVSS ASTKGPSVFPLAP EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYGSSHWYFDVWGQGTTLTVSS
508	DVD499L	AB072	AB014	DIQMTQSSSYLSVSLGGRVTITCKASDHINNLAWYQQKPGNAPRLLISGATSLETGVPSRFSGSGSGDYTLSTSLQTEDVATYYCQYWSIPLTFGAGTKLELKR TVAAP DIQMTQSPSSLSASVGDRTITCSASQDISNYLNWYQQKPKAPKVLIIYFTSSLHSGVPSRFSGSGSGDTFTLTISSLQPEDFATYYCQYSTVPWTFGQGTKVEIKR
509	DVD500H	AB014	AB072	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYGSSHWYFDVWGQGTTLTVSS ASTKGPSVFPLAP EVQLQQSGPELVKPGASVKMSCKASGYTFTSYVINWVKQKPGQGLEWIGLINPYNDGTYNEKFKVKATLTSKSSSTAYMELSSLTSEDSAVYYCASYYYGSRYYFDYWGQGTTLTVSS
510	DVD500L	AB014	AB072	DIQMTQSPSSLSASVGDRTITCSASQDISNYLNWYQQKPKAPKVLIIYFTSSLHSGVPSRFSGSGSGDTFTLTISSLQPEDFATYYCQYSTVPWTFGQGTKVEIKR TVAAP DIQMTQSSSYLSVSLGGRVTITCKASDHINNLAWYQQKPGNAPRLLISGATSLETGVPSRFSGSGSGDYTLSTSLQTEDVATYYCQYWSIPLTFGAGTKLELKR

Example 2.104: Generation of VEGF (seq. 1) and DLL4 (seq. 3) DVD-Igs with Linker Set 4

Table 137

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
511	DVD505H	AB072	AB014	EVQLQQSGPELVKPGASVKMSCKASGYTFTSYVINWVKQKPGQGLEWIGLINPYNDGTYNEKFKVKATLTSKSSSTAYMELSSLTSEDSAVYYCASYYYGSRYYFDYWGQGTTLTVSS ASTKGPEVQLVESGGGLVQPGSLRSLCAASGYTFTNYGMNWRQAPGKGLEWVGVWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMN SLRAEDTAVYYCAKYPHYGSSHWYFDVWGQGTTLVTVSS
512	DVD505L	AB072	AB014	DIQMTQSSSYLSVSLGGRVTITCKASDHINNWLAWYQKPGNAPRLLISGATSLETGVPSRFRSGSGSKDYTLISITSLQTEDVATYYCQYWSIPLTFGAGTKLELKR TVAAPSVFIFPP DIQMTQSPSSLSASVGRVITITCSASQDISNYLNWYQKPGKAPKVLITYFTSSLHSGVPSRFRSGSGSDFTLTITSSLPEDFATYYCQYSTVPWTFGQGTKEIKR
513	DVD506H	AB014	AB072	EVQLVESGGGLVQPGSLRSLCAASGYTFTNYGMNWRQAPGKGLEWVGVWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMN SLRAEDTAVYYCAKYPHYGSSHWYFDVWGQGTTLTVSS ASTKGPEVQLQQSGPELVKPGASVKMSCKASGYTFTSYVINWVKQKPGQGLEWIGLINPYNDGTYNEKFKVKATLTSKSSSTAYMELSSLTSEDSAVYYCASYYYGSRYYFDYWGQGTTLTVSS
514	DVD506L	AB014	AB072	DIQMTQSPSSLSASVGRVITITCSASQDISNYLNWYQKPGKAPKVLITYFTSSLHSGVPSRFRSGSGSDFTLTITSSLPEDFATYYCQYSTVPWTFGQGTKEIKR TVAAPSVFIFPP DIQMTQSSSYLSVSLGGRVTITCKASDHINNWLAWYQKPGNAPRLLISGATSLETGVPSRFRSGSGSKDYTLISITSLQTEDVATYYCQYWSIPLTFGAGTKLELKR

Example 2.105: Generation of VEGF (seq. 2) and DLL4 (seq. 3) DVD-Igs with Linker Set 1

Table 138

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				123456789 0 123456789 0 123456789 0 12345
515	DVD489H	AB072	AB070	EVQLQQSGPELVKPGASVKMSCKASGYTFTSYVINWVKQKPGQGLEWIGLINPYNDGTYNEKFKVKATLTSKSSSTAYMELSSLTSEDSAVYYCASYYYGSRYFDYWGQGTTLTVSS ASTKGPEVQLVESGGGLVQPGSLRLSCAASGFTISDYWIHWVRQAPGKGLEWVA GITPAGGYTYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPYAMDYWGQGTTLTVSS
516	DVD489L	AB072	AB070	DIQMTQSSSYLSVSLGGRVTITCKASDHINNLAWYQKPGNAPRLLISGATSLETGVPSRFSGSGSKDYTLSTSLQTEDVATYYCQYWSIPLTFGAGTKLELKR TVAAP DIQMTQSPSSLSASVGDRTITCRASQDVSTAVAWYQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQSYTTPPTFGQGTKVEIKR
517	DVD490H	AB070	AB072	EVQLVESGGGLVQPGSLRLSCAASGFTISDYWIHWVRQAPGKGLEWVAGITPAGGYTYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPYAMDYWGQGTTLTVSS ASTKGPEVQLQQSGPELVKPGASVKMSCKASGYTFTSYVINWVKQKPGQGLEWIGLINPYNDGTYNEKFKVKATLTSKSSSTAYMELSSLTSEDSAVYYCASYYYGSRYFDYWGQGTTLTVSS
518	DVD490L	AB070	AB072	DIQMTQSPSSLSASVGDRTITCRASQDVSTAVAWYQKPGKAPKLLIYSASFLYSGVPSRFSGSGSKDYTLSTSLQTEDVATYYCQYWSIPLTFGAGTKLELKR TVAAP DIQMTQSSSYLSVSLGGRVTITCKASDHINNLAWYQKPGNAPRLLISGATSLETGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQSYTTPPTFGQGTKVEIKR

Example 2.106: Generation of VEGF (seq. 2) and DLL4 (seq. 3) DVD-Igs with Linker Set 2

Table 139

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
519	DVD495H	AB072	AB070	EVQLQQSGPELVKPGASVKMSCKASGYTFTSYVINWVKQKPGQGLEWIGLINPYNDGTYNEKFKVKATLTSDKSSSTAYMELSSLTSEDSAVYYCASYYYGSRYYFDYWGQGTTLTVSS ASTKGPSVFPLAP EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIHWVRQAPGKGLEWVAGITPAGGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPYAMDYWGQGTTLTVSS
520	DVD495L	AB072	AB070	DIQMTQSSSYLSVSLGGRVTITCKASDHINNWLAWYQKPGNAPRLLISGATSLETGVPSRFRSGSGSKDYTLSTLSITSLQTEDVATYYCQQYWSIPLTFGAGTKLELKR TVAAPSVFIFPP DIQMTQSPSSLSASVGRVITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFRSGSGSDFTLTITSSLPEDFATYYCQQSYTTPPTFGQGTKEIKR
521	DVD496H	AB070	AB072	EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIHWVRQAPGKGLEWVAGITPAGGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPYAMDYWGQGTTLTVSS ASTKGPSVFPLAP EVQLQQSGPELVKPGASVKMSCKASGYTFTSYVINWVKQKPGQGLEWIGLINPYNDGTYNEKFKVKATLTSDKSSSTAYMELSSLTSEDSAVYYCASYYYGSRYYFDYWGQGTTLTVSS
522	DVD496L	AB070	AB072	DIQMTQSPSSLSASVGRVITITCRASQDVSTAVAWYQKPGKAPKLLIYSASFLYSGVPSRFRSGSGSDFTLTITSSLPEDFATYYCQQSYTTPPTFGQGTKEIKR TVAAPSVFIFPP DIQMTQSSSYLSVSLGGRVTITCKASDHINNWLAWYQKPGNAPRLLISGATSLETGVPSRFRSGSGSKDYTLSTLSITSLQTEDVATYYCQQYWSIPLTFGAGTKLELKR

Example 2.107: Generation of VEGF (seq. 2) and DLL4 (seq. 3) DVD-Igs with Linker Set 3

Table 140

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
523	DVD501H	AB072	AB070	EVQLQQSGPELVKPGASVKMSCKASGYTFTSYVINWVKQKPGQGLEWIGLINPYNDGTYNEKFKVKATLTSKSSSTAYMELSSLTSEDSAVYYCASYYYGSRYYFDYWGQGTTLTVSS ASTKGPSVFPLAP EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIHWVRQAPGKGLEWVAGITPAGGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPYAMDYWGQGTTLTVSS
524	DVD501L	AB072	AB070	DIQMTQSSSYLSVSLGGRVTITCKASDHINNLAWYQKPGNAPRLLISGATSLETGVPSRFSGSGSKDYTLTSLQTEDVATYYCQQYWSIPLTFGAGTKLELKR TVAAP DIQMTQSPSSLSASVGDRTITCRASQDVSTAVAWYQKPGKAPKLLIYSASFYSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQSYTTPPTFGQGTKVEIKR
525	DVD502H	AB070	AB072	EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIHWVRQAPGKGLEWVAGITPAGGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPYAMDYWGQGTTLTVSS ASTKGPSVFPLAP EVQLQQSGPELVKPGASVKMSCKASGYTFTSYVINWVKQKPGQGLEWIGLINPYNDGTYNEKFKVKATLTSKSSSTAYMELSSLTSEDSAVYYCASYYYGSRYYFDYWGQGTTLTVSS
526	DVD502L	AB070	AB072	DIQMTQSPSSLSASVGDRTITCRASQDVSTAVAWYQKPGKAPKLLIYSASFYSGVPSRFSGSGSKDYTLTSLQTEDVATYYCQQYWSIPLTFGAGTKLELKR TVAAP DIQMTQSSSYLSVSLGGRVTITCKASDHINNLAWYQKPGNAPRLLISGATSLETGVPSRFSGSGSGKDYTLTSLQTEDVATYYCQQYWSIPLTFGAGTKLELKR

Example 2.108: Generation of VEGF (seq. 2) and DLL4 (seq. 3) DVD-Igs with Linker Set 4

Table 141

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				123456789 0 123456789 0 123456789 0 12345
527	DVD507H	AB072	AB070	EVQLQQSGPELVKPGASVKMSCKASGYTFTSYVINWVKQKPGQGLEWIGLINPYNDGTYNEKFKVKATLTSKSSSTAYMELSSLTSEDSAVYYCASYYYGSRYYFDYWGQGTTLTVSS ASTKGPEVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIHWVRQAPGKGLEWVA GITPAGGYTYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPYAMDYWGQGTTLVTVSS
528	DVD507L	AB072	AB070	DIQMTQSSSYLSVSLGGRVTITCKASDHINNWLAWYQKPGNAPRLLISGATSLETGVPSRFRSGSGSGKDYTLTSLQTEDVATYYCQQYWSIPLTFGAGTKLELKR TVAAPSVFIFPP DIQMTQSPSSLSASVGRVITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFRSGSGSGTDFTLTISLQPEDFATYYCQQSYTTPPTFGQGTKEIKR
529	DVD508H	AB070	AB072	EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIHWVRQAPGKGLEWVAGITPAGGYTYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPYAMDYWGQGTTLTVSS ASTKGPEVQLQQSGPELVKPGASVKMSCKASGYTFTSYVINWVKQKPGQGLEWIGLINPYNDGTYNEKFKVKATLTSKSSSTAYMELSSLTSEDSAVYYCASYYYGSRYYFDYWGQGTTLTVSS
530	DVD508L	AB070	AB072	DIQMTQSPSSLSASVGRVITCRASQDVSTAVAWYQKPGKAPKLLIYSASFLYSGVPSRFRSGSGSGTDFTLTISLQPEDFATYYCQQSYTTPPTFGQGTKEIKR TVAAPSVFIFPP DIQMTQSSSYLSVSLGGRVTITCKASDHINNWLAWYQKPGNAPRLLISGATSLETGVPSRFRSGSGSGKDYTLTSLQTEDVATYYCQQYWSIPLTFGAGTKLELKR

Example 2.109: Generation of VEGF (seq. 3) and DLL4 (seq. 3) DVD-Igs with Linker Set 1

Table 142

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
531	DVD491H	AB072	AB071	EVQLQQSGPELVKPGASVKMSCKASGYTFTSYVINWVKQKPGQGLEWIGLINPYNDGTYNEKFKVKATLTSKSSSTAYMELSSLTSEDSAVYYCASYYYGSRYYFDYWGQGTTLTVSS ASTKGPEVQLVESGGGLVQPGSLRLSCAASGFTINASWIHWVRQAPGKGLEWVGA IYPYSGYTNYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSPWAMDYWGQGTTLTVSS
532	DVD491L	AB072	AB071	DIQMTQSSSYLSVSLGGRVTITCKASDHINNLAWYQQKPGNAPRLLISGATSLETGVPSRFSGSGSKDYTLTISLQTEDVATYYCQQYWSIPLTFGAGTKLELKR TVAAP DIQMTQSPSSLSASVGDRTITCRASQVIRRLAWYQQKPGKAPKLLIYAASNLAGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQSNTSPLTFGQGTKVEIKR
533	DVD492H	AB071	AB072	EVQLVESGGGLVQPGSLRLSCAASGFTINASWIHWVRQAPGKGLEWVGA IYPYSGYTNYADSVKGRFTISADTSKNTAYLQMN SLRAEDTAVYYCARWGHSTSPWAMDYWGQGTTLTVSS ASTKGPEVQLQQSGPELVKPGASVKMSCKASGYTFTSYVINWVKQKPGQGLEWIGLINPYNDGTYNEKFKVKATL TSKSSSTAYMELSSLTSEDSAVYYCASYYYGSRYYFDYWGQGTTLTVSS
534	DVD492L	AB071	AB072	DIQMTQSPSSLSASVGDRTITCRASQVIRRLAWYQQKPGKAPKLLIYAASNLAGVPSRFSGSGSKDYTLTISLQPEDFATYYCQQSNTSPLTFGQGTKVEIKR TVAAP DIQMTQSSSYLSVSLGGRVTITCKASDHINNLAWYQQKPGNAPRLLISGATSLETGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQSNTSPLTFGQGTKVEIKR

Example 2.110: Generation of VEGF (seq. 3) and DLL4 (seq. 3) DVD-Igs with Linker Set 2

Table 143

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
535	DVD497H	AB072	AB071	EVQLQQSGPELVKPGASVKMSCKASGYTFTSYVINWVKQKPGQGLEWIGLINPYNDGTYNEKFKVKATLTSKSSSTAYMELSSLTSEDSAVYYCASYYYGSRYYFDYWGQGTTLTVSS ASTKGPSVFPLAP EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIHWVRQAPGKGLEWVGAIYPYSGYTNADSVKGRFTISADTSKN TAYLQMNSLRAEDTAVYYCARWGHSTSPWAMDYWGQGTTLTVSS
536	DVD497L	AB072	AB071	DIQMTQSSSYLSVSLGGRVTITCKASDHINNWLAWYQKPGNAPRLLISGATSLETGVPSRFRSGSGSKDYTLSTLSLQTEDVATYYCQYWSIPLTFGAGTKLELKR TVAAPSVFIFPP DIQMTQSPSSLSASVGRVITCRASQVIRRLAWYQQKPGKAPKLLIYAASNLAGVPSRFRSGSGTDFTLTISLQPEDFATYYCQQSNTSPLTFGQGTKVEIKR
537	DVD498H	AB071	AB072	EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIHWVRQAPGKGLEWVGAIYPYSGYTNADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSPWAMDYWGQGTTLTVSS ASTKGPSVFPLAP EVQLQQSGPELVKPGASVKMSCKASGYTFTSYVINWVKQKPGQGLEWIGLINPYNDGTYNEKFKVKATLTSKSSSTAYMELSSLTSEDSAVYYCASYYYGSRYYFDYWGQGTTLTVSS
538	DVD498L	AB071	AB072	DIQMTQSPSSLSASVGRVITCRASQVIRRLAWYQKPGKAPKLLIYAASNLAGVPSRFRSGSGTDFTLTISLQPEDFATYYCQQSNTSPLTFGQGTKVEIKR TVAAPSVFIFPP DIQMTQSSSYLSVSLGGRVTITCKASDHINNWLAWYQKPGNAPRLLISGATSLETGVPSRFRSGSGSKDYTLSTLSLQTEDVATYYCQYWSIPLTFGAGTKLELKR

Example 2.111: Generation of VEGF (seq. 3) and DLL4 (seq. 3) DVD-Igs with Linker Set 3

Table 144

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
539	DVD503H	AB072	AB071	EVQLQQSGPELVKPGASVKMCKASGYTFTSYVINWVKQKPGQGLEWIGLINPYNDGTYNEKFKVKATLTSKSSSTAYMELSSLTSEDSAVYYCASYYYGSRYYFDYWGQGTTLTVSS ASTKGPSVFPLAP EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIHWVRQAPGKGLEWVGAIYPYSGYTNADSVKGRFTISADTSKN TAYLQMNSLRAEDTAVYYCARWGHSTSPWAMYWGQGTTLTVSS
540	DVD503L	AB072	AB071	DIQMTQSSSYLSVSLGGRVTITCKASDHINNLAWYQKPGNAPRLLISGATSLETGVPSRFSGSGSKDYTLTSLQTEDVATYYCQYWSIPLTFGAGTKLELKR TVAAP DIQMTQSPSSLSASVGRVITCRASQVIRRLAWYQKPGKAPKLLIYAASNLAGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQSNTSPLTFGQGTKVEIKR
541	DVD504H	AB071	AB072	EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIHWVRQAPGKGLEWVGAIYPYSGYTNADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSPWAMYWGQGTTLTVSS ASTKGPSVFPLAP EVQLQQSGPELVKPGASVKMCKASGYTFTSYVINWVKQKPGQGLEWIGLINPYNDGTYNEKFKVKATLTSKSSSTAYMELSSLTSEDSAVYYCASYYYGSRYYFDYWGQGTTLTVSS
542	DVD504L	AB071	AB072	DIQMTQSPSSLSASVGRVITCRASQVIRRLAWYQKPGKAPKLLIYAASNLAGVPSRFSGSGSKDYTLTISLQPEDFATYYCQQSNTSPLTFGQGTKVEIKR TVAAP DIQMTQSSSYLSVSLGGRVTITCKASDHINNLAWYQKPGNAPRLLISGATSLETGVPSRFSGSGSGKDYTLTSLQTEDVATYYCQYWSIPLTFGAGTKLELKR

Example 2.112: Generation of VEGF (seq. 3) and DLL4 (seq. 3) DVD-Igs with Linker Set 4

Table 145

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
543	DVD509H	AB072	AB071	EVQLQQSGPELVKPGASVKMSCKASGYTFTSYVINWVKQKPGQGLEWIGLINPYNDGTYNEKFKVKATLTSKSSSTAYMELSSLTSEDSAVYYCASYYYGSRYYFDYWGQGTTLTVSS ASTKGPEVQLVESGGGLVQPGSLR LSCAASGFTINASWIHWVRQAPGKGLEWVGAITYPYSYTYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSPWAMDYWGQGTTLTVSS
544	DVD509L	AB072	AB071	DIQMTQSSSYLSVSLGGRVTITCKASDHINNWLAWYQKPGNAPRLLISGATSLETGVPSRFRSGSGSGKDYTLSTSLQTEDVATYYCQQYWSIPLTFGAGTKLELKR TVAAPSVFIFPP DIQMTQSPSSLSASVGDVRVITCRASQVIRRLAWYQQKPGKAPKLLIYAASNLAGVPSRFRSGSGSGTDFTLTISLQPEDFATYYCQQSNTSPLTFGQGTKVEIKR
545	DVD510H	AB071	AB072	EVQLVESGGGLVQPGSLRSCAASGFTINASWIHWVRQAPGKGLEWVGAITYPYSYTYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSPWAMDYWGQGTTLTVSS ASTKGPEVQLQQSGPELVKPGASVKMSCKASGYTFTSYVINWVKQKPGQGLEWIGLINPYNDGTYNEKFKVKATLTSKSSSTAYMELSSLTSEDSAVYYCASYYYGSRYYFDYWGQGTTLTVSS
546	DVD510L	AB071	AB072	DIQMTQSPSSLSASVGDVRVITCRASQVIRRLAWYQKPGKAPKLLIYAASNLAGVPSRFRSGSGSGTDFTLTISLQPEDFATYYCQQSNTSPLTFGQGTKVEIKR TVAAPSVFIFPP DIQMTQSSSYLSVSLGGRVTITCKASDHINNWLAWYQKPGNAPRLLISGATSLETGVPSRFRSGSGSGKDYTLSTSLQTEDVATYYCQQYWSIPLTFGAGTKLELKR

Example 2.113: Generation of VEGF (seq. 1) and DLL4 (seq. 4) DVD-Igs with Linker Set 1

Table 146

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
547	DVD511H	AB073	AB014	EVQLQQSGPELEKPGASVKISCKASGYSTFGYNNM WVKQSNKGSLEWIGNIDPYFGGTNYNQKFKGKATL TVDKSSSTAYMQLKSLTSEDSAVYYCARNYDYDGG CFDYWGQGTTLTVSS ASTKGP EVQLVESGGGLVQP GGSLRLSCAASGYTFTNYGMNWRQAPGKGLEWVG WINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMN SLRAEDTAVYYCAKYPHYGSSHWYFDVWGQGTLV TVSS
548	DVD511L	AB073	AB014	QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYA NWWQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIG DKAALTITGAQTEDEAIYFCALWYSNHWVFGGKTK LTVLG QPKAAP DIQMTQSPSSLSASVGDRTITCS ASQDISNYLNWYQQKPGKAPKVLIIYFTSSLHSGVP SRFSGSGGTDFTLTITSSLPEDFATYYCQQYSTV PWFQGTGKVEIKR
549	DVD512H	AB014	AB073	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMN WVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTF SLDTSKSTAYLQMNLSLRAEDTAVYYCAKYPHYGS SHWYFDVWGQGTTLTVSS ASTKGP EVQLQQSGPEL EKGASVKISCKASGYSTFGYNNMNVKQSNKGSLE WIGNIDPYFGGTNYNQKFKGKATLTVDKSSSTAYM QLKSLTSEDSAVYYCARNYDYDGGCFDYWGQGTTL TVSS
550	DVD512L	AB014	AB073	DIQMTQSPSSLSASVGDRTITCSASQDISNYLNW YQQKPGKAPKVLIIYFTSSLHSGVPSRFSGSGGTD FTLTITSSLPEDFATYYCQQYSTVFPWFQGTGKVE IKR TVAAP QAVVTQESALTTSPGETVTLTCRSSTG AVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPA RFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNH WVFGGKTKLTVLG

Example 2.114: Generation of VEGF (seq. 1) and DLL4 (seq. 4) DVD-Igs with Linker Set 2

Table 147

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				123456789 0 123456789 0 123456789 0 12345
551	DVD517H	AB073	AB014	EVQLQQSGPELEKPGASVKISCKASGYSFTGYNMN WVKQSNKGSLEWIGNIDPYFGGTNYNQKFKGKATL TVDKSSSTAYMQLKSLTSEDSAVYYCARNYDYDGG CFDYWGQGTTLTVSS ASTKGPSVFPLAP EVQLVES GGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPG KGLEWVGWINTYTGPTYAADFKRRFTFSLDTSKS TAYLQMNSLRAEDTAVYYCAKYPHYGSSHWYFDV WGQGTTLTVSS
552	DVD517L	AB073	AB014	QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYA NWWQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIG DKAALITGAQTEDEAIYFCALWYSNHWVFGGGTK LTVLG QPKAAPSVTLFPP DIQMTQSPSSLSASVGD RVTITCSASQDISNYLNWYQQKPKAPKVLIIYFTS SLHSGVPSRFSGSGSGTDFTLTISLQPEDFATYY CQQYSTVPWTFGQGTKVEIKR
553	DVD518H	AB014	AB073	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMN WVRQAPGKGLEWVGWINTYTGPTYAADFKRRFTF SLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYGSS SHWYFDVWGQGTTLTVSS ASTKGPSVFPLAP EVQL QQSGPELEKPGASVKISCKASGYSFTGYNMNWVKQ SNGKSLEWIGNIDPYFGGTNYNQKFKGKATLTVDK SSSTAYMQLKSLTSEDSAVYYCARNYDYDGGCFDY WGQGTTLTVSS
554	DVD518L	AB014	AB073	DIQMTQSPSSLSASVGDRTVITCSASQDISNYLNW YQQKPKAPKVLIIYFTSSLHSGVPSRFSGSGSGTD FTLTISLQPEDFATYYCQQYSTVPWTFGQGTKVE IKR TVAAPSVFI FPQAVVTQESALTTSPGETVTL TCRSSTGAVTTSNYANWWQEKPDHLFTGLIGGTNN RAPGVPARFSGSLIGDKAALITGAQTEDEAIYFC ALWYSNHWVFGGGTKLTVLG

Example 2.115: Generation of VEGF (seq. 1) and DLL4 (seq. 4) DVD-Igs with Linker Set 3

Table 148

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
555	DVD523H	AB073	AB014	EVQLQQSGPELEKPGASVKISCKASGYSTFGYNNM WVKQSNKGSLEWIGNIDPYFGGTNYNQKFKGKATL TVDKSSSTAYMQLKSLTSEDSAVYYCARNYDYDGG CFDYWGQGTTLTVSS ASTKGPSVFPLAP EVQLVES GGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPG KGLEWVGWINTYTGPTYAADFKRRFTFSLDTSKS TAYLQMNSLRAEDTAVYYCAKYPHYGSSHWYFDV WGQGTTLTVSS
556	DVD523L	AB073	AB014	QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYA NWWQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIG DKAALTITGAQTEDEAIYFCALWYSNHWVFGGGTK LTVLG QPKAAP DIQMTQSPSSLSASVGDRTITCS ASQDISNYLNWYQQKPGKAPKVLIIYFTSSLHSGVP SRFSGSGSGTDFTLTITSSLPEDFATYYCQQYSTV PWTFGQGTKVEIKR
557	DVD524H	AB014	AB073	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMN WVRQAPGKGLEWVGWINTYTGPTYAADFKRRFTF SLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYGSS SHWYFDVWGQGTTLTVSS ASTKGPSVFPLAP EVQL QQSGPELEKPGASVKISCKASGYSTFGYNNMWWKQ SNGKSLEWIGNIDPYFGGTNYNQKFKGKATLTVDK SSSTAYMQLKSLTSEDSAVYYCARNYDYDGGCFDY WGQGTTLTVSS
558	DVD524L	AB014	AB073	DIQMTQSPSSLSASVGDRTITCSASQDISNYLNW YQQKPGKAPKVLIIYFTSSLHSGVPSRFSGSGSGTD FTLTITSSLPEDFATYYCQQYSTVVPWTFGQGTKVE IKR TVAAP QAVVTQESALTTSPGETVTLTCRSSTG AVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPA RFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNH WVFGGKTLTVLG

Example 2.116: Generation of VEGF (seq. 1) and DLL4 (seq. 4) DVD-Igs with Linker Set 4

Table 149

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				123456789 0 123456789 0 123456789 0 12345
559	DVD529H	AB073	AB014	EVQLQQSGPELEKPGASVKISCKASGYSFTGYNMN WVKQSNKGSLEWIGNIDPYFGGTNYNQKFKGKATL TVDKSSSTAYMQLKSLTSEDSAVYYCARNYDYDGG CFDYWGQGTTLTVSS ASTKGPEVQLVESGGGLVQP GGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVG WINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMN SLRAEDTAVYYCAKYPHYGSSHWYFDVWGQGTLV TVSS
560	DVD529L	AB073	AB014	QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYA NWWQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIG DKAALTIITGAQTEDEAIYFCALWYSNHWVFGGGTK LTVLG QPKAAPSVTLFPP DIQMTQSPSSLSASVGD RVTITCSASQDISNYLNWYQQKPGKAPKVLIIYFTS SLHSGVPSRFSGSGSGTDFTLTISLQPEDFATYY CQQYSTVPWTFGQGTKVEIKR
561	DVD530H	AB014	AB073	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMN WVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTF SLDTSKSTAYLQMNLSRAEDTAVYYCAKYPHYGSS SHWYFDVWGQGTTLTVSS ASTKGPEVQLQQSGPEL EKPGASVKISCKASGYSFTGYNMNWKQSNKGSLE WIGNIDPYFGGTNYNQKFKGKATLTVDKSSSTAYM QLKSLTSEDSAVYYCARNYDYDGGCFDYWGQGTTL TVSS
562	DVD530L	AB014	AB073	DIQMTQSPSSLSASVGD RVTITCSASQDISNYLNW YQQKPGKAPKVLIIYFTSSLHSGVPSRFSGSGSGTD FTLTISLQPEDFATYYCQQYSTVPWTFGQGTKVE IKR TVAAPSVFI FPP QAVVTQESALTTSPGETVTL TCRSSTGAVTTSNYANWWQEKPDHLFTGLIGGTNN RAPGVPARFSGSLIGDKAALTIITGAQTEDEAIYFC ALWYSNHWVFGGGTKLTVLG

Example 2.117: Generation of VEGF (seq. 2) and DLL4 (seq. 4) DVD-Igs with Linker Set 1

Table 150

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
563	DVD513H	AB073	AB070	EVQLQQSGPELEKPGASVKISCKASGYSFTGYNMN WVKQSNKGSLEWIGNIDPYFGGTNYNQKFKGKATL TVDKSSSTAYMQLKSLTSEDSAVYYCARNYDYDGG CFDYWGQGTTLTVSS ASTKGPEVQLVESGGGLVQP GGSLRLSCAASGFTISDYWIHWVRQAPGKGLEWVA GITPAGGYTYADSVKGRFTISADTSKNTAYLQMN SLRAEDTAVYYCARFVFFLPYAMDYWGQGTTLTVS S
564	DVD513L	AB073	AB070	QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYA NWWQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIG DKAALTITGAQTEDEAIYFCALWYSNHWVFGGKTR LTVLG QPKAAP DIQMTQSPSSLSASVGDRTITCR ASQDVSTAVAWYQQKPKGKAPKLLIYSASFLYSGVP SRFSGSGSGTDFTLTITSSLPEDFATYYCQQSYTT PPTFGQGTKVEIKR
565	DVD514H	AB070	AB073	EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIH WVRQAPGKGLEWVAGITPAGGYTYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPY AMDYWGQGTTLTVSS ASTKGPEVQLQQSGPELEKPG ASVKISCKASGYSFTGYNMNWWKQSNKGSLEWIG NIDPYFGGTNYNQKFKGKATLTVDKSSSTAYMQLK SLTSEDSAVYYCARNYDYDGGCFDYWGQGTTLTVS S
566	DVD514L	AB070	AB073	DIQMTQSPSSLSASVGDRTITCRASQDVSTAVAW YQQKPKGKAPKLLIYSASFLYSGVPSRFSGSGSGTD FTLTITSSLPEDFATYYCQQSYTTPPTFGQGTKVE IKR TVAAP QAVVTQESALTTSPGETVTLTCRSSTG AVTTSNYANWWQEKPDHLFTGLIGGTNNRAPGVPA RFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNH WVFGGKTKLTVLG

Example 2.118: Generation of VEGF (seq. 2) and DLL4 (seq. 4) DVD-Igs with Linker Set 2

Table 151

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
567	DVD519H	AB073	AB070	EVQLQQSGPELEKPGASVKISCKASGYSFTGYNMN WVKQSNQKSLIEWIGNIDPYFGGTNYNQKFKGKATL TVDKSSSTAYMQLKSLTSEDSAVYYCARNYDYDGG CFDYWGQGTTLTVSS ASTKGPSVFPLAP EVQLVES GGGLVQPGGSLRLSCAASGFTISDYWIHWVRQAPG KGLEWVAGITPAGGYTYADSVKGRFTISADTSKN TAYLQMNSLRAEDTAVYYCARFVFFLPYAMDYWGQ GTLTVSS
568	DVD519L	AB073	AB070	QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYA NWWQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIG DKAALTIITGAQTEDEAIYFCALWYSNHWVFGGGTK LTVLG QPKAAPSVTLFPP DIQMTQSPSSLSASVGD RVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSAS FLYSGVPSRFSGSGSGTDFTLTISLQPEDFATYY CQQSYTTPPTFGQGTKVEIKR
569	DVD520H	AB070	AB073	EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIH WVRQAPGKGLEWVAGITPAGGYTYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPY AMDYWGQGTTLTVSS ASTKGPSVFPLAP EVQLQQS GPELEKPGASVKISCKASGYSFTGYNMNWKQSNQ KSLIEWIGNIDPYFGGTNYNQKFKGKATLTVDKSSS TAYMQLKSLTSEDSAVYYCARNYDYDGGCFDYWGQ GTLTVSS
570	DVD520L	AB070	AB073	DIQMTQSPSSLSASVGDRTVITCRASQDVSTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTD FTLTISLQPEDFATYYCQQSYTTPPTFGQGTKVE IKR TVAAPSVFIIPP QAVVTQESALTTSPGETVTL TCRSSTGAVTTSNYANWWQEKPDHLFTGLIGGTNN RAPGVPARFSGSLIGDKAALTIITGAQTEDEAIYFC ALWYSNHWVFGGGTKLTVLG

Example 2.119: Generation of VEGF (seq. 2) and DLL4 (seq. 4) DVD-Igs with Linker Set 3

Table 152

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
571	DVD525H	AB073	AB070	EVQLQQSGPELEKPGASVKISCKASGYSFTGYNMN WVKQSNQKSLWIGNIDPYFGGTNYNQKFKGKATL TVDKSSSTAYMQLKSLTSEDSAVYYCARNYDYDGG CFDYWGQGTTLTVSS ASTKGPSVFPLAP EVQLVES GGGLVQPGGSLRLSCAASGFTISDYWIHWVRQAPG KGLEWVAGITPAGGYTYADSVKGRFTISADTSKN TAYLQMNSLRAEDTAVYYCARFVFFLPYAMDYWGQ GTLTVSS
572	DVD525L	AB073	AB070	QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYA NWWQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIG DKAALTITGAQTEDEAIYFCALWYSNHWVFGGKTK LTVLG QPKAAP DIQMTQSPSSLSASVGDRTITCR ASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVP SRFSGSGSGTDFTLTITSSLPEDFATYYCQQSYTT PPTFGQGTKVEIKR
573	DVD526H	AB070	AB073	EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIH WVRQAPGKGLEWVAGITPAGGYTYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPY AMDYWGQGTTLTVSS ASTKGPSVFPLAP EVQLQQS GPELEKPGASVKISCKASGYSFTGYNMNWKQSNQ KSLWIGNIDPYFGGTNYNQKFKGKATLTVDKSSS TAYMQLKSLTSEDSAVYYCARNYDYDGGCFDYWGQ GTLTVSS
574	DVD526L	AB070	AB073	DIQMTQSPSSLSASVGDRTITCRASQDVSTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTD FTLTITSSLPEDFATYYCQQSYTTPPTFGQGTKVE IKR TVAAP QAVVTQESALTTSPGETVTLTCRSSTG AVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVA RFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNH WVFGGKTLTVLG

Example 2.120: Generation of VEGF (seq. 2) and DLL4 (seq. 4) DVD-Igs with Linker Set 4

Table 153

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				123456789 0 123456789 0 123456789 0 12345
575	DVD531H	AB073	AB070	EVQLQQSGPELEKPGASVKISCKASGYSTFGYNNM WVKQSNKGSLEWIGNIDPYFGGTNYNQKFKGKATL TVDKSSSTAYMQLKSLTSEDSAVYYCARNYDYDGG CFDYWGQGTTLTVSS ASTKGPEVQLVESGGGLVQP GGSLRLSCAASGFTISDYWIHWVRQAPGKGLEWVA GITPAGGYTYADSVKGRFTISADTSKNTAYLQMN SLRAEDTAVYYCARFVFFLPYAMDYWGQGTTLTVS S
576	DVD531L	AB073	AB070	QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYA NWWQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIG DKAALTIITGAQTEDEAIYFCALWYSNHWVFGGGTK LTVLG QPKAAPSVTLFPP DIQMTQSPSSLSASVGD RVTITCRASQDVSTAVAWYQQKPKAPKLLIYSAS FLYSGVPSRFSGSGSGTDFTLTISLQPEDFATYY CQQSYTTPPTFGQGTKVEIKR
577	DVD532H	AB070	AB073	EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIH WVRQAPGKGLEWVAGITPAGGYTYADSVKGRFTI SADTSKNTAYLQMN SLRAEDTAVYYCARFVFFLPY AMDYWGQGTTLTVSS ASTKGPEVQLQQSGPELEKPG GASVKISCKASGYSTFGYNNM WVKQSNKGSLEWIG NIDPYFGGTNYNQKFKGKATLTVDKSSSTAYMQLK SLTSEDSAVYYCARNYDYDGGCFDYWGQGTTLTVS S
578	DVD532L	AB070	AB073	DIQMTQSPSSLSASVGD RV ITITCRASQDVSTAVAW YQQKPKAPKLLIYSASFLYSGVPSRFSGSGSGTD FTLTISLQPEDFATYYCQQSYTTPPTFGQGTKVE IKR TVAAPSVFI FPQAVVTQESALTTSPGETVTL TCRSSTGAVTTSNYANWWQEKPDHLFTGLIGGTNN RAPGVPARFSGSLIGDKAALTIITGAQTEDEAIYFC ALWYSNHWVFGGGTKLTVLG

Example 2.121: Generation of VEGF (seq. 3) and DLL4 (seq. 4) DVD-Igs with Linker Set 1

Table 154

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				123456789 0 123456789 0 123456789 0 12345
579	DVD515H	AB073	AB071	EVQLQQSGPELEKPGASVKISCKASGYSTFGYNNM WVKQSNKGSLEWIGNIDPYFGGTNYNQKFKGKATL TVDKSSSTAYMQLKSLTSEDSAVYYCARNYDYDGG CFDYWGQGTTLTVSS ASTKGPEVQLVESGGGLVQP GGSLRLSCAASGFTINASWIHWVRQAPGKGLEWVG AIYPYSGYTNYADSVKGRFTISADTSKNTAYLQMN SLRAEDTAVYYCARWGHSTSPWAMDYWGQGTTLTV SS
580	DVD515L	AB073	AB071	QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYA NWWQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIG DKAALTITGAQTEDEAIYFCALWYSNHWVFGGKTK LTVLG QPKAAP DIQMTQSPSSLSASVGDRTITCR ASQVIRRLAWYQQKPGKAPKLLIYAASNLASGVP SRFSGSGSDFTLTITSSLPEDFATYYCQQSNTS PLTFGQGTKVEIKR
581	DVD516H	AB071	AB073	EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIH WVRQAPGKGLEWGAIIYPYSGYTNYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSP WAMDYWGQGTTLTVSS ASTKGPEVQLQQSGPELEK PGASVKISCKASGYSTFGYNNMWWKQSNKGSLEWI GNIDPYFGGTNYNQKFKGKATLTVDKSSSTAYMQL KSLTSEDSAVYYCARNYDYDGGCFDYWGQGTTLTV SS
582	DVD516L	AB071	AB073	DIQMTQSPSSLSASVGDRTITCRASQVIRRLAW YQQKPGKAPKLLIYAASNLASGVPSRFSGSGSDT FTLTITSSLPEDFATYYCQQSNTSPLTFGQGTKVE IKR TVAAP QAVVTQESALTTSPGETVTLTCRSSTG AVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVA RFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNH WVFGGKTLTVLG

Example 2.122: Generation of VEGF (seq. 3) and DLL4 (seq. 4) DVD-Igs with Linker Set 2

Table 155

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
583	DVD521H	AB073	AB071	EVQLQQSGPELEKPGASVKISCKASGYSFTGYNMN WVKQSNKGKLEWIGNIDPYFGGTNYNQKFKGKATL TVDKSSSTAYMQLKSLTSEDSAVYYCARNYDYDGG CFDYWGQGTTLTVSS ASTKGPSVFPLAP EVQLVES GGGLVQPGGSLRLSCAASGFTINASWIHWVRQAPG KGLEWVGAIYPYSGYTNADSVKGRFTISADTSKN TAYLQMNSLRAEDTAVYYCARWGHSTSPWAMDYWG QGTTLTVSS
584	DVD521L	AB073	AB071	QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYA NWWQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIG DKAALTIITGAQTEDEAIYFCALWYSNHWVFGGGTK LTVLG QPKAAPSVTLFPP DIQMTQSPSSLSASVGD RVTITCRASQVIRRLAWYQQKPGKAPKLLIYAAS NLASGVPSRFRSGSGGTDFTLTISLQPEDFATYY CQQSNTSPLTFGGQTKVEIKR
585	DVD522H	AB071	AB073	EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIH WVRQAPGKGLEWVGAIYPYSGYTNADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSP WAMDYWGQGTTLTVSS ASTKGPSVFPLAP EVQLQQ SGPELEKPGASVKISCKASGYSFTGYNMNWKQSN GKLEWIGNIDPYFGGTNYNQKFKGKATLTVDKSS STAYMQLKSLTSEDSAVYYCARNYDYDGGCFDYWG QGTTLTVSS
586	DVD522L	AB071	AB073	DIQMTQSPSSLSASVGD RVTITCRASQVIRRLAW YQQKPGKAPKLLIYAASNLASGVPSRFRSGSGGTD FTLTISLQPEDFATYYCQQSNTSPLTFGGQTKVE IKR TVAAPSVFIIPP QAVVTQESALTTSPGETVTL TCRSSTGAVTTSNYANWWQEKPDHLFTGLIGGTNN RAPGVPARFSGSLIGDKAALTIITGAQTEDEAIYFC ALWYSNHWVFGGGTKLTVLG

Example 2.123: Generation of VEGF (seq. 3) and DLL4 (seq. 4) DVD-Igs with Linker Set 3

Table 156

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
587	DVD527H	AB073	AB071	EVQLQQSGPELEKPGASVKISCKASGYSFTGYNMN WVKQSNKGKLEWIGNIDPYFGGTNYNQKFKGKATL TVDKSSSTAYMQLKSLTSEDSAVYYCARNYDYDGG CFDYWGQGTTLTVSS ASTKGPSVFPLAP EVQLVES GGGLVQPGGSLRLSCAASGFTINASWIHWVRQAPG KGLEWVGAIYPYSGYTNADSVKGRFTISADTSKN TAYLQMNSLRAEDTAVYYCARWGHSTSPWAMDYWG QGTTLTVSS
588	DVD527L	AB073	AB071	QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYA NWWQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIG DKAALTITGAQTEDEAIYFCALWYSNHWVFGGKTK LTVLG QPKAAP DIQMTQSPSSLSASVGDRTITCR ASQVIRRLAWYQQKPGKAPKLLIYAASNLASGVP SRFSGSGSGTDFTLTITSSLPEDFATYYCQQSNTS PLTFGQGTKVEIKR
589	DVD528H	AB071	AB073	EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIH WVRQAPGKGLEWVGAIYPYSGYTNADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSP WAMDYWGQGTTLTVSS ASTKGPSVFPLAP EVQLQQ SGPELEKPGASVKISCKASGYSFTGYNMNWKQSN GKLEWIGNIDPYFGGTNYNQKFKGKATLTVDKSS STAYMQLKSLTSEDSAVYYCARNYDYDGGCFDYWG QGTTLTVSS
590	DVD528L	AB071	AB073	DIQMTQSPSSLSASVGDRTITCRASQVIRRLAW YQQKPGKAPKLLIYAASNLASGVPSRFSGSGSGTD FTLTITSSLPEDFATYYCQQSNTSPLTFGQGTKVE IKR TVAAP QAVVTQESALTTSPGETVTLTCRSSTG AVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVA RFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNH WVFGGKTKLTVLG

Example 2.124: Generation of VEGF (seq. 3) and DLL4 (seq. 4) DVD-Igs with Linker Set 4

Table 157

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				123456789 0 123456789 0 123456789 0 12345
591	DVD533H	AB073	AB071	EVQLQQSGPELEKPGASVKISCKASGYSTFGYNNM WVKQSNKGSLEWIGNIDPYFGGTNYNQKFKGKATL TVDKSSSTAYMQLKSLTSEDSAVYYCARNYDYDGG CFDYWGQGTTLTVSS ASTKGPEVQLVESGGGLVQP GGSLRLSCAASGFTINASWIHWVRQAPGKGLEWVG AIYPYSGYTNYADSVKGRFTISADTSKNTAYLQMN SLRAEDTAVYYCARWGHSTSPWAMDYWGQGTTLTV SS
592	DVD533L	AB073	AB071	QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYA NWWQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIG DKAALTIITGAQTEDEAIYFCALWYSNHWFVGGGK LTVLG QPKAAPSVTLFPP DIQMTQSPSSLSASVGD RVTITCRASQVIRRLAWYQQKPGKAPKLLIYAAS NLASGVPSRFSGSGSGTDFTLTISLQPEDFATYY CQQSNTSPLTFGQGTKVEIKR
593	DVD534H	AB071	AB073	EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIH WVRQAPGKGLEWGAIIYPYSGYTNYADSVKGRFTI SADTSKNTAYLQMNLSRAEDTAVYYCARWGHSTSP WAMDYWGQGTTLTVTVSS ASTKGPEVQLQQSGPELEK PGASVKISCKASGYSTFGYNNMNVKQSNKGSLEWI GNIDPYFGGTNYNQKFKGKATLTVDKSSSTAYMQL KSLTSEDSAVYYCARNYDYDGGCFDYWGQGTTLTV SS
594	DVD534L	AB071	AB073	DIQMTQSPSSLSASVGD RVTITCRASQVIRRLAW YQQKPGKAPKLLIYAASNLAGVPSRFSGSGSGTD FTLTISLQPEDFATYYCQQSNTSPLTFGQGTKVE IKR TVAAPSVFI FPP QAVVTQESALTTSPGETVTL TCRSSTGAVTTSNYANWWQEKPDHLFTGLIGGTNN RAPGVPARFSGSLIGDKAALTIITGAQTEDEAIYFC ALWYSNHWFVGGGKLTIVLG

Example 2.125: Generation of HER2 (seq. 1) and ErbB3 (seq. 1) DVD-Igs with Linker Set 1

Table 158

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
595	DVD387H	AB062	AB004	QVQLQQWAGALLKPSSETLSLTCAVYGGSFSGYYWS WIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTIS VETSKNQFSLKLSVTAADTAVYYCARDKWTWYFD LWGRGTLVTVSS ASTKGPSVFPLAP EVQLVESGGG LVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGL EWVARIYPTNGYTRYADSVKGRFTISADTSKNTAY LQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGT LTVSS
596	DVD387L	AB062	AB004	DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSN RNYLAWYQQNPGQPPKLLIYWASTRESGVPDRFSG SGSGTDFTLTISSLQAEDVAVYYCQQYYSTPRTFG QGTKVEIKR TVAAPSVEIFPP DIQMTQSPSSLSAS VGDRVITTCRASQDVNTAVAWYQQKPGKAPKLLIY SASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFA TYYCQQHYTTPPTFGQGTKVEIKR
597	DVD388H	AB004	AB062	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIH WVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFY AMDYWGQGTLVTVSS ASTKGPSVFPLAP QVQLQQW GAGLLKPSSETLSLTCAVYGGSFSGYYWSWIRQPPG KGLEWIGEINHSGSTNYNPSLKSRVTISVETSKNQ FSLKLSVTAADTAVYYCARDKWTWYFDLWGRGTL VTVSS
598	DVD388L	AB004	AB062	DIQMTQSPSSLSASVGDRVITTCRASQDVNTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTD FTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVE IKR TVAAPSVEIFPP DIEMTQSPDSLAVSLGERAT INCRSSQSVLYSSNRNYLAWYQQNPGQPPKLLIY WASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVA VYYCQQYYSTPRTFGQGTKVEIKR

5

Example 2.126: Generation of HER2 (seq. 1) and ErbB3 (seq. 1) DVD-Igs with Linker Set 2

Table 159

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
599	DVD391H	AB062	AB004	QVQLQQWAGALLKPSSETLSLTCAVYGGSFSGYYWS WIRQPPGKGLEWIGEINHSGSTNYNPSLKSRTIS VETSKNQFSLKLSVTAADTAVYYCARDKWTWYFD LWGRGTLVTVSS ASTKGPSVFPLAP EVQLVESGGG LVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGL EWWARIYPTNGYTRYADSVKGRFTISADTSKNTAY LQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGT LTVTVSS
600	DVD391L	AB062	AB004	DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSN RNYLAWYQQNPGQPPKLLIYWASTRESGVPDRFSG SGSGTDFTLTISLQAEDVAVYYCQQYYSTPRTFG QGTKVEIKR TVAAP DIQMTQSPSSLSASVGRVTI TCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYS GVPSRFSGSRSGTDFTLTISLQPEDFATYYCQQH YTPPTFGQGTKVEIKR
601	DVD392H	AB004	AB062	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHW VRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFY AMDYWGQGTLVTVSS ASTKGPSVFPLAP QVQLQQW GAGLLKPSSETLSLTCAVYGGSFSGYYWSWIRQPPG KGLEWIGEINHSGSTNYNPSLKSRTISVETSKNQ FSLKLSVTAADTAVYYCARDKWTWYFDLWGRGTL VTVSS
602	DVD392L	AB004	AB062	DIQMTQSPSSLSASVGRVTITCRASQDVNTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTD FTLTISLQPEDFATYYCQQHYTPPTFGQGTKVE IKR TVAAP DIEMTQSPDSLAVSLGERATINCRSSQ SVLYSSSNRNYLAWYQQNPGQPPKLLIYWASTRES GVPDRFSGSGSGTDFTLTISLQAEDVAVYYCQY YSTPRTFGQGTKVEIKR

Example 2.127: Generation of HER2 (seq. 1) and ErbB3 (seq. 1) DVD-Igs with Linker Set 3

Table 160

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
603	DVD395H	AB062	AB004	QVQLQQWAGALLKPSSETLSLTCAVYGGSFSGYYWS WIRQPPGKGLEWIGEINHSGSTNYNPSLKSRTVIS VETSKNQFSLKLSVTAADTAVYYCARDKWTWYFD LWGRGTLTVTVSS ASTKGP EVQLVESGGGLVQPGGS LRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIY PTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLR AEDTAVYYCSRWGGDGFYAMDYWGQGLTVTVSS
604	DVD395L	AB062	AB004	DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSN RNYLAWYQQNPGQPPKLLIYWASTRESGVPDRFSG SGSGTDFTLTISSLQAEDVAVYYCQYYSTPRTFG QGTKVEIKR TVAAPSVFIFPP DIQMTQSPSSLSAS VGDRVITICRASQDVNTAVAWYQQKPGKAPKLLIY SASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFA TYYCQQHYTTPPTFGQGTKVEIKR
605	DVD396H	AB004	AB062	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIH WVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFY AMDYWGQGLTVTVSS ASTKGP QVQLQQWAGALLK SETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIG EINHSGSTNYNPSLKSRTISVETSKNQFSLKLS VTAADTAVYYCARDKWTWYFDLWGRGTLTVTVSS
606	DVD396L	AB004	AB062	DIQMTQSPSSLSASVGDRVITICRASQDVNTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTD FTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVE IKR TVAAPSVFIFPP DIEMTQSPDSLAVSLGERAT INCRSSQSVLYSSSNRNYLAWYQQNPGQPPKLLIY WASTRESGVPDRFSGSGTDFTLTISSLQAEDVA VYYCQQYYSTPRTFGQGTKVEIKR

Example 2.128: Generation of HER2 (seq. 1) and ErbB3 (seq. 1) DVD-Igs with Linker Set 4

Table 161

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
607	DVD683H	AB062	AB004	QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWS WIRQPPGKGLEWIGEINHSGSTNYNPSLKSRTIS VETSKNQFSLKLSSVTAADTAVYYCARDKWTWYFD LWGRGTLVTVSS ASTKGP EVQLVESGGGLVQPGGS LRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIY PTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLR AEDTAVYYCSRWGGDGFYAMDYWGQGLTVTVSS
608	DVD683L	AB062	AB004	DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSN RNYLAWYQQNPGQPPKLLIYWASTRESGVPDRFSG SGSGTDFTLTISSLQAEDVAVYYCQYYSTPRTFG QGTKVEIKR TVAAP DIQMTQSPSSLSASVGDRTI TCRASQDVNTAVAWYQQKPGKAPKLLIYASFLYS GVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQYH YTPPTFGQGTKVEIKR
609	DVD684H	AB004	AB062	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIH WVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFY AMDYWGQGLTVTVSS ASTKGP QVQLQQWGAGLLKP SETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIG EINHSGSTNYNPSLKSRTISVETSKNQFSLKLSS VTAADTAVYYCARDKWTWYFDLWGRGTLVTVSS
610	DVD684L	AB004	AB062	DIQMTQSPSSLSASVGDRTITCRASQDVNTAVAW YQQKPGKAPKLLIYASFLYSGVPSRFSGSRSGTD FTLTISSLQPEDFATYYCQYHYTPPTFGQGTKVE IKR TVAAP DIEMTQSPDSLAVSLGERATINCRSSQ SVLYSSNRNYLAWYQQNPGQPPKLLIYWASTRES GVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQY YSTPRTFGQGTKVEIKR

Example 2.129: Generation of HER2 (seq. 1) and ErbB3 (seq. 2) DVD-Igs with Linker Set 1

Table 162

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
611	DVD399H	AB063	AB004	EVQLVESGGGLVQPGGSLRLSCAASGFTFSIYSMN WVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRDEDTAVYYCARDRGDFDA FDIWGQGTMTVTVSS ASTKGPSVFPLAP EVQLVESG GGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGK GLEWVARIYPTNGYTRYADSVKGRFTISADTSKNT AYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQG TLVTVSS
612	DVD399L	AB063	AB004	DIQMTQSPSSLSASVGDRTITCQASQDITNYLNW YQQKPGKAPKLLIYDASNLETGVPSRFGSGSGTD FTFTISLQPEDIATYNCQQCENFPITFGQGRLE IKR TVAAPSVFIFPP DIQMTQSPSSLSASVGDRT ITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLY SGVPSRFGSGSGTDFTLTISLQPEDFATYYCQQ HYTTPPTFGQGTKVEIKR
613	DVD400H	AB004	AB063	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIH WVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFY AMDYWGQGTTLVTVSS ASTKGPSVFPLAP EVQLVES GGGLVQPGGSLRLSCAASGFTFSIYSMNWVRQAPG KGLEWVSYISSSSSTIYYADSVKGRFTISRDNKN SLYLQMNSLRDEDTAVYYCARDRGDFDAFDIWGQG TMVTVSS
614	DVD400L	AB004	AB063	DIQMTQSPSSLSASVGDRTITCRASQDVNTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFGSGSGTD FTLTISLQPEDFATYYCQQHYTTPPTFGQGTKVE IKR TVAAPSVFIFPP DIQMTQSPSSLSASVGDRT ITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLE TGVPSRFGSGSGTDFFTFTISLQPEDIATYNCQQ CENFPITFGQGRLEIKR

5

Example 2.130: Generation of HER2 (seq. 1) and ErbB3 (seq. 2) DVD-Igs with Linker Set 2

Table 163

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
615	DVD403H	AB063	AB004	EVQLVESGGGLVQPGGSLRLSCAASGFTFSIYSMNWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARDRGDFDAFDIWGQGTMTVTVSS ASTKGPSVFPLAP EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGLTVTSS
616	DVD403L	AB063	AB004	DIQMTQSPSSLSASVGDRTITCQASQDITNYLNWYQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFFTISSLQPEDIATYNCQCENFPITFGQGRLEIKR TVAAP DIQMTQSPSSLSASVGDRTITCRASQDVNTAVAWYQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISLQPEDFATYYCQQHYYTTPPTFGQGTKVEIKR
617	DVD404H	AB004	AB063	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGLTVTSS ASTKGPSVFPLAP EVQLVESGGGLVQPGGSLRLSCAASGFTFSIYSMNWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARDRGDFDAFDIWGQGTMTVTVSS
618	DVD404L	AB004	AB063	DIQMTQSPSSLSASVGDRTITCRASQDVNTAVAWYQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFFTISSLQPEDFATYYCQQHYYTTPPTFGQGTKVEIKR TVAAP DIQMTQSPSSLSASVGDRTITCQASQDITNYLNWYQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFFTISSLQPEDIATYNCQCENFPITFGQGRLEIKR

Example 2.131: Generation of HER2 (seq. 1) and ErbB3 (seq. 2) DVD-Igs with Linker Set 3

Table 164

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
619	DVD407H	AB063	AB004	EVQLVESGGGLVQPGGSLRLSCAASGFTFSIYSMN WVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRDEDTAVYYCARDRGDFDA FDIWGQGTMTVTVSS ASTKGPE EVQLVESGGGLVQPG GSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVAR IYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNS LRAEDTAVYYCSRWGGDGFYAMDYWGQGLTVTVSS
620	DVD407L	AB063	AB004	DIQMTQSPSSLSASVGDRTVITCQASQDITNYLNW YQQKPGKAPKLLIYDASNLETGVPSPRFGSGSGTD FTFTISSLQPEDIATYNCQQCENFPITFGQGRLE IKR TVAAPSVFIFPP DIQMTQSPSSLSASVGDRTV ITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLY SGVPSRFGSGRSGTDFTLTISSLQPEDFATYYCQQ HYTTPPTFGQGTKVEIKR
621	DVD408H	AB004	AB063	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIH WVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFY AMDYWGQGLTVTVSS ASTKGPE EVQLVESGGGLVQPG GSLRLSCAASGFTFSIYSMNWVRQAPGKGLEWVS YISSSSSTIYYADSVKGRFTISRDNANKNSLYLQMN SLRDEDTAVYYCARDRGDFDAFDIWGQGTMTVTVSS
622	DVD408L	AB004	AB063	DIQMTQSPSSLSASVGDRTVITCRASQDVNTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFGSGRSGTD FTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVE IKR TVAAPSVFIFPP DIQMTQSPSSLSASVGDRTV ITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLE TGVPSRFGSGSGTDFTFTISSLQPEDIATYNCQQ CENFPITFGQGRLEIKR

Example 2.132: Generation of HER2 (seq. 1) and ErbB3 (seq. 2) DVD-Igs with Linker Set 4

Table 165

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
623	DVD685H	AB063	AB004	EVQLVESGGGLVQPGGSLRLSCAASGFTFSIYSMN WVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRDEDTAVYYCARDRGDFDA FDIWGQGTMTVTVSS ASTKGPE EVQLVESGGGLVQPG GSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVAR IYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNS LRAEDTAVYYCSRWGGDGFYAMDYWGQGLTVTVSS
624	DVD685L	AB063	AB004	DIQMTQSPSSLSASVGDRTITCQASQDITNYLNW YQQKPGKAPKLLIYDASNLETGVPSPRFSGSGSGTD FTFTISSLPEDIATYNCQQCFNPFITFGQGRLE IKR TVAAP DIQMTQSPSSLSASVGDRTITCRASQ DVNTAVAWYQQKPGKAPKLLIYSASFYSGVPSRF SGSRSGTDFTLTISSLPEDFATYYCQQHYTTPPT FGQGTKVEIKR
625	DVD686H	AB004	AB063	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIH WVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFY AMDYWGQGLTVTVSS ASTKGPE EVQLVESGGGLVQPG GSLRLSCAASGFTFSIYSMNWVRQAPGKGLEWVS YISSSSSTIYYADSVKGRFTISRDNKNSLYLQMN SLRDEDTAVYYCARDRGDFDAFDIWGQGTMTVTVSS
626	DVD686L	AB004	AB063	DIQMTQSPSSLSASVGDRTITCRASQDVNTAVAW YQQKPGKAPKLLIYSASFYSGVPSRFSGSRSGTD FTLTISSLPEDFATYYCQQHYTTPPTFGQGTKVE IKR TVAAP DIQMTQSPSSLSASVGDRTITCQASQ DITNYLNWYQQKPGKAPKLLIYDASNLETGVPSPRF SGSGSGTDFTFTISSLPEDIATYNCQQCFNPFIT FGQGRLEIKR

Example 2.133: Generation of EGFR (seq. 2) and ErbB3 (seq. 3) DVD-Igs with Linker Set 1

Table 166

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
627	DVD409H	AB067	AB033	EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYVMA WVRQAPGKGLEWVSSISSGGWTLYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCTRGLKMATI FDYWGQGTLVTVSS ASTKGP QVQLKQSGPGLVQPS QSL SITCTVSGFSLTNYGVHWRQSPGKLEWLGV IWSGGNTDYNTPFTSRLSINKDNSKSVFFKMNSL QSNDAIYYCARALTYDYEFAYWGQGTLVTVSA
628	DVD409L	AB067	AB033	QSALTQPASVSGSPGQSITISCTGTSSDVGSYNVV SWYQQHPGKAPKLIIEVSVQRPSGVSNRFSGSKSG NTASLTISGLQTEDEADYYCCSYAGSSIFVIFGGG TKVTVLG QPKAAP DILLTQSPVILSVSPGERVSPFS CRASQSIGTNIHWYQQRNGSPRLLIKYASESISG IPSRFSGSGSGTDFTLINSVESEDIADYYCQNN NWPTTFGAGTKLELKR
629	DVD410H	AB033	AB067	QVQLKQSGPGLVQPSQSL SITCTVSGFSLTNYGVH WVRQSPGKLEWLGVIWSGGNTDYNTPFTSRLSIN KDNSKSVFFKMNSLQSNDAIYYCARALTYDYEFAYWGQGTLVTVSS ASTKGP EVQLLESGGGLVQPG GSLRLSCAASGFTFSHYVMAWVRQAPGKLEWVSS ISSGGWTLYADSVKGRFTISRDNKNTLYLQMNS LRAEDTAVYYCTRGLKMATIFDYWGQGTLVTVSS
630	DVD410L	AB033	AB067	DILLTQSPVILSVSPGERVSPFSCRASQSIGTNIHW YQQRNGSPRLLIKYASESISGIPSRFSGSGSGTD FTLSINSVESEDIADYYCQNNNWPTTFGAGTKLE LKR TVAAP QSALTQPASVSGSPGQSITISCTGTSS DVGSYNVSWYQQHPGKAPKLIIEVSVQRPSGVS NRFSGSKSGNTASLTISGLQTEDEADYYCCSYAGSS IFVIFGGGTKVTVLG

Example 2.134: Generation of EGFR (seq. 2) and ErbB3 (seq. 3) DVD-Igs with Linker Set 2

Table 167

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
631	DVD413H	AB067	AB033	EVQLLESQGGGLVQPGGSLRLSCAASGFTFSHYVMAWVRQAPGKGLEWVSSISSGGWTLYADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCTRGLKMATIFDYWGQGLVTVSS ASTKGPSVFPLAP QVQLKQSGPGLVQPSQLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSSGGNTDYNTPFTSRLSINKDNSKSVFFKMNSLQSNDAIYYCARALTYDYEFAYWGQGLVTVSA
632	DVD413L	AB067	AB033	QSALTQPASVSGSPGQSIITISCTGTSSDVGSYNVSWYQQHPGKAPKLIIEVVSQRPSGVSNRFSGSKSGNTASLTISGLQTEDEADYCCSYAGSSIFVIFGGGTKVTVLG QPKAAPSVTLFPP DILLTQSPVILSVSPGERVFSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGGTDFTLSINSVESEDIADYYCQNNNWPTTFGAGTKLELKR
633	DVD414H	AB033	AB067	QVQLKQSGPGLVQPSQLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSSGGNTDYNTPFTSRLSINKDNSKSVFFKMNSLQSNDAIYYCARALTYDYEFAYWGQGLVTVSA ASTKGPSVFPLAP EVQLLESQGGGLVQPGGSLRLSCAASGFTFSHYVMAWVRQAPGKGLEWVSSISSGGWTLYADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCTRGLKMATIFDYWGQGLVTVSS
634	DVD414L	AB033	AB067	DILLTQSPVILSVSPGERVFSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGGTDFTLSINSVESEDIADYYCQNNNWPTTFGAGTKLELKR TVAAPSVFI FPQSALTQPASVSGSPGQSIITISCTGTSSDVGSYNVSWYQQHPGKAPKLIIEVVSQRPSGVSNRFSGSKSGNTASLTISGLQTEDEADYCCSYAGSSIFVIFGGGTKVTVLG

Example 2.135: Generation of EGFR (seq. 2) and ErbB3 (seq. 3) DVD-Igs with Linker Set 3

Table 168

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
635	DVD417H	AB067	AB033	EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYVMA WVRQAPGKGLEWVSSISSGGWTLYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCTRGLKMATI FDYWGQGLVTVSS ASTKGPSVFPLAP QVQLKQSG PGLVQPSQSLITCTVSGFSLTNYGVHWVRQSPGK GLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKQV FFKMNSLQSNDAIYYCARALTYDYEFAYWGQGT LVTVSA
636	DVD417L	AB067	AB033	QSALTQPASVSGSPGQSITISCTGTSSDVGSYNV SWYQQHPGKAPKLIIEVSVQRPSGVSNRFSGSKSG NTASLTISGLQTEDEADYYCCSYAGSSIFVIFGGG TKVTVLG QPKAAP DILLTQSPVILSVSPGERVFS CRASQSIGTNIHWYQQRNGSPRLLIKYASESISG IPSRFSGSGGTDFTLSINSVESEDIADYYCQNN NWPTTFGAGTKLELKR
637	DVD418H	AB033	AB067	QVQLKQSGPGLVQPSQSLITCTVSGFSLTNYGVH WVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSIN KDNSKQVFFKMNSLQSNDAIYYCARALTYDYEF FAYWGQGLVTVSS ASTKGPSVFPLAP EVQLLES GGLVQPGGSLRLSCAASGFTFSHYVMAWVRQAPGK GLEWVSSISSGGWTLYADSVKGRFTISRDNKNT LYLQMNSLRAEDTAVYYCTRGLKMATIFDYWGQGT LVTVSS
638	DVD418L	AB033	AB067	DILLTQSPVILSVSPGERVFS CRASQSIGTNIHWYQQRNGSPRLLIKYASESISG IPSRFSGSGGTDFTLSINSVESEDIADYYCQNN NWPTTFGAGTKLELKR TVAAP QSALTQPASVSGSPGQSITISCTGTSS DVGSYNVSWYQQHPGKAPKLIIEVSVQRPSGVS NRFSGSKSGNTASLTISGLQTEDEADYYCCSYAGSS IFVIFGGGTKVTVLG

Example 2.136: Generation of EGFR (seq. 2) and ErbB3 (seq. 3) DVD-Igs with Linker Set 4

Table 169

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
639	DVD421H	AB067	AB033	EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYVMA WVRQAPGKGLEWVSSISSGGWTLYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCTRGLKMATI FDYWGQGLVTVSS ASTKGP QVQLKQSGPGLVQPS QSL SITCTVSGFSLTNYGVHWVRQSPGKLEWLGV IWSGGNTDYNTPFTSRLSINKDNSKSVFFKMNSL QSNDAIYYCARALTYDYEFAYWGQGLVTVSA
640	DVD421L	AB067	AB033	QSALTQPASVSGSPGQSIITISCTGTSSDVGSYNVV SWYQQHPGKAPKLIIEVVSQRPSGVSNNRFGSKSG NTASLTISGLQTEDEADYCCSYAGSSIFVIFGGG TKVTVLG QPKAAPSVTLFPP DILLTQSPVILSVSP GERVSFSCRASQSIGTNIHWYQRTNGSPRLLIKY ASESISGIPSRFSGSGSGTDFTLSINSVESEDIAD YYCQNNNWPTTFGAGTKLELKR
641	DVD422H	AB033	AB067	QVQLKQSGPGLVQPSQSL SITCTVSGFSLTNYGVH WVRQSPGKLEWLGVIWSGGNTDYNTPFTSRLSIN KDNSKSVFFKMNSLQSNDAIYYCARALTYDYEFAYWGQGLVTVSSA ASTKGP EVQLLESGGGLVQPG GSLRLSCAASGFTFSHYVMAWVRQAPGKGLEWVSS ISSGGWTLYADSVKGRFTISRDNKNTLYLQMNS LRAEDTAVYYCTRGLKMATIFDYWGQGLVTVSS
642	DVD422L	AB033	AB067	DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHW YQRTNGSPRLLIKYASESISGIPSRFSGSGSGTD FTLSINSVESEDIADYYCQNNNWPTTFGAGTKLE LKR TVAAPSVFI FPP QSALTQPASVSGSPGQSIIT SCTGTSSDVGSYNVVSWYQQHPGKAPKLIIEVVSQ RPSGVSNNRFGSKSGNTASLTISGLQTEDEADYCCSYAGSSIFVIFGGGTKVTVLG

Example 2.137: Generation of HER2 (seq. 1) and ErbB3 (seq. 3) DVD-Igs with Linker Set 1

Table 170

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
643	DVD411H	AB067	AB004	EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYVMA WVRQAPGKGLEWVSSISSGGWTLYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCTRGLKMATI FDYWGQGLVTVVSS ASTKGPE EVQLVESGGGLVQPG GSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVAR IYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNS LRAEDTAVYYCSRWGGDGFYAMDYWGQGLVTVVSS
644	DVD411L	AB067	AB004	QSALTQPASVSGSPGQSIITISCTGTSSDVGSYNVV SWYQQHPGKAPKLLIIEVSVQRPSGVSNRFSGSKSG NTASLTISGLQTEDEADYYCCSYAGSSIFVIFGGG TKVTVLG QPKAAP DIQMTQSPSSLSASVGDRTIT CRASQDVNTAVAWYQQKPGKAPKLLIYSASFYSG VPSRFSGSRSGTDFTLTISLQPEDFATYYCQQHY TPPTFGQGTKVEIKR
645	DVD412H	AB004	AB067	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIH WVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFY AMDYWGQGLVTVVSS ASTKGPE EVQLLESGGGLVQPG GGSLRLSCAASGFTFSHYVMAWVRQAPGKGLEWVS SISSGGWTLYADSVKGRFTISRDNSKNTLYLQMN SLRAEDTAVYYCTRGLKMATIFDYWGQGLVTVVSS
646	DVD412L	AB004	AB067	DIQMTQSPSSLSASVGDRTITCRASQDVNTAVAW YQQKPGKAPKLLIYSASFYSGVPSRFSGSRSGTD FTLTISLQPEDFATYYCQQHYTPPTFGQGTKVE IKR TVAAP QSALTQPASVSGSPGQSIITISCTGTSS DVGSYNVVSWYQQHPGKAPKLLIIEVSVQRPSGVS NRFSGSKSNTASLTISGLQTEDEADYYCCSYAGSS IFVIFGGGTKVTVLG

Example 2.138: Generation of HER2 (seq. 1) and ErbB3 (seq. 3) DVD-Igs with Linker Set 2

Table 171

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
647	DVD415H	AB067	AB004	EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYVMA WVRQAPGKGLEWVSSISSGGWTLYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCTRGLKMATI FDYWGQGLVTVSS ASTKGPSVFPLAP EVQLVESG GGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGK GLEWVARIYPTNGYTRYADSVKGRFTISADTSKNT AYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQG TLVTVSS
648	DVD415L	AB067	AB004	QSALTQPASVSGSPGQSITISCTGTSSDVGSYNVV SWYQQHPGKAPKLLIYEVSQRPSGVSNRFSGSKSG NTASLTISGLQTEDEADYCCSYAGSSIFVIFGGG TKVTVLG QPKAAPSVTLFPP DIQMTQSPSSLSASV GDRVITICRASQDVNTAVAWYQQKPGKAPKLLIYS ASFLYSGVPSRFSGSRSGTDFLTISSLQPEDFAT YYCQQHYTTPPTFGQGTKVEIKR
649	DVD416H	AB004	AB067	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIH WVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFY AMDYWGQGLVTVSS ASTKGPSVFPLAP EVQLLES GGGLVQPGGSLRLSCAASGFTFSHYVMAWVRQAPG KGLEWVSSISSGGWTLYADSVKGRFTISRDN SKN TLYLQMNSLRAEDTAVYYCTRGLKMATIFDYWGQG TLVTVSS
650	DVD416L	AB004	AB067	DIQMTQSPSSLSASVDRVITICRASQDVNTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTD FTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVE IKR TVAAPSVFI FPQSALTQPASVSGSPGQSITI SCTGTSSDVGSYNVVSWYQQHPGKAPKLLIYEVSQ RPSGVSNRFSGSKSGNTASLTISGLQTEDEADYIC CSYAGSSIFVIFGGGTKVTVLG

Example 2.139: Generation of HER2 (seq. 1) and ErbB3 (seq. 3) DVD-Igs with Linker Set 3

Table 172

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
651	DVD419H	AB067	AB004	EVQLLES GGGLVQ PGGSLRLS CAASGFT FSHYVMA WVRQAPGKGLEWVSSISSGGWTLYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCTRGLKMATI FDYWGQGLVTVSS ASTKGPSVFPLAP EVQLVESG GGLVQPGGSLRLS CAASGFT FSHYVMAWVRQAPGK GLEWVARIYPTNGYTRYADSVKGRFTISADTSKNT AYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQG TLVTVSS
652	DVD419L	AB067	AB004	QSALTQPASVSGSPGQSITISCTGTSSDVGSYNVV SWYQQHPGKAPKLLIYEVSQRPSGVS NR FSGSKSG NTASLTISGLQTEDEADYYCCSYAGSSI FVI FGGG TKVTVLG QPKAAP DIQMTQSPSSLSASV GDRVTIT CRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSG VPSRFGSRSRSGTDFLTITISLQPEDFATYYCQQHY TTPPTFGQGTKVEIKR
653	DVD420H	AB004	AB067	EVQLVESGGGLVQPGGSLRLS CAASGFT FSHYVMAWVRQAPG WVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFY AMDYWGQGLVTVSS ASTKGPSVFPLAP EVQLLES GGGLVQPGGSLRLS CAASGFT FSHYVMAWVRQAPG KGLEWVSSISSGGWTLYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCTRGLKMATI FDYWGQGLVTVSS
654	DVD420L	AB004	AB067	DIQMTQSPSSLSASV GDRVTIT CRASQDVNTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFGSRSRSGT DFLTITISLQPEDFATYYCQQHYTTPPTFGQGTKVE IKR TVAAP QSALTQPASVSGSPGQSITISCTGTSS DVGSYNVVSWYQQHPGKAPKLLIYEVSQRPSGVS NRFGS SKSGNTASLTISGLQTEDEADYYCCSYAGSSI FVI FGGGTKVTVLG

Example 2.140: Generation of HER2 (seq. 1) and ErbB3 (seq. 3) DVD-Igs with Linker Set 4

Table 173

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
655	DVD423H	AB067	AB004	EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYVMA WVRQAPGKGLEWVSSISSGGWTLYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCTRGLKMATI FDYWGQGLVTVVSS ASTKGPE EVQLVESGGGLVQPG GSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVAR IYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNS LRAEDTAVYYCSRWGGDGFYAMDYWGQGLVTVVSS
656	DVD423L	AB067	AB004	QSALTQPASVSGSPGQSIITISCTGTSSDVGSYNVV SWYQQHPGKAPKLLIYEVSQRPSGVSNNRFGSKSG NTASLTISGLQTEDEADYYCCSYAGSSIFVIFGGG TKVTVLG QPKAAPSVTLFPP DIQMTQSPSSLSASV GDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYS ASFLYSGVPSRFGSRSRSGTDFTLTISSLQPEDFAT YYCQQHYTTPPTFGQGTKVEIKR
657	DVD424H	AB004	AB067	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIH WVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFY AMDYWGQGLVTVVSS ASTKGPE EVQLLESGGGLVQPG GSLRLSCAASGFTFSHYVMAWVRQAPGKGLEWVS SISSGGWTLYADSVKGRFTISRDNSKNTLYLQMN SLRAEDTAVYYCTRGLKMATIFDYWGQGLVTVVSS
658	DVD424L	AB004	AB067	DIQMTQSPSSLSASVSGDRVTITCRASQDVNTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFGSRSRSGTD FTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVE IKR TVAAPSVFIFPP QSALTQPASVSGSPGQSIIT SCTGTSSDVGSYNVVSWYQQHPGKAPKLLIYEVSQ RPSGVSNNRFGSKSGNTASLTISGLQTEDEADYYC CSYAGSSIFVIFGGGTKVTVLG

Example 2.141: Generation of VEGF (seq. 1) and PLGF (seq. 2) DVD-Igs with Linker Set 1

Table 174

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
659	DVD541H	AB074VH	AB014VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTTYGIH WVRQSPGKGLEWLGVMWGGDDTDYDAAFISRLSIS KDNSKSKVFFKMNSLQANDTGIYYCARYRFYGM DY WQGTSTVTVSS ASTKGP EVQLVESGGGLVQPGGSL RLSCAASGYTFTNYGMNWRQAPGKGLEWVGWINT YTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRA EDTAVYYCAKYPHYYGSSHWFYFDVWGQGLVTVSS
660	DVD541L	AB074VL	AB014VL	AIQMTQSSSSFSVSLGDRVTITCKASEDIYNRFAW YQQKPGNAPRLLISGAASLEAGVPSRFSGSGSQD YTLSTISLQTEDVATYYCQYWSTPWFEGGKLE IKR TVAAP DIQMTQSPSSLSASVGDRTITCSASQ DISNYLNWYQQKPKAPKVLIIYFTSSLHSGVPSRF SGSGSGTDFTLTISLQPEDFATYYCQYSTVPWT FGGKTKVEIKR
661	DVD542H	AB014VH	AB074VH	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMN WVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTF SLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYS SHWFYFDVWGQGLVTVSS ASTKGP QVQLKQSGPGL VQPSQSLITCTVSGFSLTTYGIHWVRQSPGKLE WLGVMWGGDDTDYDAAFISRLSISKDNSKSKVFFK MNSLQANDTGIYYCARYRFYGM DYWQGTSTVTVSS
662	DVD542L	AB014VL	AB074VL	DIQMTQSPSSLSASVGDRTITCSASQDISNYLNW YQQKPKAPKVLIIYFTSSLHSGVPSRFSGSGSGTD FTLTISLQPEDFATYYCQYSTVPWFEGGKVE IKR TVAAP AIQMTQSSSSFSVSLGDRVTITCKASE DIYNRFAWYQQKPGNAPRLLISGAASLEAGVPSRF SGSGSQDYTLSTISLQTEDVATYYCQYWSTPWT FGGKTKLEIKR

Example 2.142: Generation of VEGF (seq. 1) and PLGF (seq. 2) DVD-Igs with Linker Set 2

Table 175

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
663	DVD549H	AB074VH	AB014VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTTYGIH WVRQSPGKGLEWLGVMWSSGGDDYDAAFISRLSIS KDNSKQVFFKMNSLQANDTGIYYCARYRFYGM DY WQGTSTVTVSS ASTKGPSVFPLAP EVQLVESGGGL VQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLE WGWINTYTGEPYAADEFKRRFTFSLDTSKSTAYL QMNSLRAEDTAVYYCAKYPHYYS SHWY FDVWGQG TLVTVSS
664	DVD549L	AB074VL	AB014VL	AIQMTQSSSSFSVSLGDRVTITCKASEDIYNRFAW YQQKPGNAPRLLISGAASLEAGVPSRFRSGSGSQD YTLSITSLQTEDVATYYCQQY WSTP WTFGGGKLE IKR TVAAPSVFIFPP DIQMTQSPSSLSASVDRVT ITCSASQDISNYLNWYQQKPGKAPKVLITYFTSSLH SGVPSRFRSGSGSGTDFTLTISLQPEDFATYYCQQ YSTVPWTFGQGTKVEIKR
665	DVD550H	AB014VH	AB074VH	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMN WVRQAPGKGLEWGWINTYTGEPYAADEFKRRFTF SLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYS SHWYFDVWGQGTTLVTVSS ASTKGPSVFPLAP QVQL KQSGPGLVQPSQSLITCTVSGFSLTTYGIHWVRQ SPGKGLEWLGVMWSSGGDDYDAAFISRLSISKDNS KQVFFKMNSLQANDTGIYYCARYRFYGM DYWGQG TSVTVSS
666	DVD550L	AB014VL	AB074VL	DIQMTQSPSSLSASVDRVTITCSASQDISNYLNW YQQKPGKAPKVLITYFTSSLHSGVPSRFRSGSGSGTD FTLTISLQPEDFATYYCQQY STVP WTFGQGTKVE IKR TVAAPSVFIFPP AIQMTQSSSSFSVSLGDRVT ITCKASEDIYNRFAWYQQKPGNAPRLLISGAASLE AGVPSRFRSGSGSGQDYTLTSLQTEDVATYYCQQ Y WSTP WTFGGGKLEIKR

Example 2.143: Generation of VEGF (seq. 1) and PLGF (seq. 2) DVD-Igs with Linker Set 3

Table 176

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
667	DVD557H	AB074VH	AB014VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTTYGIH WVRQSPGKGLEWLGVMWSGGDDYDAAFISRLSIS KDNSKQVFFKMNSLQANDTGIYYCARYRFYGM DY WQGTSTVTVSS ASTKGPSVFPLAP EVQLVESGGGL VQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLE WGWINTYTGEPYAADEFKRRFTFSLDTSKSTAYL QMNSLRAEDTAVYYCAKYPHYYS SHWY FDVWGQG TLVTVSS
668	DVD557L	AB074VL	AB014VL	AIQMTQSSSSFSVSLGDRVTITCKASEDIYNRFAW YQQKPGNAPRLLISGAASLEAGVPSRFSGSGSQD YTLSITSLQTEDVATYYCQY WSTP WTFGGGKLE IKR TVAAP DIQMTQSPSSLSASVGD RV ITCSAQ DISNYLNWYQQKPKAPKVLIIYFTSSLHSGVPSRF SGSGSGTDFLTLSISLQPEDFATYYCQY STVP WTF FGGKLEIKR
669	DVD558H	AB014VH	AB074VH	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMN WVRQAPGKGLEWGWINTYTGEPYAADEFKRRFTF SLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYS SHWYFDVWGQGTTLVTVSS ASTKGPSVFPLAP QVQL KQSGPGLVQPSQSLITCTVSGFSLTTYGIHWVRQ SPGKGLEWLGVMWSGGDDYDAAFISRLSISKDNS KQVFFKMNSLQANDTGIYYCARYRFYGM DYWGQG TSVTVSS
670	DVD558L	AB014VL	AB074VL	DIQMTQSPSSLSASVGD RV ITCSAQDISNYLNW YQQKPKAPKVLIIYFTSSLHSGVPSRFSGSGGTD FTLTLSISLQPEDFATYYCQY STVP WTFGGKLE IKR TVAAP AIQMTQSSSSFSVSLGDRVTITCKASE DIYNRFAWYQQKPGNAPRLLISGAASLEAGVPSRF SGSGSQDYTLISITSLQTEDVATYYCQY WSTP WTF FGGKLEIKR

Example 2.144: Generation of VEGF (seq. 1) and PLGF (seq. 2) DVD-Igs with Linker Set 4

Table 177

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
671	DVD565H	AB074VH	AB014VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTTYGIH WVRQSPGKGLEWLGVMWSGGDDYDAAFISRLSIS KDNSKSKQVFFKMNSLQANDTGIYYCARYRFYGM DY WQGTSTVTVSS ASTKGP EVQLVESGGGLVQPGGSL RLSCAASGYTFTNYGMNWRQAPGKGLEWVGWINT YTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRA EDTAVYYCAKYPHYYGSSHWFVWVGQGLVTVSS
672	DVD565L	AB074VL	AB014VL	AIQMTQSSSSFSVSLGDRVTITCKASEDIYNRFAW YQKPGNAPRLLISGAASLEAGVPSRFSGSGSQD YTLSTISLQTEDVATYYCQYQYWSWTFGGGKLE IKR TVAAPSVFIFPP DIQMTQSPSSLSASVGDRTV ITCSASQDISNYLNWYQKPGKAPKVLIIYFTSSLH SGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQ YSTVPWTFGGGKVEIKR
673	DVD566H	AB014VH	AB074VH	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMN WVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTF SLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYS SHWFVWVGQGLVTVSS ASTKGP QVQLKQSGPGL VQPSQSLITCTVSGFSLTTYGIHWRQSPGKGLE WLGVMWSGGDDYDAAFISRLSISKDNSKSKQVFFK MNSLQANDTGIYYCARYRFYGM DYWQGTSTVTVSS
674	DVD566L	AB014VL	AB074VL	DIQMTQSPSSLSASVGDRTVITCSASQDISNYLNW YQKPGKAPKVLIIYFTSSLHSGVPSRFSGSGSGTD FTLTISSLQPEDFATYYCQYQYWSWTFGGGKVE IKR TVAAPSVFIFPP AIQMTQSSSSFSVSLGDRVT ITCKASEDIYNRFAWYQKPGNAPRLLISGAASLE AGVPSRFSGSGSGQDYTLSTISLQTEDVATYYCQQ YWSTVPWTFGGGKLEIKR

Example 2.145: Generation of VEGF (seq. 2) and PLGF (seq. 2) DVD-Igs with Linker Set 1

Table 178

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
675	DVD543H	AB074VH	AB070VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTTYGIH WVRQSPGKGLEWLGVMWSGGDDYDAAFISRLSIS KDNSKQVFFKMNSLQANDTGIYYCARYRFYGM DY WGQGTSVTVSS ASTKGP EVQLVESGGGLVQPGGSL RLSCAASGFTISDYWIHWVRQAPGKGLEWVAGITP AGGYTYADSVKGRFTISADTSKNTAYLQMNSLRA EDTAVYYCARFVFFLPYAMDYWGQGTTLVTVSS
676	DVD543L	AB074VL	AB070VL	AIQMTQSSSSFSVSLGDRVTITCKASEDIYNRFAW YQQKPGNAPRLLISGAASLEAGVPSRFSGSGSQD YTLSTLSLQTEDVATYYCQQYWSTPWTFGGGTKLE IKR TVAAP DIQMTQSPSSLSASVGDVRVITCRASQ DVSTAVAWYQQKPGKAPKLLIYSASFYSGVPSRF SGSGSGTDFTLTISLQPEDFATYYCQQSYTTPPT FGGGTKVEIKR
677	DVD544H	AB070VH	AB074VH	EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIH WVRQAPGKGLEWVAGITPAGGYTYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPY AMDYWGQGTTLVTVSS ASTKGP QVQLKQSGPGLVQ PSQSLITCTVSGFSLTTYGIHWRQSPGKGLEWLG VMWSGGDDYDAAFISRLSISKDNSKQVFFKMNS LQANDTGIYYCARYRFYGM DYWGQGTSVTVSS
678	DVD544L	AB070VL	AB074VL	DIQMTQSPSSLSASVGDVRVITCRASQDVSTAVAW YQQKPGKAPKLLIYSASFYSGVPSRFSGSGSGTD FTLTISLQPEDFATYYCQQSYTTPPTFGGGTKVE IKR TVAAP AIQMTQSSSSFSVSLGDRVTITCKASE DIYNRFAWYQQKPGNAPRLLISGAASLEAGVPSRF SGSGSGQDYTLSTLSLQTEDVATYYCQQYWSTPWT FGGGTKLEIKR

Example 2.146: Generation of VEGF (seq. 2) and PLGF (seq. 2) DVD-Igs with Linker Set 2

Table 179

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
679	DVD551H	AB074VH	AB070VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTTYGIH WVRQSPGKGLEWLGVMWSGGDDYDAAFISRLSIS KDNSKSVFFKMNSLQANDTGIYYCARYRFYGM DY WQGTSTVTVSS ASTKGPSVFPLAP EVQLVESGGGL VQPGGSLRLSCAASGFTISDYWIHWVRQAPGKGLE WVAGITPAGGYTYADSVKGRFTISADTSKNTAYL QMNSLRAEDTAVYYCARFVFFLPYAMDYWGQGLTV TVSS
680	DVD551L	AB074VL	AB070VL	AIQMTQSSSSFSVSLGDRVTITCKASEDIYNRFAW YQQKPGNAPRLLISGAASLEAGVPSRFRSGSGSQD YTLSITSLQTEDVATYYCQQYWSTPWFEGGKTLE IKR TVAAPSVFIFPP DIQMTQSPSSLSASVGDRT ITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLY SGVPSRFRSGSGSDFTLTITSSLPEDFATYYCQQ SYTTPPTFGQGTKVEIKR
681	DVD552H	AB070VH	AB074VH	EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIH WVRQAPGKGLEWVAGITPAGGYTYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPY AMDYWGQGLTVTVSS ASTKGPSVFPLAP QVQLKQS GPGLVQPSQSLITCTVSGFSLTTYGIHWVRQSPG KGLEWLGVMWSGGDDYDAAFISRLSISKDNSKQ VFFKMNSLQANDTGIYYCARYRFYGM DYWQGTSTV TVSS
682	DVD552L	AB070VL	AB074VL	DIQMTQSPSSLSASVGDRTITCRASQDVSTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFRSGSGSD FTLTITSSLPEDFATYYCQQSYTTPPTFGQGTKVE IKR TVAAPSVFIFPP AIQMTQSSSSFSVSLGDRVT ITCKASEDIYNRFAWYQQKPGNAPRLLISGAASLE AGVPSRFRSGSGSQDYTLSITSLQTEDVATYYCQQ YWSTPWFEGGKTLEIKR

Example 2.147: Generation of VEGF (seq. 2) and PLGF (seq. 2) DVD-Igs with Linker Set 3

Table 180

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
683	DVD559H	AB074VH	AB070VH	QVQLKQSGPGLVQPSSLSITCTVSGFSLTTYGIH WVRQSPGKGLEWLGVMWSSGGDDYDAAFISRLSIS KDNSKSVFFKMNSLQANDTGIYYCARYRFYGM DY WGQTSVTVSS ASTKGPSVFPLAP EVQLVESGGGL VQPGGSLRLSCAASGFTISDYWIHWVRQAPGKGLE WVAGITPAGGYTYADSVKGRFTISADTSKNTAYL QMNSLRAEDTAVYYCARFVFFLPYAMDYWGQGLV TVSS
684	DVD559L	AB074VL	AB070VL	AIQMTQSSSSFSVSLGDRVTITCKASEDIYNRFAW YQKPGNAPRLLISGAASLEAGVPSRFSGSGSQD YTLISITSLQTEDVATYYCQYWPSTPFTFGGKLE IKR TVAAP DIQMTQSPSSLSASVGDRTITCRASQ DVSTAVAWYQKPKAPKLLIYSASFLYSGVPSRF SGSGSGTDFLTITSSLPEDFATYYCQSYTTPPT FGGKLEIKR
685	DVD560H	AB070VH	AB074VH	EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIH WVRQAPGKGLEWVAGITPAGGYTYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPY AMDYWGQGLVTVSS ASTKGPSVFPLAP QVQLKQS GPGLVQPSSLSITCTVSGFSLTTYGIHWVRQSPG KGLEWLGVMWSSGGDDYDAAFISRLSISKDNSKQ VFFKMNSLQANDTGIYYCARYRFYGM DYWGQTSV TVSS
686	DVD560L	AB070VL	AB074VL	DIQMTQSPSSLSASVGDRTITCRASQDVSTAVAW YQKPKAPKLLIYSASFLYSGVPSRFSGSGSGTD FTLTITSSLPEDFATYYCQSYTTPPTFGGKLE IKR TVAAP AIQMTQSSSSFSVSLGDRVTITCKASE DIYNRFAWYQKPGNAPRLLISGAASLEAGVPSRF SGSGSQDYTLISITSLQTEDVATYYCQYWPSTPWT FGGKLEIKR

Example 2.148: Generation of VEGF (seq. 2) and PLGF (seq. 2) DVD-Igs with Linker Set 4

Table 181

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
687	DVD567H	AB074VH	AB070VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTTYGIH WVRQSPGKGLEWLGVMWSGGDDYDAAFISRLSIS KDNSKQVFFKMNSLQANDTGIYYCARYRFYGM DY WGQGTSTVTVSS ASTKGP EVQLVESGGGLVQPGGSL RLSCAASGFTISDYWIHWVRQAPGKGLEWVAGITP AGGYTYADSVKGRFTISADTSKNTAYLQMNSLRA EDTAVYYCARFVFFLPYAMDYWGQGTTLVTVSS
688	DVD567L	AB074VL	AB070VL	AIQMTQSSSSFSVSLGDRVTITCKASEDIYNRFAW YQQKPGNAPRLLISGAASLEAGVPSRFRSGSGSQD YTLSTISLQTEDVATYYCQQYWSWPWFEGGGTKLE IKR TVAAPSVFIFPP DIQMTQSPSSLSASVGDRTV ITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLY SGVPSRFRSGSGSDFTLTISLQPEDFATYYCQQ SYTTPPTEFGQGTKEIKR
689	DVD568VH	AB070VH	AB074VH	EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIH WVRQAPGKGLEWVAGITPAGGYTYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPY AMDYWGQGTTLVTVSS ASTKGP QVQLKQSGPGLVQ PSQSLITCTVSGFSLTTYGIHWRQSPGKGLEWLG VMWSGGDDYDAAFISRLSISKDNSKQVFFKMNS LQANDTGIYYCARYRFYGM DYWGQGTSTVTVSS
690	DVD568VL	AB070VL	AB074VL	DIQMTQSPSSLSASVGDRTVITCRASQDVSTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFRSGSGSD FTLTISLQPEDFATYYCQQSYTTPPTEFGQGTKE IKR TVAAPSVFIFPP AIQMTQSSSSFSVSLGDRVT ITCKASEDIYNRFAWYQQKPGNAPRLLISGAASLE AGVPSRFRSGSGSQDYTLSTISLQTEDVATYYCQQ YWSWPWFEGGGTKLEIKR

Example 2.149: Generation of VEGF (seq. 3) and PLGF (seq. 2) DVD-Igs with Linker Set 1

Table 182

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
691	DVD545H	AB074VH	AB071VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTTYGIH WVRQSPGKGLEWLGVMWSSGGDDYDAAFISRLSIS KDNSKSKVFFKMNSLQANDTGIYYCARYRFYGM DY WGQGTSTVTVSS ASTKGP EVQLVESGGGLVQPGGSL RLSCAASGFTINASWIHWVRQAPGKGLEWVGAIYP YSGYTNYADSVKGRFTISADTSKNTAYLQMNSLRA EDTAVYYCARWGHSTSPWAMDYWGQGTTLTVSS
692	DVD545L	AB074VL	AB071VL	AIQMTQSSSSFSVSLGDRVTITCKASEDIYNRFAW YQQKPGNAPRLLISGAASLEAGVPSRFSGSGSQD YTLSTISLQTEDVATYYCQQYWSTPWTFGGGTKLE IKR TVAAP DIQMTQSPSSLSASVGDRTITCRASQ VIRRSRAWYQQKPGKAPKLLIYAASNLAGVPSRF SGSGSGTDFTLTISLQPEDFATYYCQQSNTSPLT FGGQTKVEIKR
693	DVD546H	AB071VH	AB074VH	EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIH WVRQAPGKGLEWVGAIYPYSGYTNYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSP WAMDYWGQGTTLTVTVSS ASTKGP QVQLKQSGPGLVQ PSQSLITCTVSGFSLTTYGIHWVRQSPGKGLEWLG VMWSSGGDDYDAAFISRLSISKDNSKSKVFFKMN SLQANDTGIYYCARYRFYGM DYWGQGTSTVTVSS
694	DVD546L	AB071VL	AB074VL	DIQMTQSPSSLSASVGDRTITCRASQVIRRSRAW YQQKPGKAPKLLIYAASNLAGVPSRFSGSGSGTD FTLTISLQPEDFATYYCQQSNTSPLTFGGQTKVE IKR TVAAP AIQMTQSSSSFSVSLGDRVTITCKASE DIYNRFAWYQQKPGNAPRLLISGAASLEAGVPSRF SGSGSGQDYTLSTISLQTEDVATYYCQQYWSTPWT FGGGTKLEIKR

Example 2.150: Generation of VEGF (seq. 3) and PLGF (seq. 2) DVD-Igs with Linker Set 2

Table 183

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
695	DVD553H	AB074VH	AB071VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTTYGIH WVRQSPGKGLEWLGVMWSSGGDTDYDAAFISRLSIS KDNSKSVFFKMNLSLQANDTGIYYCARYRFYGM DY WQGTSTVTVSS ASTKGPSVFPLAP EVQLVESGGGL VQPGGSLRLSCAASGFTINASWIHWVRQAPGKGLE WVGAIYPYSGYTNYADSVKGRFTISADTSKNTAYL QMNSLRAEDTAVYYCARWGHSTSPWAMDYWGQGT LTVVSS
696	DVD553L	AB074VL	AB071VL	AIQMTQSSSSFSVSLGDRVTITCKASEDIYNRFAW YQQKPGNAPRLLISGAASLEAGVPSRFRSGSGSQD YTLISITSLQTEDVATYYCQQYWSPTWTFGGGKLE IKR TVAAPSVFIFPP DIQMTQSPSSLSASVDRVT ITCRASQVIRRLAWYQQKPGKAPKLLIYAASNLA SGVPSRFRSGSGSDFTLTITSSLPEDFATYYCQQ SNTSPLTFGQGTKVEIKR
697	DVD554H	AB071VH	AB074VH	EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIH WVRQAPGKGLEWVGAIYPYSGYTNYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSP WAMDYWGQGT LVTVSS ASTKGPSVFPLAP QVQLKQ SGPGLVQPSQSLITCTVSGFSLTTYGIHWVRQSP GKGLEWLGVMWSSGGDTDYDAAFISRLSISKDNSKS QVFFKMNLSLQANDTGIYYCARYRFYGM DYWGQGT S
698	DVD554L	AB071VL	AB074VL	DIQMTQSPSSLSASVDRVTITCRASQVIRRLAW YQQKPGKAPKLLIYAASNLAGVPSRFRSGSGSD FTLTITSSLPEDFATYYCQQSNTSPLTFGQGTKVE IKR TVAAPSVFIFPP AIQMTQSSSSFSVSLGDRVT ITCKASEDIYNRFAWYQQKPGNAPRLLISGAASLE AGVPSRFRSGSGSQDYTLISITSLQTEDVATYYCQQ YWSPTWTFGGGKLEIKR

Example 2.151: Generation of VEGF (seq. 3) and PLGF (seq. 2) DVD-Igs with Linker Set 3

Table 184

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
699	DVD561H	AB074VH	AB071VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTTYGIH WVRQSPGKGLEWLGVMWSSGGDTDYDAAFISRLSIS KDNSKQVFFKMNSLQANDTGIYYCARYRFYGM DY WGQGTSVTVSS ASTKGPSVFPLAP EVQLVESGGGL VQPGGSLRLSCAASGFTINASWIHWVRQAPGKGLE WVGAIPYPSGYTNYADSVKGRFTISADTSKNTAYL QMNSLRAEDTAVYYCARWGHSTSPWAMDYWGQGT LTVVSS
700	DVD561L	AB074VL	AB071VL	AIQMTQSSSSFSVSLGDRVTITCKASEDIYNRFAW YQQKPGNAPRLLISGAASLEAGVPSRFSGSGSQD YTLISITSLQTEDVATYYCQQYWSTPWFEGGKLE IKR TVAAP DIQMTQSPSSLSASVGDRTITCRASQ VIRRLAWYQQKPKAPKLLIYAASNLAGVPSRF SGSGSGTDFLTITSSLPEDFATYYCQQSNTSPLT FGGKTKVEIKR
701	DVD562H	AB071VH	AB074VH	EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIH WVRQAPGKGLEWVGAIPYPSGYTNYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSP WAMDYWGQGT LVTVSS ASTKGPSVFPLAP QVQLKQ SGPGLVQPSQSLITCTVSGFSLTTYGIHWVRQSP GKGLEWLGVMWSSGGDTDYDAAFISRLSISKDNSKS QVFFKMNSLQANDTGIYYCARYRFYGM DYWGQGTS VTVSS
702	DVD562L	AB071VL	AB074VL	DIQMTQSPSSLSASVGDRTITCRASQVIRRLAW YQQKPKAPKLLIYAASNLAGVPSRFSGSGSGTD FTLTITSSLPEDFATYYCQQSNTSPLTFGGKTKVE IKR TVAAP AIQMTQSSSSFSVSLGDRVTITCKASE DIYNRFAWYQQKPGNAPRLLISGAASLEAGVPSRF SGSGSQDYTLISITSLQTEDVATYYCQQYWSTPWT FGGKTKLEIKR

Example 2.152: Generation of VEGF (seq. 3) and PLGF (seq. 2) DVD-Igs with Linker Set 4

Table 185

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
703	DVD569H	AB074VH	AB071VH	QVQLKQSGPGLVQPSQSLTITCTVSGFSLTTYGIHWVRQSPGKGLEWLGVMWSSGGDDYDAAFISRLSISKDNSKQVFFKMNSLQANDTGIYYCARYRFYGM DYWGQTSVTVSS ASTKGP EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIHWVRQAPGKGLEWVGAIYPSGYTNYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSPWAMDYWGQGLVTVSS
704	DVD569L	AB074VL	AB071VL	AIQMTQSSSSFSVSLGDRVTITCKASEDIYNRFAWYQQKPGNAPRLLISGAASLEAGVPSRFSGSGSGQDYTLSTISLQTEDVATYYCQQYWSWTFGGGKLEIKR TVAAPSVFIFPP DIQMTQSPSSLSASVSGDRVITCRASQVIRRSLAWYQQKPGKAPKLLIYAASNLAGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQSNTSPLTFGGQTKVEIKR
705	DVD570H	AB071VH	AB074VH	EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIHWVRQAPGKGLEWVGAIYPYSGYTNADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSPWAMDYWGQGLVTVSS ASTKGP QVQLKQSGPGLVQPSQSLTITCTVSGFSLTTYGIHWVRQSPGKGLEWLGVMWSSGGDDYDAAFISRLSISKDNSKQVFFKMNSLQANDTGIYYCARYRFYGM DYWGQTSVTVSS
706	DVD570L	AB071VL	AB074VL	DIQMTQSPSSLSASVSGDRVITCRASQVIRRSLAWYQQKPGKAPKLLIYAASNLAGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQSNTSPLTFGGQTKVEIKR TVAAPSVFIFPP AIQMTQSSSSFSVSLGDRVTITCKASEDIYNRFAWYQQKPGNAPRLLISGAASLEAGVPSRFSGSGSGQDYTLSTISLQTEDVATYYCQQYWSWTFGGGKLEIKR

Example 2.153: Generation of HER2 (seq. 1) and PLGF (seq. 2) DVD-Igs with Linker Set 1

Table 186

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
707	DVD547H	AB074VH	AB004VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTTYGIH WVRQSPGKGLEWLGVMWMSGDDTDYDAAFISRLSIS KDNSKSQVFFKMNSLQANDTGIYYCARYRFYGM DY WGQGTSTVTVSS ASTKGP EVQLVESGGGLVQPGGSL RLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYP TNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRA EDTAVYYCSRWGGDGFYAMDYWGQGTTLVTVSS
708	DVD547L	AB074VL	AB004VL	AIQMTQSSSSFSVSLGDRVTITCKASEDIYNRFAW YQQKPGNAPRLLISGAASLEAGVPSRFSGSGSQD YTLSTISLQTEDVATYYCQQYWSTPWTFGGGTKLE IKR TVAAP DIQMTQSPSSLSASVGDVITCRASQ DVNTAVAWYQQKPGKAPKLLIYSASFYSGVPSRF SGSRSGTDFTLTISLQPEDFATYYCQQHYTTPPT FGGQTKVEIKR
709	DVD548H	AB004VH	AB074VH	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIH WVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFY AMDYWGQGTTLVTVSS ASTKGP QVQLKQSGPGLVQ PSQSLITCTVSGFSLTTYGIHWRQSPGKGLEWLG VMWMSGDDTDYDAAFISRLSISKDNSKSQVFFKMNS LQANDTGIYYCARYRFYGM DYWGQGTSTVTVSS
710	DVD548L	AB004VL	AB074VL	DIQMTQSPSSLSASVGDVITCRASQDVNTAVAW YQQKPGKAPKLLIYSASFYSGVPSRFSGSRSGTD FTLTISLQPEDFATYYCQQHYTTPPTFGGQTKVE IKR TVAAP AIQMTQSSSSFSVSLGDRVTITCKASE DIYNRFAWYQQKPGNAPRLLISGAASLEAGVPSRF SGSGSQDYTLSTISLQTEDVATYYCQQYWSTPWT FGGGTKLEIKR

Example 2.154: Generation of HER2 (seq. 1) and PLGF (seq. 2) DVD-Igs with Linker Set 2

Table 187

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
711	DVD555H	AB074VH	AB004VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTTYGIH WVRQSPGKGLEWLGVMWSGGDDYDAAFISRLSIS KDNSKSKVFFKMNSLQANDTGIYYCARYRFYGM DY WGQTSVTVSS ASTKGPSVFPLAP EVQLVESGGGL VQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLE WVARIYPTNGYTRYADSVKGRFTISADTSKNTAYL QMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGLTV TVSS
712	DVD555L	AB074VL	AB004VL	AIQMTQSSSSFSVSLGDRVTITCKASEDIYNRFAW YQQKPGNAPRLLISGAASLEAGVPSRFSGSGSQD YTLSITSLQTEDVATYYCQQYWSTPWFEGGGTKLE IKR TVAAPSVFIFPP DIQMTQSPSSLSASVGDRT ITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLY SGVPSRFSGSRSGTDFLTITSSLPEDFATYYCQQ HYTTPPTFGQGTKVEIKR
713	DVD556H	AB004VH	AB074VH	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHW VRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFY AMDYWGQGLTVTVSS ASTKGPSVFPLAP QVQLKQS GPGLVQPSQSLITCTVSGFSLTTYGIHWRQSPG KGLEWLGVMWSGGDDYDAAFISRLSISKDNSKSK VFFKMNSLQANDTGIYYCARYRFYGM DYWGQTSV TVSS
714	DVD556L	AB004VL	AB074VL	DIQMTQSPSSLSASVGDRTITCRASQDVNTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTD FTLTITSSLPEDFATYYCQQHYTTPPTFGQGTKVE IKR TVAAPSVFIFPP AIQMTQSSSSFSVSLGDRVT ITCKASEDIYNRFAWYQQKPGNAPRLLISGAASLE AGVPSRFSGSGSQDYTLSITSLQTEDVATYYCQQ YWSTPWFEGGGTKLEIKR

Example 2.155: Generation of HER2 (seq. 1) and PLGF (seq. 2) DVD-Igs with Linker Set 3

Table 188

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
715	DVD563H	AB074VH	AB004VH	QVQLKQSGPGLVQPQSLTITCTVSGFSLTTYGIH WVRQSPGKGLEWLGVMWSGGDDYDAAFISRLSIS KDNSKQVFFKMNSLQANDTGIYYCARYRFYGM DY WGQTSVTVSS ASTKGPSVFPLAP EVQLVESGGGL VQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLE WVARIYPTNGYTRYADSVKGRFTISADTSKNTAYL QMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGLV TVSS
716	DVD563L	AB074VL	AB004VL	AIQMTQSSSSFSVSLGDRVTITCKASEDIYNRFAW YQKPGNAPRLLISGAASLEAGVPSRFSGSGSQD YTLSITSLQTEDVATYYCQYWPWFPGGGTKLE IKR TVAAP DIQMTQSPSSLSASVGDRTITCRASQ DVNTAVAWYQKPKGKAPKLLIYSASFLYSGVPSRF SGSRSGTDFTLTISLQPEDFATYYCQHYTTPPT FGGQTKVEIKR
717	DVD564H	AB004VH	AB074VH	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGLVTVSS ASTKGPSVFPLAP QVQLKQSGPGLVQPQSLTITCTVSGFSLTTYGIHWRQSPGKGLEWLGVMWSGGDDYDAAFISRLSISKDNSKQVFFKMNSLQANDTGIYYCARYRFYGM DYWGQTSVTVSS
718	DVD564L	AB004VL	AB074VL	DIQMTQSPSSLSASVGDRTITCRASQDVNTAVAWYQKPKGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISLQPEDFATYYCQHYTTPPTFGGQTKVEIKR TVAAP AIQMTQSSSSFSVSLGDRVTITCKASEDIYNRFAWYQKPGNAPRLLISGAASLEAGVPSRFSGSGSQDYTLSITSLQTEDVATYYCQYWPWFPGGGTKLEIKR

Example 2.156: Generation of HER2 (seq. 1) and PLGF (seq. 2) DVD-Igs with Linker Set 4

Table 189

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
719	DVD571H	AB074VH	AB004VH	QVQLKQSGPGLVQPSQSLITCTVSGFSLTTYGIH WVRQSPGKGLEWLGVMWGGDDTDYDAAFISRLSIS KDNSKQVFFKMNSLQANDTGIYYCARYRFYGM DY WGQGTSTVTVSS ASTKGP EVQLVESGGGLVQPGGSL RLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYP TNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRA EDTAVYYCSRWGGDGFYAMDYWGQGTTLVTVSS
720	DVD571L	AB074VL	AB004VL	AIQMTQSSSSFSVSLGDRVTITCKASEDIYNRFAW YQQKPGNAPRLLISGAASLEAGVPSRFGSGSGQD YTLSTISLQTEDVATYYCQQYWSWPWFEGGKLE IKR TVAAPSVFIFPP DIQMTQSPSSLSASVGDRTV ITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLY SGVPSRFGSGRSGTDFTLTISLQPEDFATYYCQQ HYTTPTEFGQGTKEIKR
721	DVD572H	AB004VH	AB074VH	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIH WVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFY AMDYWGQGTTLVTVSS ASTKGP QVQLKQSGPGLVQ PSQSLITCTVSGFSLTTYGIHWRQSPGKGLEWLG VMWGGDDTDYDAAFISRLSISKDNSKQVFFKMNS LQANDTGIYYCARYRFYGM DYWGQGTSTVTVSS
722	DVD572L	AB004VL	AB004VL	DIQMTQSPSSLSASVGDRTVITCRASQDVNTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFGSGRSGTD FTLTISLQPEDFATYYCQQHYTTPTEFGQGTKE IKR TVAAPSVFIFPP AIQMTQSSSSFSVSLGDRVT ITCKASEDIYNRFAWYQQKPGNAPRLLISGAASLE AGVPSRFGSGSGQDYTLSTISLQTEDVATYYCQQ YWSWPWFEGGKLEIKR

Example 2.157: Generation of PLGF (seq. 1) and VEGF (seq. 2) DVD-Igs with Linker Set 1

Table 191

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
723	DVD573H	AB047VH	AB070VH	QVQLQQSGAELVKPGASVKISCKASGYTFTDYYINWV KLAPGQGLEWIGWIYPGSGNTKYNEKFKGKATLTIDT SSSTAYMQLSSTLSEDTAVYFCVRDSPFFDYWGQGT LTVSS ASTKGP EVQLVESGGGLVQPGGSLRLS CAASGFTISDYWIHWVRQAPGKGLEWVAGITPAGGY TYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAV YYCARFVFFLPYAMDYWGQGTLLTVSS
724	DVD573L	AB047VL	AB070VL	DIVLTQSPDLSAVSLGERVTMNCSSQSLNSGMRKS FLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGS GTDFTLTISVQAEDVAVYYCKQSYHLFTFGSGTKLEI KR TVAAP DIQMTQSPSSLSASVGDRTITCRASQDVS TAVAWYQQKPGKAPKLLIYSASFYSGVPSRFRSGSGS GTDFTLTISLQPEDFATYYCQQSYTTPPTFGQGTKV EIKR
725	DVD574H	AB070VH	AB047VH	EVQLVESGGGLVQPGGSLRLS CAASGFTISDYWIHWVRQAPGKGLEWVAGITPAGGY TYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAV YYCARFVFFLPYAMDYWGQGTLLTVSS ASTKGP QVQLQQSGAELVKPGASVKISCKASGYTFTDYYINWV KLAPGQGLEWIGWIYPGSGNTKYNEKFKGKATLTIDT SSSTAYMQLSSTLSEDTAVYFCVRDSPFFDYWGQGT LLTVSS
726	DVD574L	AB070VL	AB047VL	DIQMTQSPSSLSASVGDRTITCRASQDVS TAVAWYQQKPGKAPKLLIYSASFYSGVPSRFRSGSGS GTDFTLTISLQPEDFATYYCQQSYTTPPTFGQGTKV EIKR TVAAP DIVLTQSPDLSAVSLGERVTMNCSSQSLNSGMR KSF LAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGS GTDFTLTISVQAEDVAVYYCKQSYHLFTFGSGTKLEI EIKR

Example 2.158: Generation of PLGF (seq. 1) and VEGF (seq. 2) DVD-Igs with Linker Set 2

Table 192

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
727	DVD581H	AB047VH	AB070VH	QVQLQQSGAELVKPGASVKISCKASGYTFTDYYINWVKLAPGGGLEWIGWIYPGSGNTKYNEKFKGKATLTIDTSSSTAYMQLSSLTSEDVAVYFCVRDSPFFDYWGQGTLLTVSS ASTKGPSVFPLAP EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIHWVRQAPGKGLEWVAGITPAGGYTYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPYAMDYWGQGTLLVTVSS
728	DVD581L	AB047VL	AB070VL	DIVLTQSPDLSLAVSLGERVTMNCSSQSLNSGMRKSFRAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFLTISVQAEDVAVYYCKQSYHLFTFGSGTKLEIKR TVAAPSVFIFPP DIQMTQSPSSLSASV GDRVITITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFYSGVPSRFRSGSGTDFLTISLQPEDFATYYCQQSYTTPPTFGQGTKEIKR
729	DVD582H	AB070VH	AB047VH	EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIHWVRQAPGKGLEWVAGITPAGGYTYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPYAMDYWGQGTLLTVSS ASTKGPSVFPLAP QVQLQQSGAELVKPGASVKISCKASGYTFTDYYINWVKLAPGGLEWIGWIYPGSGNTKYNEKFKGKATLTIDTSSSTAYMQLSSLTSEDVAVYFCVRDSPFFDYWGQGTLLTVSS
730	DVD582L	AB070VL	AB047VL	DIQMTQSPSSLSASV GDRVITITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFYSGVPSRFRSGSGTDFLTISLQPEDFATYYCQQSYTTPPTFGQGTKEIKR TVAAPSVFIFPP DIVLTQSPDLSLAVSLGERVTMNCSSQSLNSGMRKSFRAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFLTISVQAEDVAVYYCKQSYHLFTFGSGTKLEIKR

Example 2.159: Generation of PLGF (seq. 1) and VEGF (seq. 2) DVD-Igs with Linker Set 3

Table 193

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
731	DVD589VH	AB047VH	AB070VH	QVQLQQSGAELVKPGASVKISCKASGYTFTDYYIN WVKLAPGGQGLEWIGWIYPGSGNTKYNEKFKGKATL TIDTSSSTAYMQLSSLTSEDVAVYFCVRDSPFFDY WQGTLLTVSS ASTKGPSVFPLAP EVQLVESGGGL VQPGGSLRLSCAASGFTISDYWIHWVRQAPGKGLE WVAGITPAGGYTYADSVKGRFTISADTSKNTAYL QMNSLRAEDTAVYYCARFVFFLPYAMDYWGQGLTV TVSS
732	DVD589VL	AB047VL	AB070VL	DIVLTQSPDLSAVSLGERVTMNCSSQSLNSGMR KSLAWYQQKPGQSPKLLIYWASTRESGVPDRFTG SGSGTDFLTLISSVQAEDVAVYYCKQSYHLFTFGS GTKLEIKR TVAAP DIQMTQSPSSLSASVGDRTIT CRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSG VPSRFSGSGSGTDFLTLISSLQPEDFATYYCQQSY TTPPTFGQGTKVEIKR
733	DVD590VH	AB070VH	AB047VH	EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIH WVRQAPGKGLEWVAGITPAGGYTYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPY AMDYWGQGLTVTVSS ASTKGPSVFPLAP QVQLQQS GAELVKPGASVKISCKASGYTFTDYYINWVKLAPG QGLEWIGWIYPGSGNTKYNEKFKGKATLTIDTSSS TAYMQLSSLTSEDVAVYFCVRDSPFFDYWGQGTLL TVSS
734	DVD590VL	AB070VL	AB047VL	DIQMTQSPSSLSASVGDRTITCRASQDVSTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTD FTLISSLQPEDFATYYCQQSYTTPPTFGQGTKVE IKR TVAAP DIVLTQSPDLSAVSLGERVTMNCSSQ SLNSGMRKSLAWYQQKPGQSPKLLIYWASTRES GVPDRFTGSGSGTDFLTLISSVQAEDVAVYYCKQ SYHLFTFGSGTKLEIKR

Example 2.160: Generation of PLGF (seq. 1) and VEGF (seq. 2) DVD-Igs with Linker Set 4

Table 194

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
735	DVD597VH	AB047VH	AB070VH	QVQLQQSGAELVKPGASVKISCKASGYTFTDYYIN WVKLAPGQGLEWIGWIYPGSGNTKYNEKFKGKATL TIDTSSSTAYMQLSSLTSEDVAVYFCVRDSPFFDY WGQGTLLTVSS ASTKGP EVQLVESGGGLVQPGGSL RLSCAASGFTISDYWIHWVRQAPGKGLEWVAGITP AGGYTYYADSVKGRFTISADTSKNTAYLQMNSLRA EDTAVYYCARFVFFLPYAMDYWGQGTLLTVSS
736	DVD597VL	AB047VL	AB070VL	DIVLTQSPDLSAVSLGERVTMNCSSQSLNLSGMR KSFRAWYQQKPGQSPKLLIYWASTRESGVPDRFTG SGSGTDFTLTISVQAEDVAVYYCKQSYHLFTFGS GTKLEIKR TVAAPSVFI FPDIQMTQSPSSLSASV GDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYS ASFLYSGVPSRFRSGSGTDFTLTISLQPEDFAT YYCQQSYTTPPTFGQGTKVEIKR
737	DVD598VH	AB070VH	AB047VH	EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIH WVRQAPGKGLEWVAGITPAGGYTYYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPY AMDYWGQGTLLTVSS ASTKGP QVQLQQSGAELVKP GASVKISCKASGYTFTDYYINWVKLAPGQGLEWIG WIYPGSGNTKYNEKFKGKATLTIDTSSSTAYMQLS SLTSEDVAVYFCVRDSPFFDYWGQGTLLTVSS
738	DVD598VL	AB070VL	AB047VL	DIQMTQSPSSLSASVSGDRVTITCRASQDVSTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFRSGSGTD FTLTISLQPEDFATYYCQQSYTTPPTFGQGTKVE IKR TVAAPSVFI FPDIVLTQSPDLSAVSLGERVT MNCSSQSLNLSGMRKSFRAWYQQKPGQSPKLLIY WASTRESGVPDRFTGSGSGTDFTLTISVQAEDVA VYYCKQSYHLFTFGSGTKLEIKR

Example 2.161: Generation of PLGF (seq. 1) and VEGF (seq. 3) DVD-Igs with Linker Set 1

Table 195

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
739	DVD575H	AB047VH	AB071VH	QVQLQQSGAELVKPGASVKISCKASGYTFTDYYIN WVKLAPGQGLEWIGWIYPGSGNTKYNEKFKGKATL TIDTSSSTAYMQLSSLTSEDVAVYFCVRDSPFFDY WQGTLLTVSS ASTKGP EVQLVESGGGLVQPGGSL RLSCAASGFTINASWIHWVRQAPGKGLEWVGAIYP YSGYTNYADSVKGRFTISADTSKNTAYLQMNSLRA EDTAVYYCARWGHSTSPWAMDYWGQGTLLTVSS
740	DVD575L	AB047VL	AB071VL	DIVLTQSPDSLAVSLGERVTMNCSSQSLNLSGMR KSLAWYQQKPGQSPKLLIYWASTRESGVPDRFTG SGSGTDFLTISSVQAEDVAVYYCKQSYHLFTFGS GTKLEIKR TVAAP DIQMTQSPSSLSASVGDRTIT CRASQVIRRSRAWYQQKPGKAPKLLIYAASNLAG VPSRFSGSGSGTDFLTISLQPEDFATYYCQSN TSPFTFGQGTKVEIKR
741	DVD576H	AB071VH	AB047VH	EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIH WVRQAPGKGLEWVGAIYPYSGYTNYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSP WAMDYWGQGTLLTVSS ASTKGP QVQLQQSGAELVK PGASVKISCKASGYTFTDYYINWVKLAPGQGLEWI GWIYPGSGNTKYNEKFKGKATLTIDTSSSTAYMQL SSLTSEDVAVYFCVRDSPFFDYWGQGTLLTVSS
742	DVD576L	AB071VL	AB047VL	DIQMTQSPSSLSASVGDRTITCRASQVIRRSRAW YQQKPGKAPKLLIYAASNLAGVPSRFSGSGSGTD FTLTISLQPEDFATYYCQSNSTSPFTFGQGTKVE IKR TVAAP DIVLTQSPDSLAVSLGERVTMNCSSQ SLNLSGMRKSLAWYQQKPGQSPKLLIYWASTRES GVPDRFTGSGSGTDFLTISSVQAEDVAVYYCKQS YHLFTFGSGTKLEIKR

Example 2.162: Generation of PLGF (seq. 1) and VEGF (seq. 3) DVD-Igs with Linker Set 2

Table 196

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
743	DVD583H	AB047VH	AB071VH	QVQLQQSGAELVKPGASVKISCKASGYTFTDYYINWVKLAPGGGLEWIGWIYPGSGNTKYNEKFKGKATLTIDTSSSTAYMQLSSLTSEDVAVYFCVRDSPFFDYWGQGTLLTVSS ASTKGPSVFPLAP EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIHWVRQAPGKGLEWVGAIPYPSGYTNYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSPWAMDYWGQGTLLTVSS
744	DVD583L	AB047VL	AB071VL	DIVLTQSPDLSAVSLGERVTMNCSSQSLNSGMRKSLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFLTISSVQAEDVAVYYCKQSYHLFTFGSGTKLEIKR TVAAPSVFIFPP DIQMTQSPSSLSASV GDRVTITCRASQVIRRLAWYQQKPGKAPKLLIYAASNLAGVPSRFRSGSGTDFLTISSLQPEDFATYYCQQSNTSPLTFGQGTKEIKR
745	DVD584H	AB071VH	AB047VH	EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIHWVRQAPGKGLEWVGAIPYPSGYTNYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSPWAMDYWGQGTLLTVSS ASTKGPSVFPLAP QVQLQQSGAELVKPGASVKISCKASGYTFTDYYINWVKLAPGGGLEWIGWIYPGSGNTKYNEKFKGKATLTIDTSSSTAYMQLSSLTSEDVAVYFCVRDSPFFDYWGQGTLLTVSS
746	DVD584L	AB071VL	AB047VL	DIQMTQSPSSLSASV GDRVTITCRASQVIRRLAWYQQKPGKAPKLLIYAASNLAGVPSRFRSGSGTDFLTISSLQPEDFATYYCQQSNTSPLTFGQGTKEIKR TVAAPSVFIFPP DIVLTQSPDLSAVSLGERVTMNCSSQSLNSGMRKSLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFLTISSVQAEDVAVYYCKQSYHLFTFGSGTKLEIKR

Example 2.163: Generation of PLGF (seq. 1) and VEGF (seq. 3) DVD-Igs with Linker Set 3

Table 197

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
747	DVD591VH	AB047VH	AB071VH	QVQLQQSGAELVKPGASVKISCKASGYTFTDYYIN WVKLAPGGGLEWIGWIYPGSGNTKYNEKFKGKATL TIDTSSSTAYMQLSSLTSEDVAVYFCVRDSPFFDY WGQGTLLTVSS ASTKGPSVFPLAP EVQLVESGGGL VQPGGSLRLSCAASGFTINASWIHWVRQAPGKGLE WVGAIYPYSGYTNVADSVKGRFTISADTSKNTAYL QMNSLRAEDTAVYYCARWGHSTSPWAMDYWGQGTLL TVVSS
748	DVD591VL	AB047VL	AB071VL	DIVLTQSPDLSLAVSLGERVTMNCSSQSLNSGMR KSLAWYQQKPGQSPKLLIYWASTRESGVPDRFTG SGSGTDFLTLISSVQAEDVAVYYCKQSYHLFTFGS GTKLEIKR TVAAP DIQMTQSPSSLSASVGDRTIT CRASQVIRRLAWYQQKPGKAPKLLIYAASNLAGS VPSRFSGSGSGTDFLTLISSLQPEDFATYYCQQSN TSPLTFGQGTKVEIKR
749	DVD592VH	AB071VH	AB047VH	EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIH WVRQAPGKGLEWVGAIYPYSGYTNVADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSP WAMDYWGQGTLLTVVSS ASTKGPSVFPLAP QVQLQQ SGAELVKPGASVKISCKASGYTFTDYYINWVKLAP GGGLEWIGWIYPGSGNTKYNEKFKGKATLITDTS STAYMQLSSLTSEDVAVYFCVRDSPFFDYWGQGTLL TVVSS
750	DVD592VL	AB071VL	AB047VL	DIQMTQSPSSLSASVGDRTITCRASQVIRRLAW YQQKPGKAPKLLIYAASNLAGVPSRFSGSGSGTD FTLISSLQPEDFATYYCQQSNSTSPPLTFGQGTKVE IKR TVAAP DIVLTQSPDLSLAVSLGERVTMNCSSQ SLNSGMRKSLAWYQQKPGQSPKLLIYWASTRES GVPDRFTGSGSGTDFLTLISSVQAEDVAVYYCKQS YHLFTFGSGTKLEIKR

Example 2.164: Generation of PLGF (seq. 1) and VEGF (seq. 3) DVD-Igs with Linker Set 4

Table 198

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
751	DVD599VH	AB047VH	AB071VH	QVQLQQSGAELVKPGASVKISCKASGYTFTDYYIN WVKLAPGQGLEWIGWIYPGSGNTKYNEKFKGKATL TIDTSSSTAYMQLSSLTSEDVAVYFCVRDSPFFDY WQGTLLTVSS ASTKGP EVQLVESGGGLVQPGGSL RLSCAASGFTINASWIHWVRQAPGKGLEWVGAIYP YSGYTNYADSVKGRFTISADTSKNTAYLQMNSLRA EDTAVYYCARWGHSTSPWAMDYWGQGTLLTVSS
752	DVD599VL	AB047VL	AB071VL	DIVLTQSPDSLAVSLGERVTMNCSSQSLNLSGMR KSLAWYQQKPGQSPKLLIYWASTRESGVPDRFTG SGSGTDFTLTISVQAEDVAVYYCKQSYHLFTFGS GTKLEIKR TVAAPSVFIFPP DIQMTQSPSSLSASV GDRVITICRASQVIRRLAWYQQKPGKAPKLLIYA ASNLAGVPSRFRSGSGTDFTLTISLQPEDFAT YYCQQSNTSPLTFGQGTKVEIKR
753	DVD600VH	AB071VH	AB047VH	EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIH WVRQAPGKGLEWVGAIYPYSGYTNYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSP WAMDYWGQGTLLTVSS ASTKGP QVQLQQSGAELVK PGASVKISCKASGYTFTDYYINWVKLAPGQGLEWI GWIYPGSGNTKYNEKFKGKATLTIDTSSSTAYMQL SSLTSEDVAVYFCVRDSPFFDYWGQGTLLTVSS
754	DVD600VL	AB071VL	AB047VL	DIQMTQSPSSLSASVDRVITICRASQVIRRLAW YQQKPGKAPKLLIYAASNLAGVPSRFRSGSGTD FTLTISLQPEDFATYYCQQSNTSPLTFGQGTKVE IKR TVAAPSVFIFPP DIVLTQSPDSLAVSLGERVT MNCSSQSLNLSGMRKSLAWYQQKPGQSPKLLIY WASTRESGVPDRFTGSGSGTDFTLTISVQAEDVA VYYCKQSYHLFTFGSGTKLEIKR

Example 2.165: Generation of HER2 (seq. 1) and PLGF (seq. 1) DVD-Igs with Linker Set 1

Table 199

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
755	DVD577H	AB047VH	AB004VH	QVQLQQSGAELVKPGASVKISCKASGYTFTDYYINWVKLAPGGGLEWIGWIYPGSGNTKYNEKFKGKATLTIDTSSSTAYMQLSSLTSEDVAVYFCVRDSPFFDYWGQGTLLTVSS ASTKGP EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLLTVSS
756	DVD577L	AB047VL	AB004VL	DIVLTQSPDLSLAVSLGERVTMNCSSQSLNLSGMRKSLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISVQAEDVAVYYCKQSYHLFTFGSGTKLEIKR TVAAP DIQMTQSPSSLSASVGDRTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFYSGVPSRFGSGRSGTDFTLTISLQPEDFATYYCQQHYTPPTFGQGTKVEIKR
757	DVD578H	AB004VH	AB047VH	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLLTVSS ASTKGP QVQLQQSGAELVKPGASVKISCKASGYTFTDYYINWVKLAPGGGLEWIGWIYPGSGNTKYNEKFKGKATLTIDTSSSTAYMQLSSLTSEDVAVYFCVRDSPFFDYWGQGTLLTVSS
758	DVD578L	AB004VL	AB047VL	DIQMTQSPSSLSASVGDRTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFYSGVPSRFGSGRSGTDFTLTISLQPEDFATYYCQQHYTPPTFGQGTKVEIKR TVAAP DIVLTQSPDLSLAVSLGERVTMNCSSQSLNLSGMRKSLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISVQAEDVAVYYCKQSYHLFTFGSGTKLEIKR

Example 2.166: Generation of HER2 (seq. 1) and PLGF (seq. 1) DVD-Igs with Linker Set 2

Table 200

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
759	DVD585H	AB047VH	AB004VH	QVQLQQSGAELVKPGASVKISCKASGYTFTDYYINWVKLAPGGLEWIGWIYPGSGNTKYNEKFKGKATLTIDTSSSTAYMQLSSLTSEDVAVYFCVRDSPFFDYWGQGTLLTVSS ASTKGPSVFPLAP EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLLVTVSS
760	DVD585L	AB047VL	AB004VL	DIVLTQSPDLSLAVSLGERVTMNCSSQSLLSNGMRKSFRAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDVAVYYCKQSYHLFTFGSGTKLEIKR TVAAPSVFIFPP DIQMTQSPSSLSASVGDVRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFYSGVPSRFRSGSRSGTDFTLTISSLPEDFATYYCQQHYTTPPTFGQGTKEIKR
761	DVD586H	AB004VH	AB047VH	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLLVTVSS ASTKGPSVFPLAP QVQLQQSGAELVKPGASVKISCKASGYTFTDYYINWVKLAPGGLEWIGWIYPGSGNTKYNEKFKGKATLTIDTSSSTAYMQLSSLTSEDVAVYFCVRDSPFFDYWGQGTLLTVSS
762	DVD586L	AB004VL	AB047VL	DIQMTQSPSSLSASVGDVRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFYSGVPSRFRSGSRSGTDFTLTISSLPEDFATYYCQQHYTTPPTFGQGTKEIKR TVAAPSVFIFPP DIVLTQSPDLSLAVSLGERVTMNCSSQSLLSNGMRKSFRAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDVAVYYCKQSYHLFTFGSGTKLEIKR

Example 2.167: Generation of HER2 (seq. 1) and PLGF (seq. 1) DVD-Igs with Linker Set 3

Table 201

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
763	DVD593VH	AB047VH	AB004VH	QVQLQQSGAELVKPGASVKISCKASGYTFTDYYINWVKLAPGGQGLEWIGWIYPGSGNTKYNEKFKGKATLTIDTSSSTAYMQLSSLTSEDVAVYFCVRDSPFFDYWGQGTLLTVSS ASTKGPSVFPLAP EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLLVTVSS
764	DVD593VL	AB047VL	AB004VL	DIVLTQSPDLSLAVSLGERVTMNCSSQSLLSNGMRKSLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFLTISSVQAEDVAVYYCKQSYHLFTFGSGTKLEIKR TVAAP DIQMTQSPSSLSASVGDRTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFYSGVPSRFGSRSRGTDFLTISLQPEDFATYYCQQHYTTPPTFGQGTKVEIKR
765	DVD594VH	AB004VH	AB047VH	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLLTVSS ASTKGPSVFPLAP QVQLQQSGAELVKPGASVKISCKASGYTFTDYYINWVKLAPGGQGLEWIGWIYPGSGNTKYNEKFKGKATLTIDTSSSTAYMQLSSLTSEDVAVYFCVRDSPFFDYWGQGTLLTVSS
766	DVD594VL	AB004VL	AB047VL	DIQMTQSPSSLSASVGDRTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFYSGVPSRFGSRSRGTDFLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKR TVAAP DIVLTQSPDLSLAVSLGERVTMNCSSQSLLSNGMRKSLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFLTISSVQAEDVAVYYCKQSYHLFTFGSGTKLEIKR

Example 2.168: Generation of HER2 (seq. 1) and PLGF (seq. 1) DVD-Igs with Linker Set 4

Table 202

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
767	DVD601VH	AB047VH	AB004VH	QVQLQQSGAELVKPGASVKISCKASGYTFTDYYINWVKLAPGQGLEWIGWIYPGSGNTKYNEKFKGKATLTIDTSSSTAYMQLSSLTSEDTAVYFCVRDSPFFDYWGQGTLLTVSS ASTKGP EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLLTVSS
768	DVD601VL	AB047VL	AB004VL	DIVLTQSPDLSLAVSLGERVTMNCSSQSLNSGMRKSLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISVQAEDVAVYYCKQSYHLFTFGSGTKLEIKR TVAAPSVFI FPDIQMTQSPSSLSASVGDVITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFYLSGVPSPRFSRSGTDFTLTISLQPEDFATYYCQQHYTTPPTFGQGTKVEIKR
769	DVD602VH	AB004VH	AB047VH	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLLTVSS ASTKGP QVQLQQSGAELVKPGASVKISCKASGYTFTDYYINWVKLAPGQGLEWIGWIYPGSGNTKYNEKFKGKATLTIDTSSSTAYMQLSSLTSEDTAVYFCVRDSPFFDYWGQGTLLTVSS
770	DVD602VL	AB004VL	AB047VL	DIQMTQSPSSLSASVGDVITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFYLSGVPSPRFSRSGTDFTLTISLQPEDFATYYCQQHYTTPPTFGQGTKVEIKR TVAAPSVFI FPDIQMTQSPDLSLAVSLGERVTMNCSSQSLNSGMRKSLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISVQAEDVAVYYCKQSYHLFTFGSGTKLEIKR

Example 2.169: Generation of HGF (seq. 1) and VEGF (seq. 2) DVD-Igs with Linker Set 1

Table 203

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				123456789 0 123456789 0 123456789 0 12345
771	DVD643H	AB012VH	AB070VH	QVQLVESGGGLV K PGGSLRLS CAASGFT FSDYYMS WIRQAPGKGLEWVSYI SSSGSTI YYADSVKGRFTI SRDNAKNSLYLQ MNSLRAEDTAVYYCAR DEYNSGW YVLFDYWGQGT LVTVSSASTKGPSVFPLAP EVQLV ESGGGLVQ PGGSLRLS CAASGFTISDYWIHWVRQA PGKGLEWVAGIT PAGGY TYADSVKGRFTISADTS KNTAYLQ MNSLRAEDTAVYYCAR FVFFLPYAMDYW GQGT LVTVSS
772	DVD643L	AB012VL	AB070VL	DIQMTQSPSSVSASV GDRVTITCRASQGI SSWLAW YQQKPGKAPNLLI YEASSLQ SGVPSR FGSGSGTD FTLTIS SLQPEDFATYYCQ QANGFPWTFGQGT KVE IKR TVAAPSVFI FPDIQMTQSPSSLSASV GDRVT ITCRASQDVSTAVAWYQQKPGKAPKLLI YSASFLY SGVPSR FGSGSGTDFTLTIS SLQPEDFATYYC Q SYTTPPTFGQGT KVEIKR
773	DVD644H	AB070VH	AB012VH	EVQLVESGGGLVQ PGGSLRLS CAASGFTISDYWIH WVRQAPGKGLEWVAGIT PAGGY TYADSVKGRFTI SADTSKNTAYLQ MNSLRAEDTAVYYCAR FVFFLPY AMDYWGQGT LVTVSSASTKGPSVFPLAP QVQLVES GGGLV KPGGSLRLS CAASGFTFSDYYMSWIRQAPG KGLEWVSYI SSSGSTI YYADSVKGRFTISRDNAKN SLYLQ MNSLRAEDTAVYYCAR DEYNSGWVLFDYW GQGT LVTVSS
774	DVD644L	AB070VL	AB012VL	DIQMTQSPSSLSASV GDRVTITCRASQDV STAVAW YQQKPGKAPKLLI YSASFLY SGVPSR FGSGSGTD FTLTIS SLQPEDFATYYCQ QSYTTPPTFGQGT KVE IKR TVAAPSVFI FPDIQMTQSPSSVSASV GDRVT ITCRASQGISSWLAWYQQKPGKAPNLLI YEASSLQ SGVPSR FGSGSGTDFTLTIS SLQPEDFATYYC Q ANGFPWTFGQGT KVEIKR

Example 2.170: Generation of HGF (seq. 1) and VEGF (seq. 2) DVD-Igs with Linker Set 2

Table 204

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
775	DVD649H	AB012VH	AB070VH	QVQLVESGGGLV ^K PGGSLRLS ^{CA} ASGFTFS ^D YYMS WIRQAPGK ^G LEWVSYI ^{SS} SGSTI ^Y YADSVKGRFTI SRDNAKNSLYLQ ^M NSLRAEDTAVYYCAR ^{DE} YNSGW YVLF ^D YWGGQTLVTVSS ASTKGPSVFPLAP EVQLV ESGGGLVQ ^P GGSLRLS ^{CA} ASGFTIS ^D YWIHWVRQA PGK ^G LEWVAGITPAGGY ^T YADSVKGRFTISADTS KNTAYLQ ^M NSLRAEDTAVYYCAR ^F VFFLPYAMDYW GGQTLVTVSS
776	DVD649L	AB012VL	AB070VL	DIQMTQSPSSVSASV ^G DRVITITCRASQGISSW ^L AW YQK ^P GKAPNLLI ^E ASSLQSGVPSR ^F GGSGSGTD FTLTIS ^S LQPEDFATYYCQ ^Q ANGFPWTFGQ ^G TKVE IKR TVAAP DIQMTQSPSSLSASV ^G DRVITITCRASQ DVSTAVAWYQ ^K PKAPKLLI ^S ASFLYSGVPSR ^F SGSGSGTDFTLTIS ^S LQPEDFATYYCQ ^Q SYTTPPT FGQ ^G TKVEIKR
777	DVD650H	AB070VH	AB012VH	EVQLVESGGGLVQ ^P GGSLRLS ^{CA} ASGFTIS ^D YWIH WVRQAPGK ^G LEWVAGITPAGGY ^T YADSVKGRFTI SADTSKNTAYLQ ^M NSLRAEDTAVYYCAR ^F VFFLPY AMDYWGQTLVTVSS ASTKGPSVFPLAP QVQLVES GGGLV ^K PGGSLRLS ^{CA} ASGFTFS ^D YYMSWIRQAPG KLEWVSYI ^{SS} SGSTI ^Y YADSVKGRFTISRDNAKN SLYLQ ^M NSLRAEDTAVYYCAR ^{DE} YNSGWVLF ^D YW GGQTLVTVSS
778	DVD650L	AB070VL	AB012VL	DIQMTQSPSSLSASV ^G DRVITITCRASQDVSTAVAW YQK ^P GKAPKLLI ^S ASFLYSGVPSR ^F GGSGSGTD FTLTIS ^S LQPEDFATYYCQ ^Q SYTTPPTFGQ ^G TKVE IKR TVAAP DIQMTQSPSSVSASV ^G DRVITITCRASQ GISSW ^L AWYQ ^K PKAPNLLI ^E ASSLQSGVPSR ^F GGSGSGTDFTLTIS ^S LQPEDFATYYCQ ^Q ANGFPWT FGQ ^G TKVEIKR

Example 2.171: Generation of HGF (seq. 1) and VEGF (seq. 2) DVD-Igs with Linker Set 3

Table 205

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
779	DVD655H	AB012VH	AB070VH	QVQLVESGGGLV K PGGSLRLSCAASGFTFS D YYS WIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTI SRDNAKNSLYLQMN S LR A EDTAVYYCARDEYNSGW YVLF D YWGQGT L VTVSS ASTKGP EVQLVESGGGLV QPGGSLRLSCAASGFTISDYWIHWVRQAPGKGLEW VAGITPAGGYTYADSVKGRFTISADTSKNTAYLQ MNSLR A EDTAVYYCARFVFFLPYAMDYWGQGT L VT VSS
780	DVD655L	AB012VL	AB070VL	DIQMTQSPSSVSASV G DRVTITCRASQGISSW L AW YQKPGKAPNLLIYEASSLQSGVPSR F GGSGSGTD FTLTIS S LQPEDFATYYCQANGFPWTFGQGT K VE IKR TVAAPSVFI FPDIQMTQSPSSLSASV G DRVT ITCRASQDVSTAVAWYQKPGKAPKLLIYSASFLY SGVPSR F GGSGSGTDFTLTIS S LQPEDFATYYCQ SYTTPPTFGQGT K VEIKR
781	DVD656H	AB070VH	AB012VH	EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWI H WVRQAPGKGLEWVAGITPAGGYTYADSVKGRFTI SADTSKNTAYLQMN S LR A EDTAVYYCARFVFFLPY AMDYWGQGT L VTVSS ASTKGP QVQLVESGGGLV K P GGSLRLSCAASGFTFS D YYSWIRQAPGKGLEWV S YISSSGSTIYYADSVKGRFTISRDN A KN S LYLQMN SLRAEDTAVYYCARDEYNSGWYVLF D YWGQGT L VT VSS
782	DVD656L	AB070VL	AB012VL	DIQMTQSPSSLSASV G DRVTITCRASQDVSTAVAW YQKPGKAPKLLIYSASFLYSGVPSR F GGSGSGTD FTLTIS S LQPEDFATYYCQSYTTPPTFGQGT K VE IKR TVAAPSVFI FPDIQMTQSPSSVSASV G DRVT ITCRASQGISSW L AWYQKPGKAPNLLIYEASSLQ SGVPSR F GGSGSGTDFTLTIS S LQPEDFATYYCQ ANGFPWTFGQGT K VEIKR

Example 2.172: Generation of HGF (seq. 1) and VEGF (seq. 2) DVD-Igs with Linker Set 4

Table 206

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
783	DVD709VH	AB012VH	AB070VH	QVQLVESGGGLVKKPGGSLRLSCAASGFTFSDYYMS WIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRAEDTAVYYCARDEYNSGW YVLFDYWGQGLTIVTSS ASTKGP EVQLVESGGGLV QPGGSLRLSCAASGFTISDYWIHWVRQAPGKGLEW VAGITPAGGYTYADSVKGRFTISADTSKNTAYLQ MNSLRAEDTAVYYCARFVFFLPYAMDYWGQGLTIVT VSS
784	DVD709VL	AB012VL	AB070VL	DIQMTQSPSSVSASVGDRTITCRASQGISSWLAW YQKPKGKAPNLLIYEASSLQSGVPSRFRFGSGSGTD FTLTISLQPEDFATYYCQQANGFPWTFGQGTKVE IKR TVAAP DIQMTQSPSSLSASVGDRTITCRASQ DVSTAVAWYQKPKGKAPKLLIYSASFLYSGVPSRF SGSGSGTDFTLTISLQPEDFATYYCQQSYTTPPT FGQGTKVEIKR
785	DVD710VH	AB070VH	AB012VH	EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIH WVRQAPGKGLEWVAGITPAGGYTYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPY AMDYWGQGLTIVTSS ASTKGP QVQLVESGGGLVKKP GGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVS YISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMN SLRAEDTAVYYCARDEYNSGWYVLFDYWGQGLTIVT VSS
786	DVD710VL	AB070VL	AB012VL	DIQMTQSPSSLSASVGDRTITCRASQDVSTAVAW YQKPKGKAPKLLIYSASFLYSGVPSRFRFGSGSGTD FTLTISLQPEDFATYYCQQSYTTPPTFGQGTKVE IKR TVAAP DIQMTQSPSSVSASVGDRTITCRASQ GISSWLAWYQKPKGKAPNLLIYEASSLQSGVPSRF GGSGSGTDFTLTISLQPEDFATYYCQQANGFPWT FGQGTKVEIKR

Example 2.173: Generation of HGF (seq. 1) and VEGF (seq. 3) DVD-Igs with Linker Set 1

Table 207

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
787	DVD645H	AB012VH	AB071VH	QVQLVESGGGLV ^K PGGSLRLS ^{CA} ASGFTFS ^D YYMS WIRQAPGK ^G LEWVSYI ^{SS} SGSTI ^Y YADSVKGRFTI SRD ^{NA} KNSLYLQ ^M NSLRAEDTAVYYCAR ^{DE} YNSGW YVLF ^D YWGGT ^L VTVSS ASTKGPSVFPLAP EVQLV ESGGGLV ^K PGGSLRLS ^{CA} ASGFTINASWI ^H WVRQA PGK ^G LEWV ^G AIYPYSGY ^T NYADSVKGRFTISADTS KNTAYLQ ^M NSLRAEDTAVYYCAR ^W GHSTSPWAMDY WGQ ^G TLVTVSS
788	DVD645L	AB012VL	AB071VL	DIQMTQSPSSVSASV ^G DRVTITCRASQGI ^{SS} SWLAW YQ ^K PGKAPNLLI ^Y EASSLQSGV ^{PS} RFGSGSGTD FTLTIS ^{SL} QPEDFATYYCQ ^Q ANGFPWTFGQ ^G TKVE IKR TVAAPSVFI^FPP DIQMTQSPSSLSASV ^G DRVT ITCRASQVIR ^R SLAWYQ ^K PGKAPKLLI ^Y AASNLA SGV ^{PS} RFGSGSGTDFTLTIS ^{SL} QPEDFATYYCQ ^Q SNTS ^{PL} TFGQ ^G TKVEIKR
789	DVD646H	AB071VH	AB012VH	EVQLVESGGGLV ^K PGGSLRLS ^{CA} ASGFTINASWI ^H WVRQAPGK ^G LEWV ^G AIYPYSGY ^T NYADSVKGRFTI SADTSKNTAYLQ ^M NSLRAEDTAVYYCAR ^W GHSTSP WAMDYWGQ ^G TLVTVSS ASTKGPSVFPLAP QVQLVE SGGGLV ^K PGGSLRLS ^{CA} ASGFTFS ^D YYMSWIRQAP GK ^G LEWV ^S YI ^{SS} SGSTI ^Y YADSVKGRFTISR ^D NAK NSLYLQ ^M NSLRAEDTAVYYCAR ^{DE} YNSGWYVLF ^D WGQ ^G TLVTVSS
790	DVD646L	AB071VL	AB012VL	DIQMTQSPSSLSASV ^G DRVTITCRASQVIR ^R SLAW YQ ^K PGKAPKLLI ^Y AASNLASGV ^{PS} RFGSGSGTD FTLTIS ^{SL} QPEDFATYYCQ ^Q SNTS ^{PL} TFGQ ^G TKVE IKR TVAAPSVFI^FPP DIQMTQSPSSVSASV ^G DRVT ITCRASQGI ^{SS} SWLAWYQ ^K PGKAPNLLI ^Y EASSLQ SGV ^{PS} RFGSGSGTDFTLTIS ^{SL} QPEDFATYYCQ ^Q ANGFPWTFGQ ^G TKVEIKR

Example 2.174: Generation of HGF (seq. 1) and VEGF (seq. 3) DVD-Igs with Linker Set 2

Table 208

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
791	DVD651H	AB012VH	AB071VH	QVQLVESGGGLV ^K PGGSLRLS ^{CA} ASGFTFSDYYMS WIRQAPGKLEWVSYISSSGSTIYYADSVKGRFTI SRDNAKNSLYLQMN ^{SL} RAEDTAVYYCARDEYNSGW YVLFDYWGQGLTVTVSS ASTKGPSVFPLAP EVQLV ESGGGLVQPGGSLRLS ^{CA} ASGFTINASWIHWVRQA PGKLEWVGAIYPYSGYTNYADSVKGRFTISADTS KNTAYLQMN ^{SL} RAEDTAVYYCARWGHSTSPWAMDY WGQGLTVTVSS
792	DVD651L	AB012VL	AB071VL	DIQMTQSPSSVSASV ^{GD} RVITITCRASQGISSWLA YQKPGKAPNLLIYEASSLQSGVPSRFGSGSGTD FTLTIS ^{SL} QPEDFATYYCQQANGFPWTFGQGTKVE IKR TVAAP DIQMTQSPSSLSASV ^{GD} RVITITCRASQ VIR ^{SL} AWYQKPGKAPKLLIYAASNLAGVPSRF SGSGSGTDFTLTIS ^{SL} QPEDFATYYCQQSNTSPLT FGQGTKVEIKR
793	DVD652H	AB071VH	AB012VH	EVQLVESGGGLVQPGGSLRLS ^{CA} ASGFTINASWI WVRQAPGKLEWVGAIYPYSGYTNYADSVKGRFTI SADTSKNTAYLQMN ^{SL} RAEDTAVYYCARWGHSTSP WAMDYWGQGLTVTVSS ASTKGPSVFPLAP QVQLVE SGGGLV ^K PGGSLRLS ^{CA} ASGFTFSDYYMSWIRQAP GKLEWVSYISSSGSTIYYADSVKGRFTISRDN AKNSLYLQMN ^{SL} RAEDTAVYYCARDEYNSGWYVLF DYWGQGLTVTVSS
794	DVD652L	AB071VL	AB012VL	DIQMTQSPSSLSASV ^{GD} RVITITCRASQVIR ^{SL} AWYQKPGKAPKLLIYAASNLAGVPSRFGSGSGTD FTLTIS ^{SL} QPEDFATYYCQQSNTSPLTFGQGTKVE IKR TVAAP DIQMTQSPSSVSASV ^{GD} RVITITCRASQ GISSWLA ^W YQKPGKAPNLLIYEASSLQSGVPSRF GGSGSGTDFTLTIS ^{SL} QPEDFATYYCQQANGFPWT FGQGTKVEIKR

Example 2.175: Generation of HGF (seq. 1) and VEGF (seq. 3) DVD-Igs with Linker Set 3

Table 209

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
795	DVD657H	AB012VH	AB071VH	QVQLVESGGGLVKGPGSLRLSCAASGFTFSDYYMS WIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRAEDTAVYYCARDEYNSGW YVLFDYWGQGLTVTVSS ASTKGP EVQLVESGGGLV QPGSLRLSCAASGFTINASWIHWVRQAPGKGLEW VGAIYPYSGYTNYADSVKGRFTISADTSKNTAYLQ MNSLRAEDTAVYYCARWGHSTSPWAMDYWGQGLV TVSS
796	DVD657L	AB012VL	AB071VL	DIQMTQSPSSVSASVGDRTITCRASQGISSWLAW YQQKPGKAPNLLIYEASLQSGVPSRFGSGSGTD FTLTISLQPEDFATYYCQQANGFPWTFGQGTKVE IKR TVAAPSVFI FPDIQMTQSPSSLSASVGDRTI ITCRASQVIRRLAWYQQKPGKAPKLLIYAASNLA SGVPSRFGSGSGTDFTLTISLQPEDFATYYCQQ SNTSPLTFGQGTKVEIKR
797	DVD658H	AB071VH	AB012VH	EVQLVESGGGLVQPGSLRLSCAASGFTINASWIH WVRQAPGKGLEWVGAIYPYSGYTNYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSP WAMDYWGQGLTVTVSS ASTKGP QVQLVESGGGLV KPGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWV SYISSSGSTIYYADSVKGRFTISRDNKNSLYLQM NSLRAEDTAVYYCARDEYNSGWYVLFDYWGQGLV TVSS
798	DVD658L	AB071VL	AB012VL	DIQMTQSPSSLSASVGDRTITCRASQVIRRLAW YQQKPGKAPKLLIYAASNLAGVPSRFGSGSGTD FTLTISLQPEDFATYYCQQSNTSPLTFGQGTKVE IKR TVAAPSVFI FPDIQMTQSPSSVSASVGDRTI ITCRASQGISSWLAWYQQKPGKAPNLLIYEASLQ SGVPSRFGSGSGTDFTLTISLQPEDFATYYCQQ ANGFPWTFGQGTKVEIKR

Example 2.176: Generation of HGF (seq. 1) and VEGF (seq. 3) DVD-Igs with Linker Set 4

Table 210

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
799	DVD711VH	AB012VH	AB071VH	QVQLVESGGGLV K PGGSLRLSCAASGFTFSDYYMS WIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTI SRDNAKNSLYLQMNSLRAEDTAVYYCARDEYNSGW YVLFDYWGQGLTVTVSS ASTKGP EVQLVESGGGLV QPGGSLRLSCAASGFTINASWIHWVRQAPGKGLEW VGAIYPYSGYTNYADSVKGRFTISADTSKNTAYLQ MNSLRAEDTAVYYCARWGHSTSPWAMDYWGQGLV TVSS
800	DVD711VL	AB012VL	AB071VL	DIQMTQSPSSVSASVGDRTITCRASQGISSWLAW YQQKPGKAPNLLIYEASSLQSGVPSRFGSGSGTD FTLTISSLQPEDFATYYCQQANGFPWTFGQGTKVE IKR TVAAP DIQMTQSPSSLSASVGDRTITCRASQ VIRRLAWYQQKPGKAPKLLIYAASNLAGVPSRF SGSGSGTDFTLTISSLQPEDFATYYCQQSNTSPLT FGQGTKVEIKR
801	DVD712VH	AB071VH	AB012VH	EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIH WVRQAPGKGLEWVGAIYPYSGYTNYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSP WAMDYWGQGLTVTVSS ASTKGP QVQLVESGGGLV KPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWV SYISSSGSTIYYADSVKGRFTISRDNKNSLYLQM NSLRAEDTAVYYCARDEYNSGWYVLFDYWGQGLV TVSS
802	DVD712VL	AB071VL	AB012VL	DIQMTQSPSSLSASVGDRTITCRASQVIRRLAW YQQKPGKAPKLLIYAASNLAGVPSRFGSGSGTD FTLTISSLQPEDFATYYCQQSNTSPLTFGQGTKVE IKR TVAAP DIQMTQSPSSVSASVGDRTITCRASQ GISSWLAWYQQKPGKAPNLLIYEASSLQSGVPSRF GGSGSGTDFTLTISSLQPEDFATYYCQQANGFPWT FGQGTKVEIKR

Example 2.177: Generation of HGF (seq. 2) and VEGF (seq. 1) DVD-Igs with Linker Set 1

Table 211

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
803	DVD659H	AB079VH	AB014VH	EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWMH WVRQMPGKGLEWMGEINPTNGHTNYNPSFQGQVTI SADKSISTAYLQWSSLKASDTAMYVCARNYVGSIF DYWGQGLVTVSS ASTKGP EVQLVESGGGLVQPGG SLRLSCAASGYFTFTNYGMNWVRQAPGKGLEWVGWI NTYTGEPTYAADEFKRRFTFSLDTSKSTAYLQMNSL RAEDTAVYYCAKYPHYHGGSSHWYFDVWGQGLVTV SS
804	DVD659L	AB079VL	AB014VL	DIQMTQSPSSLSASVGDRTITCKASENVVSYVSW YQQKPGKAPKLLIYGASNRNTGVPSRFSGSGSGTD FTLTISLQPEDFATYYCGQSYNYPYTFGQGTKLEIKR TVAAP DIQMTQSPSSLSASVGDRTITCSAQ DISNYLNWYQQKPGKAPKVLIIYFTSSLHSGVPSRF SGSGSGTDFTLTISLQPEDFATYYCQYSTVPWT FGQGTKVEIKR
805	DVD660H	AB014VH	AB079VH	EVQLVESGGGLVQPGGSLRLSCAASGYFTFTNYGMN WVRQAPGKGLEWGWINTYTGEPTYAADEFKRRFTF SLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYHGG SHWYFDVWGQGLVTVSS ASTKGP EVQLVQSGAEV KKPGESLKISCKGSGYSFTTYWMHWVRQMPGKGLE WMGEINPTNGHTNYNPSFQGQVTISADKSISTAYL QWSSLKASDTAMYVCARNYVGSIFDYWGQGLVTV SS
806	DVD660L	AB014VL	AB079VL	DIQMTQSPSSLSASVGDRTITCSAQDISNYLNW YQQKPGKAPKVLIIYFTSSLHSGVPSRFSGSGSGTD FTLTISLQPEDFATYYCQYSTVPWTFGQGTKVEIKR TVAAP DIQMTQSPSSLSASVGDRTITCKASE NVVSYVSWYQQKPGKAPKLLIYGASNRNTGVPSRF SGSGSGTDFTLTISLQPEDFATYYCGQSYNYPYTF FGQGTKLEIKR

Example 2.178: Generation of HGF (seq. 2) and VEGF (seq. 1) DVD-Igs with Linker Set 2

Table 212

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
807	DVD665H	AB079VH	AB014VH	EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWMH WVRQMPGKGLEWMGEINPTNGHTNYPNPSFQGQVTI SADKSISTAYLQWSSLKASDTAMYYCARNYVGSIF DYWGQGTLLVTVSS ASTKGPSVFPLAPE EVQLVESGG GLVQPGGSLRLSCAASGYTFTNYGMNWRQAPGKG LEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTA YLQMNSLRAEDTAVYYCAKYPHYYSSSHWFVWVG QGTLLVTVSS
808	DVD665L	AB079VL	AB014VL	DIQMTQSPSSLSASVGDRTITCKASENVVSYVSW YQQKPGKAPKLLIYGASNRNTGVPSRFGSGSGTD FTLTISLQPEDFATYYCGQSYNYPYTFGQGTKLE IKR TVAAPSVFI FPDIQMTQSPSSLSASVGDRT ITCSASQDISNYLNWYQQKPGKAPKVLIIYFTSSLH SGVPSRFGSGSGTDFTLTISLQPEDFATYYCQQ YSTVPWTFGQGTKVEIKR
809	DVD666H	AB014VH	AB079VH	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMN WVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTF SLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYS SHWYFDVWVGQGTLLVTVSS ASTKGPSVFPLAPE EVQL VQSGAEVKKPGESLKISCKGSGYSFTTYWMHWVRQ MPGKGLEWMGEINPTNGHTNYPNPSFQGQVTISADK SISTAYLQWSSLKASDTAMYYCARNYVGSIFDYWG QGTLLVTVSS
810	DVD666L	AB014VL	AB079VL	DIQMTQSPSSLSASVGDRTITCSASQDISNYLNW YQQKPGKAPKVLIIYFTSSLHSGVPSRFGSGSGTD FTLTISLQPEDFATYYCQYSTVPWTFGQGTKVE IKR TVAAPSVFI FPDIQMTQSPSSLSASVGDRT ITCKASENVVSYVSWYQQKPGKAPKLLIYGASNRN TGVPSRFGSGSGTDFTLTISLQPEDFATYYCQQ SYNYPYTFGQGTKLEIKR

Example 2.179: Generation of HGF (seq. 2) and VEGF (seq. 1) DVD-Igs with Linker Set 3

Table 213

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
811	DVD671VH	AB079VH	AB014VH	EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWMH WVRQMPGKGLEWMGEINPTNGHTNYPNPSFQGQVTI SADKSISTAYLQWSSLKASDTAMYYCARNYVGSIF DYWGQGTTLVTVSS ASTKGPSVFPLAP EVQLVESGG GLVQPGGSLRLSCAASGYTFTNYGMNWRQAPGKG LEWVGWINTYTGEPYAADFKRRFTFSLDTSKSTA YLQMNSLRAEDTAVYYCAKYPHYGSSHWFVWG QGTTLVTVSS
812	DVD671VL	AB079VL	AB014VL	DIQMTQSPSSLSASVGDRTITCKASENVVSYVSW YQQKPGKAPKLLIYGASNRNTGVPSRFSGSGSGTD FLLTISSLQPEDFATYYCGQSYNYPYTFGQGTKLE IKR TVAAP DIQMTQSPSSLSASVGDRTITCSASQ DISNYLNWYQQKPGKAPKVLIIYFTSSLHSGVPSRF SGSGSGTDFTLTISSLQPEDFATYYCQYSTVPWT FGQGTKVEIKR
813	DVD672VH	AB014VH	AB079VH	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMN WVRQAPGKGLEWVGWINTYTGEPYAADFKRRFTF SLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYGS SHWYFDVWGQGTTLVTVSS ASTKGPSVFPLAP EVQL VQSGAEVKKPGESLKISCKGSGYSFTTYWMHWVRQ MPGKGLEWMGEINPTNGHTNYPNPSFQGQVTISADK SISTAYLQWSSLKASDTAMYYCARNYVGSIFDYWG QGTTLVTVSS
814	DVD672VL	AB014VL	AB079VL	DIQMTQSPSSLSASVGDRTITCSASQDISNYLNW YQQKPGKAPKVLIIYFTSSLHSGVPSRFSGSGSGTD FLLTISSLQPEDFATYYCQYSTVPWTFGQGTKVE IKR TVAAP DIQMTQSPSSLSASVGDRTITCKASE NVVSYVSWYQQKPGKAPKLLIYGASNRNTGVPSRF SGSGSGTDFTLTISSLQPEDFATYYCGQSYNYPY TFGQGTKLEIKR

Example 2.180: Generation of HGF (seq. 2) and VEGF (seq. 1) DVD-Igs with Linker Set 4

Table 214

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
815	DVD677VH	AB079VH	AB014VH	EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWMH WVRQMPGKGLEWMGEINPTNGHTNYNPSFQGQVTI SADKSISTAYLQWSSLKASDTAMYVCARNYVGSIF DYWGQGLTIVTVSS ASTKGP EVQLVESGGGLVQPGG SLRLSCAASGYFTFTNYGMNWVRQAPGKGLEWVGWI NTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSL RAEDTAVYYCAKYPHYHGGSSHWYFDVWGQGLTIV SS
816	DVD677VL	AB079VL	AB014VL	DIQMTQSPSSLSASVGDRTITCKASENVVSYVSW YQQKPGKAPKLLIYGASNRNTGVPSRFGSGSGTD FTLTISLQPEDFATYYCGQSYNYPYTFGQGTKLE IKR TVAAPSVFI FPDIQMTQSPSSLSASVGDRT ITCSASQDISNYLNWYQQKPGKAPKVLIIYFTSSLH SGVPSRFGSGSGTDFTLTISLQPEDFATYYCQQ YSTVPWTFGQGTKVEIKR
817	DVD678VH	AB014VH	AB079VH	EVQLVESGGGLVQPGGSLRLSCAASGYFTFTNYGMN WVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTF SLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYHGS SHWYFDVWGQGLTIVTVSS ASTKGP EVQLVQSGAEV KKPGESLKISCKGSGYSFTTYWMHWVRQMPGKGLE WMGEINPTNGHTNYNPSFQGQVTISADKSISTAYL QWSSLKASDTAMYVCARNYVGSIFDYWGQGLTIV SS
818	DVD678VL	AB014VL	AB079VL	DIQMTQSPSSLSASVGDRTITCSASQDISNYLNW YQQKPGKAPKVLIIYFTSSLHSGVPSRFGSGSGTD FTLTISLQPEDFATYYCQYSTVPWTFGQGTKVE IKR TVAAPSVFI FPDIQMTQSPSSLSASVGDRT ITCKASENVVSYVSWYQQKPGKAPKLLIYGASNRN TGVPSRFGSGSGTDFTLTISLQPEDFATYYCQQ SYNYPYTFGQGTKLEIKR

Example 2.181: Generation of HGF (seq. 2) and VEGF (seq. 2) DVD-Igs with Linker Set 1

Table 215

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
819	DVD661H	AB079VH	AB070VH	EVQLVQSGAEVKKPGEGLKISCKGSGYSFTTYWMH WVRQMPGKGLEWGMGEINPTNGHTNYNPSFQGQVTI SADKSISTAYLQWSSLKASDTAMYVCARNYVGSIF DYWGQGTTLVTVSS ASTKGPE VQLVSGGGLVQPGG SLRLSCAASGFTISDYWIHWVRQAPGKGLEWVAGI TPAGGYTYADSVKGRFTISADTSKNTAYLQMNSL RAEDTAVYYCARVFFFLPYAMDYWGQGTTLVTVSS
820	DVD661L	AB079VL	AB070VL	DIQMTQSPSSLSASVGDRTITCKASENVVSYVSW YQQKPGKAPKLLIYGASNRNTGVPSRFSGSGSGTD FTLTISLQPEDFATYYCGQSYNYPYTFGQGTKLE IKR TVAAP DIQMTQSPSSLSASVGDRTITCRASQ DVSTAVAWYQQKPGKAPKLLIYSASFYSGVPSRF SGSGSGTDFTLTISLQPEDFATYYCQSYTTPPT FGQGTKVEIKR
821	DVD662H	AB070VH	AB079VH	EVQLVSGGGLVQPGGSLRLSCAASGFTISDYWIH WVRQAPGKGLEWVAGITPAGGYTYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARVFFFLPY AMDYWGQGTTLVTVSS ASTKGPE VQLVQSGAEVKKP GESLKISCKGSGYSFTTYWMHWVRQMPGKGLEWGM EINPTNGHTNYNPSFQGQVTISADKSISTAYLQWS SLKASDTAMYVCARNYVGSIFDYWGQGTTLVTVSS
822	DVD662L	AB070VL	AB079VL	DIQMTQSPSSLSASVGDRTITCRASQDVSTAVAW YQQKPGKAPKLLIYSASFYSGVPSRFSGSGSGTD FTLTISLQPEDFATYYCQSYTTPPTFGQGTKVE IKR TVAAP DIQMTQSPSSLSASVGDRTITCKASE NVVSYVSWYQQKPGKAPKLLIYGASNRNTGVPSRF SGSGSGTDFTLTISLQPEDFATYYCGQSYNYPY TFGQGTKLEIKR

Example 2.182: Generation of HGF (seq. 2) and VEGF (seq. 2) DVD-Igs with Linker Set 2

Table 216

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
823	DVD667H	AB079VH	AB070VH	EVQLVQSGAEVKKPGEISLKI SCKGSGYSFTTYWMH WVRQMPGKGLEWMGEINPTNGHTNYPNPSFQGGVTI SADKSI STAYLQWSSLKASDTAMYYCARNYVGSIF DYWGQGT LVTVSS ASTKGPSVFPLAP EVQLVESGG GLVQPGGSLRLS CAASGFTISDYWIHWVRQAPGKG LEWVAGITPAGGYTYYADSVKGRFTISADTSKNTA YLQMNSLRAEDTAVYYCARFVFFLPYAMDYWGQGT LVTVSS
824	DVD667L	AB079VL	AB070VL	DIQMTQSPSSLSASVGDRTITCKASENVVSYVSW YQQKPGKAPKLLIYGASNRNTGVPSRFSGSGSGTD FTLTISLQPEDFATYYCGQSYNYPYTFGQGTKLE IKR TVAAPSVFI FPP DIQMTQSPSSLSASVGDRT ITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLY SGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQ SYTTPPTFGQGTKVEIKR
825	DVD668H	AB070VH	AB079VH	EVQLVESGGGLVQPGGSLRLS CAASGFTISDYWIH WVRQAPGKGLEWVAGITPAGGYTYYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPY AMDYWGQGT LVTVSS ASTKGPSVFPLAP EVQLVQS GAEVKKPGEISLKI SCKGSGYSFTTYWMHWVRQMPG KGLEWMGEINPTNGHTNYPNPSFQGGVTI SADKSI TAYLQWSSLKASDTAMYYCARNYVGSIFDYWGQGT LVTVSS
826	DVD668L	AB070VL	AB079VL	DIQMTQSPSSLSASVGDRTITCRASQDVSTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTD FTLTISLQPEDFATYYCQQSYTTPPTFGQGTKVE IKR TVAAPSVFI FPP DIQMTQSPSSLSASVGDRT ITKASENVVSYVSWYQQKPGKAPKLLIYGASNRN TGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQ SYNYPYTFGQGTKLEIKR

Example 2.183: Generation of HGF (seq. 2) and VEGF (seq. 2) DVD-Igs with Linker Set 3

Table 217

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
827	DVD673VH	AB079VH	AB070VH	EVQLVQSGAEVKKPGEESLKISCKGSGYSFTTYWMH WVRQMPGKGLEWMGEINPTNGHTNYPNPSFQGGVTI SADKSISTAYLQWSSLKASDTAMYYCARNYVGSIF DYWGQGT LVTVSS ASTKGPSVFPLAP EVQLVESGG GLVQPGGSLRLSCAASGFTISDYWIHWVRQAPGKG LEWVAGITPAGGYTTYADSVKGRFTISADTSKNTA YLQMNSLRAEDTAVYYCARFVFFLPYAMDYWGQGT LVTVSS
828	DVD673VL	AB079VL	AB070VL	DIQMTQSPSSLSASVGDRTITCKASENVVSYVSW YQQKPGKAPKLLIYGASNRNTGVPSRFSGSGSGTD FLLTISLQPEDFATYYCGQSYNYPYTFGQGTKLE IKR TVAAP DIQMTQSPSSLSASVGDRTITCRASQ DVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRF SGSGSGTDFTLTISLQPEDFATYYCQSYTTPPT FGQGTKVEIKR
829	DVD674VH	AB070VH	AB079VH	EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIH WVRQAPGKGLEWVAGITPAGGYTTYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARFVFFLPY AMDYWGQGT LVTVSS ASTKGPSVFPLAP EVQLVQS GAEVKKPGEESLKISCKGSGYSFTTYWMHWVRQMPG KGLEWMGEINPTNGHTNYPNPSFQGGVTI SADKSIS TAYLQWSSLKASDTAMYYCARNYVGSIFDYWGQGT LVTVSS
830	DVD674VL	AB070VL	AB079VL	DIQMTQSPSSLSASVGDRTITCRASQDVSTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTD FLLTISLQPEDFATYYCQSYTTPPTFGQGTKVE IKR TVAAP DIQMTQSPSSLSASVGDRTITCKASE NVVSYVSWYQQKPGKAPKLLIYGASNRNTGVPSRF SGSGSGTDFTLTISLQPEDFATYYCGQSYNYPY FGQGTKLEIKR

Example 2.184: Generation of HGF (seq. 2) and VEGF (seq. 2) DVD-Igs with Linker Set 4

Table 218

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
831	DVD679VH	AB079VH	AB070VH	EVQLVQSGAEVKKKPGESLKISCKGSGYSFTTYWMH WVRQMPGKGLEWMGEINPTNGHTNYNPSFQGQVTI SADKSISTAYLQWSSLKASDTAMYVCARNYVGSIF DYWGQGTTLVTVSS ASTKGPEVQLV ESGGGLVQPGG SLRLSCAASGFTISDYWIHWVRQAPGKGLEWVAGI TPAGGYTYADSVKGRFTISADTSKNTAYLQMNSL RAEDTAVYYCARVFFFLPYAMDYWGQGTTLVTVSS
832	DVD679VL	AB079VL	AB070VL	DIQMTQSPSSLSASVGDRTITCKASENVVSYVSW YQQKPGKAPKLLIYGASNRNTGVPSRFSGSGSGTD FTLTISLQPEDFATYYCGQSYNYPYTFGQGTKLE IKR TVAAPSVFI FPPDIQMTQSPSSLSASVGDRTI ITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLY SGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQ SYTTPPTFGQGTKVEIKR
833	DVD680VH	AB070VH	AB079VH	EVQLVESGGGLVQPGGSLRLSCAASGFTISDYWIH WVRQAPGKGLEWVAGITPAGGYTYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARVFFFLPY AMDYWGQGTTLVTVSS ASTKGPEVQLV QSGAEVKKP GESLKISCKGSGYSFTTYWMHWVRQMPGKGLEWMG EINPTNGHTNYNPSFQGQVTISADKSISTAYLQWS SLKASDTAMYVCARNYVGSIFDYWGQGTTLVTVSS
834	DVD680VL	AB070VL	AB079VL	DIQMTQSPSSLSASVGDRTITCRASQDVSTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTD FTLTISLQPEDFATYYCQQSYTTPPTFGQGTKVE IKR TVAAPSVFI FPPDIQMTQSPSSLSASVGDRTI ITKASENVVSYVSWYQQKPGKAPKLLIYGASNRN TGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQ SYNYPYTFGQGTKLEIKR

Example 2.185: Generation of HGF (seq. 2) and VEGF (seq. 3) DVD-Igs with Linker Set 1

Table 219

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
835	DVD663H	AB079VH	AB071VH	EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWMH WVRQMPGKGLEWVMEINPTNGHTNYPNPSFQGVV SADKSISTAYLQWSSLKASDTAMYVCARNYVGSIF DYWGQGTLLVTVSS ASTKGPE VQLVSGGGLVQPGG SLRLSCAASGFTINASWIHWVRQAPGKGLEWVGA YPYSGYTNVADSVKGRFTISADTSKNTAYLQMN SLRAEDTAVYYCARWGHSTSPWAMDYWGQGTLLVTVSS
836	DVD663L	AB079VL	AB071VL	DIQMTQSPSSLSASVGDRTITCKASENVVSYVSW YQQKPGKAPKLLIYGASNRNTGVPSRFSGSGSD FTLTISLQPEDFATYYCGQSYNYPYTFGQGTKLE IKR TVAAP DIQMTQSPSSLSASVGDRTITCRASQ VIRRSWYQQKPGKAPKLLIYAASNLASGVPSRF SGSGSDFTLTISLQPEDFATYYCQSNTPSPLT FGQGTKVEIKR
837	DVD664H	AB071VH	AB079VH	EVQLVSGGGLVQPGGSLRLSCAASGFTINASWI WVRQAPGKGLEWVGAIPYSGYTNVADSVKGRFTI SADTSKNTAYLQMNLSRAEDTAVYYCARWGHSTSP WAMDYWGQGTLLVTVSS ASTKGPE VQLVQSGAEVKK PGESLKISCKGSGYSFTTYWMHWVRQMPGKGLEW MEINPTNGHTNYPNPSFQGVVTSADKSISTAYLQ WSSLKASDTAMYVCARNYVGSIFDYWGQGTLLVTVSS
838	DVD664L	AB071VL	AB079VL	DIQMTQSPSSLSASVGDRTITCRASQVIRRSW YQQKPGKAPKLLIYAASNLASGVPSRFSGSGSD FTLTISLQPEDFATYYCQSNTPSPLTFGQGTKVE IKR TVAAP DIQMTQSPSSLSASVGDRTITCKASE NVVSYVSWYQQKPGKAPKLLIYGASNRNTGVPSRF SGSGSDFTLTISLQPEDFATYYCGQSYNYPYTF FGQGTKLEIKR

Example 2.186: Generation of HGF (seq. 2) and VEGF (seq. 3) DVD-Igs with Linker Set 2

Table 220

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
839	DVD669H	AB079VH	AB071VH	EVQLVQSGAEVKKPGEISLKI SCKGSGYSFTTYWMH WVRQMPGKGLEWMGEINPTNGHTNYNPSFQGQVTI SADKSI STAYLQWSSLKASDTAMY YCARNYVGSIF DYWGQGT LVTVSS ASTKGPSVFPLAP EVQLVESGG GLVQPGGSLRLS CAASGFTINASWIHWVRQAPGKG LEWVGAIYPYSGY TNYADSVKGRFTISADTSKNTA YLQMNSLRAEDTAVYYCARWGHSTSPWAMDYWGQG TLTVSS
840	DVD669L	AB079VL	AB071VL	DIQMTQSPSSLSASV GDRVTITCKASENVVSYVSW YQQKPGKAPKLLIYGASNRNTGVPSRFSGSGSGTD FTLTISLQPEDFATYYCGQSYNYPYTFGQGTKLE IKR TVAAPSVFI FPP DIQMTQSPSSLSASV GDRVT ITCRASQVIRRLAWYQQKPGKAPKLLIYAASNLA SGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQ SNTSPLTFGQGTKVEIKR
841	DVD670H	AB071VH	AB079VH	EVQLVESGGGLVQPGGSLRLS CAASGFTINASWIH WVRQAPGKGLEWVGAIYPYSGY TNYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSP WAMDYWGQGT LVTVSS ASTKGPSVFPLAP EVQLVQ SGAEVKKPGEISLKI SCKGSGYSFTTYWMHWVRQMP GKGLEWMGEINPTNGHTNYNPSFQGQVTI SADKSI STAYLQWSSLKASDTAMY YCARNYVGSIFDYWGQG TLTVSS
842	DVD670L	AB071VL	AB079VL	DIQMTQSPSSLSASV GDRVTITCRASQVIRRLAW YQQKPGKAPKLLIYAASNLAGVPSRFSGSGSGTD FTLTISLQPEDFATYYCQQSNTSPLTFGQGTKVE IKR TVAAPSVFI FPP DIQMTQSPSSLSASV GDRVT ITKASENVVSYVSWYQQKPGKAPKLLIYGASNRN TGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQ SYNYPYTFGQGTKLEIKR

Example 2.187: Generation of HGF (seq. 2) and VEGF (seq. 3) DVD-Igs with Linker Set 3

Table 221

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
843	DVD675VH	AB079VH	AB071VH	EVQLVQSGAEVKKPGEISLKI SCKGSGYSFTTYWMH WVRQMPGKGLEWMGEINPTNGHTNYNPSFQGQVTI SADKSI STAYLQWSSLKASDTAMY YCARNYVGSIF DYWGQGT LVTVSS ASTKGPSVFPLAP EVQLVESGG GLVQPGGSLRLS CAASGFTINASWIHWVRQAPGKG LEWVGAIYPYSGY TNYADSVKGRFTISADTSKNTA YLQMNSLRAEDTAVYYCARWGHSTSPWAMDYWGQG TLTVSS
844	DVD675VL	AB079VL	AB071VL	DIQMTQSPSSLSASV GDRVTITCKASENVVSYVSW YQQKPGKAPKLLIYGASNRNTGVPSRFSGSGSGTD FTLTISLQPEDFATYYCGQSYNYPYTFGQGTKLE IKR TVAAP DIQMTQSPSSLSASV GDRVTITCRASQ VIRRLAWYQQKPGKAPKLLIYAASNLAGVPSRF SGSGSGTDFTLTISLQPEDFATYYCQSNTPSPLT FGQGTKVEIKR
845	DVD676VH	AB071VH	AB079VH	EVQLVESGGGLVQPGGSLRLS CAASGFTINASWIH WVRQAPGKGLEWVGAIYPYSGY TNYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARWGHSTSP WAMDYWGQGT LVTVSS ASTKGPSVFPLAP EVQLVQ SGAEVKKPGEISLKI SCKGSGYSFTTYWMHWVRQMP GKGLEWMGEINPTNGHTNYNPSFQGQVTI SADKSI STAYLQWSSLKASDTAMY YCARNYVGSIFDYWGQG TLTVSS
846	DVD676VL	AB071VL	AB079VL	DIQMTQSPSSLSASV GDRVTITCRASQVIRRLAW YQQKPGKAPKLLIYAASNLAGVPSRFSGSGSGTD FTLTISLQPEDFATYYCQSNTPSPLTFGQGTKVE IKR TVAAP DIQMTQSPSSLSASV GDRVTITCKASE NVVSYVSWYQQKPGKAPKLLIYGASNRNTGVPSRF SGSGSGTDFTLTISLQPEDFATYYCGQSYNYPY FGQGTKLEIKR

Example 2.188: Generation of HGF (seq. 2) and VEGF (seq. 3) DVD-Igs with Linker Set 4

Table 222

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
847	DVD681VH	AB079VH	AB071VH	EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWMH WVRQMPGKGLEWMGEINPTNGHTNYNPSFQGQVTI SADKSISTAYLQWSSLKASDTAMYVCARNYVGSIF DYWGQGTTLVTVSS ASTKGPEVQLV ESGGGLVQPGG SLRLSCAASGFTINASWIHWVRQAPGKGLEWVGAI YPYSGYTNVADSVKGRFTISADTSKNTAYLQMNLSL RAEDTAVYYCARWGHSTSPWAMDYWGQGTTLVTVSS
848	DVD681VL	AB079VL	AB071VL	DIQMTQSPSSLSASVGDRTVITCKASENVVSYVSW YQQKPGKAPKLLIYGASNRNTGVPSRFSGSGSGTD FTLTISLQPEDFATYYCGQSYNYPYTFGQGTKLE IKR TVAAPSVFI FPPDIQMTQSPSSLSASVGDRTV ITCRASQVIRRSLAWYQQKPGKAPKLLIYAASNLA SGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQ SNTSPLTFGQGTKVEIKR
849	DVD682VH	AB071VH	AB079VH	EVQLVESGGGLVQPGGSLRLSCAASGFTINASWIH WVRQAPGKGLEWVGAIYPYSGYTNVADSVKGRFTI SADTSKNTAYLQMNLSRAEDTAVYYCARWGHSTSP WAMDYWGQGTTLVTVSS ASTKGPEVQLV QSGAEVKK PGESLKISCKGSGYSFTTYWMHWVRQMPGKGLEWM GEINPTNGHTNYNPSFQGQVTI SADKSISTAYLQW SSLKASDTAMYVCARNYVGSIFDYWGQGTTLVTVSS
850	DVD682VL	AB071VL	AB079VL	DIQMTQSPSSLSASVGDRTVITCRASQVIRRSLAW YQQKPGKAPKLLIYAASNLAGVPSRFSGSGSGTD FTLTISLQPEDFATYYCQQSNTSPLTFGQGTKVE IKR TVAAPSVFI FPPDIQMTQSPSSLSASVGDRTV ITCKASENVVSYVSWYQQKPGKAPKLLIYGASNRN TGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQ SYNYPYTFGQGTKLEIKR

Example 2.189: Generation of HER2 (seq. 1) and HER2 (seq. 2) DVD-Igs with Linker Set 1

Table 223

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
851	DVD687H	AB004VH	AB080VH	EVQLVESGGGLVQPGGSLRLSCAASGFNIDKTYIH WVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFY AMDYWGQGTTLVTVSS ASTKGPE VQLVESGGGLVQPG GGSLRLSCAASGFNIDKTYTMDWVRQAPGKLEWVA DVNPNSSGGSIYNQRFKGRFTLSVDRSKNTLYLQMN SLRAEDTAVYYCARNLGPSFYFDYWGQGTTLVTVSS
852	DVD687L	AB004VL	AB080VL	DIQMTQSPSSLSASVGDRTITCRASQDVNTAVAW YQQKPGKAPKLLIYSASFLYSGVPSRFSGRSGTD FTLTISLQPEDFATYYCQQHYTTPTEFGQGTKVE IKR TVAAP DIQMTQSPSSLSASVGDRTITCKASQ DVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSTRF SGSGSGTDFTLTISLQPEDFATYYCQQYYIYPYT FGQGTKVEIKR
853	DVD688H	AB080VH	AB004VH	EVQLVESGGGLVQPGGSLRLSCAASGFNIDKTYIH WVRQAPGKLEWVADVNPNSSGGSIYNQRFKGRFTL SVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFY FDYWGQGTTLVTVSS ASTKGPE VQLVESGGGLVQPG GSLRLSCAASGFNIDKTYIHWVRQAPGKLEWVAR IYPTNGYTRYADSVKGRFTI SADTSKNTAYLQMN LRAEDTAVYYCSRWGGDGFYAMDYWGQGTTLVTVSS
854	DVD688L	AB080VL	AB004VL	DIQMTQSPSSLSASVGDRTITCKASQDVSIGVAW YQQKPGKAPKLLIYSASYRYTGVPSTRFSGSGSGTD FTLTISLQPEDFATYYCQQYYIYPYTFGQGTKVE IKR TVAAP DIQMTQSPSSLSASVGDRTITCRASQ DVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFR SGSRSGTDFTLTISLQPEDFATYYCQQHYTTPPT FGQGTKVEIKR

Example 2.190: Generation of HER2 (seq. 1) and HER2 (seq. 2) DVD-Igs with Linker Set 2

Table 224

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
855	DVD689H	AB004VH	AB080VH	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGLVTVSS ASTKGPSVFPLAP EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYMWRQAPGKLEWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGLVTVSS
856	DVD689L	AB004VL	AB080VL	DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFLTISLQPEDFATYYCQQHYTTPPTFGQGTKVEIKR TVAAPSVFI FPDIQMTQSPSSLSASVGDRVTITCKASQDVNSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGTDFLTISLQPEDFATYYCQYYIYPYTFGQGTKVEIKR
857	DVD690H	AB080VH	AB004VH	EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYMWRQAPGKLEWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGLVTVSS ASTKGPSVFPLAP EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGLVTVSS
858	DVD690L	AB080VL	AB004VL	DIQMTQSPSSLSASVGDRVTITCKASQDVNSIGVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFLTISLQPEDFATYYCQHYTTPPTFGQGTKVEIKR TVAAPSVFI FPDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFLTISLQPEDFATYYCQHYTTPPTFGQGTKVEIKR

Example 2.191 Generation of HER2 (seq. 1) and HER2 (seq. 2) DVD-Igs with Linker Set 3

Table 225

SEQ ID NO	DVD Variable Domain Name	Outer Variable Domain Name	Inner Variable Domain Name	Sequence
				12345678901234567890123456789012345
859	DVD691H	AB004VH	AB080VH	EVQLVESGGGLVQPGGSLRLSCAASGFTNIDYTIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGLVTVSS ASTKGPSVFPLAP EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYMHWVRQAPGKLEWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGLVTVSS
860	DVD691L	AB004VL	AB080VL	DIQMTQSPSSLSASVGRVITTCRASQDVNTAVAWYQQKPGKAPKLLIYSASFYSGVPSRFSGRSGTDFTLTISLQPEDFATYYCQQHYTTPPTFGQGTKVEIKR TVAAP DIQMTQSPSSLSASVGRVITTCRASQDVNTAVAWYQQKPGKAPKLLIYSASYRYTGVPVSRFSGSGSDFTLTISLQPEDFATYYCQQYIYPYTFGQGTKVEIKR
861	DVD692H	AB080VH	AB004VH	EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYMHWVRQAPGKLEWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGLVTVSS ASTKGPSVFPLAP EVQLVESGGGLVQPGGSLRLSCAASGFTNIDYTIHWVRQAPGKLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGLVTVSS
862	DVD692L	AB080VL	AB004VL	DIQMTQSPSSLSASVGRVITTCRASQDVNTAVAWYQQKPGKAPKLLIYSASFYSGVPSRFSGRSGTDFTLTISLQPEDFATYYCQQHYTTPPTFGQGTKVEIKR TVAAP DIQMTQSPSSLSASVGRVITTCRASQDVNTAVAWYQQKPGKAPKLLIYSASYRYTGVPVSRFSGSGSDFTLTISLQPEDFATYYCQQHYTTPPTFGQGTKVEIKR

	<p>ATCCCCGACCTCGACCTCTGGCTAATAAAGGAAATTTATTTTCATGCAA TAGTGTGTTGGAATTTTTTGTGTCTCTCACTCGGAAGGACATATGGGAGGG CAAATCATTGGTCGAGATCCCTCGGAGATCTCTAGCTAGAGGATCGATCC CCGCCCCGACGAACTAAACCTGACTACGACATCTCTGCCCTTCTTCGCG GGGCAGTGCATGTAATCCCTTCAGTTGGTTGGTACAACCTTGCCAACCTGGGC CCTGTTCCACATGTGACACGGGGGGGGACCAAACACAAAGGGGTTCTCTGA CTGTAGTTGACATCCTTAATAATGGATGTGCACATTTGCCAACACTGAGTG GCTTTCATCCTGGAGCAGACTTTCAGTCTGTGGACTGCAACACAACATTG CCTTTATGTGTAACCTTTGGCTGAAGCTCTTACACCAATGCTGGGGGACAT GTACCTCCAGGGGGCCAGGAAGACTACGGGAGGCTACACCAACGTC AATC AGAGGGGCTGTGTAGCTACCGATAAGCGGACCCTCAAGAGGGCATTAGCA ATAGTGTTTATAAGGCCCTTGTAAACCTAAACGGGTAGCATAATGCTTC CCGGGTAGTAGTATATACTATCCAGACTAACCTAATCAATAGCATATGT TACCAACGGGAAGCATATGCTATCGAATTAGGGTTAGTAAAAGGGTCCCTA AGGAACAGCGATATCTCCACCCCATGAGCTGTCACGGTTTTATTTACATG GGGTCAGGATTCACAGGGTAGTGAACCATTTTAGTCACAAGGGCAGTGG CTGAAGATCAAGGAGCGGGCAGTGAACCTCTCCTGAATCTTCGCCTGCTTCT TCATTCCTTTCGTTTAGCTAATAAGATAACTGCTGAGTTGTGAACAGTAA GGTGTATGTGAGGTGCTCGAAAACAAGGTTTCAGGTGACCCCCAGATA AAATTTGGACGGGGGTTTCAGTGGTGGCATTGTGCTATGACACCAATATA CCCTCACAAACCCCTTGGGCAATAAATACTAGTGTAGGAATGAAACATTCT GAATATCTTTAAACAATAGAAATCCATGGGGTGGGGACAAGCCGTAAAGACT GGATGTCCATCTCACACGAATTTATGGCTATGGGCAACACATAATCCTAGT GCAATATGACTGAGGTTATTAAGATGTGTCCAGGCAGGGACCAAGACA GGTGAACCATGTTGTTTACACTCTATTTGTAACAAGGGGAAAAGAGAGTGGAC GCCGACAGCAGCGGACTCCACTGGTTGTCTCTAACACCCCCGAAAATATA CGGGGCTCCACGCCAATGGGGCCATAAACAAGACAAGTGGCCACTCTTT TTTTTGAAATGTGGAGTGGGGGCACGCGTCAGCCCCACACGCCGCCCTG CGGTTTTGGACTGTAAAATAAGGGTGTAAATAACTTGGCTGATTGTAAACCC GCTAACCACTGCGGTCAAACCACTTGCCACAAAACCACTAATGGCACCCC GGGGAATACCTGCATAAAGTAGGTGGGCGGGCCAAGATAGGGGCGCGATTGC TGCGATCTGGAGGACAAAATTACACACACTTGCCTGAGCGCAAGCACAG GGTTGTTGGTCTCATATTCACGAGGTGCTGAGAGCACGGTGGGCTAATG TTGCCATGGGTAGCATATACTACCAAAATATCTGGATAGCATATGCTATCC TAATCTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCAT ATGCTATCCTAATCTATACTGGGTAGTATATGCTATCCTAATTTATATCT GGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAA TCTATATCTGGGTAGTATATGCTATCCTAATCTGTATCCGGGTAGCATATG CTATCCTAATAGAGATTAGGGTAGTATATGCTATCCTAATTTATATCTGGG TAGCATATACTACCAAAATATCTGGATAGCATATGCTATCCTAATCTATAT CTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGCATAGGCTATCCT AATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATA TGCTATCCTAATTTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTG GGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAAT CTGTATCCGGGTAGCATATGCTATCCTCATGATAAGCTGTCAAACATGAGA ATTTTCTTGAAGACGAAAGGGCCTCGTGATACGCTATTTTTATAGGTTAA TGTGATGATAAATAGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAA TGTGCGCGGAACCCCTATTTGTTTATTTTCTAAATACATTCAAAATATGTA TCCGCTCATGAGACAATAACCTGATAAATGCTTCAATAATATTGAAAAG GAAGAGTATGAGTATTCACACATTTCCGTGTCGCCCTTATTCCTTTTTTGC GGCATTGCTTCCCTGTTTTTGTCTACCCAGAAACGCTGGTGAAAGTAAA AGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAAGTGGATCT CAACAGCGGTAAGATCCTTGAGAGTTTTTCGCCCGAAGAAGTTTTTCAAT GATGAGCACTTTAAAGTCTGCTATGTGGCGGGTATTATCCCGTGTGTA GCCTGGGCAAGAGCAACTCGGTGCGCCGATACACTATCTCAGAAATGACTT GGTTGAGTACTCACCAGTACAGAAAAGCATCTTACGGATGGCATGACAGT AAGAGAATTATGAGTGTGCCATAACCATGAGTGATAAACAAGTGGGCCAA CTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGTTTTTTGCA CAACATGGGGGATCATGTAACCTCGCCTTGATCGTTGGGAACCGGAGCTGAA TGAAGCCATACCAACGACGAGCGTGACACCACGATGCTGACAGCAATGGC AACACGTTGCGCAACTATTAACCTGGCGAAGTACTTACTCTAGCTTCCC</p>
--	--

		<p>GCAACAATTAATAGACTGGATGGAGGCGGATAAAAGTTGCAGGACCCTCT GCGCTCGGCCCTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGG TGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCC CTCCCGTATCGTAGTTATCTACACGACGGGAGTCAGGCAACTATGGATGA ACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTA ACTGTGACACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACCTCA TTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGAC CAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGA AAAGATCAAAGGATCTTCTTGAGATCCTTTTTTCTGCGCGTAATCTGCTG CTTGCAAACAAAAAACCACCGCTACCAGCGGTGGTTTTGTTGCCGGATCA AGAGCTACCAACTCTTTTTCCGAAGGTAACGGCTTCAGCAGAGCGCAGAT ACCAAATACGTCTTCTTAGTGTAGCCGTAGTTAGGCCACCCTTCAAGAA CTCTGTAGCACCGCCTACATACTCGCTCTGCTAATCCTGTACCAGTGGC TGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGTTGGACTCAAGACGATA GTTACCGGATAAAGGCGCAGCGGTGGGC TGAACGGGGGGTTCGTGCACACA GCCAGCTTGAGCGAACGACCTACACCGAAGTGAATACCTACAGCGTGA GCTATGAGAAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCC GGTAAGCGGCAGGGTCGGAACAGGAGAGCGCAGAGGGAGCTTCCAGGGGG AAACGCTGGTATCTTTATAGTCTGCTGGGTTTCGCCACCTCTGACTTGA GCGTCGATTTTTGTGATGCTCGTCAGGGGGCGGAGCCTATGAAAAACGC CAGCAACGCGGCTTTTTACGGTCTTGGCTTTTGTGGCTTTTGTCTCA CATGTTCTTTCTGCGTTATCCCTGATTCGTGGATAACCGTATTACCGC CTTTGAGTGAGCTGATACCGCTCGCCGACGCCAAGCAGCCAGCGCAGCGA GTCAGTGAGCGAGGAAGCGGAAGAGCGCCAATACGCAAACCGCTCTCCC CGCGGTTGGCGATTCAATTAATGCAGCTGGCACGACAGGTTTCCCGACTG GAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTA GGCACCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAAT TGTGAGCGGATAACAATTTACACAGGAAACAGCTATGACCATGATTACGC CAAGCTCTAGCTAGAGGTGAGTCCCTCCCAGCAGGCCAGAAGTATGCAAAA GCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCTAACTCCGCCCA TCCCGCCCTAACTCCGCCAGTTCGCCCATCTCCGCCCATAGGCTGAC TAATTTTTTTTTATTTATGCAGAGGCCGAGGCCGCTCGGCCCTGAGCTAT TCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCTTAGGCTTTTGCAAAAAGC TTTGCAAAGATGGATAAAAGTTTAAACAGAGAGGAATCTTTGCAGCTAATG GACCTTCTAGGTCTTGAAGGAGTGGGAATTGGCTCCGGTCCCGTCACTG GGCAGAGCGCACATCGCCACAGTCCCGGAGAAGTTGGGGGAGGGGTCGG CAATTGAACCGGTGCC TAGAGAAGGTGGCGCGGGTAAACTGGGAAGTGA TGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATAT AAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGGCCCG AACACAGGTAAGTGCCGTGTGTGGTCCCGCGGGCCTGGCTCTTTACGGG TTATGGCCCTTGCGTGCCTTGAATTACTCCACCTGGCTGCAGTACGTGAT TCTTGATCCCGAGCTTCGGGTTGGAAGTGGGTGGGAGAGTTCCGAGCCCTG CGCTTAAGGAGCCCTTCGCCTCGTGTGTTGAGTTGAGGCTGGCCTGGCGC CTGGGGCCCGCGTGCGAATCTGGTGGCACCTTCGCGCTGTCTCGCTGC TTTCGATAAGTCTCTAGCCATTTAAAATTTTTGATGACCTGTGCGACGCT TTTTTTCTGGCAAGATAGCTTGTAAATGCGGGCAAGA TCTGCACACTGG TATTTCCGTTTTTTGGGGCCGGGGCGGGACGGGGCCCGTGGCTCCAGCG CACATGTTCCGGCAGGGCGGGCCTGCGAGCGCGCCACCAGAGAATCGGACG GGGTAGTCTCAAGCTGGCCGCTGCTCTGGTGCCTGGCCTCGCGCCCGC GTGTATCGCCCGCCCTGGGCGCAAGGCTGGCCCGTGGCACCAGTTGC GTGAGCGGAAAGATGGCCGCTTCCCGCCCTGCTGCAGGGAGCTCAAAATG GAGGACCGGGCCTCGGGAGAGCGGGCGGGTGAGTACCACACAAAGGAA AAGGGCCTTTCCGTCTCAGCCGTGCTTCAATGTGACTCCACGGAGTACCG GGCGCGTCCAGGCACCTCGATTAGTTCTCGAGCTTTTGGAGTACGTCGTC TTTAGGTTGGGGGAGGGGTTTTATGCGATGGAGTTTCCACACTAGTG GGTGAGACTGAAGTTAGGCCAGCTTGGCACTTGATGTAATCTCCTTGG ATTTGCCCTTTTTGAGTTTGGATCTTGGTTCATTCTCAAGCCTCAGACAGT GGTTCAAAGTTTTTTCTTCAATTCAGGTGTCGTGAGGAATTTCTTAGAG ATCCCTCGACCTCGAGATCCATTTGTCGCCGGGCGCCACCATGGAGTTTGGG CTGAGCTGGCTTTTCTTGTGCGGATTTAAAAGGTGTCCAGTGC</p>
v2	868	ACGGTGGCTGCACCATCTGTCTCATCTTCCCGCATCTGATGAGCAGTTG

		<p>AAATCTGGAAC TGCTCTGTGTGTGCCTGCTGAATAACTTCTATCCCAGA GAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCC CAGGAGAGTGTACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGC AGCACCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCC TGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAAGAGCTTCAAC AGGGGAGAGTGTGAGCGGCCGCTCGAGGCCGGCAAGGCCGATCCCCGA CCTCGACCTCTGGCTAATAAAGGAAATTTATTTTCATTGCAATAGTGTGTT GGAATTTTTTGTGTCTCTCACTCGGAAGGACATATGGGAGGGCAAATCATT TGGTGAGATCCCTCGGAGATCTCTAGCTAGAGGATCGATCCCCGCCCGG ACGAACTAAACCTGACTACGACATCTCTGCCCTTCTTCGCGGGGCAGTGC ATGTAATCCCTCAGTTGGTTGGTACAACCTTGCCAACCTGGGCCCTGTCCA CATGTGACACGGGGGGGACCAACACAAAGGGGTTCTCTGACTGTAGTTG ACATCCTTATAAATGGATGTGCACATTTGCCAACACTGAGTGGCTTTTATC CTGGAGCAGACTTTCAGTCTGTGGACTGCAACACAACATTGCCCTTTATGT GTAACCTTTGGCTGAAGCTCTTACACCAATGCTGGGGGACATGTACC TCCC AGGGGCCCAGGAAGACTACGGGAGGCTACACCAACGTCAATCAGAGGGGCC TGTGTAGCTACCGATAAGCGGACCCTCAAGAGGGCATTAGCAATAGTGT ATAAGGCCCTTTGTTAACCTAAACGGGTAGCATATGCTTCCCGGGTAGT AGTATATACTATCCAGACTAACCTAATTC AATAGCATATGTTACCCAACG GGAAGCATATGCTATCGAATTAGGGTTAGTAAAAGGGTCTAAGGAACAGC GATATCTCCCACCCCATGAGCTGTCACGGTTTTATTTACATGGGGTCAGGA TTCCACGAGGGTAGTGAACCATTTTAGTCAAGGGCAGTGGCTGAAGATC AAGGAGCGGGCAGTGAACCTCCTGAATCTTCGCCTGCTTCTTATTCTCC TTCGTTTAGCTAATAGAATAACTGCTGAGTTGTGAACAGTAAGGTGTATGT GAGGTGCTCGAAAAAAGGTTTCAGGTGACGCCCCGCAATAAAAATTTGGA CGGGGGGTTTCAGTGGTGGCATTGTGCTATGACACCAATAAACCCTCACAA ACCCCTTGGGCAATAAATACTAGTGTAGGAATGAAACATTTCTGAATATCTT TAACAATAGAAAATCCATGGGGTGGGGACAGCCGTAAAGACTGGATGTCCA TCTCACACGAATTTATGGCTATGGGCAACACATAATCCTAGTGAATATGA TACTGGGGTTATTAAGATGTGTCCCAGGCAGGGACCAAGACAGGTGAACCA TGTGTTACACTCTATTTGTAAACAAGGGGAAAGAGAGTGGACGCCGACAGC AGCGGACTCCACTGGTTGTCTCTAACACCCCGAAAAATTAACCGGGCTCC ACGCCAATGGGGCCATAAACAAGACAAGTGGCCACTCTTTTTTTTGGAAA TTGTGGAGTGGGGGCACGCTCAGCCCCACACGCCGCTTCGCGTTTTTGG ACTGTAATAAAGGGTGTAACTTGGCTGATTGTAACCCCGCTAACCAC TGCGGTCAAACCACTTGCCCAAAAACCACTAATGGCACCCCGGGGAATAC CTGCATAAGTAGGTGGGCGGCCAAGATAGGGGCGCATTTGCTGCGATCTG GAGGACAAATTACACACACTTGCGCCTGAGCGCAAGCACAGGGTTGTTGG TCCTCATATTCACGAGGTGCTGAGAGCACGGTGGGCTAATGTTGCCATGG GTAGCATATAC TACCCAAATATCTGGATAGCATATGCTATCCTAATCTATA TCTGGGTAGCATAGGCTATCCTAATCTATACTGGGTAGCATATGCTATCC TAATCTATATCTGGGTAGTATATGCTATCCTAATTTATATCTGGGTAGCAT AGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCT GGGTAGTATATGCTATCCTAATCTGTATCCGGGTAGCATATGCTATCCTAA TAGAGATTAGGGTAGTATATGCTATCCTAATTTATATCTGGGTAGCATATA CTACCCAAATATCTGGATAGCATATGCTATCCTAATCTATATCTGGGTAGC ATATGCTATCCTAATCTATACTGGGTAGCATAGGCTATCCTAATCTATAT CTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCT AATTTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATA TGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATCTGTATCCG GGTAGCATATGCTATCCTCATGATAAGCTGTCAAACATGAGAATTTTCTTG AAGACGAAAGGGCCTCGTGATACGCCATTTTTTATAGGTAAATGTCATGAT AATAATGGTTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGG AACCCCTATTTGTTATTTTTCTAAATACATTC AATATGTATCCGCTCAT GAGACAATAACCTGATAAAATGCTTCAATAATATTGAAAAGGAAGATAT GAGTATTCAACATTTCCGTGTCGCCCTTATTTCCCTTTTTTTCGGGCATTTTG CCTTCTGTTTTTGTCTACCCAGAAACGCTGGTGAAGTAAAAGATGCTGA AGATCAGTTGGGTGCACGAGTGGGTACATCGAACTGGA TCTCAACAGCGG TAAGATCCTTGAGAGTTTTTCGCCCCGAGAACGTTTTTCCAATGATGAGCAC TTTTAAAGTTCGCTATGTGGCGCGGTATTATCCCGTGTGACGCCGGGCA AGAGCAACTCGGTCGCCGATACACTATTCTCAGAATGACTTGGTTGAGTA</p>
--	--	--

		<p>CTCACCAGTCCAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATT ATGCAGTGCTGCCATAACCATGAGTGATAAACAAGTGGCCCAACTTACTTCT GACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGG GGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCAT ACCAAACGACGAGCGTGACACCACGATGCCGTGCAGCAATGGCAACAACGTT GCGCAAACATTAAGTGGCGAACTACTTACTTAGCTTCCCGGCAACAATT AATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCCTTCTGCGCTCGGC CCTTCCGGCTGGCTGGTTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGG GTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTAT CGTAGTTATCTACACGACGGGAGTCAGGCAACTATGGATGAACGAAATAG ACAGATCGCTGAGATAGGTGCCCTACTGATTAAGCATTGGTAACGTGTCAGA CCAAGTTTACTCATATATACCTTAGATTGATTTAAAACCTCATTTTTAAAT TAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCC TTAACGTGAGTTTTCGTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAA AGGATCTTCTTGAGATCCTTTTTTCTGCGCGTAATCTGCTGCTTGCAAC AAAAAACCACCGCTACCAGCGGTGGTTTTGTTGCCGGATCAAGAGCTACC AACTCTTTTTCCGAAGGTAAGTGGCTTCCAGCAGAGCGCAGATACCAAATAC TGTCTTCTAGTGTAGCCGTAGTTAGGCCACCCTTCAAGAACTCTGTAGC ACCGCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCGCAG TGGCGATAAGTCGTGTCTTACCAGGTTGGACTCAAGACGATAGTTACCAGGA TAAGGCGCAGCGGTGGGCTGAACGGGGGTTGCTGCACACAGCCAGCTT GGAGCGAACGACTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGA AAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGG CAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGAAACGCGCTG GTATCTTTATAGTCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCAATT TTTGTGATGCTCGTCAGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGC GGCCTTTTTACGGTTCCTGGCTTTTTGCTGGCCTTTTTGCTCATATGTTCTT TCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTG AGCTGATACCGCTCGCCGACCGCAACGACCGAGCGCAGCGAGTCAAGTGA CGAGGAAGCGGAAGAGCGCCCAATACGCAAAACCGCCTCCCCGCGCGTTG GCCGATTCATTAATGACAGCTGGCACGACAGGTTTCCCGACTGGAAAAGCGGG CAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCA GGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAAATTTGAGCGG ATAACAATTTACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCTA GCTAGAGGTGAGTCCCTCCCAGCAGGCAGAAATGCAAAAGCATGCATC TCAATTAGTCAGCAACCATAGTCCCGCCCCTAAGTCCCGCCATCCCGCCCC TAACTCCGCCAGTTCGCCCAATTCTCCGCCCATAGGCTGACTAATTTTTTT TTATTTATGCAGAGGCGGAGCCGCTCGGCCTCTGAGCTATTCCAGAAGT AGTGAGGAGGCTTTTTTGGAGGCTTAGGCTTTTGCAAAAAGCTTTGCAAA ATGGATAAAGTTTTAAACAGAGAGGAATCTTGCAGCTAATGGACCTTCTA GGCTTTGAAAGGAGTGGGAAATGGCTCCGGTGCCCGTCAAGTGGGCAGAGCG CACATCGCCACAGTCCCGAGAAGTTGGGGGGAGGGGTGGCAATTTGAAC CGGTGCTTAGAGAAGGTGGCGCGGGGTAACCTGGGAAAGTGAATGCTGTGTA CTGGCTCCGCCTTTTTCCGAGGGTGGGGGAGAACCCTATATAAGTGCAGT AGTCGCGTGAACGTTCTTTTTCGCAACGGGTTGCCGCCAGAACACAGGT AAGTGCCGTGTGTTGTTCCCGCGGGCCTGGCCTCTTTACGGGTATGGCCC TTGCGTGCCTTGAATTACTTCCACCTGGCTGCAGTACGTGATTCTTGATCC CGAGCTTCCGGTTGGAAGTGGGTGGGAGAGTTGAGGCCCTTGGCCTTAAAG AGCCCCCTCGCTCGTGTGTTGAGTTGAGGCTTGGCCTGGGCGCTGGGGCCG CCGCGTGCGAATCTGGTGGCACCTTCGCGCCTGTCTCGTGTCTTCGATAA GTCTTAGCCATTTAAAATTTTTGATGACCTGCTGCGACGCTTTTTTTCTG GCAAGATAGCTTGTAAATGCGGGCAAGATCTGCACACTGGTATTTCCGT TTTTGGGGCCCGGGCGGCGACGGGGCCCGTGGCTCCCAGCGCACATGTTT GGCGAGGGGGGCTGCGAGCGCGGCCACCAGAGAATCGGACGGGGGTAGTC TCAAGCTGGCCGCGCTGCTTGGTGCTTGGCTTGGCTCGCGCCCGCTGATCGC CCCGCCTGGGCGCAAGGCTGGCCCGGTGGCACAGTGGCTGAGCGGA AAGATGGCCGCTTCCCGCCCTGCTGCAGGGAGCTCAAAATGGAGGACGCG GCCTCGGGAGAGCGGGCGGTTGAGTCACCCACACAAAGGAAAAGGGCCTT TCCGTCTCAGCCGTCGCTTCAATGTGACTCCACGGAGTACGGGGCGCGCTC CAGGCACCTCGATTAGTTCTCGAGCTTTTGGAGTACGTCGCTTTAGGTTG GGGGAGGGGTTTTATGCGATGGAGTTTCCCACTGAGTGGGTGGAGAC</p>
--	--	--

		TGAAGTTAGGCCAGCTTGGCACTTGATGTAATTCTCCTTGAATTTGCCCT TTTTGAGTTTGGATCTTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAG TTTTTTTCTTCCATTTCAAGGTGTCGTGAGGAATTCTCTAGAGATCCCTCGA CCTCGAGATCCATTGTGCCCGGGCGCACCATGGACATGCGCGTGCCCGCCC AGCTGCTGGGCCTGCTGCTGCTGTGGTTCCTCCGGCTCGCGATGC
V3	869	CAACCCAAGGCTGCCCTCGGTCCTCTGTTCCTCCCTCTCTGAGGAG CTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCG GGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCGTCAAGGCGGGA GTGGAGACCACCACCCCTCAAACAAGCAACAACAAGTACGCGGCCAGC AGCTACCTGAGCCTGACGCCGAGCAGTGAAGTCCCACAGAAGCTACAGC TGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCATA GAATGTTTATGAGCGGCCGTCGAGGCCGGCAAGGCCGGATCCCCGACCT CGACCTCTGGCTAATAAAGGAAATTTATTTTCATTGCAATAGTGTGTGGA ATTTTTTGTGTCTCTCACTCGGAAGGACATATGGGAGGGCAAATCATTTGG TCGAGATCCCTCGGAGATCTCTAGCTAGAGGATCGATCCCCGCCCCGGACG AACTAAACCTGACTACGACATCTCTGCCCTTCTTCGCGGGGCAGTGCATG TAATCCCTTCAGTTGGTGGTACAACCTTGCCAACCTGGGCCCTGTTCCACAT GTGACACGGGGGGGACCAACAAGGGGTTCTCTGACTGTAGTTGACA TCCTTATAAATGGATGTGCACATTTGCCAACACTGAGTGGCTTTTATCCTG GAGCAGACTTTGCAGTCTGTGGACTGCAACACAACATTGCCTTTATGTGTA ACTCTTGGCTGAAGCTCTTACACCAATGCTGGGGGACATGTACCTCCCAGG GGCCAGGAAGACTACGGGAGGCTACACCAACGTCAATCAGAGGGGCCGTGT GTAGCTACCGATAAGCGGACCTCAAGAGGGCATTAGCAATAGTGTTTATA AGGCCCTTGTAAACCTAAACGGGTAGCATATGCTTCCCGGGTAGTAGT ATATACTATCCAGACTAACCTAATTCAATAGCATATGTTACCCAACGGGA AGCATATGCTATCGAATTAGGGTTAGTAAAAGGGTCTTAAGGAACAGCGAT ATCTCCACCCCATGAGCTGTCACGGTTTTATTTACATGGGGTCAGGATTC CACGAGGGTAGTAACCATTTTAGTCACAAGGGCAGTGGCTGAAGATCAAG GAGCGGGCAGTGAACCTCTCTGAATCTTCGCTGCTTCTTCATTCTCCTTC GTTTAGCTAATAGAATAACTGCTGAGTTGTGAACAGTAAGGTGTATGTGAG GTGCTCGAAAACAAGGTTTTCAGGTGACGCCCCCAAGAATAAAAATTTGGACGG GGGGTTCAGTGGTGGCATTGTGCTATGACACCAATATAACCTCACAAACC CCTTGGGCAATAAATACTAGTGTAGGAATGAAACATTTCTGAATATCTTTAA CAATAGAAATCCATGGGGTGGGGACAAGCCGTAAAGACTGGATGTCCATCT CACACGAATTTATGGCTATGGGCAACACATAATCTTAGTGCAATATGATAC TGGGGTTATTAAGATGTGTCCCAGGCAGGGACCAAGACAGGTGAACCATGT TGTACACTCTATTTGTAACAAGGGGAAAGAGAGTGGACCCGACAGCAGC GGACTCCACTGGTTGTCTCTAACACCCCCGAAAATTAACGGGGCTCCACG CCAATGGGGCCATAAACAAGACAAGTGGCCACTCTTTTTTTTGAATTTG TGGAGTGGGGGCACGCGTCAGCCCCACACGCCGCCCTGGCGTTTTGGACT GTAAAATAAGGGTGAATAAATCTGGCTGATTGTAACCCCGCTAACCACTGC GGTCAAACCCTTGCCCAAAAACCACTAATGGCACCCCGGGGAATACCTG CATAAGTAGGTGGCGGGCCAAAGATAGGGGCGCGATTGCTGCGATCTGGAG GACAAATTACACACACTTGCCTGAGCGCCAAGCACAGGGTTGTTGGTCC TCATATTCACGAGGTCGCTGAGAGCACGGTGGGCTAATGTTGCCATGGGTA GCATATACTACCAAATATCTGGATAGCATATGCTATCTTAATCTATATCT GGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAA TCTATATCTGGGTAGTATATGCTATCCTAATTTATATCTGGGTAGCATAGG CTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGG TAGTATATGCTATCCTAATCTGTATCCGGGTAGCATATGCTATCCTAATAG AGATTAGGGTAGTATATGCTATCCTAATTTATATCTGGGTAGCATATACTA CCCAAATATCTGGATAGCATATGCTATCCTAATCTATATCTGGGTAGCATA TGCTATCCTAATCTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTG GGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAAT TTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCT TATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATCTGTATCCGGGT AGCATATGCTATCCTCATGATAAGCTGTCAAACATGAGAATTTTCTTGAAG ACGAAAGGGCCTCGTGATACGCTATTTTTATAGGTTAATGTCATGATAAT AATGGTTTTCTTAGACGTCAGGTGGCACTTTTTCGGGGAAATGTGCGCGGAAC CCCTATTTGTTTTATTTTCTAAATACATTCAAAATATGATCCGCTCATGAG ACAATAACCTGATAAATGCTTCAATAATATTGAAAAGGAAGAGTATGAG

		<p>TATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTTCGGCATTTCCT TCCTGTTTTTGTCCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGA TCAGTTGGGTGCACGAGTGGGTACATCGAACTGGATCTCAACAGCGGTAA GATCCTTGAGAGTTTTCCGCCCGAAGAACGTTTTCCAATGATGAGCACTTT TAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTGACGCCGGGCAAGA GCAACTCGGTCCCGCATACTACTATTCTCAGAATGACTTGGTTGAGTACTC ACCACTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATG CAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGAC AACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGA TCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAAAGAAGCCATACC AAACGACGAGCGTGACACCAGATGCCTGCAGCAATGGCAACAACGTTGCG CAAATATTAACCTGGCGAAC TACTTACTCTAGCTTCCCGGCAACAATTAAT AGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCT TCCGGCTGGCTGGTTTATTGCTGATAAACTGAGAGCCGGTGAGCGTGGGTC TCGCGGTATCATGTCAGCAC TGGGGCCAGATGGTAAGCCCTCCCGTATCGT AGTTATCTACACGACGGGAGT CAGGCAACTATGGATGAACGAAATAGACA GATCGCTGAGATAGGTGCCTCACTGATTAAGCATTTGGTAACTGTCAGACCA AGTTACTCATA TACTTTAGATTGATTTAAAACCTCATTTTTAATTTAA AAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTA ACGTGAGTTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGG ATCTTCTTGAGATCCTTTTTTCTGCGGTAATCTGCTGCTTGCACAACAAA AAAACCACCGCTACCAGCGGTGGTTTTGTTGCCGGATCAAGAGCTACCAAC TCTTTTTCCGAAGGTAAC TGGCTTCAGCAGAGCGCAGATACCAAACTACTGT TCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACC GCCTACATAACC TCGCTCTGCTAATCCTGTTACCAGTGGCTGCCAGTGG CGATAAGTCGTGCTTACC GGGTTGGACTCAAGACGATAGTTACCGGATAA GGCGCAGCGGTCCGGCTGAACGGGGGGTTCGTGCACACAGCCAGCTTGA GCGAACGACCTACACC GAAC TGAGATACCTACAGCGTGAGCTATGAGAAAG CGCCACGCTTCCCGAAGGGAGAAAAGCGGACAGGTATCCGGTAAGCGGCAG GGTCGGAACAGGAGAGCGCAGAGGGAGCTTCCAGGGGAAACCGCTGGTA TCTTTATAGTCTGTGCGGTTTCGCCACCTCTGACTTGAGCGCTCATTTTTT GTGATGCTCGTCAGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGC CTTTTTACGGTTCTTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCC TGCGTTATCCCTGATTC TGTGGATAACCGTATTACCGCCTTTGAGTGAGC TGATAACCGCTCGCCG CAGCCGAACGACCGAGCGCAGCGAGTCACTGAGCGA GGAAGCGGAAGAGCGCCCAATACGCAACCGCCTTCCCGCGCGTTGGCC GATTCATTAATGCAGCTGGC ACGACAGGTTTCCCGACTGGAAAGCGGGCAG TGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCAGGC TTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATA ACAATTTACACAGGAAACAGCTATGACCA TGATTACGCCAAGCTCTAGCT AGAGGTCGAGTCCCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCA ATTAGTCAGCAACCATAGTCCCGCCCTAACTCCGCCCATCCCGCCCTAA CTCCGCCAGTTCCCGCCCAT TCTCCGCCCATGGCTGACTAATTTTTTTTA TTTATGCAGAGGCCGAGGCCCTCGGCCCTGAGCTATTCCAGAAGTAGT GAGGAGGCTTTTTTGGAGGCTAGGCTTTTGCAAAAAGCTTTGCAAAGATG GATAAAGTTTTTAAACAGAGAGGAATCTTTGCAGCTAATGGACCTTCTAGGT CTTGAAAGGAGTGGGAATTGGCTCCGGTGCCCGTCACTGAGGCGAGCGCAC ATCGCCACAGTCCCGAGAAGTTGGGGGGAGGGTCCGCAATTGAACCGG TGCTTAGAGAAGGTGGCGGGGTA AAC TGGAAGTGA TGCTGTACTG GCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACC GTATATAAGTGCAGTAGT CGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGGTAAG TGCCGTGTGTGGTTCCCGGGGCTGGCCTTTTACGGGTTATGGCCCTTG CGTGCTTGAATTA CTCCACTGGCTGCAGTACGTGATTCTTGATCCCGA GCTTCGGGTTGGAAGTGGGTGGGAGAGTTCGAGGCCTTGCGCTTAAGGAGC CCCTTCGCCCTGTGCTTGAGTTGAGGCC TGGCCTGGGCGCTGGGGCCGCG CGTGCGAATCTGGTGGCACCTTCGCGCCTGTCTCGCTGCTTTCGATAAGTC TCTAGCCATTTAAAATTTTTGATGACCTGCTGCGACGCTTTTTTCTGGCA AGATAGTCTTGTAAATGCGGGCCAAGATCTGCACACTGGTATTTCCGGTTTT TGGGGCCGCGGGCGGCGACGGGGCCCGTGCCTCCAGCGCACATGTTCCGGC GAGGCGGGGCTGCGAGCGGGCCACCGAGAATCGGACGGGGTAGTCTCA AGCTGGCCGGCTGCTCTGGTGCCTGGCCTCGCGCCCGCTGATTCGCCCC</p>
--	--	---

		<p>GCCCTGGGCGGCAAGGCTGGCCCGGTGCGCACCAAGTTGCGTGAGCGGAAAG ATGGCCGCTTCCCGGCCCTGCTGCAGGGAGCTCAAAATGGAGGACGCGGCG CTCGGGAGAGCGGGCGGGTGTAGTCACCCACACAAAGGAAAAGGGCCTTCC GTCTCAGCCGTCGCTTCATGTGACTCCACGGAGTACCGGGCGCCGTCCAG GCACCTCGATTAGTTCTCGAGCTTTTGGAGTACGTCGCTTTAGGTTGGGG GGAGGGGTTTTATGCGATGGAGTTTCCCCACACTGAGTGGGTGGAGACTGA AGTTAGGCCAGCTTGGCACTTGATGTAATTCTCTTGGAAATTTGCCCTTT TGAGTTTGGATCTTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTTT TTTCTTCCATTTAGGTGTCGTGAGGAATCTCTAGAGATCCCTCGACCT CGAGATCCATTGTGCCCGGGCGCCACCATGACTTGGACCCCACTCCTCTTC CTCACCTCCTCCTCCACTGCACAGGAAGCTTATCG</p>
<p>v4</p>	<p>870</p>	<p>ACGGTGGCTGCACCATCTGTCTCATCTTCCCGCCATCTGATGAGCAGTTG AAATCTGGAAC TGCCCTGTGTGTGCTGCTGAATAACTTCTATCCAGAG GAGGCCAAAGTACAGTGAAGGTGGATAACGCCCTCCAATCGGGTAACTCC CAGGAGAGTGTACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGC AGCACCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCC TCGGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAAC AGGGGAGAGTGTGAGCGGCCGCTCGAGGCCGGCAAGGCCGATCCCCCGA CCTCGACCTCTGGCTAATAAAGGAAATTTATTTTCATTGCAATAGTGTGT GGAATTTTTTGTGTCTCTCACTCGGAAGGACATATGGGAGGGCAAATCATT TGGTCGAGATCCCTCGGAGATCTCTAGCTAGAGGATCGATCCCCGCCCGG ACGAACTAAACCTGACTACGACATCTCTGCCCTTCTTCGCGGGGACAGTGC ATGTAATCCCTCAGTTGGTTGGTACAACCTTGCCAACCTGGGCCCTGTCCA CATGTGACACGGGGGGGACCAACACAAAGGGTTCTCTGACTGTAGTTG ACATCCTTATAAATGGATGTGCACATTTGCCAACACTGAGTGGCTTTCATC CTGGAGCAGACTTTCAGTCTGTGGACTGCAACACAACATTGCCCTTTATGT GTAACCTTTGGCTGAAGCTCTTACACCAATGCTGGGGGACATGTACCTCC AGGGGCCAGGAAGACTACGGGAGGCTACACCAACGTCAATCAGAGGGGCC TGTGTAGCTACCGATAAGCGGACCCTCAAGAGGGCATTAGCAATAGTGT ATAAGGCCCTTGTAAACCTAAACGGGTAGCATATGCTTCCCGGGTAGT AGTATATACATACTCAGACTAACCCCTAATTCATAGCATATGTTACCCACG GGAAGCATATGCTATCGAATTAGGGTTAGTAAAAGGGTCCTAAGGAACAGC GATATCTCCACCCCATGAGCTGTACGGTTTTATTTACATGGGGTCAGGA TTCCACGAGGGTAGTGAACCATTTTAGTCAAGGGCAGTGGCTGAAGATC AAGGAGCGGGCAGTGAACCTCCTGAATCTTCGCTGCTTCTTCAATCTCC TTCGTTTAGCTAATAGAATAACTGCTGAGTTGTGAACAGTAAGGTGTATGT GAGGTGCTCGAAAACAAGGTTTCAGGTGACGCCCCAGATAAAAATTTGGA CGGGGGGTTTCAGTGGTGGCATTGTGCTATGACACCAATAAACCCTCACA ACCCCTTGGGCAATAAATACTAGTGTAGGAATGAAACATTCTGAATATCTT TAACAATAGAAAATCCATGGGGTGGGGACAAGCCGTAAAGACTGGATGTCCA TCTCACACGAATTTATGGCTATGGGCAACACATAATCCTAGTGAATATGA TACTGGGGTTATTAAGATGTGTCCAGGCAGGGACCAAGACAGGTGAACCA TGTGTACACTCTATTTGTAAACAAGGGGAAAGAGAGTGGACCCGACAGC AGCGGACTCCACTGGTTGTCTCTAACACCCCGAAAATTAACAGGGGCTCC ACGCCAATGGGGCCATAAACAAGACAAGTGGCCACTCTTTTTTTTGGAAA TTGTGGAGTGGGGGCACGCTCAGCCCCACAGCCGCTTCGCGTTTTTGG ACTGTAATAAAGGGTGTAAATACTTGGCTGATTGTAACCCCGCTAACCCAC TCGGGTCAAACCCTTGGCCACAAAACCACTAATGGCACCCCGGGGAATAC CTGCATAAGTAGGTGGCGGGCCAAAGATAGGGGCGGATTTGCTGCGATCTG GAGGACAAATTACACACTTGCCTGAGCGCAAGCACAGGGTTGTGG TCCTCATATTCACGAGGTGCTGAGAGCACGGTGGGCTAATGTTGCCATGG GTAGCATATACACCAAATATCTGGATAGCATATGCTATCCTAATCTATA TCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCC TAATCTATATCTGGGTAGTATATGCTATCCTAATTTATATCTGGGTAGCAT AGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCT GGGTAGTATATGCTATCCTAATCTGATCCGGGTAGCATATGCTATCCTAA TAGAGATTAGGGTAGTATATGCTATCCTAATTTATATCTGGGTAGCATATA CTACCCAAATATCTGGATAGCATATGCTATCCTAATCTATATCTGGGTAGC ATATGCTATCCTAATCTATATCTGGGTAGCATAGGCTATCCTAATCTATAT CTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCT AATTTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATA</p>

		<p>TGCTATCCTAATCTATATCTGGGTAGTATAATGCTATCCTAATCTGTATCCG GGTAGCATATGCTATCCTCATGATAAGCTGTCAAACATGAGAATTTTCTTG AAGACGAAAGGGCCTCGTGATACGCCATTTTTATAGGTTAATGTCATGAT AATAATGGTTTCTTAGACGTGAGGTGGCCTTTTCGGGGAAATGTGCGCGG AACCCCTATTTGTTTATTTTCTAAATACATTCAAATATGTATCCGCTCAT GAGACAATAACCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTAT GAGTATTCAACATTTCCGTGTCGCCCTTATCCCCTTTTTGCGGCATTTG CCTTCTGTTTTTGTCTACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGA AGATCAGTTGGGTGCACGAGTGGGTACATCGAACTGGATCTCAACAGCGG TAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCAC TTTTAAAGTTCGCTATGTGGCGCGGTATTATCCCCTGTTGACGCCGGGCA AGAGCAACTCGGTCGCCGATACACTATTTCTCAGAATGACTTGGTTGAGTA CTCACCAGTCAAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATT ATGCAGTGCTGCCATAACCATGAGTGATAAAGTGGCGGCAACTTACTTCT GACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTGCACAACATGGG GGATCATGTAACTCGCCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCAT ACCAAACGACGAGCGTGACACCACGATGCCCTGCAGCAATGGCAACAACGTT GCGCAACTATTAAGTGGCGAACTACTTACTTAGCTTCCCGCAACAAT AATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCCTTCTGCGCATTTG CCTTCCGGCTGGCTGGTTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGG GTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCCTAT CGTAGTTATCTACACGACGGGAGTCAGGCAACTATGGATGAACGAAATAG ACAGATCGCTGAGATAGGTGCCCTCACTGATTAAGCATTTGGTAACTGTGAGA CCAAGTTTACTCATATATACTTTAGATTGATTTAAAACCTCATTTTTAAT TAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCC TTAACGTGAGTTTTCGTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAA AGGATCTTCTTGAGATCCTTTTTTCTGCGGTAATCTGCTGCTTGCAAC AAAAAACCACCGCTACCAGCGGTGGTTTTGTTGCCGGATCAAGAGCTACC AACTCTTTTTCCGAAGGTAAGTGGCTTCCAGCAGAGCGCAGATACCAAATAC TGTCTTCTAGTGTAGCCGTAGTTAGGCCACCCTTCAAGAACCTGTGTAGC ACCGCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAG TGGCGATAAGTCGTGTCTTACCAGGTTGGACTCAAGACGATAGTTACCAGGA TAAGGCGCAGCGGTGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTT GGAGCGAACGACTACACCGAAGTACGATACCTACAGCGTGAGCTATGAGA AAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGG CAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGAAACGCCCTG GTATCTTTATAGTCTGTGCGGTTTTCGCCACCTCTGACTGAGCGTGCAT TTTTGTGATGCTCGTACAGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGC GGCCTTTTTACGGTTCCTGGCCTTTTGTGGCCTTTTGTGCACATGTTCTT TCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTG AGCTGATACCGCTCGCCGACCGAAGCAGCCGAGCGCAGCGAGTCAAGTGA CGAGGAAGCGGAAGAGCGCCCAATACGCAAAACCGCCTTCCCCGCGCGTTG GCCGATTCATTAATGCAGCTGGCACGACAGGTTTTCCCGACTGGAAAGCGGG CAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCA GGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGG ATAACAATTTACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCTA GCTAGAGGTGAGTCCCTCCCAGCAGGCAGAAGTATGCAAAGCATGTCATC TCAATTAGTCAGCAACCATAGTCCCGCCCCAACTCCGCCCATCCCAGCCCC TAACTCCGCCAGTCCGCCATTCTCCGCCCATGGCTGACTAATTTTTTT TTATTTATGCAGAGGCGGAGCCGCTCGGCCTCTGAGCTATTCCAGAAGT AGTGAGGAGGCTTTTTGGAGGCTAGGCTTTTGCAAAAAGCTTTGCAAAAG ATGGATAAAGTTTTAAACAGAGAGGAATCTTTGCAGCTAATGGACCTTCTA GGCTTTGAAAGGAGTGGGAAATTGGCTCCGGTGCCTCAGTGGGCAGAGCG CACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTTGAA CGGTGCCCTAGAGAAGGTGGCGGGGTAAGTGGGAAAGTGAATCTGCTGTA CTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGT AGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTGCCGCCAGAACACAGGT AAGTGCCGTGTGTTTCCCGCGGGCCTGGCCTCTTTACGGTTATGGCCC TTGCGTGCCTTGAATTACTTCCACCTGGCTGCAGTACGTGATTCTTGATCC CGAGCTTCCGGTTGGAAGTGGGTGGGAGAGTTCGAGGCCTTGCGCTTAAGG AGCCCTTCGCCTCGTGTGATTGAGTTGAGGCTGGCCTGGCGCTGGGGCCG</p>
--	--	---

		<p>CCGCGTGCGAATCTGGTGGCACCTTCGCGCCTGTCTCGCTGCTTTTCGATAA GTCTCTAGCCATTTAAAATTTTGTATGACCTGCTGCGACGCTTTTTTCTG GCAAGATAGTCTTGTAATGCGGGCCAAGATCTGCACACTGGTATTTTCGGT TTTTGGGGCCCGGGCGGGCAGCGGGGCCCGTGCCTCCAGCGCACATGTTC GCGAGGGCGGGGCTGCGAGCGCGGCCACCAGAGAATCGGACGGGGGTAGTC TCAAGCTGGCCGGCCTGCTCTGGTGCCTGGCCTCGCGCCCGCTGTATCGC CCCGCCCTGGGCGGCAAGGCTGGCCCGGTGCGCACCAGTTGCGTGAGCGGA AAGATGGCCGCTTCCCGGCCCTGCTGCAGGGAGCTCAAAATGGAGGACGCG GCGCTCGGGAGAGCGGGCGGGTGAATCACCAACAAAGAAAAGGGCCTT TCCGTCTCAGCCGCTCGCTTCATGTGACTCCACGGAGTACCGGGCGCCGTC CAGGCACCTCGATTAGTTCTCGAGCTTTTGGAGTACGTCGCTTTAGGTTG GGGGAGGGGTTTTATGCGATGGAGTTTCCCACACTGAGTGGGTGGAGAC TGAAGTTAGGCCAGCTTGGCACTTGATGTAATTCTCCTTGGAAATTTGCCCT TTTTGGAGTTGGATCTTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAG TTTTCTTCCATTTCAAGGTGTCGTGAGGAATTCTCTAGAGATCCCTCGA CCTCGAGATCCATTGTGCCCGGGCGCACCATGACTTGGACCCCACTCCTCT TCCTCACCTCCTCCTCCACTGCACAGGAAGCTTATCG</p>
<p>v5</p>	<p>871</p>	<p>CAACCAAGGCTGCCCTCGGTCCTGTTCCCGCCCTCCTCTGAGGAG CTCAAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTACTTCTACCCG GGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCGTCAAGGCGGGA GTGGAGACCACCACCCCTCAAACAAGCAACAACAAGTACGCGGCCAGC AGCTACCTGAGCCTGACGCCGAGCAGTGAAGTCCCACAGAAGCTACAGC TGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCTACA GAAATGTTTATGAGCGGCCGCTCGAGGCCGGCAAGGCCGATCCCCGACCT CGACCTCTGGCTAATAAAGGAAATTTATTTTCATTGCAATAGTGTGTTGGA ATTTTTGTGTCTCTCACTCGGAAGGACATATGGGAGGGCAAATCATTTGG TCGAGATCCCTCGGAGATCTCTAGCTAGAGGATCGATCCCGCCCGGACG AACTAAACCTGACTACGACATCTCTGCCCTTCTTCGCGGGGCGAGTGCATG TAATCCCTTCAAGTTGGTGGTACAACCTTGCCAACCTGGGCCCTGTTCCACAT GTGACACGGGGGGGACCAACAACAAGGGGTTCTCTGACTGTAGTTGACA TCCTTATAAATGGATGTGCACATTTGCCAACACTGAGTGGCTTTCATCTG GAGCAGACTTTGAGTCTGTGGACTGCAACACAACATTGCCCTTATGTGTA ACTCTTGGCTGAAGCTCTTACACCAATGCTGGGGGACATGACTCCAGG GGCCAGGAAGACTACGGGAGGCTACACCAACGTCAATCAGAGGGGCCGT GTAGCTACCGATAAGCGGACCTCAAGAGGGCATTAGCAATAGTGTTTATA AGGCCCTTGTAAACCTAAACGGGTAGCATATGCTTCCCGGGTAGTAGT ATATACTATCCAGACTAACCTAATTTCAATAGCATATGTTCCCAAGGGA AGCATATGCTATCGAATTAGGGTTAGTAAAAGGGTCCTAAGGAACAGCGAT ATCTCCACCCATGAGCTGTCACGGTTTTATTTACATGGGGTCAAGATTC CACGAGGGTAGTGAACCATTTAGTCACAAGGGCAGTGGTGAAGATCAAG GAGCGGGCAGTGAACCTCTCGAATCTTCGCTGCTTCTTCAATCTCCTTC GTTTAGCTAATAGAATAACTGCTGAGTTGTGAACAGTAAGGTGTATGTGAG GTGCTCGAAAACAAGGTTTTCAGGTGACGCCCCAGAAATAAAATTTGACGG GGGGTTCAAGTGGTGGCATTGTGCTATGACACCAATATAACCTCACAAACC CCTTGGGCAATAAAATACTAGTGTAGGAATGAAACATTTGAAATATCTTTAA CAATAGAAATCCATGGGGTGGGGACAAGCCGTAAAGACTGGATGTCCATCT CACACGAATTTATGGCTATGGGCAACACATAATCTTAGTGCAATATGATAC TGGGGTTATTAAGATGTGTCCAGGCAGGGACCAAGACAGGTGAACCATGT TGTACACTCTATTTGTAACAAGGGGAAAGAGAGTGGACGCCGACAGCAGC GGACTCCACTGGTTGTCTCTAACACCCCCGAAAATTAACGGGGCTCCACG CCAATGGGGCCATAAACAAGACAAGTGGCCACTTTTTTTTTGAAATTTG TGGAGTGGGGGCACGCTCAGCCCCACACGCCCGCTGCGGTTTTGGACT GTAAAATAAGGGTGAATAACTTGGCTGATTGTAACCCCGCTAACCACTGC GGTCAAACCACTTGGCCACAAAACCACTAATGGCACCCCGGGGAATACCTG CATAAGTAGGTGGCGGGCCAAGATAGGGGCGGATGCTGCGATCTGGAG GACAAATTACACACACTTGGCCCTGAGCGCCAAGCACAGGGTTGTTGGTCC TCATATTCACGAGGTCGCTGAGAGCACGGTGGGCTAATGTTGCCATGGGTA GCATATACTACCAAAATATCTGGATAGCATATGCTATCTTAATCTATATCT GGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCTTAA TCTATATCTGGGTAGTATATGCTATCCTAATTTATATCTGGGTAGCATAGG CTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGG</p>

		<p>TAGTATATGCTATCCTAATCTGTATCCGGGTAGCATATGCTATCCTAATAG AGATTAGGGTAGTATATGCTATCCTAATTTATATCTGGGTAGCATATACTA CCCAAATATCTGGATAGCATATGCTATCCTAATCTATATCTGGGTAGCATA TGCTATCCTAATCTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTG GGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAAT TTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGC TATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATCTGTATCCGGGT AGCATATGCTATCCTCATGATAAGCTGTCAAACATGAGAATTTTCTTGAAG ACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAAT AATGGTTTTCTTAGACGTCAGGTGGCACTTTCGGGGAAAATGTGCGCGGAAC CCCTATTTGTTTTATTTTTCTAAATACATTCAAAATATGTATCCGCTCATGAG ACAATAACCCGTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAG TATTCAACATTTCCGTGTCCGCTTATTCCCTTTTTTGGCGCATTTTGCCCT TCCTGTTTTTGTCTACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGA TCAGTTGGGTGCACGAGTGGGTACATCGAACTGGATCTCAACAGCGGTAA GATCCTTGAGAGTTTTCCGCCCGAAGAACGTTTTCCAATGATGAGCACTTT TAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTGACGCCGGGCAAGA GCAACTCGGTCCGCGCATACTACTTCTCAGAATGACTTGGTTGAGTACTC ACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAAGAAATATG CAGTGCTGCCATAACCATGAGTGATAAAGCTGCGGCCAATCTACTTCTGAC AACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGA TCATGTAACCTCCCTTGATCGTTGGGAACCGGAGCTGAAAGAAGCCATACC AAACGACGAGCGTGACACCAGATGCCTGCAGCAATGGCAACAACGTTGCG CAAATATTAAGTGGCGAACACTTACTCTAGCTTCCCGCAACAATAAT AGACTGGATGGAGGCGGATAAAGTTGCAGGACCACCTTCTGCGCTCCGCCCT TCCGGCTGGCTGGTTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTC TCGCGGTATCATGTCAGCACGGGGCCAGATGGTAAGCCCTCCCGTATCGT AGTTATCTACAGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACA GATCGCTGAGATAGGTGCCTCACTGATTAAGCATTTGGTAACTGTCAGACCA AGTTACTCATATATACTTTAGATTGATTTAAAACCTCATTTTTAATTTAA AAGGATCTAGGTGAAGATCCTTTTTGATAAATCTCATGACAAAATCCCTTA ACGTGAGTTTTCTGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGG ATCTTCTTGAGATCCTTTTTTCTGCGGTAATCTGCTGCTTGAACAACAAA AAAACCACCGCTACCAGCGGTGGTTTTGTTGCCGGATCAAGAGCTACCAAC TCTTTTTCCGAAGGTAACGGCTTCAGCAGAGCGCAGATACCAATACTGT TCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACC GCCTACATAACCCTGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGG CGATAAGTCTGCTTACCAGGTTGGACTCAAGACGATAGTTACCGGATAA GGCGCAGCGGTCCGGCTGAACGGGGGGTTCGTGCACACAGCCAGCTTGGGA GCGAACGACCTACACCGAACGAGATACCTACAGCGTGAGCTATGAGAAAG CGCCACGCTTCCCGAAGGGAGAAAAGCGGGACAGGTATCCGGTAAGCGGCAG GGTCGGAACAGGAGAGCGCACAGAGGGAGCTTCCAGGGGAAAACGCTTGGTA TCTTTATAGTCTGTCGGGTTCGCCACCTCTGACTTGAGCTCGATTTTTTT GTGATGCTCGTCAGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGC CTTTTTACGGTTCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCC TGCGTTATCCCTGATTCGTGGATAACCGTATTACCGCCTTTGAGTGAGC TGATAACGCTCGCCGACGCCAACGACCGAGCGCAGCGAGTCACTGAGCGGA GGAAGCGGAAGAGCGCCCAATACGCAACCGCCTTCCCGCGCGTTGGCC GATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGAAAAGCGGGCAG TGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCAGGC TTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTTGTGAGCGGATA ACAATTTACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCTAGCT AGAGGTCGAGTCCCTCCCGCAGGCAGAAAGTATGCAAAGCATGCATCTCA ATTAGTCAGCAACCATAGTCCCGCCCTAACTCCGCCCATCCCGCCCTTAA CTCCGCCAGTTCGCGCCATTTCTCCGCCCATGGCTGACTAATTTTTTTTA TTTTATGCAGAGGCCGAGGCCCTCGGCCCTGAGCTATTCCAGAAGTAGT GAGGAGGCTTTTTTGGAGGCTAGGCTTTTTGCAAAAAGCTTTGCAAAGATG GATAAAGTTTTAAACAGAGAGGAATCTTTGAGCTAATGGACCTTCTAGGT CTTGAAAGGAGTGGGAATTGGCTCCGGTCCCGTCACTGAGGCGAGCGCAC ATCGCCACAGTCCCGAGAAGTTGGGGGAGGGGTCCGCAATTGAACCGG TGCCTAGAGAAGGTGGCGGGGTAACGTTGGAAAGTGATGTCGTGTACTG</p>
--	--	--

		<p>GCTCCGCTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGT CGCCGTGAACGTTCTTTTCGCAACGGGTTTGC CGCCAGAACACAGGTAAG TGCCGTGTGTGGTCCC CGGGGCTGGCCTTTACGGGTTATGGCCCTTG CGTGCCCTGAATTACTTCCACTGGCTGCAGTACGTGATCTTGATCCCGA GCTTCGGGTGGAAAGTGGGTGGGAGAGTTCGAGGCCTTGCCTTAAGGAGC CCCTTCGCTCGTGGTGGTGGTGGGAGAGTTCGAGGCCTGGGCGCTGGGCGCCG CGTGCGAATCTGGTGGCACCTTCGCGCCTGTCTCGCTGCTTTCGATAAGTC TCTAGCCATTTAAAATTTTTGATGACCTGCTGCGACGCTTTTTTCTGGCA AGATAGTCTTGTAAATGCGGGCCAAGATCTGCACACTGGTATTTCCGTTTT TGGGGCCGCGGGCGGCGACGGGGCCCGTGCCTCCAGCGCACATGTTCCGCG GAGGCGGGGCTGCGAGCGCGGCCACCGAGAATCGGACGGGGGTAGTCTCA AGCTGGCCGGCCTGCTCTGGTGCCTGGCTCGCGCCGCGGTATCGCCCC GCCCTGGGCGCAAGGCTGGCCCGGTGGCCACCAAGTTGCGTGAGCGGAAAG ATGGCCGCTTCCCGGCCCTGCTGCAGGGAGCTCAAAATGGAGGACGCGGCG CTCGGGAGAGCGGGCGGGTGGTGCACCCACAAAAGGAAAAGGGCCTTTCC GTCTCAGCCGTCGCTTCATGTGACTCCACGGAGTACCGGGCGCCGTCCAG GCACCTCGATTAGTCTCGAGCTTTTGGAGTACGTCGCTTTAGGTTGGGG GGAGGGTTTTATGCGATGGAGTTTCCCACTGAGTGGGTGGAGACTGA AGTTAGGCCAGCTTGGCACTTGATGTAATTCTCTTGGAAATTTGCCTTTT TGAGTTTGGATCTTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTTT TTTTCTTCCATTTAGGTGTCGTGAGGAATCTCTAGAGATCCCTCGACCT CGAGATCCATTGTGCCCGGGCGCCACCATGGACATGCGCTGCGCCGCCAG CTGCTGGGCCCTGCTGCTGCTGGTTCCTCCGGCTCGCGATGC</p>
v7	872	<p>GCGTCGACCAAGGGCCATCGGTCTTCCCCCTGGCACCTCTCCAAGAGC ACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCC GAACCGGTGACGGTGTGCTGGAACCTAGGCGCCCTGACCAGCGCGTGCAC ACCTTCCCGGCTGTCTACAGTCTCAGGACTCTACTCCCTCAGCAGCGTG GTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTG AATCACAAGCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCT TGTGACAAAATCACACATGCCACCGTGCCAGCACCTGAAGCCGCGGGG GGACCGTCAGTCTTCTCTTCCCCCAAACCAAGGACACCTCATGATC TCCCGGACCCCTGAGGTACATGCGTGGTGGTGGACGTGAGCCACGAAGAC CCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGTGCATAATGCC AAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTACG GTCTCACCGTCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGC AAGGTCTCCAACAAGCCCTCCAGCCCCATCGAGAAAACCATCTCCAAA GCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCTGCCCCCATCCGCG GAGGAGATGACCAAGAACCAGGTGAGCCTGACCTGCCTGGTCAAAGGCTTC TATCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAAC AACTACAAGACCAGCCTCCCGTGTGACTCCGACGGCTCTTCTTCTCTC TACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTC TCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGAGAAGAGC CTCTCCCTGTCTCCGGTAAATGAGCGGCCGCTCGAGGCGGCAAGCCGG ATCCCCGACCTCGACCTCTGGCTAATAAAGGAAATTTATTTTATTGCAA TAGTGTGTGGAAATTTTTGTGTCTCTCACTCGGAAGGACATATGGGAGGG CAAATCATTTGGTCGAGATCCCTCGGAGATCTTAGCTAGAGGATCGATCC CCGCCCCGGAGCAACTAAACCTGACTACGACATCTCTGCCCTTCTTCGCG GGCAGTGCATGTAATCCCTCAGTTGGTTGGTACAACCTGCCAACCTGGGC CCTGTTCCACATGTGACACGGGGGGGACCAACACAAAAGGGTTCTCTGA CTGTAGTTGACATCCTTATAAATGGATGTGCACATTTGCCAACACTGAGTG GCTTTCATCCTGGAGCAGACTTTCAGTCTGTGGACTGCAACACAACATTTG CCTTTATGTGTAACCTTTGGCTGAAGCTCTTACACCAATGCTGGGGGACAT GTACCTCCCAGGGGCCAGGAAGACTACGGGAGGCTACACCAACGTCAATC AGAGGGGCTGTGTAGCTACCGATAAGCGGACCCCAAGAGGGCATTAGCA ATAGTGTTTATAAGCCCCCTTGTAAACCCTAAACGGGTAGCATATGCTTC CCGGGTAGTAGTATATACTATCCAGACTAACCCTAATTAATAGCATATGT TACCAACGGGAAGCATAATGCTATCGAATTAGGGTTAGTAAAAGGGTCTTA AGGAACAGCGATATCTCCACCCCATGAGCTGTCACGGTTTTATTTACATG GGGTGAGGATCCACGAGGGTAGTGAACATTTTAGTCAAGGGCAGTGG CTGAAGATCAAGGAGCGGGCAGTGAACCTCCTGAATCTTCGCTGCTTCT TCATTCTCCTCGTTTAGCTAATAGAATAACTGCTGAGTTGTGAACAGTAA</p>

		<p>GGTGTATGTGAGGTGCTCGAAAACAAGGTTTCAGGTGACCCCCAGAATA AAATTTGGACGGGGGTTTCAGTGGTGGCATTGTGCTATGACACCAATATAA CCCTCACAACCCCTTGGGCAATAAATACTAGTGTAGGAATGAAACATTCT GAATATCTTTAACAATAGAAATCCATGGGGTGGGGACAAGCCGTAAAGACT GGATGTCCATCTCACACGAATTTATGGCTATGGGCAACACATAATCCTAGT GCAATATGATACTGGGGTTATTAAGATGTGTCCAGGCAGGACCAAGACA GGTGAACCATGTGTTACACTCTATTTGTAAACAAGGGAAAGAGAGTGGAC GCCGACAGCAGCGGACTCCACTGGTTGTCTCTAACACCCCCGAAAATTTAAA CGGGGCTCCACGCCAATGGGGCCATAAACAAAGACAAGTGGCCACTCTTT TTTTTTGAAATTTGGAGTGGGGGCACGCGTCAGCCCCACACGCCCGCTG CGGTTTTGGACTGTAAAATAAGGGTGTAAATAACTTGGCTGATTGTAACCC GCTAACCACTGCGGTCAAACCACTTGCCCAAAAACCATAATGGCACCCC GGGAATACCTGCATAAAGTAGGTGGGCGGGCCAAGATAGGGGCGCATGTC TGCGATCTGGAGGACAAATTACACACACTTGCGCCTGAGCGCCAAGCACAG GGTGTGGTCCATATATTCACGAGGTGCTGAGAGCACGGTGGGCTAATG TTGCCATGGGTAGCATATACTACCCAAATATCTGGATAGCATATGCTATCC TAATCTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCAT ATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATTTATATCT GGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAA TCTATATCTGGGTAGTATATGCTATCCTAATCTGTATCCGGGTAGCATATG CTATCCTAATAGAGATTAGGGTAGTATATGCTATCCTAATTTATATCTGGG TAGCATATACTACCCAAATATCTGGATAGCATATGCTATCCTAATCTATAT CTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGCATAGGCTATCCT AATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATA TGCTATCCTAATTTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTG GGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAAT CTGTATCCGGGTAGCATATGCTATCCTCATGATAAGCTGTCAAACATGAGA ATTTTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTATAGGTTAA TGTCATGATAATAATGGTTTTCTTAGACGTGAGGTGGCACTTTTCCGGGAAA TGTGCGCGGAACCCCTATTTGTTTTATTTTTCTAAATACATCAAATATGTA TCCGCTCATGAGACAATAACCTGATAAATGCTTCAATAATATGAAAAAG GAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCTTTTTTGC GGCATTTTGCCCTCCTGTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAA AGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTACATCGAACTGGATCT CAACAGCGGTAAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAAT GATGAGCACTTTTAAAGTTCGCTATGTGGCGGGTATTATCCCGTGTGTA CGCCGGCAAGAGCAACTCGGTGCGCCGATACACTATTCTCAGAACTGACTT GGTTGAGTACTCACAGTCCACAGAAAAGCATCTTACGGATGGCATGACAGT AAGAGAATTATGCAGTGCAGCATAACCATGAGTGATAAAGTGCAGGCAAA CTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCA CAACATGGGGGATCATGTAACCTCGCCTTGATCGTTGGGAACCGGAGCTGAA TGAAGCCATACCAACGACGAGCGTGACACCAGATGCTGCAGCAATGGC AACAACTTGCAGCAAACTATTAAGTGGCAACTACTTACTTAGCTTCCCG GCAACAATTAATAGACTGGATGGAGGCGGATAAAAGTGCAGGACCCTTCT GCGCTCGGCCCTCCGGCTGGCTGGTTTTATGCTGATAAATCTGGAGCCGG TGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCC CTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGA ACGAAATAGACAGATCGCTGAGATAGGTGCCCTACTGATTAAGCAATGGTA ACTGTGAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAACTTCA TTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTTGATAATCTCATGAC CAAAATCCCTTAAAGTGGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGA AAAGATCAAAGGATCTTCTTGGATCCTTTTTTTCTGCGGTAATCTGGTG CTTGCAACAAAAAACCACCGCTACCAGCGGTGGTTTTGTTGCCGGATCA AGAGCTACCAACTCTTTTTCCGAAGGTAAGTGGCTTCCAGCAGGCGCAGAT ACCAAACTACTGTCTTCTAGTGTAGCCGTAGTTAGGCCAAGGAA CTCTGTAGCACCGCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGC TGCTGCCAGTGGCGATAAGTCGTGCTTACCAGGTTGGACTCAAGACGATA GTTACCAGGATAAGGCGCAGCGGTGCGGCTGAACGGGGGTTTCGTGCACACA GCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGA GCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCC GGTAAGCGGCAGGGTCCGAAACAGGAGAGCGCACGAGGGAGCTTCCAGGGG</p>
--	--	--

		<p>AAACGCCTGGTATCTTTATAGTCTGTCGGGTTTCGCCACCTCTGACTTGA GCGTCGATTTTTGTGATGCTCGTCAGGGGGCGGAGCCTATGGAAAAACGC CAGCAACGCGGCTTTTTACGGTTCCTGGCTTTTGTGGCTTTTGTCTCA CATGTTCTTTCTGCGTTATCCCCTGATTCGTGGATAACCGTATTACCGC CTTTGAGTGAGCTGATACCGCTCGCCGACGCCGAACGACCGAGCGCAGCGA GTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCCCC CGCGGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTG GAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATT GGCACCCCAGGCTTTACTTTATGCTTCCGGCTCGTATGTTGTGTGGAAT TGTGAGCGGATAACAATTTACACAGGAAACAGCTATGACCATGATTACGC CAAGCTCTAGCTAGAGGTGAGTCCCTCCCCAGCAGGCAGAAGTATGCAAA GCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACCTCCGCCA TCCCGCCCCTAACCTCCGCCAGTTCGCCCATTCGCCCCCATGGCTGAC TAATTTTTTTTTATTTATGCAGAGGCCGAGGCCGCTCGGCCCTGAGCTAT TCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCTTAGGCTTTTGCAAAAAGC TTTGCAAAGATGGATAAAGTTTTAAACAGAGAGGAATCTTTGCAGCTAATG GACCTTCTAGGTCTTGAAGGAGTGGGAATTGGCTCCGGTGCCCGTCAGTG GGCAGAGCGCACATCGCCACAGTCCCGAGAAGTTGGGGGAGGGGTCGG CAATTGAACCGGTGCC TAGAGAAGGTGGCGCGGGTAAACTGGGAAAGTGA TGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATAT AAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAG AACACAGGTAAGTGCCGTGTGTGGTTCCCGCGGGCCTGGCTCTTTACGGG TTATGGCCCTTGCGTGCCTGAATTACTTCCACCTGGCTGCAGTACGTGAT TCTTGATCCCGAGCTTCGGGTTGGAAGTGGTGGGAGAGTTCGAGGCCTTG CGCTTAAGGAGCCCCCTCGCCTCGTGCTTGAGTTGAGGCTGGCCTGGGCG CTGGGGCCCGCGTGCGAATCTGGTGGCACCTTCGCGCCTGTCTCGCTGC TTTCGATAAGTCTCTAGCCATTTAAAATTTTTGATGACCTGCTGCGACGCT TTTTTTCTGGCAAGATAGCTTGTAATGCGGGCCAAGATCTGCACACTGG TATTTCCGGTTTTTGGGGCCCGGGCGGGCAGGGGCCCCGTGCGTCCCAGCG CACATGTTCCGCGAGGCGGGGCTGCGAGCGCGCCACCGAGAATCGGACG GGGTAGTCTCAAGCTGGCCGGCCTGCTCTGGTGCCTGGCTCGCGCCGCC GTGTATCGCCCCGCCCTGGGCGCAAGGCTGGCCCGGTGGCACCAGTTGC GTGAGCGGAAAGATGGCCGCTTCCCGCCCTGCTGCAGGGAGCTCAAAATG GAGGACGCGGCCTCGGGAGAGCGGGCGGGTGAGTACCACACAAAGGAA AAGGGCCTTTCCGTCTCAGCCGTGCTTCATGTGACTCCACGGAGTACCG GGCGCCGTCCAGGCACCTCGATTAGTTCGAGCTTTTGGAGTACGTGCTC TTTAGGTTGGGGGAGGGTTTTATGCGATGGAGTTTCCCACTGAGTG GGTGGAGACTGAAGTTAGGCCAGCTTGGCACTTGATGTAATTCTCCTTGA ATTTGCCCTTTTTGAGTTGGATCTTGGTTCATTCTCAAGCCTCAGACAGT GGTCAAAGTTTTTTCTTCCATTTCAAGGTGCTGTGAGGAATTTCTTAGAG ATCCCTCGACCTCGAGATCCATGTGCCCGGGCGCCACCATGGAGTTTGGG CTGAGCTGGCTTTTCTTGTGCGGATTTAAAAGGTGTCCAGTGC</p>
--	--	--

The present invention incorporates by reference in their entirety techniques well known in the field of molecular biology and drug delivery. These techniques include, but are not limited to, techniques described in the following publications:

- Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993);
- 5 Ausubel, F.M. et al. eds., Short Protocols In Molecular Biology (4th Ed. 1999) John Wiley & Sons, NY. (ISBN 0-471-32938-X).
- Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984);
- Giege, R. and Ducruix, A. Barrett, Crystallization of Nucleic Acids and Proteins, a Practical
- 10 Approach, 2nd ea., pp. 20 1-16, Oxford University Press, New York, New York, (1999);
- Goodson, in Medical Applications of Controlled Release, vol. 2, pp. 115-138 (1984);
- Hammerling, et al., in: Monoclonal Antibodies and T-Cell Hybridomas 563-681 (Elsevier, N.Y., 1981);
- Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed.
- 15 1988);
- Kabat et al., Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987) and (1991);
- Kabat, E.A., *et al.* (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242;
- 20 Kontermann and Dubel eds., Antibody Engineering (2001) Springer-Verlag. New York. 790 pp. (ISBN 3-540-41354-5).
- Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990);
- Lu and Weiner eds., Cloning and Expression Vectors for Gene Function Analysis (2001) BioTechniques Press. Westborough, MA. 298 pp. (ISBN 1-881299-21-X).
- 25 Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Fla. (1974);
- Old, R.W. & S.B. Primrose, Principles of Gene Manipulation: An Introduction To Genetic Engineering (3d Ed. 1985) Blackwell Scientific Publications, Boston. Studies in Microbiology; V.2:409 pp. (ISBN 0-632-01318-4).
- 30 Sambrook, J. et al. eds., Molecular Cloning: A Laboratory Manual (2d Ed. 1989) Cold Spring Harbor Laboratory Press, NY. Vols. 1-3. (ISBN 0-87969-309-6).
- Sustained and Controlled Release Drug Delivery Systems, J.R. Robinson, ed., Marcel Dekker, Inc., New York, 1978
- Winnacker, E.L. From Genes To Clones: Introduction To Gene Technology (1987) VCH
- 35 Publishers, NY (translated by Horst Ibelgaufts). 634 pp. (ISBN 0-89573-614-4).

Incorporation by Reference

The contents of all cited references (including literature references, patents, patent applications, and websites) that maybe cited throughout this application are hereby expressly incorporated by reference in their entirety, as are the references cited therein. The practice of the present invention will employ, unless otherwise indicated, conventional techniques of immunology, molecular biology and cell biology, which are well known in the art.

Equivalents

The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting of the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are therefore intended to be embraced herein.

CLAIMS:

1. A binding protein comprising first and second polypeptide chains independently comprising VD1-(X1)_n-VD2-C-(X2)_n, wherein

VD1 is a first variable domain;

VD2 is a second variable domain;

C is a constant domain;

X1 is a linker with the proviso that it is not CH1;

X2 is an Fc region;

n is 0 or 1;

wherein the VD1 domains on the first and second polypeptide chains form a first functional target binding site and the VD2 domains on the first and second polypeptide chains form a second functional target binding site, wherein the binding protein is capable of binding VEGF and DLL4, and:

(a) the variable domains that form a functional target binding site for VEGF comprise CDRs 1-3 from SEQ ID NO: 53 and CDRs 1-3 from SEQ ID NO: 54, CDRs 1-3 from SEQ ID NO: 77 and CDRs 1-3 from SEQ ID NO: 78, or CDRs 1-3 from SEQ ID NO: 79 and CDRs 1-3 from SEQ ID NO: 80;

and

(b) the variable domains that form a functional target binding site for DLL4 comprise CDRs 1-3 from SEQ ID NO: 55 and CDRs 1-3 from SEQ ID NO: 56, CDRs 1-3 from SEQ ID NO: 75 and CDRs 1-3 from SEQ ID NO: 76, CDRs 1-3 from SEQ ID NO: 81 and CDRs 1-3 from SEQ ID NO: 82, or CDRs 1-3 from SEQ ID NO: 83 and CDRs 1-3 from SEQ ID NO: 84;

wherein the binding protein is capable of binding to VEGF with a dissociation constant (K_D) of at most about 3.08×10^{-10} M as measured by surface plasmon resonance, and wherein the binding protein is capable of binding to DLL4 with a dissociation constant (K_D) of at most about 2.32×10^{-9} M as measured by surface plasmon resonance.

2. The binding protein according to claim 1, wherein the binding protein is capable of binding VEGF and DLL4, wherein:

(a) the variable domains that form a functional target binding site for VEGF comprise

SEQ ID NO: 53 and SEQ ID NO: 54,

SEQ ID NO: 77 and SEQ ID NO: 78, or

SEQ ID NO: 79 and SEQ ID NO: 80;

and

(b) the variable domains that form a functional target binding site for DLL4 comprise

SEQ ID NO: 55 and SEQ ID NO: 56,

SEQ ID NO: 75 and SEQ ID NO: 76,

SEQ ID NO: 81 and SEQ ID NO: 82, or

SEQ ID NO: 83 and SEQ ID NO: 84.

3. The binding protein according to claim 1, wherein the binding protein comprises two first polypeptide chains and two second polypeptide chains, forming four functional binding sites.

4. The binding protein according to claim 1, wherein the first polypeptide chain comprises a first VD1-(X1)_n-VD2-C-(X2)_n, wherein

VD1 is a first heavy chain variable domain;

VD2 is a second heavy chain variable domain;

C is a heavy chain constant domain;

X1 is a linker with the proviso that it is not CH1;

X2 is an Fc region;

n is 0 or 1; and

wherein the second polypeptide chain comprises a second VD1-(X1)_n-VD2-C-(X2)_n, wherein

VD1 is a first light chain variable domain;

VD2 is a second light chain variable domain;

C is a light chain constant domain;

X1 is a linker with the proviso that it is not CH1;

n is 0 or 1 for (X1)_n; and

n is 0 for (X2)_n;

wherein the VD1 domains on the first and second polypeptide chains form a first functional target binding site and the VD2 domains on the first and second polypeptide chains form a second functional target binding site.

5. The binding protein according to claim 1, wherein

- (a) X1 is any one of SEQ ID NO 1-26;
- (b) X1 is not CL;
- (c) the Fc region is a variant sequence Fc region;
- (d) the Fc region is an Fc region from an IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, or IgD; and/or
- (e) the binding protein is a crystallized binding protein.

6. A binding protein capable of binding VEGF and DLL4, wherein the binding protein comprises any one of:

- DVD043 (comprising SEQ ID NOs: 239 and 240),
- DVD044 (comprising SEQ ID NOs: 241 and 242),
- DVD441 (comprising SEQ ID NOs: 407 and 408),
- DVD442 (comprising SEQ ID NOs: 409 and 410),
- DVD447 (comprising SEQ ID NOs: 411 and 412),
- DVD448 (comprising SEQ ID NOs: 413 and 414),
- DVD453 (comprising SEQ ID NOs: 415 and 416),
- DVD454 (comprising SEQ ID NOs: 417 and 418),
- DVD459 (comprising SEQ ID NOs: 419 and 420),
- DVD460 (comprising SEQ ID NOs: 421 and 422),
- DVD443 (comprising SEQ ID NOs: 423 and 424),
- DVD444 (comprising SEQ ID NOs: 425 and 426),
- DVD449 (comprising SEQ ID NOs: 427 and 428),
- DVD450 (comprising SEQ ID NOs: 429 and 430),
- DVD455 (comprising SEQ ID NOs: 431 and 432),
- DVD456 (comprising SEQ ID NOs: 433 and 434),
- DVD461 (comprising SEQ ID NOs: 435 and 436),

DVD462 (comprising SEQ ID NOs: 437 and 438),
DVD445 (comprising SEQ ID NOs: 439 and 440),
DVD446 (comprising SEQ ID NOs: 441 and 442),
DVD451 (comprising SEQ ID NOs: 443 and 444),
DVD452 (comprising SEQ ID NOs: 445 and 446),
DVD457 (comprising SEQ ID NOs: 447 and 448),
DVD458 (comprising SEQ ID NOs: 449 and 450),
DVD463 (comprising SEQ ID NOs: 451 and 452),
DVD464 (comprising SEQ ID NOs: 453 and 454),
DVD465 (comprising SEQ ID NOs: 455 and 456),
DVD466 (comprising SEQ ID NOs: 457 and 458),
DVD471 (comprising SEQ ID NOs: 459 and 460),
DVD472 (comprising SEQ ID NOs: 461 and 462),
DVD477 (comprising SEQ ID NOs: 463 and 464),
DVD478 (comprising SEQ ID NOs: 465 and 466),
DVD483 (comprising SEQ ID NOs: 467 and 468),
DVD484 (comprising SEQ ID NOs: 469 and 470),
DVD467 (comprising SEQ ID NOs: 471 and 472),
DVD468 (comprising SEQ ID NOs: 473 and 474),
DVD473 (comprising SEQ ID NOs: 475 and 476),
DVD474 (comprising SEQ ID NOs: 477 and 478),
DVD479 (comprising SEQ ID NOs: 479 and 480),
DVD480 (comprising SEQ ID NOs: 481 and 482),
DVD485 (comprising SEQ ID NOs: 483 and 484),
DVD486 (comprising SEQ ID NOs: 485 and 486),
DVD469 (comprising SEQ ID NOs: 487 and 488),
DVD470 (comprising SEQ ID NOs: 489 and 490),
DVD475 (comprising SEQ ID NOs: 491 and 492),
DVD476 (comprising SEQ ID NOs: 493 and 494),
DVD481 (comprising SEQ ID NOs: 495 and 496),
DVD482 (comprising SEQ ID NOs: 497 and 498),

2009241589 01 Aug 2013

DVD487 (comprising SEQ ID NOs: 499 and 500),
DVD488 (comprising SEQ ID NOs: 501 and 502),
DVD493 (comprising SEQ ID NOs: 503 and 504),
DVD494 (comprising SEQ ID NOs: 505 and 506),
DVD499 (comprising SEQ ID NOs: 507 and 508),
DVD500 (comprising SEQ ID NOs: 509 and 510),
DVD505 (comprising SEQ ID NOs: 511 and 512),
DVD506 (comprising SEQ ID NOs: 513 and 514),
DVD489 (comprising SEQ ID NOs: 515 and 516),
DVD490 (comprising SEQ ID NOs: 517 and 518),
DVD495 (comprising SEQ ID NOs: 519 and 520),
DVD496 (comprising SEQ ID NOs: 521 and 522),
DVD501 (comprising SEQ ID NOs: 523 and 524),
DVD502 (comprising SEQ ID NOs: 525 and 526),
DVD507 (comprising SEQ ID NOs: 527 and 528),
DVD508 (comprising SEQ ID NOs: 529 and 530),
DVD491 (comprising SEQ ID NOs: 531 and 532),
DVD492 (comprising SEQ ID NOs: 533 and 534),
DVD497 (comprising SEQ ID NOs: 535 and 536),
DVD498 (comprising SEQ ID NOs: 537 and 538),
DVD503 (comprising SEQ ID NOs: 539 and 540),
DVD504 (comprising SEQ ID NOs: 541 and 542),
DVD509 (comprising SEQ ID NOs: 543 and 544),
DVD510 (comprising SEQ ID NOs: 545 and 546),
DVD511 (comprising SEQ ID NOs: 547 and 548),
DVD512 (comprising SEQ ID NOs: 549 and 550),
DVD517 (comprising SEQ ID NOs: 551 and 552),
DVD518 (comprising SEQ ID NOs: 553 and 554),
DVD523 (comprising SEQ ID NOs: 555 and 556),
DVD524 (comprising SEQ ID NOs: 557 and 558),
DVD529 (comprising SEQ ID NOs: 559 and 560),

DVD530 (comprising SEQ ID NOs: 561 and 562),
DVD513 (comprising SEQ ID NOs: 563 and 564),
DVD514 (comprising SEQ ID NOs: 565 and 566),
DVD519 (comprising SEQ ID NOs: 567 and 568),
DVD520 (comprising SEQ ID NOs: 569 and 570),
DVD525 (comprising SEQ ID NOs: 571 and 572),
DVD526 (comprising SEQ ID NOs: 573 and 574),
DVD531 (comprising SEQ ID NOs: 575 and 576),
DVD532 (comprising SEQ ID NOs: 577 and 578),
DVD515 (comprising SEQ ID NOs: 579 and 580),
DVD516 (comprising SEQ ID NOs: 581 and 582),
DVD521 (comprising SEQ ID NOs: 583 and 584),
DVD522 (comprising SEQ ID NOs: 585 and 586),
DVD527 (comprising SEQ ID NOs: 587 and 588),
DVD528 (comprising SEQ ID NOs: 589 and 590),
DVD533 (comprising SEQ ID NOs: 591 and 592), and
DVD534 (comprising SEQ ID NOs: 593 and 594).

7. A binding protein conjugate comprising the binding protein according to any one of claims 1-6, the binding protein conjugate further comprising an immunoadhesion molecule, an imaging agent, a therapeutic agent, or a cytotoxic agent,

wherein the imaging agent is optionally a radiolabel, an enzyme, a fluorescent label, a luminescent label, a bioluminescent label, a magnetic label, or biotin, wherein the radiolabel is optionally ^3H , ^{14}C , ^{35}S , ^{90}Y , ^{99}Tc , ^{111}In , ^{125}I , ^{131}I , ^{177}Lu , ^{166}Ho , or ^{153}Sm , or

wherein the therapeutic agent or cytotoxic agent is optionally an anti-metabolite, an alkylating agent, an antibiotic, a growth factor, a cytokine, an anti-angiogenic agent, an anti-mitotic agent, an anthracycline, a toxin, or an apoptotic agent.

8. An isolated nucleic acid encoding the binding protein amino acid sequence according to any one of claims 1-6.

2009241589 01 Aug 2013

9. A vector comprising the isolated nucleic acid according to claim 8, wherein the vector is optionally pcDNA, pTT, pTT3, pEFBOS, pBV, pJV, pcDNA3.1 TOPO, pEF6 TOPO, pBJ, or pHybE.
10. An isolated host cell comprising the vector according to claim 9, wherein the host cell is optionally a prokaryotic cell, *Escherichia coli*, a eukaryotic cell, a protist cell, an animal cell, a plant cell, a fungal cell, a yeast cell, an Sf9 cell, a mammalian cell, an avian cell, an insect cell, a CHO cell, or a COS cell.
11. A method of producing a binding protein, comprising culturing the host cell according to claim 10 in culture medium under conditions sufficient to produce the binding protein.
12. A pharmaceutical composition comprising the binding protein according to any one of claims 1-6, and a pharmaceutically acceptable carrier.
13. The pharmaceutical composition according to claim 12, further comprising at least one additional therapeutic agent, wherein the additional therapeutic agent is optionally an imaging agent, a cytotoxic agent, an angiogenesis inhibitor, a kinase inhibitor, a co-stimulation molecule blocker, an adhesion molecule blocker, an anti-cytokine antibody or functional fragment thereof, methotrexate, cyclosporine, rapamycin, FK506, a detectable label or reporter, a TNF antagonist, an antirheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, a neuromuscular blocker, an antimicrobial, an antipsoriatic, a corticosteroid, an anabolic steroid, an erythropoietin, an immunization, an immunoglobulin, an immunosuppressive, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an antidepressant, an antipsychotic, a stimulant, an asthma medication, a beta agonist, an inhaled steroid, an epinephrine or analog, a cytokine, or a cytokine antagonist.
14. Use of the binding protein according to any one of claims 1-6 in the manufacture of a medicament for treating a subject for a disease or a disorder.

15. The use according to claim 14, wherein the disorder is rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis, septic arthritis, Lyme arthritis, psoriatic arthritis, reactive arthritis, spondyloarthropathy, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, inflammatory bowel disease, insulin dependent diabetes mellitus, thyroiditis, asthma, allergic diseases, psoriasis, dermatitis scleroderma, graft versus host disease, organ transplant rejection, acute or chronic immune disease associated with organ transplantation, sarcoidosis, atherosclerosis, disseminated intravascular coagulation, Kawasaki's disease, Grave's disease, nephrotic syndrome, chronic fatigue syndrome, Wegener's granulomatosis, Henoch-Schoenlein purpura, microscopic vasculitis of the kidneys, chronic active hepatitis, uveitis, septic shock, toxic shock syndrome, sepsis syndrome, cachexia, infectious diseases, parasitic diseases, acquired immunodeficiency syndrome, acute transverse myelitis, Huntington's chorea, Parkinson's disease, Alzheimer's disease, stroke, primary biliary cirrhosis, hemolytic anemia, malignancies, heart failure, Addison's disease, sporadic, polyglandular deficiency type I and polyglandular deficiency type II, Schmidt's syndrome, adult (acute) respiratory distress syndrome, alopecia, alopecia areata, arthropathy, Reiter's disease, psoriatic arthropathy, ulcerative colitic arthropathy, enteropathic synovitis, chlamydia, yersinia and salmonella associated arthropathy, atheromatous disease/arteriosclerosis, atopic allergy, autoimmune bullous disease, pemphigus vulgaris, pemphigus foliaceus, pemphigoid, linear IgA disease, autoimmune haemolytic anaemia, Coombs positive haemolytic anaemia, acquired pernicious anaemia, juvenile pernicious anaemia, myalgic encephalitis/Royal Free Disease, chronic mucocutaneous candidiasis, giant cell arteritis, primary sclerosing hepatitis, cryptogenic autoimmune hepatitis, acquired immunodeficiency related diseases, hepatitis B, hepatitis C, common varied immunodeficiency (common variable hypogammaglobulinaemia), dilated cardiomyopathy, female infertility, ovarian failure, premature ovarian failure, fibrotic lung disease, cryptogenic fibrosing alveolitis, post-inflammatory interstitial lung disease, interstitial pneumonitis, connective tissue disease associated interstitial lung disease, mixed connective tissue disease associated lung disease, systemic sclerosis associated interstitial lung disease, rheumatoid arthritis associated interstitial lung disease, systemic lupus erythematosus associated lung disease, dermatomyositis/polymyositis associated lung disease, Sjögren's disease associated lung disease, ankylosing spondylitis associated lung disease, vasculitic diffuse lung disease, haemosiderosis associated lung disease, drug-induced interstitial lung disease, fibrosis, radiation

2009241589 01 Aug 2013

fibrosis, bronchiolitis obliterans, chronic eosinophilic pneumonia, lymphocytic infiltrative lung disease, postinfectious interstitial lung disease, gouty arthritis, autoimmune hepatitis, type-1 autoimmune hepatitis, type-2 autoimmune hepatitis (anti-LKM antibody hepatitis), autoimmune mediated hypoglycaemia, type B insulin resistance with acanthosis nigricans, hypoparathyroidism, acute immune disease associated with organ transplantation, chronic immune disease associated with organ transplantation, osteoarthritis, primary sclerosing cholangitis, psoriasis type 1, psoriasis type 2, idiopathic leucopaenia, autoimmune neutropaenia, renal disease NOS, glomerulonephritides, microscopic vasculitis of the kidneys, Lyme disease, discoid lupus erythematosus, male infertility idiopathic or NOS, sperm autoimmunity, multiple sclerosis, sympathetic ophthalmia, pulmonary hypertension secondary to connective tissue disease, Goodpasture's syndrome, pulmonary manifestation of polyarteritis nodosa, acute rheumatic fever, rheumatoid spondylitis, Still's disease, systemic sclerosis, Sjögren's syndrome, Takayasu's disease/arteritis, autoimmune thrombocytopenia, idiopathic thrombocytopenia, autoimmune thyroid disease, hyperthyroidism, goitrous autoimmune hypothyroidism (Hashimoto's disease), atrophic autoimmune hypothyroidism, primary myxoedema, phacogenic uveitis, primary vasculitis, vitiligo acute liver disease, chronic liver diseases, alcoholic cirrhosis, alcohol-induced liver injury, cholestasis, idiosyncratic liver disease, drug-induced hepatitis, non-alcoholic steatohepatitis, allergy and asthma, group B streptococci (GBS) infection, mental disorders, depression, schizophrenia, Th2 Type and Th1 Type mediated diseases, acute and chronic pain, lung cancer, breast cancer, stomach cancer, bladder cancer, colon cancer, pancreatic cancer, ovarian cancer, prostate cancer, rectal cancer, hematopoietic malignancies, leukemia, lymphoma, abetalipoproteinemia, acrocyanosis, acute and chronic parasitic or infectious processes, acute leukemia, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), acute or chronic bacterial infection, acute pancreatitis, acute renal failure, adenocarcinomas, aerial ectopic beats, AIDS dementia complex, alcohol-induced hepatitis, allergic conjunctivitis, allergic contact dermatitis, allergic rhinitis, allograft rejection, alpha-1-antitrypsin deficiency, amyotrophic lateral sclerosis, anemia, angina pectoris, anterior horn cell degeneration, anti cd3 therapy, antiphospholipid syndrome, anti-receptor hypersensitivity reactions, aortic and peripheral aneurysms, aortic dissection, arterial hypertension, arteriosclerosis, arteriovenous fistula, ataxia, atrial fibrillation (sustained or paroxysmal), atrial flutter, atrioventricular block, B cell lymphoma, bone graft rejection, bone marrow transplant

(BMT) rejection, bundle branch block, Burkitt's lymphoma, burns, cardiac arrhythmias, cardiac stun syndrome, cardiac tumors, cardiomyopathy, cardiopulmonary bypass inflammation response, cartilage transplant rejection, cerebellar cortical degenerations, cerebellar disorders, chaotic or multifocal atrial tachycardia, chemotherapy associated disorders, chronic myelocytic leukemia (CML), chronic alcoholism, chronic inflammatory pathologies, chronic lymphocytic leukemia (CLL), chronic obstructive pulmonary disease (COPD), chronic salicylate intoxication, colorectal carcinoma, congestive heart failure, conjunctivitis, contact dermatitis, cor pulmonale, coronary artery disease, Creutzfeldt-Jakob disease, culture negative sepsis, cystic fibrosis, cytokine therapy associated disorders, dementia pugilistica, demyelinating diseases, dengue hemorrhagic fever, dermatitis, dermatologic conditions, diabetes, diabetes mellitus, diabetic arteriosclerotic disease, diffuse Lewy body disease, dilated congestive cardiomyopathy, disorders of the basal ganglia, Down's syndrome in middle age, drug-induced movement disorders induced by drugs which block CNS dopamine receptors, drug sensitivity, eczema, encephalomyelitis, endocarditis, endocrinopathy, epiglottitis, Epstein-Barr virus infection, erythromelalgia, extrapyramidal and cerebellar disorders, familial hemaphagocytic lymphohistiocytosis, fetal thymus implant rejection, Friedreich's ataxia, functional peripheral arterial disorders, fungal sepsis, gas gangrene, gastric ulcer, glomerular nephritis, graft rejection of any organ or tissue, gram negative sepsis, gram positive sepsis, granulomas due to intracellular organisms, hairy cell leukemia, Hallervorden-Spatz disease, Hashimoto's thyroiditis, hay fever, heart transplant rejection, hemachromatosis, hemodialysis, hemolytic uremic syndrome/thrombolytic thrombocytopenic purpura, hemorrhage, hepatitis A, His bundle arrhythmias, HIV infection/HIV neuropathy, Hodgkin's disease, hyperkinetic movement disorders, hypersensitivity reactions, hypersensitivity pneumonitis, hypertension, hypokinetic movement disorders, hypothalamic-pituitary-adrenal axis evaluation, idiopathic Addison's disease, idiopathic pulmonary fibrosis, antibody mediated cytotoxicity, Asthenia, infantile spinal muscular atrophy, inflammation of the aorta, influenza a, ionizing radiation exposure, iridocyclitis/uveitis/optic neuritis, ischemia-reperfusion injury, ischemic stroke, juvenile rheumatoid arthritis, juvenile spinal muscular atrophy, Kaposi's sarcoma, kidney transplant rejection, legionella, leishmaniasis, leprosy, lesions of the corticospinal system, lipedema, liver transplant rejection, lymphedema, malaria, malignant lymphoma, malignant histiocytosis, malignant melanoma, meningitis, meningococemia, metabolic/idiopathic, migraine headache, mitochondrial multi-system disorder, mixed connective

tissue disease, monoclonal gammopathy, multiple myeloma, multiple systems degenerations, mycobacterium avium intracellulare, mycobacterium tuberculosis, myelodysplastic syndrome, myocardial infarction, myocardial ischemic disorders, nasopharyngeal carcinoma, neonatal chronic lung disease, nephritis, nephrosis, neurodegenerative diseases, neurogenic muscular atrophies, neutropenic fever, non-hodgkins lymphoma, occlusion of the abdominal aorta and its branches, occlusive arterial disorders, okt3 therapy, orchitis/epididymitis, orchitis/vasectomy reversal procedures, organomegaly, osteoporosis, pancreas transplant rejection, pancreatic carcinoma, paraneoplastic syndrome/hypercalcemia of malignancy, parathyroid transplant rejection, pelvic inflammatory disease, perennial rhinitis, pericardial disease, peripheral arteriosclerotic disease, peripheral vascular disorders, peritonitis, pernicious anemia, pneumocystis carinii pneumonia, pneumonia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome), post perfusion syndrome, post pump syndrome, post-MI cardiomyopathy syndrome, preeclampsia, progressive supranuclear palsy, primary pulmonary hypertension, radiation therapy, Raynaud's phenomenon and disease, Raynaud's disease, Refsum's disease, regular narrow QRS tachycardia, renovascular hypertension, reperfusion injury, restrictive cardiomyopathy, sarcomas, scleroderma, senile chorea, senile dementia of Lewy body type, seronegative arthropathies, shock, sickle cell anemia, skin allograft rejection, skin changes syndrome, small bowel transplant rejection, solid tumors, specific arrhythmias, spinal ataxia, spinocerebellar degenerations, streptococcal myositis, structural lesions of the cerebellum, subacute sclerosing panencephalitis, syncope, syphilis of the cardiovascular system, systemic anaphylaxis, systemic inflammatory response syndrome, systemic onset juvenile rheumatoid arthritis, T-cell or FAB ALL, telangiectasia, thromboangitis obliterans, thrombocytopenia, toxicity, transplants, trauma/hemorrhage, type III hypersensitivity reactions, type IV hypersensitivity, unstable angina, uremia, urosepsis, valvular heart diseases, varicose veins, vasculitis, venous diseases, venous thrombosis, ventricular fibrillation, viral and fungal infections, viral encephalitis/aseptic meningitis, viral-associated hemaphagocytic syndrome, Wernicke-Korsakoff syndrome, Wilson's disease, xenograft rejection of any organ or tissue, acute coronary syndromes, acute idiopathic polyneuritis, acute inflammatory demyelinating polyradiculoneuropathy, acute ischemia, adult Still's disease, anaphylaxis, anti-phospholipid antibody syndrome, aplastic anemia, atopic eczema, atopic dermatitis, autoimmune dermatitis, autoimmune disorder associated with

2009241589 01 Aug 2013

streptococcus infection, autoimmune enteropathy, autoimmune hearing loss, autoimmune lymphoproliferative syndrome (ALPS), autoimmune myocarditis, autoimmune premature ovarian failure, blepharitis, bronchiectasis, bullous pemphigoid, cardiovascular disease, catastrophic antiphospholipid syndrome, celiac disease, cervical spondylosis, chronic ischemia, cicatricial pemphigoid, clinically isolated syndrome (cis) with risk for multiple sclerosis, childhood onset psychiatric disorder, dacryocystitis, dermatomyositis, diabetic retinopathy, disk herniation, disk prolapse, drug induced immune hemolytic anemia, endometriosis, endophthalmitis, episcleritis, erythema multiforme, erythema multiforme major, gestational pemphigoid, Guillain-Barré syndrome (GBS), Hughes syndrome, idiopathic Parkinson's disease, idiopathic interstitial pneumonia, IgE-mediated allergy, immune hemolytic anemia, inclusion body myositis, infectious ocular inflammatory disease, inflammatory demyelinating disease, inflammatory heart disease, inflammatory kidney disease, IPF/UIP, iritis, keratitis, keratoconjunctivitis sicca, Kussmaul disease or Kussmaul-Meier disease, Landry's paralysis, Langerhan's cell histiocytosis, livedo reticularis, macular degeneration, microscopic polyangiitis, morbus bechterev, motor neuron disorders, mucous membrane pemphigoid, multiple organ failure, myasthenia gravis, myelodysplastic syndrome, myocarditis, nerve root disorders, neuropathy, non-A non-B hepatitis, optic neuritis, osteolysis, pauciarticular JRA, peripheral artery occlusive disease (PAOD), peripheral vascular disease (PVD), peripheral artery, disease (PAD), phlebitis, polyarteritis nodosa (or periarteritis nodosa), polychondritis, poliosis, polyarticular JRA, polyendocrine deficiency syndrome, polymyositis, polymyalgia rheumatica (PMR), primary Parkinsonism, prostatitis, pure red cell aplasia, primary adrenal insufficiency, recurrent neuromyelitis optica, restenosis, rheumatic heart disease, sapho (synovitis, acne, pustulosis, hyperostosis, and osteitis), secondary amyloidosis, shock lung, scleritis, sciatica, secondary adrenal insufficiency, silicone associated connective tissue disease, sneddon-wilkinson dermatosis, spondilitis ankylosans, Stevens-Johnson syndrome (SJS), temporal arteritis, toxoplasmic retinitis, toxic epidermal necrolysis, transverse myelitis, TRAPS (tumor necrosis factor receptor, type 1 allergic reaction, type II diabetes, urticaria, usual interstitial pneumonia (UIP), vasculitis, vernal conjunctivitis, viral retinitis, Vogt-Koyanagi-Harada syndrome (VKH syndrome), wet macular degeneration, or wound healing.

16. The use according to claim 14, wherein the medicament is formulated for parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal administration.

17. An in vitro method of determining the presence, amount, or concentration of at least one target or fragment thereof in a test sample by an immunoassay,

wherein the immunoassay comprises contacting the test sample with at least one binding protein and at least one detectable label,

wherein the at least one binding protein comprises the binding protein according to any one of claims 1-6.

18. The method according to claim 17 further comprising:

(a) contacting the test sample with the at least one binding protein, wherein the binding protein binds to an epitope on the target or fragment thereof so as to form a first complex;

(b) contacting the complex with the at least one detectable label, wherein the detectable label binds to the binding protein or an epitope on the target or fragment thereof that is not bound by the binding protein to form a second complex; and

(c) detecting the presence, amount, or concentration of the target or fragment thereof in the test sample based on the signal generated by the detectable label in the second complex, wherein the presence, amount, or concentration of the target or fragment thereof is directly correlated with the signal generated by the detectable label.

19. The method according to claim 17 further comprising:

(a) contacting the test sample with the at least one binding protein, wherein the binding protein binds to an epitope on the target or fragment thereof so as to form a first complex;

(b) contacting the complex with the at least one detectable label, wherein the detectable label competes with the target or fragment thereof for binding to the binding protein so as to form a second complex; and

(c) detecting the presence, amount, or concentration of the target or fragment thereof in the test sample based on the signal generated by the detectable label in the second complex, wherein the presence, amount, or concentration of the target or fragment thereof is indirectly correlated with the signal generated by the detectable label.


20. A kit for assaying an in vitro test sample for the presence, amount, or concentration of a target or fragment thereof, said kit comprising

- (a) instructions for assaying the test sample for the target or fragment thereof; and
- (b) at least one binding protein comprising the binding protein according to any one of claims 1-6.


AbbVie Inc.
Patent Attorneys for the Applicant/Nominated Person
SPRUSON & FERGUSON

Figure 1

A



B



EDITORIAL NOTE

Number: 2009241589

The specification totals more than 1000 pages. Please contact IP Australia if you wish to obtain a copy.